{ "documentInfo": { "documentType": "https://xbrl.org/2021/xbrl-json", "features": { "xbrl:canonicalValues": true }, "namespaces": { "EUR": "http://eurofins.com/2022-12-31", "ifrs-full": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "iso4217": "http://www.xbrl.org/2003/iso4217", "scheme": "http://standards.iso.org/iso/17442", "xbrl": "https://xbrl.org/2021", "xbrli": "http://www.xbrl.org/2003/instance" }, "taxonomy": [ "http://eurofins.com/2022-12-31/529900JEHFM47DYY3S57-2022-12-31.xsd" ] }, "facts": { "f90040": { "value": "6712100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Revenue", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90045": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:Revenue", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90049": { "value": "6712100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Revenue", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90054": { "value": "6717700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Revenue", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90059": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:Revenue", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90063": { "value": "6717700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Revenue", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90073": { "value": "-5199100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherOperatingIncomeExpense", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90078": { "value": "-97800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherOperatingIncomeExpense", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90083": { "value": "-5297000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherOperatingIncomeExpense", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90088": { "value": "-4816000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherOperatingIncomeExpense", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90093": { "value": "-61600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherOperatingIncomeExpense", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90098": { "value": "-4877700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherOperatingIncomeExpense", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90108": { "value": "1513000000", "decimals": -5, "dimensions": { "concept": "EUR:ProfitLossFromOperatingActivitiesBeforeInterestTaxesDepreciationAndAmortisationExpense", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90114": { "value": "-97800000", "decimals": -5, "dimensions": { "concept": "EUR:ProfitLossFromOperatingActivitiesBeforeInterestTaxesDepreciationAndAmortisationExpense", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90118": { "value": "1415100000", "decimals": -5, "dimensions": { "concept": "EUR:ProfitLossFromOperatingActivitiesBeforeInterestTaxesDepreciationAndAmortisationExpense", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90123": { "value": "1901600000", "decimals": -5, "dimensions": { "concept": "EUR:ProfitLossFromOperatingActivitiesBeforeInterestTaxesDepreciationAndAmortisationExpense", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90129": { "value": "-61600000", "decimals": -5, "dimensions": { "concept": "EUR:ProfitLossFromOperatingActivitiesBeforeInterestTaxesDepreciationAndAmortisationExpense", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90133": { "value": "1840000000", "decimals": -5, "dimensions": { "concept": "EUR:ProfitLossFromOperatingActivitiesBeforeInterestTaxesDepreciationAndAmortisationExpense", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90144": { "value": "476000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DepreciationAndAmortisationExpense", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90149": { "value": "28400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DepreciationAndAmortisationExpense", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90154": { "value": "504400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DepreciationAndAmortisationExpense", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90159": { "value": "428900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DepreciationAndAmortisationExpense", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90164": { "value": "21900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DepreciationAndAmortisationExpense", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90169": { "value": "450700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DepreciationAndAmortisationExpense", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90179": { "value": "1036900000", "decimals": -5, "dimensions": { "concept": "EUR:ProfitLossFromOperatingActivitiesBeforeExpenseFromShareBasedPaymentTransactionsWithEmployeesAndAcquisitionRelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90185": { "value": "-126200000", "decimals": -5, "dimensions": { "concept": "EUR:ProfitLossFromOperatingActivitiesBeforeExpenseFromShareBasedPaymentTransactionsWithEmployeesAndAcquisitionRelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90189": { "value": "910700000", "decimals": -5, "dimensions": { "concept": "EUR:ProfitLossFromOperatingActivitiesBeforeExpenseFromShareBasedPaymentTransactionsWithEmployeesAndAcquisitionRelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90194": { "value": "1472800000", "decimals": -5, "dimensions": { "concept": "EUR:ProfitLossFromOperatingActivitiesBeforeExpenseFromShareBasedPaymentTransactionsWithEmployeesAndAcquisitionRelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90200": { "value": "-83500000", "decimals": -5, "dimensions": { "concept": "EUR:ProfitLossFromOperatingActivitiesBeforeExpenseFromShareBasedPaymentTransactionsWithEmployeesAndAcquisitionRelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90204": { "value": "1389300000", "decimals": -5, "dimensions": { "concept": "EUR:ProfitLossFromOperatingActivitiesBeforeExpenseFromShareBasedPaymentTransactionsWithEmployeesAndAcquisitionRelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90215": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:ExpenseFromShareBasedPaymentTransactionsWithEmployeesAndAcquisitionRelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90220": { "value": "136100000", "decimals": -5, "dimensions": { "concept": "EUR:ExpenseFromShareBasedPaymentTransactionsWithEmployeesAndAcquisitionRelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90225": { "value": "136100000", "decimals": -5, "dimensions": { "concept": "EUR:ExpenseFromShareBasedPaymentTransactionsWithEmployeesAndAcquisitionRelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90229": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:ExpenseFromShareBasedPaymentTransactionsWithEmployeesAndAcquisitionRelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90234": { "value": "131000000", "decimals": -5, "dimensions": { "concept": "EUR:ExpenseFromShareBasedPaymentTransactionsWithEmployeesAndAcquisitionRelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90239": { "value": "131000000", "decimals": -5, "dimensions": { "concept": "EUR:ExpenseFromShareBasedPaymentTransactionsWithEmployeesAndAcquisitionRelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90248": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:GainsLossesRecognisedWhenControlInSubsidiaryIsLost", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90252": { "value": "141400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:GainsLossesRecognisedWhenControlInSubsidiaryIsLost", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90257": { "value": "141400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:GainsLossesRecognisedWhenControlInSubsidiaryIsLost", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90262": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:GainsLossesRecognisedWhenControlInSubsidiaryIsLost", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90267": { "value": "-100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:GainsLossesRecognisedWhenControlInSubsidiaryIsLost", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90272": { "value": "-100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:GainsLossesRecognisedWhenControlInSubsidiaryIsLost", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90282": { "value": "1036900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossFromOperatingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90288": { "value": "-120900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossFromOperatingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90292": { "value": "916000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossFromOperatingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90297": { "value": "1472800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossFromOperatingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90303": { "value": "-214600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossFromOperatingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90307": { "value": "1258200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossFromOperatingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90316": { "value": "2100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:FinanceIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90321": { "value": "200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:FinanceIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90326": { "value": "2200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:FinanceIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90331": { "value": "1800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:FinanceIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90336": { "value": "200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:FinanceIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90341": { "value": "2000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:FinanceIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90351": { "value": "136200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:FinanceCosts", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90356": { "value": "3000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:FinanceCosts", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90361": { "value": "139200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:FinanceCosts", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90366": { "value": "107800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:FinanceCosts", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90371": { "value": "97800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:FinanceCosts", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90376": { "value": "205700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:FinanceCosts", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90385": { "value": "900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90392": { "value": "900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90397": { "value": "2000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90404": { "value": "2000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90414": { "value": "903700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90420": { "value": "-123700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90424": { "value": "780000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90429": { "value": "1368800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90435": { "value": "-312200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90439": { "value": "1056600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90449": { "value": "220700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncomeTaxExpenseContinuingOperations", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90453": { "value": "-46500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncomeTaxExpenseContinuingOperations", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90459": { "value": "174200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncomeTaxExpenseContinuingOperations", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90464": { "value": "325400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncomeTaxExpenseContinuingOperations", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90468": { "value": "-51800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncomeTaxExpenseContinuingOperations", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90474": { "value": "273600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncomeTaxExpenseContinuingOperations", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90483": { "value": "683000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90488": { "value": "-77200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90492": { "value": "605800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90497": { "value": "1043400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90503": { "value": "-260400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90507": { "value": "783000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90549": { "value": "687400000", "decimals": -5, "dimensions": { "concept": "EUR:ProfitLossAttributableToOwnersOfParentAndOwnersOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90555": { "value": "-77200000", "decimals": -5, "dimensions": { "concept": "EUR:ProfitLossAttributableToOwnersOfParentAndOwnersOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90559": { "value": "610200000", "decimals": -5, "dimensions": { "concept": "EUR:ProfitLossAttributableToOwnersOfParentAndOwnersOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90564": { "value": "1043000000", "decimals": -5, "dimensions": { "concept": "EUR:ProfitLossAttributableToOwnersOfParentAndOwnersOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90570": { "value": "-260400000", "decimals": -5, "dimensions": { "concept": "EUR:ProfitLossAttributableToOwnersOfParentAndOwnersOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90574": { "value": "782600000", "decimals": -5, "dimensions": { "concept": "EUR:ProfitLossAttributableToOwnersOfParentAndOwnersOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90585": { "value": "-4400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossAttributableToNoncontrollingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90590": { "value": "-100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossAttributableToNoncontrollingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90595": { "value": "-4400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossAttributableToNoncontrollingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90599": { "value": "400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossAttributableToNoncontrollingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR" } }, "f90604": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:ProfitLossAttributableToNoncontrollingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR" } }, "f90608": { "value": "400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossAttributableToNoncontrollingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f90649": { "value": "3.57", "decimals": 2, "dimensions": { "concept": "ifrs-full:BasicEarningsLossPerShare", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90655": { "value": "-0.4", "decimals": 2, "dimensions": { "concept": "ifrs-full:BasicEarningsLossPerShare", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90659": { "value": "3.17", "decimals": 2, "dimensions": { "concept": "ifrs-full:BasicEarningsLossPerShare", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR/xbrli:shares" } }, "f90664": { "value": "5.45", "decimals": 2, "dimensions": { "concept": "ifrs-full:BasicEarningsLossPerShare", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90670": { "value": "-1.36", "decimals": 2, "dimensions": { "concept": "ifrs-full:BasicEarningsLossPerShare", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90674": { "value": "4.09", "decimals": 2, "dimensions": { "concept": "ifrs-full:BasicEarningsLossPerShare", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR/xbrli:shares" } }, "f90683": { "value": "3.43", "decimals": 2, "dimensions": { "concept": "EUR:BasicEarningsLossPerShareAttributableToOwnersOfParent", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90689": { "value": "-0.41", "decimals": 2, "dimensions": { "concept": "EUR:BasicEarningsLossPerShareAttributableToOwnersOfParent", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90693": { "value": "3.02", "decimals": 2, "dimensions": { "concept": "EUR:BasicEarningsLossPerShareAttributableToOwnersOfParent", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR/xbrli:shares" } }, "f90698": { "value": "5.29", "decimals": 2, "dimensions": { "concept": "EUR:BasicEarningsLossPerShareAttributableToOwnersOfParent", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90704": { "value": "-1.38", "decimals": 2, "dimensions": { "concept": "EUR:BasicEarningsLossPerShareAttributableToOwnersOfParent", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90708": { "value": "3.91", "decimals": 2, "dimensions": { "concept": "EUR:BasicEarningsLossPerShareAttributableToOwnersOfParent", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR/xbrli:shares" } }, "f90718": { "value": "0.15", "decimals": 2, "dimensions": { "concept": "EUR:BasicEarningsLossPerShareAttributableToOwnersOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90723": { "value": "0.01", "decimals": 2, "dimensions": { "concept": "EUR:BasicEarningsLossPerShareAttributableToOwnersOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90728": { "value": "0.15", "decimals": 2, "dimensions": { "concept": "EUR:BasicEarningsLossPerShareAttributableToOwnersOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR/xbrli:shares" } }, "f90733": { "value": "0.16", "decimals": 2, "dimensions": { "concept": "EUR:BasicEarningsLossPerShareAttributableToOwnersOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90738": { "value": "0.02", "decimals": 2, "dimensions": { "concept": "EUR:BasicEarningsLossPerShareAttributableToOwnersOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90743": { "value": "0.18", "decimals": 2, "dimensions": { "concept": "EUR:BasicEarningsLossPerShareAttributableToOwnersOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR/xbrli:shares" } }, "f90785": { "value": "3.45", "decimals": 2, "dimensions": { "concept": "ifrs-full:DilutedEarningsLossPerShare", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90791": { "value": "-0.39", "decimals": 2, "dimensions": { "concept": "ifrs-full:DilutedEarningsLossPerShare", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90795": { "value": "3.07", "decimals": 2, "dimensions": { "concept": "ifrs-full:DilutedEarningsLossPerShare", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR/xbrli:shares" } }, "f90800": { "value": "5.2", "decimals": 2, "dimensions": { "concept": "ifrs-full:DilutedEarningsLossPerShare", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90806": { "value": "-1.3", "decimals": 2, "dimensions": { "concept": "ifrs-full:DilutedEarningsLossPerShare", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90810": { "value": "3.9", "decimals": 2, "dimensions": { "concept": "ifrs-full:DilutedEarningsLossPerShare", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR/xbrli:shares" } }, "f90819": { "value": "3.31", "decimals": 2, "dimensions": { "concept": "EUR:DilutedEarningsLossPerShareAttributableToOwnersOfParent", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90825": { "value": "-0.39", "decimals": 2, "dimensions": { "concept": "EUR:DilutedEarningsLossPerShareAttributableToOwnersOfParent", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90829": { "value": "2.92", "decimals": 2, "dimensions": { "concept": "EUR:DilutedEarningsLossPerShareAttributableToOwnersOfParent", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR/xbrli:shares" } }, "f90834": { "value": "5.04", "decimals": 2, "dimensions": { "concept": "EUR:DilutedEarningsLossPerShareAttributableToOwnersOfParent", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90840": { "value": "-1.31", "decimals": 2, "dimensions": { "concept": "EUR:DilutedEarningsLossPerShareAttributableToOwnersOfParent", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90844": { "value": "3.73", "decimals": 2, "dimensions": { "concept": "EUR:DilutedEarningsLossPerShareAttributableToOwnersOfParent", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR/xbrli:shares" } }, "f90853": { "value": "0.14", "decimals": 2, "dimensions": { "concept": "EUR:DilutedEarningsLossPerShareAttributableToOwnersOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90858": { "value": "0.01", "decimals": 2, "dimensions": { "concept": "EUR:DilutedEarningsLossPerShareAttributableToOwnersOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90863": { "value": "0.15", "decimals": 2, "dimensions": { "concept": "EUR:DilutedEarningsLossPerShareAttributableToOwnersOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR/xbrli:shares" } }, "f90868": { "value": "0.15", "decimals": 2, "dimensions": { "concept": "EUR:DilutedEarningsLossPerShareAttributableToOwnersOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90873": { "value": "0.02", "decimals": 2, "dimensions": { "concept": "EUR:DilutedEarningsLossPerShareAttributableToOwnersOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:SeparatelyDisclosedItemsMember", "unit": "iso4217:EUR/xbrli:shares" } }, "f90878": { "value": "0.17", "decimals": 2, "dimensions": { "concept": "EUR:DilutedEarningsLossPerShareAttributableToOwnersOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR/xbrli:shares" } }, "f90934": { "value": "192500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:WeightedAverageShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "xbrli:shares" } }, "f90941": { "value": "192500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:WeightedAverageShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "xbrli:shares" } }, "f90946": { "value": "191500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:WeightedAverageShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "xbrli:shares" } }, "f90953": { "value": "191500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:WeightedAverageShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "xbrli:shares" } }, "f90963": { "value": "199000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustedWeightedAverageShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "xbrli:shares" } }, "f90970": { "value": "199000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustedWeightedAverageShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "xbrli:shares" } }, "f90975": { "value": "200600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustedWeightedAverageShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "EUR:AlternativePerformanceMeasuresAxis": "EUR:AdjustedResultsMember", "unit": "xbrli:shares" } }, "f90982": { "value": "200600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustedWeightedAverageShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "xbrli:shares" } }, "f91019": { "value": "605800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91024": { "value": "783000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91039": { "value": "108900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91043": { "value": "159600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91052": { "value": "69800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncomeBeforeTaxHedgesOfNetInvestmentsInForeignOperations", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91056": { "value": "113100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncomeBeforeTaxHedgesOfNetInvestmentsInForeignOperations", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91065": { "value": "5400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91069": { "value": "800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91076": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91080": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91088": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91093": { "value": "24300000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91099": { "value": "184100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91104": { "value": "249100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91116": { "value": "18000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91120": { "value": "2700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91130": { "value": "1500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91134": { "value": "11800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91143": { "value": "3700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91148": { "value": "1800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91154": { "value": "15800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91159": { "value": "12800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91166": { "value": "199900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91170": { "value": "261800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91177": { "value": "805600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91182": { "value": "1044900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91192": { "value": "810400000", "decimals": -5, "dimensions": { "concept": "EUR:ComprehensiveIncomeAttributableToOwnersOfParentAndOwnersOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91196": { "value": "1043200000", "decimals": -5, "dimensions": { "concept": "EUR:ComprehensiveIncomeAttributableToOwnersOfParentAndOwnersOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91205": { "value": "-4800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91209": { "value": "1700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91261": { "value": "2167700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:PropertyPlantAndEquipment", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91266": { "value": "1829900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:PropertyPlantAndEquipment", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91275": { "value": "4524100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Goodwill", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91280": { "value": "4115100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Goodwill", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91289": { "value": "919100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91294": { "value": "895700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91304": { "value": "5200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91309": { "value": "6200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91320": { "value": "78400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncurrentFinancialAssets", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91325": { "value": "75500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncurrentFinancialAssets", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91334": { "value": "75700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DeferredTaxAssets", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91339": { "value": "90900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DeferredTaxAssets", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91349": { "value": "7770200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncurrentAssets", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91354": { "value": "7013300000", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncurrentAssets", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91371": { "value": "145600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Inventories", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91376": { "value": "154200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Inventories", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91385": { "value": "1053300000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentTradeReceivables", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91390": { "value": "1051800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentTradeReceivables", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91399": { "value": "288400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentContractAssets", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91404": { "value": "337400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentContractAssets", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91414": { "value": "198300000", "decimals": -5, "dimensions": { "concept": "EUR:CurrentPrepaidExpensesAndOtherCurrentAssets", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91419": { "value": "183100000", "decimals": -5, "dimensions": { "concept": "EUR:CurrentPrepaidExpensesAndOtherCurrentAssets", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91429": { "value": "135600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentTaxAssetsCurrent", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91434": { "value": "76700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentTaxAssetsCurrent", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91444": { "value": "5600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentDerivativeFinancialAssets", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91449": { "value": "500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentDerivativeFinancialAssets", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91459": { "value": "486600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashAndCashEquivalents", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91464": { "value": "515300000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashAndCashEquivalents", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91473": { "value": "2313300000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentAssets", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91479": { "value": "2319000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentAssets", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91504": { "value": "10083500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Assets", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91509": { "value": "9332300000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Assets", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91526": { "value": "1900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IssuedCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91531": { "value": "1900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IssuedCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91541": { "value": "14200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:TreasuryShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91546": { "value": "3600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:TreasuryShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91554": { "value": "582700000", "decimals": -5, "dimensions": { "concept": "EUR:HybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91559": { "value": "1000000000", "decimals": -5, "dimensions": { "concept": "EUR:HybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91568": { "value": "1592900000", "decimals": -5, "dimensions": { "concept": "EUR:OtherReservesExcludingReserveOfExchangeDifferencesOnTranslation", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91573": { "value": "1578300000", "decimals": -5, "dimensions": { "concept": "EUR:OtherReservesExcludingReserveOfExchangeDifferencesOnTranslation", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91582": { "value": "2333000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:RetainedEarnings", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91587": { "value": "1964400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:RetainedEarnings", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91597": { "value": "285700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ReserveOfExchangeDifferencesOnTranslation", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91602": { "value": "106700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ReserveOfExchangeDifferencesOnTranslation", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91612": { "value": "4782100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:EquityAttributableToOwnersOfParent", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91617": { "value": "4647600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:EquityAttributableToOwnersOfParent", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91627": { "value": "68900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncontrollingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91632": { "value": "29500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncontrollingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91642": { "value": "4851000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91647": { "value": "4677200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91664": { "value": "3111800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:LongtermBorrowings", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91669": { "value": "2500300000", "decimals": -5, "dimensions": { "concept": "ifrs-full:LongtermBorrowings", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91678": { "value": "133600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DeferredTaxLiabilities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91683": { "value": "123600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DeferredTaxLiabilities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91693": { "value": "136200000", "decimals": -5, "dimensions": { "concept": "EUR:NonCurrentDeferredAcquisitionConsideration", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91698": { "value": "84300000", "decimals": -5, "dimensions": { "concept": "EUR:NonCurrentDeferredAcquisitionConsideration", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91708": { "value": "59500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91713": { "value": "75500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91722": { "value": "19200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncurrentProvisions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91727": { "value": "15700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncurrentProvisions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91736": { "value": "3460300000", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncurrentLiabilities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91741": { "value": "2799400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncurrentLiabilities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91758": { "value": "213800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91763": { "value": "253800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91774": { "value": "38000000", "decimals": -5, "dimensions": { "concept": "EUR:CurrentInterestAndExpensePayablesOnHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91779": { "value": "31400000", "decimals": -5, "dimensions": { "concept": "EUR:CurrentInterestAndExpensePayablesOnHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91788": { "value": "647700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91793": { "value": "627600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91802": { "value": "184200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentContractLiabilities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91807": { "value": "163100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentContractLiabilities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91817": { "value": "34700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentTaxLiabilitiesCurrent", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91822": { "value": "86000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentTaxLiabilitiesCurrent", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91832": { "value": "47800000", "decimals": -5, "dimensions": { "concept": "EUR:CurrentDeferredAcquisitionConsideration", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91837": { "value": "56800000", "decimals": -5, "dimensions": { "concept": "EUR:CurrentDeferredAcquisitionConsideration", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91846": { "value": "34500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentProvisions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91851": { "value": "29200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentProvisions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91860": { "value": "571600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherCurrentLiabilities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91865": { "value": "607900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherCurrentLiabilities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91874": { "value": "1772200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentLiabilities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91879": { "value": "1855700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentLiabilities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91897": { "value": "10083500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:EquityAndLiabilities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91902": { "value": "9332300000", "decimals": -5, "dimensions": { "concept": "ifrs-full:EquityAndLiabilities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91970": { "value": "780000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91975": { "value": "1056600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91985": { "value": "504400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f91990": { "value": "450700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92001": { "value": "136100000", "decimals": -5, "dimensions": { "concept": "EUR:AdjustmentsForExpenseFromShareBasedPaymentTransactionsWithEmployeesAndAcquisitionRelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92006": { "value": "131000000", "decimals": -5, "dimensions": { "concept": "EUR:AdjustmentsForExpenseFromShareBasedPaymentTransactionsWithEmployeesAndAcquisitionRelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92017": { "value": "-141400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92021": { "value": "100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92032": { "value": "-137500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustmentsForFinanceIncomeCost", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92037": { "value": "-200500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustmentsForFinanceIncomeCost", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92048": { "value": "900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustmentsForUndistributedProfitsOfAssociates", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92053": { "value": "2000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustmentsForUndistributedProfitsOfAssociates", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92064": { "value": "16400000", "decimals": -5, "dimensions": { "concept": "EUR:AdjustmentsForTransactionCostsAndIncomeRelatingToAcquisitions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92069": { "value": "13600000", "decimals": -5, "dimensions": { "concept": "EUR:AdjustmentsForTransactionCostsAndIncomeRelatingToAcquisitions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92079": { "value": "1800000", "decimals": -5, "dimensions": { "concept": "EUR:AdjustmentsForProvisionsAndAdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92085": { "value": "-1400000", "decimals": -5, "dimensions": { "concept": "EUR:AdjustmentsForProvisionsAndAdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92093": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:OtherAdjustmentsForNoncashItems", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92097": { "value": "4700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherAdjustmentsForNoncashItems", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92109": { "value": "-31200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseInWorkingCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92115": { "value": "18500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseInWorkingCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92124": { "value": "1432400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashFlowsFromUsedInOperations", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92129": { "value": "1808100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashFlowsFromUsedInOperations", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92139": { "value": "296100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92144": { "value": "296700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92153": { "value": "1136300000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashFlowsFromUsedInOperatingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92158": { "value": "1511400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashFlowsFromUsedInOperatingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92186": { "value": "576100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92191": { "value": "444400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92201": { "value": "84100000", "decimals": -5, "dimensions": { "concept": "EUR:PurchaseOfIntangibleAssetsAndPaymentsForDevelopmentProjectExpenditureClassifiedAsInvestingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92206": { "value": "62000000", "decimals": -5, "dimensions": { "concept": "EUR:PurchaseOfIntangibleAssetsAndPaymentsForDevelopmentProjectExpenditureClassifiedAsInvestingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92216": { "value": "14900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92221": { "value": "24800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92233": { "value": "-645300000", "decimals": -5, "dimensions": { "concept": "EUR:ProceedsFromSalesOfPropertyPlantAndEquipmentPurchaseOfPropertyPlantAndEquipmentProceedsFromSalesOfIntangibleAssetsAndPurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92239": { "value": "-481600000", "decimals": -5, "dimensions": { "concept": "EUR:ProceedsFromSalesOfPropertyPlantAndEquipmentPurchaseOfPropertyPlantAndEquipmentProceedsFromSalesOfIntangibleAssetsAndPurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92249": { "value": "491000000", "decimals": -5, "dimensions": { "concept": "EUR:FreeCashFlowToTheFirm", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92254": { "value": "1029800000", "decimals": -5, "dimensions": { "concept": "EUR:FreeCashFlowToTheFirm", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92273": { "value": "430000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92278": { "value": "530600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92287": { "value": "215300000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92293": { "value": "-2000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92304": { "value": "-1500000", "decimals": -5, "dimensions": { "concept": "EUR:CashPaymentsForFutureContractsForwardContractsOptionContractsAndSwapContractsCashReceiptsFromFutureContractsForwardContractsOptionContractsAndSwapContractsPurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodAndProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethodClassifiedAsInvestingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92310": { "value": "8400000", "decimals": -5, "dimensions": { "concept": "EUR:CashPaymentsForFutureContractsForwardContractsOptionContractsAndSwapContractsCashReceiptsFromFutureContractsForwardContractsOptionContractsAndSwapContractsPurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodAndProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethodClassifiedAsInvestingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92318": { "value": "2500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:InterestReceivedClassifiedAsInvestingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92323": { "value": "1700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:InterestReceivedClassifiedAsInvestingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92334": { "value": "-855900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashFlowsFromUsedInInvestingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92339": { "value": "-1021000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashFlowsFromUsedInInvestingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92365": { "value": "14600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProceedsFromIssuingShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92370": { "value": "35800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProceedsFromIssuingShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92380": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:ProceedsFromIssuingHybridCapitalClassifiedAsFinancingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92384": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:ProceedsFromIssuingHybridCapitalClassifiedAsFinancingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92393": { "value": "633900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92398": { "value": "826300000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92408": { "value": "82900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92413": { "value": "1280000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92423": { "value": "166100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92428": { "value": "153400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92438": { "value": "417300000", "decimals": -5, "dimensions": { "concept": "EUR:RepaymentOfHybridCapitalClassifiedAsFinancingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92442": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:RepaymentOfHybridCapitalClassifiedAsFinancingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92452": { "value": "15800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:PaymentsToAcquireOrRedeemEntitysShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92457": { "value": "3600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:PaymentsToAcquireOrRedeemEntitysShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92468": { "value": "192500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsPaidClassifiedAsFinancingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92473": { "value": "130400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsPaidClassifiedAsFinancingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92483": { "value": "35900000", "decimals": -5, "dimensions": { "concept": "EUR:CouponPaymentsOnHybridCapitalClassifiedAsFinancingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92488": { "value": "36300000", "decimals": -5, "dimensions": { "concept": "EUR:CouponPaymentsOnHybridCapitalClassifiedAsFinancingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92498": { "value": "49400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:InterestPaidClassifiedAsFinancingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92503": { "value": "168800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:InterestPaidClassifiedAsFinancingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92513": { "value": "-311300000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashFlowsFromUsedInFinancingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92518": { "value": "-910300000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashFlowsFromUsedInFinancingActivities", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92530": { "value": "-800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92534": { "value": "24300000", "decimals": -5, "dimensions": { "concept": "ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92546": { "value": "-31800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseInCashAndCashEquivalents", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92551": { "value": "-395500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseInCashAndCashEquivalents", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92561": { "value": "515000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92566": { "value": "910500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92577": { "value": "483200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92582": { "value": "515000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92679": { "value": "1900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f92685": { "value": "-3600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f92689": { "value": "1578300000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f92694": { "value": "106700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f92699": { "value": "1000000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f92704": { "value": "1964400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f92709": { "value": "29500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f92714": { "value": "4677200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92724": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f92728": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f92732": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f92736": { "value": "179100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f92741": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f92745": { "value": "21100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f92751": { "value": "-300000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f92755": { "value": "199900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92764": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f92768": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f92772": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f92776": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f92780": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f92784": { "value": "610200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f92790": { "value": "-4400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f92794": { "value": "605800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92804": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f92808": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f92812": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f92816": { "value": "179100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f92821": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f92825": { "value": "631300000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f92831": { "value": "-4800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f92835": { "value": "805600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92844": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f92848": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f92852": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f92856": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f92860": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f92864": { "value": "23000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f92869": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f92873": { "value": "23000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92885": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f92889": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f92893": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f92897": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f92901": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f92906": { "value": "15100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f92910": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f92915": { "value": "15100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92924": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:IssueOfShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f92928": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:IssueOfShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f92932": { "value": "14600000", "decimals": -5, "dimensions": { "concept": "EUR:IssueOfShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f92937": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:IssueOfShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f92941": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:IssueOfShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f92945": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:IssueOfShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f92949": { "value": "100000", "decimals": -5, "dimensions": { "concept": "EUR:IssueOfShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f92954": { "value": "14600000", "decimals": -5, "dimensions": { "concept": "EUR:IssueOfShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f92963": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f92968": { "value": "-10600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f92972": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f92976": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f92980": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f92985": { "value": "-5300000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f92989": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f92994": { "value": "-15800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f93003": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:RepaymentOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f93007": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:RepaymentOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f93011": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:RepaymentOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f93015": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:RepaymentOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f93020": { "value": "417300000", "decimals": -5, "dimensions": { "concept": "EUR:RepaymentOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f93024": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:RepaymentOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f93028": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:RepaymentOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f93033": { "value": "417300000", "decimals": -5, "dimensions": { "concept": "EUR:RepaymentOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f93041": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f93045": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f93049": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f93053": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f93057": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f93062": { "value": "192100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f93067": { "value": "400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f93072": { "value": "192500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f93080": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:CouponPaymentsOnHybridCapitalBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f93084": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:CouponPaymentsOnHybridCapitalBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f93088": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:CouponPaymentsOnHybridCapitalBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f93092": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:CouponPaymentsOnHybridCapitalBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f93096": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:CouponPaymentsOnHybridCapitalBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f93101": { "value": "29300000", "decimals": -5, "dimensions": { "concept": "EUR:CouponPaymentsOnHybridCapitalBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f93105": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:CouponPaymentsOnHybridCapitalBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f93110": { "value": "29300000", "decimals": -5, "dimensions": { "concept": "EUR:CouponPaymentsOnHybridCapitalBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f93119": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:TaxOnCouponPaymentsOnHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f93123": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:TaxOnCouponPaymentsOnHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f93127": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:TaxOnCouponPaymentsOnHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f93131": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:TaxOnCouponPaymentsOnHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f93135": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:TaxOnCouponPaymentsOnHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f93139": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:TaxOnCouponPaymentsOnHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f93143": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:TaxOnCouponPaymentsOnHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f93147": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:TaxOnCouponPaymentsOnHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f93157": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:IncreaseDecreaseThroughValuationOfPutOptionHeldByNonControllingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f93161": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:IncreaseDecreaseThroughValuationOfPutOptionHeldByNonControllingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f93165": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:IncreaseDecreaseThroughValuationOfPutOptionHeldByNonControllingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f93169": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:IncreaseDecreaseThroughValuationOfPutOptionHeldByNonControllingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f93173": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:IncreaseDecreaseThroughValuationOfPutOptionHeldByNonControllingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f93178": { "value": "-43900000", "decimals": -5, "dimensions": { "concept": "EUR:IncreaseDecreaseThroughValuationOfPutOptionHeldByNonControllingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f93182": { "value": "44500000", "decimals": -5, "dimensions": { "concept": "EUR:IncreaseDecreaseThroughValuationOfPutOptionHeldByNonControllingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f93187": { "value": "600000", "decimals": -5, "dimensions": { "concept": "EUR:IncreaseDecreaseThroughValuationOfPutOptionHeldByNonControllingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f93196": { "value": "1900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f93202": { "value": "-14200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f93206": { "value": "1592900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f93211": { "value": "285700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f93216": { "value": "582700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f93221": { "value": "2333000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f93226": { "value": "68900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f93231": { "value": "4851000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f93260": { "value": "1900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f93265": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f93269": { "value": "1542600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f93275": { "value": "-164700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f93279": { "value": "1000000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f93284": { "value": "1310500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f93289": { "value": "26100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f93294": { "value": "3716400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f93304": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f93308": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f93312": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f93316": { "value": "271400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f93321": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f93326": { "value": "-10800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f93330": { "value": "1300000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f93335": { "value": "261800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f93344": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f93348": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f93352": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f93356": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f93360": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f93364": { "value": "782600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f93369": { "value": "400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f93374": { "value": "783000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f93384": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f93388": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f93392": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f93396": { "value": "271400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f93401": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f93405": { "value": "771800000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f93410": { "value": "1700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f93415": { "value": "1044900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f93424": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f93428": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f93432": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f93436": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f93440": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f93444": { "value": "22100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f93449": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f93453": { "value": "22100000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f93465": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f93469": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f93473": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f93477": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f93481": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f93485": { "value": "-26900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f93490": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f93494": { "value": "-26900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f93504": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:IssueOfShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f93508": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:IssueOfShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f93512": { "value": "35800000", "decimals": -5, "dimensions": { "concept": "EUR:IssueOfShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f93517": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:IssueOfShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f93521": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:IssueOfShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f93525": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:IssueOfShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f93529": { "value": "100000", "decimals": -5, "dimensions": { "concept": "EUR:IssueOfShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f93534": { "value": "35800000", "decimals": -5, "dimensions": { "concept": "EUR:IssueOfShares", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f93543": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f93548": { "value": "-3600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f93552": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f93556": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f93560": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f93564": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f93568": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f93573": { "value": "-3600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f93582": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:RepaymentOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f93586": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:RepaymentOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f93590": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:RepaymentOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f93594": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:RepaymentOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f93598": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:RepaymentOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f93602": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:RepaymentOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f93606": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:RepaymentOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f93610": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:RepaymentOfHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f93618": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f93622": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f93626": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f93630": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f93634": { "value": "0", "decimals": -6, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f93639": { "value": "129700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f93644": { "value": "600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f93649": { "value": "130400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f93657": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:CouponPaymentsOnHybridCapitalBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f93661": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:CouponPaymentsOnHybridCapitalBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f93665": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:CouponPaymentsOnHybridCapitalBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f93669": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:CouponPaymentsOnHybridCapitalBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f93673": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:CouponPaymentsOnHybridCapitalBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f93678": { "value": "36300000", "decimals": -5, "dimensions": { "concept": "EUR:CouponPaymentsOnHybridCapitalBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f93682": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:CouponPaymentsOnHybridCapitalBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f93687": { "value": "36300000", "decimals": -5, "dimensions": { "concept": "EUR:CouponPaymentsOnHybridCapitalBeforeTax", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f93696": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:TaxOnCouponPaymentsOnHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f93700": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:TaxOnCouponPaymentsOnHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f93704": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:TaxOnCouponPaymentsOnHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f93708": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:TaxOnCouponPaymentsOnHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f93712": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:TaxOnCouponPaymentsOnHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f93716": { "value": "-2200000", "decimals": -5, "dimensions": { "concept": "EUR:TaxOnCouponPaymentsOnHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f93721": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:TaxOnCouponPaymentsOnHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f93725": { "value": "-2200000", "decimals": -5, "dimensions": { "concept": "EUR:TaxOnCouponPaymentsOnHybridCapital", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f93736": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:IncreaseDecreaseThroughValuationOfPutOptionHeldByNonControllingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f93740": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:IncreaseDecreaseThroughValuationOfPutOptionHeldByNonControllingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f93744": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:IncreaseDecreaseThroughValuationOfPutOptionHeldByNonControllingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f93748": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:IncreaseDecreaseThroughValuationOfPutOptionHeldByNonControllingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f93752": { "value": "0", "decimals": -6, "dimensions": { "concept": "EUR:IncreaseDecreaseThroughValuationOfPutOptionHeldByNonControllingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f93757": { "value": "-3200000", "decimals": -5, "dimensions": { "concept": "EUR:IncreaseDecreaseThroughValuationOfPutOptionHeldByNonControllingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f93761": { "value": "2400000", "decimals": -5, "dimensions": { "concept": "EUR:IncreaseDecreaseThroughValuationOfPutOptionHeldByNonControllingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f93767": { "value": "-800000", "decimals": -5, "dimensions": { "concept": "EUR:IncreaseDecreaseThroughValuationOfPutOptionHeldByNonControllingInterests", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "f93775": { "value": "1900000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "f93781": { "value": "-3600000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "f93785": { "value": "1578300000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MiscellaneousOtherReservesMember", "unit": "iso4217:EUR" } }, "f93790": { "value": "106700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "f93795": { "value": "1000000000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "EUR:HybridCapitalMember", "unit": "iso4217:EUR" } }, "f93800": { "value": "1964400000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "f93805": { "value": "29500000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember", "unit": "iso4217:EUR" } }, "f93810": { "value": "4677200000", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00", "unit": "iso4217:EUR" } }, "pp-value-22-1": { "value": "Eurofins Scientific, through its subsidiaries (hereafter referred to as \u201cEurofins\u201d or \u201cthe Group\u201d) is Testing for Life. Eurofins is a global leader in food, environment, pharmaceutical and cosmetic product testing and in agroscience Contract Research Organisation services. Eurofins is one of the market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and in the support of clinical studies, as well as having an emerging global presence in Contract Development and Manufacturing Organisations. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products. ", "dimensions": { "concept": "ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "f93955": { "value": "Eurofins Scientific ", "dimensions": { "concept": "ifrs-full:NameOfReportingEntityOrOtherMeansOfIdentification", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "f93956": { "value": "Eurofins Scientific ", "dimensions": { "concept": "ifrs-full:NameOfParentEntity", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "f93958": { "value": "SE", "dimensions": { "concept": "ifrs-full:LegalFormOfEntity", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "f93973": { "value": "Luxembourg", "dimensions": { "concept": "ifrs-full:DomicileOfEntity", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-25-1": { "value": "23, Val Fleuri, L-1526Luxembourg, Grand Duchy of Luxembourg.", "dimensions": { "concept": "ifrs-full:AddressOfRegisteredOfficeOfEntity", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "f94068": { "value": "Analytical Bioventures S.C.A.,", "dimensions": { "concept": "ifrs-full:NameOfUltimateParentOfGroup", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "f94083": { "value": "Luxembourg,", "dimensions": { "concept": "ifrs-full:CountryOfIncorporation", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "f94089": { "value": "Luxembourg.", "dimensions": { "concept": "ifrs-full:PrincipalPlaceOfBusiness", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-7-2": { "value": "These Consolidated Financial Statements have been authorised for issuance by the Board of Directors on 24 February 2023 and will be submitted to the Shareholders\u2019 Annual General Meeting for approval. ", "dimensions": { "concept": "ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-7-3": { "value": "These Consolidated Financial Statements have been authorised for issuance by the Board of Directors on 24 February 2023 and will be submitted to the Shareholders\u2019 Annual General Meeting for approval. Luxembourg.Analytical Bioventures S.C.A.,Luxembourg,LuxembourgWith over 61,000 staff across a decentralised and entrepreneurial network of ca. 900 laboratories in 61 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products. (The \u201cCompany\u201d) is legally and commercially registered in the Grand Duchy ofunder the number B 167 775. Grand Duchy ofThe Group is included as a subsidiary in the consolidated financial statements of located at 23 Val Fleuri, L-1526The Company\u2019s shares are traded on Euronext Paris stock exchange under the ISIN code FR0014000MR3 (ticker ERF) and theCompany has joined the CAC 40 index on 17 September 2021.", "dimensions": { "concept": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-1-2": { "value": "1. Significant accounting policiesThe significant accounting policies applied in the preparation of these Consolidated Financial Statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. 1.1. Basis of preparation Compliance with IFRS Pursuant to the European Regulation No. 1606/2002 of 19 July 2002, the Consolidated Financial Statements have been prepared in accordance with the International Financial Reporting Standards (hereinafter also IFRS) as issued by the International Accounting Standards Board (IASB) and endorsed in the European Union. These accounting policies have been consistently applied to all the years presented, unless otherwise stated. The Consolidated Financial Statements are presented in Euros, which is the presentation currency. Due to rounding, amounts may not add up precisely to the totals provided. Historical cost convention The Consolidated Financial Statements have been prepared under the historical cost convention, except for the following: \u25aa certain financial assets and liabilities (including derivative financial instruments), reference is made to Note 2.34;\u25aa defined benefit pensions plans \u2013 plan assets measured at fair value.Going concern The Directors have, at the time of approving the financial statements, a reasonable expectation that the Group have adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the financial statements. Change in presentation The Group has changed the breakdown presentation in the 2022 Consolidated Cash Flow Statement of some items to improve the readability of the cash flow statement. As a consequence, the comparative period has been restated without material impacts. In 2021, acquisition of the subsidiaries were presented net of cash acquired and net of proceeds from disposal in the Consolidated Cash Flow Statement. Due to the significant impact of the disposal of Digital Testing in 2022, the presentation of \u201cAcquisition of subsidiaries, net\u201d and \u201cProceeds from disposals of subsidiaries, net\u201d has been separated. In 2021, items \u201cPurchase of property, plant and equipment\u201d and \u201cchange in net working capital\u201d have been corrected for the capex trade payables change of the period for an amount of \u20ac13.1m. Non-cash net foreign exchange loss have also been corrected for \u20ac14.8m in the items \u201cNet effect of currency translation on cash and cash equivalents and bank overdrafts\u201d and in \u201cFinancial income and expense, net\u201d. 1.2. Significant accounting judgements and estimates The preparation of the Consolidated Financial Statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies, the reported amounts of assets, liabilities, revenues and expenses and the accompanying disclosures, and the disclosure of contingent liabilities. These estimates inherently contain a degree of uncertainty. Actual results may differ from these estimates under different assumptions or conditions. The Group evaluates these accounting judgements and estimates on an ongoing basis and bases the estimates on historical experience, current and expected future outcomes, third-party valuation and various other assumptions that the Group believes are 1.3. Basis of Consolidation The Consolidated Financial Statements comprise the financial statements of Eurofins Scientific SE and all the subsidiaries that the Group controls, i.e., when it is exposed or has rights to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Generally, there is a presumption that a majority of voting rights result in control. To support this presumption and in cases where the Group has less than a majority the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including the contractual arrangement(s) with the other vote holders of the investee, rights arising from other contractual arrangements and the Group\u2019s voting rights and potential voting rights. Subsidiaries Subsidiaries are fully consolidated from the date that control commences until the date that control ceases. They are no longer consolidated from the date such control ceases. All intercompany transactions and balances have been eliminated in the Consolidated Financial Statements. Unrealised losses are eliminated in the same way as unrealised gains, but only to the extent that there is no evidence of impairment. Associates Associates are all entities over which the Group has significant influence but no control. Significant influence is presumed with a shareholding of between 20% and 50% of the voting rights or when the Group has board representation through which it is able to exercise significant influence. Investments in associates are accounted for using the equity method and are initially recognised at cost.The carrying amount of an investment includes the carrying amount of goodwill identified on acquisition.Loss of control Upon loss of control, the Group derecognises the assets and liabilities of the subsidiary, any non-controlling interests and other components of equity (if any) related to the subsidiary. Any surplus or deficit arising from the loss of control is recognised in the Consolidated Income Statement. If the Group retains any interest in the previous subsidiary, such interest is measured at fair value at the date the control is lost. Subsequently it is accounted for as either an equity accounted investee or as a financial asset depending on the level of influence retained. Business combinations and goodwill Business combinations are accounted for using the acquisition method. Under the acquisition method, the identifiable assets acquired, liabilities assumed and any non-controlling interests in the acquiree are recognised at the acquisition date, which is the date on which control is transferred to the Group. The Group measures goodwill at the acquisition date as being the excess of: \u25aa Aggregate of the fair value of the consideration transferred and any recognised amount for non-controlling interests and anyprevious interest held;\u25aa over the net identifiable assets acquired and liabilities assumed.If the cost of acquisition is less than the fair value of the net assets of the subsidiary acquired, the difference is recognised directlyin the Consolidated Income Statement (bargain purchase or negative goodwill).reasonable under the circumstances. Existing circumstances and assumptions about future developments may change due to circumstances beyond the Group\u2019s control and are reflected in the assumptions if and when they occur. The Group revises material estimates if changes occur in the circumstances or if there is new information or experience on which an estimate was or can be based. The areas where the most significant judgements and estimates are made are: Judgements \u25aa Revenue recognition and determination of advancement for over time performance obligations;\u25aa Determination of control as part of business combination;\u25aa Determination of the lease term and more specifically the assessment whether a lease option to extend or cancel a leasein which the Group is a lessee is reasonably certain to be exercised or not;\u25aa Likelihood of occurrence of provisions, uncertain tax positions and contingent liabilities.Estimates \u25aa Assessment of the recoverable amount of goodwill and intangible assets;\u25aa Measurement of the recoverability of deferred tax assets;\u25aa Determination of amounts due from business acquisitions based on future cash flows;\u25aa Determination of fair values of acquired identifiable intangible assets as part of a business combination.For further discussion of these significant judgements and estimates, reference is made to the respective accounting policies and Notes within these Consolidated Financial Statements that relate to the above topics. Further judgement is applied when analysing impairments of goodwill and intangible assets that are performed annually and whenever a triggering event has occurred to determine whether the carrying value exceeds the recoverable amount. These analyses are generally based on estimates of discounted future cash flows. Furthermore, the Group applies judgement when actuarial assumptions are established to anticipate future events that are used in calculating post-employment benefit expenses and liabilities. These factors include assumptions with respect to interest rates, rates of increase in healthcare costs, rates of future compensation increases, turnover rates and life expectancy. If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, the acquirer reports in its financial statements provisional amounts for the items for which the accounting is incomplete and may adjust the provisional amounts recognised for a business combination during the measurement period (twelve months from the acquisition date). The Group measure non-controlling interests (NCI) at fair value (\u2018full goodwill method\u2019). Acquisition-related costs are expensed as incurred. Further information about the Group\u2019s main subsidiaries can be found in Note 3. The financial effect of the acquisition and disposal of subsidiaries of the current period is described in Note 2.26. Acquisition of and adjustments to non-controlling interests Transactions with non-controlling interests in controlled entities are treated as transactions with equity owners of the Group. For purchases from non-controlling interests, any difference between the consideration paid and the relevant share acquired is recorded in equity. Gains or losses on disposals to non-controlling interests are also recorded in equity. Amounts due from business acquisitions Amounts due for business acquisitions consist mainly of: \u25aa amounts due to former shareholders of acquired companies at the estimated fair value amount based on the achievement of objectives (in general based on revenue and / or a measure of operating profit); \u25aa the liability resulting from \u201cput and call options\u201d (part related to the transaction with non-controlling interests) at initial acquisition time. Amounts due for business acquisitions are accounted for at fair value of the expected cash flows at the acquisition date. The variation of the liability related to the time value of money is recorded in the Consolidated Income Statement as a finance cost. All re-estimations of the amounts due for business acquisitions of the purchase price are booked in the Consolidated Income Statement as an acquisition-related expense. If all or part of the acquisition price of certain acquired laboratories is paid in the Group\u2019s shares (new or existing shares): \u25aa the amount due is accounted for in \u201cAmounts due for business acquisitions\u201d in the case where the acquisition contract stipulates a fixed monetary amount payable in a variable number of the Group\u2019s shares (number to be calculated at the moment of payment); \u25aa the amount due is accounted for in \u201cretained earnings\u201d in the case where the acquisition contract stipulates a fixed number of the Group\u2019s shares. Amounts due from business acquisitions are estimated as follows: \u25aa In case of cross put and call options exercisable at a fixed price, the Group considers these instruments as being exercised from inception. Indeed, as the price is fixed, the risks and rewards are considered, in substance, to be transferred to the Group. As such, non-controlling interests are not recognised in the Consolidated Balance Sheet and the Consolidated Income Statement. \u25aa In case of cross put and call options at a variable price, the Group considers whether the risks and rewards are transferred to the Group: o Where it is determined that risks and rewards did not transfer to the Group, non-controlling interests are recognised in the Balance Sheet and the Income Statement. o Where it is determined that risks and rewards did transfer to the Group upon entering into the cross put and call options, non-controlling interests are not recognised in the Consolidated Balance Sheet and the Consolidated Income Statement. In addition, a financial liability reflecting the put option element of the transaction is recognised for an amount corresponding to the present value of the redemption amount of the put option. Such financial liability is recognised from the equity attributable to holders of the Group. 1.4. Revenue recognition Revenue recognised over time Revenue from services is recognised over a period of time as the Group transfers control of the services to the customer which is demonstrated by the customer simultaneously receiving and consuming the benefits provided by the Group. The amount of revenue is measured by reference to the progress made towards complete satisfaction of the performance obligation. Sample based service activities (excluding Clinical Diagnostic Testing activities) This activity is a repetitive business, generally with many relatively small transactions with short turnaround times ruled by short term contracts (turnaround time counted in days). These contracts for their vast majority do not include multiple performance obligations. The Group considers the input method to measure the progress for service rendered to its customers. The payment terms and conditions are most often standard, short term and highly predictable.Revenue is recorded based on the stage of completion of the services performed and net of incentives and rebates (if any). Study based activities This activity is mainly relying on medium term contracts. Revenue is recognised based on the stage of completion of the study until the delivery of the final report. Full Time Equivalent (FTE)-based activities This activity relates to Consulting activities and Professional Scientific Services. Revenue is recorded based on the stage of completion of the services performed. Revenue recognised at a point in time Product based activities Revenue from the sale of goods in the normal course of business is recognised at a point in time when the performance obligation is satisfied and it is based on the amount of the transaction price that is allocated to the performance obligation. The transaction price is the amount of the consideration to which the Group expects to be entitled in exchange for transferring the promised goods to the customer. The consideration expected by the Group may be fixed or variable. Revenue for the sale of goods is recognised when control of the asset is transferred to the buyer and only when it is highly probable that a significant reversal of revenue will not occur when uncertainties related to a variable consideration are resolved. Transfer of control varies depending on the individual terms of the contract of sale. Clinical Diagnostic Testing activities The Group recognises revenues at a point in time when the testing process is completed, and test results are reported to the ordering physician. The Group usually bills third-party payers under fee-for-service agreements. Revenue is recorded net of contractual discounts and generally based on contractual agreements. In case of absence of contractual agreement and / or uncertainty over the consideration to be received, a stand-alone selling price is estimated based on a statistical model which factors in historical collection rates based on cluster of payers showing similar aggregation characteristics. This model is regularly updated with the most recent trends and whenever required. Financing components and time value of money The Group does not expect to have any contracts where the period between the transfer of the promised goods or services to the customer and payment by the customer exceeds one year. Consequently, the Group does not adjust any of the transaction prices for the time value of money. 1.5. Intangible assets other than goodwill Acquired Intangible assets Separately acquired finite lived intangible assets are accounted for at cost. Intangible assets acquired as part of a business combination such as brands, customer relationships, technologies and other finite lived intangible assets are recognised at their fair value at the acquisition date. Acquired finite lived intangible assets are amortised using the straight-line method over their estimated useful life. The useful lives are reviewed annually. Development costs The directly attributable costs of producing identifiable and separable intangible assets (such as software development) are recognised as an intangible asset when they are controlled by the Group and it is probable that they will generate future economic benefits in excess of their cost over a period of more than one year. Other development expenditures and expenditures on research activities are recognised in the Consolidated Income Statement. Capitalised development expenditures are stated at cost less accumulated amortisation and impairment losses. Amortisation of capitalised development expenditures is charged to the Consolidated Income Statement on a straight line basis over the estimated useful lives of the intangible assets. 1.6. Impairment Impairment of goodwill and intangible assets Goodwill are not amortised but are tested for impairment annually and whenever impairment indicators require. Internal or external sources of information are considered indicators that an asset or a Cash Generating Unit (CGU) or groups of CGUs may be impaired. An impairment loss is recognised in the Consolidated Income Statement whenever and to the extent that the carrying amount of a cash generating unit exceeds the unit\u2019s recoverable amount. The recoverable amount is the higher of an asset\u2019s fair value less costs to sell and its value in use. Reference is made to Note 2.10 for further details. Intangible assets that are subject to amortisation (e.g., customer relationships, brands) are reviewed for impairment whenever triggering events or changes in circumstances indicate that the carrying value may not be recoverable. Impairment of non-financial assets other than goodwill, intangible assets, inventories, and deferred tax assets Non-financial assets other than goodwill, intangible assets, inventories and deferred tax assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets is assessed by a comparison of the carrying amount of said assets with the greater of their value in use and fair value less costs of disposal. Value in use is measured as the present value of future cash flows expected to be generated by the asset.Fair value less costs of disposal is measured as the amount obtained from a sale of an asset in an arm\u2019s length transaction, less costs of disposal.If the carrying amount of an asset is deemed not recoverable, an impairment charge is recognised in the amount by which the carrying amount of the asset exceeds the recoverable amount. The review for impairment is carried out at the level where cash flows occur that are independent of other cash flows. Impairment losses recognised in prior periods are assessed at each reporting date for any indication that the loss has decreased or no longer exists. An impairment loss is reversed if and to the extent that there has been a change in the estimates used to determine the recoverable amount. The loss is reversed only to the extent that the asset\u2019s carrying amount does not exceed the carrying amount that would have been recognised. Impairment of financial assets The Group recognises an allowance for expected credit losses (ECLs) for trade receivables, debt investments carried at fair value through other comprehensive income (FVTOCI) and amortised costs. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expect to receive. For all trade receivables and contract assets, the Group applies the IFRS 9 simplified approach to measuring ECLs. To measure the ECLs on trade receivables and contract assets, the Group takes into account credit-risk concentration, collective debt risk based on average historical losses as well as days past due. The Group also may factor in specific circumstances such as serious adverse economic conditions in a specific country or region, and other forward-looking information. The Group may also apply individual credit losses on identified trade account receivables or contract assets depending on individual circumstances. Trade receivables and contract assets are written off when there is no reasonable expectation of recovery of the asset, because of failure of a debtor to engage in a repayment plan, associated subsequent payments, bankruptcy or other form of receivership. 1.7. Leases The Group leases various offices, laboratories and cars. The Group determines whether an arrangement constitutes or contains a lease at inception, which is based on the substance of the arrangement. The arrangement constitutes or contains a lease if fulfilment is dependent on the use of a specific asset and the arrangement conveys a right to use the asset, even if that asset is not explicitly specified in the arrangement. Leases are recognised as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the Group. The right-of use asset is depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis. Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments: \u25aa fixed payments (including in-substance fixed payments) less any lease incentives receivable; \u25aa variable lease payments that are based on an index or a rate; \u25aa amounts expected to be payable by the lessee under residual value guarantees; \u25aa the exercise price of a purchase option if the lessee is reasonably certain to exercise that option; \u25aa payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option. The lease payments are discounted using the interest rate implicit of the lease. If that rate cannot be determined, the lessee\u2019s incremental borrowing rate at the lease commencement date is used, which is based on an assessment of interest rates the Group would have to pay to borrow funds in the relevant country, including the consideration of factors such as the nature of the asset and location, collateral, market terms and conditions, as applicable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset. Right-of-use assets are measured at cost comprising the following: \u25aa the amount of the initial measurement of lease liability; \u25aa any lease payments made at or before the commencement date less any lease incentives received; \u25aa any initial direct costs; restoration costs. The right-of-use assets are subsequently accounted for using principles for property, plant and equipment. Payments associated with short-term leases and leases of low-value assets are recognised on a straight-line basis as an expense in the Consolidated Income Statement. Short-term leases are leases with a lease term of 12 months or less. Low-value assets comprise IT-equipment and small items of office furniture considered to be of low value (i.e., less than \u20ac5,000). The Group determines the lease term as the non-cancellable term of the lease, together with any periods covered by an option to extend the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably certain not to be exercised. The Group applies judgement in evaluating whether it is reasonably certain to exercise the option to renew. That is, it considers all relevant factors that create an economic incentive for it to exercise the renewal. 1.8. Property, plant and equipment Property, plant and equipment are reported on the Consolidated Balance Sheet at their acquisition price, net of accumulated depreciation and impairment losses. The costs of property, plant and equipment comprise all directly attributable costs. Costs related to repair and maintenance activities are expensed in the period in which they are incurred unless leading to an extension of the original lifetime or capacity. Leasehold improvements are amortised using the straight-line method over the shorter of the lease term or the estimated useful life of the asset. 1.9. Financial Instruments Non-derivative financial assets Non-derivative financial assets comprise cash and cash equivalents, receivables and other financial assets. Depreciation is generally calculated using the straight-line method over the useful life of the asset. Recognition and initial measurement: Non-derivative financial assets are recognised when the Group becomes a party to the contractual provisions of the instrument. Purchases and sales of non-derivative financial assets in the normal course of business are accounted for at the trade date. Dividendand interest income are recognised when earned. Gains or losses, if any, are recorded in Finance income and Finance costs. Non-derivative financial assets are derecognised when the rights to receive cash flows from the asset have expired or the Group has transferred its rights to receive cash flows from the asset.assets at their fair value plus, in the case of a financial asset not measured at fair value through profit or loss (FVTPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVTPL are expensed in the Consolidated Income Statement. Classification and subsequent measurement: The Group classifies its non-derivative financial assets in the following measurement categories: \u25aa those that are measured subsequently at fair value; \u25aa those that are measured at amortised cost. In assessing the classification, the Group considers the business model for managing the financial assets and the contractual terms of the cash flows. At initial recognition, the Group measures non-derivative financial For assets measured at fair value, gains and losses will be recorded in either the Consolidated Income Statement or in Other Comprehensive Income (OCI). For investments in equity instruments that are not held for trading, classification will depend on whether the Group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through Other Comprehensive Income (FVTOCI). For investments in these equity instruments, the Group does not subsequently reclassify between FVTOCI and FVTPL. For debt investments, assets are reclassified between FVTOCI, FVTPL and amortised cost only when its business model for managing those assets changes. Cash and cash equivalents Cash and cash equivalents include cash balances, certain money market funds and short-term highly liquid investments with an original maturity of three months or less that are readily convertible into known amounts of cash. Receivables Receivable that are held to collect are subsequently measured at amortised cost and are subject to impairment (refer to impairment section in Note 1.6). Contract assets correspond to amounts accrued or due by customers for analysis in progress depending on the stage of completion of the analysis/work performed. For governmental organisations as well as healthcare insurance providers, in the case of some of its US clinical diagnostic testing services, the Group regularly assesses the state of its billing operations and the level of payer\u2019s reimbursements based on specific facts and circumstances and historical recoverability data in order to identify issues which may impact the collection of these receivables. When the financial asset is derecognised, the cumulative gain or loss previously recognised in OCI is reclassified from equity to the Consolidated Income Statement. Interest income from these financial assets is included in Financial income using the effective interest rate method. Debt instruments that do not meet the criteria for amortised cost or FVTOCI are measured at FVTPL. A gain or loss on a debt investment that is subsequently measured at FVTPL is recognised in the Consolidated Income Statement in the period in which it arises. Equity instruments For equity instruments that are not held for trading, the Group makes an irrevocable election at the time of initial recognition whether to account for the equity investment at FVTPL or FVTOCI. Where the Group has elected to present fair value gains and losses on equity investments in OCI, there is no subsequent reclassification of fair value gains and losses to the Consolidated Income Statement following the derecognition of the investment. Dividends from such investments continue to be recognised in the Consolidated Income Statement when the Group\u2019s right to receive payments is established. Other (non-)current financial assets Other (non-)current financial assets include both debt instruments and equity instruments. Debt instruments Debt instruments include those subsequently carried at amortised cost, those carried at FVTPL and those carried at FVTOCI. Classification depends on the Group\u2019s business model for managing the asset and the cash flow characteristics of the asset. Debt instruments that are held for collection of contractual cash flows, where those cash flows represent solely payments of principal and interest, are measured at amortised cost and are subject to impairment. Interest income from these financial assets is included in Finance income using the effective interest rate method. Financial assets with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payment of principal and interest. Debt instruments that are held for collection of contractual cash flows and for selling the financial assets, where the assets\u2019 cash flows represent solely payments of principal and interest, are measured at FVTOCI and are subject to impairment. Movements in the carrying amounts are taken through OCI, except for the recognition of impairment gains or losses, interest revenue and foreign exchange gains and losses, which are recognised in the Consolidated Income Statement. Debt and other financial liabilities Debt and other financial liabilities, excluding derivative financial liabilities and provisions, are initially measured at fair value and, in the case of debt and payables, net of directly attributable transaction costs. Debt and other financial liabilities are subsequently measured at amortised cost using the effective interest rate. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. Debt and other financial liabilities are derecognised when the obligation under the liability is discharged, cancelled or has expired. Equity Common shares are classified as equity. Incremental costs directly attributable to the issuance of shares are recognised as a deduction from equity. Where the Group purchases the Group\u2019s equity share capital (treasury shares), the consideration paid, including any directly attributable incremental transaction costs (net of income taxes), is deducted from equity attributable to the Group\u2019s equity holders until the shares are cancelled or reissued. Where such ordinary shares are subsequently reissued, any consideration received, net of any directly attributable incremental transaction costs and the related income tax effects, is included in equity attributable to the Group\u2019s equity holders. Dividends are recognised as a liability in the period in which they are declared and approved by shareholders. The income tax consequences of dividends are recognised when a liability to pay the dividend is recognised. Hybrid capital The structure of the hybrid capital ensures that it is recognised as a component of equity in accordance with IAS 32 as the conditions below are met: \u25aa No contractual obligation to redeem the instrument; \u25aa No contractual obligation to pay the coupon. Tax-deductible interest payments are not included in interest expense but accounted for in the same way as dividend obligations to shareholders. The distribution of coupon payments and the costs of issue are booked before tax in shareholders\u2019 equity. Reference is made to Note 2.20 for further detail about the Group\u2019s hybrid capital nature. Derivative financial instruments, including hedge accounting All derivative financial instruments are accounted for at the trade date and classified as current or non-current assets or liabilities based on the maturity date or the early termination date. The Group measures all derivative financial instruments at fair value that is derived from the market prices of the instruments, calculated on the basis of the present value of the estimated future cash flows based on observable interest yield curves, basis spread, credit spreads and foreign exchange rates, or derived from option pricing models, as appropriate. Gains or losses arising from changes in fair value of derivative financial instruments are recognised in the Consolidated Income Statement, except for derivatives that are highly effective and qualify for cash flow or net investment hedge accounting. Changes in the fair value of a derivative that is highly effective and that is designated and qualifies as a cash flow hedge are recorded in OCI until the Consolidated Income Statement are affected by the variability in cash flows of the designated hedged item. To the extent that the hedge is ineffective, changes in the fair value are recognised in the Consolidated Income Statement. The Group formally assesses, both at the hedge\u2019s inception and on an ongoing basis, whether the derivative financial instruments that are used in hedging transactions are highly effective in offsetting changes in fair values or cash flows of hedged items. When it is established that a derivative is not highly effective as a hedge or that it has ceased to be a highly effective hedge, the Group discontinues hedge accounting prospectively. When hedge accounting is discontinued because it is expected that a forecasted transaction will not occur, the Group continues to carry the derivative on the Consolidated Balance Sheet at its fair value, and gains and losses that were accumulated in OCI are recognised immediately in the same line item as they relate to in the Consolidated Income Statement. Foreign currency differences arising upon retranslation of financial instruments designated as a hedge of a net investment in a foreign operation are recognised directly in the currency translation differences reserve through OCI, to the extent that the hedge is effective. To the extent that the hedge is ineffective, such differences are recognised in the Consolidated Income Statement. 1.10. Fair value measurements The Group classifies fair value measurements using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels: \u25aa Quoted prices (unadjusted) in active markets for identical assets or liabilities (Level 1 \u2013 Marketable securities, Derivative financial instruments assets, Listed bonds); \u25aa Inputs other than quoted prices included within Level 1 that are observable for the asset or the liability, either directly (i.e., such as prices) or indirectly (i.e., derived from prices) (Level 2 \u2013 Derivative financial instruments liabilities); Inputs for the asset or liability that are not based on observable market data (Level 3). 1.11. Inventories Inventories are stated at the lower of cost or net realisable value. The cost of inventories comprises all costs of purchase, cost of conversion and other costs incurred in bringing the inventories to their present location and condition. The cost of inventories is determined using the first-in, first-out (FIFO) method. The net realisable value represents the estimated sales price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Write-downs of inventories which are considered obsolete or slow moving are computed taking into account their expected future utilisation and their net realisable value. The Group also considers other reasons that the cost of inventories may not be recoverable such as damage, obsolescence, expiration date or declines in selling price. 1.12. Provisions Provisions are recognised if as a result of past events, the Group has a present legal or constructive obligation, the amount can be estimated reliably and it is more likely than not that an outflow of resources will be required to settle the obligation. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax discount rate that reflects current market assessments of the time value of money. 1.13. Income taxes Income taxes comprise current, non-current and deferred tax. Income tax is recognised in the Consolidated Income Statement except to the extent that it relates to items recognised directly within equity or in Other Comprehensive Income. Current tax is the expected taxes payable on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. In cases where it is concluded it is not probable that tax authorities will accept a tax treatment, the effect of the uncertainty is reflected in the recognition and measurement of tax assets and liabilities or, alternatively, a provision is made for the amount that is expected to be settled, where this can be reasonably estimated. This assessment relies on estimates and assumptions and may involve a series of judgements about future events. New information may become available that causes the Group to change its judgement regarding adequacy of existing tax assets and liabilities. Such changes to tax assets and liabilities will impact the income tax expense in the period during which such a determination is made. Deferred tax assets and liabilities are recognised, using the Consolidated Balance Sheet method, for the expected tax consequences of temporary differences between the carrying amounts of assets and liabilities and the amounts used for taxation purposes. Deferred taxes are measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity or on different taxable entities, but the Group intends to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realised simultaneously A deferred tax asset is recognised for unused tax losses, tax credits and deductible temporary differences to the extent that it is probable that there will be future taxable profits against which they can be utilised. The ultimate realisation of deferred tax assets is dependent upon the generation of future taxable income in the countries where the deferred tax assets originated and during the periods when the deferred tax assets become deductible. The Group considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Foreign currency transactions The financial statements of all Group entities are measured using the currency of the primary economic environment in which the entity operates (\u201cthe functional currency\u201d). The Euro (\u20ac) is the functional currency of the Group and the presentation currency of the Consolidated Financial Statements. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions or the valuation in cases where items are remeasured. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Consolidated Income Statement, except when deferred in Other comprehensive income as qualifying cash flow hedges and qualifying net investment hedges. Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are retranslated to the functional currency using the exchange rate at the date the fair value was determined. Non-monetary items in a foreign currency that are measured based on historical cost are translated using the exchange rate at the transaction date. Foreign operations The assets and liabilities of foreign operations, including goodwill and fair value adjustments arising on acquisition, are translated to Euros at the exchange rates prevailing at the reporting date. The income and expenses of foreign operations are translated to Euros at the exchange rates prevailing at the dates of the transactions. Foreign currency differences arising upon translation of foreign operations into Euros are recognised in Other Comprehensive Income and presented as part of currency translation reserves in Shareholders Equity. When a foreign operation is disposed of such that control, significant influence or joint control is lost, the cumulative amount in the currency translation differences related to the foreign operation is reclassified to the Consolidated Income Statement as part of the gain or loss on disposal. 1.15. Non-current assets held for sale Non-current assets that are expected to be recovered primarily through sale rather than through continuing use are classified as held for sale. Non-current assets held for sale are carried at the lower of carrying amount or fair value less cost of disposal. Any gain or loss from disposal, together with the results of these operations until the date of disposal, is reported separately as discontinued operations. The financial information of discontinued operations is excluded from the respective captions in the Consolidated Financial Statements and related Notes for all periods presented. Comparatives in the Consolidated Balance Sheet are not represented when a non-current asset is classified as held for sale. Comparatives are represented for presentation of discontinued operations in the Consolidated Cash Flow Statement and Consolidated Income Statement. 1.16. Employee benefits A defined-contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. Obligations for contributions to defined-contribution pension plans are recognised as an employee benefit expense in the Consolidated Income Statement in the periods during which services are rendered by employees. A defined-benefit plan is a post-employment benefit plan other than a defined-contribution plan. Plans for which the Group has no legal or constructive obligation to pay further amounts, but to which it does pay non-fixed contributions, are also treated as a defined-benefit plan. The net pension asset or liability recognised in the Consolidated Balance Sheet in respect of defined-benefit post-employment plans is the fair value of plan assets less the present value of the projected defined-benefit obligation at the Consolidated Balance Sheet date. The defined-benefit obligation is calculated annually by qualified actuaries using the projected unit credit method. Recognised assets are limited to the present value of any reductions in future contribution or any future refunds. The net pension liability is presented as a long-term provision; no distinction is made for the short-term portion. Pension costs in respect of defined-benefit post-employment plans primarily represent the increase of the actuarial present value of the obligation for post-employment benefits based on employee service during the year and the interest on the net recognised asset or liability in respect of employee service in previous years. Remeasurements of the net defined-benefit asset or liability comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (excluding interest). The Group recognises all remeasurements in Other Comprehensive Income. The Group recognises gains and losses on the settlement of a defined-benefit plan when the settlement occurs. The gain or loss on settlement is the difference between the present value of the defined-benefit obligation being settled, as determined on the date of settlement, and the settlement price, including any plan assets transferred and any payments made directly by the Group in connection with the settlement. Past service costs arising from the introduction of a change to the benefit payable under a plan or a significant reduction of the number of employees covered by a plan (curtailment) are recognised in full in the Consolidated Income Statement. The Group\u2019s net obligation in respect of long-term employee benefits is the amount of future benefit that employees have earned in return for their service in the current and prior periods, such as jubilee entitlements. That benefit is discounted to determine its present value. Remeasurements are recognised in the Consolidated Income Statement in the period in which they arise. Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. The Group recognises a liability and an expense for bonuses and incentives based on a formula that takes into consideration the profit attributable to the Group\u2019s shareholders after certain adjustments. 1.17. Share based payments Please refer to Note 2.27 for further details about the different plans. The cost of equity-settled transactions is determined by the fair value at the date when the grant is made using an appropriate valuation model. The grant-date fair value of equity-settled share-based payment awards granted to employees is recognised as personnel expense, with a corresponding increase in equity, over the vesting period of the award. The cumulative expense recognised for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Group\u2019s best estimate of the number of equity instruments that will ultimately vest. The expense or credit in the statement of income for a period represents the movement in cumulative expense recognised at the beginning and end of that period. Service and non-market performance conditions are not taken into account when determining the grant-date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Group\u2019s best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant-date fair value. No expense is recognised for awards that do not ultimately vest because non-market performance and/or service conditions have not been met. When an award is cancelled by the entity or by the counterparty, any remaining element of the fair value of the award is expensed immediately through profit or loss. The dilutive effect of outstanding options and shares is reflected as additional share dilution in the computation of diluted earnings per share. 1.18. Finance income and costs Financial income comprises interest income on funds invested (including financial assets), dividend income, net gains on the disposal of financial assets, net fair value gains on financial assets at FVTPL, net gains on the remeasurement to fair value of any pre-existing interest in an acquiree, and net gains on foreign exchange impacts that are recognised in the Consolidated Income Statement. Interest income is recognised on an accrual basis in the Consolidated Income Statement, using the effective interest method. Dividend income is recognised in the Consolidated Income Statement on the date that the Group\u2019s right to receive payment is established, which in the case of quoted securities is normally the ex-dividend date. Financial expenses comprise interest expenses on borrowings, unwinding of the discount on provisions and contingent consideration, losses on disposal of financial assets, net fair value losses on financial assets at FVTPL, impairment losses recognised on financial assets (other than trade receivables), net interest expenses related to defined-benefit plans, interest on lease liabilities and net losses on foreign exchange impacts that are recognised in the Consolidated Income Statement. 1.19. Earnings per share The Group presents basic and diluted earnings per share (EPS) data for its common shares. Basic EPS is calculated by dividing the Net income (loss) attributable to shareholders by the weighted average number of common shares outstanding during the period, adjusted for own shares held. Diluted EPS is determined by adjusting the Net income (loss) attributable to shareholders and the weighted average number of common shares outstanding during the period, adjusted for own shares held, for the effects of all dilutive potential common shares, which comprises forward purchase contracts, restricted shares, performance shares and share options granted to employees. 1.20. Alternative performance measures (APM) The Group is providing in the Consolidated Financial Statements certain alternative performance measures (non-IFRS information). APMs used in the Consolidated Income Statement Adjusted results \u2013 reflect the ongoing performance of the mature and recurring activities excluding \u201cseparately disclosed items\u201d. Separately disclosed items (SDI) \u2013 include: \u25aa one-off costs from integration and reorganisation; \u25aa discontinued operations; \u25aa other non-recurring income and costs; \u25aa temporary losses and other costs related to network expansion, start-ups and new acquisitions undergoing significant restructuring; \u25aa share-based payment charge; \u25aa acquisition-related expenses, net \u2013 impairment of goodwill, amortisation/impairment of acquired intangible assets, negative goodwill, transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions; \u25aa gain and loss on disposal of subsidiaries, net; \u25aa net finance costs related to borrowing and investing excess cash and one-off financial effects (net of finance income); \u25aa net finance costs related to hybrid capital; \u25aa and the related tax effects. Details are provided in Notes 1.21 and 2.5. EBITDA \u2013 Earnings before interest, taxes, depreciation and amortisation, share-based payment charge, acquisition-related expenses, net and gain and loss on disposal of subsidiaries, net. EBITAS \u2013 EBITDA less depreciation and amortisation. EBIT \u2013 EBITAS less share-based payment charge, acquisition-related expenses, net and gain and loss on disposal of subsidiaries, net. These measures exclude certain items because of the nature of these items and the impact they have on the analysis of the underlying business performance and trends. The Group shows EBITDA, EBITAS, EBIT as defined in the Notes to the Consolidated Income Statement with the objective to be consistent with the information used in internal Group reporting to measure the performance of Group companies and information published by other comparable companies. APMs used in the Consolidated Cash flow Statement Net capex \u2013 Purchase, capitalisation of intangible assets, purchase of property, plant and equipment, less proceeds from disposals of such assets less capex trade payables change of the period. Free Cash Flow to the Firm \u2013 Net cash provided by operating activities, less Net capex. APMs used in the Notes Net debt \u2013 Current and non-current borrowings, less Cash and cash equivalents (Note 2.17). Net working capital \u2013 Inventories, trade receivables and contract assets, prepaid expenses and other current assets less trade accounts payable, contract liabilities and other current liabilities excluding accrued interest receivable and payable (Note 2.25). Free Cash Flow to Equity \u2013 Free Cash Flow to the Firm, less disposal/(acquisition) of investments, financial assets and derivative financial instruments, net, and after interests and premium paid net of interest received. Free cash flow to Equity does not take into account the dividends paid to shareholders and non-controlling interests as well as earnings paid to hybrid capital holders (Note 2.29). The Group believes that providing these APMs enhances investors\u2019 understanding of the Group\u2019s core operating results and future prospects, consistent with how the Group measures and forecasts the Group\u2019s performance, especially when comparing such results to previous periods or objectives and to the performance of our competitors. This enables the Group to demonstrate the underlying profitability of the business \u2013 i.e., what the performance would be if the investments as described in Note 1.21 were not undertaken. In the interest of full transparency, the Group discloses both the adjusted results (i.e., without the separately disclosed items) and full reported results (i.e., including the separately disclosed items). This information should be considered in addition to, but not in lieu of, information prepared in accordance with IFRS. 1.21. Mature scope and Separately disclosed items In order to present the performance of the Group in a clear, consistent and comparable format, certain items are disclosed separately in the Consolidated Income Statement. Mature scope Mature scope excludes start-ups and acquisitions in significant restructuring. A business will generally be considered mature when: i) The Group\u2019s systems, structure and processes have been deployed; ii) It has been audited, accredited, qualified and used by the relevant regulatory bodies and the targeted client base; iii) It no longer requires above-average annual capital expenditures, exceptional restructuring or abnormally large costs with respect to their current revenues for deploying new Group IT systems. The list of entities classified as mature is reviewed at the beginning of each year and is relevant for the whole year. In FY 2022, 96% of total Group revenues were included in the mature scope (96% as FY 2021). Separately disclosed items Separately disclosed items is defined in Note 1.20 (see details in Note 2.5). One-off costs from integration, reorganisation, discontinued operations and other non-recurring income and costs One-off costs from integration, reorganisation costs, such as reducing overhead and consolidating facilities, are included in the separately disclosed items as the Group believes that these effects are not indicative of our normal operating income and expenses. Discontinued operations are a component of the Group\u2019s core business or product lines that have been disposed of, or liquidated; or a specific business unit or a branch of a business unit that has been shut down or terminated, and are reported separately from continued operations. Other non-recurring income and costs are also disclosed separately, as they are either isolated or cannot be expected to occur again with any regularity or predictability and as the Group believes they are not indicative of the Group\u2019s normal operating gains and losses. These include gains or losses on significant litigation-related matters. Temporary losses and other costs related to network expansion, start-ups and new acquisitions undergoing significant restructuring Network expansion, start-ups or acquisitions in significant restructuring are new companies or business activities established to develop an existing business model, transfer technology or a specific strategy. They are generally greenfield operations, or, in certain cases, newly acquired businesses bought to achieve a target market share in a given geography that are not operating optimally, but that have the potential to operate efficiently and profitably once restructured or reorganised to the Group\u2019s model. However, the reorganisation measures required are so large that they have a significant negative impact on the ongoing business of the Group. Start-ups are generally undertaken in new markets, and in particular emerging markets, where there are often limited viable options for acquisitions or in developed markets when Eurofins transfers technology developed by its R&D and Competence Centers abroad. Given that the costs or operating losses incurred in the start-up or restructuring phase are temporary and should cease within a 3-5 year period on average, it is the Group\u2019s view that they should be disclosed separately. Whilst the timeframe for these temporary costs or losses is finite, and should cease gradually, the businesses should continue to generate revenues for the Group indefinitely, and these are therefore not considered temporary. Start-up activities go through various stages of development before reaching optimal efficiency levels and can take several years to become profitable. The development process includes the creation or construction of the laboratory, hiring the appropriate staff, obtaining relevant accreditations, deployment of the IT infrastructure and dedicated IT solutions, developing the sales and marketing channels, and building up volumes and the revenue base. In general, start-up periods last for 2 to 3 years in mature markets and 2 to 5 years in emerging markets. The list of entities classified as start-ups or acquisitions in significant restructuring is reviewed at the beginning of each year and is relevant for the whole year. Temporary losses and other costs related to network expansion, start-ups and new acquisitions undergoing significant restructuring are included in the separately disclosed items as these are investments in future growth prospects and distort the judgement of the underlying performance of the mature businesses of the Group. Depreciation costs specific to start-ups and new acquisitions undergoing significant restructuring The line corresponds to the line \u201cdepreciation\u201d of the entities classified as start-ups or acquisitions in significant restructuring. Share-based payment charge and acquisition-related expenses, net Separately disclosed items also include share-based payment charge, impairment of goodwill, and amortisation/impairment of acquired intangible assets, recording of negative goodwill as well as income from reversal of such costs and from unused amounts due for business acquisitions as all these transactions are without cash impact in the Consolidated Financial Statements. Furthermore, the amortisation of acquired intangible assets is included because a significant portion of the purchase price for acquisitions may be allocated to intangible assets. All transaction costs and long-term incentives/ retention bonus related to acquisitions during the year are disclosed separately. There are a number of different professionals that may assist throughout the process of planning, negotiating, performing due diligence, and closing of the transaction. Examples include intermediaries (investment bankers or business brokers), legal professionals (lawyers) and accounting professionals. These costs are specific and directly related to the transaction and are usually paid at or around the closing of the relevant transaction. These costs are disclosed separately also due to the fact that if the Group would stop its external growth, i.e., acquisitions, and would only focus on internal growth, most of these costs would disappear instantly and the EBIT would increase mechanically. Furthermore, these costs do not correspond to the Group\u2019s business of providing analytical solutions to its customers. Gain and loss on disposal of subsidiaries, net These include gains or losses on the disposal of a business or real estate to third party (e.g. Digital Testing in 2022) or liquidation. Net finance costs related to borrowing and investing excess cash and one-off financial effects (net of finance income) and related to hybrid capital Net finance costs related to excess cash and one-off financial effects correspond to cash earmarked for future investments/ acquisitions and not needed for the existing business. Excess cash is calculated as the difference between the total Consolidated cash balance at month-end and the minimum liquidity position required to operate the business, as based on a percentage of sales (considered to be 5% of the annualised revenues of the rolling last three months) and split proportionately between Equity, Gross financial debt and hybrid capital. The finance cost related to excess cash is then calculated using the weighted average interest rate of each debt instrument and coupon on hybrid capital on the Balance Sheet of the Group. Tax effect from the adjustment of all separately disclosed items On all items listed above, the related tax effects are calculated. Total impact on earnings attributable to hybrid capital investors This item corresponds to the Net finance costs related to hybrid capital excess cash. The Group believes that the separate disclosure of these items enhances investors\u2019 understanding of the Group\u2019s core operating results and future prospects and allows better comparisons of operating results which are consistent over time and with peer companies. 1.22. Application of standards, amendments and interpretations Standards, amendments and interpretations adopted by the European Union and effective as of 1 January 2022 The accounting policies applied for the preparation of these Consolidated Financial Statements are consistent with those applied in the preparation of Consolidated financial statements for the year ended 31 December 2021. Other standards, amendments and interpretations newly applicable as of 1 January 2022 Other standards, amendments and interpretations newly applicable as of 1 January 2022 have no material impact on these Consolidated Financial Statements: \u25aa Reference to the Conceptual Framework - Amendment to IFRS 3 \u25aa Property, Plant and Equipment: Proceeds before intended Use - Amendment to IAS 16 \u25aa Onerous Contracts - Cost of fulfilling a contract - Amendment to IAS 37 \u25aa AIP IFRS 1 First time Adoption of International Financial Reporting Standards - Subsidiary as a first-time adopter \u25aa AIP IFRS 9 Financial Instruments - Fees in the \u201810 per cent\u2019 test for derecognition of financial liabilities \u25aa AIP IAS 41 Agriculture - Taxation in Fair value measurement New standards and interpretations not yet adopted The following pronouncements have been issued as of 31 December 2022 with mandatory application from 1 January 2023. They have not been early adopted by the Group: \u25aa IFRS 17 Insurance contracts \u25aa Classification of Liabilities as Current or Non-current - Amendments to IAS 1 \u25aa Definition of Accounting Estimates - Amendment to IAS 8 \u25aa Disclosure of Accounting Policies - Amendments to IAS 1 and IFRS Practice Statement 2 \u25aa Deferred Tax related to Assets and Liabilities arising from a single transaction - Amendment to IAS 12 These standards are not expected to have a material impact on the Group\u2019s Consolidated Financial Statements in the current or future reporting periods and on foreseeable future transactions. 1.23. COVID-19 pandemic and geopolitical instability COVID-19 and recent geopolitical events have impacted the economy and financial markets globally. The Group\u2019s operational performance was temporarily affected by COVID-19-related measures in China in 2022. The Group\u2019s exposure to Russia and Ukraine is limited (Note 2.30 Country risks). As a consequence, these condensed consolidated financial statements were prepared with particular attention to (i) the impairment of non-current assets, (ii) the appropriateness of the allowance for trade receivables, unbilled revenue and work in progress, (iii) the level of provision for risks, as well as (iv) accounting for government grants. No material impacts were recognized in these condensed consolidated financial statements, except those listed in Notes 2.9, 2.10, 2.14 and 2.40. 2.1. Segment information Operating segments are components of the Group\u2019s business activities about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (\u201cCODM\u201d). The Group is very decentralised with a large number of small and medium size companies in many countries. For practical reasons, the sets of information provided to the CODM, who is the Chief Executive Officer of the Group, aggregate these legal entities based on geographical areas and leadership structure. This aggregation can vary over time depending on changes in management, organisation or leadership. The rapid evolving nature of the Group also results in a constant adaptation of the matrix of its organisation. When necessary, the CODM may review financial information at a more disaggregated level. As required by IFRS 8 Operating Segments, Eurofins has three reportable segments: Europe, North America and Rest of the World. Europe is the combination of three reporting segments (groups of Cash Generating Units): France, DACH countries (Germany, Austria and Switzerland) and Other European Countries (OEC). Other European Countries include Benelux, Nordic Region, UK and Ireland, Southern Europe and Central & Eastern Europe. North America corresponds to the U.S. and Canada. As Eurofins still generates modest revenues in Asia and Middle East, South America, Australia and New Zealand, those 3 regions that represent future growth potential are followed internally in a single segment \u201cRest of the World\u201d. The key segmental performance measures are the EBITDA and EBITAS, which Management believes are the most relevant measure to evaluate the financial performance of the reportable segments. Depreciation on fixed assets is calculated using the straight-line method to write off their cost to their residual values over their estimated useful lives as follows: \u25aa Buildings and leasehold improvements 5-20 years \u25aa Machinery and laboratory equipment 5 years \u25aa Office and IT equipment, furniture and vehicles 3-5 years \u25aa Right of Use over the lease period. Lands represent a value of \u20ac158m as of 31 December 2022 not depreciated as deemed to have an indefinite life. The expected useful lives of the intangible assets excluding goodwill are as follows: \u25aa Software development costs capitalised and software licences are amortised over their estimated useful life (maximum period of 3 years). \u25aa Customer relationships are amortised on a straight-line basis over their estimated useful lives (maximum period of 13 years). For outsourcing deals signed with a sales contract, the amortisation period is aligned with the duration of the contract. \u25aa Technology and other are amortised on a straight-line basis over their estimated useful lives (maximum period of 15 years). \u25aa Tradename recognised on acquisitions are amortised on a systematic basis over their estimated useful lives (maximum period of 25 years). 2.37. Related-party transactions Transactions between the Company and its subsidiaries, which are related parties of the Group, are made at arm\u2019s length conditions and have been eliminated in the consolidation process and are not disclosed in the Notes. ", "dimensions": { "concept": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-2-2": { "value": "1.1. Basis of preparation Compliance with IFRS Pursuant to the European Regulation No. 1606/2002 of 19 July 2002, the Consolidated Financial Statements have been prepared in accordance with the International Financial Reporting Standards (hereinafter also IFRS) as issued by the International Accounting Standards Board (IASB) and endorsed in the European Union. These accounting policies have been consistently applied to all the years presented, unless otherwise stated. The Consolidated Financial Statements are presented in Euros, which is the presentation currency. Due to rounding, amounts may not add up precisely to the totals provided. Historical cost convention The Consolidated Financial Statements have been prepared under the historical cost convention, except for the following: \u25aa certain financial assets and liabilities (including derivative financial instruments), reference is made to Note 2.34;\u25aa defined benefit pensions plans \u2013 plan assets measured at fair value.Going concern The Directors have, at the time of approving the financial statements, a reasonable expectation that the Group have adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the financial statements. Change in presentation The Group has changed the breakdown presentation in the 2022 Consolidated Cash Flow Statement of some items to improve the readability of the cash flow statement. As a consequence, the comparative period has been restated without material impacts. In 2021, acquisition of the subsidiaries were presented net of cash acquired and net of proceeds from disposal in the Consolidated Cash Flow Statement. Due to the significant impact of the disposal of Digital Testing in 2022, the presentation of \u201cAcquisition of subsidiaries, net\u201d and \u201cProceeds from disposals of subsidiaries, net\u201d has been separated. In 2021, items \u201cPurchase of property, plant and equipment\u201d and \u201cchange in net working capital\u201d have been corrected for the capex trade payables change of the period for an amount of \u20ac13.1m. Non-cash net foreign exchange loss have also been corrected for \u20ac14.8m in the items \u201cNet effect of currency translation on cash and cash equivalents and bank overdrafts\u201d and in \u201cFinancial income and expense, net\u201d. ", "dimensions": { "concept": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-2-3": { "value": "1.1. Basis of preparation Compliance with IFRS Pursuant to the European Regulation No. 1606/2002 of 19 July 2002, the Consolidated Financial Statements have been prepared in accordance with the International Financial Reporting Standards (hereinafter also IFRS) as issued by the International Accounting Standards Board (IASB) and endorsed in the European Union. These accounting policies have been consistently applied to all the years presented, unless otherwise stated. The Consolidated Financial Statements are presented in Euros, which is the presentation currency. Due to rounding, amounts may not add up precisely to the totals provided. ", "dimensions": { "concept": "ifrs-full:StatementOfIFRSCompliance", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-4-3": { "value": "Going concern The Directors have, at the time of approving the financial statements, a reasonable expectation that the Group have adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the financial statements. ", "dimensions": { "concept": "ifrs-full:DisclosureOfGoingConcernExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-5-3": { "value": "Change in presentation The Group has changed the breakdown presentation in the 2022 Consolidated Cash Flow Statement of some items to improve the readability of the cash flow statement. As a consequence, the comparative period has been restated without material impacts. In 2021, acquisition of the subsidiaries were presented net of cash acquired and net of proceeds from disposal in the Consolidated Cash Flow Statement. Due to the significant impact of the disposal of Digital Testing in 2022, the presentation of \u201cAcquisition of subsidiaries, net\u201d and \u201cProceeds from disposals of subsidiaries, net\u201d has been separated. In 2021, items \u201cPurchase of property, plant and equipment\u201d and \u201cchange in net working capital\u201d have been corrected for the capex trade payables change of the period for an amount of \u20ac13.1m. Non-cash net foreign exchange loss have also been corrected for \u20ac14.8m in the items \u201cNet effect of currency translation on cash and cash equivalents and bank overdrafts\u201d and in \u201cFinancial income and expense, net\u201d. ", "dimensions": { "concept": "ifrs-full:DisclosureOfReclassificationsOrChangesInPresentationExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-6-2": { "value": "1.2. Significant accounting judgements and estimates The preparation of the Consolidated Financial Statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies, the reported amounts of assets, liabilities, revenues and expenses and the accompanying disclosures, and the disclosure of contingent liabilities. These estimates inherently contain a degree of uncertainty. Actual results may differ from these estimates under different assumptions or conditions. The Group evaluates these accounting judgements and estimates on an ongoing basis and bases the estimates on historical experience, current and expected future outcomes, third-party valuation and various other assumptions that the Group believes are reasonable under the circumstances. Existing circumstances and assumptions about future developments may change due to circumstances beyond the Group\u2019s control and are reflected in the assumptions if and when they occur. The Group revises material estimates if changes occur in the circumstances or if there is new information or experience on which an estimate was or can be based. The areas where the most significant judgements and estimates are made are: Judgements \u25aa Revenue recognition and determination of advancement for over time performance obligations;\u25aa Determination of control as part of business combination;\u25aa Determination of the lease term and more specifically the assessment whether a lease option to extend or cancel a leasein which the Group is a lessee is reasonably certain to be exercised or not;\u25aa Likelihood of occurrence of provisions, uncertain tax positions and contingent liabilities.Estimates \u25aa Assessment of the recoverable amount of goodwill and intangible assets;\u25aa Measurement of the recoverability of deferred tax assets;\u25aa Determination of amounts due from business acquisitions based on future cash flows;\u25aa Determination of fair values of acquired identifiable intangible assets as part of a business combination.For further discussion of these significant judgements and estimates, reference is made to the respective accounting policies and Notes within these Consolidated Financial Statements that relate to the above topics. Further judgement is applied when analysing impairments of goodwill and intangible assets that are performed annually and whenever a triggering event has occurred to determine whether the carrying value exceeds the recoverable amount. These analyses are generally based on estimates of discounted future cash flows. Furthermore, the Group applies judgement when actuarial assumptions are established to anticipate future events that are used in calculating post-employment benefit expenses and liabilities. These factors include assumptions with respect to interest rates, rates of increase in healthcare costs, rates of future compensation increases, turnover rates and life expectancy. ", "dimensions": { "concept": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-6-3": { "value": "1.2. Significant accounting judgements and estimates The preparation of the Consolidated Financial Statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies, the reported amounts of assets, liabilities, revenues and expenses and the accompanying disclosures, and the disclosure of contingent liabilities. These estimates inherently contain a degree of uncertainty. Actual results may differ from these estimates under different assumptions or conditions. The Group evaluates these accounting judgements and estimates on an ongoing basis and bases the estimates on historical experience, current and expected future outcomes, third-party valuation and various other assumptions that the Group believes are reasonable under the circumstances. Existing circumstances and assumptions about future developments may change due to circumstances beyond the Group\u2019s control and are reflected in the assumptions if and when they occur. The Group revises material estimates if changes occur in the circumstances or if there is new information or experience on which an estimate was or can be based. The areas where the most significant judgements and estimates are made are: Judgements \u25aa Revenue recognition and determination of advancement for over time performance obligations;\u25aa Determination of control as part of business combination;\u25aa Determination of the lease term and more specifically the assessment whether a lease option to extend or cancel a leasein which the Group is a lessee is reasonably certain to be exercised or not;\u25aa Likelihood of occurrence of provisions, uncertain tax positions and contingent liabilities.Estimates \u25aa Assessment of the recoverable amount of goodwill and intangible assets;\u25aa Measurement of the recoverability of deferred tax assets;\u25aa Determination of amounts due from business acquisitions based on future cash flows;\u25aa Determination of fair values of acquired identifiable intangible assets as part of a business combination.For further discussion of these significant judgements and estimates, reference is made to the respective accounting policies and Notes within these Consolidated Financial Statements that relate to the above topics. Further judgement is applied when analysing impairments of goodwill and intangible assets that are performed annually and whenever a triggering event has occurred to determine whether the carrying value exceeds the recoverable amount. These analyses are generally based on estimates of discounted future cash flows. Furthermore, the Group applies judgement when actuarial assumptions are established to anticipate future events that are used in calculating post-employment benefit expenses and liabilities. These factors include assumptions with respect to interest rates, rates of increase in healthcare costs, rates of future compensation increases, turnover rates and life expectancy. Goodwill Impairment testing The calculation model description is provided in Note 1.6. For impairment testing, goodwill is allocated to cash generating units (typically one level below segment level, i.e., at the business level), which represent the lowest level at which the goodwill is monitored internally for management purposes. Unless otherwise noted, the basis of the recoverable amount used in the annual impairment tests for the units disclosed further in this Note is the value in use. Key assumptions used in the value in use impairment tests for the units were sales growth rates, EBITDA margin and the rates used for discounting the projected cash flows (WACC). These cash flow projections were determined using Eurofins management\u2019s internal forecasts that cover an initial period from 2023 to 2027 after which a terminal value was calculated for 2028. For terminal value calculation, growth rates were capped at a historical long-term average growth rate. This methodology is consistent with the methodology applied in prior periods. The sales growth rates and EBITDA margin used to estimate cash flows are based on past performance, external market growth assumptions and industry long-term growth averages. Management believes that the volume of sales in each period is the main driver for revenue and costs. Eurofins takes into consideration inflation on the profits, margins, liquidity as well as on their overall level of activity in its assumptions. The rates used for discounting the projected cash flows in goodwill impairment testing is based on a weighted cost of capital (WACC), which in turn is based on business-specific inputs along with other inputs. The WACC is based on post-tax cost of equity and cost of debt, and is further calculated based on market data and inputs to accurately capture changes to the time value of money, such as the risk-free interest rate, the beta factor and country risk premium. In order to properly reflect the different risk-profiles of different businesses, a WACC is determined for each group of CGUs. The key assumptions used for value in use calculations and values in use are as follows: 12In \u20ac millions Long term growth ratePre-tax discount rateValue in use 2022 2021 2022 2021 2022 2021 North America 2.50% 2.00% 9.4% 6.0% 7,367 10,631 France 2.00% 2.00% 10.3% 6.6% 1,499 2,850 DACH 2.00% 2.00% 9.8% 6.2% 969 2,017 OEC 2.50% 2.00% 10.4% 6.5% 2,681 4,869 ROW 3.50% 2.50% 10.6% 6.4% 1,554 2,333 Total 14,070 22,700 1 Weighted average growth rate used to extrapolate cash flows beyond the initial five-year period. 2 As required by IAS 36, pre-tax discount rate is derived from the WACC (calculated on a post-tax basis as defined above). The average annual growth rate of the revenues over the initial five-year period used in 2022 is between 3.5% and 9% depending on geographical area excluding COVID-19 business (was between 4% and 9% in 2021). The average EBITDA margin used is between 16% and 24% of the revenues depending on geographic area for the 5-year period (in line with percentages used in 2021). COVID-19 related business activity is excluded from 2023 onwards assumptions. In 2022, no impairment is required as these values are above the carrying value of each group of CGUs. The accumulated impairment is \u20ac13.0m as of 31 December 2022 (same as of December 2021). The results of the annual impairment test indicate that a reasonably possible change in key assumptions would not cause the value in use to fall to the level of the carrying value for any of the Group CGUs (e.g., raising the WACC rate by 1 percentage point would not lead to any impairment). 2.14. Inventories In \u20ac millions 2022 2021 Inventories (gross) 173.6 193.0 Inventory allowance -28.0 -38.8 Inventories 145.6 154.2 Gross value of inventories decreased to \u20ac174m as of 31 December 2022 (\u20ac193m in 2021). The cost of inventories recognised as an expense during the period and included in \u201cOperating costs, net\u201d amounts to \u20ac786.5m in 2022 (2021: \u20ac804.3m). The inventory allowance mainly relates to COVID-19 testing kits, swabs and consumable based on management\u2019s expectation of future usage and consumption, adjusted for uncertainties surrounding the resilience of the COVID-19 testing market such as but not limited to, the number of tests expected to be performed. At year end 2022, the carrying amount of the COVID-19 inventory amounts to \u20ac5.6m after an inventory allowance of \u20ac16.8m (carrying amount of \u20ac 33.9m after an allowance of \u20ac31.5m in 2021). ", "dimensions": { "concept": "ifrs-full:ExplanationOfAssumptionAboutFutureWithSignificantRiskOfResultingInMaterialAdjustments", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-27-2": { "value": "1.3. Basis of Consolidation The Consolidated Financial Statements comprise the financial statements of Eurofins Scientific SE and all the subsidiaries that the Group controls, i.e., when it is exposed or has rights to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Generally, there is a presumption that a majority of voting rights result in control. To support this presumption and in cases where the Group has less than a majority the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including the contractual arrangement(s) with the other vote holders of the investee, rights arising from other contractual arrangements and the Group\u2019s voting rights and potential voting rights. Subsidiaries Subsidiaries are fully consolidated from the date that control commences until the date that control ceases. They are no longer consolidated from the date such control ceases. All intercompany transactions and balances have been eliminated in the Consolidated Financial Statements. Unrealised losses are eliminated in the same way as unrealised gains, but only to the extent that there is no evidence of impairment. Associates Associates are all entities over which the Group has significant influence but no control. Significant influence is presumed with a shareholding of between 20% and 50% of the voting rights or when the Group has board representation through which it is able to exercise significant influence. Investments in associates are accounted for using the equity method and are initially recognised at cost.The carrying amount of an investment includes the carrying amount of goodwill identified on acquisition.Loss of control Upon loss of control, the Group derecognises the assets and liabilities of the subsidiary, any non-controlling interests and other components of equity (if any) related to the subsidiary. Any surplus or deficit arising from the loss of control is recognised in the Consolidated Income Statement. If the Group retains any interest in the previous subsidiary, such interest is measured at fair value at the date the control is lost. Subsequently it is accounted for as either an equity accounted investee or as a financial asset depending on the level of influence retained. Business combinations and goodwill Business combinations are accounted for using the acquisition method. Under the acquisition method, the identifiable assets acquired, liabilities assumed and any non-controlling interests in the acquiree are recognised at the acquisition date, which is the date on which control is transferred to the Group. The Group measures goodwill at the acquisition date as being the excess of: \u25aa Aggregate of the fair value of the consideration transferred and any recognised amount for non-controlling interests and anyprevious interest held;\u25aa over the net identifiable assets acquired and liabilities assumed.If the cost of acquisition is less than the fair value of the net assets of the subsidiary acquired, the difference is recognised directlyin the Consolidated Income Statement (bargain purchase or negative goodwill).If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, the acquirer reports in its financial statements provisional amounts for the items for which the accounting is incomplete and may adjust the provisional amounts recognised for a business combination during the measurement period (twelve months from the acquisition date). The Group measure non-controlling interests (NCI) at fair value (\u2018full goodwill method\u2019). Acquisition-related costs are expensed as incurred. Further information about the Group\u2019s main subsidiaries can be found in Note 3. The financial effect of the acquisition and disposal of subsidiaries of the current period is described in Note 2.26. Acquisition of and adjustments to non-controlling interests Transactions with non-controlling interests in controlled entities are treated as transactions with equity owners of the Group. For purchases from non-controlling interests, any difference between the consideration paid and the relevant share acquired is recorded in equity. Gains or losses on disposals to non-controlling interests are also recorded in equity. Amounts due from business acquisitions Amounts due for business acquisitions consist mainly of: \u25aa amounts due to former shareholders of acquired companies at the estimated fair value amount based on the achievement of objectives (in general based on revenue and / or a measure of operating profit); \u25aa the liability resulting from \u201cput and call options\u201d (part related to the transaction with non-controlling interests) at initial acquisition time. Amounts due for business acquisitions are accounted for at fair value of the expected cash flows at the acquisition date. The variation of the liability related to the time value of money is recorded in the Consolidated Income Statement as a finance cost. All re-estimations of the amounts due for business acquisitions of the purchase price are booked in the Consolidated Income Statement as an acquisition-related expense. If all or part of the acquisition price of certain acquired laboratories is paid in the Group\u2019s shares (new or existing shares): \u25aa the amount due is accounted for in \u201cAmounts due for business acquisitions\u201d in the case where the acquisition contract stipulates a fixed monetary amount payable in a variable number of the Group\u2019s shares (number to be calculated at the moment of payment); \u25aa the amount due is accounted for in \u201cretained earnings\u201d in the case where the acquisition contract stipulates a fixed number of the Group\u2019s shares. Amounts due from business acquisitions are estimated as follows: \u25aa In case of cross put and call options exercisable at a fixed price, the Group considers these instruments as being exercised from inception. Indeed, as the price is fixed, the risks and rewards are considered, in substance, to be transferred to the Group. As such, non-controlling interests are not recognised in the Consolidated Balance Sheet and the Consolidated Income Statement. \u25aa In case of cross put and call options at a variable price, the Group considers whether the risks and rewards are transferred to the Group: o Where it is determined that risks and rewards did not transfer to the Group, non-controlling interests are recognised in the Balance Sheet and the Income Statement. o Where it is determined that risks and rewards did transfer to the Group upon entering into the cross put and call options, non-controlling interests are not recognised in the Consolidated Balance Sheet and the Consolidated Income Statement. In addition, a financial liability reflecting the put option element of the transaction is recognised for an amount corresponding to the present value of the redemption amount of the put option. Such financial liability is recognised from the equity attributable to holders of the Group. ", "dimensions": { "concept": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-28-4": { "value": "Subsidiaries Subsidiaries are fully consolidated from the date that control commences until the date that control ceases. They are no longer consolidated from the date such control ceases. All intercompany transactions and balances have been eliminated in the Consolidated Financial Statements. Unrealised losses are eliminated in the same way as unrealised gains, but only to the extent that there is no evidence of impairment. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForSubsidiariesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-29-4": { "value": "Associates Associates are all entities over which the Group has significant influence but no control. Significant influence is presumed with a shareholding of between 20% and 50% of the voting rights or when the Group has board representation through which it is able to exercise significant influence. Investments in associates are accounted for using the equity method and are initially recognised at cost.The carrying amount of an investment includes the carrying amount of goodwill identified on acquisition.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-29-5": { "value": "Associates Associates are all entities over which the Group has significant influence but no control. Significant influence is presumed with a shareholding of between 20% and 50% of the voting rights or when the Group has board representation through which it is able to exercise significant influence. Investments in associates are accounted for using the equity method and are initially recognised at cost.The carrying amount of an investment includes the carrying amount of goodwill identified on acquisition.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociates", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-31-4": { "value": "Loss of control Upon loss of control, the Group derecognises the assets and liabilities of the subsidiary, any non-controlling interests and other components of equity (if any) related to the subsidiary. Any surplus or deficit arising from the loss of control is recognised in the Consolidated Income Statement. If the Group retains any interest in the previous subsidiary, such interest is measured at fair value at the date the control is lost. Subsequently it is accounted for as either an equity accounted investee or as a financial asset depending on the level of influence retained. ", "dimensions": { "concept": "EUR:DescriptionOfAccountingPolicyForLossOfControl", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-32-4": { "value": "Business combinations and goodwill Business combinations are accounted for using the acquisition method. Under the acquisition method, the identifiable assets acquired, liabilities assumed and any non-controlling interests in the acquiree are recognised at the acquisition date, which is the date on which control is transferred to the Group. The Group measures goodwill at the acquisition date as being the excess of: \u25aa Aggregate of the fair value of the consideration transferred and any recognised amount for non-controlling interests and anyprevious interest held;\u25aa over the net identifiable assets acquired and liabilities assumed.If the cost of acquisition is less than the fair value of the net assets of the subsidiary acquired, the difference is recognised directlyin the Consolidated Income Statement (bargain purchase or negative goodwill).If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, the acquirer reports in its financial statements provisional amounts for the items for which the accounting is incomplete and may adjust the provisional amounts recognised for a business combination during the measurement period (twelve months from the acquisition date). The Group measure non-controlling interests (NCI) at fair value (\u2018full goodwill method\u2019). Acquisition-related costs are expensed as incurred. Amounts due from business acquisitions Amounts due for business acquisitions consist mainly of: \u25aa amounts due to former shareholders of acquired companies at the estimated fair value amount based on the achievement of objectives (in general based on revenue and / or a measure of operating profit); \u25aa the liability resulting from \u201cput and call options\u201d (part related to the transaction with non-controlling interests) at initial acquisition time. Amounts due for business acquisitions are accounted for at fair value of the expected cash flows at the acquisition date. The variation of the liability related to the time value of money is recorded in the Consolidated Income Statement as a finance cost. All re-estimations of the amounts due for business acquisitions of the purchase price are booked in the Consolidated Income Statement as an acquisition-related expense. If all or part of the acquisition price of certain acquired laboratories is paid in the Group\u2019s shares (new or existing shares): \u25aa the amount due is accounted for in \u201cAmounts due for business acquisitions\u201d in the case where the acquisition contract stipulates a fixed monetary amount payable in a variable number of the Group\u2019s shares (number to be calculated at the moment of payment); \u25aa the amount due is accounted for in \u201cretained earnings\u201d in the case where the acquisition contract stipulates a fixed number of the Group\u2019s shares. Amounts due from business acquisitions are estimated as follows: \u25aa In case of cross put and call options exercisable at a fixed price, the Group considers these instruments as being exercised from inception. Indeed, as the price is fixed, the risks and rewards are considered, in substance, to be transferred to the Group. As such, non-controlling interests are not recognised in the Consolidated Balance Sheet and the Consolidated Income Statement. \u25aa In case of cross put and call options at a variable price, the Group considers whether the risks and rewards are transferred to the Group: o Where it is determined that risks and rewards did not transfer to the Group, non-controlling interests are recognised in the Balance Sheet and the Income Statement. o Where it is determined that risks and rewards did transfer to the Group upon entering into the cross put and call options, non-controlling interests are not recognised in the Consolidated Balance Sheet and the Consolidated Income Statement. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-32-5": { "value": "Business combinations and goodwill Business combinations are accounted for using the acquisition method. Under the acquisition method, the identifiable assets acquired, liabilities assumed and any non-controlling interests in the acquiree are recognised at the acquisition date, which is the date on which control is transferred to the Group. The Group measures goodwill at the acquisition date as being the excess of: \u25aa Aggregate of the fair value of the consideration transferred and any recognised amount for non-controlling interests and anyprevious interest held;\u25aa over the net identifiable assets acquired and liabilities assumed.If the cost of acquisition is less than the fair value of the net assets of the subsidiary acquired, the difference is recognised directlyin the Consolidated Income Statement (bargain purchase or negative goodwill).If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, the acquirer reports in its financial statements provisional amounts for the items for which the accounting is incomplete and may adjust the provisional amounts recognised for a business combination during the measurement period (twelve months from the acquisition date). The Group measure non-controlling interests (NCI) at fair value (\u2018full goodwill method\u2019). Acquisition-related costs are expensed as incurred. Amounts due from business acquisitions Amounts due for business acquisitions consist mainly of: \u25aa amounts due to former shareholders of acquired companies at the estimated fair value amount based on the achievement of objectives (in general based on revenue and / or a measure of operating profit); \u25aa the liability resulting from \u201cput and call options\u201d (part related to the transaction with non-controlling interests) at initial acquisition time. Amounts due for business acquisitions are accounted for at fair value of the expected cash flows at the acquisition date. The variation of the liability related to the time value of money is recorded in the Consolidated Income Statement as a finance cost. All re-estimations of the amounts due for business acquisitions of the purchase price are booked in the Consolidated Income Statement as an acquisition-related expense. If all or part of the acquisition price of certain acquired laboratories is paid in the Group\u2019s shares (new or existing shares): \u25aa the amount due is accounted for in \u201cAmounts due for business acquisitions\u201d in the case where the acquisition contract stipulates a fixed monetary amount payable in a variable number of the Group\u2019s shares (number to be calculated at the moment of payment); \u25aa the amount due is accounted for in \u201cretained earnings\u201d in the case where the acquisition contract stipulates a fixed number of the Group\u2019s shares. Amounts due from business acquisitions are estimated as follows: \u25aa In case of cross put and call options exercisable at a fixed price, the Group considers these instruments as being exercised from inception. Indeed, as the price is fixed, the risks and rewards are considered, in substance, to be transferred to the Group. As such, non-controlling interests are not recognised in the Consolidated Balance Sheet and the Consolidated Income Statement. \u25aa In case of cross put and call options at a variable price, the Group considers whether the risks and rewards are transferred to the Group: o Where it is determined that risks and rewards did not transfer to the Group, non-controlling interests are recognised in the Balance Sheet and the Income Statement. o Where it is determined that risks and rewards did transfer to the Group upon entering into the cross put and call options, non-controlling interests are not recognised in the Consolidated Balance Sheet and the Consolidated Income Statement. In addition, a financial liability reflecting the put option element of the transaction is recognised for an amount corresponding to the present value of the redemption amount of the put option. Such financial liability is recognised from the equity attributable to holders of the Group. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-32-6": { "value": "Business combinations and goodwill Business combinations are accounted for using the acquisition method. Under the acquisition method, the identifiable assets acquired, liabilities assumed and any non-controlling interests in the acquiree are recognised at the acquisition date, which is the date on which control is transferred to the Group. The Group measures goodwill at the acquisition date as being the excess of: \u25aa Aggregate of the fair value of the consideration transferred and any recognised amount for non-controlling interests and anyprevious interest held;\u25aa over the net identifiable assets acquired and liabilities assumed.If the cost of acquisition is less than the fair value of the net assets of the subsidiary acquired, the difference is recognised directlyin the Consolidated Income Statement (bargain purchase or negative goodwill).If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, the acquirer reports in its financial statements provisional amounts for the items for which the accounting is incomplete and may adjust the provisional amounts recognised for a business combination during the measurement period (twelve months from the acquisition date). The Group measure non-controlling interests (NCI) at fair value (\u2018full goodwill method\u2019). Acquisition-related costs are expensed as incurred. 1.6. Impairment Impairment of goodwill and intangible assets Goodwill are not amortised but are tested for impairment annually and whenever impairment indicators require. Internal or external sources of information are considered indicators that an asset or a Cash Generating Unit (CGU) or groups of CGUs may be impaired. An impairment loss is recognised in the Consolidated Income Statement whenever and to the extent that the carrying amount of a cash generating unit exceeds the unit\u2019s recoverable amount. The recoverable amount is the higher of an asset\u2019s fair value less costs to sell and its value in use. Reference is made to Note 2.10 for further details. Intangible assets that are subject to amortisation (e.g., customer relationships, brands) are reviewed for impairment whenever triggering events or changes in circumstances indicate that the carrying value may not be recoverable. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-32-7": { "value": "Business combinations and goodwill Business combinations are accounted for using the acquisition method. Under the acquisition method, the identifiable assets acquired, liabilities assumed and any non-controlling interests in the acquiree are recognised at the acquisition date, which is the date on which control is transferred to the Group. The Group measures goodwill at the acquisition date as being the excess of: \u25aa Aggregate of the fair value of the consideration transferred and any recognised amount for non-controlling interests and anyprevious interest held;\u25aa over the net identifiable assets acquired and liabilities assumed.If the cost of acquisition is less than the fair value of the net assets of the subsidiary acquired, the difference is recognised directlyin the Consolidated Income Statement (bargain purchase or negative goodwill).If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, the acquirer reports in its financial statements provisional amounts for the items for which the accounting is incomplete and may adjust the provisional amounts recognised for a business combination during the measurement period (twelve months from the acquisition date). The Group measure non-controlling interests (NCI) at fair value (\u2018full goodwill method\u2019). Acquisition-related costs are expensed as incurred. 1.5. Intangible assets other than goodwill Acquired Intangible assets Separately acquired finite lived intangible assets are accounted for at cost. Intangible assets acquired as part of a business combination such as brands, customer relationships, technologies and other finite lived intangible assets are recognised at their fair value at the acquisition date. Acquired finite lived intangible assets are amortised using the straight-line method over their estimated useful life. The useful lives are reviewed annually. Development costs The directly attributable costs of producing identifiable and separable intangible assets (such as software development) are recognised as an intangible asset when they are controlled by the Group and it is probable that they will generate future economic benefits in excess of their cost over a period of more than one year. Other development expenditures and expenditures on research activities are recognised in the Consolidated Income Statement. Capitalised development expenditures are stated at cost less accumulated amortisation and impairment losses. Amortisation of capitalised development expenditures is charged to the Consolidated Income Statement on a straight line basis over the estimated useful lives of the intangible assets. 1.6. Impairment Impairment of goodwill and intangible assets Goodwill are not amortised but are tested for impairment annually and whenever impairment indicators require. Internal or external sources of information are considered indicators that an asset or a Cash Generating Unit (CGU) or groups of CGUs may be impaired. An impairment loss is recognised in the Consolidated Income Statement whenever and to the extent that the carrying amount of a cash generating unit exceeds the unit\u2019s recoverable amount. The recoverable amount is the higher of an asset\u2019s fair value less costs to sell and its value in use. Reference is made to Note 2.10 for further details. Intangible assets that are subject to amortisation (e.g., customer relationships, brands) are reviewed for impairment whenever triggering events or changes in circumstances indicate that the carrying value may not be recoverable. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-35-3": { "value": "Further information about the Group\u2019s main subsidiaries can be found in Note 3. The financial effect of the acquisition and disposal of subsidiaries of the current period is described in Note 2.26. 3.1. Incorporation of the year The companies below have been incorporated during the year and are fully consolidated (at 100%): % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Regional Service Centre ANZ Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 08/22 Gembloux Rue Phocas Lejeune Real Estate NV BfB Oil research SA BE 100.00% 04/22 Eurofins Digital Agency NV Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. BE 100.00% 01/22 Eurofins GSC IT Solutions & Operations SA Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 12/22 Eurofins Product Testing Service (Hangzhou) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 07/22 Eurofins Electrical Testing Service (Shanghai) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 10/22 Eurofins Discoverx Products (Shanghai) Co., Ltd. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CN 100.00% 01/22 Eurofins Cosmetic Testing Service (Shanghai) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 10/22 Eurofins Testing Technology Service (Shenzhen) Co., Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 10/22 Ltd. Eurofins Testing Inspection Certification (Xiamen) Co., Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 09/22 Ltd. Eurofins NBLSC Forensic Germany GmbH Eurofins MWG Holding GmbH DE 100.00% 01/22 Eurofins Genomics GMP Products and Services GmbH Eurofins MWG Holding GmbH DE 100.00% 07/22 Eurofins Aquatic Ecotoxicology GmbH Eurofins Agroscience Services Germany Holding DE 100.00% 08/22 GmbH Eurofins RBLSC BioPharma Product Testing Germany Eurofins BioPharma Services Holding Germany GmbH DE 100.00% 09/22 GmbH Eurofins Genomics Europe Research Products & Eurofins MWG Holding GmbH DE 100.00% 10/22 Services Synthesis GmbH Eurofins Genomics Europe IT Services GmbH Eurofins MWG Holding GmbH DE 100.00% 10/22 Eurofins Genomics Europe Pharma and Diagnostics Eurofins MWG Holding GmbH DE 100.00% 10/22 Porducts & Services Sales GmbH Eurofins Genomics Europe Research Products & Eurofins MWG Holding GmbH DE 100.00% 10/22 Services NGS GmbH Eurofins Genomics Europe Research Products & Eurofins MWG Holding GmbH DE 100.00% 10/22 Services Sanger GmbH Ishoj Baldershoj Real Estate ApS Eurofins Real Estate LUX Holding S.\u00e0 r.l. DK 100.00% 06/22 Eurofins Diagnosticos Clinicos RD, SAS Eurofins Latin American Ventures, S.L.U. DO 100.00% 11/22 Eurofins Biomed 2022 1 SAS Eurofins NSC Finance France SAS FR 100.00% 01/22 Eurofins Biomed 2022 2 SAS Eurofins NSC Finance France SAS FR 100.00% 01/22 Eurofins Biomed 2022 3 SAS Eurofins NSC Finance France SAS FR 100.00% 01/22 Eurofins Biomed 2022 4 SAS Eurofins NSC Finance France SAS FR 100.00% 01/22 Eurofins Biomed 2022 5 SAS Eurofins NSC Finance France SAS FR 100.00% 01/22 Eurofins Biomed Basse-Normandie SELAS Eurofins Labazur Provence SELAS FR 100.00% 09/22 Eurofins Biomed Ile de France Est SELAS Eurofins Labazur Provence SELAS FR 100.00% 12/22 Eurofins Newco 2023 1 SAS Eurofins NSC Finance France SAS FR 100.00% 11/22 Eurofins Newco 2023 2 SAS Eurofins NSC Finance France SAS FR 100.00% 11/22 Eurofins Newco 2023 3 SAS Eurofins NSC Finance France SAS FR 100.00% 11/22 Eurofins Newco 2023 4 SAS Eurofins NSC Finance France SAS FR 100.00% 11/22 SCI Eurofins 2023 1 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/22 SCI Eurofins 2023 2 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/22 SCI Eurofins 2023 3 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/22 SCI Eurofins 2023 4 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/22 Eurofins Biopharma Product Testing Croatia D.O.O. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. HR 100.00% 01/22 % of Date ISO interest Company Subsidiary of: of code by the entry Group Empowerdx Ireland Ltd. Eurofins Direct To Consumer Testing LUX Holding S.\u00e0 IE 100.00% 04/22 r.l Eurofins South Bengaluru Resources Private Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. IN 100.00% 02/22 Eurofins It Enabled Services India Private Limited Eurofins Support Services LUX Holding S.\u00e0 r.l. IN 100.00% 03/22 Eurofins Regulatory & Consultancy Services Italy Srl Eurofins Pharma Services Italia Holding Srl IT 100.00% 05/22 Vimodrone Via Grandi Real Estate Invest Srl Eurofins Real Estate LUX Holding S.\u00e0 r.l. IT 100.00% 06/22 Eurofins BioPharma Product Testing Europe RBLSC Eurofins Pharma Services Italia Holding Srl IT 100.00% 06/22 Srl Eurofins Clinical Testing Japan Holding Ltd. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. JP 100.00% 01/22 Imizu Hibari Real Estate KK Eurofins Real Estate LUX Holding S.\u00e0 r.l. JP 100.00% 01/22 Hamamatsu Nishijima Real Estate KK Eurofins Real Estate LUX Holding S.\u00e0 r.l. JP 100.00% 03/22 Eurofins Food & Feed Testing Japan Holding KK Eurofins Food Testing LUX Holding S.\u00e0 r.l. JP 100.00% 05/22 Eurofins Genomic Services Japan Holding KK Eurofins Genomics LUX Holding S.\u00e0 r.l. JP 100.00% 04/22 Eurofins Tribology LUX Holding S.\u00e0 r.l Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 05/22 Eurofins Direct To Consumer Testing LUX Holding S.\u00e0 Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 05/22 r.l Eurofins Re LUX Holding S.\u00e0 r.l Eurofins Scientific SE LU 100.00% 12/22 Eurofins Genomics It Solutions Latvia Sia Eurofins Genomics LUX Holding S.\u00e0 r.l. LV 100.00% 06/22 Eurofins Environment Testing Holding Malaysia Sdn. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. MY 100.00% 08/22 Bhd. Leiden Bioscience Park Real Estate B.V. Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 04/22 Amersfoort Koningsbergenweg Real Estate B.V. Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 04/22 Eurofins Project Flow B.V. Eurofins Clinical Diagnostics Netherlands Holding BV NL 100.00% 04/22 Eurofins NBLSC Food Testing Netherlands B.V. Eurofins Food Testing Netherlands Holding BV NL 100.00% 09/22 Eurofins BioPharma Product Testing Poland Sp. z.o.o. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. PL 100.00% 01/22 Katowice Real Estate Sp. z.o.o Eurofins Real Estate LUX Holding S.\u00e0 r.l. PL 100.00% 03/22 Eurofins GSC IT Romania SRL Eurofins Support Services LUX Holding S.\u00e0 r.l. RO 100.00% 02/22 Eurofins Vitamins Testing Romania SRL Eurofins Food & Feed Testing Romania Holding SRL RO 100.00% 05/22 Eurofins Clinical Diagnostics (Thailand) Co., Ltd. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. TH 100.00% 02/22 Eurofins Environment Testing Holding (Thailand) Co., Eurofins Environment Testing LUX Holding S.\u00e0 r.l. TH 100.00% 10/22 Ltd. Eurofins Eag Materials Science Taiwan Ltd. Eurofins Material Sciences LUX Holding S.\u00e0 r.l. TW 100.00% 03/22 Eurofins Genomics Europe Dtc - Population Genetics Eurofins Genomics LUX Holding S.\u00e0 r.l. UK 100.00% 03/22 Products & Services Limited Eurofins Biomnis Edinburgh Limited Eurofins Clinical Diagnostic Testing UK Holding Limited UK 100.00% 07/22 Empowerdx Uk Limited Eurofins Direct To Consumer Testing LUX Holding S.\u00e0 UK 100.00% 05/22 r.l DDC UK Services Limited Eurofins Direct To Consumer Testing LUX Holding S.\u00e0 UK 100.00% 07/22 r.l Orlando Newburyport Avenue Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 01/22 San Diego Convoy Court Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 04/22 Eurofins BioPharma Product Testing Enco, Inc. Eurofins Pharma US Holdings II, Inc. US 100.00% 04/22 St. Charles 25 Research Park Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 06/22 Cary Maynard Road Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 07/22 Fremont Bayside Parkway Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 07/22 Chicago Crossing Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 10/22 Eurofins Food Assurance US Holdings, Inc. Eurofins Assurance LUX Holding S.\u00e0 r.l. US 100.00% 11/22 Mounds View Woodale Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 12/22 3.2. Acquisition of the year The companies below have been acquired during the year and are fully consolidated (at 100%): % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Apal Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 02/22 Eurofins Euraceta NV Eurofins Food Testing LUX Holding S.\u00e0 r.l. BE 100.00% 12/22 Manara Medical Laboratories W.L.L. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. BH 100.00% 12/22 Spincontrol Am\u00e9rique du Nord, Inc. Eurofins Product Testing clinical and ex-vivo France CA 60.20% 08/22 Holding SAS Microscan Service SA Eurofins Qute Holding AG CH 100.00% 06/22 Modern Genomic Services Co., Ltd. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. CN 100.00% 03/22 TA Technology (Shanghai) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 12/22 Lunaria s.r.o. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CZ 100.00% 06/22 Cll Chemnitzer Laborleistungs GmbH Eurofins NDSC Umweltanalytik GmbH DE 100.00% 04/22 Eurofins Umweltanalytik S\u00fcd GmbH Eurofins NDSC Umweltanalytik GmbH DE 100.00% 04/22 Eurofins Food Testing S\u00fcd GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 04/22 GmbH Stella Analyse GmbH Eurofins Environment Testing Netherlands Holding BV DE 100.00% 03/22 Inpac Medizintechnik GmbH Eurofins BioPharma Services Holding Germany GmbH DE 100.00% 03/22 Reco Planegg Behringstra\u00dfe Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 03/22 BECIT GmbH Eurofins Food Testing Germany East Holding GmbH DE 100.00% 07/22 Dr. Lauk & Dr. Breitling GmbH Eurofins Forensics LUX Holding S.\u00e0 r.l. DE 100.00% 09/22 Biocontrol Y Calidad Alimentaria, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 03/22 Laboratorios Vital, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 03/22 Granada Bailen Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 04/22 Bio-9000, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 05/22 Eurofins Cavendish, S.L.U. Eurofins Environment Testing Spain Holding, S.L.U. ES 100.00% 10/22 Laboratori Cat-Gairin, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 10/22 Laboratorios Munuera, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 07/22 Cidesal Analisis Alimentos, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 08/22 Derio Idorsolo Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 07/22 Eurofins Biotalde, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 08/22 Convet, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 12/22 Clinilab Laboratorio Cl\u00ednico Huelva, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 12/22 Bestlab Oy Eurofins Environment Testing Finland Holding Oy FI 100.00% 06/22 Eurofins Bio Sant\u00e9 SELAS Eurofins Biologie M\u00e9dicale Holding France SAS FR 100.00% 10/22 Spincontrol SAS Eurofins Product Testing clinical and ex-vivo France FR 60.20% 08/22 Holding SAS Soci\u00e9t\u00e9 Financi\u00e8re Bio Callens Holding SARL Eurofins Product Testing clinical and ex-vivo France FR 60.20% 08/22 Holding SAS Centre de Recherches Biologiques et Eurofins Product Testing clinical and ex-vivo France FR 60.20% 08/22 d'Exp\u00e9rimentations Cutan\u00e9es - BIO-EC SAS Holding SAS Genex SAS Centre de Recherches Biologiques et FR 60.20% 08/22 d'Exp\u00e9rimentations Cutan\u00e9es - BIO-EC SAS GEA (Grand Est Analyses) SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 10/22 SAS Laboratories of Biological-Chemical Trials and Eurofins Food Testing LUX Holding S.\u00e0 r.l. GR 100.00% 06/22 Analyses, SA Wessling Hungary Kft. Eurofins Environment Testing Hungary Holding Kft. HU 100.00% 08/22 Wessling Vagyonkezel\u0151 Kft. Wessling Hungary Kft. HU 100.00% 08/22 % of Date ISO interest Company Subsidiary of: of code by the entry Group BIOMI Biotechnol\u00f3giai Szolg\u00e1ltat\u00f3 Korl\u00e1tolt Felel\u0151ss\u00e9g\u0171 Wessling Hungary Kft. HU 100.00% 08/22 T\u00e1rsas\u00e1g Kft. Wessling Nemzetk\u00f6zi Kutat\u00f3 \u00e9s Oktat\u00f3 K\u00f6zpont Wessling Hungary Kft. HU 100.00% 08/22 Nonprofit Korl\u00e1tolt Felel\u0151ss\u00e9g\u0171 T\u00e1rsas\u00e1g Kft. Medserv Kft. Eurofins Clinical Testing Hungary Holding Kft. HU 61.25% 09/22 Sejtdiagnosztika Kft. Medserv Kft. HU 61.25% 09/22 PT Modern Testing Services Indonesia Eurofins Product Testing LUX Holding S.\u00e0 r.l. ID 100.00% 01/22 Eurofins Limed Ltd. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. IL 50.10% 04/22 Eurofins Sisthema Srl Eurofins Assurance LUX Holding S.\u00e0 r.l. IT 100.00% 02/22 Environ-Lab Srl Eurofins Environment Testing LUX Holding S.\u00e0 r.l. IT 100.00% 06/22 Genetic Lab Co., Ltd. Eurofins Clinical Testing Japan Holding Ltd. JP 100.00% 01/22 Repertoire Genesis Inc. Eurofins Clinical Testing Japan Holding Ltd. JP 55.00% 06/22 QSAI Analysis and Research Center Co.,Ltd. Eurofins Food & Feed Testing Japan Holding KK JP 85.00% 09/22 CRA Korea Co, Ltd. Eurofins Product Testing Korea Holding Co., Ltd. KR 60.00% 06/22 Eurofins Mediscan Laboratories Sdn Bhd Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. MY 100.00% 05/22 Stella Analyse B.V. Eurofins Environment Testing Netherlands Holding BV NL 100.00% 03/22 Plm Laboratorium Services B.V. Eurofins Environment Testing Netherlands Holding BV NL 100.00% 03/22 Dia-Go B.V. Eurofins Environment Testing Netherlands Holding BV NL 100.00% 03/22 Przedsi\u0119biorstwo Bada\u0144 I Ekspertyz \u015arodowiska Eurofins Environment Testing Poland Holding Sp. z o.o. PL 100.00% 04/22 \"Sepo\" Sp. z.o.o. Lagra Laborat\u00f4rio Agr\u00edcola do Alentejo Lda. Eurofins Food Testing LUX Holding S.\u00e0 r.l. PT 100.00% 07/22 Eurofins Saudi Ajal Laboratories Eurofins Food Testing LUX Holding S.\u00e0 r.l. SA 55.00% 06/22 Svensk Arbetshygien AB Eurofins Environment Testing Sweden Holding AB SE 100.00% 10/22 Thai Environmental Technic Co., Ltd. Eurofins Environment Testing Holding (Thailand) Co., TH 75.00% 10/22 Ltd. Altair Analytical Limited Eurofins Food Testing UK Holding Limited UK 100.00% 04/22 Sensory Dimensions Limited Eurofins Sensory, Consumer research and Product UK 100.00% 09/22 design LUX Holding S.\u00e0 r.l. Bio Search (N.I.) Limited Eurofins Food Testing UK Holding Limited UK 100.00% 07/22 Eurofins Analytics LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 03/22 Human Factors Md, LLC Eurofins Pharma US Holdings II, Inc. US 100.00% 05/22 Little Rock Kanis Road Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 11/22 American Interplex, LLC Eurofins Environment Testing South Central, LLC US 100.00% 11/22 Genetic Testing Service JSC Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. VN 67.00% 02/22 3.3. Merged entities The companies below have been merged with another Eurofins entities during the year: % of ISO interest Date Company Subsidiary of: Code by the of exit Group Eurofins NSC Finance Germany GmbH Eurofins Support Services LUX Holding S.\u00e0 r.l. DE 100.00% 07/22 Eurofins NSC Finance Clinical Diagnostics Germany Eurofins Support Services LUX Holding S.\u00e0 r.l. DE 100.00% 07/22 GmbH Eurofins Alfalab Internacional, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Laboratorio Calbo, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Laboratorio Bernad-Mu\u00f1oz, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Laboratorio Cl\u00ednico Sanitario, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 % of ISO interest Date Company Subsidiary of: Code by the of exit Group Eurofins Laboratorio Dres. Cerme\u00f1o, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Laboratorio Pilar Larraz, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Laboratorio Recio, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 EUROFINS Laboratorio Medicantabria S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Laboratorio Virtudes, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Labrovet, S.L.U. Eurofins Mas Control, S.L.U. ES 100.00% 06/22 Eurofins An\u00e1lisis Cl\u00ednicos Canarias, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Laboratorio Garc\u00eda L\u00f3pez, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Prelevement Pour Le Batiment Sud Ouest Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 07/22 SAS SAS Eurofins Alpabio Prestations SAS Alpa Environnement Holding France SAS FR 100.00% 07/22 Alpa Support Services SAS Alpa Environnement Holding France SAS FR 100.00% 07/22 Alpa Hygiene Alimentaire SAS Alpa Alimentaire Holding France SAS FR 100.00% 07/22 Medical Consultants Pathology Holdings Limited Eurofins Biomnis Ireland Limited IE 100.00% 11/22 Eurofins Cyber Security Assurance & Advisory Eurofins Cyber Security Netherlands Holding BV NL 100.00% 06/22 Netherlands BV Eurofins Cyber Security Hacking & Testing BV Eurofins Cyber Security Netherlands Holding BV NL 100.00% 06/22 Eurofins Cyber Security Products & Services BV Eurofins Cyber Security Netherlands Holding BV NL 100.00% 06/22 Maser Engineering BV Eurofins Maser BV NL 90.02% 08/22 Eurofins Environment Services Polska Sp. z.o.o. Eurofins Environment Testing Poland Holding Sp. z o.o. PL 100.00% 06/22 Research For Hire, Inc. Eurofins Agroscience Services, LLC US 100.00% 10/22 Eurofins NTD, LLC Eurofins Viracor, LLC US 100.00% 12/22 Eurofins GSD Holdings, Inc. Eurofins Technologies US Holdings, Inc. US 100.00% 08/22 Eurofins Viracor Oncology, LLC Eurofins Clinical Testing US Holdings, Inc. US 100.00% 11/22 Pomona 900 Corporate Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 08/22 Eurofins Ana Laboratories, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 04/22 3.4. Discontinued operations The companies below have been liquidated or sold during the year: % of ISO interest Date Company Subsidiary of: Code by the of exit Group Eurofins GSC Finance NV Eurofins Scientific SE BE 100.00% 12/22 Eurofins Digital Testing Belgium NV Eurofins Digital Testing International LUX Holding S.\u00e0 BE 100.00% 12/22 r.l Eurofins Digital Testing Shenzhen Co., Ltd. Eurofins Digital Testing International LUX Holding S.\u00e0 CN 100.00% 12/22 r.l BELM Pet\u0151fi utca 45 Real Estate Kft. Eurofins Real Estate LUX Holding S.\u00e0 r.l. HU 100.00% 03/22 Sandyford Clinical Diagnostics Limited Eurofins Biomnis Ireland Limited IE 100.00% 11/22 Eurofins Digital Testing India Private Limited Eurofins Digital Testing International LUX Holding S.\u00e0 IN 100.00% 11/22 r.l Eurofins SAM Sensory And Marketing Italy Srl Eurofins Food & Feed Testing Italia Holding Srl IT 100.00% 03/22 Eurofins Digital Testing International LUX Holding S.\u00e0 Eurofins Product Testing LUX Holding S.\u00e0 r.l. LU 100.00% 12/22 r.l Commissum Sdn Bhd Eurofins Product Testing LUX Holding S.\u00e0 r.l. MY 100.00% 12/22 Heerenveen Leeuwarderstraatweg Real Estate BV Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 01/22 Eurofins Digital Testing and Cyber Security Netherlands Eurofins Digital Testing International LUX Holding S.\u00e0 NL 100.00% 12/22 BV r.l % of ISO interest Date Company Subsidiary of: Code by the of exit Group Eurofins Cyber Security Netherlands Holding B.V. Eurofins Product Testing LUX Holding S.\u00e0 r.l. NL 100.00% 12/22 Eurofins Digital Testing Sweden AB Eurofins Product Testing LUX Holding S.\u00e0 r.l. SE 100.00% 12/22 Eurofins Pharma Discovery Services UK Limited Eurofins Discovery Services LUX Holding S.\u00e0 r.l. UK 100.00% 03/22 Chemtest Holdings Limited Eurofins Environment Testing UK Holding Limited UK 100.00% 08/22 Southern Real Estate Investment UK Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. UK 100.00% 08/22 Eurofins Covid Testing Services Limited Eurofins Forensics LUX Holding S.\u00e0 r.l. UK 100.00% 12/22 Eurofins Digital Product Testing UK Limited Eurofins Digital Testing International LUX Holding S.\u00e0 UK 100.00% 12/22 r.l Edge Testing Solutions Limited Eurofins Digital Testing UK Holding Limited UK 100.00% 12/22 Eurofins Digital Testing UK Holding Limited Eurofins Digital Testing International LUX Holding S.\u00e0 UK 100.00% 12/22 r.l Commissum Associates Limited Eurofins Digital Testing UK Holding Limited UK 85.00% 12/22 Eurofins Digital Media Services, LLC Eurofins Product Testing US Holdings, Inc. US 100.00% 12/22 3.5. Principal subsidiary undertakings The Companies below are fully consolidated (at 100%). % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Scientific SE LU Eurofins Biomnis Middle East LLC Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. AE 100.00% 11/19 Agrohuarpes - Eurofins Agrosciences Services SA Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. AR 100.00% 08/17 Eurofins Lebensmittelanalytik \u00d6sterreich GmbH Eurofins Food Testing LUX Holding S.\u00e0 r.l. AT 100.00% 01/07 Eurofins Genomics Austria GmbH Eurofins Genomics LUX Holding S.\u00e0 r.l. AT 100.00% 09/11 Eurofins Agroscience Services Austria GmbH Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. AT 100.00% 12/12 Eurofins Environment Testing Austria Holding GmbH Eurofins Environment Testing LUX Holding S.\u00e0 r.l. AT 100.00% 03/15 Eurofins Umwelt \u00d6sterreich GmbH & Co.KG Eurofins Environment Testing Austria Holding GmbH AT 100.00% 03/15 Eurofins NUA Austria Holding GmbH Eurofins Environment Testing Austria Holding GmbH AT 100.00% 01/16 Eurofins Water & Waste GmbH Eurofins Environment Testing Austria Holding GmbH AT 100.00% 12/15 Wiener Neudorf Palmersstra\u00dfe Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. AT 100.00% 12/16 Eurofins NSC Austria GmbH Eurofins Support Services LUX Holding S.\u00e0 r.l. AT 100.00% 12/18 Eurofins Analytics & Services Austria GmbH Eurofins Environment Testing Austria Holding GmbH AT 100.00% 09/20 Eurofins Professional Scientific Services Austria GmbH Eurofins Pharma Services LUX Holding S.\u00e0 r.l. AT 100.00% 10/20 Eurofins Environment Testing Australia Pty Ltd. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. AU 100.00% 01/13 Eurofins Agroscience Services Pty Ltd. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. AU 100.00% 07/13 Eurofins Agroscience Testing Pty Ltd. Eurofins Agrosciences Services France Holding SAS AU 100.00% 07/13 Eurofins Animal Health Australia Pty Ltd. Eurofins Agrosciences Services France Holding SAS AU 100.00% 01/16 Eurofins ams Laboratories Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 03/16 Eurofins Australia New Zealand Holding Pty Ltd. Eurofins Environment Testing France Australia Holding AU 100.00% 05/16 SAS Eurofins Food Testing Australia Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 07/16 Girraween Magowar Road Real Estate Pty Ltd. Eurofins Real Estate LUX Holding S.\u00e0 r.l. AU 100.00% 05/17 Dandenong South Monterey Road Real Estate Pty Ltd. Eurofins Real Estate LUX Holding S.\u00e0 r.l. AU 100.00% 05/17 Eurofins Dermatest Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 07/17 Eurofins Technologies Australia Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 08/17 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Chemical Analysis Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 03/19 Eurofins ProMicro Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 11/20 Eurofins ARL Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 11/20 Eurofins NBLSC Environment Testing ANZ Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 11/20 AQM Bangladesh Limited AQM HK Co., Ltd. BD 100.00% 06/19 Eurofins GSC Management Services NV Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 06/01 Eurofins Belgium NV Eurofins Environment Testing Belgium Holding NV BE 100.00% 11/07 Eurofins Food Testing Belgium NV Eurofins Food Testing LUX Holding S.\u00e0 r.l. BE 100.00% 10/10 Eurofins Environment Testing Belgium Holding NV Eurofins Environment Testing LUX Holding S.\u00e0 r.l. BE 100.00% 09/11 Nazareth Venecoweg Real Estate NV Eurofins Real Estate LUX Holding S.\u00e0 r.l. BE 100.00% 09/11 Eurofins Forensics Belgium BVBA Eurofins Forensics LUX Holding S.\u00e0 r.l. BE 100.00% 10/11 Eurofins Pharmaceutical Product Testing Belgium NV Eurofins Pharma Services LUX Holding S.\u00e0 r.l. BE 100.00% 11/11 Eurofins Agro Testing Belgium NV Eurofins Food Testing LUX Holding S.\u00e0 r.l. BE 100.00% 07/13 Eurofins Professional Scientific Services Belgium NV Eurofins Pharma Services LUX Holding S.\u00e0 r.l. BE 100.00% 06/14 Eurofins GSC IT Solutions NV Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 07/14 Eurofins GSC Finance & Administration NV Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 09/16 Eurofins Biological Testing Belgium NV Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. BE 100.00% 02/17 Eurofins Asbestos Testing Belgium NV Eurofins Environment Testing Belgium Holding NV BE 100.00% 08/17 Eurofins Amatsigroup NV Eurofins Amatsigroup SAS BE 100.00% 09/17 Eurofins Labo Van Poucke BVBA Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. BE 100.00% 02/18 Eurofins NSC Belgium BVBA Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 12/18 Eurofins GSC Consulting NV Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 09/19 Eurofins Air Monitoring Belgium NV Eurofins Air Monitoring LUX Holding S.\u00e0 r.l. BE 100.00% 12/19 Transportation, Facility and Logistic Services NV Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 12/19 Eurofins GSC Transformation & Operational Excellence Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 12/20 NV Eurofins GSC Facility Management NV Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 12/20 BfB Oil research SA Eurofins IESPM SAS BE 100.00% 04/21 Eurofins GSC Finance & Controlling Systems SA Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 12/21 Eurofins Agroscience Services EOOD Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. BG 100.00% 11/08 Eurofins HOS Testing Bulgaria EOOD Eurofins Food Testing LUX Holding S.\u00e0 r.l. BG 100.00% 09/16 Eurofins do Brasil An\u00e1lises de Alimentos Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 07/03 Eurofins Agroscience Services Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 06/12 Laborat\u00f3rio ALAC Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 04/12 Integrated Petroleum Expertise Company - Servi\u00e7os Eurofins Latin American Ventures, S.L.U. BR 100.00% 09/14 em Petroleo Ltda. Eurofins Clinical Santos Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 12/17 Eurofins Clinical Imagem Santos Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 12/17 Centro de Analise e Tipagem de Genomas Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 08/19 Eurofins Clinical Testing Brazil Holding Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 06/21 Eurofins Food Testing Brazil Holding Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 06/21 Itapema Laboratorio de Analises Clinicas Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 12/22 Eurofins Experchem Laboratories, Inc. Eurofins Food Testing LUX Holding S.\u00e0 r.l. CA 100.00% 04/15 Quebec St. Bruno Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. CA 100.00% 12/16 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins CDMO Alphora, Inc. Eurofins Pharma Services Canada Holding, Inc. CA 100.00% 06/17 Eurofins NSC Canada, Inc. Eurofins Support Services LUX Holding S.\u00e0 r.l. CA 100.00% 06/17 Eurofins BioPharma Product Testing Toronto, Inc. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CA 100.00% 05/18 Oakville Portland Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. CA 100.00% 06/18 Mississauga Hadwen Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. CA 100.00% 06/18 Mississauga Speakman Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. CA 100.00% 06/18 Eurofins Environment Testing Canada, Inc. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. CA 100.00% 11/18 Eurofins Cosmetics and Personal Care Testing Eurofins Product Testing LUX Holding S.\u00e0 r.l. CA 100.00% 09/19 Canada, Inc. Eurofins Professional Scientific Services Canada, Inc. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CA 100.00% 10/20 Eurofins Pharma Services Canada Holding, Inc. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CA 100.00% 07/21 Eurofins Enviro-Works, Inc. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. CA 100.00% 12/21 Eurofins Scientific AG Eurofins Food Testing LUX Holding S.\u00e0 r.l. CH 100.00% 07/00 Eurofins Regulatory AG Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. CH 100.00% 12/11 Eurofins BioPharma Product Testing Switzerland AG Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CH 100.00% 01/13 Eurofins Professional Scientific Services Switzerland Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CH 100.00% 03/17 AG Eurofins Electric & Electronic Product Testing AG Eurofins Product Testing LUX Holding S.\u00e0 r.l. CH 100.00% 06/17 Route de Montena Real Estate AG Eurofins Real Estate LUX Holding S.\u00e0 r.l. CH 100.00% 06/17 Eurofins PHAST Pharma AG Eurofins PHAST GmbH CH 100.00% 07/18 Eurofins NSC Switzerland AG Eurofins Support Services LUX Holding S.\u00e0 r.l. CH 100.00% 01/20 SAM Sensory and Marketing International Switzerland Eurofins Sensory, Consumer research and Product CH 100.00% 12/20 AG design LUX Holding S.\u00e0 r.l. Eurofins Qualitech AG Eurofins Qute Holding AG CH 100.00% 07/21 Eurofins Qute Holding AG Eurofins Material Sciences LUX Holding S.\u00e0 r.l. CH 100.00% 07/21 Scitec Research SA Eurofins Environment Testing LUX Holding S.\u00e0 r.l. CH 100.00% 09/21 Swanfort Services SA DNA Consolidated BV CH 100.00% 08/21 AgeaCare Switzerland S.\u00e0 r.l DNA Consolidated BV CH 100.00% 08/21 Eurofins Testing Chile SA Eurofins Latin American Ventures, S.L.U. CL 100.00% 03/13 Eurofins Training Chile SA Eurofins Testing Chile SA CL 100.00% 03/13 Eurofins Agroscience Services Chile SA Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. CL 100.00% 06/17 Eurofins Product Testing Hong Kong, Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 03/06 Eurofins Technology Service (Suzhou) Co., Ltd. Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/06 Eurofins Product Testing Service (Shanghai) Co., Ltd. Eurofins Shanghai Holding, Ltd. CN 100.00% 11/09 Eurofins Testing Technology (Shenzhen) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 10/09 Eurofins Shanghai Holding, Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 08/09 Eurofins Central Laboratory China Co., Ltd. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CN 100.00% 05/12 Eurofins Food Testing Hong Kong, Ltd. Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 03/12 Eurofins NSC Shanghai Co., Ltd. Eurofins Support Services LUX Holding S.\u00e0 r.l. CN 100.00% 06/14 Eurofins NSC Hong Kong, Ltd. Eurofins Support Services LUX Holding S.\u00e0 r.l. CN 100.00% 02/14 Eurofins Sensory Consumer and Product Research Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 05/15 (Shanghai) Co., Ltd. Eurofins Food Testing Service(Dalian)Co.,Ltd. Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 06/16 Eurofins Technology Service (Qingdao) Co., Ltd. Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 06/16 Evans Materials Technology (Shanghai) Co., Ltd. Eurofins EAG Materials Science, LLC CN 100.00% 12/17 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Consumer Product Testing (Guangzhou) Co., Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 12/18 Ltd Eurofins Electrical Testing Service (Shenzhen) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/18 Eurofins EAG Materials Science China (Shanghai) Co., Eurofins Material Sciences LUX Holding S.\u00e0 r.l. CN 100.00% 09/19 Ltd. Eurofins BioPharma Product Testing (Shanghai ) Co., Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CN 100.00% 12/19 Ltd. AQM HK Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 06/19 Eurofins Technology Service (Guangzhou) Co., Ltd. Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 10/19 AQM China Co., Ltd. AQM HK Co., Ltd. CN 100.00% 06/19 Eurofins Technologies (Shanghai) Co., Ltd. Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. CN 100.00% 07/20 Eurofins Assurance China Co., Ltd. Eurofins Assurance LUX Holding S.\u00e0 r.l. CN 100.00% 05/21 Eurofins-UNPA Natural Health Product Quality Services Eurofins Food Testing Hong Kong, Ltd. CN 60.00% 08/21 (Beijing) Co., Ltd. Eurofins Wireless Testing Service (Shenzhen) Co., Ltd. A Test Lab Techno Co., Ltd. CN 100.00% 07/21 Eurofins Testing Inspection Certification (Chengdu) Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 07/21 Co., Ltd. Eurofins MTS Consumer Product Testing (Hong Kong) Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/21 Co., Ltd. Modern Testing Services (Hong Kong) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/21 Modern Testing Services (International) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/21 Eurofins Assurance (Hong Kong) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/21 Modern Testing Services(Dongguan) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/21 Eurofins MTS Consumer Product Testing (Shanghai) Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/21 Co., Ltd Eurofins Megalab Colombia, SAS Eurofins Megalab, S.A.U. CO 100.00% 09/21 Eurofins IT Infrastructure GSC S.A. Eurofins Support Services LUX Holding S.\u00e0 r.l. CR 100.00% 08/18 Eurofins Food & Feed Testing Czech Republic s.r.o. Eurofins Holding CZ s.r.o. CZ 100.00% 10/06 Eurofins Holding CZ s.r.o. Eurofins Food Testing LUX Holding S.\u00e0 r.l. CZ 100.00% 08/19 Eurofins Food Testing Hamburg Germany Holding Eurofins GeneScan Holding GmbH DE 100.00% 05/98 GmbH RECO Homburg Entenmuehlstrasse Real Estate Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 11/98 GmbH Eurofins GeneScan Holding GmbH Eurofins Food Testing LUX Holding S.\u00e0 r.l. DE 100.00% 07/03 Eurofins Analytik GmbH Eurofins GfA Lab Service GmbH DE 100.00% 12/98 Eurofins Dr. Specht International GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 04/05 GmbH Eurofins GeneScan GmbH Eurofins GeneScan Holding GmbH DE 100.00% 07/03 Eurofins SOFIA GmbH Eurofins Food Testing Pesticides Germany Holding DE 100.00% 04/06 GmbH Eurofins GfA GmbH Eurofins Air Monitoring Germany Holding GmbH DE 100.00% 01/01 Eurofins \u00d6kometric GmbH Eurofins NDSC Umweltanalytik GmbH DE 100.00% 12/02 Eurofins NDSC Umweltanalytik GmbH Eurofins Environment Testing LUX Holding S.\u00e0 r.l. DE 100.00% 03/05 Eurofins Umwelt West GmbH Eurofins Environment Testing Germany Holding West DE 100.00% 04/05 GmbH Eurofins Umwelt Ost GmbH Eurofins NDSC Umweltanalytik GmbH DE 100.00% 01/06 Eurofins Institut J\u00e4ger GmbH Eurofins NDSC Umweltanalytik GmbH DE 100.00% 04/06 Eurofins Genomics Europe Applied Genomics GmbH Eurofins MWG Holding GmbH DE 100.00% 07/01 Eurofins Agroscience Services EcoChem GmbH Eurofins Agroscience Services Germany Holding DE 100.00% 01/06 GmbH Eurofins BioPharma Product Testing Munich GmbH Eurofins BioPharma Services Holding Germany GmbH DE 100.00% 10/06 Eurofins MWG Holding GmbH Eurofins Genomics BV DE 100.00% 01/05 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Genomics Germany GmbH Eurofins MWG Holding GmbH DE 100.00% 01/07 Eurofins Food Testing Pesticides Germany Holding Eurofins Food Testing LUX Holding S.\u00e0 r.l. DE 100.00% 12/06 GmbH Eurofins Dr. Specht Laboratorien GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 03/07 GmbH Eurofins Genomics Europe Synthesis GmbH Eurofins MWG Holding GmbH DE 100.00% 01/07 Eurofins Food Testing General Chemistry Germany Eurofins Laborservices GmbH DE 100.00% 04/07 Holding GmbH Eurofins Institut Dr. Rothe GmbH Eurofins Food Testing General Chemistry Germany DE 100.00% 04/07 Holding GmbH Eurofins Product Testing Verwaltungs GmbH Eurofins Product Service GmbH DE 100.00% 03/07 Eurofins Environment Testing Germany Holding West Eurofins Environment Testing LUX Holding S.\u00e0 r.l. DE 100.00% 12/07 GmbH Eurofins Agroscience Services Germany Holding Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. DE 100.00% 04/07 GmbH FP Friedrichsdorf Professor-Wagner-Strasse Real Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 04/07 Estate GmbH Eurofins Umwelt Nord GmbH Eurofins NDSC Umweltanalytik GmbH DE 100.00% 05/07 Eurofins Laborservices GmbH Eurofins Food Testing LUX Holding S.\u00e0 r.l. DE 100.00% 04/07 Eurofins NSC IT Infrastructure Germany GmbH Eurofins Support Services LUX Holding S.\u00e0 r.l. DE 100.00% 12/07 Eurofins INLAB GmbH Eurofins Food Testing General Chemistry Germany DE 100.00% 12/07 Holding GmbH Eurofins Product Service GmbH Eurofins Scientific SE DE 100.00% 01/08 Eurofins Information Systems GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 11/07 GmbH Eurofins Consumer Product Testing GmbH Eurofins Product Testing Verwaltungs GmbH DE 100.00% 01/08 Eurofins Food Testing Germany East Holding GmbH Eurofins Food Testing LUX Holding S.\u00e0 r.l. DE 100.00% 01/08 Eurofins Agroscience Services Chem GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 02/08 GmbH Eurofins Food Control Services GmbH Eurofins Food Testing LUX Holding S.\u00e0 r.l. DE 100.00% 12/08 Eurofins WEJ Contaminants GmbH Eurofins GfA Lab Service GmbH DE 100.00% 12/08 Eurofins BioTesting Services Nord GmbH Eurofins GfA Lab Service GmbH DE 100.00% 12/08 HS Hamburg Stenzelring Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 06/08 Eurofins Global Control GmbH Eurofins Food Testing Pesticides Germany Holding DE 100.00% 04/09 GmbH Eurofins Food & Feed Testing Leipzig GmbH Dr. Appelt Beteiligungs GmbH DE 100.00% 05/09 RECO Ebersberg Anzinger Strasse Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 08/09 Eurofins BioPharma Product Testing Hamburg GmbH Eurofins BioPharma Services Holding Germany GmbH DE 100.00% 07/09 Eurofins Food Integrity Control Services GmbH Dr. Appelt Beteiligungs GmbH DE 100.00% 05/09 Eurofins Institut Dr. Appelt Hilter GmbH Dr. Appelt Beteiligungs GmbH DE 100.00% 05/09 Dr. Appelt Beteiligungs GmbH Eurofins Food Testing Germany East Holding GmbH DE 100.00% 05/09 Gold Standard Diagnostics Freiburg GmbH Eurofins Technologies Germany Holding GmbH DE 100.00% 05/09 Eurofins GfA Lab Service GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 10/10 GmbH Eurofins NDSC Food Testing Germany GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 03/11 GmbH Eurofins Agroscience Services GmbH Eurofins Agroscience Services Germany Holding DE 100.00% 07/11 GmbH Eurofins Facility Management Germany GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 11/11 GmbH Eurofins Umwelt S\u00fcdwest GmbH Eurofins Environment Testing Germany Holding West DE 100.00% 06/12 GmbH Eurofins Medigenomix Forensik GmbH Eurofins MWG Holding GmbH DE 100.00% 08/12 Eurofins Food Consulting Services GmbH Dr. Appelt Beteiligungs GmbH DE 100.00% 01/13 Eurofins GSC Germany GmbH Eurofins Support Services LUX Holding S.\u00e0 r.l. DE 100.00% 04/13 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins CLF Specialised Nutrition Testing Services Eurofins Food Testing Germany East Holding GmbH DE 100.00% 08/13 GmbH BLGG Deutschland GmbH Eurofins Agro Testing Netherlands Holding BV DE 100.00% 07/13 RECO Hamburg Neul\u00e4nder Kamp 1 Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 07/13 Eurofins HT-Analytik GmbH Eurofins NDSC Umweltanalytik GmbH DE 100.00% 03/14 Eurofins Hygiene Institut Berg GmbH Eurofins Environment Testing Germany Holding West DE 100.00% 05/14 GmbH Eurofins Agraranalytik Deutschland GmbH Eurofins Food Testing LUX Holding S.\u00e0 r.l. DE 100.00% 12/14 Eurofins BioPharma Services Holding Germany GmbH Eurofins MWG Holding GmbH DE 100.00% 03/15 Eurofins Agroscience Services Ecotox GmbH Eurofins Agroscience Services Germany Holding DE 100.00% 08/15 GmbH Eurofins Professional Scientific Services Germany Eurofins BioPharma Services Holding Germany GmbH DE 100.00% 10/15 GmbH St. Marien Krankenhaus Lampertheim GmbH Eurofins Clinical Testing Services Germany LUX DE 100.00% 08/16 Holding S.\u00e0 r.l. Eurofins Air Monitoring Germany Holding GmbH Eurofins Air Monitoring LUX Holding S.\u00e0 r.l. DE 100.00% 07/16 Eurofins Finance Transactions Germany GmbH Eurofins Support Services LUX Holding S.\u00e0 r.l. DE 100.00% 10/16 Eurofins Dr. Specht Express GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 04/16 GmbH Eurofins MVZ Medizinisches Labor Gelsenkirchen St. Marien Krankenhaus Lampertheim GmbH DE 100.00% 07/17 GmbH Eurofins Laborbetriebsgesellschaft Gelsenkirchen Eurofins MVZ Medizinisches Labor Gelsenkirchen DE 100.00% 07/17 GmbH GmbH Eurofins Genomics Europe Sequencing GmbH Eurofins MWG Holding GmbH DE 100.00% 07/17 Eurofins LifeCodexx GmbH Eurofins Genomics Europe Sequencing GmbH DE 100.00% 07/17 Eurofins Institut Nehring GmbH Eurofins Food Testing General Chemistry Germany DE 100.00% 10/17 Holding GmbH IfB Institut f\u00fcr Blutgruppenforschung GmbH Eurofins MWG Holding GmbH DE 100.00% 10/17 SAM Sensory and Marketing International GmbH KKG Holding GmbH DE 100.00% 11/17 KKG Holding GmbH Eurofins Sensory, Consumer research and Product DE 100.00% 11/17 design LUX Holding S.\u00e0 r.l. Eurofins Agroscience Services EAG Laboratories Eurofins Agroscience Services Germany Holding DE 100.00% 12/17 GmbH GmbH Evans Analytical Group Holdings GmbH Eurofins EAG Materials Science, LLC DE 100.00% 12/17 Eurofins WKS Labservice GmbH Eurofins Product Testing Verwaltungs GmbH DE 75.00% 12/17 Eurofins PHAST GmbH Eurofins BioPharma Services Holding Germany GmbH DE 100.00% 07/18 Eurofins PHAST Development GmbH & Co. KG Eurofins PHAST GmbH DE 100.00% 07/18 PHAST Development Verwaltungs GmbH Eurofins PHAST GmbH DE 100.00% 07/18 Agrartest GmbH Eurofins Agroscience Services Germany Holding DE 100.00% 07/18 GmbH NovaTec Immundiagnostica GmbH Eurofins Technologies Germany Holding GmbH DE 100.00% 08/20 Gold Standard Diagnostics Kassel GmbH Eurofins Technologies Germany Holding GmbH DE 100.00% 01/19 Eurofins Genomics Europe Shared Services GmbH Eurofins MWG Holding GmbH DE 100.00% 02/19 Eurofins Q-Bioanalytic GmbH Eurofins BioTesting Services Nord GmbH DE 100.00% 11/18 LL Leipzig Landsteiner Strasse Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 05/19 Eurofins Technologies Germany Holding GmbH Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. DE 100.00% 03/19 Gold Standard Diagnostics CD Kassel GmbH Eurofins Technologies Germany Holding GmbH DE 100.00% 01/19 Virotech Diagnostics GmbH Eurofins Technologies Germany Holding GmbH DE 100.00% 02/19 Eurofins Agroscience Services Regulatory Germany Eurofins Agroscience Services Germany Holding DE 100.00% 12/19 GmbH GmbH Eurofins BioTesting Services Ost GmbH Dr. Appelt Beteiligungs GmbH DE 100.00% 01/20 MF M\u00fcnchen Friedenheimer Br\u00fccke Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 05/20 % of Date ISO interest Company Subsidiary of: of code by the entry Group Pr\u00e4natal-Medizin M\u00fcnchen Frauen\u00e4rzte und St. Marien Krankenhaus Lampertheim GmbH DE 100.00% 05/20 Humangenetiker MVZ GmbH Eurofins BioPharma Services Consulting Munich GmbH Eurofins BioPharma Services Holding Germany GmbH DE 100.00% 11/20 RECO 2. Verwaltungsgesellschaft GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 07/21 Eurofins NBLSC Technologies Germany GmbH Eurofins Technologies Germany Holding GmbH DE 100.00% 06/21 RECO Troisdorf Gierlichstrasse Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 12/20 Eurofins Derma Tronnier GmbH Eurofins Product Testing Verwaltungs GmbH DE 100.00% 12/20 Tronnier Verwaltungs GmbH Eurofins Product Testing Verwaltungs GmbH DE 100.00% 12/20 RECO 1. Verwaltungsgesellschaft GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 01/21 Eurofins EmpowerDX Europe GmbH St. Marien Krankenhaus Lampertheim GmbH DE 100.00% 06/21 Bioskin GmbH Eurofins Product Testing Verwaltungs GmbH DE 100.00% 08/21 Modern Testing Services (Germany) GmbH Modern Technology Holdings Limited DE 100.00% 11/21 Eurofins NSC Denmark A/S Eurofins Support Services LUX Holding S.\u00e0 r.l. DK 100.00% 12/03 Eurofins Biopharma Product Testing Denmark A/S Eurofins BioPharma Product Testing Denmark Holding DK 100.00% 03/06 A/S Eurofins Product Testing Denmark A/S Eurofins Product Testing LUX Holding S.\u00e0 r.l. DK 100.00% 08/08 Eurofins Miljo A/S Eurofins Environment Denmark Holding A/S DK 100.00% 06/05 Eurofins Steins Laboratorium A/S Eurofins Food Denmark Holding A/S DK 100.00% 07/06 Eurofins Environment Denmark Holding A/S Eurofins Environment Testing LUX Holding S.\u00e0 r.l. DK 100.00% 04/07 Eurofins Food Denmark Holding A/S Eurofins Food Testing LUX Holding S.\u00e0 r.l. DK 100.00% 04/07 Eurofins Genomics Holding Denmark A/S Eurofins Genomics LUX Holding S.\u00e0 r.l. DK 100.00% 11/13 Eurofins Genomics Europe Genotyping A/S Eurofins Genomics Holding Denmark A/S DK 100.00% 01/13 Eurofins Milj\u00f8 Vand A/S Eurofins Environment Denmark Holding A/S DK 100.00% 10/13 Eurofins Agro Testing Denmark A/S Eurofins Food Denmark Holding A/S DK 100.00% 12/14 Eurofins Milj\u00f8 Luft A/S Eurofins Environment Denmark Holding A/S DK 100.00% 08/14 Eurofins BioPharma Product Testing Denmark Holding Eurofins Pharma Services LUX Holding S.\u00e0 r.l. DK 100.00% 08/15 A/S Eurofins Professional Scientific Services Denmark A/S Eurofins BioPharma Product Testing Denmark Holding DK 100.00% 08/15 A/S Eurofins Genomics Denmark A/S Eurofins Genomics Holding Denmark A/S DK 100.00% 12/15 Eurofins Safer At Work Nordics A/S Eurofins Genomics Holding Denmark A/S DK 100.00% 09/16 Eurofins Milk Testing Denmark A/S Eurofins Food Denmark Holding A/S DK 100.00% 01/17 Eurofins Vitamin Testing Denmark A/S Eurofins Food Denmark Holding A/S DK 100.00% 01/17 Aabybro Industrivej Real Estate ApS Eurofins Real Estate LUX Holding S.\u00e0 r.l. DK 100.00% 03/17 Eurofins VBM Laboratoriet A/S Eurofins Environment Denmark Holding A/S DK 100.00% 03/17 Eurofins VBM Geo ApS Eurofins Environment Denmark Holding A/S DK 100.00% 10/18 Eurofins Environment Testing Holding Estonia O\u00dc Eurofins Environment Testing LUX Holding S.\u00e0 r.l. EE 100.00% 04/17 Eurofins Environment Testing Estonia O\u00dc Eurofins Environment Testing Holding Estonia O\u00dc EE 100.00% 04/17 Rae Village Vana-Sutikase ja Tammi tee Real Estate Eurofins Real Estate LUX Holding S.\u00e0 r.l. EE 100.00% 12/19 O\u00dc Eurofins Agroscience Services, S.L.U. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. ES 100.00% 01/06 Eurofins BioPharma Product Testing Spain, S.L.U. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. ES 100.00% 01/07 Eurofins Latin American Ventures, S.L.U. Eurofins International Holdings LUX S.\u00e0 r.l. ES 100.00% 04/09 Eurofins Sicaagriq, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 07/13 Eurofins Analisis Alimentario Holding Espana S.L.U. Eurofins Food Testing LUX Holding S.\u00e0 r.l. ES 100.00% 09/13 Sensory and Marketing Spain, S.L.U. Eurofins Sensory, Consumer research and Product ES 100.00% 09/13 design LUX Holding S.\u00e0 r.l. % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins An\u00e1lisis Alimentario, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 05/14 Eurofins Food Barcelona, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 05/14 Eurofins An\u00e1lisis Agro, S.A. Eurofins Food Barcelona, S.L.U. ES 90.21% 05/14 Eurofins Product Testing, Cosmetics & Personal Care Eurofins Product Testing Holding Spain, S.L.U. ES 100.00% 07/15 Spain, S.L.U. Eurofins Trialcamp, S.L.U. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. ES 100.00% 06/15 Eurofins Laboratorio Sarr\u00f3, S.L.U. Eurofins Biologie M\u00e9dicale Holding France SAS ES 100.00% 07/15 Eurofins NSC Spain, S.L.U. Eurofins Support Services LUX Holding S.\u00e0 r.l. ES 100.00% 01/16 Eurofins Histolog, S.L.U. France Anapath Holding SAS ES 100.00% 01/16 Eurofins NDSC Food Testing Spain, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 04/16 Eurofins Product Testing Holding Spain, S.L.U. Eurofins Product Testing LUX Holding S.\u00e0 r.l. ES 100.00% 04/16 Eurofins Professional Scientific Services Spain, S.L.U. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. ES 100.00% 01/17 Eurofins Megalab, S.A.U. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. ES 100.00% 09/16 Eurofins Laboratorio \u00c1ngel M\u00e9ndez, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 09/16 Eurofins Laboratorio Surlab, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 09/16 Megalab Medio Ambiente, S.L. Eurofins Megalab, S.A.U. ES 70.00% 09/16 Eurofins Laboratorio Dr. Valenzuela, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 09/16 Eurofins Laboratorio Prefasi, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 05/17 Eurofins Villapharma Research, S.L.U. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. ES 100.00% 03/17 Eurofins Laboratorios de Castilla y Le\u00f3n, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 05/17 Eurofins Textile Testing Spain, S.L.U. Eurofins Product Testing Holding Spain, S.L.U. ES 100.00% 04/17 Fuente \u00c1lamo de Murcia - El Estrech Real Estate, Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 12/17 S.L.U. Eurofins Analclinic, S.A.U. Eurofins Megalab, S.A.U. ES 100.00% 11/17 Eurofins Technologies Holding Spain, S.L.U. Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. ES 100.00% 02/18 Madrid Garc\u00eda Noblejas Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 07/18 Eurofins Mas Control, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 03/18 Eurofins Ingenasa, S.A. Eurofins Technologies Holding Spain, S.L.U. ES 94.10% 02/18 Eurofins Agroscience Services Regulatory Spain, Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. ES 100.00% 04/18 S.L.U. Santa Cruz Diesel Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 07/18 Eurofins Audit & Inspection, S.A.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 07/18 Eurofins Agroscience Services Iberica Holding, S.L.U. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. ES 100.00% 12/18 Eurofins LGS Megalab An\u00e1lisis Cl\u00ednicos, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 07/18 Eurofins Ecosur, S.A.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 07/18 Eurofins LGS Megalab An\u00e1lisis Veterinarios, S.L.U. Eurofins LGS Megalab An\u00e1lisis Cl\u00ednicos, S.L.U. ES 100.00% 12/18 Lorqui Castillo de Aledo, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 03/19 Eurofins Environment Testing Spain Holding, S.L.U. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. ES 100.00% 04/19 Eurofins GSC Spain, S.L.U. Eurofins Support Services LUX Holding S.\u00e0 r.l. ES 100.00% 04/19 Eurofins M\u00e9todos Servicios Agr\u00edcolas, S.L.U. Eurofins Agroscience Services Iberica Holding, S.L.U. ES 100.00% 03/19 Eurofins Iproma, S.L.U. Eurofins Environment Testing Spain Holding, S.L.U. ES 100.00% 07/19 Alfredo Montoro Soriano, S.L.U. Eurofins Analclinic, S.A.U. ES 100.00% 06/19 Mazarr\u00f3n Campico Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 03/20 Abar\u00e1n Rellano Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 08/20 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Laboratorio Montoro Botella, S.L.U. Alfredo Montoro Soriano, S.L.U. ES 100.00% 06/19 Castell\u00f3n Lituania Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 03/20 Eurofins Envira Ingenieros Asesores, S.L.U. Eurofins Environment Testing Spain Holding, S.L.U. ES 100.00% 11/20 Premiumlab, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 12/20 Eurofins Quimico Onubense, S.L.U. Eurofins Environment Testing Spain Holding, S.L.U. ES 100.00% 08/21 Oricain Ezcabarte Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 03/21 Paterna Les Ones Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 07/21 Cimera Estudios Aplicados, S.L.U. Eurofins Environment Testing Spain Holding, S.L.U. ES 100.00% 05/21 Eurofins NBLSC Environment Testing Spain, S.L.U. Eurofins Environment Testing Spain Holding, S.L.U. ES 100.00% 05/21 Eurofins Centro Anal\u00ectico M\u00ecguez Mu\u00ecnos, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 08/21 Eurofins Scientific Finland Oy Eurofins Food Testing LUX Holding S.\u00e0 r.l. FI 100.00% 10/07 Eurofins Viljavuuspalvelu Oy Eurofins Food Testing LUX Holding S.\u00e0 r.l. FI 100.00% 12/12 Eurofins Environment Testing Finland Holding Oy Eurofins Environment Testing LUX Holding S.\u00e0 r.l. FI 100.00% 01/17 Eurofins Ahma Oy Eurofins Environment Testing Finland Holding Oy FI 100.00% 02/17 Eurofins Environment Testing Finland Oy Eurofins Environment Testing Finland Holding Oy FI 100.00% 04/17 Eurofins Nab Labs Group Oy Eurofins Environment Testing Finland Holding Oy FI 100.00% 06/17 Eurofins Nab Labs Oy Eurofins Nab Labs Group Oy FI 100.00% 06/17 Eurofins Expert Services Oy Eurofins Product Testing LUX Holding S.\u00e0 r.l. FI 100.00% 06/18 Eurofins Labtium Oy Eurofins Environment Testing Finland Holding Oy FI 100.00% 06/18 Oulu Nuottasaari Real Estate Oy Eurofins Real Estate LUX Holding S.\u00e0 r.l. FI 100.00% 09/19 Eurofins Product Testing Finland Holding Oy Eurofins Product Testing LUX Holding S.\u00e0 r.l. FI 100.00% 04/21 Eurofins Electric & Electronics Finland Oy Eurofins Product Testing Finland Holding Oy FI 100.00% 04/21 Eurofins Microbiologie France Holding SAS Eurofins Hygi\u00e8ne Alimentaire France LUX Holding S.\u00e0 FR 100.00% 01/99 r.l. Eurofins Analytics France SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 07/99 Eurofins Hygi\u00e8ne Alimentaire Formation SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 07/99 Eurofins Certification SAS Eurofins Assurance and Inspection Services France FR 100.00% 07/03 Holding SAS Eurofins Laboratoire De Microbiologie De L'Est SAS Eurofins Microbiologie France Holding SAS FR 100.00% 01/06 Eurofins ATS SAS Eurofins Product Testing LUX Holding S.\u00e0 r.l. FR 100.00% 01/99 Eurofins Hydrologie France Holding SAS Eurofins Hydrologie France LUX Holding S.\u00e0 r.l. FR 100.00% 07/05 Eurofins Analyses Pour L'Environnement France SAS Eurofins Analyses Environnementales Pour Les FR 100.00% 07/05 Industriels France SAS Eurofins Analyses Pour Le B\u00e2timent Est SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 01/01 SAS Eurofins BioPharma Product Testing & Professional Eurofins Pharma Services France LUX Holding S.\u00e0 r.l. FR 100.00% 06/06 Scientific Services France Holding SAS Eurofins Genomics France SAS Eurofins Genomics LUX Holding S.\u00e0 r.l. FR 100.00% 07/05 Institut Francais Des Empreintes Genetiques SAS Eurofins Forensics LUX Holding S.\u00e0 r.l. FR 75.00% 11/05 Toxlab SAS Eurofins Forensics LUX Holding S.\u00e0 r.l. FR 98.64% 02/05 Eurofins ADME Bioanalyses SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 10/04 Scientific Services France Holding SAS Eurofins Optimed SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 01/06 Scientific Services France Holding SAS Eurofins Pharma Quality Control SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 01/06 Scientific Services France Holding SAS Eurofins Agroscience Services France SAS Eurofins Agrosciences Services France Holding SAS FR 100.00% 01/06 Eurofins Agroscience Services SAS Eurofins Agrosciences Services France Holding SAS FR 100.00% 01/06 % of Date ISO interest Company Subsidiary of: of code by the entry Group Chemtox SAS Eurofins Forensics LUX Holding S.\u00e0 r.l. FR 98.90% 01/08 Eurofins Laboratoires De Microbiologie Ouest SAS Eurofins Microbiologie France Holding SAS FR 100.00% 10/06 Eurofins Cervac Sud SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 10/06 Eurofins NSC Finance France SAS Eurofins Support Services LUX Holding S.\u00e0 r.l. FR 100.00% 10/06 SAM Consumer International France SAS Eurofins Sensory Holding France SAS FR 100.00% 10/06 Eurofins Hydrologie France SAS Eurofins Hydrologie France Holding SAS FR 100.00% 01/01 Eurofins Food Chemistry Testing France Holding SAS Eurofins Food Chemistry Testing France LUX Holding FR 100.00% 09/07 S.\u00e0 r.l. Eurofins Optimed Lyon SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 09/07 Scientific Services France Holding SAS Eurofins NSC IT Infrastructure France SAS Eurofins Support Services LUX Holding S.\u00e0 r.l. FR 100.00% 12/07 Eurofins Hydrologie Centre Est SAS Eurofins Hydrologie France Holding SAS FR 100.00% 04/08 Eurofins Laboratoire Centre SAS Eurofins Microbiologie France Holding SAS FR 100.00% 07/10 Eurofins Laboratoire Nord SAS Eurofins Microbiologie France Holding SAS FR 100.00% 07/10 Eurofins Consulting Agroalimentaire SAS Eurofins Assurance and Inspection Services France FR 100.00% 07/10 Holding SAS Eurofins GSC France SAS Eurofins Support Services LUX Holding S.\u00e0 r.l. FR 100.00% 07/10 Eurofins NDSC IT Solution Food France SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 08/10 Eurofins NDSC Environnement France SAS Eurofins NDSC Environnement France Holding SAS FR 100.00% 08/10 Eurofins Analyses Pour Le Batiment France Holding Eurofins Analyses pour la Construction France LUX FR 100.00% 08/10 SAS Holding S.\u00e0 r.l. Eurofins NBLSC Analyses Pour Le B\u00e2timent France Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 09/10 SAS SAS Eurofins Analyses Environnementales Pour Les Eurofins Analyses Environnementales pour les FR 100.00% 10/10 Industriels France SAS Industriels France LUX Holding S.\u00e0 r.l. Eurofins NSC Developpement France SAS Eurofins Support Services LUX Holding S.\u00e0 r.l. FR 100.00% 10/10 Eurofins Agroscience Services Chem SAS Eurofins Agrosciences Services France Holding SAS FR 100.00% 12/10 Eurofins Analyses pour le B\u00e2timent Ile de France SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 12/10 SAS Eurofins Analyses pour le B\u00e2timent Nord SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 12/10 SAS Eurofins Analyses pour le B\u00e2timent Sud Est SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 12/10 SAS Eurofins Analyses pour le B\u00e2timent Ouest SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 12/10 SAS Eurofins Analyses des Mat\u00e9riaux et Combustibles Eurofins Expertises France Holding SAS FR 100.00% 12/10 France SAS Eurofins Hydrologie Nord SAS Eurofins Hydrologie France Holding SAS FR 100.00% 11/11 Eurofins LCAM - Eurofins Laboratoire Central Eurofins Microbiologie France Holding SAS FR 100.00% 11/11 d'Analyses de la Moselle SAS Eurofins Hydrologie Ile De France SAS Eurofins Hydrologie France Holding SAS FR 100.00% 11/11 Eurofins Hydrologie Est SAS Eurofins Hydrologie France SAS FR 100.00% 11/11 Eurofins Hydrologie Sud SAS Eurofins Hydrologie France Holding SAS FR 100.00% 11/11 Eurofins Asbestos Testing Europe SAS Eurofins Industrial Testing LUX S.\u00e0 r.l. FR 100.00% 11/11 Eurofins Laboratoire Contaminants Sud SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 12/11 Eurofins Laboratoire De Pathologie V\u00e9g\u00e9tale SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 12/11 Eurofins Hydrologie Ouest SAS Eurofins Hydrologie France Holding SAS FR 100.00% 02/12 Eurofins NBLSC Forensics SAS Eurofins Forensics LUX Holding S.\u00e0 r.l. FR 100.00% 02/12 Eurofins Ecotoxicologie France SAS Eurofins Expertises France Holding SAS FR 100.00% 04/12 Eurofins NDSC Environnement France Holding SAS Eurofins Environment Testing LUX Holding S.\u00e0 r.l. FR 100.00% 05/12 Eurofins NDSCE Support France SAS Eurofins NDSC Environnement France Holding SAS FR 100.00% 01/12 Eurofins Agrosciences Services France Holding SAS Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. FR 100.00% 12/12 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins GSC CADET SAS Eurofins Support Services LUX Holding S.\u00e0 r.l. FR 100.00% 11/12 Eurofins Environnement Logistique France SAS Eurofins Analyses Environnementales Pour Les FR 100.00% 12/12 Industriels France SAS Eurofins Pharma Products Testing France Eurofins BioPharma Product Testing & Professional FR 100.00% 12/12 Management SAS Scientific Services France Holding SAS Eurofins Pharma Products Engineering SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 12/12 Scientific Services France Holding SAS Eurofins Cerep SA Eurofins Discovery Services LUX Holding S.\u00e0 r.l. FR 95.78% 03/13 Eurofins MITOX FOPSE SARL Eurofins Agrosciences Services France Holding SAS FR 100.00% 07/13 Eurofins Analyses Pour Le Batiment Sud-Ouest SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 09/13 SAS Eurofins ID MYK SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 01/14 Scientific Services France Holding SAS Eurofins Prelevement Pour Le Batiment France Holding Eurofins Analyses pour lEnvironnement France LUX FR 100.00% 08/14 SAS Holding S.\u00e0 r.l. Eurofins Prelevement Pour Le Batiment Est SAS Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 09/14 SAS Eurofins Prelevement Pour Le Batiment France SAS Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 10/14 SAS Eurofins Prelevement Pour Le Batiment Ouest SAS Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 10/14 SAS Eurofins NSC HR France SAS Eurofins Support Services LUX Holding S.\u00e0 r.l. FR 100.00% 07/14 Eurofins Analyses Pour Le B\u00e2timent Sud SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 08/14 SAS Eurofins Prelevement Pour Le Batiment Nord SAS Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 09/14 SAS Eurofins Prelevement Pour Le Batiment Sud-Est SAS Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 09/14 SAS Eurofins Pr\u00e9l\u00e8vement pour le B\u00e2timent \u00cele-de-France Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 09/14 SAS SAS Eurofins NDSC Hydrologie France SAS Eurofins Hydrologie France Holding SAS FR 100.00% 11/14 Eurofins NDSC Microbiologie Alimentaire France SAS Eurofins Microbiologie France Holding SAS FR 100.00% 12/14 SCI Vennecy Les Esses Galerne Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 11/14 Eurofins Product Testing France Holding SAS Eurofins Product Testing LUX Holding S.\u00e0 r.l. FR 100.00% 12/14 Eurofins Analyses Pour Le B\u00e2timent Nord-Ouest Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 04/15 CEBAT SAS SAS Eurofins Evic Product Testing France SAS Eurofins Product Testing France Holding SAS FR 100.00% 07/15 Eurofins Hygi\u00e8ne Hospitali\u00e8re Sud SAS Eurofins Expertises France Holding SAS FR 100.00% 07/15 Eurofins Environment Testing France Australia Holding Eurofins Environment Testing LUX Holding S.\u00e0 r.l. FR 100.00% 06/15 SAS Eurofins Biologie M\u00e9dicale Holding France SAS Eurofins Clinical Testing Services France LUX Holding FR 100.00% 07/15 S.\u00e0 r.l. Eurofins Labazur Provence SELAS Eurofins Laboratorio Sarr\u00f3, S.L.U. FR 100.00% 07/15 Eurofins Labazur Guyane SELAS Eurofins Labazur Provence SELAS FR 100.00% 07/15 Eurofins Labazur Nice SELAS Eurofins Labazur Provence SELAS FR 100.00% 07/15 Eurofins Labazur Rhone-Alpes SELAS Eurofins Labazur Provence SELAS FR 100.00% 07/15 Eurofins Labazur Bretagne SELAS Eurofins Labazur Provence SELAS FR 100.00% 07/15 Eurofins Labazur Alpes-Sud Var SELAS Eurofins Labazur Provence SELAS FR 100.00% 07/15 France Anapath Holding SAS Eurofins Clinical Testing Services France LUX Holding FR 100.00% 07/15 S.\u00e0 r.l. Eurofins Galys SAS Eurofins Food Chemistry Testing France LUX Holding FR 100.00% 12/15 S.\u00e0 r.l. Eurofins Hydrologie Sud Ouest SAS Eurofins Hydrologie France Holding SAS FR 100.00% 11/15 Biomnis Empreintes Genetiques SAS Eurofins Forensics LUX Holding S.\u00e0 r.l. FR 100.00% 10/15 Eurofins Hydrobiologie France SAS Eurofins Expertises France Holding SAS FR 100.00% 10/15 Eurofins Biologie Sp\u00e9cialis\u00e9e France SAS Eurofins Clinical Testing Services France LUX Holding FR 100.00% 10/15 S.\u00e0 r.l. % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Biomnis Sample Library SAS Eurofins Biologie Sp\u00e9cialis\u00e9e France SAS FR 100.00% 10/15 SCI du Val d'Ouest Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 10/15 Eurofins Biomnis SELAS Eurofins Biomnis Ireland Limited FR 100.00% 10/15 Eurofins CBM69 SELAS Eurofins Labazur Provence SELAS FR 100.00% 10/15 Eurofins CEF SELAS Eurofins Labazur Provence SELAS FR 100.00% 10/15 Eurofins Bioffice SELAS Eurofins Labazur Provence SELAS FR 100.00% 10/15 Biosphere GIE Eurofins Biomnis SELAS FR 100.00% 10/15 Eurofins Biotech Germande SAS Eurofins Hydrologie France Holding SAS FR 100.00% 01/16 Eurofins Phyliae SAS Eurofins Agrosciences Services France Holding SAS FR 100.00% 11/15 Sci Garlin Bearn Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/15 Eurofins Agro-Analyses SAS Eurofins Microbiologie France Holding SAS FR 100.00% 05/16 Eurofins LCDI SAS Eurofins Hydrologie France Holding SAS FR 100.00% 07/16 SCI Lentilly Aqueduc Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 11/16 Eurofins Pathologie SELAS Eurofins Histolog, S.L.U. FR 100.00% 04/17 Eurofins NDSC Alimentaire France SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 08/17 Eurofins NDSC Chimie Alimentaire France SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 08/17 Eurofins Biologie Moleculaire France SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 08/17 Eurofins Laboratoire Nutrition Animale France SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 08/17 SAM Sensory International France SAS Eurofins Sensory Holding France SAS FR 100.00% 08/17 Eurofins Expertises France Holding SAS Eurofins Analyses Environnementales pour les FR 100.00% 09/17 Industriels France LUX Holding S.\u00e0 r.l. Eurofins Amatsigroup SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 09/17 Scientific Services France Holding SAS Immobiliere Amatsi SAS Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 09/17 Eurofins Disposable Lab SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 09/17 Scientific Services France Holding SAS Eurofins Amatsiaquitaine SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 09/17 Scientific Services France Holding SAS Eurofins Anapath France Holding SAS Eurofins Clinical Testing Services France LUX Holding FR 100.00% 09/17 S.\u00e0 r.l. Eurofins NDSC Pollution France SAS Eurofins Analyses Environnementales Pour Les FR 100.00% 09/17 Industriels France SAS Eurofins Agroscience Services Seeds France SAS Eurofins Agrosciences Services France Holding SAS FR 100.00% 09/17 SAM Retail France SAS Eurofins Sensory Holding France SAS FR 100.00% 09/17 Eurofins NSC Clinical Diagnostics France GIE Eurofins Biomnis SELAS FR 100.00% 11/17 Eurofins Agroscience Services Regulatory France SAS Eurofins Agrosciences Services France Holding SAS FR 100.00% 10/17 Eurofins Amatsi Analytics SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 10/17 Scientific Services France Holding SAS Eurofins Product Testing 2 France Holding SAS Eurofins Product Testing LUX Holding S.\u00e0 r.l. FR 100.00% 10/17 Eurofins Biologie Medicale Sud-Ouest SAS Eurofins Clinical Testing Services France LUX Holding FR 100.00% 10/18 S.\u00e0 r.l. Eurofins EAG Materials Science France SAS Eurofins EAG Materials Science, LLC FR 100.00% 12/17 Eurofins Eichrom Amiante SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 04/18 SAS Eurofins Eichrom Radioactivite SAS Eurofins Expertises France Holding SAS FR 100.00% 04/18 SCI Bruz Bastie Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 04/18 Eurofins LEA SAS Eurofins Hydrologie France Holding SAS FR 100.00% 04/18 Eurofins Lanagram SAS Eurofins Microbiologie France Holding SAS FR 100.00% 04/18 Eurofins Bactup SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 05/18 Scientific Services France Holding SAS % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins 3 Ohms SAS Eurofins Product Testing France Holding SAS FR 100.00% 07/18 Eurofins Interlab SELAS Eurofins Labazur Provence SELAS FR 100.00% 10/18 SCI Rosporden Renan Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 10/18 Eurofins Bio Lab Eurofins Labazur Provence SELAS FR 100.00% 07/18 Eurofins Biologie Medicale Ile De France SAS Eurofins Clinical Testing Services France LUX Holding FR 100.00% 07/18 S.\u00e0 r.l. Eurofins Laboratoire De Bromatologie Ouest Et Eurofins Microbiologie France Holding SAS FR 100.00% 07/18 Bretagne SAS Eurofins Hydrologie Normandie SAS Eurofins Hydrologie France Holding SAS FR 100.00% 12/18 Eurofins Pr\u00e9l\u00e8vement pour le B\u00e2timent Nord Est SAS Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 12/18 SAS Alpa Environnement Holding France SAS Eurofins Water Testing LUX S.\u00e0 r.l. FR 100.00% 12/18 SCI Lentilly Parc d'Activit\u00e9 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 Eurofins DSC Product Testing SAS Eurofins Product Testing LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 Eurofins NDSC Audit Et Consulting France SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 12/18 SCI 2 Laponie Les Ulis Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 SCI Landerneau L\u00e9on Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 SCI Loos Palissy Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 SCI Martillac Newton Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 SCI Maxeville Cuenot Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 SCI Saint Augustin Paillard Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 SCI Saint Gely Vautes Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 Eurofins Expertise Microbiologique France SAS Eurofins Expertises France Holding SAS FR 100.00% 12/18 Eurofins Dispositifs au Contact de l'Eau France SAS Eurofins Expertises France Holding SAS FR 100.00% 12/18 SCI Idron Mazerolles Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 Eurofins Laboratoire Dermscan SAS Eurofins Product Testing 2 France Holding SAS FR 100.00% 11/18 Alpa Alimentaire Holding France SAS Eurofins Water Testing LUX S.\u00e0 r.l. FR 100.00% 11/18 Eurofins Chimie Alimentaire Rouen SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 11/18 Eurofins Sensory Holding France SAS Eurofins Sensory, Consumer research and Product FR 100.00% 01/19 design LUX Holding S.\u00e0 r.l. Eurofins Alpabio SAS Alpa Environnement Holding France SAS FR 100.00% 12/18 Eurofins DiscoverX Products France SAS Eurofins Discovery Services LUX Holding S.\u00e0 r.l. FR 100.00% 03/19 Eurofins NDSC Expertises France SAS Eurofins Expertises France Holding SAS FR 100.00% 01/19 Eurofins Analyses de l'Air SAS Eurofins Analyses Environnementales Pour Les FR 100.00% 02/19 Industriels France SAS Eurofins Clinical Trial Supplies France SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 02/19 Scientific Services France Holding SAS Eurofins Analyses Nutritionnelles France SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 02/19 Eurofins Laboratoire de Microbiologie Sud SAS Eurofins Microbiologie France Holding SAS FR 100.00% 02/19 Eurofins Assurance France SAS Eurofins Assurance and Inspection Services France FR 100.00% 12/19 Holding SAS Eurofins Laboratoire Microbiologie Rh\u00f4ne-Alpes SAS Eurofins Microbiologie France Holding SAS FR 100.00% 12/19 Eurofins GeneScan Technologies France SAS Gold Standard Diagnostics France Holding SAS FR 100.00% 12/19 Eurofins Hygi\u00e8ne Hospitali\u00e8re Nord SAS Eurofins Expertises France Holding SAS FR 100.00% 12/19 Eurofins BioPharma Product Testing Biologics SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 12/19 Scientific Services France Holding SAS Eurofins Microbiologie des Eaux Ouest SAS Eurofins Microbiologie France Holding SAS FR 100.00% 12/19 Eurofins Hygi\u00e8ne Alimentaire Nord-Ouest SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 01/20 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Hygi\u00e8ne Alimentaire Sud-Est SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 01/20 Eurofins Hygi\u00e8ne Alimentaire Nord-Est SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 01/20 Eurofins Hygi\u00e8ne Alimentaire SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 01/20 Eurofins Hygi\u00e8ne Alimentaire Ile de France SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 01/20 Eurofins Hygi\u00e8ne Alimentaire Sud-Ouest SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 01/20 Eurofins Labazur Pays De La Loire SELAS Eurofins Biologie M\u00e9dicale Holding France SAS FR 100.00% 11/20 Gold Standard Diagnostics Millidrop SAS Gold Standard Diagnostics France Holding SAS FR 100.00% 11/21 Gold Standard Diagnostics France Holding SAS Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. FR 100.00% 12/20 Eurofins Electrical and Electronics France SAS Eurofins Product Testing France Holding SAS FR 100.00% 12/20 Eurofins Hygi\u00e8ne Alimentaire France Holding Eurofins Hygi\u00e8ne Alimentaire France LUX Holding S.\u00e0 FR 100.00% 12/20 r.l. Eurofins Assurance and Inspection Services France Eurofins Assurance LUX Holding S.\u00e0 r.l. FR 100.00% 12/20 Holding SAS SCI Verneuil Papin Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/20 SCI Venissieux Docteur Georges Levy Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/20 SCI Pleyben Carn Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/20 SCI Villejust Zephyr Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/20 SCI Eurofins 2021 5 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/20 Eurofins IESPM SAS Eurofins Expertises France Holding SAS FR 100.00% 07/21 Eurofins BioMed Ouest Guyane SAS Eurofins Biologie M\u00e9dicale Holding France SAS FR 100.00% 10/21 SCI Eurofins 2022 1 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/21 SCI Saint Maximin Laouve Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/21 SCI Eurofins BioMed France Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/21 SCI Management BioMed France Eurofins Real Estate France Holding SAS FR 100.00% 12/21 SCI EUROFINS 2022 5 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/21 Eurofins Toxicological and Regulatory Expertise C&PC Eurofins Product Testing France Holding SAS FR 100.00% 11/21 France SAS Eurofins Medical Device Testing France SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 11/21 Scientific Services France Holding SAS Eurofins Product Testing clinical and ex-vivo France Eurofins Product Testing France Holding SAS FR 60.20% 11/21 Holding SAS Eurofins Real Estate France Holding SAS Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 11/21 Eurofins Environnement Formation et Conseil SAS Eurofins Hygi\u00e8ne Hospitali\u00e8re France Holding SAS FR 100.00% 11/21 Eurofins Hygi\u00e8ne Hospitali\u00e8re France Holding SAS Eurofins Hydrologie France LUX Holding S.\u00e0 r.l. FR 100.00% 11/21 Eurofins NBLSC Hygi\u00e8ne Hospitali\u00e8re France SAS Eurofins Hygi\u00e8ne Hospitali\u00e8re France Holding SAS FR 100.00% 11/21 Eurofins Discovery, Central Laboratory and BioAnalysis Eurofins Discovery Services LUX Holding S.\u00e0 r.l. FR 100.00% 11/21 France Holding SAS Eurofins Laboratoire Distribution Alimentaire SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 11/21 Eurofins NewCo Fractale 2 Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 11/21 Eurofins Croatiakontrola d.o.o. Eurofins Croatia Food Testing HoldCo d.o.o. HR 99.21% 09/19 Karlovacka Real Estate d.o.o Eurofins Real Estate LUX Holding S.\u00e0 r.l. HR 100.00% 09/19 Eurofins Croatia Food Testing HoldCo d.o.o. Eurofins Food Testing LUX Holding S.\u00e0 r.l. HR 100.00% 03/20 Eurofins Agroscience Services Kft. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. HU 100.00% 09/07 Eurofins NBLSC Food&Feed Testing Hungary Kft. Eurofins Food Testing Hungary Holding Kft. HU 100.00% 08/16 Eurofins Technologies Hungary Kft. Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. HU 100.00% 05/17 Eurofins Food Testing Hungary Holding Kft. Eurofins Food Testing LUX Holding S.\u00e0 r.l. HU 100.00% 10/17 Gyula Henyei 5 utca Real Estate Kft. Eurofins Real Estate LUX Holding S.\u00e0 r.l. HU 100.00% 10/17 % of Date ISO interest Company Subsidiary of: of code by the entry Group Gyula Henyei Mikl\u00f3s utca 52 Real Estate Kft. Eurofins Real Estate LUX Holding S.\u00e0 r.l. HU 100.00% 11/17 SZE Kesely\u0171si 9 Real Estate Kft. Eurofins Real Estate LUX Holding S.\u00e0 r.l. HU 100.00% 11/17 Eurofins Minerag Kft. Eurofins Food Testing Hungary Holding Kft. HU 100.00% 12/17 Eurofins Food Analytica Kft. Eurofins Food Testing Hungary Holding Kft. HU 100.00% 01/18 Eurofins Environment Testing Hungary Holding Kft. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. HU 100.00% 07/18 BUD Foti 56 Real Estate Kft. Eurofins Real Estate LUX Holding S.\u00e0 r.l. HU 100.00% 08/18 Eurofins Clinical Testing Hungary Holding Kft. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. HU 100.00% 08/18 Eurofins NSC Hungary Kft. Eurofins Support Services LUX Holding S.\u00e0 r.l. HU 100.00% 09/18 Eurofins KVI-PLUSZ K\u00f6rnyezetv\u00e9delmi Vizsg\u00e1l\u00f3 Iroda Eurofins Environment Testing Hungary Holding Kft. HU 100.00% 07/18 Kft. Gold Standard Diagnostics International Kft. Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. HU 100.00% 06/20 Eurofins Vetcontrol Kft. Eurofins Food Testing Hungary Holding Kft. HU 100.00% 10/20 Eurofins BioPharma Product Testing Hungary Kft. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. HU 100.00% 12/21 Eurofins Scientific (Ireland) Limited Eurofins GSC LUX S.\u00e0 r.l. IE 100.00% 05/03 Eurofins Food Testing Ireland Limited Eurofins Food Testing LUX Holding S.\u00e0 r.l. IE 100.00% 04/09 Eurofins BioPharma Product Testing Ireland Holding Eurofins Pharma Services LUX Holding S.\u00e0 r.l. IE 100.00% 02/11 Limited Eurofins BioPharma Product Testing Ireland Limited Eurofins BioPharma Product Testing Ireland Holding IE 100.00% 04/11 Limited Clogherane Real Estate Investment Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. IE 100.00% 11/15 Eurofins Biomnis Ireland Limited Eurofins Biologie Sp\u00e9cialis\u00e9e France SAS IE 100.00% 10/15 Eurofins Lablink Limited Eurofins Biomnis Ireland Limited IE 100.00% 10/15 Eurofins Professional Scientific Services Ireland Limited Eurofins BioPharma Product Testing Ireland Holding IE 100.00% 07/16 Limited Medical Consultants Pathology Holdings Limited Eurofins Biomnis Ireland Limited IE 100.00% 01/17 Eurofins MC Pathology Limited Medical Consultants Pathology Holdings Limited IE 100.00% 01/17 Environmental Laboratory Services Limited Eurofins Environment Testing LUX Holding S.\u00e0 r.l. IE 100.00% 07/17 Eurofins Scientific Services Ireland Limited Eurofins GSC LUX S.\u00e0 r.l. IE 100.00% 10/17 Eurofins Environmental Testing Ireland Holding Limited Eurofins Environment Testing LUX Holding S.\u00e0 r.l. IE 100.00% 03/18 Eurofins Environment Testing Ireland Limited Eurofins Environmental Testing Ireland Holding Limited IE 100.00% 02/18 Eurofins Gynae-Screen Limited Eurofins Biomnis Ireland Limited IE 100.00% 05/18 Eurofins NSC Ireland Limited Eurofins Support Services LUX Holding S.\u00e0 r.l. IE 100.00% 01/19 Cork Real Estate Investment Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. IE 100.00% 12/19 Eurofins Genomics India Private Limited Eurofins Genomics LUX Holding S.\u00e0 r.l. IN 100.00% 01/05 Eurofins Analytical Services India Private Limited Eurofins Food Testing LUX Holding S.\u00e0 r.l. IN 100.00% 05/09 Eurofins Pharma Services India Private Limited Eurofins Pharma Services LUX Holding S.\u00e0 r.l. IN 100.00% 01/11 Eurofins IT Solutions India Private Limited Eurofins Support Services LUX Holding S.\u00e0 r.l. IN 100.00% 02/12 Eurofins Resources India Private Limited Eurofins International Holdings LUX S.\u00e0 r.l. IN 100.00% 03/12 Eurofins AgroScience Services Private Limited Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. IN 100.00% 10/13 Eurofins Clinical Diagnostics Bangalore Private Limited Eurofins Genomics LUX Holding S.\u00e0 r.l. IN 100.00% 12/15 Eurofins Product Testing India Private Limited Eurofins Product Testing LUX Holding S.\u00e0 r.l. IN 100.00% 10/16 Eurofins Advinus Private Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. IN 100.00% 10/17 Spectro Analytical Labs Private Limited Eurofins Environment Testing LUX Holding S.\u00e0 r.l. IN 100.00% 11/17 Eurofins NSC India Private Limited Eurofins Support Services LUX Holding S.\u00e0 r.l. IN 100.00% 04/18 Eurofins Advinus AgroSciences Services India Private Eurofins Real Estate LUX Holding S.\u00e0 r.l. IN 100.00% 10/17 Limited % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Amar Immunodiagnostics Private Limited Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. IN 100.00% 12/18 Eurofins Advinus BioPharma Services India Private Eurofins Pharma Services LUX Holding S.\u00e0 r.l. IN 100.00% 12/19 Limited Eurofins Advinus Discovery Services Private Limited Eurofins International Holdings LUX S.\u00e0 r.l. IN 100.00% 10/17 Alexandre Quality Management Private Private Limited AQM HK Co., Ltd. IN 100.00% 06/19 Eurofins BPO (India) Private Limited Eurofins Support Services LUX Holding S.\u00e0 r.l. IN 100.00% 01/20 Eurofins Assurance India Private Limited Eurofins Assurance LUX Holding S.\u00e0 r.l. IN 100.00% 10/20 Spectro SSA Labs Private Limited Spectro Analytical Labs Private Limited IN 100.00% 10/17 Spectro Research Lab Ventures Private Limited Spectro Analytical Labs Private Limited IN 100.00% 11/17 Spectro Testing Private Limited Spectro Analytical Labs Private Limited IN 100.00% 11/17 Eurofins AME IT Services Private Limited Eurofins Support Services LUX Holding S.\u00e0 r.l. IN 100.00% 05/21 Eurofins BioPharma Product Testing India Private Eurofins Pharma Services LUX Holding S.\u00e0 r.l. IN 100.00% 07/21 Limited Modern Testing Services (India) Private Limited Eurofins Product Testing LUX Holding S.\u00e0 r.l. IN 100.00% 11/21 Eurofins Agroscience Services Italy Srl Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. IT 100.00% 02/04 Eurofins Food & Feed Testing Italia Holding Srl Eurofins Food Testing LUX Holding S.\u00e0 r.l. IT 100.00% 07/06 Eurofins Chemical Control Srl Eurofins Food & Feed Testing Italia Holding Srl IT 100.00% 09/06 Eurofins Biolab Srl Eurofins Pharma Services Italia Holding Srl IT 100.00% 01/07 Eurofins Product Testing Italy Srl Eurofins Product Testing Italia Holding Srl IT 100.00% 10/08 Eurofins NSC Italia Srl Eurofins Support Services LUX Holding S.\u00e0 r.l. IT 100.00% 01/12 Eurofins Product Testing Italia Holding Srl Eurofins Product Testing LUX Holding S.\u00e0 r.l. IT 100.00% 10/12 Eurofins Clinical Testing Italia Holding Srl Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. IT 100.00% 10/12 Eurofins Genomics Italy Srl Eurofins Genomics LUX Holding S.\u00e0 r.l. IT 100.00% 09/12 Eurofins Pivetti Srl Eurofins Food & Feed Testing Italia Holding Srl IT 100.00% 11/12 Eurofins Pharma Services Italia Holding Srl Eurofins Pharma Services LUX Holding S.\u00e0 r.l. IT 100.00% 01/13 Eurofins Modulo Uno Srl Eurofins Product Testing Italia Holding Srl IT 100.00% 07/12 Padova Via Austria Real Estate Invest Srl Eurofins Real Estate LUX Holding S.\u00e0 r.l. IT 100.00% 04/14 Torino Via Cuorgn\u00e8 Real Estate Invest Srl Eurofins Real Estate LUX Holding S.\u00e0 r.l. IT 100.00% 03/15 Eurofins Cosmetics & Personal Care Italy Srl Eurofins Product Testing Italia Holding Srl IT 100.00% 07/15 Eurofins Food Assurance Italia Srl Eurofins Assurance LUX Holding S.\u00e0 r.l. IT 100.00% 09/15 Gold Standard Diagnostics Trieste Srl Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. IT 100.00% 06/16 Eurofins Professional Scientific Services Italy Srl Eurofins Pharma Services Italia Holding Srl IT 100.00% 12/16 Eurofins Genoma Group Srl Eurofins Clinical Testing Italia Holding Srl IT 100.00% 07/17 SAM Sensory and Marketing Italy srl Eurofins Sensory, Consumer research and Product IT 100.00% 11/18 design LUX Holding S.\u00e0 r.l. Eurofins NDSC Food Testing Italy Srl Eurofins Food & Feed Testing Italia Holding Srl IT 100.00% 02/19 Vimodrone Via Buozzi Real Estate Srl Eurofins Real Estate LUX Holding S.\u00e0 r.l. IT 100.00% 08/19 Eurofins Lab Solution Srl Eurofins Product Testing Italia Holding Srl IT 100.00% 06/19 Milano Fino Mornasco Via Tevere Real Estate Srl Eurofins Real Estate LUX Holding S.\u00e0 r.l. IT 100.00% 11/19 Cucciago Via Volta Real Estate Srl Eurofins Real Estate LUX Holding S.\u00e0 r.l. IT 100.00% 11/19 Cuneo Via Celdit Real Estate Srl Eurofins Real Estate LUX Holding S.\u00e0 r.l. IT 100.00% 03/20 Eurofins Safer@work Italy Srl Eurofins Clinical Testing Italia Holding Srl IT 100.00% 05/21 Eurofins NSC Japan KK Eurofins Support Services LUX Holding S.\u00e0 r.l. JP 100.00% 03/06 Eurofins Genomics KK Eurofins Genomic Services Japan Holding KK JP 100.00% 12/07 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Product Testing Japan KK Eurofins Food Testing LUX Holding S.\u00e0 r.l. JP 100.00% 01/09 Eurofins DNA Synthesis KK Eurofins Genomics LUX Holding S.\u00e0 r.l. JP 66.00% 07/11 Eurofins Nihon Kankyo KK Eurofins Environment Testing Japan Holding Co., Ltd. JP 100.00% 04/12 Eurofins Nihon Soken KK Eurofins Environment Testing Japan Holding Co., Ltd. JP 100.00% 07/15 Eurofins Clinical Genetics KK Eurofins Genomics KK JP 100.00% 12/15 Eurofins NBLSC Environment Testing Japan KK Eurofins Environment Testing Japan Holding Co., Ltd. JP 100.00% 04/16 Eurofins Japan Analytical Chemistry Consultants Co., Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. JP 100.00% 08/17 Ltd. Eurofins EAG Materials Science Tokyo Corporation KK Eurofins EAG Materials Science, LLC JP 100.00% 12/17 Saitama Kankyo Service KK Eurofins Environment Testing Japan Holding Co., Ltd. JP 67.00% 12/17 Eurofins BioPharma Services Japan Holding KK Eurofins Pharma Services LUX Holding S.\u00e0 r.l. JP 100.00% 09/18 Eurofins Analytical Science Laboratories KK Eurofins BioPharma Services Japan Holding KK JP 100.00% 11/18 Eurofins Taiyo Techno Research KK Eurofins Environment Testing Japan Holding Co., Ltd. JP 100.00% 12/20 Eurofins Environment Testing Japan Holding Co., Ltd. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. JP 100.00% 09/20 Eurofins Earth Consul KK Eurofins Environment Testing Japan Holding Co., Ltd. JP 100.00% 12/20 Eurofins GeneTech KK Eurofins Clinical Testing Japan Holding Ltd. JP 100.00% 09/20 Eurofins EAG Materials Science Japan Holding KK Eurofins Material Sciences LUX Holding S.\u00e0 r.l. JP 100.00% 05/21 Eurofins Food Testing Japan KK Eurofins Food Testing LUX Holding S.\u00e0 r.l. JP 100.00% 08/21 Eurofins FQL Ltd. Eurofins EAG Materials Science Japan Holding KK JP 100.00% 07/21 AQM (Cambodia) Limited AQM HK Co., Ltd. KH 100.00% 06/19 Eurofins MTS Consumer Product Testing (Cambodia) Eurofins Product Testing LUX Holding S.\u00e0 r.l. KH 100.00% 11/21 Co., Ltd. Eurofins MET Korea Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. KR 100.00% 01/18 Eurofins Korea Analytic Service Co., Ltd. Eurofins Food and Environment Testing Korea Holding KR 100.00% 04/18 Co., Ltd. Eurofins Food and Environment Testing Korea Holding Eurofins Environment Testing LUX Holding S.\u00e0 r.l. KR 100.00% 07/20 Co., Ltd. Eurofins Woosol Co., Ltd. Eurofins Food and Environment Testing Korea Holding KR 100.00% 10/20 Co., Ltd. Eurofins EAG Materials Science Korea Co., Ltd. Eurofins Material Sciences LUX Holding S.\u00e0 r.l. KR 100.00% 10/21 Eurofins Product Testing Korea Holding Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. KR 100.00% 08/21 Eurofins KCTL Co., Ltd. Eurofins Product Testing Korea Holding Co., Ltd. KR 100.00% 10/21 Modern Testing Services Lanka Private Limited Eurofins Product Testing LUX Holding S.\u00e0 r.l. LK 100.00% 11/21 Eurofins Labtarna Lietuva UAB Eurofins Food Testing LUX Holding S.\u00e0 r.l. LT 100.00% 11/17 Eurofins Food Testing LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 12/06 Eurofins Environment Testing LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 12/06 Eurofins Pharma Services LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 12/06 Eurofins GSC LUX S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 10/06 Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 07/07 Eurofins Product Testing LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 04/08 Eurofins Real Estate LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 05/10 Eurofins Genomics LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 07/10 Eurofins Forensics LUX Holding S.\u00e0 r.l. Eurofins Scientific SE (French Branch) LU 100.00% 07/10 Eurofins Industrial Testing LUX S.\u00e0 r.l. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. LU 100.00% 09/10 Eurofins International Holdings LUX S.\u00e0 r.l. Eurofins Scientific SE LU 100.00% 12/10 Eurofins Water Testing LUX S.\u00e0 r.l. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. LU 100.00% 10/11 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Pharma Services France LUX Holding S.\u00e0 r.l. Eurofins Scientific SE (French Branch) LU 100.00% 12/11 Eurofins Food Chemistry Testing France LUX Holding Eurofins Scientific SE (French Branch) LU 100.00% 12/11 S.\u00e0 r.l. Eurofins Hygi\u00e8ne Alimentaire France LUX Holding S.\u00e0 Eurofins Scientific SE (French Branch) LU 100.00% 12/11 r.l. Eurofins Analyses pour la Construction France LUX Eurofins Scientific SE (French Branch) LU 100.00% 12/11 Holding S.\u00e0 r.l. Eurofins Analyses pour lEnvironnement France LUX Eurofins Scientific SE (French Branch) LU 100.00% 12/11 Holding S.\u00e0 r.l. Eurofins Analyses Environnementales pour les Eurofins Scientific SE (French Branch) LU 100.00% 12/11 Industriels France LUX Holding S.\u00e0 r.l. Eurofins Hydrologie France LUX Holding S.\u00e0 r.l. Eurofins Scientific SE (French Branch) LU 100.00% 12/11 Eurofins Discovery Services LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 11/12 Eurofins International Support Services LUX S.\u00e0 r.l. Eurofins Scientific SE LU 100.00% 11/12 Eurofins Special Nutrition Testing LUX Holding S.\u00e0 r.l. Eurofins Food Testing LUX Holding S.\u00e0 r.l. LU 100.00% 12/12 Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 11/14 Eurofins Clinical Testing Services France LUX Holding Eurofins Scientific SE (French Branch) LU 100.00% 05/15 S.\u00e0 r.l. Eurofins Air Monitoring LUX Holding S.\u00e0 r.l. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. LU 100.00% 02/16 Eurofins Support Services LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 04/16 Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 05/16 Eurofins Re LUX SA Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 09/17 Alpha Services LUX SA Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 12/17 Eurofins Material Sciences LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 05/18 Eurofins Sensory, Consumer research and Product Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 06/18 design LUX Holding S.\u00e0 r.l. Eurofins Assurance LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 05/20 Eurofins Clinical Testing Services Germany LUX Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 12/20 Holding S.\u00e0 r.l. Eurofins Central Lab Holdings LUX S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 12/20 Eurofins Finance Luxembourg S.\u00e0 r.l. Eurofins Scientific SE LU 100.00% 06/19 Eurofins Agroscience Services Maroc S.\u00e0 r.l Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. MA 98.20% 06/18 Eurofins Sam Sensory & Marketing Morocco S.\u00e0 r.l Eurofins Sensory, Consumer research and Product MA 100.00% 10/18 design LUX Holding S.\u00e0 r.l. Eurofins Biomnis Maroc S.\u00e0 r.l. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. MA 100.00% 12/19 Eurofins Assurance Myanmar Ltd. Eurofins Assurance LUX Holding S.\u00e0 r.l. MM 100.00% 06/19 Insight Technologies Ltd. Eurofins Laboratoire Dermscan SAS MU 100.00% 11/18 Eurofins NM Laboratory Sdn Bhd Eurofins Environment Testing LUX Holding S.\u00e0 r.l. MY 100.00% 11/15 Eurofins North Malaya Laboratory Sdn Bhd Eurofins Environment Testing LUX Holding S.\u00e0 r.l. MY 100.00% 11/15 Eurofins GSC IT Malaysia Sdn. Bhd Eurofins Support Services LUX Holding S.\u00e0 r.l. MY 100.00% 01/19 Eurofins Food Testing Malaysia Sdn Bhd Eurofins Food Testing LUX Holding S.\u00e0 r.l. MY 100.00% 05/19 Eurofins Environment Testing Netherlands Holding BV Eurofins Environment Testing LUX Holding S.\u00e0 r.l. NL 100.00% 04/01 Eurofins Food Testing Netherlands BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 10/00 Eurofins Analytico BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 04/01 Eurofins Central Laboratory BV Eurofins Pharma Services LUX Holding S.\u00e0 r.l. NL 100.00% 04/01 Eurofins Genomics BV Eurofins Scientific SE NL 100.00% 06/06 Eurofins C-Mark BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 03/11 Eurofins NSC Netherlands BV Eurofins Support Services LUX Holding S.\u00e0 r.l. NL 100.00% 05/11 Eurofins Food Testing Netherlands Holding BV Eurofins Food Testing LUX Holding S.\u00e0 r.l. NL 100.00% 05/11 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Food Testing Rotterdam BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 03/12 Zandbergsestraat Graauw RE Invest BV Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 01/13 Eurofins Lab Zeeuws-Vlaanderen (LZV) BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 01/13 Eurofins Logistics Benelux BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 04/13 Eurofins MITOX BV Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. NL 100.00% 07/13 Eurofins Agro Testing Netherlands Holding BV Eurofins Food Testing LUX Holding S.\u00e0 r.l. NL 100.00% 07/13 Eurofins Agro Testing Wageningen BV Eurofins Agro Testing Netherlands Holding BV NL 100.00% 07/13 Eurofins KBBL BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 01/14 Eurofins Food Safety Solutions BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 02/14 Eurofins Omegam BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 01/14 Duivendrecht Real Estate Invest BV Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 07/14 Eurofins Professional Scientific Services Netherlands Eurofins Pharma Services LUX Holding S.\u00e0 r.l. NL 100.00% 09/14 BV Eurofins NDSC Environment Testing Benelux BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 09/14 Eurofins De Bredelaar BV Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. NL 100.00% 07/15 Nieuw Biesterveld BV Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 07/15 Eurofins BioPharma Product Testing Netherlands Eurofins Pharma Services LUX Holding S.\u00e0 r.l. NL 100.00% 01/16 Holding BV Eurofins Bactimm BV Eurofins BioPharma Product Testing Netherlands NL 100.00% 01/16 Holding BV Eurofins PROXY Laboratories BV Eurofins BioPharma Product Testing Netherlands NL 100.00% 01/16 Holding BV Eurofins Spinnovation Analytical BV Eurofins BioPharma Product Testing Netherlands NL 100.00% 01/16 Holding BV Eurofins Bureau de Wit BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 06/16 Barneveld Gildeweg Real Estate BV Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 08/16 Eurofins Survey Netherlands BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 06/17 Heerenveen Hermes Icarus Real Estate BV Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 09/17 Eurofins Sanitas Inspections BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 11/17 Sanitas Milieukundig Adviesbureau BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 11/17 Eurofins Sanitas Testing BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 11/17 Eurofins Clinical Diagnostics Netherlands Holding BV Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. NL 100.00% 03/18 Eurofins Nederlands Moleculair Diagnostisch Eurofins Clinical Diagnostics Netherlands Holding BV NL 100.00% 03/18 Laboratorium BV Eurofins LCPL BV Eurofins Clinical Diagnostics Netherlands Holding BV NL 100.00% 03/18 Eurofins EAG Materials Science Netherlands BV Eurofins Material Sciences LUX Holding S.\u00e0 r.l. NL 100.00% 12/18 ACMAA Groep BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 07/18 ACMAA Inspectie BV ACMAA Groep BV NL 100.00% 07/18 ACMAA Laboratoria BV ACMAA Groep BV NL 100.00% 07/18 Eurofins Salux BV Eurofins Clinical Diagnostics Netherlands Holding BV NL 100.00% 05/19 The Maastricht Forensic Institute BV Eurofins Forensics LUX Holding S.\u00e0 r.l. NL 100.00% 12/19 Eurofins Bacteriologisch Adviesburo BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 10/20 Eurofins Medische Microbiologie BV Eurofins Clinical Diagnostics Netherlands Holding BV NL 100.00% 01/21 Eurofins EAG Materials and Engineering Science Eurofins Material Sciences LUX Holding S.\u00e0 r.l. NL 100.00% 06/21 Netherlands Holdings BV Eurofins PAMM BV Eurofins Clinical Diagnostics Netherlands Holding BV NL 100.00% 10/21 Certification Limited company BV Eurofins E&E CML Limited NL 100.00% 02/19 DNA Consolidated BV DDC Worldwide Ltd. NL 100.00% 08/21 % of Date ISO interest Company Subsidiary of: of code by the entry Group NorthSea Marketing BV DNA Consolidated BV NL 100.00% 08/21 Eurofins Maser BV Eurofins EAG Materials and Engineering Science NL 90.02% 10/21 Netherlands Holdings BV Eurofins Environment Testing Norway AS Eurofins Environment Testing Norway Holding AS NO 100.00% 05/06 Eurofins Environment Testing Norway Holding AS Eurofins Environment Testing LUX Holding S.\u00e0 r.l. NO 100.00% 09/07 Eurofins Food & Feed Testing Norway AS Eurofins Food Testing Norway Holding AS NO 100.00% 09/07 Eurofins Food Testing Norway Holding AS Eurofins Food Testing LUX Holding S.\u00e0 r.l. NO 100.00% 08/07 Eurofins Norge NSC AS Eurofins Support Services LUX Holding S.\u00e0 r.l. NO 100.00% 12/07 Eurofins Agro Testing Norway AS Eurofins Food Testing Norway Holding AS NO 100.00% 08/14 Moss Property Invest AS Eurofins Real Estate LUX Holding S.\u00e0 r.l. NO 100.00% 08/14 Eurofins Radonlab AS Eurofins Environment Testing Norway Holding AS NO 100.00% 12/15 Eurofins Havlandet AS Eurofins Food Testing Norway Holding AS NO 56.50% 02/20 Penrose NZ Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. NZ 100.00% 04/12 Eurofins Food Analytics NZ Limited Eurofins Food Testing LUX Holding S.\u00e0 r.l. NZ 100.00% 06/12 Eurofins ELS Limited Eurofins Australia New Zealand Holding Pty Ltd. NZ 100.00% 11/12 Eurofins Agroscience Services NZ Limited Eurofins Agrosciences Services France Holding SAS NZ 100.00% 07/13 Eurofins Agroscience Testing NZ Limited Eurofins Agrosciences Services France Holding SAS NZ 100.00% 07/13 Eurofins Bay Of Plenty Limited Eurofins Australia New Zealand Holding Pty Ltd. NZ 100.00% 06/16 Eurofins Environment Testing NZ Limited Eurofins Australia New Zealand Holding Pty Ltd. NZ 100.00% 03/17 Eurofins BioPharma Product Testing NZ Limited Eurofins Australia New Zealand Holding Pty Ltd. NZ 100.00% 10/17 Wellington Port Road Real Estate Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. NZ 100.00% 06/18 Eurofins Animal Health New Zealand Limited Eurofins Agroscience Services Pty Ltd. NZ 100.00% 12/18 Eurofins Scientific Services Philippines, Inc. Eurofins Food Testing LUX Holding S.\u00e0 r.l. PH 100.00% 09/19 AQM Pakistan Pvt. Ltd. AQM HK Co., Ltd. PK 100.00% 06/19 Eurofins Agroscience Services Sp. z.o.o. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. PL 100.00% 01/06 Eurofins Polska Sp. z.o.o. Eurofins Food Testing LUX Holding S.\u00e0 r.l. PL 100.00% 07/06 Eurofins Environment Testing Polska Sp. z o.o. Eurofins Industrial Testing LUX S.\u00e0 r.l. PL 100.00% 07/15 Eurofins GSC Poland Sp. z o.o. Eurofins Support Services LUX Holding S.\u00e0 r.l. PL 100.00% 02/16 \u0141\u00f3d\u017a Dubois Real Estate Sp. z o.o. Eurofins Real Estate LUX Holding S.\u00e0 r.l. PL 100.00% 12/18 Eurofins Dermscan Poland Sp. Z.o.o. Eurofins Product Testing LUX Holding S.\u00e0 r.l. PL 100.00% 11/18 Eurofins Business Services Poland Sp. z o.o. Eurofins Support Services LUX Holding S.\u00e0 r.l. PL 100.00% 12/19 Eurofins GSC IT Poland Sp. z o.o. Eurofins Support Services LUX Holding S.\u00e0 r.l. PL 100.00% 12/19 Eurofins NSC Polska Sp. z o.o. Eurofins Support Services LUX Holding S.\u00e0 r.l. PL 100.00% 04/20 Malbork Al. Wojska Polskiego Real Estate sp. z o.o. Eurofins Real Estate LUX Holding S.\u00e0 r.l. PL 100.00% 12/19 Eurofins Environment Testing Poland Holding Sp. z o.o. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. PL 100.00% 07/19 Eurofins OBIK\u015a Polska Sp. z.o.o. Eurofins Environment Testing Poland Holding Sp. z o.o. PL 100.00% 09/19 Eurofins Lab Environment Testing Portugal, Unipessoal Eurofins Industrial Testing LUX S.\u00e0 r.l. PT 100.00% 06/15 Lda. Sobrosa, Ac\u00e1cio J.A. Pereira, Real Estate, Unipessoal, Eurofins Real Estate LUX Holding S.\u00e0 r.l. PT 100.00% 12/18 Lda. Eurofins Food Testing Lisboa, Unipessoal Lda. Eurofins Analisis Alimentario Holding Espana S.L.U. PT 100.00% 06/19 Laborat\u00f3rio de An\u00e1lises Clinicas J. Pinto de Barros, SA Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. PT 100.00% 04/21 Eurofins Agroscience Services Romania SRL Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. RO 100.00% 08/09 Eurofins Evic Product Testing Romania SRL Eurofins Product Testing LUX Holding S.\u00e0 r.l. RO 100.00% 07/15 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Food Testing SRL Eurofins Food & Feed Testing Romania Holding SRL RO 100.00% 11/16 Bucharest Preciziei Real Estate SRL Eurofins Real Estate LUX Holding S.\u00e0 r.l. RO 100.00% 03/17 Eurofins Food & Feed Testing Romania Holding SRL Eurofins Food Testing LUX Holding S.\u00e0 r.l. RO 100.00% 11/17 Eurofins Asbestos Testing Romania SRL Eurofins Industrial Testing LUX S.\u00e0 r.l. RO 100.00% 12/17 Eurofins Food Analytica SRL Eurofins Food & Feed Testing Romania Holding SRL RO 100.00% 01/18 Eurofins Agro Testing Sweden AB Eurofins Food Testing Sweden Holding AB SE 100.00% 01/04 Eurofins Milk Testing Sweden AB Eurofins Food Testing Sweden Holding AB SE 100.00% 07/06 Eurofins Food Testing Sweden Holding AB Eurofins Food Testing LUX Holding S.\u00e0 r.l. SE 100.00% 09/07 Eurofins Environment Testing Sweden AB Eurofins Environment Testing Sweden Holding AB SE 100.00% 10/07 Eurofins Environment Testing Sweden Holding AB Eurofins Environment Testing LUX Holding S.\u00e0 r.l. SE 100.00% 09/07 Eurofins Food & Feed Testing Sweden AB Eurofins Food Testing Sweden Holding AB SE 100.00% 10/07 Eurofins NSC Sweden AB Eurofins Support Services LUX Holding S.\u00e0 r.l. SE 100.00% 01/08 Eurofins Biopharma Product Testing Sweden AB Eurofins Pharma Services LUX Holding S.\u00e0 r.l. SE 100.00% 04/11 Eurofins Pegasuslab AB Eurofins Environment Testing Sweden Holding AB SE 100.00% 06/12 Uppsala Property Invest AB Eurofins Real Estate LUX Holding S.\u00e0 r.l. SE 100.00% 03/14 Eurofins Radon Testing Sweden AB Eurofins Environment Testing Sweden Holding AB SE 100.00% 09/16 Eurofins Water Testing Sweden AB Eurofins Environment Testing Sweden Holding AB SE 100.00% 08/17 Eurofins Genomics Sweden AB Eurofins Genomics Europe Sequencing GmbH SE 100.00% 07/17 Lidk\u00f6ping Sj\u00f6hagsgatan Real Estate AB Eurofins Real Estate LUX Holding S.\u00e0 r.l. SE 100.00% 12/17 Eurofins Biofuel & Energy Testing Sweden AB Eurofins Environment Testing Sweden Holding AB SE 100.00% 04/18 Eurofins Clinical Testing Sweden AB Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. SE 100.00% 03/21 Eurofins Central Laboratory Pte. Ltd. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. SG 100.00% 12/06 Gold Standard Diagnostics Singapore Pte. Ltd. Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. SG 100.00% 12/15 Eurofins Mechem Pte. Ltd. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. SG 100.00% 03/17 Eurofins EAG Materials Science Singapore, Pte. Ltd. Eurofins Material Sciences LUX Holding S.\u00e0 r.l. SG 100.00% 12/17 Eurofins Food Testing Singapore Pte. Ltd Eurofins Food Testing LUX Holding S.\u00e0 r.l. SG 100.00% 08/18 Eurofins Clinical Diagnostics Pte. Ltd. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. SG 100.00% 08/19 Eurofins Holding za okoljske raziskave d.o.o. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. SI 100.00% 06/17 Velenje nepremi\u010dnine d.o.o., poslovanje z Eurofins Real Estate LUX Holding S.\u00e0 r.l. SI 100.00% 07/17 nepremi\u010dninami Eurofins ERICo Slovenia d.o.o. Eurofins Holding za okoljske raziskave d.o.o. SI 100.00% 07/17 Eurofins Bel/Novamann s.r.o. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. SK 100.00% 10/07 Eurofins NSC Central and Eastern Europe s.r.o. Eurofins Support Services LUX Holding S.\u00e0 r.l. SK 100.00% 06/15 Nov\u00e9 Z\u00e1mky Komjatick\u00e1 Real Estate s.r.o. Eurofins Real Estate LUX Holding S.\u00e0 r.l. SK 100.00% 10/16 Eurofins Food & Feed Testing Slovakia Holding s.r.o. Eurofins Food Testing LUX Holding S.\u00e0 r.l. SK 100.00% 08/19 Eurofins Food Testing Slovakia s.r.o Eurofins Food & Feed Testing Slovakia Holding s.r.o. SK 100.00% 10/19 Eurofins Environment Testing Holding Slovakia s.r.o. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. SK 100.00% 07/20 Tur\u010dianske Teplice Robotn\u00edcka Real Estate s.r.o. Eurofins Real Estate LUX Holding S.\u00e0 r.l. SK 100.00% 11/20 Eurofins Environment Testing Slovakia s.r.o. Eurofins Environment Testing Holding Slovakia s.r.o. SK 100.00% 11/20 Eurofins RBLSC IT CEE s.r.o. Eurofins Food Testing LUX Holding S.\u00e0 r.l. SK 100.00% 04/21 Eurofins Product Service (Thailand) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. TH 100.00% 07/08 Eurofins Agroscience Services Thailand Co., Ltd. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. TH 100.00% 05/16 Eurofins Food Testing (Thailand) Co., Ltd. Eurofins International Holdings LUX S.\u00e0 r.l. TH 100.00% 02/20 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Environment Testing Data Services Bangkok TestAmerica Laboratories, Inc. TH 100.00% 11/18 Co., Ltd. EUROFINS DERMSCAN TUNISIE SARL Eurofins Laboratoire Dermscan SAS TN 100.00% 11/18 Eurofins Turkey Analiz Hizmetleri Limited \u015eirketi Eurofins Food Testing LUX Holding S.\u00e0 r.l. TR 100.00% 05/12 Eurofins \u0130stanbul G\u0131da Kontrol Laboratuvarlar\u0131 A.\u015e. Eurofins Food Testing LUX Holding S.\u00e0 r.l. TR 100.00% 03/17 Denet Endustriyel Hizmetler Anonim \u015eirket A.\u015e. Eurofins \u0130stanbul G\u0131da Kontrol Laboratuvarlar\u0131 A.\u015e. TR 100.00% 03/17 Eurofins T\u00fcketici \u00dcr\u00fcnleri Test Hizmetleri A.\u015e Eurofins Product Testing LUX Holding S.\u00e0 r.l. TR 100.00% 08/17 Eurofins \u0130zmir G\u0131da Analiz Laboratuvarlar\u0131 Limited Eurofins Food Testing Turkey Holding A.\u015e. TR 100.00% 07/18 \u015eirketi Eurofins Food Testing Turkey Holding A.\u015e. Eurofins Food Testing LUX Holding S.\u00e0 r.l. TR 100.00% 06/19 Eurofins NSC Turkey Destek Hizmetleri A.\u015e. Eurofins Support Services LUX Holding S.\u00e0 r.l. TR 100.00% 11/19 Eurofins Assurance Turkey Kalite ve Denetim AQM HK Co., Ltd. TR 100.00% 06/19 Hizmetleri Limited \u015eirketi \u0130zmir Bornova Gayrimenkul A.\u015e. Eurofins Real Estate LUX Holding S.\u00e0 r.l. TR 100.00% 06/21 Eurofins Dr. Global G\u0131da Analiz Laboratuvar\u0131 A.\u015e. Eurofins Food Testing Turkey Holding A.\u015e. TR 100.00% 11/21 Eurofins Environment Testing Holding Taiwan Co., Ltd. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. TW 100.00% 03/15 Pharmacology Discovery Services Taiwan, Ltd. Eurofins Discovery Services LUX Holding S.\u00e0 r.l. TW 100.00% 08/16 Eurofins Panlabs Discovery Services Taiwan, Ltd. Eurofins Discovery Services LUX Holding S.\u00e0 r.l. TW 100.00% 08/16 Eurofins Food Testing Taiwan, Ltd. Eurofins Environment Testing Holding Taiwan Co., Ltd. TW 100.00% 08/17 Eurofins NSC Taiwan, Ltd. Eurofins Support Services LUX Holding S.\u00e0 r.l. TW 100.00% 06/18 Eurofins Tsing Hua Environment Testing Co., Ltd. Eurofins Environment Testing Holding Taiwan Co., Ltd. TW 100.00% 01/18 Eurofins Summit Tsiande Environmental Co., Ltd. Eurofins Environment Testing Holding Taiwan Co., Ltd. TW 100.00% 01/18 Eurofins E&E Taiwan Co., Ltd. Eurofins Consumer Product Testing Taiwan Holding TW 100.00% 01/18 Ltd. Eurofins SunDream Environmental Technical Co., Ltd. Eurofins Environment Testing Holding Taiwan Co., Ltd. TW 100.00% 09/20 Eurofins Blue Formosa Environmental Technical Co., Eurofins Environment Testing Holding Taiwan Co., Ltd. TW 100.00% 09/20 Ltd. Eurofins Universe Environmental Technical Co., Ltd. Eurofins Environment Testing Holding Taiwan Co., Ltd. TW 100.00% 09/20 Eurofins Consumer Product Testing Taiwan Holding Eurofins Product Testing LUX Holding S.\u00e0 r.l. TW 100.00% 06/21 Ltd. A Test Lab Techno Co., Ltd. Eurofins Consumer Product Testing Taiwan Holding TW 100.00% 07/21 Ltd. Eurofins NSC UK Limited Eurofins Support Services LUX Holding S.\u00e0 r.l. UK 100.00% 01/06 Eurofins Food Testing UK Limited Eurofins Food Testing UK Holding Limited UK 100.00% 01/04 Eurofins Genomics UK Limited Eurofins Genomics LUX Holding S.\u00e0 r.l. UK 100.00% 07/05 Eurofins Food Testing UK Holding Limited Eurofins Food Testing LUX Holding S.\u00e0 r.l. UK 100.00% 04/07 Eurofins Agroscience Services Limited Eurofins Agroscience Services UK Holding Limited UK 100.00% 04/07 Eurofins Product Testing Services Limited Eurofins Product Testing UK Holding Limited UK 100.00% 10/10 Public Analyst Scientific Services Limited Eurofins Food Testing UK Holding Limited UK 100.00% 07/11 Wolverhampton i54 Real Estate Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. UK 100.00% 07/12 Eurofins Water Hygiene Testing UK Limited Eurofins Food Testing UK Holding Limited UK 100.00% 10/15 Eurofins Biomnis UK Limited Eurofins Biologie Sp\u00e9cialis\u00e9e France SAS UK 100.00% 10/15 Eurofins Agro Testing UK Limited Eurofins Food Testing UK Holding Limited UK 100.00% 03/16 Eurofins Biopharma Product Testing UK Limited Eurofins Pharma Services LUX Holding S.\u00e0 r.l. UK 100.00% 07/16 Eurofins NDSM Limited Eurofins Agroscience Services UK Holding Limited UK 100.00% 07/16 Eurofins Agroscience Services UK Holding Limited Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. UK 100.00% 07/16 Livingston Cochrane Square Real Estate Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. UK 100.00% 08/16 Eurofins Food Safety Solutions Limited Eurofins Assurance LUX Holding S.\u00e0 r.l. UK 100.00% 11/16 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins York Limited Eurofins Product Testing UK Holding Limited UK 100.00% 07/17 Eurofins Forensic Services Limited Eurofins Forensics LUX Holding S.\u00e0 r.l. UK 100.00% 10/17 Eurofins Professional Scientific Services UK Limited Eurofins Pharma Services LUX Holding S.\u00e0 r.l. UK 100.00% 09/17 Eurofins Product Testing UK Holding Limited Eurofins Product Testing LUX Holding S.\u00e0 r.l. UK 100.00% 12/17 Eurofins Selcia Limited Eurofins Agroscience Services UK Holding Limited UK 100.00% 12/17 Ashwood UK Limited Eurofins Food Testing UK Holding Limited UK 100.00% 12/17 Eurofins E&E Hursley Limited Eurofins Product Testing UK Holding Limited UK 100.00% 02/18 Eurofins E&E ETC Limited Eurofins Product Testing UK Holding Limited UK 100.00% 01/18 Eurofins BLC Leather Technology Centre Limited Eurofins Product Testing UK Holding Limited UK 100.00% 04/18 Eurofins County Pathology Limited Eurofins Clinical Diagnostic Testing UK Holding Limited UK 100.00% 10/18 Eurofins Integrated Discovery UK Limited Eurofins Discovery Services LUX Holding S.\u00e0 r.l. UK 100.00% 12/18 Eurofins Clinical Diagnostic Testing UK Holding Limited Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. UK 100.00% 08/19 Eurofins E&E CML Limited Eurofins Product Testing UK Holding Limited UK 100.00% 02/19 Eurofins Environment Testing UK Holding Limited Eurofins Environment Testing LUX Holding S.\u00e0 r.l. UK 100.00% 03/19 Eurofins Chemtest Limited Eurofins Environment Testing UK Holding Limited UK 100.00% 04/19 Heathrow Dukes Green Real Estate Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. UK 100.00% 09/19 Eurofins Food Testing ATL Limited Eurofins Food Testing UK Holding Limited UK 100.00% 05/21 Eurofins Electrical and Electronic UK London Limited Eurofins Product Testing UK Holding Limited UK 100.00% 10/21 Eurofins MGS Laboratories Limited Eurofins Biopharma Product Testing UK Holding UK 75.00% 08/21 Limited Eurofins Alba Science Limited Eurofins Product Testing UK Holding Limited UK 90.00% 08/21 Eurofins Biopharma Product Testing UK Holding Eurofins Pharma Services LUX Holding S.\u00e0 r.l. UK 100.00% 08/21 Limited Tamworth Tungsten Park Real Estate Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. UK 100.00% 08/21 High Street Textile Testing Services Limited Eurofins MTS Consumer Product Testing UK Limited UK 100.00% 11/21 Modern Technology Holdings Limited Eurofins Product Testing LUX Holding S.\u00e0 r.l. UK 100.00% 11/21 Eurofins MTS Consumer Product Testing UK Limited Eurofins Product Testing LUX Holding S.\u00e0 r.l. UK 100.00% 11/21 Eurofins Food Chemistry Testing Des Moines, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 01/92 Eurofins Central Laboratory, LLC Eurofins Central Lab US Holdings, Inc. US 100.00% 06/06 Eurofins Analytical Laboratories, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 04/07 Eurofins Genomics, LLC Eurofins Genomics US Holdings, Inc. US 100.00% 12/07 Eurofins Food Testing US Holdings, Inc. Eurofins Food Testing LUX Holding S.\u00e0 r.l. US 100.00% 04/07 Eurofins Agroscience Services, LLC Eurofins Agrosciences Services US Holdings, Inc. US 100.00% 01/07 Eurofins Microbiology Laboratories, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 06/09 Eurofins NSC US, Inc. Eurofins Support Services LUX Holding S.\u00e0 r.l. US 100.00% 10/10 Eurofins Pharma US Holdings II, Inc. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. US 100.00% 01/11 Eurofins Lancaster Laboratories, Inc. Eurofins Pharma US Holdings II, Inc. US 100.00% 04/11 Eurofins DQCI, LLC Eurofins Food Testing US Holdings, Inc. US 100.00% 10/11 Eurofins Environment Testing Northern California, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 01/12 Eurofins QTA, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 02/12 Eurofins Eaton Analytical, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 07/12 Eurofins Environment Testing Northwest, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 09/12 Eurofins Panlabs, Inc. Eurofins Discovery Services & Products US Holdings, US 100.00% 10/12 Inc. % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Lancaster Laboratories Environment Testing, Eurofins Environment Testing America Holdings, Inc. US 100.00% 01/13 LLC Eurofins Pharma BioAnalytics Services US, LLC Eurofins Central Lab US Holdings, Inc. US 100.00% 01/13 South Bend Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 05/14 Eurofins Environment Testing Southwest, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 05/14 Eurofins Viracor, LLC Eurofins Clinical Testing US Holdings, Inc. US 100.00% 07/14 Eurofins SF Analytical Laboratories, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 11/14 Eurofins Clinical Testing US Holdings, Inc. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. US 100.00% 11/14 Boston Heart Diagnostics Corp. Eurofins Clinical Testing US Holdings, Inc. US 100.00% 01/15 Eurofins Lancaster Laboratories Professional Scientific Eurofins Lancaster Laboratories, Inc. US 100.00% 02/15 Services, LLC Eurofins Product Testing US, Inc. Eurofins Product Testing US Holdings, Inc. US 100.00% 02/15 Eurofins BioDiagnostics, Inc. Eurofins Genomics US Holdings, Inc. US 100.00% 02/15 Eurofins Environment Testing Philadelphia, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 04/15 Eurofins Diatherix Laboratories, LLC Eurofins Viracor, LLC US 100.00% 05/15 Eurofins Environment Testing Northeast, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 07/15 Eurofins Advantar Laboratories, Inc. Eurofins Pharma US Holdings II, Inc. US 100.00% 04/16 North Kingstown (R.I.) Camp Avenue Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 05/16 Eurofins Donor & Product Testing, Inc. Eurofins Clinical Testing US Holdings, Inc. US 100.00% 09/16 DeSoto Falcon Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 09/16 Lafayette Horizon Avenue Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 09/16 Eurofins Clinical Diagnostic US NDSC, Inc. Eurofins Clinical Testing US Holdings, Inc. US 100.00% 09/16 Agawam Silver Street Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 11/16 New Berlin 170th Street Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 11/16 Eurofins DiscoverX Corporation, Inc. Eurofins Discovery Services & Products US Holdings, US 100.00% 09/17 Inc. Eurofins Abraxis, Inc. Eurofins Technologies US Holdings, Inc. US 100.00% 10/17 Eurofins Technologies US Holdings, Inc. Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. US 100.00% 09/17 Eurofins Product Testing US Holdings, Inc. Eurofins Product Testing LUX Holding S.\u00e0 r.l. US 100.00% 09/17 Eurofins EAG Materials Science, LLC Eurofins EAG Materials Science US Holding, Inc. US 100.00% 12/17 Eurofins BioPharma Product Testing Columbia, Inc. Eurofins Pharma US Holdings II, Inc. US 100.00% 12/17 Eurofins Electrical and Electronic Testing NA, Inc. Eurofins Product Testing US Holdings, Inc. US 100.00% 12/17 Eurofins CEI, Inc. Eurofins Environment Testing America Holdings, Inc. US 100.00% 01/18 Eurofins Genomics Engineering LLC Eurofins Genomics US Holdings, Inc. US 100.00% 03/18 The National Food Lab, Inc. Eurofins Sensory, Consumer Research and Product US 100.00% 08/18 Design US Holding, Inc. Eurofins Sensory, Consumer Research and Product Eurofins Sensory, Consumer research and Product US 100.00% 08/18 Design US Holding, Inc. design LUX Holding S.\u00e0 r.l. Eurofins Food Chemistry Testing Madison, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 08/18 Eurofins Botanical Testing US, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 08/18 Battle Creek 55 Hamblin Avenue Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 08/18 Eurofins EAG Agroscience, LLC Eurofins Agrosciences Services US Holdings, Inc. US 100.00% 05/18 Eurofins CRL Cosmetics, Inc. Eurofins Product Testing US Holdings, Inc. US 100.00% 08/18 Gold Standard Diagnostics Corp, Inc. Eurofins Technologies US Holdings, Inc. US 100.00% 07/20 Eurofins Nanolab Technologies, Inc. Eurofins EAG Materials Science US Holding, Inc. US 100.00% 08/18 TestAmerica Laboratories, Inc. Eurofins Environment Testing America Holdings, Inc. US 100.00% 11/18 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins EPK Built Environment Testing, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 11/18 Environmental Sampling Supply, Inc. Eurofins Technologies US Holdings, Inc. US 100.00% 11/18 Eurofins Aerotech Built Environment Testing, Inc. Eurofins EPK Built Environment Testing, LLC US 100.00% 11/18 Madison Merchant Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 08/18 Eurofins EAG Engineering Science, LLC Eurofins EAG Materials Science US Holding, Inc. US 100.00% 12/18 Eurofins EAG Materials Science US Holding, Inc. Eurofins Material Sciences LUX Holding S.\u00e0 r.l. US 100.00% 04/19 Eurofins Genomics Blue Heron LLC Eurofins Genomics US Holdings, Inc. US 100.00% 04/19 Eurofins Viracor BioPharma Services, Inc. Eurofins Viracor, LLC US 100.00% 01/20 Transplant Genomics Inc. Eurofins Clinical Testing US Holdings, Inc. US 100.00% 05/19 Eurofins J3 Resources, Inc. Eurofins Environment Testing America Holdings, Inc. US 100.00% 10/19 Eurofins DiscoverX Products, LLC Eurofins DiscoverX Corporation, Inc. US 100.00% 12/19 Tustin Dow Avenue Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 11/19 Eurofins ARCA Technology, Inc. Eurofins Diatherix Laboratories, LLC US 100.00% 01/20 Pasadena Red Bluff Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 12/19 Lenexa 99th Street Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 12/19 Eurofins Environment Testing America Holdings, Inc. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. US 100.00% 12/19 Eurofins Environment Testing South Central, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 07/20 Stafford Greenbriar Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 01/20 Eurofins Precision TEM, LLC Eurofins EAG Materials Science US Holding, Inc. US 100.00% 04/20 Eurofins NDSC Environment Testing Americas, Inc. Eurofins Environment Testing America Holdings, Inc. US 100.00% 01/20 Clinical Enterprise, Inc. Eurofins Clinical Testing US Holdings, Inc. US 100.00% 03/20 Eurofins Beacon Discovery Holdings, Inc. Eurofins Discovery Services & Products US Holdings, US 100.00% 03/21 Inc. Eurofins Beacon Discovery, Inc. Eurofins Beacon Discovery Holdings, Inc. US 100.00% 03/21 Amherst Hazelwood Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 01/21 Eurofins Genomics US Holdings, Inc. Eurofins Genomics LUX Holding S.\u00e0 r.l. US 100.00% 01/21 Eurofins Agrosciences Services US Holdings, Inc. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. US 100.00% 01/21 Eurofins Central Lab US Holdings, Inc. Eurofins Central Lab Holdings LUX S.\u00e0 r.l. US 100.00% 01/21 Eurofins Discovery Services & Products US Holdings, Eurofins Discovery Services LUX Holding S.\u00e0 r.l. US 100.00% 01/21 Inc. Eurofins Food Assurance US, LLC Eurofins Food Testing US Holdings, Inc. US 100.00% 01/21 Eurofins Food Assurance Certification US, LLC Eurofins Food Testing US Holdings, Inc. US 100.00% 01/21 Louisville Plantside Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 01/21 Columbia ABC Lane Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 02/21 Leola New Holland Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 02/21 Eurofins Pandemic Prevention Services, Inc. Eurofins Pharma US Holdings II, Inc. US 100.00% 02/21 Eurofins TestOil, Inc. Eurofins Environment Testing America Holdings, Inc. US 100.00% 07/21 Eurofins CellTx, Inc. Eurofins Clinical Testing US Holdings, Inc. US 100.00% 07/21 Dallas Harry Hines Blvd. Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 07/21 DNA Diagnostics Center, Inc. Eurofins Clinical Testing US Holdings, Inc. US 100.00% 08/21 Eurofins Reservoirs Environmental, Inc. Eurofins Environment Testing America Holdings, Inc. US 100.00% 10/21 Barberton Van Buren Avenue Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 08/21 DDC Worldwide Corp. DNA Diagnostics Center, Inc. US 100.00% 08/21 Experchem US, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 09/21 % of Date ISO interest Company Subsidiary of: of code by the entry Group Tacoma Fife 8th Street Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 09/21 West Valley City Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 09/21 Clayton Powhatan Road Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 11/21 Eurofins Environment Testing Southeast, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 09/21 Eurofins Environment Testing North Central, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 10/21 Eurofins MTS Consumer Product Testing US, LLC Eurofins Product Testing US Holdings, Inc. US 100.00% 11/21 Horsham Road Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 11/21 Eurofins Sac Ky Hai Dang Co., Ltd. Eurofins Food Testing LUX Holding S.\u00e0 r.l. VN 100.00% 05/15 Eurofins Consumer Product Testing Vietnam Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. VN 100.00% 08/17 Eurofins Assurance Vietnam Co., Ltd. Eurofins Assurance LUX Holding S.\u00e0 r.l. VN 100.00% 06/19 Modern Testing Services (Vietnam) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. VN 100.00% 11/21 Please note that for commercial confidentiality and security reasons the information provided above is not comprehensive. 3.6. Other subsidiaries undertakings The companies below are not fully consolidated: % of ISO interest Method of Company Subsidiary of: code by the consolidation Group Z.F.D. GmbH DE Eurofins \u00d6kometric GmbH 33.00% Equity method Eurofins Laboratoire C\u0153ur de France SAEML FR Eurofins Microbiologie France Holding SAS 49.00% Equity method Fasmac Co. Ltd. JP Eurofins Genomics LUX Holding S.\u00e0 r.l. 41.00% Equity method Dermscan Asia Co., Ltd. TH Eurofins Laboratoire Dermscan SAS 34.00% Equity method T-rex Ltd. ZA Eurofins Agrosciences Services LUX Holding S.\u00e0 20.00% Equity method r.l. ", "dimensions": { "concept": "ifrs-full:DisclosureOfCompositionOfGroupExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-36-4": { "value": "Acquisition of and adjustments to non-controlling interests Transactions with non-controlling interests in controlled entities are treated as transactions with equity owners of the Group. For purchases from non-controlling interests, any difference between the consideration paid and the relevant share acquired is recorded in equity. Gains or losses on disposals to non-controlling interests are also recorded in equity. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForTransactionsWithNoncontrollingInterestsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-38-5": { "value": "In addition, a financial liability reflecting the put option element of the transaction is recognised for an amount corresponding to the present value of the redemption amount of the put option. Such financial liability is recognised from the equity attributable to holders of the Group. Debt and other financial liabilities Debt and other financial liabilities, excluding derivative financial liabilities and provisions, are initially measured at fair value and, in the case of debt and payables, net of directly attributable transaction costs. Debt and other financial liabilities are subsequently measured at amortised cost using the effective interest rate. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. Debt and other financial liabilities are derecognised when the obligation under the liability is discharged, cancelled or has expired. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-39-3": { "value": "1.4. Revenue recognition Revenue recognised over time Revenue from services is recognised over a period of time as the Group transfers control of the services to the customer which is demonstrated by the customer simultaneously receiving and consuming the benefits provided by the Group. The amount of revenue is measured by reference to the progress made towards complete satisfaction of the performance obligation. Sample based service activities (excluding Clinical Diagnostic Testing activities) This activity is a repetitive business, generally with many relatively small transactions with short turnaround times ruled by short term contracts (turnaround time counted in days). These contracts for their vast majority do not include multiple performance obligations. The Group considers the input method to measure the progress for service rendered to its customers. The payment terms and conditions are most often standard, short term and highly predictable.Revenue is recorded based on the stage of completion of the services performed and net of incentives and rebates (if any). Study based activities This activity is mainly relying on medium term contracts. Revenue is recognised based on the stage of completion of the study until the delivery of the final report. Full Time Equivalent (FTE)-based activities This activity relates to Consulting activities and Professional Scientific Services. Revenue is recorded based on the stage of completion of the services performed. Revenue recognised at a point in time Product based activities Revenue from the sale of goods in the normal course of business is recognised at a point in time when the performance obligation is satisfied and it is based on the amount of the transaction price that is allocated to the performance obligation. The transaction price is the amount of the consideration to which the Group expects to be entitled in exchange for transferring the promised goods to the customer. The consideration expected by the Group may be fixed or variable. Revenue for the sale of goods is recognised when control of the asset is transferred to the buyer and only when it is highly probable that a significant reversal of revenue will not occur when uncertainties related to a variable consideration are resolved. Transfer of control varies depending on the individual terms of the contract of sale. Clinical Diagnostic Testing activities The Group recognises revenues at a point in time when the testing process is completed, and test results are reported to the ordering physician. The Group usually bills third-party payers under fee-for-service agreements. Revenue is recorded net of contractual discounts and generally based on contractual agreements. In case of absence of contractual agreement and / or uncertainty over the consideration to be received, a stand-alone selling price is estimated based on a statistical model which factors in historical collection rates based on cluster of payers showing similar aggregation characteristics. This model is regularly updated with the most recent trends and whenever required. Financing components and time value of money The Group does not expect to have any contracts where the period between the transfer of the promised goods or services to the customer and payment by the customer exceeds one year. Consequently, the Group does not adjust any of the transaction prices for the time value of money. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-39-4": { "value": "1.4. Revenue recognition Revenue recognised over time Revenue from services is recognised over a period of time as the Group transfers control of the services to the customer which is demonstrated by the customer simultaneously receiving and consuming the benefits provided by the Group. The amount of revenue is measured by reference to the progress made towards complete satisfaction of the performance obligation. Sample based service activities (excluding Clinical Diagnostic Testing activities) This activity is a repetitive business, generally with many relatively small transactions with short turnaround times ruled by short term contracts (turnaround time counted in days). These contracts for their vast majority do not include multiple performance obligations. The Group considers the input method to measure the progress for service rendered to its customers. The payment terms and conditions are most often standard, short term and highly predictable.Revenue is recorded based on the stage of completion of the services performed and net of incentives and rebates (if any). Study based activities This activity is mainly relying on medium term contracts. Revenue is recognised based on the stage of completion of the study until the delivery of the final report. Full Time Equivalent (FTE)-based activities This activity relates to Consulting activities and Professional Scientific Services. Revenue is recorded based on the stage of completion of the services performed. Revenue recognised at a point in time Product based activities Revenue from the sale of goods in the normal course of business is recognised at a point in time when the performance obligation is satisfied and it is based on the amount of the transaction price that is allocated to the performance obligation. The transaction price is the amount of the consideration to which the Group expects to be entitled in exchange for transferring the promised goods to the customer. The consideration expected by the Group may be fixed or variable. Revenue for the sale of goods is recognised when control of the asset is transferred to the buyer and only when it is highly probable that a significant reversal of revenue will not occur when uncertainties related to a variable consideration are resolved. Transfer of control varies depending on the individual terms of the contract of sale. Clinical Diagnostic Testing activities The Group recognises revenues at a point in time when the testing process is completed, and test results are reported to the ordering physician. The Group usually bills third-party payers under fee-for-service agreements. Revenue is recorded net of contractual discounts and generally based on contractual agreements. In case of absence of contractual agreement and / or uncertainty over the consideration to be received, a stand-alone selling price is estimated based on a statistical model which factors in historical collection rates based on cluster of payers showing similar aggregation characteristics. This model is regularly updated with the most recent trends and whenever required. Financing components and time value of money The Group does not expect to have any contracts where the period between the transfer of the promised goods or services to the customer and payment by the customer exceeds one year. Consequently, the Group does not adjust any of the transaction prices for the time value of money. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForDiscountsAndRebatesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-45-4": { "value": "1.5. Intangible assets other than goodwill Acquired Intangible assets Separately acquired finite lived intangible assets are accounted for at cost. Intangible assets acquired as part of a business combination such as brands, customer relationships, technologies and other finite lived intangible assets are recognised at their fair value at the acquisition date. Acquired finite lived intangible assets are amortised using the straight-line method over their estimated useful life. The useful lives are reviewed annually. Development costs The directly attributable costs of producing identifiable and separable intangible assets (such as software development) are recognised as an intangible asset when they are controlled by the Group and it is probable that they will generate future economic benefits in excess of their cost over a period of more than one year. Other development expenditures and expenditures on research activities are recognised in the Consolidated Income Statement. Capitalised development expenditures are stated at cost less accumulated amortisation and impairment losses. Amortisation of capitalised development expenditures is charged to the Consolidated Income Statement on a straight line basis over the estimated useful lives of the intangible assets. 1.6. Impairment Impairment of goodwill and intangible assets Goodwill are not amortised but are tested for impairment annually and whenever impairment indicators require. Internal or external sources of information are considered indicators that an asset or a Cash Generating Unit (CGU) or groups of CGUs may be impaired. An impairment loss is recognised in the Consolidated Income Statement whenever and to the extent that the carrying amount of a cash generating unit exceeds the unit\u2019s recoverable amount. The recoverable amount is the higher of an asset\u2019s fair value less costs to sell and its value in use. Reference is made to Note 2.10 for further details. Intangible assets that are subject to amortisation (e.g., customer relationships, brands) are reviewed for impairment whenever triggering events or changes in circumstances indicate that the carrying value may not be recoverable. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-45-5": { "value": "1.5. Intangible assets other than goodwill Acquired Intangible assets Separately acquired finite lived intangible assets are accounted for at cost. Intangible assets acquired as part of a business combination such as brands, customer relationships, technologies and other finite lived intangible assets are recognised at their fair value at the acquisition date. Acquired finite lived intangible assets are amortised using the straight-line method over their estimated useful life. The useful lives are reviewed annually. Development costs The directly attributable costs of producing identifiable and separable intangible assets (such as software development) are recognised as an intangible asset when they are controlled by the Group and it is probable that they will generate future economic benefits in excess of their cost over a period of more than one year. Other development expenditures and expenditures on research activities are recognised in the Consolidated Income Statement. Capitalised development expenditures are stated at cost less accumulated amortisation and impairment losses. Amortisation of capitalised development expenditures is charged to the Consolidated Income Statement on a straight line basis over the estimated useful lives of the intangible assets. Depreciation is generally calculated using the straight-line method over the useful life of the asset. Depreciation on fixed assets is calculated using the straight-line method to write off their cost to their residual values over their estimated useful lives as follows: \u25aa Buildings and leasehold improvements 5-20 years \u25aa Machinery and laboratory equipment 5 years \u25aa Office and IT equipment, furniture and vehicles 3-5 years \u25aa Right of Use over the lease period. Lands represent a value of \u20ac158m as of 31 December 2022 not depreciated as deemed to have an indefinite life. The expected useful lives of the intangible assets excluding goodwill are as follows: \u25aa Software development costs capitalised and software licences are amortised over their estimated useful life (maximum period of 3 years). \u25aa Customer relationships are amortised on a straight-line basis over their estimated useful lives (maximum period of 13 years). For outsourcing deals signed with a sales contract, the amortisation period is aligned with the duration of the contract. \u25aa Technology and other are amortised on a straight-line basis over their estimated useful lives (maximum period of 15 years). \u25aa Tradename recognised on acquisitions are amortised on a systematic basis over their estimated useful lives (maximum period of 25 years). ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForDepreciationExpenseExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-46-6": { "value": "Development costs The directly attributable costs of producing identifiable and separable intangible assets (such as software development) are recognised as an intangible asset when they are controlled by the Group and it is probable that they will generate future economic benefits in excess of their cost over a period of more than one year. Other development expenditures and expenditures on research activities are recognised in the Consolidated Income Statement. Capitalised development expenditures are stated at cost less accumulated amortisation and impairment losses. Amortisation of capitalised development expenditures is charged to the Consolidated Income Statement on a straight line basis over the estimated useful lives of the intangible assets. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-47-6": { "value": "1.6. Impairment Impairment of goodwill and intangible assets Goodwill are not amortised but are tested for impairment annually and whenever impairment indicators require. Internal or external sources of information are considered indicators that an asset or a Cash Generating Unit (CGU) or groups of CGUs may be impaired. An impairment loss is recognised in the Consolidated Income Statement whenever and to the extent that the carrying amount of a cash generating unit exceeds the unit\u2019s recoverable amount. The recoverable amount is the higher of an asset\u2019s fair value less costs to sell and its value in use. Reference is made to Note 2.10 for further details. Intangible assets that are subject to amortisation (e.g., customer relationships, brands) are reviewed for impairment whenever triggering events or changes in circumstances indicate that the carrying value may not be recoverable. Impairment of non-financial assets other than goodwill, intangible assets, inventories, and deferred tax assets Non-financial assets other than goodwill, intangible assets, inventories and deferred tax assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets is assessed by a comparison of the carrying amount of said assets with the greater of their value in use and fair value less costs of disposal. Value in use is measured as the present value of future cash flows expected to be generated by the asset.Fair value less costs of disposal is measured as the amount obtained from a sale of an asset in an arm\u2019s length transaction, less costs of disposal.If the carrying amount of an asset is deemed not recoverable, an impairment charge is recognised in the amount by which the carrying amount of the asset exceeds the recoverable amount. The review for impairment is carried out at the level where cash flows occur that are independent of other cash flows. Impairment losses recognised in prior periods are assessed at each reporting date for any indication that the loss has decreased or no longer exists. An impairment loss is reversed if and to the extent that there has been a change in the estimates used to determine the recoverable amount. The loss is reversed only to the extent that the asset\u2019s carrying amount does not exceed the carrying amount that would have been recognised. Impairment of financial assets The Group recognises an allowance for expected credit losses (ECLs) for trade receivables, debt investments carried at fair value through other comprehensive income (FVTOCI) and amortised costs. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expect to receive. For all trade receivables and contract assets, the Group applies the IFRS 9 simplified approach to measuring ECLs. To measure the ECLs on trade receivables and contract assets, the Group takes into account credit-risk concentration, collective debt risk based on average historical losses as well as days past due. The Group also may factor in specific circumstances such as serious adverse economic conditions in a specific country or region, and other forward-looking information. The Group may also apply individual credit losses on identified trade account receivables or contract assets depending on individual circumstances. Trade receivables and contract assets are written off when there is no reasonable expectation of recovery of the asset, because of failure of a debtor to engage in a repayment plan, associated subsequent payments, bankruptcy or other form of receivership. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-47-7": { "value": "1.6. Impairment Impairment of goodwill and intangible assets Goodwill are not amortised but are tested for impairment annually and whenever impairment indicators require. Internal or external sources of information are considered indicators that an asset or a Cash Generating Unit (CGU) or groups of CGUs may be impaired. An impairment loss is recognised in the Consolidated Income Statement whenever and to the extent that the carrying amount of a cash generating unit exceeds the unit\u2019s recoverable amount. The recoverable amount is the higher of an asset\u2019s fair value less costs to sell and its value in use. Reference is made to Note 2.10 for further details. Intangible assets that are subject to amortisation (e.g., customer relationships, brands) are reviewed for impairment whenever triggering events or changes in circumstances indicate that the carrying value may not be recoverable. Impairment of non-financial assets other than goodwill, intangible assets, inventories, and deferred tax assets Non-financial assets other than goodwill, intangible assets, inventories and deferred tax assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets is assessed by a comparison of the carrying amount of said assets with the greater of their value in use and fair value less costs of disposal. Value in use is measured as the present value of future cash flows expected to be generated by the asset.If the carrying amount of an asset is deemed not recoverable, an impairment charge is recognised in the amount by which the carrying amount of the asset exceeds the recoverable amount. The review for impairment is carried out at the level where cash flows occur that are independent of other cash flows. Impairment losses recognised in prior periods are assessed at each reporting date for any indication that the loss has decreased or no longer exists. An impairment loss is reversed if and to the extent that there has been a change in the estimates used to determine the recoverable amount. The loss is reversed only to the extent that the asset\u2019s carrying amount does not exceed the carrying amount that would have been recognised. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-50-4": { "value": "Fair value less costs of disposal is measured as the amount obtained from a sale of an asset in an arm\u2019s length transaction, less costs of disposal.1.10. Fair value measurements The Group classifies fair value measurements using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels: \u25aa Quoted prices (unadjusted) in active markets for identical assets or liabilities (Level 1 \u2013 Marketable securities, Derivative financial instruments assets, Listed bonds); \u25aa Inputs other than quoted prices included within Level 1 that are observable for the asset or the liability, either directly (i.e., such as prices) or indirectly (i.e., derived from prices) (Level 2 \u2013 Derivative financial instruments liabilities); Inputs for the asset or liability that are not based on observable market data (Level 3). ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-55-4": { "value": "Impairment of financial assets The Group recognises an allowance for expected credit losses (ECLs) for trade receivables, debt investments carried at fair value through other comprehensive income (FVTOCI) and amortised costs. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expect to receive. For all trade receivables and contract assets, the Group applies the IFRS 9 simplified approach to measuring ECLs. To measure the ECLs on trade receivables and contract assets, the Group takes into account credit-risk concentration, collective debt risk based on average historical losses as well as days past due. The Group also may factor in specific circumstances such as serious adverse economic conditions in a specific country or region, and other forward-looking information. The Group may also apply individual credit losses on identified trade account receivables or contract assets depending on individual circumstances. Trade receivables and contract assets are written off when there is no reasonable expectation of recovery of the asset, because of failure of a debtor to engage in a repayment plan, associated subsequent payments, bankruptcy or other form of receivership. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-56-5": { "value": "The Group may also apply individual credit losses on identified trade account receivables or contract assets depending on individual circumstances. Trade receivables and contract assets are written off when there is no reasonable expectation of recovery of the asset, because of failure of a debtor to engage in a repayment plan, associated subsequent payments, bankruptcy or other form of receivership. Receivables Receivable that are held to collect are subsequently measured at amortised cost and are subject to impairment (refer to impairment section in Note 1.6). Contract assets correspond to amounts accrued or due by customers for analysis in progress depending on the stage of completion of the analysis/work performed. For governmental organisations as well as healthcare insurance providers, in the case of some of its US clinical diagnostic testing services, the Group regularly assesses the state of its billing operations and the level of payer\u2019s reimbursements based on specific facts and circumstances and historical recoverability data in order to identify issues which may impact the collection of these receivables. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-57-3": { "value": "1.7. Leases The Group leases various offices, laboratories and cars. The Group determines whether an arrangement constitutes or contains a lease at inception, which is based on the substance of the arrangement. The arrangement constitutes or contains a lease if fulfilment is dependent on the use of a specific asset and the arrangement conveys a right to use the asset, even if that asset is not explicitly specified in the arrangement. Leases are recognised as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the Group. The right-of use asset is depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis. Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments: \u25aa fixed payments (including in-substance fixed payments) less any lease incentives receivable; \u25aa variable lease payments that are based on an index or a rate; \u25aa amounts expected to be payable by the lessee under residual value guarantees; \u25aa the exercise price of a purchase option if the lessee is reasonably certain to exercise that option; \u25aa payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option. The lease payments are discounted using the interest rate implicit of the lease. If that rate cannot be determined, the lessee\u2019s incremental borrowing rate at the lease commencement date is used, which is based on an assessment of interest rates the Group would have to pay to borrow funds in the relevant country, including the consideration of factors such as the nature of the asset and location, collateral, market terms and conditions, as applicable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset. Right-of-use assets are measured at cost comprising the following: \u25aa the amount of the initial measurement of lease liability; \u25aa any lease payments made at or before the commencement date less any lease incentives received; \u25aa any initial direct costs; restoration costs. The right-of-use assets are subsequently accounted for using principles for property, plant and equipment. Payments associated with short-term leases and leases of low-value assets are recognised on a straight-line basis as an expense in the Consolidated Income Statement. Short-term leases are leases with a lease term of 12 months or less. Low-value assets comprise IT-equipment and small items of office furniture considered to be of low value (i.e., less than \u20ac5,000). The Group determines the lease term as the non-cancellable term of the lease, together with any periods covered by an option to extend the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably certain not to be exercised. The Group applies judgement in evaluating whether it is reasonably certain to exercise the option to renew. That is, it considers all relevant factors that create an economic incentive for it to exercise the renewal. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-58-3": { "value": "1.8. Property, plant and equipment Property, plant and equipment are reported on the Consolidated Balance Sheet at their acquisition price, net of accumulated depreciation and impairment losses. The costs of property, plant and equipment comprise all directly attributable costs. Costs related to repair and maintenance activities are expensed in the period in which they are incurred unless leading to an extension of the original lifetime or capacity. Leasehold improvements are amortised using the straight-line method over the shorter of the lease term or the estimated useful life of the asset. Depreciation is generally calculated using the straight-line method over the useful life of the asset. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-59-4": { "value": "Costs related to repair and maintenance activities are expensed in the period in which they are incurred unless leading to an extension of the original lifetime or capacity. Leasehold improvements are amortised using the straight-line method over the shorter of the lease term or the estimated useful life of the asset. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForRepairsAndMaintenanceExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-60-3": { "value": "1.9. Financial Instruments Non-derivative financial assets Non-derivative financial assets comprise cash and cash equivalents, receivables and other financial assets. Recognition and initial measurement: Non-derivative financial assets are recognised when the Group becomes a party to the contractual provisions of the instrument. Purchases and sales of non-derivative financial assets in the normal course of business are accounted for at the trade date. Dividendand interest income are recognised when earned. Gains or losses, if any, are recorded in Finance income and Finance costs. Non-derivative financial assets are derecognised when the rights to receive cash flows from the asset have expired or the Group has transferred its rights to receive cash flows from the asset.assets at their fair value plus, in the case of a financial asset not measured at fair value through profit or loss (FVTPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVTPL are expensed in the Consolidated Income Statement. Classification and subsequent measurement: The Group classifies its non-derivative financial assets in the following measurement categories: \u25aa those that are measured subsequently at fair value; \u25aa those that are measured at amortised cost. In assessing the classification, the Group considers the business model for managing the financial assets and the contractual terms of the cash flows. At initial recognition, the Group measures non-derivative financial For assets measured at fair value, gains and losses will be recorded in either the Consolidated Income Statement or in Other Comprehensive Income (OCI). For investments in equity instruments that are not held for trading, classification will depend on whether the Group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through Other Comprehensive Income (FVTOCI). For investments in these equity instruments, the Group does not subsequently reclassify between FVTOCI and FVTPL. For debt investments, assets are reclassified between FVTOCI, FVTPL and amortised cost only when its business model for managing those assets changes. Cash and cash equivalents Cash and cash equivalents include cash balances, certain money market funds and short-term highly liquid investments with an original maturity of three months or less that are readily convertible into known amounts of cash. Receivables Receivable that are held to collect are subsequently measured at amortised cost and are subject to impairment (refer to impairment section in Note 1.6). Contract assets correspond to amounts accrued or due by customers for analysis in progress depending on the stage of completion of the analysis/work performed. For governmental organisations as well as healthcare insurance providers, in the case of some of its US clinical diagnostic testing services, the Group regularly assesses the state of its billing operations and the level of payer\u2019s reimbursements based on specific facts and circumstances and historical recoverability data in order to identify issues which may impact the collection of these receivables. When the financial asset is derecognised, the cumulative gain or loss previously recognised in OCI is reclassified from equity to the Consolidated Income Statement. Interest income from these financial assets is included in Financial income using the effective interest rate method. Debt instruments that do not meet the criteria for amortised cost or FVTOCI are measured at FVTPL. A gain or loss on a debt investment that is subsequently measured at FVTPL is recognised in the Consolidated Income Statement in the period in which it arises. Equity instruments For equity instruments that are not held for trading, the Group makes an irrevocable election at the time of initial recognition whether to account for the equity investment at FVTPL or FVTOCI. Where the Group has elected to present fair value gains and losses on equity investments in OCI, there is no subsequent reclassification of fair value gains and losses to the Consolidated Income Statement following the derecognition of the investment. Dividends from such investments continue to be recognised in the Consolidated Income Statement when the Group\u2019s right to receive payments is established. Other (non-)current financial assets Other (non-)current financial assets include both debt instruments and equity instruments. Debt instruments Debt instruments include those subsequently carried at amortised cost, those carried at FVTPL and those carried at FVTOCI. Classification depends on the Group\u2019s business model for managing the asset and the cash flow characteristics of the asset. Debt instruments that are held for collection of contractual cash flows, where those cash flows represent solely payments of principal and interest, are measured at amortised cost and are subject to impairment. Interest income from these financial assets is included in Finance income using the effective interest rate method. Financial assets with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payment of principal and interest. Debt instruments that are held for collection of contractual cash flows and for selling the financial assets, where the assets\u2019 cash flows represent solely payments of principal and interest, are measured at FVTOCI and are subject to impairment. Movements in the carrying amounts are taken through OCI, except for the recognition of impairment gains or losses, interest revenue and foreign exchange gains and losses, which are recognised in the Consolidated Income Statement. Debt and other financial liabilities Debt and other financial liabilities, excluding derivative financial liabilities and provisions, are initially measured at fair value and, in the case of debt and payables, net of directly attributable transaction costs. Debt and other financial liabilities are subsequently measured at amortised cost using the effective interest rate. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. Debt and other financial liabilities are derecognised when the obligation under the liability is discharged, cancelled or has expired. Equity Common shares are classified as equity. Incremental costs directly attributable to the issuance of shares are recognised as a deduction from equity. Where the Group purchases the Group\u2019s equity share capital (treasury shares), the consideration paid, including any directly attributable incremental transaction costs (net of income taxes), is deducted from equity attributable to the Group\u2019s equity holders until the shares are cancelled or reissued. Where such ordinary shares are subsequently reissued, any consideration received, net of any directly attributable incremental transaction costs and the related income tax effects, is included in equity attributable to the Group\u2019s equity holders. Dividends are recognised as a liability in the period in which they are declared and approved by shareholders. The income tax consequences of dividends are recognised when a liability to pay the dividend is recognised. Hybrid capital The structure of the hybrid capital ensures that it is recognised as a component of equity in accordance with IAS 32 as the conditions below are met: \u25aa No contractual obligation to redeem the instrument; \u25aa No contractual obligation to pay the coupon. Tax-deductible interest payments are not included in interest expense but accounted for in the same way as dividend obligations to shareholders. The distribution of coupon payments and the costs of issue are booked before tax in shareholders\u2019 equity. Reference is made to Note 2.20 for further detail about the Group\u2019s hybrid capital nature. Derivative financial instruments, including hedge accounting All derivative financial instruments are accounted for at the trade date and classified as current or non-current assets or liabilities based on the maturity date or the early termination date. The Group measures all derivative financial instruments at fair value that is derived from the market prices of the instruments, calculated on the basis of the present value of the estimated future cash flows based on observable interest yield curves, basis spread, credit spreads and foreign exchange rates, or derived from option pricing models, as appropriate. Gains or losses arising from changes in fair value of derivative financial instruments are recognised in the Consolidated Income Statement, except for derivatives that are highly effective and qualify for cash flow or net investment hedge accounting. Changes in the fair value of a derivative that is highly effective and that is designated and qualifies as a cash flow hedge are recorded in OCI until the Consolidated Income Statement are affected by the variability in cash flows of the designated hedged item. To the extent that the hedge is ineffective, changes in the fair value are recognised in the Consolidated Income Statement. The Group formally assesses, both at the hedge\u2019s inception and on an ongoing basis, whether the derivative financial instruments that are used in hedging transactions are highly effective in offsetting changes in fair values or cash flows of hedged items. When it is established that a derivative is not highly effective as a hedge or that it has ceased to be a highly effective hedge, the Group discontinues hedge accounting prospectively. When hedge accounting is discontinued because it is expected that a forecasted transaction will not occur, the Group continues to carry the derivative on the Consolidated Balance Sheet at its fair value, and gains and losses that were accumulated in OCI are recognised immediately in the same line item as they relate to in the Consolidated Income Statement. Foreign currency differences arising upon retranslation of financial instruments designated as a hedge of a net investment in a foreign operation are recognised directly in the currency translation differences reserve through OCI, to the extent that the hedge is effective. To the extent that the hedge is ineffective, such differences are recognised in the Consolidated Income Statement. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-60-4": { "value": "1.9. Financial Instruments Non-derivative financial assets Non-derivative financial assets comprise cash and cash equivalents, receivables and other financial assets. Recognition and initial measurement: Non-derivative financial assets are recognised when the Group becomes a party to the contractual provisions of the instrument. Purchases and sales of non-derivative financial assets in the normal course of business are accounted for at the trade date. Dividendand interest income are recognised when earned. Gains or losses, if any, are recorded in Finance income and Finance costs. Non-derivative financial assets are derecognised when the rights to receive cash flows from the asset have expired or the Group has transferred its rights to receive cash flows from the asset.assets at their fair value plus, in the case of a financial asset not measured at fair value through profit or loss (FVTPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVTPL are expensed in the Consolidated Income Statement. Classification and subsequent measurement: The Group classifies its non-derivative financial assets in the following measurement categories: \u25aa those that are measured subsequently at fair value; \u25aa those that are measured at amortised cost. In assessing the classification, the Group considers the business model for managing the financial assets and the contractual terms of the cash flows. At initial recognition, the Group measures non-derivative financial For assets measured at fair value, gains and losses will be recorded in either the Consolidated Income Statement or in Other Comprehensive Income (OCI). For investments in equity instruments that are not held for trading, classification will depend on whether the Group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through Other Comprehensive Income (FVTOCI). For investments in these equity instruments, the Group does not subsequently reclassify between FVTOCI and FVTPL. For debt investments, assets are reclassified between FVTOCI, FVTPL and amortised cost only when its business model for managing those assets changes. Cash and cash equivalents Cash and cash equivalents include cash balances, certain money market funds and short-term highly liquid investments with an original maturity of three months or less that are readily convertible into known amounts of cash. Receivables Receivable that are held to collect are subsequently measured at amortised cost and are subject to impairment (refer to impairment section in Note 1.6). Contract assets correspond to amounts accrued or due by customers for analysis in progress depending on the stage of completion of the analysis/work performed. For governmental organisations as well as healthcare insurance providers, in the case of some of its US clinical diagnostic testing services, the Group regularly assesses the state of its billing operations and the level of payer\u2019s reimbursements based on specific facts and circumstances and historical recoverability data in order to identify issues which may impact the collection of these receivables. When the financial asset is derecognised, the cumulative gain or loss previously recognised in OCI is reclassified from equity to the Consolidated Income Statement. Interest income from these financial assets is included in Financial income using the effective interest rate method. Debt instruments that do not meet the criteria for amortised cost or FVTOCI are measured at FVTPL. A gain or loss on a debt investment that is subsequently measured at FVTPL is recognised in the Consolidated Income Statement in the period in which it arises. Equity instruments For equity instruments that are not held for trading, the Group makes an irrevocable election at the time of initial recognition whether to account for the equity investment at FVTPL or FVTOCI. Where the Group has elected to present fair value gains and losses on equity investments in OCI, there is no subsequent reclassification of fair value gains and losses to the Consolidated Income Statement following the derecognition of the investment. Dividends from such investments continue to be recognised in the Consolidated Income Statement when the Group\u2019s right to receive payments is established. Other (non-)current financial assets Other (non-)current financial assets include both debt instruments and equity instruments. Debt instruments Debt instruments include those subsequently carried at amortised cost, those carried at FVTPL and those carried at FVTOCI. Classification depends on the Group\u2019s business model for managing the asset and the cash flow characteristics of the asset. Debt instruments that are held for collection of contractual cash flows, where those cash flows represent solely payments of principal and interest, are measured at amortised cost and are subject to impairment. Interest income from these financial assets is included in Finance income using the effective interest rate method. Financial assets with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payment of principal and interest. Debt instruments that are held for collection of contractual cash flows and for selling the financial assets, where the assets\u2019 cash flows represent solely payments of principal and interest, are measured at FVTOCI and are subject to impairment. Movements in the carrying amounts are taken through OCI, except for the recognition of impairment gains or losses, interest revenue and foreign exchange gains and losses, which are recognised in the Consolidated Income Statement. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-63-5": { "value": "Non-derivative financial assets are derecognised when the rights to receive cash flows from the asset have expired or the Group has transferred its rights to receive cash flows from the asset.When the financial asset is derecognised, the cumulative gain or loss previously recognised in OCI is reclassified from equity to the Consolidated Income Statement. Interest income from these financial assets is included in Financial income using the effective interest rate method. Debt instruments that do not meet the criteria for amortised cost or FVTOCI are measured at FVTPL. A gain or loss on a debt investment that is subsequently measured at FVTPL is recognised in the Consolidated Income Statement in the period in which it arises. Debt and other financial liabilities are derecognised when the obligation under the liability is discharged, cancelled or has expired. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-67-5": { "value": "For assets measured at fair value, gains and losses will be recorded in either the Consolidated Income Statement or in Other Comprehensive Income (OCI). The Group measures all derivative financial instruments at fair value that is derived from the market prices of the instruments, calculated on the basis of the present value of the estimated future cash flows based on observable interest yield curves, basis spread, credit spreads and foreign exchange rates, or derived from option pricing models, as appropriate. Gains or losses arising from changes in fair value of derivative financial instruments are recognised in the Consolidated Income Statement, except for derivatives that are highly effective and qualify for cash flow or net investment hedge accounting. Changes in the fair value of a derivative that is highly effective and that is designated and qualifies as a cash flow hedge are recorded in OCI until the Consolidated Income Statement are affected by the variability in cash flows of the designated hedged item. To the extent that the hedge is ineffective, changes in the fair value are recognised in the Consolidated Income Statement. The Group formally assesses, both at the hedge\u2019s inception and on an ongoing basis, whether the derivative financial instruments that are used in hedging transactions are highly effective in offsetting changes in fair values or cash flows of hedged items. When it is established that a derivative is not highly effective as a hedge or that it has ceased to be a highly effective hedge, the Group discontinues hedge accounting prospectively. When hedge accounting is discontinued because it is expected that a forecasted transaction will not occur, the Group continues to carry the derivative on the Consolidated Balance Sheet at its fair value, and gains and losses that were accumulated in OCI are recognised immediately in the same line item as they relate to in the Consolidated Income Statement. Foreign currency differences arising upon retranslation of financial instruments designated as a hedge of a net investment in a foreign operation are recognised directly in the currency translation differences reserve through OCI, to the extent that the hedge is effective. To the extent that the hedge is ineffective, such differences are recognised in the Consolidated Income Statement. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-69-5": { "value": "For investments in these equity instruments, the Group does not subsequently reclassify between FVTOCI and FVTPL. For debt investments, assets are reclassified between FVTOCI, FVTPL and amortised cost only when its business model for managing those assets changes. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-70-5": { "value": "Cash and cash equivalents Cash and cash equivalents include cash balances, certain money market funds and short-term highly liquid investments with an original maturity of three months or less that are readily convertible into known amounts of cash. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-73-5": { "value": "Equity instruments For equity instruments that are not held for trading, the Group makes an irrevocable election at the time of initial recognition whether to account for the equity investment at FVTPL or FVTOCI. Where the Group has elected to present fair value gains and losses on equity investments in OCI, there is no subsequent reclassification of fair value gains and losses to the Consolidated Income Statement following the derecognition of the investment. Dividends from such investments continue to be recognised in the Consolidated Income Statement when the Group\u2019s right to receive payments is established. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-75-5": { "value": "Debt and other financial liabilities Debt and other financial liabilities, excluding derivative financial liabilities and provisions, are initially measured at fair value and, in the case of debt and payables, net of directly attributable transaction costs. Debt and other financial liabilities are subsequently measured at amortised cost using the effective interest rate. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. Debt and other financial liabilities are derecognised when the obligation under the liability is discharged, cancelled or has expired. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-75-6": { "value": "Debt and other financial liabilities Debt and other financial liabilities, excluding derivative financial liabilities and provisions, are initially measured at fair value and, in the case of debt and payables, net of directly attributable transaction costs. Debt and other financial liabilities are subsequently measured at amortised cost using the effective interest rate. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. Debt and other financial liabilities are derecognised when the obligation under the liability is discharged, cancelled or has expired. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForBorrowingsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-75-7": { "value": "Debt and other financial liabilities Debt and other financial liabilities, excluding derivative financial liabilities and provisions, are initially measured at fair value and, in the case of debt and payables, net of directly attributable transaction costs. Debt and other financial liabilities are subsequently measured at amortised cost using the effective interest rate. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. Debt and other financial liabilities are derecognised when the obligation under the liability is discharged, cancelled or has expired. 1.18. Finance income and costs Financial income comprises interest income on funds invested (including financial assets), dividend income, net gains on the disposal of financial assets, net fair value gains on financial assets at FVTPL, net gains on the remeasurement to fair value of any pre-existing interest in an acquiree, and net gains on foreign exchange impacts that are recognised in the Consolidated Income Statement. Interest income is recognised on an accrual basis in the Consolidated Income Statement, using the effective interest method. Dividend income is recognised in the Consolidated Income Statement on the date that the Group\u2019s right to receive payment is established, which in the case of quoted securities is normally the ex-dividend date. Financial expenses comprise interest expenses on borrowings, unwinding of the discount on provisions and contingent consideration, losses on disposal of financial assets, net fair value losses on financial assets at FVTPL, impairment losses recognised on financial assets (other than trade receivables), net interest expenses related to defined-benefit plans, interest on lease liabilities and net losses on foreign exchange impacts that are recognised in the Consolidated Income Statement. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForFinanceCostsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-77-4": { "value": "Equity Common shares are classified as equity. Incremental costs directly attributable to the issuance of shares are recognised as a deduction from equity. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-78-4": { "value": "Where the Group purchases the Group\u2019s equity share capital (treasury shares), the consideration paid, including any directly attributable incremental transaction costs (net of income taxes), is deducted from equity attributable to the Group\u2019s equity holders until the shares are cancelled or reissued. Where such ordinary shares are subsequently reissued, any consideration received, net of any directly attributable incremental transaction costs and the related income tax effects, is included in equity attributable to the Group\u2019s equity holders. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-79-4": { "value": "Dividends are recognised as a liability in the period in which they are declared and approved by shareholders. The income tax consequences of dividends are recognised when a liability to pay the dividend is recognised. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForDividendsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-80-4": { "value": "Hybrid capital The structure of the hybrid capital ensures that it is recognised as a component of equity in accordance with IAS 32 as the conditions below are met: \u25aa No contractual obligation to redeem the instrument; \u25aa No contractual obligation to pay the coupon. Tax-deductible interest payments are not included in interest expense but accounted for in the same way as dividend obligations to shareholders. The distribution of coupon payments and the costs of issue are booked before tax in shareholders\u2019 equity. Reference is made to Note 2.20 for further detail about the Group\u2019s hybrid capital nature. ", "dimensions": { "concept": "EUR:DescriptionOfAccountingPolicyForHybridCapital", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-81-4": { "value": "Derivative financial instruments, including hedge accounting All derivative financial instruments are accounted for at the trade date and classified as current or non-current assets or liabilities based on the maturity date or the early termination date. The Group measures all derivative financial instruments at fair value that is derived from the market prices of the instruments, calculated on the basis of the present value of the estimated future cash flows based on observable interest yield curves, basis spread, credit spreads and foreign exchange rates, or derived from option pricing models, as appropriate. Gains or losses arising from changes in fair value of derivative financial instruments are recognised in the Consolidated Income Statement, except for derivatives that are highly effective and qualify for cash flow or net investment hedge accounting. Changes in the fair value of a derivative that is highly effective and that is designated and qualifies as a cash flow hedge are recorded in OCI until the Consolidated Income Statement are affected by the variability in cash flows of the designated hedged item. To the extent that the hedge is ineffective, changes in the fair value are recognised in the Consolidated Income Statement. The Group formally assesses, both at the hedge\u2019s inception and on an ongoing basis, whether the derivative financial instruments that are used in hedging transactions are highly effective in offsetting changes in fair values or cash flows of hedged items. When it is established that a derivative is not highly effective as a hedge or that it has ceased to be a highly effective hedge, the Group discontinues hedge accounting prospectively. When hedge accounting is discontinued because it is expected that a forecasted transaction will not occur, the Group continues to carry the derivative on the Consolidated Balance Sheet at its fair value, and gains and losses that were accumulated in OCI are recognised immediately in the same line item as they relate to in the Consolidated Income Statement. Foreign currency differences arising upon retranslation of financial instruments designated as a hedge of a net investment in a foreign operation are recognised directly in the currency translation differences reserve through OCI, to the extent that the hedge is effective. To the extent that the hedge is ineffective, such differences are recognised in the Consolidated Income Statement. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-81-5": { "value": "Derivative financial instruments, including hedge accounting All derivative financial instruments are accounted for at the trade date and classified as current or non-current assets or liabilities based on the maturity date or the early termination date. The Group measures all derivative financial instruments at fair value that is derived from the market prices of the instruments, calculated on the basis of the present value of the estimated future cash flows based on observable interest yield curves, basis spread, credit spreads and foreign exchange rates, or derived from option pricing models, as appropriate. Gains or losses arising from changes in fair value of derivative financial instruments are recognised in the Consolidated Income Statement, except for derivatives that are highly effective and qualify for cash flow or net investment hedge accounting. Changes in the fair value of a derivative that is highly effective and that is designated and qualifies as a cash flow hedge are recorded in OCI until the Consolidated Income Statement are affected by the variability in cash flows of the designated hedged item. To the extent that the hedge is ineffective, changes in the fair value are recognised in the Consolidated Income Statement. The Group formally assesses, both at the hedge\u2019s inception and on an ongoing basis, whether the derivative financial instruments that are used in hedging transactions are highly effective in offsetting changes in fair values or cash flows of hedged items. When it is established that a derivative is not highly effective as a hedge or that it has ceased to be a highly effective hedge, the Group discontinues hedge accounting prospectively. When hedge accounting is discontinued because it is expected that a forecasted transaction will not occur, the Group continues to carry the derivative on the Consolidated Balance Sheet at its fair value, and gains and losses that were accumulated in OCI are recognised immediately in the same line item as they relate to in the Consolidated Income Statement. Foreign currency differences arising upon retranslation of financial instruments designated as a hedge of a net investment in a foreign operation are recognised directly in the currency translation differences reserve through OCI, to the extent that the hedge is effective. To the extent that the hedge is ineffective, such differences are recognised in the Consolidated Income Statement. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-81-6": { "value": "Derivative financial instruments, including hedge accounting All derivative financial instruments are accounted for at the trade date and classified as current or non-current assets or liabilities based on the maturity date or the early termination date. The Group measures all derivative financial instruments at fair value that is derived from the market prices of the instruments, calculated on the basis of the present value of the estimated future cash flows based on observable interest yield curves, basis spread, credit spreads and foreign exchange rates, or derived from option pricing models, as appropriate. Gains or losses arising from changes in fair value of derivative financial instruments are recognised in the Consolidated Income Statement, except for derivatives that are highly effective and qualify for cash flow or net investment hedge accounting. Changes in the fair value of a derivative that is highly effective and that is designated and qualifies as a cash flow hedge are recorded in OCI until the Consolidated Income Statement are affected by the variability in cash flows of the designated hedged item. To the extent that the hedge is ineffective, changes in the fair value are recognised in the Consolidated Income Statement. The Group formally assesses, both at the hedge\u2019s inception and on an ongoing basis, whether the derivative financial instruments that are used in hedging transactions are highly effective in offsetting changes in fair values or cash flows of hedged items. When it is established that a derivative is not highly effective as a hedge or that it has ceased to be a highly effective hedge, the Group discontinues hedge accounting prospectively. When hedge accounting is discontinued because it is expected that a forecasted transaction will not occur, the Group continues to carry the derivative on the Consolidated Balance Sheet at its fair value, and gains and losses that were accumulated in OCI are recognised immediately in the same line item as they relate to in the Consolidated Income Statement. Foreign currency differences arising upon retranslation of financial instruments designated as a hedge of a net investment in a foreign operation are recognised directly in the currency translation differences reserve through OCI, to the extent that the hedge is effective. To the extent that the hedge is ineffective, such differences are recognised in the Consolidated Income Statement. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForHedgingExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-84-3": { "value": "1.11. Inventories Inventories are stated at the lower of cost or net realisable value. The cost of inventories comprises all costs of purchase, cost of conversion and other costs incurred in bringing the inventories to their present location and condition. The cost of inventories is determined using the first-in, first-out (FIFO) method. The net realisable value represents the estimated sales price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Write-downs of inventories which are considered obsolete or slow moving are computed taking into account their expected future utilisation and their net realisable value. The Group also considers other reasons that the cost of inventories may not be recoverable such as damage, obsolescence, expiration date or declines in selling price. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-86-3": { "value": "1.12. Provisions Provisions are recognised if as a result of past events, the Group has a present legal or constructive obligation, the amount can be estimated reliably and it is more likely than not that an outflow of resources will be required to settle the obligation. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax discount rate that reflects current market assessments of the time value of money. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-87-3": { "value": "1.13. Income taxes Income taxes comprise current, non-current and deferred tax. Income tax is recognised in the Consolidated Income Statement except to the extent that it relates to items recognised directly within equity or in Other Comprehensive Income. Current tax is the expected taxes payable on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. In cases where it is concluded it is not probable that tax authorities will accept a tax treatment, the effect of the uncertainty is reflected in the recognition and measurement of tax assets and liabilities or, alternatively, a provision is made for the amount that is expected to be settled, where this can be reasonably estimated. This assessment relies on estimates and assumptions and may involve a series of judgements about future events. New information may become available that causes the Group to change its judgement regarding adequacy of existing tax assets and liabilities. Such changes to tax assets and liabilities will impact the income tax expense in the period during which such a determination is made. Deferred tax assets and liabilities are recognised, using the Consolidated Balance Sheet method, for the expected tax consequences of temporary differences between the carrying amounts of assets and liabilities and the amounts used for taxation purposes. Deferred taxes are measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity or on different taxable entities, but the Group intends to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realised simultaneously A deferred tax asset is recognised for unused tax losses, tax credits and deductible temporary differences to the extent that it is probable that there will be future taxable profits against which they can be utilised. The ultimate realisation of deferred tax assets is dependent upon the generation of future taxable income in the countries where the deferred tax assets originated and during the periods when the deferred tax assets become deductible. The Group considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-87-4": { "value": "1.13. Income taxes Income taxes comprise current, non-current and deferred tax. Income tax is recognised in the Consolidated Income Statement except to the extent that it relates to items recognised directly within equity or in Other Comprehensive Income. Current tax is the expected taxes payable on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. In cases where it is concluded it is not probable that tax authorities will accept a tax treatment, the effect of the uncertainty is reflected in the recognition and measurement of tax assets and liabilities or, alternatively, a provision is made for the amount that is expected to be settled, where this can be reasonably estimated. This assessment relies on estimates and assumptions and may involve a series of judgements about future events. New information may become available that causes the Group to change its judgement regarding adequacy of existing tax assets and liabilities. Such changes to tax assets and liabilities will impact the income tax expense in the period during which such a determination is made. Deferred tax assets and liabilities are recognised, using the Consolidated Balance Sheet method, for the expected tax consequences of temporary differences between the carrying amounts of assets and liabilities and the amounts used for taxation purposes. Deferred taxes are measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity or on different taxable entities, but the Group intends to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realised simultaneously A deferred tax asset is recognised for unused tax losses, tax credits and deductible temporary differences to the extent that it is probable that there will be future taxable profits against which they can be utilised. The ultimate realisation of deferred tax assets is dependent upon the generation of future taxable income in the countries where the deferred tax assets originated and during the periods when the deferred tax assets become deductible. The Group considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-88-3": { "value": "Foreign currency transactions The financial statements of all Group entities are measured using the currency of the primary economic environment in which the entity operates (\u201cthe functional currency\u201d). The Euro (\u20ac) is the functional currency of the Group and the presentation currency of the Consolidated Financial Statements. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions or the valuation in cases where items are remeasured. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-88-4": { "value": "Foreign currency transactions The financial statements of all Group entities are measured using the currency of the primary economic environment in which the entity operates (\u201cthe functional currency\u201d). The Euro (\u20ac) is the functional currency of the Group and the presentation currency of the Consolidated Financial Statements. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions or the valuation in cases where items are remeasured. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Consolidated Income Statement, except when deferred in Other comprehensive income as qualifying cash flow hedges and qualifying net investment hedges. Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are retranslated to the functional currency using the exchange rate at the date the fair value was determined. Non-monetary items in a foreign currency that are measured based on historical cost are translated using the exchange rate at the transaction date. Foreign operations The assets and liabilities of foreign operations, including goodwill and fair value adjustments arising on acquisition, are translated to Euros at the exchange rates prevailing at the reporting date. The income and expenses of foreign operations are translated to Euros at the exchange rates prevailing at the dates of the transactions. Foreign currency differences arising upon translation of foreign operations into Euros are recognised in Other Comprehensive Income and presented as part of currency translation reserves in Shareholders Equity. When a foreign operation is disposed of such that control, significant influence or joint control is lost, the cumulative amount in the currency translation differences related to the foreign operation is reclassified to the Consolidated Income Statement as part of the gain or loss on disposal. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-91-3": { "value": "1.15. Non-current assets held for sale Non-current assets that are expected to be recovered primarily through sale rather than through continuing use are classified as held for sale. Non-current assets held for sale are carried at the lower of carrying amount or fair value less cost of disposal. Any gain or loss from disposal, together with the results of these operations until the date of disposal, is reported separately as discontinued operations. The financial information of discontinued operations is excluded from the respective captions in the Consolidated Financial Statements and related Notes for all periods presented. Comparatives in the Consolidated Balance Sheet are not represented when a non-current asset is classified as held for sale. Comparatives are represented for presentation of discontinued operations in the Consolidated Cash Flow Statement and Consolidated Income Statement. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-91-4": { "value": "1.15. Non-current assets held for sale Non-current assets that are expected to be recovered primarily through sale rather than through continuing use are classified as held for sale. Non-current assets held for sale are carried at the lower of carrying amount or fair value less cost of disposal. Any gain or loss from disposal, together with the results of these operations until the date of disposal, is reported separately as discontinued operations. The financial information of discontinued operations is excluded from the respective captions in the Consolidated Financial Statements and related Notes for all periods presented. Comparatives in the Consolidated Balance Sheet are not represented when a non-current asset is classified as held for sale. Comparatives are represented for presentation of discontinued operations in the Consolidated Cash Flow Statement and Consolidated Income Statement. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForDiscontinuedOperationsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-91-5": { "value": "1.15. Non-current assets held for sale Non-current assets that are expected to be recovered primarily through sale rather than through continuing use are classified as held for sale. Non-current assets held for sale are carried at the lower of carrying amount or fair value less cost of disposal. Any gain or loss from disposal, together with the results of these operations until the date of disposal, is reported separately as discontinued operations. The financial information of discontinued operations is excluded from the respective captions in the Consolidated Financial Statements and related Notes for all periods presented. Comparatives in the Consolidated Balance Sheet are not represented when a non-current asset is classified as held for sale. Comparatives are represented for presentation of discontinued operations in the Consolidated Cash Flow Statement and Consolidated Income Statement. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-92-3": { "value": "1.16. Employee benefits A defined-contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. Obligations for contributions to defined-contribution pension plans are recognised as an employee benefit expense in the Consolidated Income Statement in the periods during which services are rendered by employees. A defined-benefit plan is a post-employment benefit plan other than a defined-contribution plan. Plans for which the Group has no legal or constructive obligation to pay further amounts, but to which it does pay non-fixed contributions, are also treated as a defined-benefit plan. The net pension asset or liability recognised in the Consolidated Balance Sheet in respect of defined-benefit post-employment plans is the fair value of plan assets less the present value of the projected defined-benefit obligation at the Consolidated Balance Sheet date. The defined-benefit obligation is calculated annually by qualified actuaries using the projected unit credit method. Recognised assets are limited to the present value of any reductions in future contribution or any future refunds. The net pension liability is presented as a long-term provision; no distinction is made for the short-term portion. Pension costs in respect of defined-benefit post-employment plans primarily represent the increase of the actuarial present value of the obligation for post-employment benefits based on employee service during the year and the interest on the net recognised asset or liability in respect of employee service in previous years. Remeasurements of the net defined-benefit asset or liability comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (excluding interest). The Group recognises all remeasurements in Other Comprehensive Income. The Group recognises gains and losses on the settlement of a defined-benefit plan when the settlement occurs. The gain or loss on settlement is the difference between the present value of the defined-benefit obligation being settled, as determined on the date of settlement, and the settlement price, including any plan assets transferred and any payments made directly by the Group in connection with the settlement. Past service costs arising from the introduction of a change to the benefit payable under a plan or a significant reduction of the number of employees covered by a plan (curtailment) are recognised in full in the Consolidated Income Statement. The Group\u2019s net obligation in respect of long-term employee benefits is the amount of future benefit that employees have earned in return for their service in the current and prior periods, such as jubilee entitlements. That benefit is discounted to determine its present value. Remeasurements are recognised in the Consolidated Income Statement in the period in which they arise. Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. The Group recognises a liability and an expense for bonuses and incentives based on a formula that takes into consideration the profit attributable to the Group\u2019s shareholders after certain adjustments. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-93-3": { "value": "1.17. Share based payments Please refer to Note 2.27 for further details about the different plans. The cost of equity-settled transactions is determined by the fair value at the date when the grant is made using an appropriate valuation model. The grant-date fair value of equity-settled share-based payment awards granted to employees is recognised as personnel expense, with a corresponding increase in equity, over the vesting period of the award. The cumulative expense recognised for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Group\u2019s best estimate of the number of equity instruments that will ultimately vest. The expense or credit in the statement of income for a period represents the movement in cumulative expense recognised at the beginning and end of that period. Service and non-market performance conditions are not taken into account when determining the grant-date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Group\u2019s best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant-date fair value. No expense is recognised for awards that do not ultimately vest because non-market performance and/or service conditions have not been met. When an award is cancelled by the entity or by the counterparty, any remaining element of the fair value of the award is expensed immediately through profit or loss. The dilutive effect of outstanding options and shares is reflected as additional share dilution in the computation of diluted earnings per share. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-94-4": { "value": "1.18. Finance income and costs Financial income comprises interest income on funds invested (including financial assets), dividend income, net gains on the disposal of financial assets, net fair value gains on financial assets at FVTPL, net gains on the remeasurement to fair value of any pre-existing interest in an acquiree, and net gains on foreign exchange impacts that are recognised in the Consolidated Income Statement. Interest income is recognised on an accrual basis in the Consolidated Income Statement, using the effective interest method. Dividend income is recognised in the Consolidated Income Statement on the date that the Group\u2019s right to receive payment is established, which in the case of quoted securities is normally the ex-dividend date. Financial expenses comprise interest expenses on borrowings, unwinding of the discount on provisions and contingent consideration, losses on disposal of financial assets, net fair value losses on financial assets at FVTPL, impairment losses recognised on financial assets (other than trade receivables), net interest expenses related to defined-benefit plans, interest on lease liabilities and net losses on foreign exchange impacts that are recognised in the Consolidated Income Statement. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-94-5": { "value": "1.18. Finance income and costs Financial income comprises interest income on funds invested (including financial assets), dividend income, net gains on the disposal of financial assets, net fair value gains on financial assets at FVTPL, net gains on the remeasurement to fair value of any pre-existing interest in an acquiree, and net gains on foreign exchange impacts that are recognised in the Consolidated Income Statement. Interest income is recognised on an accrual basis in the Consolidated Income Statement, using the effective interest method. Dividend income is recognised in the Consolidated Income Statement on the date that the Group\u2019s right to receive payment is established, which in the case of quoted securities is normally the ex-dividend date. Financial expenses comprise interest expenses on borrowings, unwinding of the discount on provisions and contingent consideration, losses on disposal of financial assets, net fair value losses on financial assets at FVTPL, impairment losses recognised on financial assets (other than trade receivables), net interest expenses related to defined-benefit plans, interest on lease liabilities and net losses on foreign exchange impacts that are recognised in the Consolidated Income Statement. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-95-3": { "value": "1.19. Earnings per share The Group presents basic and diluted earnings per share (EPS) data for its common shares. Basic EPS is calculated by dividing the Net income (loss) attributable to shareholders by the weighted average number of common shares outstanding during the period, adjusted for own shares held. Diluted EPS is determined by adjusting the Net income (loss) attributable to shareholders and the weighted average number of common shares outstanding during the period, adjusted for own shares held, for the effects of all dilutive potential common shares, which comprises forward purchase contracts, restricted shares, performance shares and share options granted to employees. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-97-3": { "value": "1.20. Alternative performance measures (APM) The Group is providing in the Consolidated Financial Statements certain alternative performance measures (non-IFRS information). APMs used in the Consolidated Income Statement Adjusted results \u2013 reflect the ongoing performance of the mature and recurring activities excluding \u201cseparately disclosed items\u201d. Separately disclosed items (SDI) \u2013 include: \u25aa one-off costs from integration and reorganisation; \u25aa discontinued operations; \u25aa other non-recurring income and costs; \u25aa temporary losses and other costs related to network expansion, start-ups and new acquisitions undergoing significant restructuring; \u25aa share-based payment charge; \u25aa acquisition-related expenses, net \u2013 impairment of goodwill, amortisation/impairment of acquired intangible assets, negative goodwill, transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions; \u25aa gain and loss on disposal of subsidiaries, net; \u25aa net finance costs related to borrowing and investing excess cash and one-off financial effects (net of finance income); \u25aa net finance costs related to hybrid capital; \u25aa and the related tax effects. Details are provided in Notes 1.21 and 2.5. EBITDA \u2013 Earnings before interest, taxes, depreciation and amortisation, share-based payment charge, acquisition-related expenses, net and gain and loss on disposal of subsidiaries, net. EBITAS \u2013 EBITDA less depreciation and amortisation. EBIT \u2013 EBITAS less share-based payment charge, acquisition-related expenses, net and gain and loss on disposal of subsidiaries, net. These measures exclude certain items because of the nature of these items and the impact they have on the analysis of the underlying business performance and trends. The Group shows EBITDA, EBITAS, EBIT as defined in the Notes to the Consolidated Income Statement with the objective to be consistent with the information used in internal Group reporting to measure the performance of Group companies and information published by other comparable companies. APMs used in the Consolidated Cash flow Statement Net capex \u2013 Purchase, capitalisation of intangible assets, purchase of property, plant and equipment, less proceeds from disposals of such assets less capex trade payables change of the period. Free Cash Flow to the Firm \u2013 Net cash provided by operating activities, less Net capex. APMs used in the Notes Net debt \u2013 Current and non-current borrowings, less Cash and cash equivalents (Note 2.17). Net working capital \u2013 Inventories, trade receivables and contract assets, prepaid expenses and other current assets less trade accounts payable, contract liabilities and other current liabilities excluding accrued interest receivable and payable (Note 2.25). Free Cash Flow to Equity \u2013 Free Cash Flow to the Firm, less disposal/(acquisition) of investments, financial assets and derivative financial instruments, net, and after interests and premium paid net of interest received. Free cash flow to Equity does not take into account the dividends paid to shareholders and non-controlling interests as well as earnings paid to hybrid capital holders (Note 2.29). The Group believes that providing these APMs enhances investors\u2019 understanding of the Group\u2019s core operating results and future prospects, consistent with how the Group measures and forecasts the Group\u2019s performance, especially when comparing such results to previous periods or objectives and to the performance of our competitors. This enables the Group to demonstrate the underlying profitability of the business \u2013 i.e., what the performance would be if the investments as described in Note 1.21 were not undertaken. In the interest of full transparency, the Group discloses both the adjusted results (i.e., without the separately disclosed items) and full reported results (i.e., including the separately disclosed items). This information should be considered in addition to, but not in lieu of, information prepared in accordance with IFRS. 1.21. Mature scope and Separately disclosed items In order to present the performance of the Group in a clear, consistent and comparable format, certain items are disclosed separately in the Consolidated Income Statement. Mature scope Mature scope excludes start-ups and acquisitions in significant restructuring. A business will generally be considered mature when: i) The Group\u2019s systems, structure and processes have been deployed; ii) It has been audited, accredited, qualified and used by the relevant regulatory bodies and the targeted client base; iii) It no longer requires above-average annual capital expenditures, exceptional restructuring or abnormally large costs with respect to their current revenues for deploying new Group IT systems. The list of entities classified as mature is reviewed at the beginning of each year and is relevant for the whole year. In FY 2022, 96% of total Group revenues were included in the mature scope (96% as FY 2021). Separately disclosed items Separately disclosed items is defined in Note 1.20 (see details in Note 2.5). One-off costs from integration, reorganisation, discontinued operations and other non-recurring income and costs One-off costs from integration, reorganisation costs, such as reducing overhead and consolidating facilities, are included in the separately disclosed items as the Group believes that these effects are not indicative of our normal operating income and expenses. Discontinued operations are a component of the Group\u2019s core business or product lines that have been disposed of, or liquidated; or a specific business unit or a branch of a business unit that has been shut down or terminated, and are reported separately from continued operations. Other non-recurring income and costs are also disclosed separately, as they are either isolated or cannot be expected to occur again with any regularity or predictability and as the Group believes they are not indicative of the Group\u2019s normal operating gains and losses. These include gains or losses on significant litigation-related matters. Temporary losses and other costs related to network expansion, start-ups and new acquisitions undergoing significant restructuring Network expansion, start-ups or acquisitions in significant restructuring are new companies or business activities established to develop an existing business model, transfer technology or a specific strategy. They are generally greenfield operations, or, in certain cases, newly acquired businesses bought to achieve a target market share in a given geography that are not operating optimally, but that have the potential to operate efficiently and profitably once restructured or reorganised to the Group\u2019s model. However, the reorganisation measures required are so large that they have a significant negative impact on the ongoing business of the Group. Start-ups are generally undertaken in new markets, and in particular emerging markets, where there are often limited viable options for acquisitions or in developed markets when Eurofins transfers technology developed by its R&D and Competence Centers abroad. Given that the costs or operating losses incurred in the start-up or restructuring phase are temporary and should cease within a 3-5 year period on average, it is the Group\u2019s view that they should be disclosed separately. Whilst the timeframe for these temporary costs or losses is finite, and should cease gradually, the businesses should continue to generate revenues for the Group indefinitely, and these are therefore not considered temporary. Start-up activities go through various stages of development before reaching optimal efficiency levels and can take several years to become profitable. The development process includes the creation or construction of the laboratory, hiring the appropriate staff, obtaining relevant accreditations, deployment of the IT infrastructure and dedicated IT solutions, developing the sales and marketing channels, and building up volumes and the revenue base. In general, start-up periods last for 2 to 3 years in mature markets and 2 to 5 years in emerging markets. The list of entities classified as start-ups or acquisitions in significant restructuring is reviewed at the beginning of each year and is relevant for the whole year. Temporary losses and other costs related to network expansion, start-ups and new acquisitions undergoing significant restructuring are included in the separately disclosed items as these are investments in future growth prospects and distort the judgement of the underlying performance of the mature businesses of the Group. Depreciation costs specific to start-ups and new acquisitions undergoing significant restructuring The line corresponds to the line \u201cdepreciation\u201d of the entities classified as start-ups or acquisitions in significant restructuring. Share-based payment charge and acquisition-related expenses, net Separately disclosed items also include share-based payment charge, impairment of goodwill, and amortisation/impairment of acquired intangible assets, recording of negative goodwill as well as income from reversal of such costs and from unused amounts due for business acquisitions as all these transactions are without cash impact in the Consolidated Financial Statements. Furthermore, the amortisation of acquired intangible assets is included because a significant portion of the purchase price for acquisitions may be allocated to intangible assets. All transaction costs and long-term incentives/ retention bonus related to acquisitions during the year are disclosed separately. There are a number of different professionals that may assist throughout the process of planning, negotiating, performing due diligence, and closing of the transaction. Examples include intermediaries (investment bankers or business brokers), legal professionals (lawyers) and accounting professionals. These costs are specific and directly related to the transaction and are usually paid at or around the closing of the relevant transaction. These costs are disclosed separately also due to the fact that if the Group would stop its external growth, i.e., acquisitions, and would only focus on internal growth, most of these costs would disappear instantly and the EBIT would increase mechanically. Furthermore, these costs do not correspond to the Group\u2019s business of providing analytical solutions to its customers. Gain and loss on disposal of subsidiaries, net These include gains or losses on the disposal of a business or real estate to third party (e.g. Digital Testing in 2022) or liquidation. Net finance costs related to borrowing and investing excess cash and one-off financial effects (net of finance income) and related to hybrid capital Net finance costs related to excess cash and one-off financial effects correspond to cash earmarked for future investments/ acquisitions and not needed for the existing business. Excess cash is calculated as the difference between the total Consolidated cash balance at month-end and the minimum liquidity position required to operate the business, as based on a percentage of sales (considered to be 5% of the annualised revenues of the rolling last three months) and split proportionately between Equity, Gross financial debt and hybrid capital. The finance cost related to excess cash is then calculated using the weighted average interest rate of each debt instrument and coupon on hybrid capital on the Balance Sheet of the Group. Tax effect from the adjustment of all separately disclosed items On all items listed above, the related tax effects are calculated. Total impact on earnings attributable to hybrid capital investors This item corresponds to the Net finance costs related to hybrid capital excess cash. The Group believes that the separate disclosure of these items enhances investors\u2019 understanding of the Group\u2019s core operating results and future prospects and allows better comparisons of operating results which are consistent over time and with peer companies. ", "dimensions": { "concept": "EUR:DescriptionOfAccountingPolicyForAlternativePerformanceMeasures", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-100-2": { "value": "1.22. Application of standards, amendments and interpretations Standards, amendments and interpretations adopted by the European Union and effective as of 1 January 2022 The accounting policies applied for the preparation of these Consolidated Financial Statements are consistent with those applied in the preparation of Consolidated financial statements for the year ended 31 December 2021. Other standards, amendments and interpretations newly applicable as of 1 January 2022 Other standards, amendments and interpretations newly applicable as of 1 January 2022 have no material impact on these Consolidated Financial Statements: \u25aa Reference to the Conceptual Framework - Amendment to IFRS 3 \u25aa Property, Plant and Equipment: Proceeds before intended Use - Amendment to IAS 16 \u25aa Onerous Contracts - Cost of fulfilling a contract - Amendment to IAS 37 \u25aa AIP IFRS 1 First time Adoption of International Financial Reporting Standards - Subsidiary as a first-time adopter \u25aa AIP IFRS 9 Financial Instruments - Fees in the \u201810 per cent\u2019 test for derecognition of financial liabilities \u25aa AIP IAS 41 Agriculture - Taxation in Fair value measurement New standards and interpretations not yet adopted The following pronouncements have been issued as of 31 December 2022 with mandatory application from 1 January 2023. They have not been early adopted by the Group: \u25aa IFRS 17 Insurance contracts \u25aa Classification of Liabilities as Current or Non-current - Amendments to IAS 1 \u25aa Definition of Accounting Estimates - Amendment to IAS 8 \u25aa Disclosure of Accounting Policies - Amendments to IAS 1 and IFRS Practice Statement 2 \u25aa Deferred Tax related to Assets and Liabilities arising from a single transaction - Amendment to IAS 12 These standards are not expected to have a material impact on the Group\u2019s Consolidated Financial Statements in the current or future reporting periods and on foreseeable future transactions. ", "dimensions": { "concept": "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-100-3": { "value": "1.22. Application of standards, amendments and interpretations Standards, amendments and interpretations adopted by the European Union and effective as of 1 January 2022 The accounting policies applied for the preparation of these Consolidated Financial Statements are consistent with those applied in the preparation of Consolidated financial statements for the year ended 31 December 2021. Other standards, amendments and interpretations newly applicable as of 1 January 2022 Other standards, amendments and interpretations newly applicable as of 1 January 2022 have no material impact on these Consolidated Financial Statements: \u25aa Reference to the Conceptual Framework - Amendment to IFRS 3 \u25aa Property, Plant and Equipment: Proceeds before intended Use - Amendment to IAS 16 \u25aa Onerous Contracts - Cost of fulfilling a contract - Amendment to IAS 37 \u25aa AIP IFRS 1 First time Adoption of International Financial Reporting Standards - Subsidiary as a first-time adopter \u25aa AIP IFRS 9 Financial Instruments - Fees in the \u201810 per cent\u2019 test for derecognition of financial liabilities \u25aa AIP IAS 41 Agriculture - Taxation in Fair value measurement New standards and interpretations not yet adopted The following pronouncements have been issued as of 31 December 2022 with mandatory application from 1 January 2023. They have not been early adopted by the Group: \u25aa IFRS 17 Insurance contracts \u25aa Classification of Liabilities as Current or Non-current - Amendments to IAS 1 \u25aa Definition of Accounting Estimates - Amendment to IAS 8 \u25aa Disclosure of Accounting Policies - Amendments to IAS 1 and IFRS Practice Statement 2 \u25aa Deferred Tax related to Assets and Liabilities arising from a single transaction - Amendment to IAS 12 These standards are not expected to have a material impact on the Group\u2019s Consolidated Financial Statements in the current or future reporting periods and on foreseeable future transactions. ", "dimensions": { "concept": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-101-3": { "value": "1.23. COVID-19 pandemic and geopolitical instability COVID-19 and recent geopolitical events have impacted the economy and financial markets globally. The Group\u2019s operational performance was temporarily affected by COVID-19-related measures in China in 2022. The Group\u2019s exposure to Russia and Ukraine is limited (Note 2.30 Country risks). As a consequence, these condensed consolidated financial statements were prepared with particular attention to (i) the impairment of non-current assets, (ii) the appropriateness of the allowance for trade receivables, unbilled revenue and work in progress, (iii) the level of provision for risks, as well as (iv) accounting for government grants. No material impacts were recognized in these condensed consolidated financial statements, except those listed in Notes 2.9, 2.10, 2.14 and 2.40. ", "dimensions": { "concept": "EUR:DescriptionOfAccountingPolicyForCovid19", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-102-3": { "value": "2.1. Segment information Operating segments are components of the Group\u2019s business activities about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (\u201cCODM\u201d). The Group is very decentralised with a large number of small and medium size companies in many countries. For practical reasons, the sets of information provided to the CODM, who is the Chief Executive Officer of the Group, aggregate these legal entities based on geographical areas and leadership structure. This aggregation can vary over time depending on changes in management, organisation or leadership. The rapid evolving nature of the Group also results in a constant adaptation of the matrix of its organisation. When necessary, the CODM may review financial information at a more disaggregated level. As required by IFRS 8 Operating Segments, Eurofins has three reportable segments: Europe, North America and Rest of the World. Europe is the combination of three reporting segments (groups of Cash Generating Units): France, DACH countries (Germany, Austria and Switzerland) and Other European Countries (OEC). Other European Countries include Benelux, Nordic Region, UK and Ireland, Southern Europe and Central & Eastern Europe. North America corresponds to the U.S. and Canada. As Eurofins still generates modest revenues in Asia and Middle East, South America, Australia and New Zealand, those 3 regions that represent future growth potential are followed internally in a single segment \u201cRest of the World\u201d. The key segmental performance measures are the EBITDA and EBITAS, which Management believes are the most relevant measure to evaluate the financial performance of the reportable segments. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-103-2": { "value": "In \u20ac millions North Rest of the Group service Europe 1 Total 2022 America World functionsRevenues 3,507.0 2,494.1 711.0 - 6,712.1 2Intersegment revenues50.9 39.2 22.4 - 112.5 Operating costs, net -2,826.9 -1,851.6 -567.7 -50.8 -5,297.0 EBITDA 680.1 642.5 143.3 -50.8 1,415.1 Depreciation and amortisation -222.0 -167.1 -63.7 -51.6 -504.4 EBITAS 458.2 475.4 79.6 -102.4 910.7 Share-based payment charge and -40.7 -56.4 -11.3 -27.7 -136.1 acquisition-related expenses, net Gain and loss on disposal of subsidiaries, 113.5 24.6 3.3 - 141.4 net EBIT 531.0 443.6 71.5 -130.1 916.0 Finance income 0.1 0.3 1.5 0.3 2.2 Finance costs -13.7 -21.7 -9.0 -94.8 -139.2 Share of profit of associates 0.8 - - 0.1 0.9 Profit before income taxes 518.2 422.2 64.0 -224.5 780.0 Income tax expense -65.9 -50.0 -10.9 -47.4 -174.2 Net profit for the year 452.3 372.2 53.2 -271.9 605.8 3 Total assets4,338.3 4,002.4 1,252.0 490.8 10,083.5 Cash and cash equivalents 112.3 74.2 94.7 205.3 486.6 3 Net capex-226.7 -260.0 -87.6 -70.9 -645.3 2021 Revenues 3,999.1 2,146.9 571.6 - 6,717.7 2Intersegment revenues50.0 33.3 31.0 - 114.3 Operating costs, net -2,826.8 -1,538.5 -406.6 -105.8 -4,877.7 EBITDA 1,172.3 608.4 165.1 -105.8 1,840.0 Depreciation and amortisation -226.5 -141.4 -46.0 -36.8 -450.7 EBITAS 945.9 467.0 119.0 -142.7 1,389.3 Share-based payment charge and -49.2 -69.7 -9.6 -2.4 -131.0 acquisition-related expenses, net Gain and loss on disposal of subsidiaries, 0.6 - -0.7 - -0.1 net EBIT 897.2 397.4 108.8 -145.1 1,258.2 Finance income 0.1 0.1 1.5 0.3 2.0 Finance costs -13.8 -19.2 -3.5 -169.2 -205.7 Share of profit of associates 1.4 - 0.6 - 2.0 Profit before income taxes 884.9 378.3 107.4 -314.0 1,056.6 Income tax expense -153.0 -42.4 -19.9 -58.3 -273.6 Net profit for the year 731.9 335.9 87.5 -372.3 783.0 3Total assets4,191.9 3,647.0 1,021.7 471.7 9,332.3 Cash and cash equivalents 125.2 53.8 88.2 248.1 515.3 3 Net capex-210.9 -136.6 -48.2 -85.8 -481.6 1 Corresponds to Group services functions (GSF) for Income Statement informations and Group holding companies\u2019 transactions for the other captions.GSF costs were more reallocated in 2022 to each reportable segments. 2 Intersegment revenues are limited between segments and made at arm\u2019s length, but intrasegment revenues are more significant within each segment under Eurofins hub and spoke model. 3 Total assets and Net capex are shown in the geographical area in which the assets are located. ", "dimensions": { "concept": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-104-2": { "value": "2.2. Revenues Set out below is the reconciliation of the revenue from contracts with customers with the amounts disclosed in the segment information (Note 2.1): Europe North America Rest of the World Total In \u20ac millions 2022 2021 2022 2021 2022 2021 2022 2021 Major service lines 1Sample-based business3,030.1 3,533.8 1,967.8 1,699.3 590.1 476.9 5,588.0 5,709.9 Study-based business 271.8 267.1 219.8 183.6 79.9 67.1 571.6 517.8 FTE-based business 158.4 147.9 237.6 193.4 30.3 15.3 426.3 356.6 Product-based business 46.7 50.3 68.7 70.6 10.6 12.3 126.0 133.3 Other - - 0.2 - - - 0.2 - Total 3,507.0 3,999.1 2,494.1 2,146.9 711.0 571.6 6,712.1 6,717.7 Timing of revenue recognition Revenue recognised at a 1,374.2 1,993.2 871.5 825.7 116.9 123.0 2,362.5 2,941.9 point in time1Revenue recognised over 2,132.9 2,005.9 1,622.6 1,321.2 594.1 448.6 4,349.6 3,775.8 time Total 3,507.0 3,999.1 2,494.1 2,146.9 711.0 571.6 6,712.1 6,717.7 1 including Clinical Diagnostic Testing activities related to COVID-19. The Group\u2019s contract balances are as follows: In \u20ac millions Note 2022 2021 Accrued sales 124.2 188.3 Amounts due by customers for analysis in progress 164.2 149.1 Contract assets 2.15 288.4 337.4 Advance payments received -53.1 -55.1 Deferred revenues -131.1 -107.9 Contract liabilities -184.2 -163.1 Net Balance Sheet position 104.2 174.3 % of total revenues due by customers for analysis in progress, net of deferred revenues 0.5% 0.6% The remaining performance obligations (unsatisfied or partially satisfied) on contracts with a duration over a year, expected to be recognised in the following years amount to \u20ac368m as of 31 December 2022, of which \u20ac234m are expected to be recognised in revenue in 2023. ", "dimensions": { "concept": "ifrs-full:DisclosureOfRevenueExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-104-3": { "value": "2.2. Revenues Set out below is the reconciliation of the revenue from contracts with customers with the amounts disclosed in the segment information (Note 2.1): Europe North America Rest of the World Total In \u20ac millions 2022 2021 2022 2021 2022 2021 2022 2021 Major service lines 1Sample-based business3,030.1 3,533.8 1,967.8 1,699.3 590.1 476.9 5,588.0 5,709.9 Study-based business 271.8 267.1 219.8 183.6 79.9 67.1 571.6 517.8 FTE-based business 158.4 147.9 237.6 193.4 30.3 15.3 426.3 356.6 Product-based business 46.7 50.3 68.7 70.6 10.6 12.3 126.0 133.3 Other - - 0.2 - - - 0.2 - Total 3,507.0 3,999.1 2,494.1 2,146.9 711.0 571.6 6,712.1 6,717.7 Timing of revenue recognition Revenue recognised at a 1,374.2 1,993.2 871.5 825.7 116.9 123.0 2,362.5 2,941.9 point in time1Revenue recognised over 2,132.9 2,005.9 1,622.6 1,321.2 594.1 448.6 4,349.6 3,775.8 time Total 3,507.0 3,999.1 2,494.1 2,146.9 711.0 571.6 6,712.1 6,717.7 1 including Clinical Diagnostic Testing activities related to COVID-19. The Group\u2019s contract balances are as follows: In \u20ac millions Note 2022 2021 Accrued sales 124.2 188.3 Amounts due by customers for analysis in progress 164.2 149.1 Contract assets 2.15 288.4 337.4 Advance payments received -53.1 -55.1 Deferred revenues -131.1 -107.9 Contract liabilities -184.2 -163.1 Net Balance Sheet position 104.2 174.3 % of total revenues due by customers for analysis in progress, net of deferred revenues 0.5% 0.6% The remaining performance obligations (unsatisfied or partially satisfied) on contracts with a duration over a year, expected to be recognised in the following years amount to \u20ac368m as of 31 December 2022, of which \u20ac234m are expected to be recognised in revenue in 2023. ", "dimensions": { "concept": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-105-4": { "value": "The Group\u2019s contract balances are as follows: In \u20ac millions Note 2022 2021 Accrued sales 124.2 188.3 Amounts due by customers for analysis in progress 164.2 149.1 Contract assets 2.15 288.4 337.4 Advance payments received -53.1 -55.1 Deferred revenues -131.1 -107.9 Contract liabilities -184.2 -163.1 Net Balance Sheet position 104.2 174.3 % of total revenues due by customers for analysis in progress, net of deferred revenues 0.5% 0.6% The remaining performance obligations (unsatisfied or partially satisfied) on contracts with a duration over a year, expected to be recognised in the following years amount to \u20ac368m as of 31 December 2022, of which \u20ac234m are expected to be recognised in revenue in 2023. ", "dimensions": { "concept": "ifrs-full:DisclosureOfDeferredIncomeExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-107-2": { "value": "2.3. Operating costs, net In \u20ac millions 2022 2021 Cost of materials and services -2,227.0 -2,149.7 Personnel expenses -3,053.6 -2,689.8 Other operating income and expenses, net -16.4 -38.2 Total -5,297.0 -4,877.7 ", "dimensions": { "concept": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-107-3": { "value": "2.3. Operating costs, net In \u20ac millions 2022 2021 Cost of materials and services -2,227.0 -2,149.7 Personnel expenses -3,053.6 -2,689.8 Other operating income and expenses, net -16.4 -38.2 Total -5,297.0 -4,877.7 ", "dimensions": { "concept": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-106-2": { "value": "2.4. Employees The average number of full time employees per geographical location is summarised as follows: Weighted average 2022 2021 Europe 29,438 27,924 North America 13,859 12,921 Rest of the World 9,243 6,907 Group service functions 3,090 2,605 Total FTE 55,631 50,357 As of 31 December 2022, the total headcount within the Group reached 61,379 employees (57,992 in 2021). ", "dimensions": { "concept": "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-108-2": { "value": "2.5. Separately disclosed items In \u20ac millions Note 2022 2021 One-off costs from integration, reorganisation, discontinued operations and -39.0 -32.2 other non-recurring income and costs Temporary losses and other costs related to network expansion, start-ups -58.8 -29.5 and new acquisitions undergoing significant restructuring EBITDA impact -97.8 -61.6 Depreciation costs specific to start-ups and new acquisitions undergoing -28.4 -21.9 significant restructuring EBITAS impact -126.2 -83.5 Share-based payment charge and acquisition-related expenses, net 2.6 -136.1 -130.9 Gain and loss on disposal of subsidiaries, net 2.26 141.4 -0.1 EBIT impact -120.9 -214.6 Net finance costs related to borrowing and investing excess cash and one--2.8 -97.6 off financial effects (net of finance income) Tax effect from the adjustment of all separately disclosed items 46.5 51.8 Net Profit impact -77.2 -260.4 Non-controlling interests of separately disclosed items -0.1 - Earnings attributable to owners and hybrid capital investors impact -77.2 -260.4 Earnings attributable to hybrid capital investors impact -1.4 -3.3 (net finance costs related to hybrid capital excess cash) The EBITDA impact of the separately disclosed items (SDIs) amounted to \u20ac97.8m (\u20ac61.6m in 2021). This includes in 2022: \u25aa One-off costs from integrations, reorganisations and discontinued operations, and other non-recurring income and costs of \u20ac39m. The costs included disposals of machines related to discontinued operations in the UK, relocations/reorganisations including the moves in the U.S. of Eurofins Viracor and Eurofins Eaton Analytical to their new consolidated facilities, litigation-related expenses in Clinical Diagnostics in the U.S. as well as restructurings in Spain and Germany. \u25aa Temporary losses and other costs related to network expansion, start-ups and new acquisitions in significant restructuring totalled \u20ac59m, significantly higher than in FY 2021 (\u20ac29m). This increase was driven by: o The greater number of start-ups launches undertaken in FY 2022 and recent years, most notably in areas related to Clinical Diagnostics (including Transplant Genomics Inc. in the U.S.), BioPharma Services (including Eurofins Panlabs and new laboratory in China) and Food Testing (including in China, Philippines, Poland and Romania). o Restructuring expenses for recently acquired companies in Clinical Diagnostics in the U.S., U.K. and Germany and Environment Testing in the U.S. Depreciation costs specific to start-ups and new acquisitions undergoing significant restructuring increased in 2022 mainly due to the increase in number of start-ups. Gain and loss on disposal of subsidiaries, net corresponds mainly to the sale of the Digital Testing business. The finance costs included within the SDIs for 2022 relate primarily to interest paid on excess cash. In 2021, the finance costs related mainly to premiums and tender fees incurred and paid for \u20ac92.5m on the redemption of various issuances of unsecured Eurobonds for a total amount of \u20ac1.1bn (\u20ac0.4m in 2022). See Notes 2.7 and 2.18 for further discussion on the bonds anticipated redemption. In 2022, the average monthly cash balance, net of overdrafts was \u20ac563m (\u20ac751m in 2021). The position as of 31 December 2022 was \u20ac483m (\u20ac515m as of 31 December 2021). This led to a decreasing average excess cash of \u20ac224m in 2022 (\u20ac421m in 2021). The borrowing and investment of this excess cash have generated net finance costs of \u20ac-2.4m on the financial result and an impact of \u20ac-1.4m on earnings attributable to hybrid capital investors in 2022 (\u20ac-5.1m and \u20ac-3.3m respectively in 2021). ", "dimensions": { "concept": "EUR:DisclosureOfAlternativePerformanceMeasures", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-109-2": { "value": "2.6. Share-based payment charge and acquisition-related expenses, net In \u20ac millions Note 2022 2021 Share-based payment charge 2.27 -23.0 -22.1 Amortisation of acquired intangible assets 2.11 -104.5 -91.9 Impairment of acquired intangible assets 2.11 -13.3 -5.7 Transaction costs related to acquisitions -16.4 -13.6 Reversal of amounts due for business acquisitions not paid 2.22 21.0 2.4 Acquisition-related expenses, net -113.1 -108.9 Total -136.1 -131.0 Intangible assets related to acquisition and brand increased by \u20ac90m in 2022 and \u20ac107m in 2021 (Note 2.11). The reversal of unpaid amounts due for business acquisitions mainly relate to the non-achievement of Eurofins Beacon Discovery business plan and delays in the implementation of Transplant Genomics Inc. business plan. ", "dimensions": { "concept": "EUR:DisclosureOfSharebasedPaymentChargeAndAcquisitionRelatedExpenses", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-109-3": { "value": "2.6. Share-based payment charge and acquisition-related expenses, net In \u20ac millions Note 2022 2021 Share-based payment charge 2.27 -23.0 -22.1 Amortisation of acquired intangible assets 2.11 -104.5 -91.9 Impairment of acquired intangible assets 2.11 -13.3 -5.7 Transaction costs related to acquisitions -16.4 -13.6 Reversal of amounts due for business acquisitions not paid 2.22 21.0 2.4 Acquisition-related expenses, net -113.1 -108.9 Total -136.1 -131.0 Intangible assets related to acquisition and brand increased by \u20ac90m in 2022 and \u20ac107m in 2021 (Note 2.11). The reversal of unpaid amounts due for business acquisitions mainly relate to the non-achievement of Eurofins Beacon Discovery business plan and delays in the implementation of Transplant Genomics Inc. business plan. Stock option plans Stock options are granted to certain directors, managers and employees of the Company and its subsidiaries. Movements in the number of stock options outstanding are as follows: 2022 2021 Number of Weighted Number of Weighted Stock options stock options average stock options average outstanding exercise price outstanding exercise price 1 January 7,005,744 50 8,093,000 42 Granted1,264,902 63 605,700 113 Exercised -387,207 28 -1,047,506 25 Expired or lost -675,046 62 -645,450 49 Outstanding as of 31 December 7,208,393 52 7,005,744 50 Exercisable as of 31 December 1,794,067 39 1,671,149 33 The weighted average share price based on Eurofins share price at the date of exercise was \u20ac75 for the 387,207 options exercised in 2022 and was \u20ac100 for the 1,047,506 options exercised in 2021. As at 31 December 2022, 7,208,393 stock options awarded are still outstanding. Further details can be found in the \u201cEurofins Group Remuneration Report 2022\u201d. The exercise price of the granted stock options is generally at least equal to the 20-day volume weighted average market price of Eurofins shares traded on Euronext Paris stock exchange prior to the plan award date including a hurdle of 2%. Options/ Restricted stock units are conditional on the employee completing the vesting period (4 to 5 years). Subject to continued employment and other conditions such as performance conditions for some beneficiaries (\u2018Senior Executives\u2019), vested options can be exercised and have a contractual option term of ten years. The fair value of options granted during the period is determined using the Black-Scholes or Bermudan valuation model from 2019 onwards including a behaviour factor for the expected exercise period. An annual risk-free interest rate of 3.2% is used for the 2022 plans. The volatility measured is based on the statistical analysis of daily share prices over the last three years. Volatility used for 2022 plans was 34%. Number of Weighted average fair stock options Vesting period Average exercise price value of options Plan initially granted (Years) (\u20ac) (\u20ac) 10/10/2011 1,583,500 4/5 5.78 2.4/2.6 02/03/2012 462,500 4/5 6.56 2.5/2.7 19/12/2012 1,914,750 4/5 12.01 4.1/4.5 01/10/2013 1,390,650 4/5 18.23 6.1/6.7 23/10/2014 1,209,500 4/5 18.83 6.1/6.7 07/04/2015 600,000 4/5 25.19 8.0/8.8 22/10/2015 352,500 4/5 28.28 8.9/9.9 21/01/2016 939,200 4/5 28.63 9.1/10.1 01/08/2016 1,227,400 4/5 33.69 10.9/12.0 04/04/2017 413,900 4/5 40.49 10.5/11.6 13/12/2017 1,696,950 4/5 50.87 13.2/14.6 08/01/2019 2,175,880 4/5 32.50 10.3/10.6 18/07/2019 20,000 4/5 38.58 9.0/9.3 24/10/2019 1,629,250 4/5 44.68 11.2/11.6 16/12/2020 1,493,150 4/5 67.50 23.8/24.7 20/10/2021 605,700 4/5 112.59 32.8/34.8 17/10/2022 1,264,902 4/5 62.78 19.8/21.8 Restricted stock units Restricted stock units are granted to eligible managers and employees. Vesting period Fair value of Number of restricted (Years) restricted Plan stock units stock units initially granted (\u20ac) 29/07/2016 4/5 59,850 33.55 01/08/2016 4/5 44,960 33.69 04/04/2017 4/5 9,400 40.49 13/12/2017 4/5 134,000 50.87 08/01/2019 4/5 149,280 35.12 24/10/2019 4/5 88,880 43.56 26/06/2020 4/5 20,200 55.20 16/12/2020 4/5 83,800 68.42 24/02/2021 4/5 91,000 74.99 20/10/2021 4/5 28,350 111.98 20/10/2021 2/3/4/5 22,500 111.98 17/10/2022 4/5 95,424 64.12 Movements in the number of restricted stock units outstanding are as follows: Restricted stock units 2022 2021 1 January 446,700 436,580 Granted 95,424 141,850 Vested -39,060 -83,610 Expired or lost -60,351 -48,120 Outstanding as of 31 December 442,713 446,700 On the 39,060 vested restricted stock units, 1,450 new shares have been issued and 37,610 were served from own treasury shares (share repurchase plan). Further details can be found in the \u201cEurofins Group Remuneration Report 2022\u201d. 2014 BSA Leaders Warrants In July 2014, the Company issued 117,820 capital-providing securities in the form of stock purchase warrants. Following the ten-for-one stock split completed in November 2020, the 2014 BSA Leaders warrants gave their holders the right to subscribe for ten shares of the Company for each 2014 BSA Leaders Warrant at a fixed exercise price of \u20ac281.58 between 1 July 2018 and 30 June 2022. The subscription price was set at \u20ac18.15 per warrant. Movements in the number of 2014 BSA Leaders Warrants were as follows: 2014 BSA Leaders Warrants 2022 2021 1 January 4,760 37,449 Exercised -4,760 -32,689 Expired or lost - - Outstanding as of 31 December - 4,760 Exercisable as of 31 December - 4,760 2018 BSA Leaders warrants In June 2018, Eurofins issued 124,460 capital-providing securities in the form of stock purchase warrants. Following the ten-for-one stock split completed in November 2020, the 2018 BSA Leaders warrants give their holders the right to subscribe for ten shares of the Company for each 2018 BSA Leaders Warrant at a fixed exercise price of \u20ac529.65 between 1 June 2022 and 31 May 2026. The subscription price was set at \u20ac34.36 per warrant. Movements in the number of 2018 BSA Leaders Warrants outstanding were as follows: 2018 BSA Leaders Warrants 2022 2021 1 January 107,419 109,419 Exercised -5,142 - Expired or lost -200 -2,000 Outstanding as of 31 December 102,077 107,419 Exercisable as of 31 December 102,077 - ", "dimensions": { "concept": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-110-2": { "value": "2.7. Finance income and costs In \u20ac millions Note 2022 2021 Other financial income 2.2 2.0 Finance income 2.2 2.0 Interest expense on: Borrowings -11.5 -7.4 Bonds -39.6 -38.1 Schuldschein loan -10.4 -9.7 Lease liabilities -26.3 -24.9 Defined benefit plans 2.23 -0.8 -0.7 Net foreign exchange loss -32.9 -17.9 Unwind of discount on amounts due for business acquisitions 2.22 -13.2 -6.9 Unwind of discount on issuance costs 2.18 -3.8 -7.3 Derivative financial instruments on interest rate hedging, net 2.30 -0.3 -0.3 Other financial expenses -0.5 -92.5 Finance costs -139.2 -205.7 Total Finance income and costs, net -136.9 -203.7 In 2022, other financial expenses are primarily related to tender fees incurred and paid of \u20ac0.5m. In 2021, other financial expenses were primarily related to premiums and tender fees incurred and paid for \u20ac92.5m on the redemption of various unsecured Eurobonds for a total amount of \u20ac1.1bn (Note 2.18). Net foreign exchange loss is mainly related to USD cash pooling owned by Eurofins Finance Luxembourg S.\u00e0 r.l., the Group\u2019s treasury entity which manages cash centralization for Group companies. This net foreign exchange loss is non-cash, unrealised and due to the appreciation of 6% of $ versus \u20ac in 2022 (Balance Sheet end of period rates). ", "dimensions": { "concept": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-110-3": { "value": "2.7. Finance income and costs In \u20ac millions Note 2022 2021 Other financial income 2.2 2.0 Finance income 2.2 2.0 Interest expense on: Borrowings -11.5 -7.4 Bonds -39.6 -38.1 Schuldschein loan -10.4 -9.7 Lease liabilities -26.3 -24.9 Defined benefit plans 2.23 -0.8 -0.7 Net foreign exchange loss -32.9 -17.9 Unwind of discount on amounts due for business acquisitions 2.22 -13.2 -6.9 Unwind of discount on issuance costs 2.18 -3.8 -7.3 Derivative financial instruments on interest rate hedging, net 2.30 -0.3 -0.3 Other financial expenses -0.5 -92.5 Finance costs -139.2 -205.7 Total Finance income and costs, net -136.9 -203.7 In 2022, other financial expenses are primarily related to tender fees incurred and paid of \u20ac0.5m. In 2021, other financial expenses were primarily related to premiums and tender fees incurred and paid for \u20ac92.5m on the redemption of various unsecured Eurobonds for a total amount of \u20ac1.1bn (Note 2.18). Net foreign exchange loss is mainly related to USD cash pooling owned by Eurofins Finance Luxembourg S.\u00e0 r.l., the Group\u2019s treasury entity which manages cash centralization for Group companies. This net foreign exchange loss is non-cash, unrealised and due to the appreciation of 6% of $ versus \u20ac in 2022 (Balance Sheet end of period rates). ", "dimensions": { "concept": "ifrs-full:DisclosureOfFinanceIncomeExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-110-4": { "value": "2.7. Finance income and costs In \u20ac millions Note 2022 2021 Other financial income 2.2 2.0 Finance income 2.2 2.0 Interest expense on: Borrowings -11.5 -7.4 Bonds -39.6 -38.1 Schuldschein loan -10.4 -9.7 Lease liabilities -26.3 -24.9 Defined benefit plans 2.23 -0.8 -0.7 Net foreign exchange loss -32.9 -17.9 Unwind of discount on amounts due for business acquisitions 2.22 -13.2 -6.9 Unwind of discount on issuance costs 2.18 -3.8 -7.3 Derivative financial instruments on interest rate hedging, net 2.30 -0.3 -0.3 Other financial expenses -0.5 -92.5 Finance costs -139.2 -205.7 Total Finance income and costs, net -136.9 -203.7 In 2022, other financial expenses are primarily related to tender fees incurred and paid of \u20ac0.5m. In 2021, other financial expenses were primarily related to premiums and tender fees incurred and paid for \u20ac92.5m on the redemption of various unsecured Eurobonds for a total amount of \u20ac1.1bn (Note 2.18). Net foreign exchange loss is mainly related to USD cash pooling owned by Eurofins Finance Luxembourg S.\u00e0 r.l., the Group\u2019s treasury entity which manages cash centralization for Group companies. This net foreign exchange loss is non-cash, unrealised and due to the appreciation of 6% of $ versus \u20ac in 2022 (Balance Sheet end of period rates). ", "dimensions": { "concept": "ifrs-full:DisclosureOfFinanceCostExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-110-5": { "value": "2.7. Finance income and costs In \u20ac millions Note 2022 2021 Other financial income 2.2 2.0 Finance income 2.2 2.0 Interest expense on: Borrowings -11.5 -7.4 Bonds -39.6 -38.1 Schuldschein loan -10.4 -9.7 Lease liabilities -26.3 -24.9 Defined benefit plans 2.23 -0.8 -0.7 Net foreign exchange loss -32.9 -17.9 Unwind of discount on amounts due for business acquisitions 2.22 -13.2 -6.9 Unwind of discount on issuance costs 2.18 -3.8 -7.3 Derivative financial instruments on interest rate hedging, net 2.30 -0.3 -0.3 Other financial expenses -0.5 -92.5 Finance costs -139.2 -205.7 Total Finance income and costs, net -136.9 -203.7 In 2022, other financial expenses are primarily related to tender fees incurred and paid of \u20ac0.5m. In 2021, other financial expenses were primarily related to premiums and tender fees incurred and paid for \u20ac92.5m on the redemption of various unsecured Eurobonds for a total amount of \u20ac1.1bn (Note 2.18). Net foreign exchange loss is mainly related to USD cash pooling owned by Eurofins Finance Luxembourg S.\u00e0 r.l., the Group\u2019s treasury entity which manages cash centralization for Group companies. This net foreign exchange loss is non-cash, unrealised and due to the appreciation of 6% of $ versus \u20ac in 2022 (Balance Sheet end of period rates). ", "dimensions": { "concept": "ifrs-full:DisclosureOfInterestIncomeExpenseExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-110-6": { "value": "2.7. Finance income and costs In \u20ac millions Note 2022 2021 Other financial income 2.2 2.0 Finance income 2.2 2.0 Interest expense on: Borrowings -11.5 -7.4 Bonds -39.6 -38.1 Schuldschein loan -10.4 -9.7 Lease liabilities -26.3 -24.9 Defined benefit plans 2.23 -0.8 -0.7 Net foreign exchange loss -32.9 -17.9 Unwind of discount on amounts due for business acquisitions 2.22 -13.2 -6.9 Unwind of discount on issuance costs 2.18 -3.8 -7.3 Derivative financial instruments on interest rate hedging, net 2.30 -0.3 -0.3 Other financial expenses -0.5 -92.5 Finance costs -139.2 -205.7 Total Finance income and costs, net -136.9 -203.7 In 2022, other financial expenses are primarily related to tender fees incurred and paid of \u20ac0.5m. In 2021, other financial expenses were primarily related to premiums and tender fees incurred and paid for \u20ac92.5m on the redemption of various unsecured Eurobonds for a total amount of \u20ac1.1bn (Note 2.18). Net foreign exchange loss is mainly related to USD cash pooling owned by Eurofins Finance Luxembourg S.\u00e0 r.l., the Group\u2019s treasury entity which manages cash centralization for Group companies. This net foreign exchange loss is non-cash, unrealised and due to the appreciation of 6% of $ versus \u20ac in 2022 (Balance Sheet end of period rates). ", "dimensions": { "concept": "ifrs-full:DisclosureOfInterestExpenseExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-110-7": { "value": "2.7. Finance income and costs In \u20ac millions Note 2022 2021 Other financial income 2.2 2.0 Finance income 2.2 2.0 Interest expense on: Borrowings -11.5 -7.4 Bonds -39.6 -38.1 Schuldschein loan -10.4 -9.7 Lease liabilities -26.3 -24.9 Defined benefit plans 2.23 -0.8 -0.7 Net foreign exchange loss -32.9 -17.9 Unwind of discount on amounts due for business acquisitions 2.22 -13.2 -6.9 Unwind of discount on issuance costs 2.18 -3.8 -7.3 Derivative financial instruments on interest rate hedging, net 2.30 -0.3 -0.3 Other financial expenses -0.5 -92.5 Finance costs -139.2 -205.7 Total Finance income and costs, net -136.9 -203.7 In 2022, other financial expenses are primarily related to tender fees incurred and paid of \u20ac0.5m. In 2021, other financial expenses were primarily related to premiums and tender fees incurred and paid for \u20ac92.5m on the redemption of various unsecured Eurobonds for a total amount of \u20ac1.1bn (Note 2.18). Net foreign exchange loss is mainly related to USD cash pooling owned by Eurofins Finance Luxembourg S.\u00e0 r.l., the Group\u2019s treasury entity which manages cash centralization for Group companies. This net foreign exchange loss is non-cash, unrealised and due to the appreciation of 6% of $ versus \u20ac in 2022 (Balance Sheet end of period rates). ", "dimensions": { "concept": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-111-2": { "value": "2.8. Income and deferred tax In 2022, the income tax expense amounted to \u20ac174m (\u20ac274m in 2021). The components of income tax expense are as follows: In \u20ac millions 2022 2021 Current tax expense -201.2 -299.9 Deferred tax income 27.0 26.3 Income tax expense -174.2 -273.6 Eurofins\u2019 operations are subject to income taxes in various jurisdictions. The statutory income tax rate varies by country, the below table gives the weigthed average theoretical income tax rate. Please note that the Luxembourg\u2019s income tax rate remains unchanged at 24.94%. A reconciliation of the weighted average statutory income tax rate to the effective income tax rate is as follows: In \u20ac millions 2022 2021 Profit before income taxes 780.0 1,056.6 Theoretical income tax expense -162.9 -218.7 Weighted average theoretical income tax rate (%) 20.9% 20.7% 1Withholding and other taxes-29.4 -28.6 2Non-deductible expenses (-) / Non-taxable income (+)11.5 -40.6 Deductible expenses not accounted for in the Consolidated Income Statement 25.8 14.3 3Unrecognised tax loss and credit carryforwards-18.3 4.3 Tax expense (benefits) due to change in uncertain tax treatments -0.8 -4.3 Effective income tax expense -174.2 -273.6 4Effective income tax rate22.3% 25.9% 1 This line includes taxes based on other taxable income aggregate such as CVAE (\u201ccotisation sur la valeur ajout\u00e9e des entreprises\u201d) in France and IRAP (\u201cimposta regionale sulle attivit\u00e0 produttive\u201d) in Italy as well as withholding taxes and non-recoverable value added tax paid. 2 Non-taxable income in 2022 are mainly related to the sale of the digital testing activities. Non-deductible expenses are mainly related to the finance costs not deductible in Luxembourg and France due to change of dividends and tax rules and the Base Erosion and Anti-Abuse Tax (BEAT) in the U.S. 3 2022 unrecognised tax losses are linked to tax losses in companies with no possibility to create deferred tax assets as of 31 December 2022. 4 The effective income tax rate FY 2022 has improved vs FY 2021 due to the sale of the digital testing activities, for which the capital gain is not taxable. The income tax paid for each period is the following: In \u20ac millions 2022 2021 Income taxes paid -296.1 -296.7 Income taxes paid in 2022 is very similar to income tax paid in 2021, as in many countries, the income tax on 2021 profits have been paid in 2022. This time difference between effective income tax expense and income tax paid has been wider in the past three years, in relation to the extra income realised through the COVID-19 testing activities, and should normalise in the future periods. In \u20ac millions 2022 2021 Corporate income tax assets 135.6 76.7 Corporate income tax liabilities 34.7 86.0 Corporate tax assets and liabilities positions, net 100.9 -9.3 Deferred taxes positions are shown on the balance sheet as follows: 2022 2021 Deferred tax Deferred tax Deferred tax Deferred tax In \u20ac millions assets liabilities assets liabilities Total deferred tax assets / (liabilities) 189.7 -247.6 193.5 -226.2 Offset of deferred taxes -114.0 114.0 -102.6 102.6 Deferred tax assets / (liabilities), net 75.7 -133.6 90.9 -123.6 Deferred tax assets and liabilities positions, net - -57.9 - -32.7 Movements in net deferred tax relate to the following underlying assets and liabilities and tax loss carry forwards (including tax credit carry forward) and their movements during the year 2022 and 2021 respectively are presented in the table below: In \u20ac millions Classification 2022 2021 Balance as of 1 January -32.7 -38.7 Business combinations -29.0 -15.1 Deferred taxes on retirement benefit obligations and FVCOI change in OCI -3.7 -1.8 Deferred taxes on net investment hedge change in OCI - -24.3 Deferred taxes on hybrid capital distribution change in Equity - 2.2 Tax credit relating to share-based payment charge change in Equity -15.1 26.9 Deferred tax income Income Statement 27.0 26.3 Translation differences and other -4.3 -8.2 Balance as of 31 December -57.9 -32.7 Deferred tax assets are recognised for temporary differences, unused tax losses and unused tax credits to the extent that realisation of the related tax benefits is probable. The ultimate realisation of deferred tax assets is dependent upon the generation of future taxable income in the countries where the deferred tax assets originated and during the periods when the deferred tax assets become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. The Business combinations relate to the deferred taxes on intangible assets recognised on the purchase price allocation (Note 2.26). Tax credit relating to share-based payment charge are linked to potential US employees gain on stock options deductible from the tax result (\u20ac-15.1m in 2022 versus \u20ac+26.9m in 2021). In 2022, deferred taxes liabilities on net investment hedge positive revaluation are netted against deferred tax assets on capital hybrid distribution and tax losses without impact in OCI and Equity (reversal in 2021 of 22.2m of tax loss carryfowards) due to the loss-making situation of the Luxembourg tax unity. Movements in deferred tax assets and liabilities during the year are broken down as follows: In \u20ac millions Balance Recognised Recognised Business Translation Balance as of in Income in Equity & combina-differences as of 2022 1 January Statement OCI tions and other 31 December Intangible assets -226.2 5.5 - -20.2 -6.7 -247.6 Property, plant and equipment 48.2 -4.8 - -0.1 0.1 43.4 Tax loss carryforwards 34.0 -9.0 - - -1.1 23.9 Retirement benefit obligations 15.0 1.2 -3.5 0.2 -0.4 12.5 Other liabilities 96.3 34.2 -15.2 -9.0 3.7 109.9 Net deferred tax liabilities -32.7 27.0 -18.8 -29.0 -4.3 -57.9 2021 Intangible assets -205.8 10.2 - -21.2 -9.4 -226.2 Property, plant and equipment 43.7 14.2 - 1.0 -10.7 48.2 Tax loss carryforwards 49.4 -7.6 -22.2 5.2 9.2 34.0 Retirement benefit obligations 14.9 0.8 -0.6 - -0.1 15.0 Other liabilities 59.1 8.7 25.8 -0.1 2.9 96.3 Net deferred tax liabilities -38.7 26.3 3.0 -15.1 -8.2 -32.7 The deferred tax liabilities on temporary differences in intangible assets amortisation and fixed assets depreciation are related to differences between amounts per consolidation books and amounts per tax books on intangible assets recognised as part of the acquisition; and on fixed assets and goodwill in case of taxable stock acquisition (e.g. eligible under \u00a7338(h)(10) in the US). No deferred tax is recognised for non-tax-deductible goodwill amounts. As of 31 December 2022, the Group held an aggregate amount of \u20ac865m of tax losses (\u20ac711m in 2021) to carry forward against future taxable income and which have not been recognised as tax assets due to the uncertainty of their recoverability. The Group has available tax loss and credit carryforwards which expire as follows: 2022 2021 In \u20ac millions Total Balance Unrecognised balance Total Balance Unrecognised balance Within 5 years 68 67 61 60 Later than 5 years 216 207 257 220 Unlimited 686 599 537 431 Total 970 873 855 711 The deferred tax assets on tax losses capitalised mainly include Eurofins Food Chemistry Testing US, Inc. (\u20ac3.2m) and Eurofins DNA Diagnostics Center, Inc. (\u20ac2.1m) in the U.S., Eurofins Biologie Sp\u00e9cialis\u00e9e SAS (\u20ac2.8m) and Eurofins Cerep SAS (\u20ac2.5m) in France, with an expectation to be used within the next seven years. ", "dimensions": { "concept": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-111-3": { "value": "2.8. Income and deferred tax In 2022, the income tax expense amounted to \u20ac174m (\u20ac274m in 2021). The components of income tax expense are as follows: In \u20ac millions 2022 2021 Current tax expense -201.2 -299.9 Deferred tax income 27.0 26.3 Income tax expense -174.2 -273.6 Eurofins\u2019 operations are subject to income taxes in various jurisdictions. The statutory income tax rate varies by country, the below table gives the weigthed average theoretical income tax rate. Please note that the Luxembourg\u2019s income tax rate remains unchanged at 24.94%. A reconciliation of the weighted average statutory income tax rate to the effective income tax rate is as follows: In \u20ac millions 2022 2021 Profit before income taxes 780.0 1,056.6 Theoretical income tax expense -162.9 -218.7 Weighted average theoretical income tax rate (%) 20.9% 20.7% 1Withholding and other taxes-29.4 -28.6 2Non-deductible expenses (-) / Non-taxable income (+)11.5 -40.6 Deductible expenses not accounted for in the Consolidated Income Statement 25.8 14.3 3Unrecognised tax loss and credit carryforwards-18.3 4.3 Tax expense (benefits) due to change in uncertain tax treatments -0.8 -4.3 Effective income tax expense -174.2 -273.6 4Effective income tax rate22.3% 25.9% 1 This line includes taxes based on other taxable income aggregate such as CVAE (\u201ccotisation sur la valeur ajout\u00e9e des entreprises\u201d) in France and IRAP (\u201cimposta regionale sulle attivit\u00e0 produttive\u201d) in Italy as well as withholding taxes and non-recoverable value added tax paid. 2 Non-taxable income in 2022 are mainly related to the sale of the digital testing activities. Non-deductible expenses are mainly related to the finance costs not deductible in Luxembourg and France due to change of dividends and tax rules and the Base Erosion and Anti-Abuse Tax (BEAT) in the U.S. 3 2022 unrecognised tax losses are linked to tax losses in companies with no possibility to create deferred tax assets as of 31 December 2022. 4 The effective income tax rate FY 2022 has improved vs FY 2021 due to the sale of the digital testing activities, for which the capital gain is not taxable. The income tax paid for each period is the following: In \u20ac millions 2022 2021 Income taxes paid -296.1 -296.7 Income taxes paid in 2022 is very similar to income tax paid in 2021, as in many countries, the income tax on 2021 profits have been paid in 2022. This time difference between effective income tax expense and income tax paid has been wider in the past three years, in relation to the extra income realised through the COVID-19 testing activities, and should normalise in the future periods. In \u20ac millions 2022 2021 Corporate income tax assets 135.6 76.7 Corporate income tax liabilities 34.7 86.0 Corporate tax assets and liabilities positions, net 100.9 -9.3 Deferred taxes positions are shown on the balance sheet as follows: 2022 2021 Deferred tax Deferred tax Deferred tax Deferred tax In \u20ac millions assets liabilities assets liabilities Total deferred tax assets / (liabilities) 189.7 -247.6 193.5 -226.2 Offset of deferred taxes -114.0 114.0 -102.6 102.6 Deferred tax assets / (liabilities), net 75.7 -133.6 90.9 -123.6 Deferred tax assets and liabilities positions, net - -57.9 - -32.7 Movements in net deferred tax relate to the following underlying assets and liabilities and tax loss carry forwards (including tax credit carry forward) and their movements during the year 2022 and 2021 respectively are presented in the table below: In \u20ac millions Classification 2022 2021 Balance as of 1 January -32.7 -38.7 Business combinations -29.0 -15.1 Deferred taxes on retirement benefit obligations and FVCOI change in OCI -3.7 -1.8 Deferred taxes on net investment hedge change in OCI - -24.3 Deferred taxes on hybrid capital distribution change in Equity - 2.2 Tax credit relating to share-based payment charge change in Equity -15.1 26.9 Deferred tax income Income Statement 27.0 26.3 Translation differences and other -4.3 -8.2 Balance as of 31 December -57.9 -32.7 Deferred tax assets are recognised for temporary differences, unused tax losses and unused tax credits to the extent that realisation of the related tax benefits is probable. The ultimate realisation of deferred tax assets is dependent upon the generation of future taxable income in the countries where the deferred tax assets originated and during the periods when the deferred tax assets become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. The Business combinations relate to the deferred taxes on intangible assets recognised on the purchase price allocation (Note 2.26). Tax credit relating to share-based payment charge are linked to potential US employees gain on stock options deductible from the tax result (\u20ac-15.1m in 2022 versus \u20ac+26.9m in 2021). In 2022, deferred taxes liabilities on net investment hedge positive revaluation are netted against deferred tax assets on capital hybrid distribution and tax losses without impact in OCI and Equity (reversal in 2021 of 22.2m of tax loss carryfowards) due to the loss-making situation of the Luxembourg tax unity. Movements in deferred tax assets and liabilities during the year are broken down as follows: In \u20ac millions Balance Recognised Recognised Business Translation Balance as of in Income in Equity & combina-differences as of 2022 1 January Statement OCI tions and other 31 December Intangible assets -226.2 5.5 - -20.2 -6.7 -247.6 Property, plant and equipment 48.2 -4.8 - -0.1 0.1 43.4 Tax loss carryforwards 34.0 -9.0 - - -1.1 23.9 Retirement benefit obligations 15.0 1.2 -3.5 0.2 -0.4 12.5 Other liabilities 96.3 34.2 -15.2 -9.0 3.7 109.9 Net deferred tax liabilities -32.7 27.0 -18.8 -29.0 -4.3 -57.9 2021 Intangible assets -205.8 10.2 - -21.2 -9.4 -226.2 Property, plant and equipment 43.7 14.2 - 1.0 -10.7 48.2 Tax loss carryforwards 49.4 -7.6 -22.2 5.2 9.2 34.0 Retirement benefit obligations 14.9 0.8 -0.6 - -0.1 15.0 Other liabilities 59.1 8.7 25.8 -0.1 2.9 96.3 Net deferred tax liabilities -38.7 26.3 3.0 -15.1 -8.2 -32.7 The deferred tax liabilities on temporary differences in intangible assets amortisation and fixed assets depreciation are related to differences between amounts per consolidation books and amounts per tax books on intangible assets recognised as part of the acquisition; and on fixed assets and goodwill in case of taxable stock acquisition (e.g. eligible under \u00a7338(h)(10) in the US). No deferred tax is recognised for non-tax-deductible goodwill amounts. As of 31 December 2022, the Group held an aggregate amount of \u20ac865m of tax losses (\u20ac711m in 2021) to carry forward against future taxable income and which have not been recognised as tax assets due to the uncertainty of their recoverability. The Group has available tax loss and credit carryforwards which expire as follows: 2022 2021 In \u20ac millions Total Balance Unrecognised balance Total Balance Unrecognised balance Within 5 years 68 67 61 60 Later than 5 years 216 207 257 220 Unlimited 686 599 537 431 Total 970 873 855 711 The deferred tax assets on tax losses capitalised mainly include Eurofins Food Chemistry Testing US, Inc. (\u20ac3.2m) and Eurofins DNA Diagnostics Center, Inc. (\u20ac2.1m) in the U.S., Eurofins Biologie Sp\u00e9cialis\u00e9e SAS (\u20ac2.8m) and Eurofins Cerep SAS (\u20ac2.5m) in France, with an expectation to be used within the next seven years. ", "dimensions": { "concept": "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-114-2": { "value": "2.9. Property, plant and equipment Office and IT Land, buildings and Machinery and equipment, Assets in In \u20ac millions leasehold laboratory Total furniture and progress improvements equipment vehicles Right of Right of Right of Right of 1Owneduse Owned use Owned use Owned Owned use Total assets assets assets assets 2022 Cost 994.1 819.5 1,561.0 31.8 382.1 49.3 183.0 3,120.3 900.6 4,020.9 Accumulated -383.4 -358.0 -1,137.6 -25.8 -261.4 -24.6 - -1,782.5 -408.4 -2,190.9 depreciation Balance as of 610.7 461.5 423.3 5.9 120.8 24.8 183.0 1,337.8 492.1 1,829.9 1 January Business 35.1 24.1 24.2 0.4 8.2 1.7 15.1 82.6 26.2 108.8 Combinations 2Additions265.2 82.7 226.9 2.5 60.6 15.8 36.0 588.7 101.1 689.8 Disposals -5.1 -8.5 -9.0 -0.4 -2.3 -1.7 - -16.3 -10.5 -26.9 Depreciation -80.8 -118.2 -184.1 -3.4 -44.2 -15.1 - -309.1 -136.7 -445.8 3Impairment- - -1.6 - - - - -1.6 - -1.6 Translation differences and 1.3 6.9 5.1 - - -0.1 0.3 6.6 6.9 13.5 other Balance as of 826.4 448.6 484.8 5.1 143.1 25.3 234.4 1,688.6 479.0 2,167.7 31 December Cost 1,282.4 871.6 1,819.6 28.2 449.7 50.8 234.4 3,786.1 950.6 4,736.7 Accumulated -456.1 -423.0 -1,334.8 -23.1 -306.6 -25.5 - -2,097.5 -471.6 -2,569.1 depreciation 2021 Cost 784.1 753.6 1,278.3 36.0 306.6 42.1 144.2 2,513.1 831.7 3,344.8 Accumulated -308.1 -290.6 -896.1 -28.1 -225.8 -21.3 - -1,430.0 -339.9 -1,769.9 depreciation Balance as of 476.0 463.1 382.1 7.9 80.8 20.9 144.2 1,083.1 491.8 1,574.9 1 January Business 34.3 23.2 25.8 - 3.6 0.2 3.4 67.1 23.5 90.6 Combinations 2Additions155.5 85.4 178.5 1.7 86.9 18.3 36.6 457.6 105.4 562.9 Disposals -6.2 -8.2 -5.9 -0.4 -19.1 -1.3 - -31.2 -9.9 -41.0 Depreciation -67.5 -114.0 -157.8 -3.5 -37.7 -13.3 - -263.0 -130.8 -393.8 3Impairment- - -17.4 - - - -17.4 - -17.4 Translation differences and 18.6 12.0 17.9 0.1 6.3 - -1.2 41.6 12.1 53.7 other Balance as of 610.7 461.5 423.3 5.9 120.8 24.8 183.0 1,337.8 492.1 1,829.9 31 December Cost 994.1 819.5 1,561.0 31.8 382.1 49.3 183.0 3,120.3 900.6 4,020.9 Accumulated -383.4 -358.0 -1,137.6 -25.8 -261.4 -24.6 - -1,782.5 -408.4 -2,190.9 depreciation 1 Owned land, buildings and leasehold improvements include investment in the owned Group sites and leasehold improvements in third party sites. On the net book value of \u20ac826.4m, land and buildings in the owned Group sites represents a value above \u20ac600m. 2 In the Consolidated Cash Flow Statement, purchase of property, plant and equipments takes in consideration Owned additions (\u20ac588.7m) less Capex trade payables change of the period (\u20ac12.6 in 2022). 3 The Group, in line with its accounting policies defined in Note 1.6 Impairment, has performed an assessment of whether the carrying amount of its laboratory equipment dedicated to COVID-19 testing was supported by cash flows expected to be generated in future periods. These calculations use financial data and assumptions based on financial budgets approved by management, which reflect the information available at the time, based on past performance, management\u2019s expectations of future market developments, and specific risks relating to uncertainties regarding the sustainability of the COVID-19 testing market such as but not limited to, the number of tests expected to be performed in combination with the effectiveness of the vaccine campaigns in the various countries where the Group operates. Based on this assessment the Group adjusted the carrying amount of its laboratory equipment to the present value of the cumulated cash flows expected to be generated. At year-end 2022, the COVID-19 laboratory equipment carrying value amounts to \u20ac1m after an additional impairment of \u20ac2m in 2022 (\u20ac17m in 2021) as the Group additionally invested in laboratory equipment in an amount of \u20ac1m in 2022. In 2022, the Group acquired significant owned buildings as part of new acquisitions for an amount of \u20ac30m (\u20ac31m in 2021), included in property, plant and equipment, and located in various locations across Hungary (Budapest), Spain (Murcia), Germany (Birkenfeld), the United States (Altamonte Springs, FA and Little Rock, AR). The Group acquired also right-of-use assets of operating leases for an amount of \u20ac24.6m in 2022. ", "dimensions": { "concept": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-114-3": { "value": "2.9. Property, plant and equipment Office and IT Land, buildings and Machinery and equipment, Assets in In \u20ac millions leasehold laboratory Total furniture and progress improvements equipment vehicles Right of Right of Right of Right of 1Owneduse Owned use Owned use Owned Owned use Total assets assets assets assets 2022 Cost 994.1 819.5 1,561.0 31.8 382.1 49.3 183.0 3,120.3 900.6 4,020.9 Accumulated -383.4 -358.0 -1,137.6 -25.8 -261.4 -24.6 - -1,782.5 -408.4 -2,190.9 depreciation Balance as of 610.7 461.5 423.3 5.9 120.8 24.8 183.0 1,337.8 492.1 1,829.9 1 January Business 35.1 24.1 24.2 0.4 8.2 1.7 15.1 82.6 26.2 108.8 Combinations 2Additions265.2 82.7 226.9 2.5 60.6 15.8 36.0 588.7 101.1 689.8 Disposals -5.1 -8.5 -9.0 -0.4 -2.3 -1.7 - -16.3 -10.5 -26.9 Depreciation -80.8 -118.2 -184.1 -3.4 -44.2 -15.1 - -309.1 -136.7 -445.8 3Impairment- - -1.6 - - - - -1.6 - -1.6 Translation differences and 1.3 6.9 5.1 - - -0.1 0.3 6.6 6.9 13.5 other Balance as of 826.4 448.6 484.8 5.1 143.1 25.3 234.4 1,688.6 479.0 2,167.7 31 December Cost 1,282.4 871.6 1,819.6 28.2 449.7 50.8 234.4 3,786.1 950.6 4,736.7 Accumulated -456.1 -423.0 -1,334.8 -23.1 -306.6 -25.5 - -2,097.5 -471.6 -2,569.1 depreciation 2021 Cost 784.1 753.6 1,278.3 36.0 306.6 42.1 144.2 2,513.1 831.7 3,344.8 Accumulated -308.1 -290.6 -896.1 -28.1 -225.8 -21.3 - -1,430.0 -339.9 -1,769.9 depreciation Balance as of 476.0 463.1 382.1 7.9 80.8 20.9 144.2 1,083.1 491.8 1,574.9 1 January Business 34.3 23.2 25.8 - 3.6 0.2 3.4 67.1 23.5 90.6 Combinations 2Additions155.5 85.4 178.5 1.7 86.9 18.3 36.6 457.6 105.4 562.9 Disposals -6.2 -8.2 -5.9 -0.4 -19.1 -1.3 - -31.2 -9.9 -41.0 Depreciation -67.5 -114.0 -157.8 -3.5 -37.7 -13.3 - -263.0 -130.8 -393.8 3Impairment- - -17.4 - - - -17.4 - -17.4 Translation differences and 18.6 12.0 17.9 0.1 6.3 - -1.2 41.6 12.1 53.7 other Balance as of 610.7 461.5 423.3 5.9 120.8 24.8 183.0 1,337.8 492.1 1,829.9 31 December Cost 994.1 819.5 1,561.0 31.8 382.1 49.3 183.0 3,120.3 900.6 4,020.9 Accumulated -383.4 -358.0 -1,137.6 -25.8 -261.4 -24.6 - -1,782.5 -408.4 -2,190.9 depreciation 1 Owned land, buildings and leasehold improvements include investment in the owned Group sites and leasehold improvements in third party sites. On the net book value of \u20ac826.4m, land and buildings in the owned Group sites represents a value above \u20ac600m. 2 In the Consolidated Cash Flow Statement, purchase of property, plant and equipments takes in consideration Owned additions (\u20ac588.7m) less Capex trade payables change of the period (\u20ac12.6 in 2022). 3 The Group, in line with its accounting policies defined in Note 1.6 Impairment, has performed an assessment of whether the carrying amount of its laboratory equipment dedicated to COVID-19 testing was supported by cash flows expected to be generated in future periods. These calculations use financial data and assumptions based on financial budgets approved by management, which reflect the information available at the time, based on past performance, management\u2019s expectations of future market developments, and specific risks relating to uncertainties regarding the sustainability of the COVID-19 testing market such as but not limited to, the number of tests expected to be performed in combination with the effectiveness of the vaccine campaigns in the various countries where the Group operates. Based on this assessment the Group adjusted the carrying amount of its laboratory equipment to the present value of the cumulated cash flows expected to be generated. At year-end 2022, the COVID-19 laboratory equipment carrying value amounts to \u20ac1m after an additional impairment of \u20ac2m in 2022 (\u20ac17m in 2021) as the Group additionally invested in laboratory equipment in an amount of \u20ac1m in 2022. 2.11. Other intangible assets Intangible assets 2Other intangible In \u20ac millions related to SoftwareTotal 1assets acquisitions2022 Cost 1,290.3 412.1 9.8 1,712.2 Accumulated amortisation -498.7 -314.5 -3.2 -816.5 Balance as of 1 January 791.6 97.6 6.5 895.7 Business combinations 90.1 1.5 0.8 92.4 Additions - 75.8 8.3 84.1 Disposals -10.9 0.1 - -10.8 Depreciation -55.4 -1.5 -56.9 Amortisation of acquired assets -104.5 - - -104.5 Impairment -13.3 - - -13.3 Translation differences and other 31.1 1.8 -0.5 32.4 Balance as of 31 December 784.2 121.3 13.6 919.1 Cost 1,407.3 492.9 18.0 1,918.2 Accumulated amortisation -623.1 -371.6 -4.4 -999.2 2021 Cost 1,128.8 354.9 4.9 1,488.6 Accumulated amortisation -383.6 -276.8 -3.0 -663.5 Balance as of 1 January 745.2 78.1 1.9 825.1 Business combinations 107.0 0.7 0.7 108.5 Additions - 57.9 4.2 62.0 Disposals - -0.6 - -0.6 Depreciation -38.6 -1.0 -39.6 Amortisation of acquired assets -91.9 - - -91.9 Impairment -5.7 - - -5.7 Translation differences and other 36.9 0.1 0.8 37.7 Balance as of 31 December 791.6 97.6 6.5 895.7 Cost 1,290.3 412.1 9.8 1,712.2 Accumulated amortisation -498.7 -314.5 -3.2 -816.5 1 In 2022, intangible assets related to acquisitions increased by \u20ac90m. Balance of intangible assets related to acquisitions as of 31 December 2022 include customer relationships (\u20ac671m), technology (\u20ac72m), tradename (\u20ac28m), and other (i.e., branding and marketing, backlog, non compete agreements assets: \u20ac13m).2 Software includes \u20ac58m of internal development costs capitalised in 2022 (versus \u20ac46m in 2021). ", "dimensions": { "concept": "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-114-4": { "value": "2.9. Property, plant and equipment Office and IT Land, buildings and Machinery and equipment, Assets in In \u20ac millions leasehold laboratory Total furniture and progress improvements equipment vehicles Right of Right of Right of Right of 1Owneduse Owned use Owned use Owned Owned use Total assets assets assets assets 2022 Cost 994.1 819.5 1,561.0 31.8 382.1 49.3 183.0 3,120.3 900.6 4,020.9 Accumulated -383.4 -358.0 -1,137.6 -25.8 -261.4 -24.6 - -1,782.5 -408.4 -2,190.9 depreciation Balance as of 610.7 461.5 423.3 5.9 120.8 24.8 183.0 1,337.8 492.1 1,829.9 1 January Business 35.1 24.1 24.2 0.4 8.2 1.7 15.1 82.6 26.2 108.8 Combinations 2Additions265.2 82.7 226.9 2.5 60.6 15.8 36.0 588.7 101.1 689.8 Disposals -5.1 -8.5 -9.0 -0.4 -2.3 -1.7 - -16.3 -10.5 -26.9 Depreciation -80.8 -118.2 -184.1 -3.4 -44.2 -15.1 - -309.1 -136.7 -445.8 3Impairment- - -1.6 - - - - -1.6 - -1.6 Translation differences and 1.3 6.9 5.1 - - -0.1 0.3 6.6 6.9 13.5 other Balance as of 826.4 448.6 484.8 5.1 143.1 25.3 234.4 1,688.6 479.0 2,167.7 31 December Cost 1,282.4 871.6 1,819.6 28.2 449.7 50.8 234.4 3,786.1 950.6 4,736.7 Accumulated -456.1 -423.0 -1,334.8 -23.1 -306.6 -25.5 - -2,097.5 -471.6 -2,569.1 depreciation 2021 Cost 784.1 753.6 1,278.3 36.0 306.6 42.1 144.2 2,513.1 831.7 3,344.8 Accumulated -308.1 -290.6 -896.1 -28.1 -225.8 -21.3 - -1,430.0 -339.9 -1,769.9 depreciation Balance as of 476.0 463.1 382.1 7.9 80.8 20.9 144.2 1,083.1 491.8 1,574.9 1 January Business 34.3 23.2 25.8 - 3.6 0.2 3.4 67.1 23.5 90.6 Combinations 2Additions155.5 85.4 178.5 1.7 86.9 18.3 36.6 457.6 105.4 562.9 Disposals -6.2 -8.2 -5.9 -0.4 -19.1 -1.3 - -31.2 -9.9 -41.0 Depreciation -67.5 -114.0 -157.8 -3.5 -37.7 -13.3 - -263.0 -130.8 -393.8 3Impairment- - -17.4 - - - -17.4 - -17.4 Translation differences and 18.6 12.0 17.9 0.1 6.3 - -1.2 41.6 12.1 53.7 other Balance as of 610.7 461.5 423.3 5.9 120.8 24.8 183.0 1,337.8 492.1 1,829.9 31 December Cost 994.1 819.5 1,561.0 31.8 382.1 49.3 183.0 3,120.3 900.6 4,020.9 Accumulated -383.4 -358.0 -1,137.6 -25.8 -261.4 -24.6 - -1,782.5 -408.4 -2,190.9 depreciation 1 Owned land, buildings and leasehold improvements include investment in the owned Group sites and leasehold improvements in third party sites. On the net book value of \u20ac826.4m, land and buildings in the owned Group sites represents a value above \u20ac600m. 2 In the Consolidated Cash Flow Statement, purchase of property, plant and equipments takes in consideration Owned additions (\u20ac588.7m) less Capex trade payables change of the period (\u20ac12.6 in 2022). 3 The Group, in line with its accounting policies defined in Note 1.6 Impairment, has performed an assessment of whether the carrying amount of its laboratory equipment dedicated to COVID-19 testing was supported by cash flows expected to be generated in future periods. These calculations use financial data and assumptions based on financial budgets approved by management, which reflect the information available at the time, based on past performance, management\u2019s expectations of future market developments, and specific risks relating to uncertainties regarding the sustainability of the COVID-19 testing market such as but not limited to, the number of tests expected to be performed in combination with the effectiveness of the vaccine campaigns in the various countries where the Group operates. Based on this assessment the Group adjusted the carrying amount of its laboratory equipment to the present value of the cumulated cash flows expected to be generated. At year-end 2022, the COVID-19 laboratory equipment carrying value amounts to \u20ac1m after an additional impairment of \u20ac2m in 2022 (\u20ac17m in 2021) as the Group additionally invested in laboratory equipment in an amount of \u20ac1m in 2022. Goodwill Impairment testing The calculation model description is provided in Note 1.6. For impairment testing, goodwill is allocated to cash generating units (typically one level below segment level, i.e., at the business level), which represent the lowest level at which the goodwill is monitored internally for management purposes. Unless otherwise noted, the basis of the recoverable amount used in the annual impairment tests for the units disclosed further in this Note is the value in use. Key assumptions used in the value in use impairment tests for the units were sales growth rates, EBITDA margin and the rates used for discounting the projected cash flows (WACC). These cash flow projections were determined using Eurofins management\u2019s internal forecasts that cover an initial period from 2023 to 2027 after which a terminal value was calculated for 2028. For terminal value calculation, growth rates were capped at a historical long-term average growth rate. This methodology is consistent with the methodology applied in prior periods. The sales growth rates and EBITDA margin used to estimate cash flows are based on past performance, external market growth assumptions and industry long-term growth averages. Management believes that the volume of sales in each period is the main driver for revenue and costs. Eurofins takes into consideration inflation on the profits, margins, liquidity as well as on their overall level of activity in its assumptions. The rates used for discounting the projected cash flows in goodwill impairment testing is based on a weighted cost of capital (WACC), which in turn is based on business-specific inputs along with other inputs. The WACC is based on post-tax cost of equity and cost of debt, and is further calculated based on market data and inputs to accurately capture changes to the time value of money, such as the risk-free interest rate, the beta factor and country risk premium. In order to properly reflect the different risk-profiles of different businesses, a WACC is determined for each group of CGUs. The key assumptions used for value in use calculations and values in use are as follows: 12In \u20ac millions Long term growth ratePre-tax discount rateValue in use 2022 2021 2022 2021 2022 2021 North America 2.50% 2.00% 9.4% 6.0% 7,367 10,631 France 2.00% 2.00% 10.3% 6.6% 1,499 2,850 DACH 2.00% 2.00% 9.8% 6.2% 969 2,017 OEC 2.50% 2.00% 10.4% 6.5% 2,681 4,869 ROW 3.50% 2.50% 10.6% 6.4% 1,554 2,333 Total 14,070 22,700 1 Weighted average growth rate used to extrapolate cash flows beyond the initial five-year period. 2 As required by IAS 36, pre-tax discount rate is derived from the WACC (calculated on a post-tax basis as defined above). The average annual growth rate of the revenues over the initial five-year period used in 2022 is between 3.5% and 9% depending on geographical area excluding COVID-19 business (was between 4% and 9% in 2021). The average EBITDA margin used is between 16% and 24% of the revenues depending on geographic area for the 5-year period (in line with percentages used in 2021). COVID-19 related business activity is excluded from 2023 onwards assumptions. In 2022, no impairment is required as these values are above the carrying value of each group of CGUs. The accumulated impairment is \u20ac13.0m as of 31 December 2022 (same as of December 2021). The results of the annual impairment test indicate that a reasonably possible change in key assumptions would not cause the value in use to fall to the level of the carrying value for any of the Group CGUs (e.g., raising the WACC rate by 1 percentage point would not lead to any impairment). 2.11. Other intangible assets Intangible assets 2Other intangible In \u20ac millions related to SoftwareTotal 1assets acquisitions2022 Cost 1,290.3 412.1 9.8 1,712.2 Accumulated amortisation -498.7 -314.5 -3.2 -816.5 Balance as of 1 January 791.6 97.6 6.5 895.7 Business combinations 90.1 1.5 0.8 92.4 Additions - 75.8 8.3 84.1 Disposals -10.9 0.1 - -10.8 Depreciation -55.4 -1.5 -56.9 Amortisation of acquired assets -104.5 - - -104.5 Impairment -13.3 - - -13.3 Translation differences and other 31.1 1.8 -0.5 32.4 Balance as of 31 December 784.2 121.3 13.6 919.1 Cost 1,407.3 492.9 18.0 1,918.2 Accumulated amortisation -623.1 -371.6 -4.4 -999.2 2021 Cost 1,128.8 354.9 4.9 1,488.6 Accumulated amortisation -383.6 -276.8 -3.0 -663.5 Balance as of 1 January 745.2 78.1 1.9 825.1 Business combinations 107.0 0.7 0.7 108.5 Additions - 57.9 4.2 62.0 Disposals - -0.6 - -0.6 Depreciation -38.6 -1.0 -39.6 Amortisation of acquired assets -91.9 - - -91.9 Impairment -5.7 - - -5.7 Translation differences and other 36.9 0.1 0.8 37.7 Balance as of 31 December 791.6 97.6 6.5 895.7 Cost 1,290.3 412.1 9.8 1,712.2 Accumulated amortisation -498.7 -314.5 -3.2 -816.5 1 In 2022, intangible assets related to acquisitions increased by \u20ac90m. Balance of intangible assets related to acquisitions as of 31 December 2022 include customer relationships (\u20ac671m), technology (\u20ac72m), tradename (\u20ac28m), and other (i.e., branding and marketing, backlog, non compete agreements assets: \u20ac13m).2 Software includes \u20ac58m of internal development costs capitalised in 2022 (versus \u20ac46m in 2021). ", "dimensions": { "concept": "ifrs-full:DisclosureOfImpairmentOfAssetsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-116-2": { "value": "2.10. Goodwill Eurofins has identified five groups of cash generating units: France, DACH countries (Germany/Austria/Switzerland), Other European Countries (OEC), North America and Rest of the World (ROW). The following is a summary of goodwill allocation for each group of CGUs as of 31 December: Acquisition Change In \u20ac millions through due to Beginning Dispo-Impair Translation Ending Gross Impair business purchase Gross Impair balance sals -ment differences Balance 2022 value -ment combi-price value -ment nations adjustment North 1,894.1 - 1,894.1 40.7 -9.0 - - 113.2 2,039.0 2,039.0 - America France 904.0 - 904.0 85.9 -5.7 - - 0.0 984.1 984.1 - DACH 279.6 - 279.6 38.7 - - - 1.5 319.8 319.8 - OEC 664.1 2.0 662.1 94.0 -41.6 - - -13.5 701.0 703.0 2.0 ROW 386.3 11.0 375.3 102.5 - - - 2.2 480.1 491.1 11.0 Total 4,128.1 13.0 4,115.1 361.8 -56.3 - - 103.4 4,524.1 4,537.1 13.0 2021 North 1,589.6 - 1,589.6 173.5 - - - 131.0 1,894.1 1,894.1 - America France 859.4 - 859.4 44.6 - - - - 904.0 904.0 - DACH 242.7 - 242.7 35.7 - - - 1.2 279.6 279.6 - OEC 617.1 2.0 615.1 39.0 - - - 8.1 662.1 664.1 2.0 ROW 228.4 11.0 217.4 136.7 - 9.7 - 11.5 375.3 386.3 11.0 Total 3,537.1 13.0 3,524.1 429.5 - 9.7 - 151.8 4,115.1 4,128.1 13.0 The \u201cAcquisition through business combinations\u201d and \u201cDisposals\u201d disclosure are further detailed in Note 2.26 and 3.2 and 3.4. Goodwill Impairment testing The calculation model description is provided in Note 1.6. For impairment testing, goodwill is allocated to cash generating units (typically one level below segment level, i.e., at the business level), which represent the lowest level at which the goodwill is monitored internally for management purposes. Unless otherwise noted, the basis of the recoverable amount used in the annual impairment tests for the units disclosed further in this Note is the value in use. Key assumptions used in the value in use impairment tests for the units were sales growth rates, EBITDA margin and the rates used for discounting the projected cash flows (WACC). These cash flow projections were determined using Eurofins management\u2019s internal forecasts that cover an initial period from 2023 to 2027 after which a terminal value was calculated for 2028. For terminal value calculation, growth rates were capped at a historical long-term average growth rate. This methodology is consistent with the methodology applied in prior periods. The sales growth rates and EBITDA margin used to estimate cash flows are based on past performance, external market growth assumptions and industry long-term growth averages. Management believes that the volume of sales in each period is the main driver for revenue and costs. Eurofins takes into consideration inflation on the profits, margins, liquidity as well as on their overall level of activity in its assumptions. The rates used for discounting the projected cash flows in goodwill impairment testing is based on a weighted cost of capital (WACC), which in turn is based on business-specific inputs along with other inputs. The WACC is based on post-tax cost of equity and cost of debt, and is further calculated based on market data and inputs to accurately capture changes to the time value of money, such as the risk-free interest rate, the beta factor and country risk premium. In order to properly reflect the different risk-profiles of different businesses, a WACC is determined for each group of CGUs. The key assumptions used for value in use calculations and values in use are as follows: 12In \u20ac millions Long term growth ratePre-tax discount rateValue in use 2022 2021 2022 2021 2022 2021 North America 2.50% 2.00% 9.4% 6.0% 7,367 10,631 France 2.00% 2.00% 10.3% 6.6% 1,499 2,850 DACH 2.00% 2.00% 9.8% 6.2% 969 2,017 OEC 2.50% 2.00% 10.4% 6.5% 2,681 4,869 ROW 3.50% 2.50% 10.6% 6.4% 1,554 2,333 Total 14,070 22,700 1 Weighted average growth rate used to extrapolate cash flows beyond the initial five-year period. 2 As required by IAS 36, pre-tax discount rate is derived from the WACC (calculated on a post-tax basis as defined above). The average annual growth rate of the revenues over the initial five-year period used in 2022 is between 3.5% and 9% depending on geographical area excluding COVID-19 business (was between 4% and 9% in 2021). The average EBITDA margin used is between 16% and 24% of the revenues depending on geographic area for the 5-year period (in line with percentages used in 2021). COVID-19 related business activity is excluded from 2023 onwards assumptions. In 2022, no impairment is required as these values are above the carrying value of each group of CGUs. The accumulated impairment is \u20ac13.0m as of 31 December 2022 (same as of December 2021). The results of the annual impairment test indicate that a reasonably possible change in key assumptions would not cause the value in use to fall to the level of the carrying value for any of the Group CGUs (e.g., raising the WACC rate by 1 percentage point would not lead to any impairment). 2.11. Other intangible assets Intangible assets 2Other intangible In \u20ac millions related to SoftwareTotal 1assets acquisitions2022 Cost 1,290.3 412.1 9.8 1,712.2 Accumulated amortisation -498.7 -314.5 -3.2 -816.5 Balance as of 1 January 791.6 97.6 6.5 895.7 Business combinations 90.1 1.5 0.8 92.4 Additions - 75.8 8.3 84.1 Disposals -10.9 0.1 - -10.8 Depreciation -55.4 -1.5 -56.9 Amortisation of acquired assets -104.5 - - -104.5 Impairment -13.3 - - -13.3 Translation differences and other 31.1 1.8 -0.5 32.4 Balance as of 31 December 784.2 121.3 13.6 919.1 Cost 1,407.3 492.9 18.0 1,918.2 Accumulated amortisation -623.1 -371.6 -4.4 -999.2 2021 Cost 1,128.8 354.9 4.9 1,488.6 Accumulated amortisation -383.6 -276.8 -3.0 -663.5 Balance as of 1 January 745.2 78.1 1.9 825.1 Business combinations 107.0 0.7 0.7 108.5 Additions - 57.9 4.2 62.0 Disposals - -0.6 - -0.6 Depreciation -38.6 -1.0 -39.6 Amortisation of acquired assets -91.9 - - -91.9 Impairment -5.7 - - -5.7 Translation differences and other 36.9 0.1 0.8 37.7 Balance as of 31 December 791.6 97.6 6.5 895.7 Cost 1,290.3 412.1 9.8 1,712.2 Accumulated amortisation -498.7 -314.5 -3.2 -816.5 1 In 2022, intangible assets related to acquisitions increased by \u20ac90m. Balance of intangible assets related to acquisitions as of 31 December 2022 include customer relationships (\u20ac671m), technology (\u20ac72m), tradename (\u20ac28m), and other (i.e., branding and marketing, backlog, non compete agreements assets: \u20ac13m).2 Software includes \u20ac58m of internal development costs capitalised in 2022 (versus \u20ac46m in 2021). The goodwill is attributable to the workforce of the acquired business and the synergies expected to arise after acquisition. The part of goodwill and other intangible assets related to acquisitions completed in 2022 that is tax deductible represents an amount of \u20ac58m. ", "dimensions": { "concept": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-116-3": { "value": "2.10. Goodwill Eurofins has identified five groups of cash generating units: France, DACH countries (Germany/Austria/Switzerland), Other European Countries (OEC), North America and Rest of the World (ROW). The following is a summary of goodwill allocation for each group of CGUs as of 31 December: Acquisition Change In \u20ac millions through due to Beginning Dispo-Impair Translation Ending Gross Impair business purchase Gross Impair balance sals -ment differences Balance 2022 value -ment combi-price value -ment nations adjustment North 1,894.1 - 1,894.1 40.7 -9.0 - - 113.2 2,039.0 2,039.0 - America France 904.0 - 904.0 85.9 -5.7 - - 0.0 984.1 984.1 - DACH 279.6 - 279.6 38.7 - - - 1.5 319.8 319.8 - OEC 664.1 2.0 662.1 94.0 -41.6 - - -13.5 701.0 703.0 2.0 ROW 386.3 11.0 375.3 102.5 - - - 2.2 480.1 491.1 11.0 Total 4,128.1 13.0 4,115.1 361.8 -56.3 - - 103.4 4,524.1 4,537.1 13.0 2021 North 1,589.6 - 1,589.6 173.5 - - - 131.0 1,894.1 1,894.1 - America France 859.4 - 859.4 44.6 - - - - 904.0 904.0 - DACH 242.7 - 242.7 35.7 - - - 1.2 279.6 279.6 - OEC 617.1 2.0 615.1 39.0 - - - 8.1 662.1 664.1 2.0 ROW 228.4 11.0 217.4 136.7 - 9.7 - 11.5 375.3 386.3 11.0 Total 3,537.1 13.0 3,524.1 429.5 - 9.7 - 151.8 4,115.1 4,128.1 13.0 The \u201cAcquisition through business combinations\u201d and \u201cDisposals\u201d disclosure are further detailed in Note 2.26 and 3.2 and 3.4. Goodwill Impairment testing The calculation model description is provided in Note 1.6. For impairment testing, goodwill is allocated to cash generating units (typically one level below segment level, i.e., at the business level), which represent the lowest level at which the goodwill is monitored internally for management purposes. Unless otherwise noted, the basis of the recoverable amount used in the annual impairment tests for the units disclosed further in this Note is the value in use. Key assumptions used in the value in use impairment tests for the units were sales growth rates, EBITDA margin and the rates used for discounting the projected cash flows (WACC). These cash flow projections were determined using Eurofins management\u2019s internal forecasts that cover an initial period from 2023 to 2027 after which a terminal value was calculated for 2028. For terminal value calculation, growth rates were capped at a historical long-term average growth rate. This methodology is consistent with the methodology applied in prior periods. The sales growth rates and EBITDA margin used to estimate cash flows are based on past performance, external market growth assumptions and industry long-term growth averages. Management believes that the volume of sales in each period is the main driver for revenue and costs. Eurofins takes into consideration inflation on the profits, margins, liquidity as well as on their overall level of activity in its assumptions. The rates used for discounting the projected cash flows in goodwill impairment testing is based on a weighted cost of capital (WACC), which in turn is based on business-specific inputs along with other inputs. The WACC is based on post-tax cost of equity and cost of debt, and is further calculated based on market data and inputs to accurately capture changes to the time value of money, such as the risk-free interest rate, the beta factor and country risk premium. In order to properly reflect the different risk-profiles of different businesses, a WACC is determined for each group of CGUs. The key assumptions used for value in use calculations and values in use are as follows: 12In \u20ac millions Long term growth ratePre-tax discount rateValue in use 2022 2021 2022 2021 2022 2021 North America 2.50% 2.00% 9.4% 6.0% 7,367 10,631 France 2.00% 2.00% 10.3% 6.6% 1,499 2,850 DACH 2.00% 2.00% 9.8% 6.2% 969 2,017 OEC 2.50% 2.00% 10.4% 6.5% 2,681 4,869 ROW 3.50% 2.50% 10.6% 6.4% 1,554 2,333 Total 14,070 22,700 1 Weighted average growth rate used to extrapolate cash flows beyond the initial five-year period. 2 As required by IAS 36, pre-tax discount rate is derived from the WACC (calculated on a post-tax basis as defined above). The average annual growth rate of the revenues over the initial five-year period used in 2022 is between 3.5% and 9% depending on geographical area excluding COVID-19 business (was between 4% and 9% in 2021). The average EBITDA margin used is between 16% and 24% of the revenues depending on geographic area for the 5-year period (in line with percentages used in 2021). COVID-19 related business activity is excluded from 2023 onwards assumptions. In 2022, no impairment is required as these values are above the carrying value of each group of CGUs. The accumulated impairment is \u20ac13.0m as of 31 December 2022 (same as of December 2021). The results of the annual impairment test indicate that a reasonably possible change in key assumptions would not cause the value in use to fall to the level of the carrying value for any of the Group CGUs (e.g., raising the WACC rate by 1 percentage point would not lead to any impairment). The goodwill is attributable to the workforce of the acquired business and the synergies expected to arise after acquisition. The part of goodwill and other intangible assets related to acquisitions completed in 2022 that is tax deductible represents an amount of \u20ac58m. ", "dimensions": { "concept": "ifrs-full:DisclosureOfGoodwillExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-120-5": { "value": "2.11. Other intangible assets Intangible assets 2Other intangible In \u20ac millions related to SoftwareTotal 1assets acquisitions2022 Cost 1,290.3 412.1 9.8 1,712.2 Accumulated amortisation -498.7 -314.5 -3.2 -816.5 Balance as of 1 January 791.6 97.6 6.5 895.7 Business combinations 90.1 1.5 0.8 92.4 Additions - 75.8 8.3 84.1 Disposals -10.9 0.1 - -10.8 Depreciation -55.4 -1.5 -56.9 Amortisation of acquired assets -104.5 - - -104.5 Impairment -13.3 - - -13.3 Translation differences and other 31.1 1.8 -0.5 32.4 Balance as of 31 December 784.2 121.3 13.6 919.1 Cost 1,407.3 492.9 18.0 1,918.2 Accumulated amortisation -623.1 -371.6 -4.4 -999.2 2021 Cost 1,128.8 354.9 4.9 1,488.6 Accumulated amortisation -383.6 -276.8 -3.0 -663.5 Balance as of 1 January 745.2 78.1 1.9 825.1 Business combinations 107.0 0.7 0.7 108.5 Additions - 57.9 4.2 62.0 Disposals - -0.6 - -0.6 Depreciation -38.6 -1.0 -39.6 Amortisation of acquired assets -91.9 - - -91.9 Impairment -5.7 - - -5.7 Translation differences and other 36.9 0.1 0.8 37.7 Balance as of 31 December 791.6 97.6 6.5 895.7 Cost 1,290.3 412.1 9.8 1,712.2 Accumulated amortisation -498.7 -314.5 -3.2 -816.5 1 In 2022, intangible assets related to acquisitions increased by \u20ac90m. Balance of intangible assets related to acquisitions as of 31 December 2022 include customer relationships (\u20ac671m), technology (\u20ac72m), tradename (\u20ac28m), and other (i.e., branding and marketing, backlog, non compete agreements assets: \u20ac13m).2 Software includes \u20ac58m of internal development costs capitalised in 2022 (versus \u20ac46m in 2021). ", "dimensions": { "concept": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-122-2": { "value": "2.12. Investments in associates Investment in associates in 2022 (details in Note 3.6) amounts to \u20ac5.2m (\u20ac6.2m in 2021). Other investments in associates were as follows: Main associates undertaking: Total Revenues Net profit Equity % of interest In \u20ac millions assets 12022Fasmac Co. Ltd. (JP) 11.5 0.6 9.4 8.1 41% Eurofins Laboratoire Coeur de France SAEML (FR) 6.2 0.6 2.8 1.6 49% Dermscan Asia Co., Ltd (TH)1.1 0.4 0.9 0.8 34% 2Z.F.D. GmbH (DE)- - - - 33% 12021Fasmac Co. Ltd. (JP) 12.4 1.3 9.8 8.3 41% Eurofins Laboratoire Coeur de France SAEML (FR) 13.0 3.0 7.3 4.0 49% Dermscan Asia Co., Ltd (TH)0.8 0.2 0.7 0.6 34% Z.F.D. GmbH (DE) 1.7 0.1 1.2 0.8 33% 1 Unaudited figures. 2 Z.F.D.GmbH (DE) figures from current period are not available. TREX, Ltd (ZA) equity share value is \u20ac3k; revenues, net profit and total assets of this company are not significant. There are no quoted prices available for the companies consolidated by equity method due to their small size (in annual revenues and assets). These five companies are not considered to be material. Share of profit of associates amounts to \u20ac0.9m in 2022 (\u20ac2.0m in 2021). 3.6. Other subsidiaries undertakings The companies below are not fully consolidated: % of ISO interest Method of Company Subsidiary of: code by the consolidation Group Z.F.D. GmbH DE Eurofins \u00d6kometric GmbH 33.00% Equity method Eurofins Laboratoire C\u0153ur de France SAEML FR Eurofins Microbiologie France Holding SAS 49.00% Equity method Fasmac Co. Ltd. JP Eurofins Genomics LUX Holding S.\u00e0 r.l. 41.00% Equity method Dermscan Asia Co., Ltd. TH Eurofins Laboratoire Dermscan SAS 34.00% Equity method T-rex Ltd. ZA Eurofins Agrosciences Services LUX Holding S.\u00e0 20.00% Equity method r.l. ", "dimensions": { "concept": "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-122-3": { "value": "2.12. Investments in associates Investment in associates in 2022 (details in Note 3.6) amounts to \u20ac5.2m (\u20ac6.2m in 2021). Other investments in associates were as follows: Main associates undertaking: Total Revenues Net profit Equity % of interest In \u20ac millions assets 12022Fasmac Co. Ltd. (JP) 11.5 0.6 9.4 8.1 41% Eurofins Laboratoire Coeur de France SAEML (FR) 6.2 0.6 2.8 1.6 49% Dermscan Asia Co., Ltd (TH)1.1 0.4 0.9 0.8 34% 2Z.F.D. GmbH (DE)- - - - 33% 12021Fasmac Co. Ltd. (JP) 12.4 1.3 9.8 8.3 41% Eurofins Laboratoire Coeur de France SAEML (FR) 13.0 3.0 7.3 4.0 49% Dermscan Asia Co., Ltd (TH)0.8 0.2 0.7 0.6 34% Z.F.D. GmbH (DE) 1.7 0.1 1.2 0.8 33% 1 Unaudited figures. 2 Z.F.D.GmbH (DE) figures from current period are not available. TREX, Ltd (ZA) equity share value is \u20ac3k; revenues, net profit and total assets of this company are not significant. There are no quoted prices available for the companies consolidated by equity method due to their small size (in annual revenues and assets). These five companies are not considered to be material. Share of profit of associates amounts to \u20ac0.9m in 2022 (\u20ac2.0m in 2021). 3.6. Other subsidiaries undertakings The companies below are not fully consolidated: % of ISO interest Method of Company Subsidiary of: code by the consolidation Group Z.F.D. GmbH DE Eurofins \u00d6kometric GmbH 33.00% Equity method Eurofins Laboratoire C\u0153ur de France SAEML FR Eurofins Microbiologie France Holding SAS 49.00% Equity method Fasmac Co. Ltd. JP Eurofins Genomics LUX Holding S.\u00e0 r.l. 41.00% Equity method Dermscan Asia Co., Ltd. TH Eurofins Laboratoire Dermscan SAS 34.00% Equity method T-rex Ltd. ZA Eurofins Agrosciences Services LUX Holding S.\u00e0 20.00% Equity method r.l. ", "dimensions": { "concept": "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-122-4": { "value": "2.12. Investments in associates Investment in associates in 2022 (details in Note 3.6) amounts to \u20ac5.2m (\u20ac6.2m in 2021). Other investments in associates were as follows: Main associates undertaking: Total Revenues Net profit Equity % of interest In \u20ac millions assets 12022Fasmac Co. Ltd. (JP) 11.5 0.6 9.4 8.1 41% Eurofins Laboratoire Coeur de France SAEML (FR) 6.2 0.6 2.8 1.6 49% Dermscan Asia Co., Ltd (TH)1.1 0.4 0.9 0.8 34% 2Z.F.D. GmbH (DE)- - - - 33% 12021Fasmac Co. Ltd. (JP) 12.4 1.3 9.8 8.3 41% Eurofins Laboratoire Coeur de France SAEML (FR) 13.0 3.0 7.3 4.0 49% Dermscan Asia Co., Ltd (TH)0.8 0.2 0.7 0.6 34% Z.F.D. GmbH (DE) 1.7 0.1 1.2 0.8 33% 1 Unaudited figures. 2 Z.F.D.GmbH (DE) figures from current period are not available. TREX, Ltd (ZA) equity share value is \u20ac3k; revenues, net profit and total assets of this company are not significant. There are no quoted prices available for the companies consolidated by equity method due to their small size (in annual revenues and assets). These five companies are not considered to be material. Share of profit of associates amounts to \u20ac0.9m in 2022 (\u20ac2.0m in 2021). 3.6. Other subsidiaries undertakings The companies below are not fully consolidated: % of ISO interest Method of Company Subsidiary of: code by the consolidation Group Z.F.D. GmbH DE Eurofins \u00d6kometric GmbH 33.00% Equity method Eurofins Laboratoire C\u0153ur de France SAEML FR Eurofins Microbiologie France Holding SAS 49.00% Equity method Fasmac Co. Ltd. JP Eurofins Genomics LUX Holding S.\u00e0 r.l. 41.00% Equity method Dermscan Asia Co., Ltd. TH Eurofins Laboratoire Dermscan SAS 34.00% Equity method T-rex Ltd. ZA Eurofins Agrosciences Services LUX Holding S.\u00e0 20.00% Equity method r.l. ", "dimensions": { "concept": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-123-2": { "value": "2.13. Non-current financial assets Non-current Non-current Non-current financial In \u20ac millions financial assets at financial assets at assets at amortised Total 2022 12FVTPLFVTOCIcost Balance as of 1 January 2.6 21.4 51.5 75.5 Changes : Acquisitions/additions - - 12.0 12.0 Sales/redemptions/reductions - - -13.2 -13.2 Business combinations - - 3.6 3.6 Value adjustment through OCI - 1.5 - 1.5 Value adjustment through P&L - - - - Translation differences and other - -1.0 0.2 -0.9 Balance as of 31 December 2.6 21.8 54.1 78.4 2021 Balance as of 1 January - 8.5 42.5 51.0 Changes : Acquisitions/additions - - 12.3 12.3 Sales/redemptions/reductions - - -5.0 -5.0 Business combinations - - 1.1 1.1 Value adjustment through OCI - 12.3 - 12.3 Value adjustment through P&L 2.6 - - 2.6 Translation differences and other - 0.6 0.6 1.2 Balance as of 31 December 2.6 21.4 51.5 75.5 1 Fair value through profit or loss 2 Fair value through other comprehensive income FVTOCI relates to an investment in Vimta Labs Limited, a publicly listed company in India. Non-current financial assets at amortised cost are mainly lease deposits. ", "dimensions": { "concept": "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-123-3": { "value": "2.13. Non-current financial assets Non-current Non-current Non-current financial In \u20ac millions financial assets at financial assets at assets at amortised Total 2022 12FVTPLFVTOCIcost Balance as of 1 January 2.6 21.4 51.5 75.5 Changes : Acquisitions/additions - - 12.0 12.0 Sales/redemptions/reductions - - -13.2 -13.2 Business combinations - - 3.6 3.6 Value adjustment through OCI - 1.5 - 1.5 Value adjustment through P&L - - - - Translation differences and other - -1.0 0.2 -0.9 Balance as of 31 December 2.6 21.8 54.1 78.4 2021 Balance as of 1 January - 8.5 42.5 51.0 Changes : Acquisitions/additions - - 12.3 12.3 Sales/redemptions/reductions - - -5.0 -5.0 Business combinations - - 1.1 1.1 Value adjustment through OCI - 12.3 - 12.3 Value adjustment through P&L 2.6 - - 2.6 Translation differences and other - 0.6 0.6 1.2 Balance as of 31 December 2.6 21.4 51.5 75.5 1 Fair value through profit or loss 2 Fair value through other comprehensive income FVTOCI relates to an investment in Vimta Labs Limited, a publicly listed company in India. Non-current financial assets at amortised cost are mainly lease deposits. ", "dimensions": { "concept": "ifrs-full:DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-124-3": { "value": "2.14. Inventories In \u20ac millions 2022 2021 Inventories (gross) 173.6 193.0 Inventory allowance -28.0 -38.8 Inventories 145.6 154.2 Gross value of inventories decreased to \u20ac174m as of 31 December 2022 (\u20ac193m in 2021). The cost of inventories recognised as an expense during the period and included in \u201cOperating costs, net\u201d amounts to \u20ac786.5m in 2022 (2021: \u20ac804.3m). The inventory allowance mainly relates to COVID-19 testing kits, swabs and consumable based on management\u2019s expectation of future usage and consumption, adjusted for uncertainties surrounding the resilience of the COVID-19 testing market such as but not limited to, the number of tests expected to be performed. At year end 2022, the carrying amount of the COVID-19 inventory amounts to \u20ac5.6m after an inventory allowance of \u20ac16.8m (carrying amount of \u20ac 33.9m after an allowance of \u20ac31.5m in 2021). ", "dimensions": { "concept": "ifrs-full:DisclosureOfInventoriesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-127-2": { "value": "2.15. Trade receivables In \u20ac millions 2022 2021 Trade receivables (gross) 1,111.2 1,106.9 Valuation allowance -57.9 -55.1 Trade receivables 1,053.3 1,051.8 The ageing analysis of trade receivables (gross) is set out below: In \u20ac millions 2022 2021 Current 758.3 765.2 Overdue 1-90 days 240.8 231.4 Overdue 91-360 days 69.1 69.3 Overdue > 360 days 42.9 41.0 Total 1,111.2 1,106.9 Provision for impairment of trade receivables amounts to \u20ac57.9m in 2022 (\u20ac55.1m in 2021). In \u20ac millions Valuation allowance 2022 2021 Balance as of 1 January 55.1 44.9 Additional allowance 13.5 19.2 Reversal -14.7 -11.5 Business Combinations 3.5 1.6 Translation differences and other 0.5 0.9 Balance as of 31 December 57.9 55.1 The maximum exposure to credit risk at the reporting date is the carrying value of the trade receivables mentioned above. The loss allowance at 31 December 2022 and 31 December 2021 was determined as follows: 1-90 days past 91-360 days Over 360 days In \u20ac millions Current Total due past due past due 2022 Expected credit loss rates 0.5% 1.8% 15.5% 100.0% Trade accounts receivable (excl. VAT) 694.1 223.1 63.6 39.2 1,020.1 Contract assets (excl. VAT) 262.8 262.8 Loss allowance 4.9 3.9 9.9 39.2 57.9 2021 Expected credit loss rates 0.5% 1.7% 13.1% 100% Trade accounts receivable (excl. VAT) 702.3 214.5 66.5 37.5 1,020.8 Contract assets (excl. VAT) 308.6 308.6 Loss allowance 5.3 3.6 8.7 37.5 55.1 For more details regarding the credit risk of the Group, refer to Note 2.30. The contract assets (work in progress and accrued sales) decreased in 2022 vs 2021 due to the end of specific COVID-19 contracts. ", "dimensions": { "concept": "ifrs-full:DisclosureOfAllowanceForCreditLossesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-127-3": { "value": "2.15. Trade receivables In \u20ac millions 2022 2021 Trade receivables (gross) 1,111.2 1,106.9 Valuation allowance -57.9 -55.1 Trade receivables 1,053.3 1,051.8 The ageing analysis of trade receivables (gross) is set out below: In \u20ac millions 2022 2021 Current 758.3 765.2 Overdue 1-90 days 240.8 231.4 Overdue 91-360 days 69.1 69.3 Overdue > 360 days 42.9 41.0 Total 1,111.2 1,106.9 Provision for impairment of trade receivables amounts to \u20ac57.9m in 2022 (\u20ac55.1m in 2021). In \u20ac millions Valuation allowance 2022 2021 Balance as of 1 January 55.1 44.9 Additional allowance 13.5 19.2 Reversal -14.7 -11.5 Business Combinations 3.5 1.6 Translation differences and other 0.5 0.9 Balance as of 31 December 57.9 55.1 The maximum exposure to credit risk at the reporting date is the carrying value of the trade receivables mentioned above. The loss allowance at 31 December 2022 and 31 December 2021 was determined as follows: 1-90 days past 91-360 days Over 360 days In \u20ac millions Current Total due past due past due 2022 Expected credit loss rates 0.5% 1.8% 15.5% 100.0% Trade accounts receivable (excl. VAT) 694.1 223.1 63.6 39.2 1,020.1 Contract assets (excl. VAT) 262.8 262.8 Loss allowance 4.9 3.9 9.9 39.2 57.9 2021 Expected credit loss rates 0.5% 1.7% 13.1% 100% Trade accounts receivable (excl. VAT) 702.3 214.5 66.5 37.5 1,020.8 Contract assets (excl. VAT) 308.6 308.6 Loss allowance 5.3 3.6 8.7 37.5 55.1 The Group does not hold any collateral as security. For more details regarding the credit risk of the Group, refer to Note 2.30. The contract assets (work in progress and accrued sales) decreased in 2022 vs 2021 due to the end of specific COVID-19 contracts. 2.16. Prepaid expenses and other current assets In \u20ac millions 2022 2021 Prepaid expenses 78.3 68.0 Other receivables 119.9 114.7 Accrued interest receivables 0.1 0.4 Total 198.3 183.1 Other receivables correspond mainly to tax and social receivables. ", "dimensions": { "concept": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "f119112": { "value": "The Group does not hold any collateral as security. ", "dimensions": { "concept": "ifrs-full:DisclosureOfCollateralExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-131-3": { "value": "2.16. Prepaid expenses and other current assets In \u20ac millions 2022 2021 Prepaid expenses 78.3 68.0 Other receivables 119.9 114.7 Accrued interest receivables 0.1 0.4 Total 198.3 183.1 Other receivables correspond mainly to tax and social receivables. ", "dimensions": { "concept": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-131-4": { "value": "2.16. Prepaid expenses and other current assets In \u20ac millions 2022 2021 Prepaid expenses 78.3 68.0 Other receivables 119.9 114.7 Accrued interest receivables 0.1 0.4 Total 198.3 183.1 Other receivables correspond mainly to tax and social receivables. ", "dimensions": { "concept": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-131-5": { "value": "2.16. Prepaid expenses and other current assets In \u20ac millions 2022 2021 Prepaid expenses 78.3 68.0 Other receivables 119.9 114.7 Accrued interest receivables 0.1 0.4 Total 198.3 183.1 Other receivables correspond mainly to tax and social receivables. ", "dimensions": { "concept": "ifrs-full:DisclosureOfOtherAssetsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-132-2": { "value": "2.17. Cash and cash equivalents, bank overdrafts and Net Debt In \u20ac millions 2022 2021 Short term deposits 54.4 17.4 Cash in hand 432.2 497.9 Cash and cash equivalents 486.6 515.3 Bank overdrafts -3.4 -0.3 Cash and cash equivalents less bank overdrafts 483.2 515.0 Short term deposits with banks are mostly owned by Eurofins Scientific SE in Luxembourg for \u20ac18.7m and by its French branch for \u20ac28.7m. ", "dimensions": { "concept": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-133-2": { "value": "In \u20ac millions Note 2022 2021 Total borrowings 2.18 3,325.6 2,754.1 Cash and cash equivalents -486.6 -515.3 Net debt 2,839.0 2,238.8 ", "dimensions": { "concept": "EUR:DisclosureOfNetDebt", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-134-2": { "value": "2.18. Borrowings Variation of borrowings In \u20ac millions Schuld-Com-Bank Bank Lease Issu-2022 Bonds shein mercial Credit Borro-Liabili-ance Total Loan Paper Lines wings ties Costs Balance as of 1 January 1,500.0 582.0 80.0 - 71.5 538.9 -18.6 2,753.8 Cash impact Increase of borrowings 600.0 - - - 45.9 - -12.0 633.9 Repayment of borrowings - -45.5 -5.0 - -32.4 - - -82.9 1Repayment of lease liabilities- - - - - -139.8 - -139.8 Non cash impact Lease subscriptions - - - - - 101.1 - 101.1 Exit of lease liabilities - - - - - -11.8 - -11.8 Amortisation of issuance costs - - - - - - 3.8 3.8 Business combinations - - - - 26.4 30.1 - 56.5 Translation differences and other - - - - -1.5 9.1 - 7.6 Total 2,100.0 536.5 75.0 - 109.9 527.6 -26.8 3,322.2 Bank overdrafts 3.4 Balance as of 31 December 3,325.6 2021 Balance as of 1 January 1,882.8 679.0 15.0 - 53.7 533.7 -11.3 3,152.9 Cash impact Increase of borrowings 750.0 - 65.0 - 25.9 - -14.5 826.3 Repayment of borrowings -1,132.8 -97.0 - - -50.1 - - -1,280.0 1Repayment of lease liabilities- - - - - -128.5 - -128.5 Non cash impact Lease subscriptions - - - - - 105.4 - 105.4 Exit of lease liabilities - - - - - -12.1 - -12.1 Amortisation of issuance costs - - - - - - 7.3 7.3 Business combinations - - - - 41.5 25.2 - 66.8 Translation differences and other - - - - 0.5 15.2 - 15.8 Total 1,500.0 582.0 80.0 - 71.5 538.9 -18.6 2,753.8 Bank overdrafts 0.3 Balance as of 31 December 2,754.1 1 Repayment of lease liabilities excl. interest paid (Note 2.7) The split of the borrowings between current and non-current are as follows:In \u20ac millions 2022 2021 Current Non-Current Total Current Non-Current Total Bonds - 2,100.0 2,100.0 - 1,500.0 1,500.0 Schuldschein loan - 536.5 536.5 45.5 536.5 582.0 Commercial paper 75.0 - 75.0 80.0 - 80.0 Bank borrowings 11.3 98.6 109.9 10.3 61.2 71.5 Lease liabilities 128.6 399.0 527.6 120.7 418.2 538.9 Issuance costs -4.6 -22.3 -26.8 -2.9 -15.7 -18.6 Bank overdrafts 3.4 - 3.4 0.3 - 0.3 Total borrowings 213.8 3,111.8 3,325.6 253.8 2,500.3 2,754.1 Eurobonds In \u20ac millions 31 December 31 December Nominal Nominal Issue date Maturity 2022 2021 value upon interest rate issuance Eurobond 2024 447.8 447.8 650.0 2.125% July 2017 July 2024 Eurobond 2026 302.2 302.2 600.0 3.75% May 2020 July 2026 Eurobond 2029 600.0 - 600.0 4.00% June 2022 July 2029 Eurobond 2031 750.0 750.0 750.0 0.875% May 2021 May 2031 Total 2,100.0 1,500.0 In June 2022, the Group raised \u20ac600m of senior unsecured Eurobonds. The bonds have a 7-year maturity (due on 6 July 2029) and bear an annual fixed rate coupon of 4%. The Bonds are listed on the regulated market of the Luxembourg stock exchange (ISIN XS2491664137). The net proceeds of the bonds were primarily used for the partial redemption of two hybrid capital instruments (see note 2.20). In May 2021, the Group raised \u20ac750m of senior unsecured Eurobonds. The bonds have a 10-year maturity (due on 19 May 2031) and bear an annual fixed rate of 0.875%. The bonds are listed on the regulated market of the Luxembourg stock exchange (ISIN XS2343114687). The net proceeds of the bonds were primarily used for the redemption of the various Eurobond issuances for an amount of \u20ac1,133m. The quoted values of the Company\u2019s Eurobonds are disclosed in Note 2.34. Commercial paper In September 2017, Eurofins set up a Negotiable European Commercial Paper program (\u201cNEU CP\u201d) on the French capital market. This program is used to issue short term notes with a minimum size of \u20ac0.2m and maturity of less than one year. The maximum amount of the program is \u20ac750m as of 31 December 2022 (same as of 31 December 2021). At the end of December 2022, notes were outstanding for an amount of \u20ac75m under this program (\u20ac80m notes outstanding as of 31 December 2021). Schuldschein loan In July 2018, Eurofins issued a \u20ac550m Schuldschein loan (\u201cCertificate of Indebtedness\u201d). The Schuldschein loan was structured in tranches with maturities of 4 and 7 years, with both fixed and floating interest rates. In the 4-year tranches, the fixed rate tranche was priced at a fixed rate of 1.073% per annum and the floating rate tranche at a variable rate of 6-months-Euribor (floored at 0%) plus 95bps per annum. In the 7-year tranches, the fixed rate tranche was priced at a fixed rate of 1.834% per annum and the floating rate tranche at a variable rate of 6-months-Euribor (floored at 0%) plus 130bps. In October 2020, the Company reimbursed \u20ac221m of the Schuldschein loan tranches maturing in July 2022. In January 2021, the Company reimbursed an additional \u20ac97m of the Schuldschein loan tranches maturing in July 2022. In July 2022, the Company reimbursed the remaining tranche of \u20ac45.5m. The remaining Schuldschein loan 2018 amounts to \u20ac186.5m at the end of December 2022. In October 2020, the Company issued a new \u20ac350m Schuldschein loan (\u201cCertificate of Indebtedness\u201d) offering a blended interest rate of 1.78% with an average maturity of 7.8 years. This Schuldschein loan is structured in tranches of 5, 7 and 10 years, with both fixed and floating interest rates, with more than 85% of the transaction on the 7 and 10-year tenors. Leases The following table presents a reconciliation between the total of future minimum lease payments and their present value. 2022 2021 Future Interest Present Future Interest Present value minimum lease value of minimum lease of minimum payments minimum payments lease lease payments In \u20ac millions payments Less than one year 151.6 23.1 128.6 142.8 22.1 120.7 Between one and five years 355.3 36.3 319.0 364.1 44.8 319.3 More than five years 88.7 8.7 80.0 108.6 9.7 98.9 Lease liabilities 595.6 68.1 527.6 615.5 76.6 538.9 The repayment of lease liabilities amounted to \u20ac166.1m (repayment of lease liabilities excl. interest paid: \u20ac139.8m and interests on lease liabilities: \u20ac26.3m). Bilateral credit lines At year-end 2022 and 2021, Eurofins had not used any of its bilateral credit lines. As of 31 December 2022, Eurofins had access to over \u20ac1bn committed mid-term (3 to 5 years) bilateral bank credit lines (same as in 2021). None of the bilateral credit lines is maturing in 2023. The Group\u2019s net exposure to interest rate risk for the borrowings (excluding lease liabilities) as per Balance Sheet date, before taking into account the above hedging transactions is presented below: 2022 2021 Borrowings at fixed interest rates 90% 88% Borrowings at floating interest rates 10% 12% Given the breakdown between fixed rate and floating rate assets and liabilities as at 31 December 2022, a 1% increase or decrease in interest rates would have a full-year impact of +/- \u20ac1.7m on results before income taxes (excluding lease liabilities). Rate Up to 2-5 Over Total In \u20ac millions 1 year years 5 years Short term deposits Fixed -54.4 - - -54.4 Floating - - - - Bonds Fixed - 750.0 1,350.0 2,100.0 Floating - - - - Schuldschein Fixed - 177.5 97.5 275.0 Variable - 231.5 30.0 261.5 Commercial paper Fixed 75.0 - - 75.0 Floating - - - - Bank borrowings Fixed 10.8 45.5 43.7 100.0 Floating 0.5 3.4 6.0 9.9 Lease liabilities Fixed 6.5 25.0 8.1 39.6 Floating 122.1 293.9 71.9 487.9 Net exposure Fixed 37.9 998.0 1,499.3 2,535.2 Before hedge Floating 122.6 528.8 107.9 759.3 Hedge Fixed - 99.0 - 99.0 Floating - -99.0 - -99.0 Net exposure Fixed 37.9 1,097.0 1,499.3 2,634.2 After hedge Floating 122.6 429.8 107.9 660.3 Borrowings pledged by assets or with covenants The liabilities and borrowings listed below are already included in the Group\u2019s Consolidated Balance Sheet. The following table only repeats these amounts when these borrowings are secured by covenants or securities on assets. In \u20ac millions 2022 2021 Bank borrowings secured over buildings and other assets 80.3 51.7 1Finance leases secured over buildings and other assets41.5 42.8 Bank borrowings secured by covenants and assets 2.8 2.9 Total borrowings and leases secured 124.7 97.4 Bank borrowings secured by covenants - - Bank borrowings guaranteed by the direct parent of the borrower - - Total 124.7 97.4 1 Finance lease liabilities are effectively secured as the rights to the leased asset revert to the lessor in the event of default. ", "dimensions": { "concept": "ifrs-full:DisclosureOfBorrowingsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-134-3": { "value": "2.18. Borrowings Variation of borrowings In \u20ac millions Schuld-Com-Bank Bank Lease Issu-2022 Bonds shein mercial Credit Borro-Liabili-ance Total Loan Paper Lines wings ties Costs Balance as of 1 January 1,500.0 582.0 80.0 - 71.5 538.9 -18.6 2,753.8 Cash impact Increase of borrowings 600.0 - - - 45.9 - -12.0 633.9 Repayment of borrowings - -45.5 -5.0 - -32.4 - - -82.9 1Repayment of lease liabilities- - - - - -139.8 - -139.8 Non cash impact Lease subscriptions - - - - - 101.1 - 101.1 Exit of lease liabilities - - - - - -11.8 - -11.8 Amortisation of issuance costs - - - - - - 3.8 3.8 Business combinations - - - - 26.4 30.1 - 56.5 Translation differences and other - - - - -1.5 9.1 - 7.6 Total 2,100.0 536.5 75.0 - 109.9 527.6 -26.8 3,322.2 Bank overdrafts 3.4 Balance as of 31 December 3,325.6 2021 Balance as of 1 January 1,882.8 679.0 15.0 - 53.7 533.7 -11.3 3,152.9 Cash impact Increase of borrowings 750.0 - 65.0 - 25.9 - -14.5 826.3 Repayment of borrowings -1,132.8 -97.0 - - -50.1 - - -1,280.0 1Repayment of lease liabilities- - - - - -128.5 - -128.5 Non cash impact Lease subscriptions - - - - - 105.4 - 105.4 Exit of lease liabilities - - - - - -12.1 - -12.1 Amortisation of issuance costs - - - - - - 7.3 7.3 Business combinations - - - - 41.5 25.2 - 66.8 Translation differences and other - - - - 0.5 15.2 - 15.8 Total 1,500.0 582.0 80.0 - 71.5 538.9 -18.6 2,753.8 Bank overdrafts 0.3 Balance as of 31 December 2,754.1 1 Repayment of lease liabilities excl. interest paid (Note 2.7) The split of the borrowings between current and non-current are as follows:In \u20ac millions 2022 2021 Current Non-Current Total Current Non-Current Total Bonds - 2,100.0 2,100.0 - 1,500.0 1,500.0 Schuldschein loan - 536.5 536.5 45.5 536.5 582.0 Commercial paper 75.0 - 75.0 80.0 - 80.0 Bank borrowings 11.3 98.6 109.9 10.3 61.2 71.5 Lease liabilities 128.6 399.0 527.6 120.7 418.2 538.9 Issuance costs -4.6 -22.3 -26.8 -2.9 -15.7 -18.6 Bank overdrafts 3.4 - 3.4 0.3 - 0.3 Total borrowings 213.8 3,111.8 3,325.6 253.8 2,500.3 2,754.1 Eurobonds In \u20ac millions 31 December 31 December Nominal Nominal Issue date Maturity 2022 2021 value upon interest rate issuance Eurobond 2024 447.8 447.8 650.0 2.125% July 2017 July 2024 Eurobond 2026 302.2 302.2 600.0 3.75% May 2020 July 2026 Eurobond 2029 600.0 - 600.0 4.00% June 2022 July 2029 Eurobond 2031 750.0 750.0 750.0 0.875% May 2021 May 2031 Total 2,100.0 1,500.0 In June 2022, the Group raised \u20ac600m of senior unsecured Eurobonds. The bonds have a 7-year maturity (due on 6 July 2029) and bear an annual fixed rate coupon of 4%. The Bonds are listed on the regulated market of the Luxembourg stock exchange (ISIN XS2491664137). The net proceeds of the bonds were primarily used for the partial redemption of two hybrid capital instruments (see note 2.20). In May 2021, the Group raised \u20ac750m of senior unsecured Eurobonds. The bonds have a 10-year maturity (due on 19 May 2031) and bear an annual fixed rate of 0.875%. The bonds are listed on the regulated market of the Luxembourg stock exchange (ISIN XS2343114687). The net proceeds of the bonds were primarily used for the redemption of the various Eurobond issuances for an amount of \u20ac1,133m. The quoted values of the Company\u2019s Eurobonds are disclosed in Note 2.34. Commercial paper In September 2017, Eurofins set up a Negotiable European Commercial Paper program (\u201cNEU CP\u201d) on the French capital market. This program is used to issue short term notes with a minimum size of \u20ac0.2m and maturity of less than one year. The maximum amount of the program is \u20ac750m as of 31 December 2022 (same as of 31 December 2021). At the end of December 2022, notes were outstanding for an amount of \u20ac75m under this program (\u20ac80m notes outstanding as of 31 December 2021). Schuldschein loan In July 2018, Eurofins issued a \u20ac550m Schuldschein loan (\u201cCertificate of Indebtedness\u201d). The Schuldschein loan was structured in tranches with maturities of 4 and 7 years, with both fixed and floating interest rates. In the 4-year tranches, the fixed rate tranche was priced at a fixed rate of 1.073% per annum and the floating rate tranche at a variable rate of 6-months-Euribor (floored at 0%) plus 95bps per annum. In the 7-year tranches, the fixed rate tranche was priced at a fixed rate of 1.834% per annum and the floating rate tranche at a variable rate of 6-months-Euribor (floored at 0%) plus 130bps. In October 2020, the Company reimbursed \u20ac221m of the Schuldschein loan tranches maturing in July 2022. In January 2021, the Company reimbursed an additional \u20ac97m of the Schuldschein loan tranches maturing in July 2022. In July 2022, the Company reimbursed the remaining tranche of \u20ac45.5m. The remaining Schuldschein loan 2018 amounts to \u20ac186.5m at the end of December 2022. In October 2020, the Company issued a new \u20ac350m Schuldschein loan (\u201cCertificate of Indebtedness\u201d) offering a blended interest rate of 1.78% with an average maturity of 7.8 years. This Schuldschein loan is structured in tranches of 5, 7 and 10 years, with both fixed and floating interest rates, with more than 85% of the transaction on the 7 and 10-year tenors. Leases The following table presents a reconciliation between the total of future minimum lease payments and their present value. 2022 2021 Future Interest Present Future Interest Present value minimum lease value of minimum lease of minimum payments minimum payments lease lease payments In \u20ac millions payments Less than one year 151.6 23.1 128.6 142.8 22.1 120.7 Between one and five years 355.3 36.3 319.0 364.1 44.8 319.3 More than five years 88.7 8.7 80.0 108.6 9.7 98.9 Lease liabilities 595.6 68.1 527.6 615.5 76.6 538.9 The repayment of lease liabilities amounted to \u20ac166.1m (repayment of lease liabilities excl. interest paid: \u20ac139.8m and interests on lease liabilities: \u20ac26.3m). Bilateral credit lines At year-end 2022 and 2021, Eurofins had not used any of its bilateral credit lines. As of 31 December 2022, Eurofins had access to over \u20ac1bn committed mid-term (3 to 5 years) bilateral bank credit lines (same as in 2021). None of the bilateral credit lines is maturing in 2023. Financial liabilities Total Up to 1 year 2-5 years Over 5 years In \u20ac millions 2022 1Bonds2,100.0 - 750.0 1,350.0 1Schuldschein536.5 - 409.0 127.5 Commercial paper 75.0 75.0 - - 1Bank borrowings109.9 11.3 48.8 49.7 Bank overdrafts 3.4 3.4 - - Lease liabilities 527.6 128.6 319.0 80.0 Amounts due for business acq. (not 216.7 50.3 127.0 39.4 discounted) Earnings due on hybrid capital 7.7 7.7 - - 2Current and future interest due434.6 87.8 243.3 103.6 Trade accounts payable 647.7 647.7 - - Total 4,659.1 1,011.9 1,897.1 1,750.2 2021 1Bonds1,500.0 - 750.0 750.0 1Schuldschein582.0 45.5 233.5 303.0 Commercial paper 80.0 80.0 - - 1Bank borrowings71.5 10.2 32.6 28.7 Bank overdrafts 0.3 0.3 - - Lease liabilities 538.9 120.7 319.3 98.9 Amounts due for business acq. (not 141.3 56.9 78.4 6.0 discounted) Earnings due on hybrid capital 14.3 14.3 - - 2Current and future interest due292.6 61.2 173.8 57.6 Trade accounts payable 627.6 627.6 - - Total 3,848.5 1,016.7 1,587.6 1,244.2 1 Par value.2 Including interests due on borrowings until their full repayment and the impact of any derivative financial instruments. 2.34. Fair value of financial assets and liability The estimated fair value of financial instruments has been determined by the Group using available market information and appropriate valuation methods. The estimates presented are not necessarily indicative of the amounts that will ultimately be realised by the Group upon maturity or disposal. The use of different market assumptions and/or estimation methods may have a material effect on the estimated fair value amounts. The following tables show the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy. Fair value information for financial assets and financial liabilities not carried at fair value is not included if the carrying amount is a reasonable approximation of fair value. As of 31 December 2022 Carrying Fair value Level 1 Level 2 Level 3 In \u20ac millions amount Financial assets Financial assets carried at FVTOCI 21.8 21.8 21.8 - - Financial assets carried at FVTPL 2.6 2.6 - - 2.6 Derivative financial instruments 5.6 5.6 - 5.6 - Financial assets carried at fair value 30.0 30.0 21.8 5.6 2.6 Cash and cash equivalents 486.6 - - - - Receivables \u2013 current 1,461.7 - - - - Receivables - non-current 54.1 - - - - Financial assets carried at (amortised) costs 2,002.4 - - - - Total financial assets 2,032.4 30.0 21.8 5.6 2.6 Financial liabilities Contingent consideration 184.0 184.0 - - 184.0 Financial liabilities carried at FVTPL 184.0 184.0 - - 184.0 Derivative financial instruments - - - - - Financial liabilities carried at fair value 184.0 184.0 - - 184.0 Payables and contract liabilities 831.9 - - - - Interest accrual 38.0 - - - - Bonds 2,100.0 1,898.7 1,898.7 - - Other borrowings 1,225.6 - - - - Other liabilities 571.6 - - - - Financial liabilities carried at (amortised) costs 4,767.0 1,898.7 1,898.7 - - Total financial liabilities 4,951.0 2,082.7 1,898.7 - 184.0 As of 31 December 2021 Carrying Fair value Level 1 Level 2 Level 3 In \u20ac millions amount Financial assets Financial assets carried at FVTOCI 21.4 21.4 21.4 - - Financial assets carried at FVTPL 2.6 2.6 - - 2.6 Derivative financial instruments 0.5 0.5 - 0.5 - Financial assets carried at fair value 24.5 24.5 21.4 0.5 2.6 Cash and cash equivalents 515.3 - - - - Receivables \u2013 current 1,504.4 - - - - Receivables - non-current 51.5 - - - - Financial assets carried at (amortised) costs 2,071.2 - - - - Total financial assets 2,095.7 24.5 21.4 0.5 2.6 Financial liabilities Contingent consideration 141.1 141.1 - - 141.1 Financial liabilities carried at FVTPL 141.1 141.1 - - 141.1 Derivative financial instruments - - - - - Financial liabilities carried at fair value 141.1 141.1 - - 141.1 Payables and contract liabilities 790.7 - - - - Interest accrual 31.4 - - - - Bonds 1,500.0 1,555.6 1,555.6 - - Other borrowings 1,254.1 - - - - Other liabilities 607.9 - - - - Financial liabilities carried at (amortised) costs 4,184.0 1,555.6 1,555.6 - - Total financial liabilities 4,325.1 1,696.7 1,555.6 - 141.1 Specific valuation techniques used to value financial instruments include: Level 1 Instruments included in level 1 are comprised primarily of listed equity investments classified as financial assets carried at fair value through profit or loss or carried at fair value through Other Comprehensive Income. The fair value of financial instruments traded in active markets is based on quoted market prices at the Balance Sheet date. A market is regarded as active if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm\u2019s length basis. Level 2 The fair value of financial instruments that are not traded in an active market (for example, over-the-counter derivatives or convertible bond instruments) is determined by using valuation techniques. These valuation techniques maximise the use of observable market data where it is available and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are based on observable market data, the instrument is included in level 2. The fair value of derivatives is calculated as the present value of the estimated future cash flows based on observable interest yield curves, basis spread and foreign exchange rates. The valuation of convertible bond instruments uses observable market quoted data for the options and present value calculations using observable yield curves for the fair value of the bonds. Level 3 If one or more of the significant inputs are not based on observable market data, such as third-party pricing information without adjustments, the instrument is included in level 3. With the exception of the borrowings, the Group considers the carrying value of the financial instruments to approximate their fair value. Regarding borrowings, their fair value is based on: \u25aa A quoted price included in Level 1 of the fair value hierarchy for the Eurobond 2024 (fair value amount of \u20ac438.7m against acarrying value of \u20ac447.8m - ISIN XS1651444140).\u25aa A quoted price included in Level 1 of the fair value hierarchy for the Eurobond 2026 (fair value amount of \u20ac306.2m against acarrying value of \u20ac302.2m - ISIN XS2167595672).\u25aa A quoted price included in Level 1 of the fair value hierarchy for the Eurobond 2029 (fair value amount of \u20ac589.0m against acarrying value of \u20ac600m - ISIN XS2491664137).\u25aa A quoted price included in Level 1 of the fair value hierarchy for the Eurobond 2031 (fair value amount of \u20ac564.8m against acarrying value of \u20ac750m - ISIN XS2343114687).", "dimensions": { "concept": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-134-4": { "value": "2.18. Borrowings Variation of borrowings In \u20ac millions Schuld-Com-Bank Bank Lease Issu-2022 Bonds shein mercial Credit Borro-Liabili-ance Total Loan Paper Lines wings ties Costs Balance as of 1 January 1,500.0 582.0 80.0 - 71.5 538.9 -18.6 2,753.8 Cash impact Increase of borrowings 600.0 - - - 45.9 - -12.0 633.9 Repayment of borrowings - -45.5 -5.0 - -32.4 - - -82.9 1Repayment of lease liabilities- - - - - -139.8 - -139.8 Non cash impact Lease subscriptions - - - - - 101.1 - 101.1 Exit of lease liabilities - - - - - -11.8 - -11.8 Amortisation of issuance costs - - - - - - 3.8 3.8 Business combinations - - - - 26.4 30.1 - 56.5 Translation differences and other - - - - -1.5 9.1 - 7.6 Total 2,100.0 536.5 75.0 - 109.9 527.6 -26.8 3,322.2 Bank overdrafts 3.4 Balance as of 31 December 3,325.6 2021 Balance as of 1 January 1,882.8 679.0 15.0 - 53.7 533.7 -11.3 3,152.9 Cash impact Increase of borrowings 750.0 - 65.0 - 25.9 - -14.5 826.3 Repayment of borrowings -1,132.8 -97.0 - - -50.1 - - -1,280.0 1Repayment of lease liabilities- - - - - -128.5 - -128.5 Non cash impact Lease subscriptions - - - - - 105.4 - 105.4 Exit of lease liabilities - - - - - -12.1 - -12.1 Amortisation of issuance costs - - - - - - 7.3 7.3 Business combinations - - - - 41.5 25.2 - 66.8 Translation differences and other - - - - 0.5 15.2 - 15.8 Total 1,500.0 582.0 80.0 - 71.5 538.9 -18.6 2,753.8 Bank overdrafts 0.3 Balance as of 31 December 2,754.1 1 Repayment of lease liabilities excl. interest paid (Note 2.7) The split of the borrowings between current and non-current are as follows:In \u20ac millions 2022 2021 Current Non-Current Total Current Non-Current Total Bonds - 2,100.0 2,100.0 - 1,500.0 1,500.0 Schuldschein loan - 536.5 536.5 45.5 536.5 582.0 Commercial paper 75.0 - 75.0 80.0 - 80.0 Bank borrowings 11.3 98.6 109.9 10.3 61.2 71.5 Lease liabilities 128.6 399.0 527.6 120.7 418.2 538.9 Issuance costs -4.6 -22.3 -26.8 -2.9 -15.7 -18.6 Bank overdrafts 3.4 - 3.4 0.3 - 0.3 Total borrowings 213.8 3,111.8 3,325.6 253.8 2,500.3 2,754.1 Eurobonds In \u20ac millions 31 December 31 December Nominal Nominal Issue date Maturity 2022 2021 value upon interest rate issuance Eurobond 2024 447.8 447.8 650.0 2.125% July 2017 July 2024 Eurobond 2026 302.2 302.2 600.0 3.75% May 2020 July 2026 Eurobond 2029 600.0 - 600.0 4.00% June 2022 July 2029 Eurobond 2031 750.0 750.0 750.0 0.875% May 2021 May 2031 Total 2,100.0 1,500.0 In June 2022, the Group raised \u20ac600m of senior unsecured Eurobonds. The bonds have a 7-year maturity (due on 6 July 2029) and bear an annual fixed rate coupon of 4%. The Bonds are listed on the regulated market of the Luxembourg stock exchange (ISIN XS2491664137). The net proceeds of the bonds were primarily used for the partial redemption of two hybrid capital instruments (see note 2.20). In May 2021, the Group raised \u20ac750m of senior unsecured Eurobonds. The bonds have a 10-year maturity (due on 19 May 2031) and bear an annual fixed rate of 0.875%. The bonds are listed on the regulated market of the Luxembourg stock exchange (ISIN XS2343114687). The net proceeds of the bonds were primarily used for the redemption of the various Eurobond issuances for an amount of \u20ac1,133m. The quoted values of the Company\u2019s Eurobonds are disclosed in Note 2.34. Commercial paper In September 2017, Eurofins set up a Negotiable European Commercial Paper program (\u201cNEU CP\u201d) on the French capital market. This program is used to issue short term notes with a minimum size of \u20ac0.2m and maturity of less than one year. The maximum amount of the program is \u20ac750m as of 31 December 2022 (same as of 31 December 2021). At the end of December 2022, notes were outstanding for an amount of \u20ac75m under this program (\u20ac80m notes outstanding as of 31 December 2021). Schuldschein loan In July 2018, Eurofins issued a \u20ac550m Schuldschein loan (\u201cCertificate of Indebtedness\u201d). The Schuldschein loan was structured in tranches with maturities of 4 and 7 years, with both fixed and floating interest rates. In the 4-year tranches, the fixed rate tranche was priced at a fixed rate of 1.073% per annum and the floating rate tranche at a variable rate of 6-months-Euribor (floored at 0%) plus 95bps per annum. In the 7-year tranches, the fixed rate tranche was priced at a fixed rate of 1.834% per annum and the floating rate tranche at a variable rate of 6-months-Euribor (floored at 0%) plus 130bps. In October 2020, the Company reimbursed \u20ac221m of the Schuldschein loan tranches maturing in July 2022. In January 2021, the Company reimbursed an additional \u20ac97m of the Schuldschein loan tranches maturing in July 2022. In July 2022, the Company reimbursed the remaining tranche of \u20ac45.5m. The remaining Schuldschein loan 2018 amounts to \u20ac186.5m at the end of December 2022. In October 2020, the Company issued a new \u20ac350m Schuldschein loan (\u201cCertificate of Indebtedness\u201d) offering a blended interest rate of 1.78% with an average maturity of 7.8 years. This Schuldschein loan is structured in tranches of 5, 7 and 10 years, with both fixed and floating interest rates, with more than 85% of the transaction on the 7 and 10-year tenors. Bilateral credit lines At year-end 2022 and 2021, Eurofins had not used any of its bilateral credit lines. As of 31 December 2022, Eurofins had access to over \u20ac1bn committed mid-term (3 to 5 years) bilateral bank credit lines (same as in 2021). None of the bilateral credit lines is maturing in 2023. ", "dimensions": { "concept": "ifrs-full:DisclosureOfDebtSecuritiesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-134-5": { "value": "2.18. Borrowings Variation of borrowings In \u20ac millions Schuld-Com-Bank Bank Lease Issu-2022 Bonds shein mercial Credit Borro-Liabili-ance Total Loan Paper Lines wings ties Costs Balance as of 1 January 1,500.0 582.0 80.0 - 71.5 538.9 -18.6 2,753.8 Cash impact Increase of borrowings 600.0 - - - 45.9 - -12.0 633.9 Repayment of borrowings - -45.5 -5.0 - -32.4 - - -82.9 1Repayment of lease liabilities- - - - - -139.8 - -139.8 Non cash impact Lease subscriptions - - - - - 101.1 - 101.1 Exit of lease liabilities - - - - - -11.8 - -11.8 Amortisation of issuance costs - - - - - - 3.8 3.8 Business combinations - - - - 26.4 30.1 - 56.5 Translation differences and other - - - - -1.5 9.1 - 7.6 Total 2,100.0 536.5 75.0 - 109.9 527.6 -26.8 3,322.2 Bank overdrafts 3.4 Balance as of 31 December 3,325.6 2021 Balance as of 1 January 1,882.8 679.0 15.0 - 53.7 533.7 -11.3 3,152.9 Cash impact Increase of borrowings 750.0 - 65.0 - 25.9 - -14.5 826.3 Repayment of borrowings -1,132.8 -97.0 - - -50.1 - - -1,280.0 1Repayment of lease liabilities- - - - - -128.5 - -128.5 Non cash impact Lease subscriptions - - - - - 105.4 - 105.4 Exit of lease liabilities - - - - - -12.1 - -12.1 Amortisation of issuance costs - - - - - - 7.3 7.3 Business combinations - - - - 41.5 25.2 - 66.8 Translation differences and other - - - - 0.5 15.2 - 15.8 Total 1,500.0 582.0 80.0 - 71.5 538.9 -18.6 2,753.8 Bank overdrafts 0.3 Balance as of 31 December 2,754.1 1 Repayment of lease liabilities excl. interest paid (Note 2.7) The split of the borrowings between current and non-current are as follows:In \u20ac millions 2022 2021 Current Non-Current Total Current Non-Current Total Bonds - 2,100.0 2,100.0 - 1,500.0 1,500.0 Schuldschein loan - 536.5 536.5 45.5 536.5 582.0 Commercial paper 75.0 - 75.0 80.0 - 80.0 Bank borrowings 11.3 98.6 109.9 10.3 61.2 71.5 Lease liabilities 128.6 399.0 527.6 120.7 418.2 538.9 Issuance costs -4.6 -22.3 -26.8 -2.9 -15.7 -18.6 Bank overdrafts 3.4 - 3.4 0.3 - 0.3 Total borrowings 213.8 3,111.8 3,325.6 253.8 2,500.3 2,754.1 Leases The following table presents a reconciliation between the total of future minimum lease payments and their present value. 2022 2021 Future Interest Present Future Interest Present value minimum lease value of minimum lease of minimum payments minimum payments lease lease payments In \u20ac millions payments Less than one year 151.6 23.1 128.6 142.8 22.1 120.7 Between one and five years 355.3 36.3 319.0 364.1 44.8 319.3 More than five years 88.7 8.7 80.0 108.6 9.7 98.9 Lease liabilities 595.6 68.1 527.6 615.5 76.6 538.9 The repayment of lease liabilities amounted to \u20ac166.1m (repayment of lease liabilities excl. interest paid: \u20ac139.8m and interests on lease liabilities: \u20ac26.3m). Leases The Group has lease contracts for various items of real estate, vehicles and other equipment used in its operations. The Group has multiple extension and termination options in a number of lease contracts. These are used to maximise operational flexibility in terms of managing the assets used in the Group's operations. The options considered reasonably certain are part of lease liabilities. However, the options not considered reasonably certain are not part of lease liability, which exposes the Company to potential future cash outflows amounting to \u20ac41m. In addition, the Group is not committed to leases not yet commenced. The Group's lease contracts do not contain any financial covenants. The Group has the following minimum lease payments commitments: Total Up to 1 year 2-5 years Over 5 years In \u20ac millions 1- Buildings7.1 7.1 - - - Equipments, cars and others 1.6 1.0 0.6 - Total 8.7 8.1 0.6 - 1 Undiscounted sum of future aggregate minimum lease payments, non-cancellable other than lease liabilities already reported in Note 2.18. The Group recorded in 2022 expenses of \u20ac12.4m related to short term leases and an expense of ca. \u20ac1m relating to low-value assets, which are recognised in other operating expenses. ", "dimensions": { "concept": "ifrs-full:DisclosureOfLeasesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-138-2": { "value": "2.19. Interest due on borrowings and earnings due on hybrid capital In \u20ac millions 2022 2021 Interest due on borrowings 30.3 17.1 Earnings due on hybrid capital callable in 2022 - 2.6 Earnings due on hybrid capital callable in 2023 6.0 9.9 Earnings due on hybrid capital callable in 2025 1.7 1.7 Earnings due on hybrid capital 7.7 14.3 Total 38.0 31.4 ", "dimensions": { "concept": "EUR:DisclosureOfInterestDueOnBorrowingsAndEarningsDueOnHybridCapital", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-139-2": { "value": "2.20. Hybrid capital Amount 31 December 31 December redeemed or 2022 2021 In \u20ac millions repurchased Hybrid capital with a first call date on 11 August 2022 - -300.0 300.0 Hybrid capital with a first call date on 29 April 2023 182.7 -117.3 300.0 Hybrid capital with a first call date on 13 November 2025 400.0 - 400.0 Outstanding as of end of period 582.7 -417.3 1,000.0 A new hybrid capital has been issued in January 2023 for an amount of \u20ac600m (Note 2.44). Hybrid capital with a first call date on 11 August 2022 In September 2019, Eurofins raised a \u20ac300m hybrid capital. The instrument had a perpetual maturity but was callable at par by Eurofins at the soonest in August 2022. This hybrid capital bore a fixed annual coupon of 2.875% for the first three years, and a floating coupon of Euribor3m + 605.8 bps thereafter. The instrument was listed on the regulated market of the Luxembourg stock exchange (ISIN XS2051471105). This hybrid capital was fully repurchased in 2022. Hybrid capital with a first call date on 29 April 2023 In April 2015, Eurofins raised a \u20ac300m hybrid capital. The instrument has a perpetual maturity but is callable at par by Eurofins in April 2023. This hybrid capital bears a fixed annual coupon of 4.875% until the first call date and a floating coupon of Euribor3m + 701 bps thereafter. The instrument is listed on the regulated market of the Luxembourg stock exchange (ISIN XS1224953882). In June 2022, Eurofins purchased \u20ac117.3m of this existing hybrid capital. Hybrid capital with a first call date on 13 November 2025 In November 2017, Eurofins raised a \u20ac400m hybrid capital. The instrument has a perpetual maturity but is callable at par by Eurofins in November 2025. This hybrid capital bears a fixed annual coupon of 3.25% until the first call date; then a floating coupon of Euribor3m + 266.7bps until November 2027; then a floating coupon of Euribor3m +366.7bps. The instrument is listed on the regulated market of the Luxembourg stock exchange (ISIN XS1716945586). The earnings outflow related to hybrid capital outstanding reflected in the Consolidated Cash Flow Statement is outlined in greater detail as follows: In \u20ac millions 2022 2021 Earnings paid on hybrid capital callable in 2022 7.3 8.6 Earnings paid on hybrid capital callable in 2023 15.6 14.6 Earnings paid on hybrid capital callable in 2025 13.0 13.0 Total earnings distribution on hybrid capital 35.9 36.3 The impact of the hybrid capital earnings distribution on the equity and of the net profit attributable to hybrid capital holders used for the calculation of the earnings per share is broken down as follows: In \u20ac millions Note 2022 2021 Earnings on hybrid capital callable in 2022 4.6 8.6 Earnings on hybrid capital callable in 2023 11.7 14.6 Earnings on hybrid capital callable in 2025 13.0 13.0 Deferred taxes on hybrid capital distribution 2.8 - -2.2 Total earnings distribution on hybrid capital 2.35 29.3 34.1 ", "dimensions": { "concept": "EUR:DisclosureOfHybridCapital", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-140-2": { "value": "2.21. Trade accounts payable and other current liabilities In \u20ac millions 2022 2021 Trade accounts payable 347.4 322.9 Trade accruals payable 300.3 304.7 Total trade accounts payable 647.7 627.6 In \u20ac millions 2022 2021 Tax and social security payables 170.3 209.3 Tax and social security accruals 335.1 329.2 Other payables 66.2 69.4 Total other current liabilities 571.6 607.9 ", "dimensions": { "concept": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-140-3": { "value": "2.21. Trade accounts payable and other current liabilities In \u20ac millions 2022 2021 Trade accounts payable 347.4 322.9 Trade accruals payable 300.3 304.7 Total trade accounts payable 647.7 627.6 In \u20ac millions 2022 2021 Tax and social security payables 170.3 209.3 Tax and social security accruals 335.1 329.2 Other payables 66.2 69.4 Total other current liabilities 571.6 607.9 ", "dimensions": { "concept": "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-141-4": { "value": "In \u20ac millions 2022 2021 Tax and social security payables 170.3 209.3 Tax and social security accruals 335.1 329.2 Other payables 66.2 69.4 Total other current liabilities 571.6 607.9 ", "dimensions": { "concept": "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-141-5": { "value": "In \u20ac millions 2022 2021 Tax and social security payables 170.3 209.3 Tax and social security accruals 335.1 329.2 Other payables 66.2 69.4 Total other current liabilities 571.6 607.9 ", "dimensions": { "concept": "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-141-6": { "value": "In \u20ac millions 2022 2021 Tax and social security payables 170.3 209.3 Tax and social security accruals 335.1 329.2 Other payables 66.2 69.4 Total other current liabilities 571.6 607.9 ", "dimensions": { "concept": "ifrs-full:DisclosureOfTaxReceivablesAndPayablesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-142-2": { "value": "2.22. Amounts due for business acquisitions Amounts due for business acquisitions include conditional clauses impacting the price payable to former shareholders of purchased companies. The analysis of amounts due for business acquisitions is set out below: In \u20ac millions Note 2022 2021 Balance as of 1 January 141.1 104.4 Business combinations 2.26 82.4 44.6 Change due to purchase price adjustment 2.26 - 9.7 Amounts due for business acquisitions paid 2.26 -34.5 -27.5 Reversal of amounts due for business acquisitions not paid 2.6 -21.0 -2.4 Unwind of discount on amounts due for business acquisitions 2.7 13.2 6.9 Translation differences and other 2.7 5.4 Balance as of 31 December 184.0 141.1 Current 47.8 56.8 Non-current 136.2 84.3 Total 184.0 141.1 Amounts due on transaction with former shareholders 118.0 120.5 Put and call options transactions 65.9 20.6 Total 184.0 141.1 Within the amounts due for business acquisitions, the Group has contingent arrangements in relation with 81 past acquisitions (including put and call options). The assumptions used are based on the business plans provided at acquisition time and reviewed during the first 12 months following the acquisition in case of significant changes, then reviewed every year based on actual performance for multi-year arrangements to re-assess deferred considerations to be paid. This is a level 3 fair value measurement. The businesses acquired are already fully consolidated and the liabilities related to the deferred consideration (including put and call options) are already included in the line \u201cAmounts due for business acquisitions\u201d. The potential undiscounted amounts of all future payments that the Group could be required to make under these arrangements are estimated between \u20ac130m and \u20ac245m, depending on changes in financial performance of acquired companies. Main significant amounts due on transactions with former shareholders In July 2017, Eurofins acquired 100% of Eurofins Genoma Group Srl in Italy. The Earn-out Consideration is based on the average EBITDA of the company over the period January 2017 to December 2019 (see Note 2.36). In June 2019, Eurofins acquired 100% of Transplant Genomics, Inc. in the U.S. The first Earn-out consideration was a milestone based upon expected reimbursement price per test paid in 2020 for $20m, as local authorities confirmed the Medicare coverage in November 2019. The second Earn-out consideration is based on Net Revenue achieved over calendar years 2020 through 2024. The fair value of the second contingent consideration arrangement was estimated at a discounted amount of $28m at the end of 2022 ($32m at the end of 2021). The other contingent consideration arrangements are individually estimated at less than \u20ac25m. The new main contingent considerations with previous shareholders in 2022 are: \u25aa Eurofins Bio Sant\u00e9 in France; \u25aa Laboratorios Cavendish in Spain. Put and call options transactions with non-controlling interests at a variable price The aggregate value of these put and call agreements is estimated at less than \u20ac66m as of 31 December 2022. The following put and call agreements were exercised in 2022 for the remaining shares: \u25aa 15% of the shares in Eurofins Lab Solution S.r.l. (Italy); \u25aa 11% of the shares in Eurofins GSD Holdings, Inc. (US). The put and call of 15% of the shares in Commissum Associates (UK/SG) were discontinued through the Digital Testing sale in 2022. Put and call agreements signed in 2021 or before, remaining at the end of December 2022 are as follows: \u25aa 43.5% of the shares in Havlandet Forskningslabratorium (NO); \u25aa 30% of the shares in Eurofins Beacon Discovery, Inc (US); \u25aa 10% of the shares in Alba Science Ltd (UK); \u25aa 10% of the shares in Maser Facilities B.V. (NL); \u25aa 25% of the shares in MGS Laboratories Limited (UK). In 2022, other put and call agreements have been signed for the remaining: \u25aa 39.8% of Bio-EC Group (FR); \u25aa 38.75% of Medserv Kft (HU); \u25aa 49.9% of Eurofins Limed Ltd. (IL); \u25aa 40% of CRA Korea Co. Ltd. (KR); \u25aa 45% of Eurofins Saudi Ajal Laboratories (SA) ; \u25aa 25% of Thai Environmental Technic Co., Ltd. (TH); \u25aa 33% of Genetic Testing Service JSC (VN); \u25aa 45% of Repertoire Genesis Inc. (JP). ", "dimensions": { "concept": "EUR:DisclosureOfAmountsDueFromBusinessAcquisitions", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-144-2": { "value": "2.23. Post-employment benefits The Group operates retirement benefit obligations plans in France, Germany, Sweden, Norway, the Netherlands, Italy, Japan, India and Taiwan. Those plans can either be defined benefit plans (DB) or jubilee payments and have been established in accordance with the legal requirements, customs and the local practice in the countries concerned. Risks related to DB plans DB plans expose the company to various demographic and economic risks such as longevity risk, investment risk, currency and interest rate risk and in some cases inflation risk. The latter plays a role in the assumed wage increase but more importantly in some countries where indexation of pensions is mandatory. France The Group runs a jubilee scheme where a lump sum payment is provided to all employees upon retirement. The amount is dependent on different factors such as years of service with the company, compensation at retirement age (between age of 63 and 65) and collective agreements. This is a legal requirement. Some companies in France also have some work anniversary awards agreements (\u201cm\u00e9daille du travail\u201d). The lump sum amount is defined by the collective agreement and based on the number of years of service with the company. Sweden The Group runs a final salary scheme DB plan for some of its employees in Sweden (ITP2). The ITP2 plan can be funded in two different ways, either by paying premiums to Alecta Pensionsf\u00f6rs\u00e4kring (a mutual life insurance company) or by using a book reserve system in combination with credit insurance through PRI Pensionsgaranti. Eurofins is using the latter. Germany The Group runs a DB plan for the employees of Central Laboratories Friedrichsdorf as well as to former managers of companies acquired by Eurofins who are no longer part of the Group in 2022. Company pension commitments in Germany are partly protected against employer bankruptcy via the \u201cPensions-Sicherungs-Verein\u201d which charges a fee to all German companies providing pension schemes. Norway The Group runs a DB plan (\u201cMulti-Employer Scheme\u201d) for employees who have previously been employed in the public sector. Other In Japan, India and Taiwan, the defined benefit plan mainly corresponds to a lump sum payment made upon retirement or upon ending an employment contract with the company. In the Netherlands, the benefit obligation relates to work anniversary award plans \u2018Jubilee\u2019. In Italy it relates to the TFR (\u2018Trattamento di Fine Rapporto\u2019). It is an end-of-employment provision accrued for each single employee and paid out upon termination of the employment contract. The Group has followed the recommendations of IFRIC update 05/21. The cumulative impacts on pension liability in prior periods as well as the current period are not deemed significant. Summary of pre-tax costs for post-employment benefits and reconciliation The amounts recognised in the Consolidated Income Statement for the defined benefit plans are determined as follows: In \u20ac millions 2022 2021 Defined benefit plans - Included in operating costs, net from operations 4.5 4.6 - Included in finance costs 0.8 0.7 - Included in discontinued operations - - Defined contribution plans - Included in operating costs, net from operations 56.7 47.4 - Included in income from discontinued operations - - Post-employment benefits costs 62.0 52.7 2022 movements in employee benefit obligations between present value of obligations and fair value of plan assets are broken down as follows: 2022 2021 Pension Pension Present Present Fair value of liability in the Fair value of liability in the In \u20ac millions value of value of plan assets Balance plan assets Balance obligations obligations Sheet Sheet As of 1 January 85.6 -10.0 75.5 83.2 -9.9 73.3 Current service cost 4.9 - 4.9 4.8 - 4.8 Past service costs - - - - - - Effects of curtailments -0.4 - -0.4 -0.1 - -0.1 Operating costs, net 4.5 - 4.5 4.6 - 4.6 Interest expense/(income) 1.0 -0.3 0.8 0.8 -0.1 0.7 Amounts recognised in the Consolidated Income 5.6 -0.3 5.3 5.4 -0.1 5.3 Statement Remeasurements: Return on plan assets, excluding amounts included - -0.5 -0.5 - -0.2 -0.2 in interest expense/(income) (Gain)/loss from change in -0.3 - -0.3 0.1 - 0.1 demographic assumptions (Gain)/loss from change in -17.1 - -17.1 -4.0 - -4.0 financial assumptions Experience (gains)/losses -0.1 - -0.1 1.3 - 1.3 Amounts recognised in Other Comprehensive -17.4 -0.5 -18.0 -2.6 -0.2 -2.7 Income Translation differences and -2.1 -0.1 -2.1 3.5 -0.8 2.7 other Business Combinations 2.1 - 2.1 0.2 - 0.2 Contributions: - Employers - - - - -0.2 -0.2 - Plan participants - - - - - - Benefit payments: - From plans -0.6 0.6 0.0 -1.1 1.1 - - From employers -3.4 - -3.4 -3.1 - -3.1 As of 31 December 69.8 -10.3 59.5 85.6 -10.0 75.5 The amounts recognised in the Balance Sheet are broken down as follows on a country basis: 2022 2021 Present value of Fair value Pension liability Present value Pension liability Fair value of Country funded of plan in the Balance of funded in the Balance plan assets obligations assets Sheet obligations Sheet France 28.6 - 28.6 34.6 - 34.6 Sweden 12.7 - 12.7 20.3 - 20.3 Other 28.5 -10.3 18.1 30.7 -10.0 20.6 Total 69.8 -10.3 59.5 85.6 -10.0 75.5 Plan assets Plans assets represent an amount of \u20ac10.3m mainly in cash and corporate bonds as of 31 December 2022 (\u20ac10m as of 31 December 2021). Assumptions The main actuarial assumptions used for defined benefit obligations (DBO) are detailed as follows: Pension increase In % Discount rate Salary increase rate Inflation rate rate France 3.7% 3.5% N/A 3.5% Sweden 4.0% 3.1% 3.1% 2.1% Assumptions regarding future mortality rates are set based on widely known actuarial data and mortality tables. Sensitivity analysis The following table illustrates the approximate impact on the DBO from movements in key assumptions. The DBO was recalculated using a change in the assumptions of 0.5% which overall is considered a reasonably possible change. Salary growth rate Pension growth rate In \u20ac millions Discount rate (incl. inflation) (incl. inflation) Change in assumption +/- 0.5% +/-0.5% +/- 0.5% Net liability amount 59.5 59.5 59.5 Increase of rate in assumption -1.9 4.6 5.0 Decrease of rate in assumption 6.4 -0.3 2.3 The expected employer contributions to the defined benefit plans for 2022 amount to \u20ac0.2m. The average duration of the DBO of the DB plans is 16 years (France: 17, Sweden: 21 and Other: 12) as of 31 December 2022 (2021: 15 years). ", "dimensions": { "concept": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-147-2": { "value": "2.24. Provisions Reorganisations charges comprise lease termination penalties and employee termination payments. Provisions for other charges are mainly related to litigations. Reorganisation Other charges Total In \u20ac millions charges 2022 Balance as of 1 January 15.1 29.8 44.9 Business combinations -0.2 9.3 9.1 Additional provisions 5.1 17.1 22.3 Used during year -7.6 -9.0 -16.6 Unused amounts reversed -1.6 -4.3 -5.8 Translation differences and other -2.4 2.1 -0.2 Balance as of 31 December 8.6 45.2 53.7 Current 7.7 26.8 34.5 Non-current 0.8 18.4 19.2 2021 Balance as of 1 January 24.3 20.3 44.6 Business combinations - 1.1 1.1 Additional provisions 7.9 16.4 24.2 Used during year -11.7 -5.9 -17.6 Unused amounts reversed -6.1 -3.9 -10.0 Translation differences and other 0.7 1.9 2.6 Balance as of 31 December 15.1 29.8 44.9 Current 14.8 14.5 29.2 Non-current 0.3 15.4 15.7 In 2022, the additional provisions mainly relate to litigations in US and The Netherlands. The reversal of provisions is mainly related to the end of some restructuring processes in The Netherlands. The additional provisions and unused amounts reversed are included in the separately disclosed items (Note 2.5). The periods in which the provision for other liabilities and charges could be paid are broken down as follows: In \u20ac millions 2022 2021 Up to one year 34.5 29.2 1 to 5 years 12.7 8.5 Over 5 years 6.5 7.2 Total 53.7 44.9 ", "dimensions": { "concept": "ifrs-full:DisclosureOfProvisionsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-148-2": { "value": "2.25. Change in net working capital The change in net working capital as disclosed in the cash flow statement is as follows: In \u20ac millions Note 2022 2021 Change in: Trade receivables 2.15 -1.5 -103.3 Contract assets 2.2 49.0 -92.4 Inventories 2.14 8.6 2.8 1Prepaid expenses and other current assets2.16 -15.4 5.9 Trade accounts payable 2.21 20.1 85.6 Contract liabilities 2.2 21.1 26.3 Other current liabilities 2.21 -36.3 55.6 Total changes (Balance Sheet) 45.6 -19.6 Business combinations \u2013 current assets 30.9 42.0 Tax credit accruals receivable transfer -7.5 -6.3 Business combinations \u2013 current liabilities -24.0 -38.6 Capex trade payables -12.6 -13.1 Translation differences and other -1.2 17.2 Change in net working capital (Cash Flow Statement) 31.2 -18.5 1 Prepaid expenses and other current assets, excluding accrued interest receivables. Tax credit accruals receivable transfer is related to the transfer of corporate tax receivables in France once the tax statements are filed in the following year (Tax Credit for Research). Other current liabilities correspond to tax and social security payables and accruals and other payables. ", "dimensions": { "concept": "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-149-2": { "value": "2.26. Business combinations and outsourcing Acquisitions During 2022, the Group completed 59 acquisitions of which 9 were asset deals. These companies/activities have been fully consolidated from the date the Group took control of these entities. The percentage of ownership of the following acquisitions is provided in Note 3.2. As the Group carries out multiple acquisitions every year, in accordance with paragraph B67 of IFRS 3, the Group is only disclosing individual acquisitions above an acquisition price threshold of \u20ac35 million. In March 2022, Eurofins acquired INPAC Medizintechnik (Inpac) of Birkenfeld, Germany, a cleaning, packaging, and sterilization services firm for the medical device, biotech and pharma industries. At the end of July 2022, Eurofins completed the acquisition of Wessling Hungary, one of the leading environmental, food and biopharma product testing laboratories in Hungary located in Budapest. In October 2022, Eurofins completed the acquisition of Bio Sant\u00e9, one of the leading clinical diagnostic laboratories in Martinique (France). The businesses acquired contributed to Eurofins\u2019 consolidated revenues for \u20ac150m and to consolidated Net profit for \u20ac1m in 2022. The contribution to Adjusted EBITDA for the same period amounted to \u20ac31m. If the effective dates of these acquisitions would have been 1 January 2022, Group consolidated revenues would have been increased by an additional ca. \u20ac120m and consolidated Net Profit by an additional ca. \u20ac10m. The Adjusted EBITDA would also have been increased by an additional \u20ac25m. Part consolidated in 2022 Of which Total acquisitions Wessling In \u20ac millions Inpac Bio Sant\u00e9 Hungary Revenues 149.6 16.2 7.7 4.8 Adjusted EBITDA 30.6 2.6 1.6 - Net Profit 0.8 0.2 0.6 -0.6 FTE 1,407 164 118 41 Part non-consolidated in 2022 Of which Total acquisitions Wessling In \u20ac millions Inpac Bio Sant\u00e9 Hungary Revenues 119.6 2.5 8.6 17.8 Adjusted EBITDA 25.5 0.4 1.2 3.8 Net Profit 9.9 0.1 0.5 2.1 The aggregate fair value of assets and liabilities and the non-controlling interests acquired is per below. For some acquisitions, due to timing constraints, the allocation of the aggregate purchase consideration is provisional as of 31 December 2022. 2022 2021 Of which Wessling Bio Fair In \u20ac millions Fair value Inpac Hungary Sant\u00e9 value Purchase price, cash consideration 465.2 44.9 40.9 63.8 536.8 Purchase price, contingent consideration 82.4 - 1.0 9.6 44.6 Net purchase consideration 547.6 44.9 41.9 73.4 581.5 Property, plant and equipment 110.8 6.5 18.0 7.3 91.5 Intangible assets 92.5 9.9 1.0 1.5 108.2 Other non-current assets 4.5 - 0.2 0.5 2.9 Trade accounts receivable 36.3 1.5 2.8 1.8 31.8 Other current assets 10.6 3.4 0.4 0.4 11.6 Cash and cash equivalents 69.1 1.9 2.0 4.2 34.1 Borrowings -56.5 -1.0 -3.4 -11.7 -67.1 Other current liabilities -49.2 -1.1 -2.7 -1.7 -43.6 Other non-current liabilities -32.4 -3.1 -1.0 -1.2 -17.4 Identifiable net assets acquired 185.7 18.0 17.3 1.0 152.0 Goodwill 361.8 26.9 24.7 72.4 429.5 Net purchase consideration 547.6 44.9 41.9 73.4 581.5 Reconciliation to Cash Flow Statement: Cash and cash equivalents -69.1 -1.9 -2.0 -4.2 -34.1 Purchase price, contingent consideration of the period - unpaid -82.4 - -1.0 -9.6 -44.6 Purchase price, contingent consideration - paid 34.5 - - - 27.5 Non-controlling interests -0.6 - - - 0.3 Net cash outflow on acquisitions 430.0 43.0 38.9 59.6 530.6 The net cash outflow on acquisitions concerns both acquisitions completed in 2022 and in previous years (in case of payment of deferred considerations). During 2022 the Group paid amounts due to former shareholders of previously acquired companies for \u20ac34.5m. In 2022, the Group acquired significant owned buildings as part of new acquisitions for an amount of \u20ac30m (\u20ac31m in 2021), included in property, plant and equipment, and located in various locations across Hungary (Budapest), Spain (Murcia), Germany (Birkenfeld), the United States (Altamonte Springs, FA and Little Rock, AR). The Group acquired also right-of-use assets of operating leases for an amount of \u20ac24.6m in 2022. The goodwill is attributable to the workforce of the acquired business and the synergies expected to arise after acquisition. The part of goodwill and other intangible assets related to acquisitions completed in 2022 that is tax deductible represents an amount of \u20ac58m. For all companies acquired in 2022, the fair value of net assets acquired was as follows: In \u20ac millions 2022 Book value prior to Fair value on Fair value adjustment acquisition acquisition Property plant and equipment 102.7 8.1 110.8 Intangible assets 2.9 89.6 92.5 Other non-current assets 4.1 0.4 4.5 Trade accounts receivable36.8 -0.5 36.3 Other current assets 10.4 0.2 10.6 Cash and cash equivalents 69.1 - 69.1 Borrowings -56.4 -0.1 -56.5 Other current liabilities -50.0 0.8 -49.2 Other non-current liabilities -33.7 1.3 -32.4 Identifiable net assets acquired 85.9 99.8 185.7 The intangible assets include amounts recognised for the fair value of acquired brands, technology and customer-based assets (see main amounts in previous table for Inpac, Wessling Hungary and Bio Sant\u00e9). Outsourcing Eurofins signed in May 2022 an outsourcing agreement with Stichting PAMM Laboratoria voor Pathologie en Medische Microbiologie (\u201cPAMM\u201d), a medical microbiology and pathology laboratory diagnostics company in The Netherlands. PAMM employs over 265 employees and pathologists. ", "dimensions": { "concept": "ifrs-full:DisclosureOfBusinessCombinationsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-155-2": { "value": "Divestment In December 2022, the Group divested its Digital Testing business to Stirling Square Capital Partners (\u201cStirling Square\u201d), present in Europe, North America and ROW. This business represented approximately 1 percent of the Group\u2019s sales and employed over 600 staff. In addition, during 2022, the Group divested or discontinued some small unprofitable businesses mainly in the United States, France and New Zealand (annual revenues including Digital Testing of \u20ac94m in 2021). If the effective dates of these divestments would have been 1 January 2022, Group consolidated revenues would have been decreased by an amount ca. \u20ac75m (of which \u20ac66m related to Digital Testing) and adjusted EBITDA would also have been decreased by ca. \u20ac5m (of which \u20ac10m related to Digital Testing). Consolidated Net Profit would have increased by ca. \u20ac4m (considering only Digital Testing, Consolidated Net Profit would have decreased by ca. \u20ac2m). 2022 Of which In \u20ac millions Total Digital Testing Selling price, cash consideration -220.2 -211.6 Selling price, contingent consideration 0.1 0.1 Net sale consideration -220.1 -211.6 Property, plant and equipment -2.0 -1.8 Intangible assets -10.8 -10.8 Goodwill -56.3 -49.2 Other non-current assets -0.9 -0.9 Trade accounts receivable -14.3 -14.3 Other current assets -1.5 -1.4 Cash and cash equivalents -4.9 -4.3 Other current liabilities 10.7 10.7 Other non-current liabilities 1.2 1.1 Identifiable net assets divested -78.7 -70.9 Gain on disposal of subsidiaries -141.4 -140.6 Proceeds from subsidiaries -220.1 -211.6 Net cash divested 4.9 4.3 Net cash received -215.3 -207.3 3.4. Discontinued operations The companies below have been liquidated or sold during the year: % of ISO interest Date Company Subsidiary of: Code by the of exit Group Eurofins GSC Finance NV Eurofins Scientific SE BE 100.00% 12/22 Eurofins Digital Testing Belgium NV Eurofins Digital Testing International LUX Holding S.\u00e0 BE 100.00% 12/22 r.l Eurofins Digital Testing Shenzhen Co., Ltd. Eurofins Digital Testing International LUX Holding S.\u00e0 CN 100.00% 12/22 r.l BELM Pet\u0151fi utca 45 Real Estate Kft. Eurofins Real Estate LUX Holding S.\u00e0 r.l. HU 100.00% 03/22 Sandyford Clinical Diagnostics Limited Eurofins Biomnis Ireland Limited IE 100.00% 11/22 Eurofins Digital Testing India Private Limited Eurofins Digital Testing International LUX Holding S.\u00e0 IN 100.00% 11/22 r.l Eurofins SAM Sensory And Marketing Italy Srl Eurofins Food & Feed Testing Italia Holding Srl IT 100.00% 03/22 Eurofins Digital Testing International LUX Holding S.\u00e0 Eurofins Product Testing LUX Holding S.\u00e0 r.l. LU 100.00% 12/22 r.l Commissum Sdn Bhd Eurofins Product Testing LUX Holding S.\u00e0 r.l. MY 100.00% 12/22 Heerenveen Leeuwarderstraatweg Real Estate BV Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 01/22 Eurofins Digital Testing and Cyber Security Netherlands Eurofins Digital Testing International LUX Holding S.\u00e0 NL 100.00% 12/22 BV r.l % of ISO interest Date Company Subsidiary of: Code by the of exit Group Eurofins Cyber Security Netherlands Holding B.V. Eurofins Product Testing LUX Holding S.\u00e0 r.l. NL 100.00% 12/22 Eurofins Digital Testing Sweden AB Eurofins Product Testing LUX Holding S.\u00e0 r.l. SE 100.00% 12/22 Eurofins Pharma Discovery Services UK Limited Eurofins Discovery Services LUX Holding S.\u00e0 r.l. UK 100.00% 03/22 Chemtest Holdings Limited Eurofins Environment Testing UK Holding Limited UK 100.00% 08/22 Southern Real Estate Investment UK Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. UK 100.00% 08/22 Eurofins Covid Testing Services Limited Eurofins Forensics LUX Holding S.\u00e0 r.l. UK 100.00% 12/22 Eurofins Digital Product Testing UK Limited Eurofins Digital Testing International LUX Holding S.\u00e0 UK 100.00% 12/22 r.l Edge Testing Solutions Limited Eurofins Digital Testing UK Holding Limited UK 100.00% 12/22 Eurofins Digital Testing UK Holding Limited Eurofins Digital Testing International LUX Holding S.\u00e0 UK 100.00% 12/22 r.l Commissum Associates Limited Eurofins Digital Testing UK Holding Limited UK 85.00% 12/22 Eurofins Digital Media Services, LLC Eurofins Product Testing US Holdings, Inc. US 100.00% 12/22 ", "dimensions": { "concept": "ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-158-3": { "value": "2.27. Shareholders\u2019 equity and potentially dilutive instruments Share capital and other reserves As of 31 December 2022, the Company\u2019s share capital is composed of 192,739,583 shares of \u20ac0.01 each (versus 192,251,906 shares as of 31 December 2021 of \u20ac0.01 each). The allotted, called-up and fully paid capital amounts to \u20ac1.9m. During 2022, share capital and other reserves increased by \u20ac14.6m through: \u25aa 387,207 new shares issued from the exercise of stock options, \u25aa 47,600 new shares issued from the exercise of Eurofins 2014 BSA Leaders warrants, \u25aa 51,420 new shares issued from the exercise of Eurofins 2018 BSA Leaders warrants, \u25aa 1,450 new shares issued from restricted stock units. ", "dimensions": { "concept": "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-159-3": { "value": "Other reserves correspond to the legal reserve and share premium. Retained earnings correspond to the accumulated reserves not distributed. Currency translation differences Exchange differences arising on translation of the foreign controlled entity are recognised in other comprehensive income, and accumulated in a separate reserve within equity. As of 31 December 2022, the Company had a Currency translation reserve for an amount of \u20ac285.7m, varying from \u20ac179.1m through Other comprehensive income / loss, mainly impacted by the variation of USD, GBP, INR and JPY compared to the Euro. Treasury shares Plan 1 \u00ab Liquidity \u00bb contract On 1 November 2021, the Company entered into an agreement with Kepler Cheuvreux in order to enhance the liquidity of its shares. This agreement was valid up until 31 December 2022 and is renewable for one-year periods thereafter. An amount of cash of \u20ac15m has been allocated to a liquidity account by the Company to fund this program. As of 31 December 2022, the Company held 135,677 of its own shares under this liquidity contract (0.07% of the total number of shares at that date) representing an amount of \u20ac9.0m (38,100 shares for an amount of \u20ac3.6m as of 31 December 2021). Plan 2 Share Repurchase Plan The Share Repurchase Plan allows the acquisition of a maximum amount representing up to 2% of the Company\u2019s share capital, over a maximum period of twelve months as per the authorisation granted by the Company\u2019s Extraordinary General Meeting of shareholders held on 25 April 2019 (the \u201cEGM\u201d). The Company may at any time interrupt this program in view of market conditions and/or evolution of its investment strategy. The shares to be purchased under this program will be primarily used to hedge the Company\u2019s Long-Term Incentive plans but may also be cancelled, used to partially finance acquisitions or for other purposes approved by the Board of Directors and within the authorization of the EGM. On 3 October 2022, the Company mandated an independent provider of financial services to buy-back some of its own shares. The first tranche was completed on 3 December 2022. Between 3 October and 3 December, 121,493 shares were repurchased at an average price of 61.31 EUR, representing 0.06% of the current share capital. It is currently intended that all purchased shares may be used as previously communicated, including to cover the Company\u2019s Long-Term Incentive plans as approved by the Board of Directors at its meeting on 19 December 2022. The second tranche will cover a maximum volume of up to one million shares or 0.52% of the Company\u2019s current share capital. The purchase period will start on 22 December 2022 and will last until 3 May 2023 at the latest. Under this plan, as of 31 December 2022, the Company held 83,883 of its own shares (0.04% of the total number of shares) representing an amount of \u20ac5.2m. ", "dimensions": { "concept": "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "s7_notes__6__7-1": { "value": "Dividends paid In April 2022, the General Assembly approved the dividends to shareholders of \u20ac1 per ordinary share for a total gross amount of \u20ac192.25m (of which \u20ac0.13m on own shares). In previous year, the dividends to shareholders were \u20ac0.68 per ordinary share for a total amount of \u20ac129.7m. Dividends proposal The Board of Directors intends to propose, at the upcoming Annual General Meeting (AGM) on 27 April 2023, dividends to shareholders of \u20ac1 per ordinary share for a total gross amount of \u20ac192.7m.2.27. Shareholders\u2019 equity and potentially dilutive instruments Share capital and other reserves As of 31 December 2022, the Company\u2019s share capital is composed of 192,739,583 shares of \u20ac0.01 each (versus 192,251,906 shares as of 31 December 2021 of \u20ac0.01 each). The allotted, called-up and fully paid capital amounts to \u20ac1.9m. During 2022, share capital and other reserves increased by \u20ac14.6m through: \u25aa 387,207 new shares issued from the exercise of stock options, \u25aa 47,600 new shares issued from the exercise of Eurofins 2014 BSA Leaders warrants, \u25aa 51,420 new shares issued from the exercise of Eurofins 2018 BSA Leaders warrants, \u25aa 1,450 new shares issued from restricted stock units. Other reserves correspond to the legal reserve and share premium. Retained earnings correspond to the accumulated reserves not distributed. Currency translation differences Exchange differences arising on translation of the foreign controlled entity are recognised in other comprehensive income, and accumulated in a separate reserve within equity. As of 31 December 2022, the Company had a Currency translation reserve for an amount of \u20ac285.7m, varying from \u20ac179.1m through Other comprehensive income / loss, mainly impacted by the variation of USD, GBP, INR and JPY compared to the Euro. Stock option plans Stock options are granted to certain directors, managers and employees of the Company and its subsidiaries. Movements in the number of stock options outstanding are as follows: 2022 2021 Number of Weighted Number of Weighted Stock options stock options average stock options average outstanding exercise price outstanding exercise price 1 January 7,005,744 50 8,093,000 42 Granted1,264,902 63 605,700 113 Exercised -387,207 28 -1,047,506 25 Expired or lost -675,046 62 -645,450 49 Outstanding as of 31 December 7,208,393 52 7,005,744 50 Exercisable as of 31 December 1,794,067 39 1,671,149 33 The weighted average share price based on Eurofins share price at the date of exercise was \u20ac75 for the 387,207 options exercised in 2022 and was \u20ac100 for the 1,047,506 options exercised in 2021. As at 31 December 2022, 7,208,393 stock options awarded are still outstanding. Further details can be found in the \u201cEurofins Group Remuneration Report 2022\u201d. The exercise price of the granted stock options is generally at least equal to the 20-day volume weighted average market price of Eurofins shares traded on Euronext Paris stock exchange prior to the plan award date including a hurdle of 2%. Options/ Restricted stock units are conditional on the employee completing the vesting period (4 to 5 years). Subject to continued employment and other conditions such as performance conditions for some beneficiaries (\u2018Senior Executives\u2019), vested options can be exercised and have a contractual option term of ten years. The fair value of options granted during the period is determined using the Black-Scholes or Bermudan valuation model from 2019 onwards including a behaviour factor for the expected exercise period. An annual risk-free interest rate of 3.2% is used for the 2022 plans. The volatility measured is based on the statistical analysis of daily share prices over the last three years. Volatility used for 2022 plans was 34%. Number of Weighted average fair stock options Vesting period Average exercise price value of options Plan initially granted (Years) (\u20ac) (\u20ac) 10/10/2011 1,583,500 4/5 5.78 2.4/2.6 02/03/2012 462,500 4/5 6.56 2.5/2.7 19/12/2012 1,914,750 4/5 12.01 4.1/4.5 01/10/2013 1,390,650 4/5 18.23 6.1/6.7 23/10/2014 1,209,500 4/5 18.83 6.1/6.7 07/04/2015 600,000 4/5 25.19 8.0/8.8 22/10/2015 352,500 4/5 28.28 8.9/9.9 21/01/2016 939,200 4/5 28.63 9.1/10.1 01/08/2016 1,227,400 4/5 33.69 10.9/12.0 04/04/2017 413,900 4/5 40.49 10.5/11.6 13/12/2017 1,696,950 4/5 50.87 13.2/14.6 08/01/2019 2,175,880 4/5 32.50 10.3/10.6 18/07/2019 20,000 4/5 38.58 9.0/9.3 24/10/2019 1,629,250 4/5 44.68 11.2/11.6 16/12/2020 1,493,150 4/5 67.50 23.8/24.7 20/10/2021 605,700 4/5 112.59 32.8/34.8 17/10/2022 1,264,902 4/5 62.78 19.8/21.8 Restricted stock units Restricted stock units are granted to eligible managers and employees. Vesting period Fair value of Number of restricted (Years) restricted Plan stock units stock units initially granted (\u20ac) 29/07/2016 4/5 59,850 33.55 01/08/2016 4/5 44,960 33.69 04/04/2017 4/5 9,400 40.49 13/12/2017 4/5 134,000 50.87 08/01/2019 4/5 149,280 35.12 24/10/2019 4/5 88,880 43.56 26/06/2020 4/5 20,200 55.20 16/12/2020 4/5 83,800 68.42 24/02/2021 4/5 91,000 74.99 20/10/2021 4/5 28,350 111.98 20/10/2021 2/3/4/5 22,500 111.98 17/10/2022 4/5 95,424 64.12 Movements in the number of restricted stock units outstanding are as follows: Restricted stock units 2022 2021 1 January 446,700 436,580 Granted 95,424 141,850 Vested -39,060 -83,610 Expired or lost -60,351 -48,120 Outstanding as of 31 December 442,713 446,700 On the 39,060 vested restricted stock units, 1,450 new shares have been issued and 37,610 were served from own treasury shares (share repurchase plan). Further details can be found in the \u201cEurofins Group Remuneration Report 2022\u201d. 2014 BSA Leaders Warrants In July 2014, the Company issued 117,820 capital-providing securities in the form of stock purchase warrants. Following the ten-for-one stock split completed in November 2020, the 2014 BSA Leaders warrants gave their holders the right to subscribe for ten shares of the Company for each 2014 BSA Leaders Warrant at a fixed exercise price of \u20ac281.58 between 1 July 2018 and 30 June 2022. The subscription price was set at \u20ac18.15 per warrant. Movements in the number of 2014 BSA Leaders Warrants were as follows: 2014 BSA Leaders Warrants 2022 2021 1 January 4,760 37,449 Exercised -4,760 -32,689 Expired or lost - - Outstanding as of 31 December - 4,760 Exercisable as of 31 December - 4,760 2018 BSA Leaders warrants In June 2018, Eurofins issued 124,460 capital-providing securities in the form of stock purchase warrants. Following the ten-for-one stock split completed in November 2020, the 2018 BSA Leaders warrants give their holders the right to subscribe for ten shares of the Company for each 2018 BSA Leaders Warrant at a fixed exercise price of \u20ac529.65 between 1 June 2022 and 31 May 2026. The subscription price was set at \u20ac34.36 per warrant. Movements in the number of 2018 BSA Leaders Warrants outstanding were as follows: 2018 BSA Leaders Warrants 2022 2021 1 January 107,419 109,419 Exercised -5,142 - Expired or lost -200 -2,000 Outstanding as of 31 December 102,077 107,419 Exercisable as of 31 December 102,077 - Beneficiary units Beneficiary units are allocated under certain conditions to holders of fully paid-up shares as provided in the Company\u2019s articles of association, at a price of \u20ac0.01 per unit. Upon subscription, beneficiary units from each category of Class A, Class B and Class C confer their holders with one voting right per unit but no rights to dividends. Class A beneficiary units Class A beneficiary units, which confer no right to dividends but a right to one vote each, can be allocated to holders of fully paid-up shares for which (i) proof is provided of registration in the name of the same shareholder for at least three consecutive years as provided for in article 12bis.2 of the Company\u2019s Articles of Association (ii) request to subscribe class A beneficiary units was sent in writing by the relevant shareholder to the Company at the latest by 30 June 2020 and (iii) subject to the Company receiving payment of a subscription price of \u20ac0.01 per class A beneficiary unit. Therefore, the subscription period of class A beneficiary units has now expired. Class B beneficiary units Class B beneficiary units, which confer no right to dividends but a right to one vote each, are allocated to holders of fully paid-up shares for which (i) proof is provided of registration in the name of the same shareholder for at least five consecutive years as provided for in article 12bis.3 of the Company\u2019s Articles of Association (ii) request to subscribe class B beneficiary units was sent in writing by the relevant shareholder to the Company at the latest by 30 June 2021 and (iii) subject to the Company receiving payment of a subscription price of \u20ac0.01 per class B beneficiary unit. Therefore, the subscription period of class B beneficiary units has now expired. Class C beneficiary units Class C beneficiary units, which confer no right to dividends but a right to one vote each, are allocated to holders of fully paid-up shares for which (i) proof is provided of registration in the name of the same shareholder for at least two consecutive years as provided for in article 12bis.4 of the Company\u2019s Articles of Association (ii) request to subscribe class C beneficiary units is sent in writing by the relevant shareholder to the Company at the latest by 30 June 2023 and (iii) subject to the Company receiving payment of a subscription price of \u20ac0.01 per class C beneficiary unit. The Company\u2019s main shareholder Analytical Bioventures S.C.A. paid in 2021 a cash contribution of \u20ac766k equivalent to \u20ac0.01 per Class B & C beneficiary unit (Note 2.37) (2022: 0). Movements in the number of beneficiary units issued were as follows: 2022 Beneficiary units Class A Class B Class C Total 1 January 2022 63,977,852 63,000,000 63,000,000 189,977,852 Beneficiary units subscribed - - - - Beneficiary units cancelled -177.354 - - -177,354 31 December 2022 63,800,498 63,000,000 63,000,000 189,800,498 2021 Beneficiary units Class A Class B Class C Total 1 January 2021 64,577,670 50,000,000 - 114,577,670 Beneficiary units subscribed - 13,550,000 63,000,000 76,550,000 Beneficiary units cancelled -599,818 -550,000 - -1,149,818 31 December 2021 63,977,852 63,000,000 63,000,000 189,977,852 Voting rights Voting rights attached to shares are proportional to the capital quota they represent ie. each share gives the right to one vote. In addition, class A, class B and class C beneficiary units (\u201cparts b\u00e9n\u00e9ficiaires de cat\u00e9gorie A, B et C\u201d) carrying an extra voting right each, can be allocated to fully paid-up shares fulfilling conditions as specified in previous paragraphs about class A, class B and class C beneficiary units. As at 31 December 2022, a total amount of 189,800,498 class A, class B and class C beneficiary units has been issued and the total number of voting rights amounts to 382,320,521. Partial and optional acquisition price payments in Eurofins shares As at 31 December 2022 and 2021, the overall number of Eurofins shares potentially deliverable was nil. Treasury shares Plan 1 \u00ab Liquidity \u00bb contract On 1 November 2021, the Company entered into an agreement with Kepler Cheuvreux in order to enhance the liquidity of its shares. This agreement was valid up until 31 December 2022 and is renewable for one-year periods thereafter. An amount of cash of \u20ac15m has been allocated to a liquidity account by the Company to fund this program. As of 31 December 2022, the Company held 135,677 of its own shares under this liquidity contract (0.07% of the total number of shares at that date) representing an amount of \u20ac9.0m (38,100 shares for an amount of \u20ac3.6m as of 31 December 2021). Plan 2 Share Repurchase Plan The Share Repurchase Plan allows the acquisition of a maximum amount representing up to 2% of the Company\u2019s share capital, over a maximum period of twelve months as per the authorisation granted by the Company\u2019s Extraordinary General Meeting of shareholders held on 25 April 2019 (the \u201cEGM\u201d). The Company may at any time interrupt this program in view of market conditions and/or evolution of its investment strategy. The shares to be purchased under this program will be primarily used to hedge the Company\u2019s Long-Term Incentive plans but may also be cancelled, used to partially finance acquisitions or for other purposes approved by the Board of Directors and within the authorization of the EGM. On 3 October 2022, the Company mandated an independent provider of financial services to buy-back some of its own shares. The first tranche was completed on 3 December 2022. Between 3 October and 3 December, 121,493 shares were repurchased at an average price of 61.31 EUR, representing 0.06% of the current share capital. It is currently intended that all purchased shares may be used as previously communicated, including to cover the Company\u2019s Long-Term Incentive plans as approved by the Board of Directors at its meeting on 19 December 2022. The second tranche will cover a maximum volume of up to one million shares or 0.52% of the Company\u2019s current share capital. The purchase period will start on 22 December 2022 and will last until 3 May 2023 at the latest. Under this plan, as of 31 December 2022, the Company held 83,883 of its own shares (0.04% of the total number of shares) representing an amount of \u20ac5.2m. ", "dimensions": { "concept": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "s7_notes__6__6": { "value": "Dividends paid In April 2022, the General Assembly approved the dividends to shareholders of \u20ac1 per ordinary share for a total gross amount of \u20ac192.25m (of which \u20ac0.13m on own shares). In previous year, the dividends to shareholders were \u20ac0.68 per ordinary share for a total amount of \u20ac129.7m. Dividends proposal The Board of Directors intends to propose, at the upcoming Annual General Meeting (AGM) on 27 April 2023, dividends to shareholders of \u20ac1 per ordinary share for a total gross amount of \u20ac192.7m.", "dimensions": { "concept": "ifrs-full:DisclosureOfDividendsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "s7_notes__6__5-1": { "value": "Dividends paid In April 2022, the General Assembly approved the dividends to shareholders of \u20ac1 per ordinary share for a total gross amount of \u20ac192.25m (of which \u20ac0.13m on own shares). In previous year, the dividends to shareholders were \u20ac0.68 per ordinary share for a total amount of \u20ac129.7m. Dividends proposal The Board of Directors intends to propose, at the upcoming Annual General Meeting (AGM) on 27 April 2023, dividends to shareholders of \u20ac1 per ordinary share for a total gross amount of \u20ac192.7m.1. Significant accounting policiesThe significant accounting policies applied in the preparation of these Consolidated Financial Statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. 1.1. Basis of preparation Compliance with IFRS Pursuant to the European Regulation No. 1606/2002 of 19 July 2002, the Consolidated Financial Statements have been prepared in accordance with the International Financial Reporting Standards (hereinafter also IFRS) as issued by the International Accounting Standards Board (IASB) and endorsed in the European Union. These accounting policies have been consistently applied to all the years presented, unless otherwise stated. The Consolidated Financial Statements are presented in Euros, which is the presentation currency. Due to rounding, amounts may not add up precisely to the totals provided. Historical cost convention The Consolidated Financial Statements have been prepared under the historical cost convention, except for the following: \u25aa certain financial assets and liabilities (including derivative financial instruments), reference is made to Note 2.34;\u25aa defined benefit pensions plans \u2013 plan assets measured at fair value.Going concern The Directors have, at the time of approving the financial statements, a reasonable expectation that the Group have adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the financial statements. Change in presentation The Group has changed the breakdown presentation in the 2022 Consolidated Cash Flow Statement of some items to improve the readability of the cash flow statement. As a consequence, the comparative period has been restated without material impacts. In 2021, acquisition of the subsidiaries were presented net of cash acquired and net of proceeds from disposal in the Consolidated Cash Flow Statement. Due to the significant impact of the disposal of Digital Testing in 2022, the presentation of \u201cAcquisition of subsidiaries, net\u201d and \u201cProceeds from disposals of subsidiaries, net\u201d has been separated. In 2021, items \u201cPurchase of property, plant and equipment\u201d and \u201cchange in net working capital\u201d have been corrected for the capex trade payables change of the period for an amount of \u20ac13.1m. Non-cash net foreign exchange loss have also been corrected for \u20ac14.8m in the items \u201cNet effect of currency translation on cash and cash equivalents and bank overdrafts\u201d and in \u201cFinancial income and expense, net\u201d. 1.2. Significant accounting judgements and estimates The preparation of the Consolidated Financial Statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies, the reported amounts of assets, liabilities, revenues and expenses and the accompanying disclosures, and the disclosure of contingent liabilities. These estimates inherently contain a degree of uncertainty. Actual results may differ from these estimates under different assumptions or conditions. The Group evaluates these accounting judgements and estimates on an ongoing basis and bases the estimates on historical experience, current and expected future outcomes, third-party valuation and various other assumptions that the Group believes are These Consolidated Financial Statements have been authorised for issuance by the Board of Directors on 24 February 2023 and will be submitted to the Shareholders\u2019 Annual General Meeting for approval. Luxembourg.Analytical Bioventures S.C.A.,Luxembourg,LuxembourgWith over 61,000 staff across a decentralised and entrepreneurial network of ca. 900 laboratories in 61 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products. (The \u201cCompany\u201d) is legally and commercially registered in the Grand Duchy ofunder the number B 167 775. Grand Duchy ofThe Group is included as a subsidiary in the consolidated financial statements of located at 23 Val Fleuri, L-1526The Company\u2019s shares are traded on Euronext Paris stock exchange under the ISIN code FR0014000MR3 (ticker ERF) and theCompany has joined the CAC 40 index on 17 September 2021.1.3. Basis of Consolidation The Consolidated Financial Statements comprise the financial statements of Eurofins Scientific SE and all the subsidiaries that the Group controls, i.e., when it is exposed or has rights to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Generally, there is a presumption that a majority of voting rights result in control. To support this presumption and in cases where the Group has less than a majority the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including the contractual arrangement(s) with the other vote holders of the investee, rights arising from other contractual arrangements and the Group\u2019s voting rights and potential voting rights. Subsidiaries Subsidiaries are fully consolidated from the date that control commences until the date that control ceases. They are no longer consolidated from the date such control ceases. All intercompany transactions and balances have been eliminated in the Consolidated Financial Statements. Unrealised losses are eliminated in the same way as unrealised gains, but only to the extent that there is no evidence of impairment. Associates Associates are all entities over which the Group has significant influence but no control. Significant influence is presumed with a shareholding of between 20% and 50% of the voting rights or when the Group has board representation through which it is able to exercise significant influence. Investments in associates are accounted for using the equity method and are initially recognised at cost.The carrying amount of an investment includes the carrying amount of goodwill identified on acquisition.Loss of control Upon loss of control, the Group derecognises the assets and liabilities of the subsidiary, any non-controlling interests and other components of equity (if any) related to the subsidiary. Any surplus or deficit arising from the loss of control is recognised in the Consolidated Income Statement. If the Group retains any interest in the previous subsidiary, such interest is measured at fair value at the date the control is lost. Subsequently it is accounted for as either an equity accounted investee or as a financial asset depending on the level of influence retained. Business combinations and goodwill Business combinations are accounted for using the acquisition method. Under the acquisition method, the identifiable assets acquired, liabilities assumed and any non-controlling interests in the acquiree are recognised at the acquisition date, which is the date on which control is transferred to the Group. The Group measures goodwill at the acquisition date as being the excess of: \u25aa Aggregate of the fair value of the consideration transferred and any recognised amount for non-controlling interests and anyprevious interest held;\u25aa over the net identifiable assets acquired and liabilities assumed.If the cost of acquisition is less than the fair value of the net assets of the subsidiary acquired, the difference is recognised directlyin the Consolidated Income Statement (bargain purchase or negative goodwill).reasonable under the circumstances. Existing circumstances and assumptions about future developments may change due to circumstances beyond the Group\u2019s control and are reflected in the assumptions if and when they occur. The Group revises material estimates if changes occur in the circumstances or if there is new information or experience on which an estimate was or can be based. The areas where the most significant judgements and estimates are made are: Judgements \u25aa Revenue recognition and determination of advancement for over time performance obligations;\u25aa Determination of control as part of business combination;\u25aa Determination of the lease term and more specifically the assessment whether a lease option to extend or cancel a leasein which the Group is a lessee is reasonably certain to be exercised or not;\u25aa Likelihood of occurrence of provisions, uncertain tax positions and contingent liabilities.Estimates \u25aa Assessment of the recoverable amount of goodwill and intangible assets;\u25aa Measurement of the recoverability of deferred tax assets;\u25aa Determination of amounts due from business acquisitions based on future cash flows;\u25aa Determination of fair values of acquired identifiable intangible assets as part of a business combination.For further discussion of these significant judgements and estimates, reference is made to the respective accounting policies and Notes within these Consolidated Financial Statements that relate to the above topics. Further judgement is applied when analysing impairments of goodwill and intangible assets that are performed annually and whenever a triggering event has occurred to determine whether the carrying value exceeds the recoverable amount. These analyses are generally based on estimates of discounted future cash flows. Furthermore, the Group applies judgement when actuarial assumptions are established to anticipate future events that are used in calculating post-employment benefit expenses and liabilities. These factors include assumptions with respect to interest rates, rates of increase in healthcare costs, rates of future compensation increases, turnover rates and life expectancy. If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, the acquirer reports in its financial statements provisional amounts for the items for which the accounting is incomplete and may adjust the provisional amounts recognised for a business combination during the measurement period (twelve months from the acquisition date). The Group measure non-controlling interests (NCI) at fair value (\u2018full goodwill method\u2019). Acquisition-related costs are expensed as incurred. Further information about the Group\u2019s main subsidiaries can be found in Note 3. The financial effect of the acquisition and disposal of subsidiaries of the current period is described in Note 2.26. Acquisition of and adjustments to non-controlling interests Transactions with non-controlling interests in controlled entities are treated as transactions with equity owners of the Group. For purchases from non-controlling interests, any difference between the consideration paid and the relevant share acquired is recorded in equity. Gains or losses on disposals to non-controlling interests are also recorded in equity. Amounts due from business acquisitions Amounts due for business acquisitions consist mainly of: \u25aa amounts due to former shareholders of acquired companies at the estimated fair value amount based on the achievement of objectives (in general based on revenue and / or a measure of operating profit); \u25aa the liability resulting from \u201cput and call options\u201d (part related to the transaction with non-controlling interests) at initial acquisition time. Amounts due for business acquisitions are accounted for at fair value of the expected cash flows at the acquisition date. The variation of the liability related to the time value of money is recorded in the Consolidated Income Statement as a finance cost. All re-estimations of the amounts due for business acquisitions of the purchase price are booked in the Consolidated Income Statement as an acquisition-related expense. If all or part of the acquisition price of certain acquired laboratories is paid in the Group\u2019s shares (new or existing shares): \u25aa the amount due is accounted for in \u201cAmounts due for business acquisitions\u201d in the case where the acquisition contract stipulates a fixed monetary amount payable in a variable number of the Group\u2019s shares (number to be calculated at the moment of payment); \u25aa the amount due is accounted for in \u201cretained earnings\u201d in the case where the acquisition contract stipulates a fixed number of the Group\u2019s shares. Amounts due from business acquisitions are estimated as follows: \u25aa In case of cross put and call options exercisable at a fixed price, the Group considers these instruments as being exercised from inception. Indeed, as the price is fixed, the risks and rewards are considered, in substance, to be transferred to the Group. As such, non-controlling interests are not recognised in the Consolidated Balance Sheet and the Consolidated Income Statement. \u25aa In case of cross put and call options at a variable price, the Group considers whether the risks and rewards are transferred to the Group: o Where it is determined that risks and rewards did not transfer to the Group, non-controlling interests are recognised in the Balance Sheet and the Income Statement. o Where it is determined that risks and rewards did transfer to the Group upon entering into the cross put and call options, non-controlling interests are not recognised in the Consolidated Balance Sheet and the Consolidated Income Statement. In addition, a financial liability reflecting the put option element of the transaction is recognised for an amount corresponding to the present value of the redemption amount of the put option. Such financial liability is recognised from the equity attributable to holders of the Group. 1.4. Revenue recognition Revenue recognised over time Revenue from services is recognised over a period of time as the Group transfers control of the services to the customer which is demonstrated by the customer simultaneously receiving and consuming the benefits provided by the Group. The amount of revenue is measured by reference to the progress made towards complete satisfaction of the performance obligation. Sample based service activities (excluding Clinical Diagnostic Testing activities) This activity is a repetitive business, generally with many relatively small transactions with short turnaround times ruled by short term contracts (turnaround time counted in days). These contracts for their vast majority do not include multiple performance obligations. The Group considers the input method to measure the progress for service rendered to its customers. The payment terms and conditions are most often standard, short term and highly predictable.Revenue is recorded based on the stage of completion of the services performed and net of incentives and rebates (if any). Study based activities This activity is mainly relying on medium term contracts. Revenue is recognised based on the stage of completion of the study until the delivery of the final report. Full Time Equivalent (FTE)-based activities This activity relates to Consulting activities and Professional Scientific Services. Revenue is recorded based on the stage of completion of the services performed. Revenue recognised at a point in time Product based activities Revenue from the sale of goods in the normal course of business is recognised at a point in time when the performance obligation is satisfied and it is based on the amount of the transaction price that is allocated to the performance obligation. The transaction price is the amount of the consideration to which the Group expects to be entitled in exchange for transferring the promised goods to the customer. The consideration expected by the Group may be fixed or variable. Revenue for the sale of goods is recognised when control of the asset is transferred to the buyer and only when it is highly probable that a significant reversal of revenue will not occur when uncertainties related to a variable consideration are resolved. Transfer of control varies depending on the individual terms of the contract of sale. Clinical Diagnostic Testing activities The Group recognises revenues at a point in time when the testing process is completed, and test results are reported to the ordering physician. The Group usually bills third-party payers under fee-for-service agreements. Revenue is recorded net of contractual discounts and generally based on contractual agreements. In case of absence of contractual agreement and / or uncertainty over the consideration to be received, a stand-alone selling price is estimated based on a statistical model which factors in historical collection rates based on cluster of payers showing similar aggregation characteristics. This model is regularly updated with the most recent trends and whenever required. Financing components and time value of money The Group does not expect to have any contracts where the period between the transfer of the promised goods or services to the customer and payment by the customer exceeds one year. Consequently, the Group does not adjust any of the transaction prices for the time value of money. 1.5. Intangible assets other than goodwill Acquired Intangible assets Separately acquired finite lived intangible assets are accounted for at cost. Intangible assets acquired as part of a business combination such as brands, customer relationships, technologies and other finite lived intangible assets are recognised at their fair value at the acquisition date. Acquired finite lived intangible assets are amortised using the straight-line method over their estimated useful life. The useful lives are reviewed annually. Development costs The directly attributable costs of producing identifiable and separable intangible assets (such as software development) are recognised as an intangible asset when they are controlled by the Group and it is probable that they will generate future economic benefits in excess of their cost over a period of more than one year. Other development expenditures and expenditures on research activities are recognised in the Consolidated Income Statement. Capitalised development expenditures are stated at cost less accumulated amortisation and impairment losses. Amortisation of capitalised development expenditures is charged to the Consolidated Income Statement on a straight line basis over the estimated useful lives of the intangible assets. 1.6. Impairment Impairment of goodwill and intangible assets Goodwill are not amortised but are tested for impairment annually and whenever impairment indicators require. Internal or external sources of information are considered indicators that an asset or a Cash Generating Unit (CGU) or groups of CGUs may be impaired. An impairment loss is recognised in the Consolidated Income Statement whenever and to the extent that the carrying amount of a cash generating unit exceeds the unit\u2019s recoverable amount. The recoverable amount is the higher of an asset\u2019s fair value less costs to sell and its value in use. Reference is made to Note 2.10 for further details. Intangible assets that are subject to amortisation (e.g., customer relationships, brands) are reviewed for impairment whenever triggering events or changes in circumstances indicate that the carrying value may not be recoverable. Impairment of non-financial assets other than goodwill, intangible assets, inventories, and deferred tax assets Non-financial assets other than goodwill, intangible assets, inventories and deferred tax assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets is assessed by a comparison of the carrying amount of said assets with the greater of their value in use and fair value less costs of disposal. Value in use is measured as the present value of future cash flows expected to be generated by the asset.Fair value less costs of disposal is measured as the amount obtained from a sale of an asset in an arm\u2019s length transaction, less costs of disposal.If the carrying amount of an asset is deemed not recoverable, an impairment charge is recognised in the amount by which the carrying amount of the asset exceeds the recoverable amount. The review for impairment is carried out at the level where cash flows occur that are independent of other cash flows. Impairment losses recognised in prior periods are assessed at each reporting date for any indication that the loss has decreased or no longer exists. An impairment loss is reversed if and to the extent that there has been a change in the estimates used to determine the recoverable amount. The loss is reversed only to the extent that the asset\u2019s carrying amount does not exceed the carrying amount that would have been recognised. Impairment of financial assets The Group recognises an allowance for expected credit losses (ECLs) for trade receivables, debt investments carried at fair value through other comprehensive income (FVTOCI) and amortised costs. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expect to receive. For all trade receivables and contract assets, the Group applies the IFRS 9 simplified approach to measuring ECLs. To measure the ECLs on trade receivables and contract assets, the Group takes into account credit-risk concentration, collective debt risk based on average historical losses as well as days past due. The Group also may factor in specific circumstances such as serious adverse economic conditions in a specific country or region, and other forward-looking information. The Group may also apply individual credit losses on identified trade account receivables or contract assets depending on individual circumstances. Trade receivables and contract assets are written off when there is no reasonable expectation of recovery of the asset, because of failure of a debtor to engage in a repayment plan, associated subsequent payments, bankruptcy or other form of receivership. 1.7. Leases The Group leases various offices, laboratories and cars. The Group determines whether an arrangement constitutes or contains a lease at inception, which is based on the substance of the arrangement. The arrangement constitutes or contains a lease if fulfilment is dependent on the use of a specific asset and the arrangement conveys a right to use the asset, even if that asset is not explicitly specified in the arrangement. Leases are recognised as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the Group. The right-of use asset is depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis. Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments: \u25aa fixed payments (including in-substance fixed payments) less any lease incentives receivable; \u25aa variable lease payments that are based on an index or a rate; \u25aa amounts expected to be payable by the lessee under residual value guarantees; \u25aa the exercise price of a purchase option if the lessee is reasonably certain to exercise that option; \u25aa payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option. The lease payments are discounted using the interest rate implicit of the lease. If that rate cannot be determined, the lessee\u2019s incremental borrowing rate at the lease commencement date is used, which is based on an assessment of interest rates the Group would have to pay to borrow funds in the relevant country, including the consideration of factors such as the nature of the asset and location, collateral, market terms and conditions, as applicable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset. Right-of-use assets are measured at cost comprising the following: \u25aa the amount of the initial measurement of lease liability; \u25aa any lease payments made at or before the commencement date less any lease incentives received; \u25aa any initial direct costs; restoration costs. The right-of-use assets are subsequently accounted for using principles for property, plant and equipment. Payments associated with short-term leases and leases of low-value assets are recognised on a straight-line basis as an expense in the Consolidated Income Statement. Short-term leases are leases with a lease term of 12 months or less. Low-value assets comprise IT-equipment and small items of office furniture considered to be of low value (i.e., less than \u20ac5,000). The Group determines the lease term as the non-cancellable term of the lease, together with any periods covered by an option to extend the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably certain not to be exercised. The Group applies judgement in evaluating whether it is reasonably certain to exercise the option to renew. That is, it considers all relevant factors that create an economic incentive for it to exercise the renewal. 1.8. Property, plant and equipment Property, plant and equipment are reported on the Consolidated Balance Sheet at their acquisition price, net of accumulated depreciation and impairment losses. The costs of property, plant and equipment comprise all directly attributable costs. Costs related to repair and maintenance activities are expensed in the period in which they are incurred unless leading to an extension of the original lifetime or capacity. Leasehold improvements are amortised using the straight-line method over the shorter of the lease term or the estimated useful life of the asset. 1.9. Financial Instruments Non-derivative financial assets Non-derivative financial assets comprise cash and cash equivalents, receivables and other financial assets. Depreciation is generally calculated using the straight-line method over the useful life of the asset. Recognition and initial measurement: Non-derivative financial assets are recognised when the Group becomes a party to the contractual provisions of the instrument. Purchases and sales of non-derivative financial assets in the normal course of business are accounted for at the trade date. Dividendand interest income are recognised when earned. Gains or losses, if any, are recorded in Finance income and Finance costs. Non-derivative financial assets are derecognised when the rights to receive cash flows from the asset have expired or the Group has transferred its rights to receive cash flows from the asset.assets at their fair value plus, in the case of a financial asset not measured at fair value through profit or loss (FVTPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVTPL are expensed in the Consolidated Income Statement. Classification and subsequent measurement: The Group classifies its non-derivative financial assets in the following measurement categories: \u25aa those that are measured subsequently at fair value; \u25aa those that are measured at amortised cost. In assessing the classification, the Group considers the business model for managing the financial assets and the contractual terms of the cash flows. At initial recognition, the Group measures non-derivative financial For assets measured at fair value, gains and losses will be recorded in either the Consolidated Income Statement or in Other Comprehensive Income (OCI). For investments in equity instruments that are not held for trading, classification will depend on whether the Group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through Other Comprehensive Income (FVTOCI). For investments in these equity instruments, the Group does not subsequently reclassify between FVTOCI and FVTPL. For debt investments, assets are reclassified between FVTOCI, FVTPL and amortised cost only when its business model for managing those assets changes. Cash and cash equivalents Cash and cash equivalents include cash balances, certain money market funds and short-term highly liquid investments with an original maturity of three months or less that are readily convertible into known amounts of cash. Receivables Receivable that are held to collect are subsequently measured at amortised cost and are subject to impairment (refer to impairment section in Note 1.6). Contract assets correspond to amounts accrued or due by customers for analysis in progress depending on the stage of completion of the analysis/work performed. For governmental organisations as well as healthcare insurance providers, in the case of some of its US clinical diagnostic testing services, the Group regularly assesses the state of its billing operations and the level of payer\u2019s reimbursements based on specific facts and circumstances and historical recoverability data in order to identify issues which may impact the collection of these receivables. When the financial asset is derecognised, the cumulative gain or loss previously recognised in OCI is reclassified from equity to the Consolidated Income Statement. Interest income from these financial assets is included in Financial income using the effective interest rate method. Debt instruments that do not meet the criteria for amortised cost or FVTOCI are measured at FVTPL. A gain or loss on a debt investment that is subsequently measured at FVTPL is recognised in the Consolidated Income Statement in the period in which it arises. Equity instruments For equity instruments that are not held for trading, the Group makes an irrevocable election at the time of initial recognition whether to account for the equity investment at FVTPL or FVTOCI. Where the Group has elected to present fair value gains and losses on equity investments in OCI, there is no subsequent reclassification of fair value gains and losses to the Consolidated Income Statement following the derecognition of the investment. Dividends from such investments continue to be recognised in the Consolidated Income Statement when the Group\u2019s right to receive payments is established. Other (non-)current financial assets Other (non-)current financial assets include both debt instruments and equity instruments. Debt instruments Debt instruments include those subsequently carried at amortised cost, those carried at FVTPL and those carried at FVTOCI. Classification depends on the Group\u2019s business model for managing the asset and the cash flow characteristics of the asset. Debt instruments that are held for collection of contractual cash flows, where those cash flows represent solely payments of principal and interest, are measured at amortised cost and are subject to impairment. Interest income from these financial assets is included in Finance income using the effective interest rate method. Financial assets with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payment of principal and interest. Debt instruments that are held for collection of contractual cash flows and for selling the financial assets, where the assets\u2019 cash flows represent solely payments of principal and interest, are measured at FVTOCI and are subject to impairment. Movements in the carrying amounts are taken through OCI, except for the recognition of impairment gains or losses, interest revenue and foreign exchange gains and losses, which are recognised in the Consolidated Income Statement. Debt and other financial liabilities Debt and other financial liabilities, excluding derivative financial liabilities and provisions, are initially measured at fair value and, in the case of debt and payables, net of directly attributable transaction costs. Debt and other financial liabilities are subsequently measured at amortised cost using the effective interest rate. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. Debt and other financial liabilities are derecognised when the obligation under the liability is discharged, cancelled or has expired. Equity Common shares are classified as equity. Incremental costs directly attributable to the issuance of shares are recognised as a deduction from equity. Where the Group purchases the Group\u2019s equity share capital (treasury shares), the consideration paid, including any directly attributable incremental transaction costs (net of income taxes), is deducted from equity attributable to the Group\u2019s equity holders until the shares are cancelled or reissued. Where such ordinary shares are subsequently reissued, any consideration received, net of any directly attributable incremental transaction costs and the related income tax effects, is included in equity attributable to the Group\u2019s equity holders. Dividends are recognised as a liability in the period in which they are declared and approved by shareholders. The income tax consequences of dividends are recognised when a liability to pay the dividend is recognised. Hybrid capital The structure of the hybrid capital ensures that it is recognised as a component of equity in accordance with IAS 32 as the conditions below are met: \u25aa No contractual obligation to redeem the instrument; \u25aa No contractual obligation to pay the coupon. Tax-deductible interest payments are not included in interest expense but accounted for in the same way as dividend obligations to shareholders. The distribution of coupon payments and the costs of issue are booked before tax in shareholders\u2019 equity. Reference is made to Note 2.20 for further detail about the Group\u2019s hybrid capital nature. Derivative financial instruments, including hedge accounting All derivative financial instruments are accounted for at the trade date and classified as current or non-current assets or liabilities based on the maturity date or the early termination date. The Group measures all derivative financial instruments at fair value that is derived from the market prices of the instruments, calculated on the basis of the present value of the estimated future cash flows based on observable interest yield curves, basis spread, credit spreads and foreign exchange rates, or derived from option pricing models, as appropriate. Gains or losses arising from changes in fair value of derivative financial instruments are recognised in the Consolidated Income Statement, except for derivatives that are highly effective and qualify for cash flow or net investment hedge accounting. Changes in the fair value of a derivative that is highly effective and that is designated and qualifies as a cash flow hedge are recorded in OCI until the Consolidated Income Statement are affected by the variability in cash flows of the designated hedged item. To the extent that the hedge is ineffective, changes in the fair value are recognised in the Consolidated Income Statement. The Group formally assesses, both at the hedge\u2019s inception and on an ongoing basis, whether the derivative financial instruments that are used in hedging transactions are highly effective in offsetting changes in fair values or cash flows of hedged items. When it is established that a derivative is not highly effective as a hedge or that it has ceased to be a highly effective hedge, the Group discontinues hedge accounting prospectively. When hedge accounting is discontinued because it is expected that a forecasted transaction will not occur, the Group continues to carry the derivative on the Consolidated Balance Sheet at its fair value, and gains and losses that were accumulated in OCI are recognised immediately in the same line item as they relate to in the Consolidated Income Statement. Foreign currency differences arising upon retranslation of financial instruments designated as a hedge of a net investment in a foreign operation are recognised directly in the currency translation differences reserve through OCI, to the extent that the hedge is effective. To the extent that the hedge is ineffective, such differences are recognised in the Consolidated Income Statement. 1.10. Fair value measurements The Group classifies fair value measurements using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels: \u25aa Quoted prices (unadjusted) in active markets for identical assets or liabilities (Level 1 \u2013 Marketable securities, Derivative financial instruments assets, Listed bonds); \u25aa Inputs other than quoted prices included within Level 1 that are observable for the asset or the liability, either directly (i.e., such as prices) or indirectly (i.e., derived from prices) (Level 2 \u2013 Derivative financial instruments liabilities); Inputs for the asset or liability that are not based on observable market data (Level 3). 1.11. Inventories Inventories are stated at the lower of cost or net realisable value. The cost of inventories comprises all costs of purchase, cost of conversion and other costs incurred in bringing the inventories to their present location and condition. The cost of inventories is determined using the first-in, first-out (FIFO) method. The net realisable value represents the estimated sales price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Write-downs of inventories which are considered obsolete or slow moving are computed taking into account their expected future utilisation and their net realisable value. The Group also considers other reasons that the cost of inventories may not be recoverable such as damage, obsolescence, expiration date or declines in selling price. 1.12. Provisions Provisions are recognised if as a result of past events, the Group has a present legal or constructive obligation, the amount can be estimated reliably and it is more likely than not that an outflow of resources will be required to settle the obligation. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax discount rate that reflects current market assessments of the time value of money. 1.13. Income taxes Income taxes comprise current, non-current and deferred tax. Income tax is recognised in the Consolidated Income Statement except to the extent that it relates to items recognised directly within equity or in Other Comprehensive Income. Current tax is the expected taxes payable on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. In cases where it is concluded it is not probable that tax authorities will accept a tax treatment, the effect of the uncertainty is reflected in the recognition and measurement of tax assets and liabilities or, alternatively, a provision is made for the amount that is expected to be settled, where this can be reasonably estimated. This assessment relies on estimates and assumptions and may involve a series of judgements about future events. New information may become available that causes the Group to change its judgement regarding adequacy of existing tax assets and liabilities. Such changes to tax assets and liabilities will impact the income tax expense in the period during which such a determination is made. Deferred tax assets and liabilities are recognised, using the Consolidated Balance Sheet method, for the expected tax consequences of temporary differences between the carrying amounts of assets and liabilities and the amounts used for taxation purposes. Deferred taxes are measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity or on different taxable entities, but the Group intends to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realised simultaneously A deferred tax asset is recognised for unused tax losses, tax credits and deductible temporary differences to the extent that it is probable that there will be future taxable profits against which they can be utilised. The ultimate realisation of deferred tax assets is dependent upon the generation of future taxable income in the countries where the deferred tax assets originated and during the periods when the deferred tax assets become deductible. The Group considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Foreign currency transactions The financial statements of all Group entities are measured using the currency of the primary economic environment in which the entity operates (\u201cthe functional currency\u201d). The Euro (\u20ac) is the functional currency of the Group and the presentation currency of the Consolidated Financial Statements. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions or the valuation in cases where items are remeasured. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Consolidated Income Statement, except when deferred in Other comprehensive income as qualifying cash flow hedges and qualifying net investment hedges. Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are retranslated to the functional currency using the exchange rate at the date the fair value was determined. Non-monetary items in a foreign currency that are measured based on historical cost are translated using the exchange rate at the transaction date. Foreign operations The assets and liabilities of foreign operations, including goodwill and fair value adjustments arising on acquisition, are translated to Euros at the exchange rates prevailing at the reporting date. The income and expenses of foreign operations are translated to Euros at the exchange rates prevailing at the dates of the transactions. Foreign currency differences arising upon translation of foreign operations into Euros are recognised in Other Comprehensive Income and presented as part of currency translation reserves in Shareholders Equity. When a foreign operation is disposed of such that control, significant influence or joint control is lost, the cumulative amount in the currency translation differences related to the foreign operation is reclassified to the Consolidated Income Statement as part of the gain or loss on disposal. 1.15. Non-current assets held for sale Non-current assets that are expected to be recovered primarily through sale rather than through continuing use are classified as held for sale. Non-current assets held for sale are carried at the lower of carrying amount or fair value less cost of disposal. Any gain or loss from disposal, together with the results of these operations until the date of disposal, is reported separately as discontinued operations. The financial information of discontinued operations is excluded from the respective captions in the Consolidated Financial Statements and related Notes for all periods presented. Comparatives in the Consolidated Balance Sheet are not represented when a non-current asset is classified as held for sale. Comparatives are represented for presentation of discontinued operations in the Consolidated Cash Flow Statement and Consolidated Income Statement. 1.16. Employee benefits A defined-contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. Obligations for contributions to defined-contribution pension plans are recognised as an employee benefit expense in the Consolidated Income Statement in the periods during which services are rendered by employees. A defined-benefit plan is a post-employment benefit plan other than a defined-contribution plan. Plans for which the Group has no legal or constructive obligation to pay further amounts, but to which it does pay non-fixed contributions, are also treated as a defined-benefit plan. The net pension asset or liability recognised in the Consolidated Balance Sheet in respect of defined-benefit post-employment plans is the fair value of plan assets less the present value of the projected defined-benefit obligation at the Consolidated Balance Sheet date. The defined-benefit obligation is calculated annually by qualified actuaries using the projected unit credit method. Recognised assets are limited to the present value of any reductions in future contribution or any future refunds. The net pension liability is presented as a long-term provision; no distinction is made for the short-term portion. Pension costs in respect of defined-benefit post-employment plans primarily represent the increase of the actuarial present value of the obligation for post-employment benefits based on employee service during the year and the interest on the net recognised asset or liability in respect of employee service in previous years. Remeasurements of the net defined-benefit asset or liability comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (excluding interest). The Group recognises all remeasurements in Other Comprehensive Income. The Group recognises gains and losses on the settlement of a defined-benefit plan when the settlement occurs. The gain or loss on settlement is the difference between the present value of the defined-benefit obligation being settled, as determined on the date of settlement, and the settlement price, including any plan assets transferred and any payments made directly by the Group in connection with the settlement. Past service costs arising from the introduction of a change to the benefit payable under a plan or a significant reduction of the number of employees covered by a plan (curtailment) are recognised in full in the Consolidated Income Statement. The Group\u2019s net obligation in respect of long-term employee benefits is the amount of future benefit that employees have earned in return for their service in the current and prior periods, such as jubilee entitlements. That benefit is discounted to determine its present value. Remeasurements are recognised in the Consolidated Income Statement in the period in which they arise. Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. The Group recognises a liability and an expense for bonuses and incentives based on a formula that takes into consideration the profit attributable to the Group\u2019s shareholders after certain adjustments. 1.17. Share based payments Please refer to Note 2.27 for further details about the different plans. The cost of equity-settled transactions is determined by the fair value at the date when the grant is made using an appropriate valuation model. The grant-date fair value of equity-settled share-based payment awards granted to employees is recognised as personnel expense, with a corresponding increase in equity, over the vesting period of the award. The cumulative expense recognised for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Group\u2019s best estimate of the number of equity instruments that will ultimately vest. The expense or credit in the statement of income for a period represents the movement in cumulative expense recognised at the beginning and end of that period. Service and non-market performance conditions are not taken into account when determining the grant-date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Group\u2019s best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant-date fair value. No expense is recognised for awards that do not ultimately vest because non-market performance and/or service conditions have not been met. When an award is cancelled by the entity or by the counterparty, any remaining element of the fair value of the award is expensed immediately through profit or loss. The dilutive effect of outstanding options and shares is reflected as additional share dilution in the computation of diluted earnings per share. 1.18. Finance income and costs Financial income comprises interest income on funds invested (including financial assets), dividend income, net gains on the disposal of financial assets, net fair value gains on financial assets at FVTPL, net gains on the remeasurement to fair value of any pre-existing interest in an acquiree, and net gains on foreign exchange impacts that are recognised in the Consolidated Income Statement. Interest income is recognised on an accrual basis in the Consolidated Income Statement, using the effective interest method. Dividend income is recognised in the Consolidated Income Statement on the date that the Group\u2019s right to receive payment is established, which in the case of quoted securities is normally the ex-dividend date. Financial expenses comprise interest expenses on borrowings, unwinding of the discount on provisions and contingent consideration, losses on disposal of financial assets, net fair value losses on financial assets at FVTPL, impairment losses recognised on financial assets (other than trade receivables), net interest expenses related to defined-benefit plans, interest on lease liabilities and net losses on foreign exchange impacts that are recognised in the Consolidated Income Statement. 1.19. Earnings per share The Group presents basic and diluted earnings per share (EPS) data for its common shares. Basic EPS is calculated by dividing the Net income (loss) attributable to shareholders by the weighted average number of common shares outstanding during the period, adjusted for own shares held. Diluted EPS is determined by adjusting the Net income (loss) attributable to shareholders and the weighted average number of common shares outstanding during the period, adjusted for own shares held, for the effects of all dilutive potential common shares, which comprises forward purchase contracts, restricted shares, performance shares and share options granted to employees. 1.20. Alternative performance measures (APM) The Group is providing in the Consolidated Financial Statements certain alternative performance measures (non-IFRS information). APMs used in the Consolidated Income Statement Adjusted results \u2013 reflect the ongoing performance of the mature and recurring activities excluding \u201cseparately disclosed items\u201d. Separately disclosed items (SDI) \u2013 include: \u25aa one-off costs from integration and reorganisation; \u25aa discontinued operations; \u25aa other non-recurring income and costs; \u25aa temporary losses and other costs related to network expansion, start-ups and new acquisitions undergoing significant restructuring; \u25aa share-based payment charge; \u25aa acquisition-related expenses, net \u2013 impairment of goodwill, amortisation/impairment of acquired intangible assets, negative goodwill, transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions; \u25aa gain and loss on disposal of subsidiaries, net; \u25aa net finance costs related to borrowing and investing excess cash and one-off financial effects (net of finance income); \u25aa net finance costs related to hybrid capital; \u25aa and the related tax effects. Details are provided in Notes 1.21 and 2.5. EBITDA \u2013 Earnings before interest, taxes, depreciation and amortisation, share-based payment charge, acquisition-related expenses, net and gain and loss on disposal of subsidiaries, net. EBITAS \u2013 EBITDA less depreciation and amortisation. EBIT \u2013 EBITAS less share-based payment charge, acquisition-related expenses, net and gain and loss on disposal of subsidiaries, net. These measures exclude certain items because of the nature of these items and the impact they have on the analysis of the underlying business performance and trends. The Group shows EBITDA, EBITAS, EBIT as defined in the Notes to the Consolidated Income Statement with the objective to be consistent with the information used in internal Group reporting to measure the performance of Group companies and information published by other comparable companies. APMs used in the Consolidated Cash flow Statement Net capex \u2013 Purchase, capitalisation of intangible assets, purchase of property, plant and equipment, less proceeds from disposals of such assets less capex trade payables change of the period. Free Cash Flow to the Firm \u2013 Net cash provided by operating activities, less Net capex. APMs used in the Notes Net debt \u2013 Current and non-current borrowings, less Cash and cash equivalents (Note 2.17). Net working capital \u2013 Inventories, trade receivables and contract assets, prepaid expenses and other current assets less trade accounts payable, contract liabilities and other current liabilities excluding accrued interest receivable and payable (Note 2.25). Free Cash Flow to Equity \u2013 Free Cash Flow to the Firm, less disposal/(acquisition) of investments, financial assets and derivative financial instruments, net, and after interests and premium paid net of interest received. Free cash flow to Equity does not take into account the dividends paid to shareholders and non-controlling interests as well as earnings paid to hybrid capital holders (Note 2.29). The Group believes that providing these APMs enhances investors\u2019 understanding of the Group\u2019s core operating results and future prospects, consistent with how the Group measures and forecasts the Group\u2019s performance, especially when comparing such results to previous periods or objectives and to the performance of our competitors. This enables the Group to demonstrate the underlying profitability of the business \u2013 i.e., what the performance would be if the investments as described in Note 1.21 were not undertaken. In the interest of full transparency, the Group discloses both the adjusted results (i.e., without the separately disclosed items) and full reported results (i.e., including the separately disclosed items). This information should be considered in addition to, but not in lieu of, information prepared in accordance with IFRS. 1.21. Mature scope and Separately disclosed items In order to present the performance of the Group in a clear, consistent and comparable format, certain items are disclosed separately in the Consolidated Income Statement. Mature scope Mature scope excludes start-ups and acquisitions in significant restructuring. A business will generally be considered mature when: i) The Group\u2019s systems, structure and processes have been deployed; ii) It has been audited, accredited, qualified and used by the relevant regulatory bodies and the targeted client base; iii) It no longer requires above-average annual capital expenditures, exceptional restructuring or abnormally large costs with respect to their current revenues for deploying new Group IT systems. The list of entities classified as mature is reviewed at the beginning of each year and is relevant for the whole year. In FY 2022, 96% of total Group revenues were included in the mature scope (96% as FY 2021). Separately disclosed items Separately disclosed items is defined in Note 1.20 (see details in Note 2.5). One-off costs from integration, reorganisation, discontinued operations and other non-recurring income and costs One-off costs from integration, reorganisation costs, such as reducing overhead and consolidating facilities, are included in the separately disclosed items as the Group believes that these effects are not indicative of our normal operating income and expenses. Discontinued operations are a component of the Group\u2019s core business or product lines that have been disposed of, or liquidated; or a specific business unit or a branch of a business unit that has been shut down or terminated, and are reported separately from continued operations. Other non-recurring income and costs are also disclosed separately, as they are either isolated or cannot be expected to occur again with any regularity or predictability and as the Group believes they are not indicative of the Group\u2019s normal operating gains and losses. These include gains or losses on significant litigation-related matters. Temporary losses and other costs related to network expansion, start-ups and new acquisitions undergoing significant restructuring Network expansion, start-ups or acquisitions in significant restructuring are new companies or business activities established to develop an existing business model, transfer technology or a specific strategy. They are generally greenfield operations, or, in certain cases, newly acquired businesses bought to achieve a target market share in a given geography that are not operating optimally, but that have the potential to operate efficiently and profitably once restructured or reorganised to the Group\u2019s model. However, the reorganisation measures required are so large that they have a significant negative impact on the ongoing business of the Group. Start-ups are generally undertaken in new markets, and in particular emerging markets, where there are often limited viable options for acquisitions or in developed markets when Eurofins transfers technology developed by its R&D and Competence Centers abroad. Given that the costs or operating losses incurred in the start-up or restructuring phase are temporary and should cease within a 3-5 year period on average, it is the Group\u2019s view that they should be disclosed separately. Whilst the timeframe for these temporary costs or losses is finite, and should cease gradually, the businesses should continue to generate revenues for the Group indefinitely, and these are therefore not considered temporary. Start-up activities go through various stages of development before reaching optimal efficiency levels and can take several years to become profitable. The development process includes the creation or construction of the laboratory, hiring the appropriate staff, obtaining relevant accreditations, deployment of the IT infrastructure and dedicated IT solutions, developing the sales and marketing channels, and building up volumes and the revenue base. In general, start-up periods last for 2 to 3 years in mature markets and 2 to 5 years in emerging markets. The list of entities classified as start-ups or acquisitions in significant restructuring is reviewed at the beginning of each year and is relevant for the whole year. Temporary losses and other costs related to network expansion, start-ups and new acquisitions undergoing significant restructuring are included in the separately disclosed items as these are investments in future growth prospects and distort the judgement of the underlying performance of the mature businesses of the Group. Depreciation costs specific to start-ups and new acquisitions undergoing significant restructuring The line corresponds to the line \u201cdepreciation\u201d of the entities classified as start-ups or acquisitions in significant restructuring. Share-based payment charge and acquisition-related expenses, net Separately disclosed items also include share-based payment charge, impairment of goodwill, and amortisation/impairment of acquired intangible assets, recording of negative goodwill as well as income from reversal of such costs and from unused amounts due for business acquisitions as all these transactions are without cash impact in the Consolidated Financial Statements. Furthermore, the amortisation of acquired intangible assets is included because a significant portion of the purchase price for acquisitions may be allocated to intangible assets. All transaction costs and long-term incentives/ retention bonus related to acquisitions during the year are disclosed separately. There are a number of different professionals that may assist throughout the process of planning, negotiating, performing due diligence, and closing of the transaction. Examples include intermediaries (investment bankers or business brokers), legal professionals (lawyers) and accounting professionals. These costs are specific and directly related to the transaction and are usually paid at or around the closing of the relevant transaction. These costs are disclosed separately also due to the fact that if the Group would stop its external growth, i.e., acquisitions, and would only focus on internal growth, most of these costs would disappear instantly and the EBIT would increase mechanically. Furthermore, these costs do not correspond to the Group\u2019s business of providing analytical solutions to its customers. Gain and loss on disposal of subsidiaries, net These include gains or losses on the disposal of a business or real estate to third party (e.g. Digital Testing in 2022) or liquidation. Net finance costs related to borrowing and investing excess cash and one-off financial effects (net of finance income) and related to hybrid capital Net finance costs related to excess cash and one-off financial effects correspond to cash earmarked for future investments/ acquisitions and not needed for the existing business. Excess cash is calculated as the difference between the total Consolidated cash balance at month-end and the minimum liquidity position required to operate the business, as based on a percentage of sales (considered to be 5% of the annualised revenues of the rolling last three months) and split proportionately between Equity, Gross financial debt and hybrid capital. The finance cost related to excess cash is then calculated using the weighted average interest rate of each debt instrument and coupon on hybrid capital on the Balance Sheet of the Group. Tax effect from the adjustment of all separately disclosed items On all items listed above, the related tax effects are calculated. Total impact on earnings attributable to hybrid capital investors This item corresponds to the Net finance costs related to hybrid capital excess cash. The Group believes that the separate disclosure of these items enhances investors\u2019 understanding of the Group\u2019s core operating results and future prospects and allows better comparisons of operating results which are consistent over time and with peer companies. 1.22. Application of standards, amendments and interpretations Standards, amendments and interpretations adopted by the European Union and effective as of 1 January 2022 The accounting policies applied for the preparation of these Consolidated Financial Statements are consistent with those applied in the preparation of Consolidated financial statements for the year ended 31 December 2021. Other standards, amendments and interpretations newly applicable as of 1 January 2022 Other standards, amendments and interpretations newly applicable as of 1 January 2022 have no material impact on these Consolidated Financial Statements: \u25aa Reference to the Conceptual Framework - Amendment to IFRS 3 \u25aa Property, Plant and Equipment: Proceeds before intended Use - Amendment to IAS 16 \u25aa Onerous Contracts - Cost of fulfilling a contract - Amendment to IAS 37 \u25aa AIP IFRS 1 First time Adoption of International Financial Reporting Standards - Subsidiary as a first-time adopter \u25aa AIP IFRS 9 Financial Instruments - Fees in the \u201810 per cent\u2019 test for derecognition of financial liabilities \u25aa AIP IAS 41 Agriculture - Taxation in Fair value measurement New standards and interpretations not yet adopted The following pronouncements have been issued as of 31 December 2022 with mandatory application from 1 January 2023. They have not been early adopted by the Group: \u25aa IFRS 17 Insurance contracts \u25aa Classification of Liabilities as Current or Non-current - Amendments to IAS 1 \u25aa Definition of Accounting Estimates - Amendment to IAS 8 \u25aa Disclosure of Accounting Policies - Amendments to IAS 1 and IFRS Practice Statement 2 \u25aa Deferred Tax related to Assets and Liabilities arising from a single transaction - Amendment to IAS 12 These standards are not expected to have a material impact on the Group\u2019s Consolidated Financial Statements in the current or future reporting periods and on foreseeable future transactions. 1.23. COVID-19 pandemic and geopolitical instability COVID-19 and recent geopolitical events have impacted the economy and financial markets globally. The Group\u2019s operational performance was temporarily affected by COVID-19-related measures in China in 2022. The Group\u2019s exposure to Russia and Ukraine is limited (Note 2.30 Country risks). As a consequence, these condensed consolidated financial statements were prepared with particular attention to (i) the impairment of non-current assets, (ii) the appropriateness of the allowance for trade receivables, unbilled revenue and work in progress, (iii) the level of provision for risks, as well as (iv) accounting for government grants. No material impacts were recognized in these condensed consolidated financial statements, except those listed in Notes 2.9, 2.10, 2.14 and 2.40. 2.1. Segment information Operating segments are components of the Group\u2019s business activities about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (\u201cCODM\u201d). The Group is very decentralised with a large number of small and medium size companies in many countries. For practical reasons, the sets of information provided to the CODM, who is the Chief Executive Officer of the Group, aggregate these legal entities based on geographical areas and leadership structure. This aggregation can vary over time depending on changes in management, organisation or leadership. The rapid evolving nature of the Group also results in a constant adaptation of the matrix of its organisation. When necessary, the CODM may review financial information at a more disaggregated level. As required by IFRS 8 Operating Segments, Eurofins has three reportable segments: Europe, North America and Rest of the World. Europe is the combination of three reporting segments (groups of Cash Generating Units): France, DACH countries (Germany, Austria and Switzerland) and Other European Countries (OEC). Other European Countries include Benelux, Nordic Region, UK and Ireland, Southern Europe and Central & Eastern Europe. North America corresponds to the U.S. and Canada. As Eurofins still generates modest revenues in Asia and Middle East, South America, Australia and New Zealand, those 3 regions that represent future growth potential are followed internally in a single segment \u201cRest of the World\u201d. The key segmental performance measures are the EBITDA and EBITAS, which Management believes are the most relevant measure to evaluate the financial performance of the reportable segments. In \u20ac millions North Rest of the Group service Europe 1 Total 2022 America World functionsRevenues 3,507.0 2,494.1 711.0 - 6,712.1 2Intersegment revenues50.9 39.2 22.4 - 112.5 Operating costs, net -2,826.9 -1,851.6 -567.7 -50.8 -5,297.0 EBITDA 680.1 642.5 143.3 -50.8 1,415.1 Depreciation and amortisation -222.0 -167.1 -63.7 -51.6 -504.4 EBITAS 458.2 475.4 79.6 -102.4 910.7 Share-based payment charge and -40.7 -56.4 -11.3 -27.7 -136.1 acquisition-related expenses, net Gain and loss on disposal of subsidiaries, 113.5 24.6 3.3 - 141.4 net EBIT 531.0 443.6 71.5 -130.1 916.0 Finance income 0.1 0.3 1.5 0.3 2.2 Finance costs -13.7 -21.7 -9.0 -94.8 -139.2 Share of profit of associates 0.8 - - 0.1 0.9 Profit before income taxes 518.2 422.2 64.0 -224.5 780.0 Income tax expense -65.9 -50.0 -10.9 -47.4 -174.2 Net profit for the year 452.3 372.2 53.2 -271.9 605.8 3 Total assets4,338.3 4,002.4 1,252.0 490.8 10,083.5 Cash and cash equivalents 112.3 74.2 94.7 205.3 486.6 3 Net capex-226.7 -260.0 -87.6 -70.9 -645.3 2021 Revenues 3,999.1 2,146.9 571.6 - 6,717.7 2Intersegment revenues50.0 33.3 31.0 - 114.3 Operating costs, net -2,826.8 -1,538.5 -406.6 -105.8 -4,877.7 EBITDA 1,172.3 608.4 165.1 -105.8 1,840.0 Depreciation and amortisation -226.5 -141.4 -46.0 -36.8 -450.7 EBITAS 945.9 467.0 119.0 -142.7 1,389.3 Share-based payment charge and -49.2 -69.7 -9.6 -2.4 -131.0 acquisition-related expenses, net Gain and loss on disposal of subsidiaries, 0.6 - -0.7 - -0.1 net EBIT 897.2 397.4 108.8 -145.1 1,258.2 Finance income 0.1 0.1 1.5 0.3 2.0 Finance costs -13.8 -19.2 -3.5 -169.2 -205.7 Share of profit of associates 1.4 - 0.6 - 2.0 Profit before income taxes 884.9 378.3 107.4 -314.0 1,056.6 Income tax expense -153.0 -42.4 -19.9 -58.3 -273.6 Net profit for the year 731.9 335.9 87.5 -372.3 783.0 3Total assets4,191.9 3,647.0 1,021.7 471.7 9,332.3 Cash and cash equivalents 125.2 53.8 88.2 248.1 515.3 3 Net capex-210.9 -136.6 -48.2 -85.8 -481.6 1 Corresponds to Group services functions (GSF) for Income Statement informations and Group holding companies\u2019 transactions for the other captions.GSF costs were more reallocated in 2022 to each reportable segments. 2 Intersegment revenues are limited between segments and made at arm\u2019s length, but intrasegment revenues are more significant within each segment under Eurofins hub and spoke model. 3 Total assets and Net capex are shown in the geographical area in which the assets are located. 2.2. Revenues Set out below is the reconciliation of the revenue from contracts with customers with the amounts disclosed in the segment information (Note 2.1): Europe North America Rest of the World Total In \u20ac millions 2022 2021 2022 2021 2022 2021 2022 2021 Major service lines 1Sample-based business3,030.1 3,533.8 1,967.8 1,699.3 590.1 476.9 5,588.0 5,709.9 Study-based business 271.8 267.1 219.8 183.6 79.9 67.1 571.6 517.8 FTE-based business 158.4 147.9 237.6 193.4 30.3 15.3 426.3 356.6 Product-based business 46.7 50.3 68.7 70.6 10.6 12.3 126.0 133.3 Other - - 0.2 - - - 0.2 - Total 3,507.0 3,999.1 2,494.1 2,146.9 711.0 571.6 6,712.1 6,717.7 Timing of revenue recognition Revenue recognised at a 1,374.2 1,993.2 871.5 825.7 116.9 123.0 2,362.5 2,941.9 point in time1Revenue recognised over 2,132.9 2,005.9 1,622.6 1,321.2 594.1 448.6 4,349.6 3,775.8 time Total 3,507.0 3,999.1 2,494.1 2,146.9 711.0 571.6 6,712.1 6,717.7 1 including Clinical Diagnostic Testing activities related to COVID-19. The Group\u2019s contract balances are as follows: In \u20ac millions Note 2022 2021 Accrued sales 124.2 188.3 Amounts due by customers for analysis in progress 164.2 149.1 Contract assets 2.15 288.4 337.4 Advance payments received -53.1 -55.1 Deferred revenues -131.1 -107.9 Contract liabilities -184.2 -163.1 Net Balance Sheet position 104.2 174.3 % of total revenues due by customers for analysis in progress, net of deferred revenues 0.5% 0.6% The remaining performance obligations (unsatisfied or partially satisfied) on contracts with a duration over a year, expected to be recognised in the following years amount to \u20ac368m as of 31 December 2022, of which \u20ac234m are expected to be recognised in revenue in 2023. 2.4. Employees The average number of full time employees per geographical location is summarised as follows: Weighted average 2022 2021 Europe 29,438 27,924 North America 13,859 12,921 Rest of the World 9,243 6,907 Group service functions 3,090 2,605 Total FTE 55,631 50,357 As of 31 December 2022, the total headcount within the Group reached 61,379 employees (57,992 in 2021). 2.3. Operating costs, net In \u20ac millions 2022 2021 Cost of materials and services -2,227.0 -2,149.7 Personnel expenses -3,053.6 -2,689.8 Other operating income and expenses, net -16.4 -38.2 Total -5,297.0 -4,877.7 2.5. Separately disclosed items In \u20ac millions Note 2022 2021 One-off costs from integration, reorganisation, discontinued operations and -39.0 -32.2 other non-recurring income and costs Temporary losses and other costs related to network expansion, start-ups -58.8 -29.5 and new acquisitions undergoing significant restructuring EBITDA impact -97.8 -61.6 Depreciation costs specific to start-ups and new acquisitions undergoing -28.4 -21.9 significant restructuring EBITAS impact -126.2 -83.5 Share-based payment charge and acquisition-related expenses, net 2.6 -136.1 -130.9 Gain and loss on disposal of subsidiaries, net 2.26 141.4 -0.1 EBIT impact -120.9 -214.6 Net finance costs related to borrowing and investing excess cash and one--2.8 -97.6 off financial effects (net of finance income) Tax effect from the adjustment of all separately disclosed items 46.5 51.8 Net Profit impact -77.2 -260.4 Non-controlling interests of separately disclosed items -0.1 - Earnings attributable to owners and hybrid capital investors impact -77.2 -260.4 Earnings attributable to hybrid capital investors impact -1.4 -3.3 (net finance costs related to hybrid capital excess cash) The EBITDA impact of the separately disclosed items (SDIs) amounted to \u20ac97.8m (\u20ac61.6m in 2021). This includes in 2022: \u25aa One-off costs from integrations, reorganisations and discontinued operations, and other non-recurring income and costs of \u20ac39m. The costs included disposals of machines related to discontinued operations in the UK, relocations/reorganisations including the moves in the U.S. of Eurofins Viracor and Eurofins Eaton Analytical to their new consolidated facilities, litigation-related expenses in Clinical Diagnostics in the U.S. as well as restructurings in Spain and Germany. \u25aa Temporary losses and other costs related to network expansion, start-ups and new acquisitions in significant restructuring totalled \u20ac59m, significantly higher than in FY 2021 (\u20ac29m). This increase was driven by: o The greater number of start-ups launches undertaken in FY 2022 and recent years, most notably in areas related to Clinical Diagnostics (including Transplant Genomics Inc. in the U.S.), BioPharma Services (including Eurofins Panlabs and new laboratory in China) and Food Testing (including in China, Philippines, Poland and Romania). o Restructuring expenses for recently acquired companies in Clinical Diagnostics in the U.S., U.K. and Germany and Environment Testing in the U.S. Depreciation costs specific to start-ups and new acquisitions undergoing significant restructuring increased in 2022 mainly due to the increase in number of start-ups. Gain and loss on disposal of subsidiaries, net corresponds mainly to the sale of the Digital Testing business. The finance costs included within the SDIs for 2022 relate primarily to interest paid on excess cash. In 2021, the finance costs related mainly to premiums and tender fees incurred and paid for \u20ac92.5m on the redemption of various issuances of unsecured Eurobonds for a total amount of \u20ac1.1bn (\u20ac0.4m in 2022). See Notes 2.7 and 2.18 for further discussion on the bonds anticipated redemption. In 2022, the average monthly cash balance, net of overdrafts was \u20ac563m (\u20ac751m in 2021). The position as of 31 December 2022 was \u20ac483m (\u20ac515m as of 31 December 2021). This led to a decreasing average excess cash of \u20ac224m in 2022 (\u20ac421m in 2021). The borrowing and investment of this excess cash have generated net finance costs of \u20ac-2.4m on the financial result and an impact of \u20ac-1.4m on earnings attributable to hybrid capital investors in 2022 (\u20ac-5.1m and \u20ac-3.3m respectively in 2021). 2.6. Share-based payment charge and acquisition-related expenses, net In \u20ac millions Note 2022 2021 Share-based payment charge 2.27 -23.0 -22.1 Amortisation of acquired intangible assets 2.11 -104.5 -91.9 Impairment of acquired intangible assets 2.11 -13.3 -5.7 Transaction costs related to acquisitions -16.4 -13.6 Reversal of amounts due for business acquisitions not paid 2.22 21.0 2.4 Acquisition-related expenses, net -113.1 -108.9 Total -136.1 -131.0 Intangible assets related to acquisition and brand increased by \u20ac90m in 2022 and \u20ac107m in 2021 (Note 2.11). The reversal of unpaid amounts due for business acquisitions mainly relate to the non-achievement of Eurofins Beacon Discovery business plan and delays in the implementation of Transplant Genomics Inc. business plan. 2.7. Finance income and costs In \u20ac millions Note 2022 2021 Other financial income 2.2 2.0 Finance income 2.2 2.0 Interest expense on: Borrowings -11.5 -7.4 Bonds -39.6 -38.1 Schuldschein loan -10.4 -9.7 Lease liabilities -26.3 -24.9 Defined benefit plans 2.23 -0.8 -0.7 Net foreign exchange loss -32.9 -17.9 Unwind of discount on amounts due for business acquisitions 2.22 -13.2 -6.9 Unwind of discount on issuance costs 2.18 -3.8 -7.3 Derivative financial instruments on interest rate hedging, net 2.30 -0.3 -0.3 Other financial expenses -0.5 -92.5 Finance costs -139.2 -205.7 Total Finance income and costs, net -136.9 -203.7 In 2022, other financial expenses are primarily related to tender fees incurred and paid of \u20ac0.5m. In 2021, other financial expenses were primarily related to premiums and tender fees incurred and paid for \u20ac92.5m on the redemption of various unsecured Eurobonds for a total amount of \u20ac1.1bn (Note 2.18). Net foreign exchange loss is mainly related to USD cash pooling owned by Eurofins Finance Luxembourg S.\u00e0 r.l., the Group\u2019s treasury entity which manages cash centralization for Group companies. This net foreign exchange loss is non-cash, unrealised and due to the appreciation of 6% of $ versus \u20ac in 2022 (Balance Sheet end of period rates). 2.8. Income and deferred tax In 2022, the income tax expense amounted to \u20ac174m (\u20ac274m in 2021). The components of income tax expense are as follows: In \u20ac millions 2022 2021 Current tax expense -201.2 -299.9 Deferred tax income 27.0 26.3 Income tax expense -174.2 -273.6 Eurofins\u2019 operations are subject to income taxes in various jurisdictions. The statutory income tax rate varies by country, the below table gives the weigthed average theoretical income tax rate. Please note that the Luxembourg\u2019s income tax rate remains unchanged at 24.94%. A reconciliation of the weighted average statutory income tax rate to the effective income tax rate is as follows: In \u20ac millions 2022 2021 Profit before income taxes 780.0 1,056.6 Theoretical income tax expense -162.9 -218.7 Weighted average theoretical income tax rate (%) 20.9% 20.7% 1Withholding and other taxes-29.4 -28.6 2Non-deductible expenses (-) / Non-taxable income (+)11.5 -40.6 Deductible expenses not accounted for in the Consolidated Income Statement 25.8 14.3 3Unrecognised tax loss and credit carryforwards-18.3 4.3 Tax expense (benefits) due to change in uncertain tax treatments -0.8 -4.3 Effective income tax expense -174.2 -273.6 4Effective income tax rate22.3% 25.9% 1 This line includes taxes based on other taxable income aggregate such as CVAE (\u201ccotisation sur la valeur ajout\u00e9e des entreprises\u201d) in France and IRAP (\u201cimposta regionale sulle attivit\u00e0 produttive\u201d) in Italy as well as withholding taxes and non-recoverable value added tax paid. 2 Non-taxable income in 2022 are mainly related to the sale of the digital testing activities. Non-deductible expenses are mainly related to the finance costs not deductible in Luxembourg and France due to change of dividends and tax rules and the Base Erosion and Anti-Abuse Tax (BEAT) in the U.S. 3 2022 unrecognised tax losses are linked to tax losses in companies with no possibility to create deferred tax assets as of 31 December 2022. 4 The effective income tax rate FY 2022 has improved vs FY 2021 due to the sale of the digital testing activities, for which the capital gain is not taxable. The income tax paid for each period is the following: In \u20ac millions 2022 2021 Income taxes paid -296.1 -296.7 Income taxes paid in 2022 is very similar to income tax paid in 2021, as in many countries, the income tax on 2021 profits have been paid in 2022. This time difference between effective income tax expense and income tax paid has been wider in the past three years, in relation to the extra income realised through the COVID-19 testing activities, and should normalise in the future periods. In \u20ac millions 2022 2021 Corporate income tax assets 135.6 76.7 Corporate income tax liabilities 34.7 86.0 Corporate tax assets and liabilities positions, net 100.9 -9.3 Deferred taxes positions are shown on the balance sheet as follows: 2022 2021 Deferred tax Deferred tax Deferred tax Deferred tax In \u20ac millions assets liabilities assets liabilities Total deferred tax assets / (liabilities) 189.7 -247.6 193.5 -226.2 Offset of deferred taxes -114.0 114.0 -102.6 102.6 Deferred tax assets / (liabilities), net 75.7 -133.6 90.9 -123.6 Deferred tax assets and liabilities positions, net - -57.9 - -32.7 Movements in net deferred tax relate to the following underlying assets and liabilities and tax loss carry forwards (including tax credit carry forward) and their movements during the year 2022 and 2021 respectively are presented in the table below: In \u20ac millions Classification 2022 2021 Balance as of 1 January -32.7 -38.7 Business combinations -29.0 -15.1 Deferred taxes on retirement benefit obligations and FVCOI change in OCI -3.7 -1.8 Deferred taxes on net investment hedge change in OCI - -24.3 Deferred taxes on hybrid capital distribution change in Equity - 2.2 Tax credit relating to share-based payment charge change in Equity -15.1 26.9 Deferred tax income Income Statement 27.0 26.3 Translation differences and other -4.3 -8.2 Balance as of 31 December -57.9 -32.7 Deferred tax assets are recognised for temporary differences, unused tax losses and unused tax credits to the extent that realisation of the related tax benefits is probable. The ultimate realisation of deferred tax assets is dependent upon the generation of future taxable income in the countries where the deferred tax assets originated and during the periods when the deferred tax assets become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. The Business combinations relate to the deferred taxes on intangible assets recognised on the purchase price allocation (Note 2.26). Tax credit relating to share-based payment charge are linked to potential US employees gain on stock options deductible from the tax result (\u20ac-15.1m in 2022 versus \u20ac+26.9m in 2021). In 2022, deferred taxes liabilities on net investment hedge positive revaluation are netted against deferred tax assets on capital hybrid distribution and tax losses without impact in OCI and Equity (reversal in 2021 of 22.2m of tax loss carryfowards) due to the loss-making situation of the Luxembourg tax unity. Movements in deferred tax assets and liabilities during the year are broken down as follows: In \u20ac millions Balance Recognised Recognised Business Translation Balance as of in Income in Equity & combina-differences as of 2022 1 January Statement OCI tions and other 31 December Intangible assets -226.2 5.5 - -20.2 -6.7 -247.6 Property, plant and equipment 48.2 -4.8 - -0.1 0.1 43.4 Tax loss carryforwards 34.0 -9.0 - - -1.1 23.9 Retirement benefit obligations 15.0 1.2 -3.5 0.2 -0.4 12.5 Other liabilities 96.3 34.2 -15.2 -9.0 3.7 109.9 Net deferred tax liabilities -32.7 27.0 -18.8 -29.0 -4.3 -57.9 2021 Intangible assets -205.8 10.2 - -21.2 -9.4 -226.2 Property, plant and equipment 43.7 14.2 - 1.0 -10.7 48.2 Tax loss carryforwards 49.4 -7.6 -22.2 5.2 9.2 34.0 Retirement benefit obligations 14.9 0.8 -0.6 - -0.1 15.0 Other liabilities 59.1 8.7 25.8 -0.1 2.9 96.3 Net deferred tax liabilities -38.7 26.3 3.0 -15.1 -8.2 -32.7 The deferred tax liabilities on temporary differences in intangible assets amortisation and fixed assets depreciation are related to differences between amounts per consolidation books and amounts per tax books on intangible assets recognised as part of the acquisition; and on fixed assets and goodwill in case of taxable stock acquisition (e.g. eligible under \u00a7338(h)(10) in the US). No deferred tax is recognised for non-tax-deductible goodwill amounts. As of 31 December 2022, the Group held an aggregate amount of \u20ac865m of tax losses (\u20ac711m in 2021) to carry forward against future taxable income and which have not been recognised as tax assets due to the uncertainty of their recoverability. The Group has available tax loss and credit carryforwards which expire as follows: 2022 2021 In \u20ac millions Total Balance Unrecognised balance Total Balance Unrecognised balance Within 5 years 68 67 61 60 Later than 5 years 216 207 257 220 Unlimited 686 599 537 431 Total 970 873 855 711 The deferred tax assets on tax losses capitalised mainly include Eurofins Food Chemistry Testing US, Inc. (\u20ac3.2m) and Eurofins DNA Diagnostics Center, Inc. (\u20ac2.1m) in the U.S., Eurofins Biologie Sp\u00e9cialis\u00e9e SAS (\u20ac2.8m) and Eurofins Cerep SAS (\u20ac2.5m) in France, with an expectation to be used within the next seven years. 2.9. Property, plant and equipment Office and IT Land, buildings and Machinery and equipment, Assets in In \u20ac millions leasehold laboratory Total furniture and progress improvements equipment vehicles Right of Right of Right of Right of 1Owneduse Owned use Owned use Owned Owned use Total assets assets assets assets 2022 Cost 994.1 819.5 1,561.0 31.8 382.1 49.3 183.0 3,120.3 900.6 4,020.9 Accumulated -383.4 -358.0 -1,137.6 -25.8 -261.4 -24.6 - -1,782.5 -408.4 -2,190.9 depreciation Balance as of 610.7 461.5 423.3 5.9 120.8 24.8 183.0 1,337.8 492.1 1,829.9 1 January Business 35.1 24.1 24.2 0.4 8.2 1.7 15.1 82.6 26.2 108.8 Combinations 2Additions265.2 82.7 226.9 2.5 60.6 15.8 36.0 588.7 101.1 689.8 Disposals -5.1 -8.5 -9.0 -0.4 -2.3 -1.7 - -16.3 -10.5 -26.9 Depreciation -80.8 -118.2 -184.1 -3.4 -44.2 -15.1 - -309.1 -136.7 -445.8 3Impairment- - -1.6 - - - - -1.6 - -1.6 Translation differences and 1.3 6.9 5.1 - - -0.1 0.3 6.6 6.9 13.5 other Balance as of 826.4 448.6 484.8 5.1 143.1 25.3 234.4 1,688.6 479.0 2,167.7 31 December Cost 1,282.4 871.6 1,819.6 28.2 449.7 50.8 234.4 3,786.1 950.6 4,736.7 Accumulated -456.1 -423.0 -1,334.8 -23.1 -306.6 -25.5 - -2,097.5 -471.6 -2,569.1 depreciation 2021 Cost 784.1 753.6 1,278.3 36.0 306.6 42.1 144.2 2,513.1 831.7 3,344.8 Accumulated -308.1 -290.6 -896.1 -28.1 -225.8 -21.3 - -1,430.0 -339.9 -1,769.9 depreciation Balance as of 476.0 463.1 382.1 7.9 80.8 20.9 144.2 1,083.1 491.8 1,574.9 1 January Business 34.3 23.2 25.8 - 3.6 0.2 3.4 67.1 23.5 90.6 Combinations 2Additions155.5 85.4 178.5 1.7 86.9 18.3 36.6 457.6 105.4 562.9 Disposals -6.2 -8.2 -5.9 -0.4 -19.1 -1.3 - -31.2 -9.9 -41.0 Depreciation -67.5 -114.0 -157.8 -3.5 -37.7 -13.3 - -263.0 -130.8 -393.8 3Impairment- - -17.4 - - - -17.4 - -17.4 Translation differences and 18.6 12.0 17.9 0.1 6.3 - -1.2 41.6 12.1 53.7 other Balance as of 610.7 461.5 423.3 5.9 120.8 24.8 183.0 1,337.8 492.1 1,829.9 31 December Cost 994.1 819.5 1,561.0 31.8 382.1 49.3 183.0 3,120.3 900.6 4,020.9 Accumulated -383.4 -358.0 -1,137.6 -25.8 -261.4 -24.6 - -1,782.5 -408.4 -2,190.9 depreciation 1 Owned land, buildings and leasehold improvements include investment in the owned Group sites and leasehold improvements in third party sites. On the net book value of \u20ac826.4m, land and buildings in the owned Group sites represents a value above \u20ac600m. 2 In the Consolidated Cash Flow Statement, purchase of property, plant and equipments takes in consideration Owned additions (\u20ac588.7m) less Capex trade payables change of the period (\u20ac12.6 in 2022). 3 The Group, in line with its accounting policies defined in Note 1.6 Impairment, has performed an assessment of whether the carrying amount of its laboratory equipment dedicated to COVID-19 testing was supported by cash flows expected to be generated in future periods. These calculations use financial data and assumptions based on financial budgets approved by management, which reflect the information available at the time, based on past performance, management\u2019s expectations of future market developments, and specific risks relating to uncertainties regarding the sustainability of the COVID-19 testing market such as but not limited to, the number of tests expected to be performed in combination with the effectiveness of the vaccine campaigns in the various countries where the Group operates. Based on this assessment the Group adjusted the carrying amount of its laboratory equipment to the present value of the cumulated cash flows expected to be generated. At year-end 2022, the COVID-19 laboratory equipment carrying value amounts to \u20ac1m after an additional impairment of \u20ac2m in 2022 (\u20ac17m in 2021) as the Group additionally invested in laboratory equipment in an amount of \u20ac1m in 2022. 2.10. Goodwill Eurofins has identified five groups of cash generating units: France, DACH countries (Germany/Austria/Switzerland), Other European Countries (OEC), North America and Rest of the World (ROW). The following is a summary of goodwill allocation for each group of CGUs as of 31 December: Acquisition Change In \u20ac millions through due to Beginning Dispo-Impair Translation Ending Gross Impair business purchase Gross Impair balance sals -ment differences Balance 2022 value -ment combi-price value -ment nations adjustment North 1,894.1 - 1,894.1 40.7 -9.0 - - 113.2 2,039.0 2,039.0 - America France 904.0 - 904.0 85.9 -5.7 - - 0.0 984.1 984.1 - DACH 279.6 - 279.6 38.7 - - - 1.5 319.8 319.8 - OEC 664.1 2.0 662.1 94.0 -41.6 - - -13.5 701.0 703.0 2.0 ROW 386.3 11.0 375.3 102.5 - - - 2.2 480.1 491.1 11.0 Total 4,128.1 13.0 4,115.1 361.8 -56.3 - - 103.4 4,524.1 4,537.1 13.0 2021 North 1,589.6 - 1,589.6 173.5 - - - 131.0 1,894.1 1,894.1 - America France 859.4 - 859.4 44.6 - - - - 904.0 904.0 - DACH 242.7 - 242.7 35.7 - - - 1.2 279.6 279.6 - OEC 617.1 2.0 615.1 39.0 - - - 8.1 662.1 664.1 2.0 ROW 228.4 11.0 217.4 136.7 - 9.7 - 11.5 375.3 386.3 11.0 Total 3,537.1 13.0 3,524.1 429.5 - 9.7 - 151.8 4,115.1 4,128.1 13.0 The \u201cAcquisition through business combinations\u201d and \u201cDisposals\u201d disclosure are further detailed in Note 2.26 and 3.2 and 3.4. Goodwill Impairment testing The calculation model description is provided in Note 1.6. For impairment testing, goodwill is allocated to cash generating units (typically one level below segment level, i.e., at the business level), which represent the lowest level at which the goodwill is monitored internally for management purposes. Unless otherwise noted, the basis of the recoverable amount used in the annual impairment tests for the units disclosed further in this Note is the value in use. Key assumptions used in the value in use impairment tests for the units were sales growth rates, EBITDA margin and the rates used for discounting the projected cash flows (WACC). These cash flow projections were determined using Eurofins management\u2019s internal forecasts that cover an initial period from 2023 to 2027 after which a terminal value was calculated for 2028. For terminal value calculation, growth rates were capped at a historical long-term average growth rate. This methodology is consistent with the methodology applied in prior periods. The sales growth rates and EBITDA margin used to estimate cash flows are based on past performance, external market growth assumptions and industry long-term growth averages. Management believes that the volume of sales in each period is the main driver for revenue and costs. Eurofins takes into consideration inflation on the profits, margins, liquidity as well as on their overall level of activity in its assumptions. The rates used for discounting the projected cash flows in goodwill impairment testing is based on a weighted cost of capital (WACC), which in turn is based on business-specific inputs along with other inputs. The WACC is based on post-tax cost of equity and cost of debt, and is further calculated based on market data and inputs to accurately capture changes to the time value of money, such as the risk-free interest rate, the beta factor and country risk premium. In order to properly reflect the different risk-profiles of different businesses, a WACC is determined for each group of CGUs. Depreciation on fixed assets is calculated using the straight-line method to write off their cost to their residual values over their estimated useful lives as follows: \u25aa Buildings and leasehold improvements 5-20 years \u25aa Machinery and laboratory equipment 5 years \u25aa Office and IT equipment, furniture and vehicles 3-5 years \u25aa Right of Use over the lease period. Lands represent a value of \u20ac158m as of 31 December 2022 not depreciated as deemed to have an indefinite life. The key assumptions used for value in use calculations and values in use are as follows: 12In \u20ac millions Long term growth ratePre-tax discount rateValue in use 2022 2021 2022 2021 2022 2021 North America 2.50% 2.00% 9.4% 6.0% 7,367 10,631 France 2.00% 2.00% 10.3% 6.6% 1,499 2,850 DACH 2.00% 2.00% 9.8% 6.2% 969 2,017 OEC 2.50% 2.00% 10.4% 6.5% 2,681 4,869 ROW 3.50% 2.50% 10.6% 6.4% 1,554 2,333 Total 14,070 22,700 1 Weighted average growth rate used to extrapolate cash flows beyond the initial five-year period. 2 As required by IAS 36, pre-tax discount rate is derived from the WACC (calculated on a post-tax basis as defined above). The average annual growth rate of the revenues over the initial five-year period used in 2022 is between 3.5% and 9% depending on geographical area excluding COVID-19 business (was between 4% and 9% in 2021). The average EBITDA margin used is between 16% and 24% of the revenues depending on geographic area for the 5-year period (in line with percentages used in 2021). COVID-19 related business activity is excluded from 2023 onwards assumptions. In 2022, no impairment is required as these values are above the carrying value of each group of CGUs. The accumulated impairment is \u20ac13.0m as of 31 December 2022 (same as of December 2021). The results of the annual impairment test indicate that a reasonably possible change in key assumptions would not cause the value in use to fall to the level of the carrying value for any of the Group CGUs (e.g., raising the WACC rate by 1 percentage point would not lead to any impairment). 2.11. Other intangible assets Intangible assets 2Other intangible In \u20ac millions related to SoftwareTotal 1assets acquisitions2022 Cost 1,290.3 412.1 9.8 1,712.2 Accumulated amortisation -498.7 -314.5 -3.2 -816.5 Balance as of 1 January 791.6 97.6 6.5 895.7 Business combinations 90.1 1.5 0.8 92.4 Additions - 75.8 8.3 84.1 Disposals -10.9 0.1 - -10.8 Depreciation -55.4 -1.5 -56.9 Amortisation of acquired assets -104.5 - - -104.5 Impairment -13.3 - - -13.3 Translation differences and other 31.1 1.8 -0.5 32.4 Balance as of 31 December 784.2 121.3 13.6 919.1 Cost 1,407.3 492.9 18.0 1,918.2 Accumulated amortisation -623.1 -371.6 -4.4 -999.2 2021 Cost 1,128.8 354.9 4.9 1,488.6 Accumulated amortisation -383.6 -276.8 -3.0 -663.5 Balance as of 1 January 745.2 78.1 1.9 825.1 Business combinations 107.0 0.7 0.7 108.5 Additions - 57.9 4.2 62.0 Disposals - -0.6 - -0.6 Depreciation -38.6 -1.0 -39.6 Amortisation of acquired assets -91.9 - - -91.9 Impairment -5.7 - - -5.7 Translation differences and other 36.9 0.1 0.8 37.7 Balance as of 31 December 791.6 97.6 6.5 895.7 Cost 1,290.3 412.1 9.8 1,712.2 Accumulated amortisation -498.7 -314.5 -3.2 -816.5 1 In 2022, intangible assets related to acquisitions increased by \u20ac90m. Balance of intangible assets related to acquisitions as of 31 December 2022 include customer relationships (\u20ac671m), technology (\u20ac72m), tradename (\u20ac28m), and other (i.e., branding and marketing, backlog, non compete agreements assets: \u20ac13m).2 Software includes \u20ac58m of internal development costs capitalised in 2022 (versus \u20ac46m in 2021). The expected useful lives of the intangible assets excluding goodwill are as follows: \u25aa Software development costs capitalised and software licences are amortised over their estimated useful life (maximum period of 3 years). \u25aa Customer relationships are amortised on a straight-line basis over their estimated useful lives (maximum period of 13 years). For outsourcing deals signed with a sales contract, the amortisation period is aligned with the duration of the contract. 2.12. Investments in associates Investment in associates in 2022 (details in Note 3.6) amounts to \u20ac5.2m (\u20ac6.2m in 2021). Other investments in associates were as follows: Main associates undertaking: Total Revenues Net profit Equity % of interest In \u20ac millions assets 12022Fasmac Co. Ltd. (JP) 11.5 0.6 9.4 8.1 41% Eurofins Laboratoire Coeur de France SAEML (FR) 6.2 0.6 2.8 1.6 49% Dermscan Asia Co., Ltd (TH)1.1 0.4 0.9 0.8 34% 2Z.F.D. GmbH (DE)- - - - 33% 12021Fasmac Co. Ltd. (JP) 12.4 1.3 9.8 8.3 41% Eurofins Laboratoire Coeur de France SAEML (FR) 13.0 3.0 7.3 4.0 49% Dermscan Asia Co., Ltd (TH)0.8 0.2 0.7 0.6 34% Z.F.D. GmbH (DE) 1.7 0.1 1.2 0.8 33% 1 Unaudited figures. 2 Z.F.D.GmbH (DE) figures from current period are not available. TREX, Ltd (ZA) equity share value is \u20ac3k; revenues, net profit and total assets of this company are not significant. There are no quoted prices available for the companies consolidated by equity method due to their small size (in annual revenues and assets). These five companies are not considered to be material. Share of profit of associates amounts to \u20ac0.9m in 2022 (\u20ac2.0m in 2021). 2.13. Non-current financial assets Non-current Non-current Non-current financial In \u20ac millions financial assets at financial assets at assets at amortised Total 2022 12FVTPLFVTOCIcost Balance as of 1 January 2.6 21.4 51.5 75.5 Changes : Acquisitions/additions - - 12.0 12.0 Sales/redemptions/reductions - - -13.2 -13.2 Business combinations - - 3.6 3.6 Value adjustment through OCI - 1.5 - 1.5 Value adjustment through P&L - - - - Translation differences and other - -1.0 0.2 -0.9 Balance as of 31 December 2.6 21.8 54.1 78.4 2021 Balance as of 1 January - 8.5 42.5 51.0 Changes : Acquisitions/additions - - 12.3 12.3 Sales/redemptions/reductions - - -5.0 -5.0 Business combinations - - 1.1 1.1 Value adjustment through OCI - 12.3 - 12.3 Value adjustment through P&L 2.6 - - 2.6 Translation differences and other - 0.6 0.6 1.2 Balance as of 31 December 2.6 21.4 51.5 75.5 1 Fair value through profit or loss 2 Fair value through other comprehensive income FVTOCI relates to an investment in Vimta Labs Limited, a publicly listed company in India. Non-current financial assets at amortised cost are mainly lease deposits. 2.14. Inventories In \u20ac millions 2022 2021 Inventories (gross) 173.6 193.0 Inventory allowance -28.0 -38.8 Inventories 145.6 154.2 Gross value of inventories decreased to \u20ac174m as of 31 December 2022 (\u20ac193m in 2021). \u25aa Technology and other are amortised on a straight-line basis over their estimated useful lives (maximum period of 15 years). \u25aa Tradename recognised on acquisitions are amortised on a systematic basis over their estimated useful lives (maximum period of 25 years). The cost of inventories recognised as an expense during the period and included in \u201cOperating costs, net\u201d amounts to \u20ac786.5m in 2022 (2021: \u20ac804.3m). The inventory allowance mainly relates to COVID-19 testing kits, swabs and consumable based on management\u2019s expectation of future usage and consumption, adjusted for uncertainties surrounding the resilience of the COVID-19 testing market such as but not limited to, the number of tests expected to be performed. At year end 2022, the carrying amount of the COVID-19 inventory amounts to \u20ac5.6m after an inventory allowance of \u20ac16.8m (carrying amount of \u20ac 33.9m after an allowance of \u20ac31.5m in 2021). 2.15. Trade receivables In \u20ac millions 2022 2021 Trade receivables (gross) 1,111.2 1,106.9 Valuation allowance -57.9 -55.1 Trade receivables 1,053.3 1,051.8 The ageing analysis of trade receivables (gross) is set out below: In \u20ac millions 2022 2021 Current 758.3 765.2 Overdue 1-90 days 240.8 231.4 Overdue 91-360 days 69.1 69.3 Overdue > 360 days 42.9 41.0 Total 1,111.2 1,106.9 Provision for impairment of trade receivables amounts to \u20ac57.9m in 2022 (\u20ac55.1m in 2021). In \u20ac millions Valuation allowance 2022 2021 Balance as of 1 January 55.1 44.9 Additional allowance 13.5 19.2 Reversal -14.7 -11.5 Business Combinations 3.5 1.6 Translation differences and other 0.5 0.9 Balance as of 31 December 57.9 55.1 The maximum exposure to credit risk at the reporting date is the carrying value of the trade receivables mentioned above. The loss allowance at 31 December 2022 and 31 December 2021 was determined as follows: 1-90 days past 91-360 days Over 360 days In \u20ac millions Current Total due past due past due 2022 Expected credit loss rates 0.5% 1.8% 15.5% 100.0% Trade accounts receivable (excl. VAT) 694.1 223.1 63.6 39.2 1,020.1 Contract assets (excl. VAT) 262.8 262.8 Loss allowance 4.9 3.9 9.9 39.2 57.9 2021 Expected credit loss rates 0.5% 1.7% 13.1% 100% Trade accounts receivable (excl. VAT) 702.3 214.5 66.5 37.5 1,020.8 Contract assets (excl. VAT) 308.6 308.6 Loss allowance 5.3 3.6 8.7 37.5 55.1 The Group does not hold any collateral as security. For more details regarding the credit risk of the Group, refer to Note 2.30. The contract assets (work in progress and accrued sales) decreased in 2022 vs 2021 due to the end of specific COVID-19 contracts. 2.16. Prepaid expenses and other current assets In \u20ac millions 2022 2021 Prepaid expenses 78.3 68.0 Other receivables 119.9 114.7 Accrued interest receivables 0.1 0.4 Total 198.3 183.1 Other receivables correspond mainly to tax and social receivables. 2.17. Cash and cash equivalents, bank overdrafts and Net Debt In \u20ac millions 2022 2021 Short term deposits 54.4 17.4 Cash in hand 432.2 497.9 Cash and cash equivalents 486.6 515.3 Bank overdrafts -3.4 -0.3 Cash and cash equivalents less bank overdrafts 483.2 515.0 Short term deposits with banks are mostly owned by Eurofins Scientific SE in Luxembourg for \u20ac18.7m and by its French branch for \u20ac28.7m. In \u20ac millions Note 2022 2021 Total borrowings 2.18 3,325.6 2,754.1 Cash and cash equivalents -486.6 -515.3 Net debt 2,839.0 2,238.8 2.18. Borrowings Variation of borrowings In \u20ac millions Schuld-Com-Bank Bank Lease Issu-2022 Bonds shein mercial Credit Borro-Liabili-ance Total Loan Paper Lines wings ties Costs Balance as of 1 January 1,500.0 582.0 80.0 - 71.5 538.9 -18.6 2,753.8 Cash impact Increase of borrowings 600.0 - - - 45.9 - -12.0 633.9 Repayment of borrowings - -45.5 -5.0 - -32.4 - - -82.9 1Repayment of lease liabilities- - - - - -139.8 - -139.8 Non cash impact Lease subscriptions - - - - - 101.1 - 101.1 Exit of lease liabilities - - - - - -11.8 - -11.8 Amortisation of issuance costs - - - - - - 3.8 3.8 Business combinations - - - - 26.4 30.1 - 56.5 Translation differences and other - - - - -1.5 9.1 - 7.6 Total 2,100.0 536.5 75.0 - 109.9 527.6 -26.8 3,322.2 Bank overdrafts 3.4 Balance as of 31 December 3,325.6 2021 Balance as of 1 January 1,882.8 679.0 15.0 - 53.7 533.7 -11.3 3,152.9 Cash impact Increase of borrowings 750.0 - 65.0 - 25.9 - -14.5 826.3 Repayment of borrowings -1,132.8 -97.0 - - -50.1 - - -1,280.0 1Repayment of lease liabilities- - - - - -128.5 - -128.5 Non cash impact Lease subscriptions - - - - - 105.4 - 105.4 Exit of lease liabilities - - - - - -12.1 - -12.1 Amortisation of issuance costs - - - - - - 7.3 7.3 Business combinations - - - - 41.5 25.2 - 66.8 Translation differences and other - - - - 0.5 15.2 - 15.8 Total 1,500.0 582.0 80.0 - 71.5 538.9 -18.6 2,753.8 Bank overdrafts 0.3 Balance as of 31 December 2,754.1 1 Repayment of lease liabilities excl. interest paid (Note 2.7) The split of the borrowings between current and non-current are as follows:In \u20ac millions 2022 2021 Current Non-Current Total Current Non-Current Total Bonds - 2,100.0 2,100.0 - 1,500.0 1,500.0 Schuldschein loan - 536.5 536.5 45.5 536.5 582.0 Commercial paper 75.0 - 75.0 80.0 - 80.0 Bank borrowings 11.3 98.6 109.9 10.3 61.2 71.5 Lease liabilities 128.6 399.0 527.6 120.7 418.2 538.9 Issuance costs -4.6 -22.3 -26.8 -2.9 -15.7 -18.6 Bank overdrafts 3.4 - 3.4 0.3 - 0.3 Total borrowings 213.8 3,111.8 3,325.6 253.8 2,500.3 2,754.1 Eurobonds In \u20ac millions 31 December 31 December Nominal Nominal Issue date Maturity 2022 2021 value upon interest rate issuance Eurobond 2024 447.8 447.8 650.0 2.125% July 2017 July 2024 Eurobond 2026 302.2 302.2 600.0 3.75% May 2020 July 2026 Eurobond 2029 600.0 - 600.0 4.00% June 2022 July 2029 Eurobond 2031 750.0 750.0 750.0 0.875% May 2021 May 2031 Total 2,100.0 1,500.0 In June 2022, the Group raised \u20ac600m of senior unsecured Eurobonds. The bonds have a 7-year maturity (due on 6 July 2029) and bear an annual fixed rate coupon of 4%. The Bonds are listed on the regulated market of the Luxembourg stock exchange (ISIN XS2491664137). The net proceeds of the bonds were primarily used for the partial redemption of two hybrid capital instruments (see note 2.20). In May 2021, the Group raised \u20ac750m of senior unsecured Eurobonds. The bonds have a 10-year maturity (due on 19 May 2031) and bear an annual fixed rate of 0.875%. The bonds are listed on the regulated market of the Luxembourg stock exchange (ISIN XS2343114687). The net proceeds of the bonds were primarily used for the redemption of the various Eurobond issuances for an amount of \u20ac1,133m. The quoted values of the Company\u2019s Eurobonds are disclosed in Note 2.34. Commercial paper In September 2017, Eurofins set up a Negotiable European Commercial Paper program (\u201cNEU CP\u201d) on the French capital market. This program is used to issue short term notes with a minimum size of \u20ac0.2m and maturity of less than one year. The maximum amount of the program is \u20ac750m as of 31 December 2022 (same as of 31 December 2021). At the end of December 2022, notes were outstanding for an amount of \u20ac75m under this program (\u20ac80m notes outstanding as of 31 December 2021). Schuldschein loan In July 2018, Eurofins issued a \u20ac550m Schuldschein loan (\u201cCertificate of Indebtedness\u201d). The Schuldschein loan was structured in tranches with maturities of 4 and 7 years, with both fixed and floating interest rates. In the 4-year tranches, the fixed rate tranche was priced at a fixed rate of 1.073% per annum and the floating rate tranche at a variable rate of 6-months-Euribor (floored at 0%) plus 95bps per annum. In the 7-year tranches, the fixed rate tranche was priced at a fixed rate of 1.834% per annum and the floating rate tranche at a variable rate of 6-months-Euribor (floored at 0%) plus 130bps. In October 2020, the Company reimbursed \u20ac221m of the Schuldschein loan tranches maturing in July 2022. In January 2021, the Company reimbursed an additional \u20ac97m of the Schuldschein loan tranches maturing in July 2022. In July 2022, the Company reimbursed the remaining tranche of \u20ac45.5m. The remaining Schuldschein loan 2018 amounts to \u20ac186.5m at the end of December 2022. In October 2020, the Company issued a new \u20ac350m Schuldschein loan (\u201cCertificate of Indebtedness\u201d) offering a blended interest rate of 1.78% with an average maturity of 7.8 years. This Schuldschein loan is structured in tranches of 5, 7 and 10 years, with both fixed and floating interest rates, with more than 85% of the transaction on the 7 and 10-year tenors. Leases The following table presents a reconciliation between the total of future minimum lease payments and their present value. 2022 2021 Future Interest Present Future Interest Present value minimum lease value of minimum lease of minimum payments minimum payments lease lease payments In \u20ac millions payments Less than one year 151.6 23.1 128.6 142.8 22.1 120.7 Between one and five years 355.3 36.3 319.0 364.1 44.8 319.3 More than five years 88.7 8.7 80.0 108.6 9.7 98.9 Lease liabilities 595.6 68.1 527.6 615.5 76.6 538.9 The repayment of lease liabilities amounted to \u20ac166.1m (repayment of lease liabilities excl. interest paid: \u20ac139.8m and interests on lease liabilities: \u20ac26.3m). Bilateral credit lines At year-end 2022 and 2021, Eurofins had not used any of its bilateral credit lines. As of 31 December 2022, Eurofins had access to over \u20ac1bn committed mid-term (3 to 5 years) bilateral bank credit lines (same as in 2021). None of the bilateral credit lines is maturing in 2023. 2.19. Interest due on borrowings and earnings due on hybrid capital In \u20ac millions 2022 2021 Interest due on borrowings 30.3 17.1 Earnings due on hybrid capital callable in 2022 - 2.6 Earnings due on hybrid capital callable in 2023 6.0 9.9 Earnings due on hybrid capital callable in 2025 1.7 1.7 Earnings due on hybrid capital 7.7 14.3 Total 38.0 31.4 2.20. Hybrid capital Amount 31 December 31 December redeemed or 2022 2021 In \u20ac millions repurchased Hybrid capital with a first call date on 11 August 2022 - -300.0 300.0 Hybrid capital with a first call date on 29 April 2023 182.7 -117.3 300.0 Hybrid capital with a first call date on 13 November 2025 400.0 - 400.0 Outstanding as of end of period 582.7 -417.3 1,000.0 A new hybrid capital has been issued in January 2023 for an amount of \u20ac600m (Note 2.44). Hybrid capital with a first call date on 11 August 2022 In September 2019, Eurofins raised a \u20ac300m hybrid capital. The instrument had a perpetual maturity but was callable at par by Eurofins at the soonest in August 2022. This hybrid capital bore a fixed annual coupon of 2.875% for the first three years, and a floating coupon of Euribor3m + 605.8 bps thereafter. The instrument was listed on the regulated market of the Luxembourg stock exchange (ISIN XS2051471105). This hybrid capital was fully repurchased in 2022. Hybrid capital with a first call date on 29 April 2023 In April 2015, Eurofins raised a \u20ac300m hybrid capital. The instrument has a perpetual maturity but is callable at par by Eurofins in April 2023. This hybrid capital bears a fixed annual coupon of 4.875% until the first call date and a floating coupon of Euribor3m + 701 bps thereafter. The instrument is listed on the regulated market of the Luxembourg stock exchange (ISIN XS1224953882). In June 2022, Eurofins purchased \u20ac117.3m of this existing hybrid capital. Hybrid capital with a first call date on 13 November 2025 In November 2017, Eurofins raised a \u20ac400m hybrid capital. The instrument has a perpetual maturity but is callable at par by Eurofins in November 2025. This hybrid capital bears a fixed annual coupon of 3.25% until the first call date; then a floating coupon of Euribor3m + 266.7bps until November 2027; then a floating coupon of Euribor3m +366.7bps. The instrument is listed on the regulated market of the Luxembourg stock exchange (ISIN XS1716945586). The earnings outflow related to hybrid capital outstanding reflected in the Consolidated Cash Flow Statement is outlined in greater detail as follows: In \u20ac millions 2022 2021 Earnings paid on hybrid capital callable in 2022 7.3 8.6 Earnings paid on hybrid capital callable in 2023 15.6 14.6 Earnings paid on hybrid capital callable in 2025 13.0 13.0 Total earnings distribution on hybrid capital 35.9 36.3 The impact of the hybrid capital earnings distribution on the equity and of the net profit attributable to hybrid capital holders used for the calculation of the earnings per share is broken down as follows: In \u20ac millions Note 2022 2021 Earnings on hybrid capital callable in 2022 4.6 8.6 Earnings on hybrid capital callable in 2023 11.7 14.6 Earnings on hybrid capital callable in 2025 13.0 13.0 Deferred taxes on hybrid capital distribution 2.8 - -2.2 Total earnings distribution on hybrid capital 2.35 29.3 34.1 2.21. Trade accounts payable and other current liabilities In \u20ac millions 2022 2021 Trade accounts payable 347.4 322.9 Trade accruals payable 300.3 304.7 Total trade accounts payable 647.7 627.6 In \u20ac millions 2022 2021 Tax and social security payables 170.3 209.3 Tax and social security accruals 335.1 329.2 Other payables 66.2 69.4 Total other current liabilities 571.6 607.9 2.22. Amounts due for business acquisitions Amounts due for business acquisitions include conditional clauses impacting the price payable to former shareholders of purchased companies. The analysis of amounts due for business acquisitions is set out below: In \u20ac millions Note 2022 2021 Balance as of 1 January 141.1 104.4 Business combinations 2.26 82.4 44.6 Change due to purchase price adjustment 2.26 - 9.7 Amounts due for business acquisitions paid 2.26 -34.5 -27.5 Reversal of amounts due for business acquisitions not paid 2.6 -21.0 -2.4 Unwind of discount on amounts due for business acquisitions 2.7 13.2 6.9 Translation differences and other 2.7 5.4 Balance as of 31 December 184.0 141.1 Current 47.8 56.8 Non-current 136.2 84.3 Total 184.0 141.1 Amounts due on transaction with former shareholders 118.0 120.5 Put and call options transactions 65.9 20.6 Total 184.0 141.1 Within the amounts due for business acquisitions, the Group has contingent arrangements in relation with 81 past acquisitions (including put and call options). The assumptions used are based on the business plans provided at acquisition time and reviewed during the first 12 months following the acquisition in case of significant changes, then reviewed every year based on actual performance for multi-year arrangements to re-assess deferred considerations to be paid. This is a level 3 fair value measurement. The businesses acquired are already fully consolidated and the liabilities related to the deferred consideration (including put and call options) are already included in the line \u201cAmounts due for business acquisitions\u201d. The potential undiscounted amounts of all future payments that the Group could be required to make under these arrangements are estimated between \u20ac130m and \u20ac245m, depending on changes in financial performance of acquired companies. Main significant amounts due on transactions with former shareholders In July 2017, Eurofins acquired 100% of Eurofins Genoma Group Srl in Italy. The Earn-out Consideration is based on the average EBITDA of the company over the period January 2017 to December 2019 (see Note 2.36). In June 2019, Eurofins acquired 100% of Transplant Genomics, Inc. in the U.S. The first Earn-out consideration was a milestone based upon expected reimbursement price per test paid in 2020 for $20m, as local authorities confirmed the Medicare coverage in November 2019. The second Earn-out consideration is based on Net Revenue achieved over calendar years 2020 through 2024. The fair value of the second contingent consideration arrangement was estimated at a discounted amount of $28m at the end of 2022 ($32m at the end of 2021). The other contingent consideration arrangements are individually estimated at less than \u20ac25m. The new main contingent considerations with previous shareholders in 2022 are: \u25aa Eurofins Bio Sant\u00e9 in France; \u25aa Laboratorios Cavendish in Spain. Put and call options transactions with non-controlling interests at a variable price The aggregate value of these put and call agreements is estimated at less than \u20ac66m as of 31 December 2022. The following put and call agreements were exercised in 2022 for the remaining shares: \u25aa 15% of the shares in Eurofins Lab Solution S.r.l. (Italy); \u25aa 11% of the shares in Eurofins GSD Holdings, Inc. (US). The put and call of 15% of the shares in Commissum Associates (UK/SG) were discontinued through the Digital Testing sale in 2022. Put and call agreements signed in 2021 or before, remaining at the end of December 2022 are as follows: \u25aa 43.5% of the shares in Havlandet Forskningslabratorium (NO); \u25aa 30% of the shares in Eurofins Beacon Discovery, Inc (US); \u25aa 10% of the shares in Alba Science Ltd (UK); \u25aa 10% of the shares in Maser Facilities B.V. (NL); \u25aa 25% of the shares in MGS Laboratories Limited (UK). In 2022, other put and call agreements have been signed for the remaining: \u25aa 39.8% of Bio-EC Group (FR); \u25aa 38.75% of Medserv Kft (HU); \u25aa 49.9% of Eurofins Limed Ltd. (IL); \u25aa 40% of CRA Korea Co. Ltd. (KR); \u25aa 45% of Eurofins Saudi Ajal Laboratories (SA) ; \u25aa 25% of Thai Environmental Technic Co., Ltd. (TH); \u25aa 33% of Genetic Testing Service JSC (VN); \u25aa 45% of Repertoire Genesis Inc. (JP). 2.23. Post-employment benefits The Group operates retirement benefit obligations plans in France, Germany, Sweden, Norway, the Netherlands, Italy, Japan, India and Taiwan. Those plans can either be defined benefit plans (DB) or jubilee payments and have been established in accordance with the legal requirements, customs and the local practice in the countries concerned. Risks related to DB plans DB plans expose the company to various demographic and economic risks such as longevity risk, investment risk, currency and interest rate risk and in some cases inflation risk. The latter plays a role in the assumed wage increase but more importantly in some countries where indexation of pensions is mandatory. France The Group runs a jubilee scheme where a lump sum payment is provided to all employees upon retirement. The amount is dependent on different factors such as years of service with the company, compensation at retirement age (between age of 63 and 65) and collective agreements. This is a legal requirement. Some companies in France also have some work anniversary awards agreements (\u201cm\u00e9daille du travail\u201d). The lump sum amount is defined by the collective agreement and based on the number of years of service with the company. Sweden The Group runs a final salary scheme DB plan for some of its employees in Sweden (ITP2). The ITP2 plan can be funded in two different ways, either by paying premiums to Alecta Pensionsf\u00f6rs\u00e4kring (a mutual life insurance company) or by using a book reserve system in combination with credit insurance through PRI Pensionsgaranti. Eurofins is using the latter. Germany The Group runs a DB plan for the employees of Central Laboratories Friedrichsdorf as well as to former managers of companies acquired by Eurofins who are no longer part of the Group in 2022. Company pension commitments in Germany are partly protected against employer bankruptcy via the \u201cPensions-Sicherungs-Verein\u201d which charges a fee to all German companies providing pension schemes. Norway The Group runs a DB plan (\u201cMulti-Employer Scheme\u201d) for employees who have previously been employed in the public sector. Other In Japan, India and Taiwan, the defined benefit plan mainly corresponds to a lump sum payment made upon retirement or upon ending an employment contract with the company. In the Netherlands, the benefit obligation relates to work anniversary award plans \u2018Jubilee\u2019. In Italy it relates to the TFR (\u2018Trattamento di Fine Rapporto\u2019). It is an end-of-employment provision accrued for each single employee and paid out upon termination of the employment contract. The Group has followed the recommendations of IFRIC update 05/21. The cumulative impacts on pension liability in prior periods as well as the current period are not deemed significant. Summary of pre-tax costs for post-employment benefits and reconciliation The amounts recognised in the Consolidated Income Statement for the defined benefit plans are determined as follows: In \u20ac millions 2022 2021 Defined benefit plans - Included in operating costs, net from operations 4.5 4.6 - Included in finance costs 0.8 0.7 - Included in discontinued operations - - Defined contribution plans - Included in operating costs, net from operations 56.7 47.4 - Included in income from discontinued operations - - Post-employment benefits costs 62.0 52.7 2022 movements in employee benefit obligations between present value of obligations and fair value of plan assets are broken down as follows: 2022 2021 Pension Pension Present Present Fair value of liability in the Fair value of liability in the In \u20ac millions value of value of plan assets Balance plan assets Balance obligations obligations Sheet Sheet As of 1 January 85.6 -10.0 75.5 83.2 -9.9 73.3 Current service cost 4.9 - 4.9 4.8 - 4.8 Past service costs - - - - - - Effects of curtailments -0.4 - -0.4 -0.1 - -0.1 Operating costs, net 4.5 - 4.5 4.6 - 4.6 Interest expense/(income) 1.0 -0.3 0.8 0.8 -0.1 0.7 Amounts recognised in the Consolidated Income 5.6 -0.3 5.3 5.4 -0.1 5.3 Statement Remeasurements: Return on plan assets, excluding amounts included - -0.5 -0.5 - -0.2 -0.2 in interest expense/(income) (Gain)/loss from change in -0.3 - -0.3 0.1 - 0.1 demographic assumptions (Gain)/loss from change in -17.1 - -17.1 -4.0 - -4.0 financial assumptions Experience (gains)/losses -0.1 - -0.1 1.3 - 1.3 Amounts recognised in Other Comprehensive -17.4 -0.5 -18.0 -2.6 -0.2 -2.7 Income Translation differences and -2.1 -0.1 -2.1 3.5 -0.8 2.7 other Business Combinations 2.1 - 2.1 0.2 - 0.2 Contributions: - Employers - - - - -0.2 -0.2 - Plan participants - - - - - - Benefit payments: - From plans -0.6 0.6 0.0 -1.1 1.1 - - From employers -3.4 - -3.4 -3.1 - -3.1 As of 31 December 69.8 -10.3 59.5 85.6 -10.0 75.5 The amounts recognised in the Balance Sheet are broken down as follows on a country basis: 2022 2021 Present value of Fair value Pension liability Present value Pension liability Fair value of Country funded of plan in the Balance of funded in the Balance plan assets obligations assets Sheet obligations Sheet France 28.6 - 28.6 34.6 - 34.6 Sweden 12.7 - 12.7 20.3 - 20.3 Other 28.5 -10.3 18.1 30.7 -10.0 20.6 Total 69.8 -10.3 59.5 85.6 -10.0 75.5 Plan assets Plans assets represent an amount of \u20ac10.3m mainly in cash and corporate bonds as of 31 December 2022 (\u20ac10m as of 31 December 2021). Assumptions The main actuarial assumptions used for defined benefit obligations (DBO) are detailed as follows: Pension increase In % Discount rate Salary increase rate Inflation rate rate France 3.7% 3.5% N/A 3.5% Sweden 4.0% 3.1% 3.1% 2.1% Assumptions regarding future mortality rates are set based on widely known actuarial data and mortality tables. Sensitivity analysis The following table illustrates the approximate impact on the DBO from movements in key assumptions. The DBO was recalculated using a change in the assumptions of 0.5% which overall is considered a reasonably possible change. Salary growth rate Pension growth rate In \u20ac millions Discount rate (incl. inflation) (incl. inflation) Change in assumption +/- 0.5% +/-0.5% +/- 0.5% Net liability amount 59.5 59.5 59.5 Increase of rate in assumption -1.9 4.6 5.0 Decrease of rate in assumption 6.4 -0.3 2.3 The expected employer contributions to the defined benefit plans for 2022 amount to \u20ac0.2m. The average duration of the DBO of the DB plans is 16 years (France: 17, Sweden: 21 and Other: 12) as of 31 December 2022 (2021: 15 years). 2.24. Provisions Reorganisations charges comprise lease termination penalties and employee termination payments. Provisions for other charges are mainly related to litigations. Reorganisation Other charges Total In \u20ac millions charges 2022 Balance as of 1 January 15.1 29.8 44.9 Business combinations -0.2 9.3 9.1 Additional provisions 5.1 17.1 22.3 Used during year -7.6 -9.0 -16.6 Unused amounts reversed -1.6 -4.3 -5.8 Translation differences and other -2.4 2.1 -0.2 Balance as of 31 December 8.6 45.2 53.7 Current 7.7 26.8 34.5 Non-current 0.8 18.4 19.2 2021 Balance as of 1 January 24.3 20.3 44.6 Business combinations - 1.1 1.1 Additional provisions 7.9 16.4 24.2 Used during year -11.7 -5.9 -17.6 Unused amounts reversed -6.1 -3.9 -10.0 Translation differences and other 0.7 1.9 2.6 Balance as of 31 December 15.1 29.8 44.9 Current 14.8 14.5 29.2 Non-current 0.3 15.4 15.7 In 2022, the additional provisions mainly relate to litigations in US and The Netherlands. The reversal of provisions is mainly related to the end of some restructuring processes in The Netherlands. The additional provisions and unused amounts reversed are included in the separately disclosed items (Note 2.5). The periods in which the provision for other liabilities and charges could be paid are broken down as follows: In \u20ac millions 2022 2021 Up to one year 34.5 29.2 1 to 5 years 12.7 8.5 Over 5 years 6.5 7.2 Total 53.7 44.9 2.25. Change in net working capital The change in net working capital as disclosed in the cash flow statement is as follows: In \u20ac millions Note 2022 2021 Change in: Trade receivables 2.15 -1.5 -103.3 Contract assets 2.2 49.0 -92.4 Inventories 2.14 8.6 2.8 1Prepaid expenses and other current assets2.16 -15.4 5.9 Trade accounts payable 2.21 20.1 85.6 Contract liabilities 2.2 21.1 26.3 Other current liabilities 2.21 -36.3 55.6 Total changes (Balance Sheet) 45.6 -19.6 Business combinations \u2013 current assets 30.9 42.0 Tax credit accruals receivable transfer -7.5 -6.3 Business combinations \u2013 current liabilities -24.0 -38.6 Capex trade payables -12.6 -13.1 Translation differences and other -1.2 17.2 Change in net working capital (Cash Flow Statement) 31.2 -18.5 1 Prepaid expenses and other current assets, excluding accrued interest receivables. Tax credit accruals receivable transfer is related to the transfer of corporate tax receivables in France once the tax statements are filed in the following year (Tax Credit for Research). Other current liabilities correspond to tax and social security payables and accruals and other payables. 2.26. Business combinations and outsourcing Acquisitions During 2022, the Group completed 59 acquisitions of which 9 were asset deals. These companies/activities have been fully consolidated from the date the Group took control of these entities. The percentage of ownership of the following acquisitions is provided in Note 3.2. As the Group carries out multiple acquisitions every year, in accordance with paragraph B67 of IFRS 3, the Group is only disclosing individual acquisitions above an acquisition price threshold of \u20ac35 million. In March 2022, Eurofins acquired INPAC Medizintechnik (Inpac) of Birkenfeld, Germany, a cleaning, packaging, and sterilization services firm for the medical device, biotech and pharma industries. At the end of July 2022, Eurofins completed the acquisition of Wessling Hungary, one of the leading environmental, food and biopharma product testing laboratories in Hungary located in Budapest. In October 2022, Eurofins completed the acquisition of Bio Sant\u00e9, one of the leading clinical diagnostic laboratories in Martinique (France). The businesses acquired contributed to Eurofins\u2019 consolidated revenues for \u20ac150m and to consolidated Net profit for \u20ac1m in 2022. The contribution to Adjusted EBITDA for the same period amounted to \u20ac31m. If the effective dates of these acquisitions would have been 1 January 2022, Group consolidated revenues would have been increased by an additional ca. \u20ac120m and consolidated Net Profit by an additional ca. \u20ac10m. The Adjusted EBITDA would also have been increased by an additional \u20ac25m. Part consolidated in 2022 Of which Total acquisitions Wessling In \u20ac millions Inpac Bio Sant\u00e9 Hungary Revenues 149.6 16.2 7.7 4.8 Adjusted EBITDA 30.6 2.6 1.6 - Net Profit 0.8 0.2 0.6 -0.6 FTE 1,407 164 118 41 Part non-consolidated in 2022 Of which Total acquisitions Wessling In \u20ac millions Inpac Bio Sant\u00e9 Hungary Revenues 119.6 2.5 8.6 17.8 Adjusted EBITDA 25.5 0.4 1.2 3.8 Net Profit 9.9 0.1 0.5 2.1 The aggregate fair value of assets and liabilities and the non-controlling interests acquired is per below. For some acquisitions, due to timing constraints, the allocation of the aggregate purchase consideration is provisional as of 31 December 2022. 2022 2021 Of which Wessling Bio Fair In \u20ac millions Fair value Inpac Hungary Sant\u00e9 value Purchase price, cash consideration 465.2 44.9 40.9 63.8 536.8 Purchase price, contingent consideration 82.4 - 1.0 9.6 44.6 Net purchase consideration 547.6 44.9 41.9 73.4 581.5 Property, plant and equipment 110.8 6.5 18.0 7.3 91.5 Intangible assets 92.5 9.9 1.0 1.5 108.2 Other non-current assets 4.5 - 0.2 0.5 2.9 Trade accounts receivable 36.3 1.5 2.8 1.8 31.8 Other current assets 10.6 3.4 0.4 0.4 11.6 Cash and cash equivalents 69.1 1.9 2.0 4.2 34.1 Borrowings -56.5 -1.0 -3.4 -11.7 -67.1 Other current liabilities -49.2 -1.1 -2.7 -1.7 -43.6 Other non-current liabilities -32.4 -3.1 -1.0 -1.2 -17.4 Identifiable net assets acquired 185.7 18.0 17.3 1.0 152.0 Goodwill 361.8 26.9 24.7 72.4 429.5 Net purchase consideration 547.6 44.9 41.9 73.4 581.5 Reconciliation to Cash Flow Statement: Cash and cash equivalents -69.1 -1.9 -2.0 -4.2 -34.1 Purchase price, contingent consideration of the period - unpaid -82.4 - -1.0 -9.6 -44.6 Purchase price, contingent consideration - paid 34.5 - - - 27.5 Non-controlling interests -0.6 - - - 0.3 Net cash outflow on acquisitions 430.0 43.0 38.9 59.6 530.6 The net cash outflow on acquisitions concerns both acquisitions completed in 2022 and in previous years (in case of payment of deferred considerations). During 2022 the Group paid amounts due to former shareholders of previously acquired companies for \u20ac34.5m. In 2022, the Group acquired significant owned buildings as part of new acquisitions for an amount of \u20ac30m (\u20ac31m in 2021), included in property, plant and equipment, and located in various locations across Hungary (Budapest), Spain (Murcia), Germany (Birkenfeld), the United States (Altamonte Springs, FA and Little Rock, AR). The Group acquired also right-of-use assets of operating leases for an amount of \u20ac24.6m in 2022. The goodwill is attributable to the workforce of the acquired business and the synergies expected to arise after acquisition. The part of goodwill and other intangible assets related to acquisitions completed in 2022 that is tax deductible represents an amount of \u20ac58m. For all companies acquired in 2022, the fair value of net assets acquired was as follows: In \u20ac millions 2022 Book value prior to Fair value on Fair value adjustment acquisition acquisition Property plant and equipment 102.7 8.1 110.8 Intangible assets 2.9 89.6 92.5 Other non-current assets 4.1 0.4 4.5 Trade accounts receivable36.8 -0.5 36.3 Other current assets 10.4 0.2 10.6 Cash and cash equivalents 69.1 - 69.1 Borrowings -56.4 -0.1 -56.5 Other current liabilities -50.0 0.8 -49.2 Other non-current liabilities -33.7 1.3 -32.4 Identifiable net assets acquired 85.9 99.8 185.7 The intangible assets include amounts recognised for the fair value of acquired brands, technology and customer-based assets (see main amounts in previous table for Inpac, Wessling Hungary and Bio Sant\u00e9). Divestment In December 2022, the Group divested its Digital Testing business to Stirling Square Capital Partners (\u201cStirling Square\u201d), present in Europe, North America and ROW. This business represented approximately 1 percent of the Group\u2019s sales and employed over 600 staff. In addition, during 2022, the Group divested or discontinued some small unprofitable businesses mainly in the United States, France and New Zealand (annual revenues including Digital Testing of \u20ac94m in 2021). If the effective dates of these divestments would have been 1 January 2022, Group consolidated revenues would have been decreased by an amount ca. \u20ac75m (of which \u20ac66m related to Digital Testing) and adjusted EBITDA would also have been decreased by ca. \u20ac5m (of which \u20ac10m related to Digital Testing). Consolidated Net Profit would have increased by ca. \u20ac4m (considering only Digital Testing, Consolidated Net Profit would have decreased by ca. \u20ac2m). Outsourcing Eurofins signed in May 2022 an outsourcing agreement with Stichting PAMM Laboratoria voor Pathologie en Medische Microbiologie (\u201cPAMM\u201d), a medical microbiology and pathology laboratory diagnostics company in The Netherlands. PAMM employs over 265 employees and pathologists. 2022 Of which In \u20ac millions Total Digital Testing Selling price, cash consideration -220.2 -211.6 Selling price, contingent consideration 0.1 0.1 Net sale consideration -220.1 -211.6 Property, plant and equipment -2.0 -1.8 Intangible assets -10.8 -10.8 Goodwill -56.3 -49.2 Other non-current assets -0.9 -0.9 Trade accounts receivable -14.3 -14.3 Other current assets -1.5 -1.4 Cash and cash equivalents -4.9 -4.3 Other current liabilities 10.7 10.7 Other non-current liabilities 1.2 1.1 Identifiable net assets divested -78.7 -70.9 Gain on disposal of subsidiaries -141.4 -140.6 Proceeds from subsidiaries -220.1 -211.6 Net cash divested 4.9 4.3 Net cash received -215.3 -207.3 2.27. Shareholders\u2019 equity and potentially dilutive instruments Share capital and other reserves As of 31 December 2022, the Company\u2019s share capital is composed of 192,739,583 shares of \u20ac0.01 each (versus 192,251,906 shares as of 31 December 2021 of \u20ac0.01 each). The allotted, called-up and fully paid capital amounts to \u20ac1.9m. During 2022, share capital and other reserves increased by \u20ac14.6m through: \u25aa 387,207 new shares issued from the exercise of stock options, \u25aa 47,600 new shares issued from the exercise of Eurofins 2014 BSA Leaders warrants, \u25aa 51,420 new shares issued from the exercise of Eurofins 2018 BSA Leaders warrants, \u25aa 1,450 new shares issued from restricted stock units. Other reserves correspond to the legal reserve and share premium. Retained earnings correspond to the accumulated reserves not distributed. Currency translation differences Exchange differences arising on translation of the foreign controlled entity are recognised in other comprehensive income, and accumulated in a separate reserve within equity. As of 31 December 2022, the Company had a Currency translation reserve for an amount of \u20ac285.7m, varying from \u20ac179.1m through Other comprehensive income / loss, mainly impacted by the variation of USD, GBP, INR and JPY compared to the Euro. Stock option plans Stock options are granted to certain directors, managers and employees of the Company and its subsidiaries. Movements in the number of stock options outstanding are as follows: 2022 2021 Number of Weighted Number of Weighted Stock options stock options average stock options average outstanding exercise price outstanding exercise price 1 January 7,005,744 50 8,093,000 42 Granted1,264,902 63 605,700 113 Exercised -387,207 28 -1,047,506 25 Expired or lost -675,046 62 -645,450 49 Outstanding as of 31 December 7,208,393 52 7,005,744 50 Exercisable as of 31 December 1,794,067 39 1,671,149 33 The weighted average share price based on Eurofins share price at the date of exercise was \u20ac75 for the 387,207 options exercised in 2022 and was \u20ac100 for the 1,047,506 options exercised in 2021. As at 31 December 2022, 7,208,393 stock options awarded are still outstanding. Further details can be found in the \u201cEurofins Group Remuneration Report 2022\u201d. The exercise price of the granted stock options is generally at least equal to the 20-day volume weighted average market price of Eurofins shares traded on Euronext Paris stock exchange prior to the plan award date including a hurdle of 2%. Options/ Restricted stock units are conditional on the employee completing the vesting period (4 to 5 years). Subject to continued employment and other conditions such as performance conditions for some beneficiaries (\u2018Senior Executives\u2019), vested options can be exercised and have a contractual option term of ten years. The fair value of options granted during the period is determined using the Black-Scholes or Bermudan valuation model from 2019 onwards including a behaviour factor for the expected exercise period. An annual risk-free interest rate of 3.2% is used for the 2022 plans. The volatility measured is based on the statistical analysis of daily share prices over the last three years. Volatility used for 2022 plans was 34%. Number of Weighted average fair stock options Vesting period Average exercise price value of options Plan initially granted (Years) (\u20ac) (\u20ac) 10/10/2011 1,583,500 4/5 5.78 2.4/2.6 02/03/2012 462,500 4/5 6.56 2.5/2.7 19/12/2012 1,914,750 4/5 12.01 4.1/4.5 01/10/2013 1,390,650 4/5 18.23 6.1/6.7 23/10/2014 1,209,500 4/5 18.83 6.1/6.7 07/04/2015 600,000 4/5 25.19 8.0/8.8 22/10/2015 352,500 4/5 28.28 8.9/9.9 21/01/2016 939,200 4/5 28.63 9.1/10.1 01/08/2016 1,227,400 4/5 33.69 10.9/12.0 04/04/2017 413,900 4/5 40.49 10.5/11.6 13/12/2017 1,696,950 4/5 50.87 13.2/14.6 08/01/2019 2,175,880 4/5 32.50 10.3/10.6 18/07/2019 20,000 4/5 38.58 9.0/9.3 24/10/2019 1,629,250 4/5 44.68 11.2/11.6 16/12/2020 1,493,150 4/5 67.50 23.8/24.7 20/10/2021 605,700 4/5 112.59 32.8/34.8 17/10/2022 1,264,902 4/5 62.78 19.8/21.8 Restricted stock units Restricted stock units are granted to eligible managers and employees. Vesting period Fair value of Number of restricted (Years) restricted Plan stock units stock units initially granted (\u20ac) 29/07/2016 4/5 59,850 33.55 01/08/2016 4/5 44,960 33.69 04/04/2017 4/5 9,400 40.49 13/12/2017 4/5 134,000 50.87 08/01/2019 4/5 149,280 35.12 24/10/2019 4/5 88,880 43.56 26/06/2020 4/5 20,200 55.20 16/12/2020 4/5 83,800 68.42 24/02/2021 4/5 91,000 74.99 20/10/2021 4/5 28,350 111.98 20/10/2021 2/3/4/5 22,500 111.98 17/10/2022 4/5 95,424 64.12 Movements in the number of restricted stock units outstanding are as follows: Restricted stock units 2022 2021 1 January 446,700 436,580 Granted 95,424 141,850 Vested -39,060 -83,610 Expired or lost -60,351 -48,120 Outstanding as of 31 December 442,713 446,700 On the 39,060 vested restricted stock units, 1,450 new shares have been issued and 37,610 were served from own treasury shares (share repurchase plan). Further details can be found in the \u201cEurofins Group Remuneration Report 2022\u201d. 2014 BSA Leaders Warrants In July 2014, the Company issued 117,820 capital-providing securities in the form of stock purchase warrants. Following the ten-for-one stock split completed in November 2020, the 2014 BSA Leaders warrants gave their holders the right to subscribe for ten shares of the Company for each 2014 BSA Leaders Warrant at a fixed exercise price of \u20ac281.58 between 1 July 2018 and 30 June 2022. The subscription price was set at \u20ac18.15 per warrant. Movements in the number of 2014 BSA Leaders Warrants were as follows: 2014 BSA Leaders Warrants 2022 2021 1 January 4,760 37,449 Exercised -4,760 -32,689 Expired or lost - - Outstanding as of 31 December - 4,760 Exercisable as of 31 December - 4,760 2018 BSA Leaders warrants In June 2018, Eurofins issued 124,460 capital-providing securities in the form of stock purchase warrants. Following the ten-for-one stock split completed in November 2020, the 2018 BSA Leaders warrants give their holders the right to subscribe for ten shares of the Company for each 2018 BSA Leaders Warrant at a fixed exercise price of \u20ac529.65 between 1 June 2022 and 31 May 2026. The subscription price was set at \u20ac34.36 per warrant. Movements in the number of 2018 BSA Leaders Warrants outstanding were as follows: 2018 BSA Leaders Warrants 2022 2021 1 January 107,419 109,419 Exercised -5,142 - Expired or lost -200 -2,000 Outstanding as of 31 December 102,077 107,419 Exercisable as of 31 December 102,077 - Beneficiary units Beneficiary units are allocated under certain conditions to holders of fully paid-up shares as provided in the Company\u2019s articles of association, at a price of \u20ac0.01 per unit. Upon subscription, beneficiary units from each category of Class A, Class B and Class C confer their holders with one voting right per unit but no rights to dividends. Class A beneficiary units Class A beneficiary units, which confer no right to dividends but a right to one vote each, can be allocated to holders of fully paid-up shares for which (i) proof is provided of registration in the name of the same shareholder for at least three consecutive years as provided for in article 12bis.2 of the Company\u2019s Articles of Association (ii) request to subscribe class A beneficiary units was sent in writing by the relevant shareholder to the Company at the latest by 30 June 2020 and (iii) subject to the Company receiving payment of a subscription price of \u20ac0.01 per class A beneficiary unit. Therefore, the subscription period of class A beneficiary units has now expired. Class B beneficiary units Class B beneficiary units, which confer no right to dividends but a right to one vote each, are allocated to holders of fully paid-up shares for which (i) proof is provided of registration in the name of the same shareholder for at least five consecutive years as provided for in article 12bis.3 of the Company\u2019s Articles of Association (ii) request to subscribe class B beneficiary units was sent in writing by the relevant shareholder to the Company at the latest by 30 June 2021 and (iii) subject to the Company receiving payment of a subscription price of \u20ac0.01 per class B beneficiary unit. Therefore, the subscription period of class B beneficiary units has now expired. Class C beneficiary units Class C beneficiary units, which confer no right to dividends but a right to one vote each, are allocated to holders of fully paid-up shares for which (i) proof is provided of registration in the name of the same shareholder for at least two consecutive years as provided for in article 12bis.4 of the Company\u2019s Articles of Association (ii) request to subscribe class C beneficiary units is sent in writing by the relevant shareholder to the Company at the latest by 30 June 2023 and (iii) subject to the Company receiving payment of a subscription price of \u20ac0.01 per class C beneficiary unit. The Company\u2019s main shareholder Analytical Bioventures S.C.A. paid in 2021 a cash contribution of \u20ac766k equivalent to \u20ac0.01 per Class B & C beneficiary unit (Note 2.37) (2022: 0). Movements in the number of beneficiary units issued were as follows: 2022 Beneficiary units Class A Class B Class C Total 1 January 2022 63,977,852 63,000,000 63,000,000 189,977,852 Beneficiary units subscribed - - - - Beneficiary units cancelled -177.354 - - -177,354 31 December 2022 63,800,498 63,000,000 63,000,000 189,800,498 2021 Beneficiary units Class A Class B Class C Total 1 January 2021 64,577,670 50,000,000 - 114,577,670 Beneficiary units subscribed - 13,550,000 63,000,000 76,550,000 Beneficiary units cancelled -599,818 -550,000 - -1,149,818 31 December 2021 63,977,852 63,000,000 63,000,000 189,977,852 Voting rights Voting rights attached to shares are proportional to the capital quota they represent ie. each share gives the right to one vote. In addition, class A, class B and class C beneficiary units (\u201cparts b\u00e9n\u00e9ficiaires de cat\u00e9gorie A, B et C\u201d) carrying an extra voting right each, can be allocated to fully paid-up shares fulfilling conditions as specified in previous paragraphs about class A, class B and class C beneficiary units. As at 31 December 2022, a total amount of 189,800,498 class A, class B and class C beneficiary units has been issued and the total number of voting rights amounts to 382,320,521. Partial and optional acquisition price payments in Eurofins shares As at 31 December 2022 and 2021, the overall number of Eurofins shares potentially deliverable was nil. Treasury shares Plan 1 \u00ab Liquidity \u00bb contract On 1 November 2021, the Company entered into an agreement with Kepler Cheuvreux in order to enhance the liquidity of its shares. This agreement was valid up until 31 December 2022 and is renewable for one-year periods thereafter. An amount of cash of \u20ac15m has been allocated to a liquidity account by the Company to fund this program. As of 31 December 2022, the Company held 135,677 of its own shares under this liquidity contract (0.07% of the total number of shares at that date) representing an amount of \u20ac9.0m (38,100 shares for an amount of \u20ac3.6m as of 31 December 2021). Plan 2 Share Repurchase Plan The Share Repurchase Plan allows the acquisition of a maximum amount representing up to 2% of the Company\u2019s share capital, over a maximum period of twelve months as per the authorisation granted by the Company\u2019s Extraordinary General Meeting of shareholders held on 25 April 2019 (the \u201cEGM\u201d). The Company may at any time interrupt this program in view of market conditions and/or evolution of its investment strategy. The shares to be purchased under this program will be primarily used to hedge the Company\u2019s Long-Term Incentive plans but may also be cancelled, used to partially finance acquisitions or for other purposes approved by the Board of Directors and within the authorization of the EGM. On 3 October 2022, the Company mandated an independent provider of financial services to buy-back some of its own shares. The first tranche was completed on 3 December 2022. Between 3 October and 3 December, 121,493 shares were repurchased at an average price of 61.31 EUR, representing 0.06% of the current share capital. It is currently intended that all purchased shares may be used as previously communicated, including to cover the Company\u2019s Long-Term Incentive plans as approved by the Board of Directors at its meeting on 19 December 2022. The second tranche will cover a maximum volume of up to one million shares or 0.52% of the Company\u2019s current share capital. The purchase period will start on 22 December 2022 and will last until 3 May 2023 at the latest. Under this plan, as of 31 December 2022, the Company held 83,883 of its own shares (0.04% of the total number of shares) representing an amount of \u20ac5.2m. 2.28. Non-controlling interests Non-controlling interests relate to minority stakes held by third parties in consolidated group companies: \u25aa Eurofins Cerep SA for the remaining non-controlling interests of circa 4.2%. This is a level 1 fair value measurement. \u25aa QSAI Analysis and Research Center Co.,Ltd. (JP) for the remaining non-controlling interests of 15%. \u25aa The companies with remaining NCI and put and call options are: already controlled by the Group in 2021: - Havlandet Forskningslabratorium (NO): 43.5%; - Eurofins Beacon Discovery, Inc. (US): 30%; - Alba Science Limited (UK): 10%; - Maser Facilities BV (NL): 10%; - MGS Laboratories Limited (UK): 25%. newly consolidated companies in 2022: - Bio-EC Group (FR): 39.8%; - Medserv Kft. (HU): 38.75%; - Eurofins Limed (IL): 49.9%; - CRA Korea Co, Ltd. (KR): 40%; - Eurofins Saudi Ajal Laboratories (SA): 45%; - Thai Environmental Technic Co., Ltd (TH): 25%; - Genetic Testing Service JSC (VN): 33%; - Repertoire Genesis Inc. (JP): 45%. The change in the value of the Put and Call option amounts to \u20ac52m for the period 2022 (Note 2.22). This is a level 3 fair value measurement. Other companies with non-controlling interests but without put and call option are listed in Note 3. Below is the impact of the companies with non-controlling interests integrated in the Consolidated Financial Statements: In \u20ac millions 2022 2021 Revenues 151.5 140.8 Net Profit 16.8 10.5 The non-controlling interests of the companies listed above consequently bear the risks and rewards attached to their shareholding, which are recognised as non-controlling interests. Most minority shareholders are managing directors of the companies and they have a right to the dividend of the company in which they hold a non-controlling interest. The Group has elected the full goodwill method on the consolidation of these assets; the non-controlling interests have been in consequence recognised at their fair value against goodwill at acquisition time. In accordance with IAS 32.23, the Group has recognised its obligation to purchase the shares under the put option as a financial liability under the caption \u201camounts due for business acquisitions\u201d (Note 2.22). The same paragraph states that the financial liability is reclassified from equity. During 2022, the Group acquired the remaining non-controlling interests for an amount of \u20ac9.6m in 11% interest of Eurofins GSD Holdings, Inc. (US), in 15% interest of Eurofins Lab Solution Srl (Italy), in 7% interest of Toxlab SAS (FR), in 7% Cimera Estudios Aplicados, SL (ES), in 40% Insight Technologies, Ltd. (MU) and in 2% Chemtest Holdings Limited (UK) including discontinued the remaining 15% non-controlling interests in Commissum Associates (UK/SG), (part of Digital testing) for an amount of \u20ac1.6m. 2.29. Free Cash Flow to the Firm and Equity In \u20ac millions Note 2022 2021 Free Cash Flow to the Firm (Cash Flow Statement) 491.0 1,029.8 Disposals/(acquisition) of investments, financial assets and derivative financial 1.5 -8.4 instruments, net Repayment of lease liabilities 2.18 -166.1 -153.4 Interest received (Cash Flow Statement) 2.5 1.7 Interests and premium paid (Cash Flow Statement) 2.7 -49.4 -168.8 Free Cash Flow to Equity 279.5 700.9 Free Cash Flow to the Firm decrease in 2022 compared to 2021 due to exceptional activity related to COVID-19 in 2021 and higher investments in 2022 especially in the Group\u2019s own sites. 2.30. Financial risk management The Group is exposed to several types of financial risks. This Note further analyses financial risks. The Group does not purchase or hold any derivative financial instruments for speculative purposes. Liquidity risk Liquidity risk is the risk that an entity might encounter difficulty in meeting its obligations associated with its financial liabilities. Liquidity risk for the Group is monitored through / by the Group Treasury Team, which tracks the development of the actual cash flow position for the Group and uses inputs from a number of sources in order to forecast the overall liquidity position on both a short- and longer-term basis. Eurofins invests surplus cash in short-term deposits with appropriate maturities to ensure sufficient liquidity is available to meet liabilities when due. The rating of the Company\u2019s debt may improve or deteriorate. As a result, the Group\u2019s future borrowing capacity may be influenced, and its financing costs may fluctuate. The Group has various sources to mitigate its liquidity risk. As at 31 December 2022, the Group had \u20ac486.6m in cash and cash equivalents (2021: \u20ac515.3m). Cash and cash equivalents include all cash balances and short-term highly liquid investments with an original maturity of three months or less that are readily convertible into known amounts of cash. The Group pools cash from subsidiaries to the extent legally and economically feasible. In addition to its capacity to generate cash-flows from its operations, Eurofins relies on the NEU CP market for its short-term needs as well its bank credit facilities at competitive interest rate. Those bank credit facilities can also be used to fund any type of general corporate purpose. None of those credit lines was drawn at the end of 2022 nor will be maturing in 2023. Eurofins believes it has sufficient liquidity to execute on the Group\u2019s growth plans for 2023. Ratings In July 2020, Eurofins received its first public long-term issuer credit rating by Moody\u2019s Investor Services (\u201cMoody\u2019s\u201d) which assigned an investment grade rating of Baa3 with a stable outlook. Moody\u2019s confirmed the Baa3 rating and upgraded the outlook to positive in May 2022. In May 2021, Eurofins received its second credit rating by Fitch Ratings which assigned an investment grade credit rating of BBB- with a stable outlook. Fitch Ratings confirmed the BBB- rating and the stable outlook in May 2022. Some loans/facilities are secured by contingent securities over assets determined at local level (Note 2.32). The hybrid capital, Eurobonds, Schuldschein loans and bilateral credit lines are neither secured nor include any financial covenants. The table below presents a summary of the Group\u2019s fixed contractual cash obligations and commitments as of 31 December 2022. These amounts are an estimate of future payments which could change as a result of various factors such as a change in interest rates, foreign exchange, contractual provisions, as well as changes in our business strategy and needs. Therefore, the actual payments made in future periods may vary from those presented in the following table: Financial liabilities Total Up to 1 year 2-5 years Over 5 years In \u20ac millions 2022 1Bonds2,100.0 - 750.0 1,350.0 1Schuldschein536.5 - 409.0 127.5 Commercial paper 75.0 75.0 - - 1Bank borrowings109.9 11.3 48.8 49.7 Bank overdrafts 3.4 3.4 - - Lease liabilities 527.6 128.6 319.0 80.0 Amounts due for business acq. (not 216.7 50.3 127.0 39.4 discounted) Earnings due on hybrid capital 7.7 7.7 - - 2Current and future interest due434.6 87.8 243.3 103.6 Trade accounts payable 647.7 647.7 - - Total 4,659.1 1,011.9 1,897.1 1,750.2 2021 1Bonds1,500.0 - 750.0 750.0 1Schuldschein582.0 45.5 233.5 303.0 Commercial paper 80.0 80.0 - - 1Bank borrowings71.5 10.2 32.6 28.7 Bank overdrafts 0.3 0.3 - - Lease liabilities 538.9 120.7 319.3 98.9 Amounts due for business acq. (not 141.3 56.9 78.4 6.0 discounted) Earnings due on hybrid capital 14.3 14.3 - - 2Current and future interest due292.6 61.2 173.8 57.6 Trade accounts payable 627.6 627.6 - - Total 3,848.5 1,016.7 1,587.6 1,244.2 1 Par value.2 Including interests due on borrowings until their full repayment and the impact of any derivative financial instruments. Leases The Group has lease contracts for various items of real estate, vehicles and other equipment used in its operations. The Group has multiple extension and termination options in a number of lease contracts. These are used to maximise operational flexibility in terms of managing the assets used in the Group's operations. The options considered reasonably certain are part of lease liabilities. However, the options not considered reasonably certain are not part of lease liability, which exposes the Company to potential future cash outflows amounting to \u20ac41m. In addition, the Group is not committed to leases not yet commenced. The Group's lease contracts do not contain any financial covenants. The Group has the following minimum lease payments commitments: Total Up to 1 year 2-5 years Over 5 years In \u20ac millions 1- Buildings7.1 7.1 - - - Equipments, cars and others 1.6 1.0 0.6 - Total 8.7 8.1 0.6 - 1 Undiscounted sum of future aggregate minimum lease payments, non-cancellable other than lease liabilities already reported in Note 2.18. The Group recorded in 2022 expenses of \u20ac12.4m related to short term leases and an expense of ca. \u20ac1m relating to low-value assets, which are recognised in other operating expenses. Currency risk Currency risk is the risk that reported financial performance, or the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Group operates in many countries and currencies and therefore currency fluctuations may impact Eurofins\u2019 financial results. Eurofins is exposed to currency risk in the following areas: \u25aa Transaction exposures, related to anticipated sales and purchases and on balance-sheet receivables/payables resulting from such transactions; \u25aa Translation exposure of foreign-currency intercompany and external debt and deposits; \u25aa Translation exposure of net income in foreign entities; \u25aa Translation exposure of foreign-currency-denominated equity invested in consolidated companies; \u25aa Translation exposure to equity interests in non-functional-currency investments in associates and other non-current financial assets. In 2022, the Group generated around 57% of its revenues outside of the Euro-Zone. The Group will continue to conduct its business activities in the future via subsidiaries in various countries. However, in most cases, the revenues and operating results as well as most items on the Balance Sheet of its subsidiaries (intangible, fixed and current assets, some financial and current liabilities) are settled in the domestic currency without any real exchange risk. Accounting-wise, these operating results and Balance Sheet items are recorded in the relevant foreign currency and then converted into Euro, for translation into the Consolidated Financial Statements at the applicable exchange rate. In some cases, where an exchange rate risk might be applicable with revenues and cost structures in different currencies, the Company may enter into some currency hedging instruments to avoid any exchange rate fluctuations. The most significant currencies for the Group were translated at the following exchange rates into Euro: Value Balance Sheet Income Statement of \u20ac1 End of period rates average rates 31 December 2022 31 December 2021 2022 2021 US Dollar 1.07 1.14 1.05 1.18 Pound Sterling 0.89 0.84 0.85 0.86 Japanese Yen 140.41 130.91 138.08 129.87 Canadian Dollar 1.45 1.44 1.37 1.48 Indian Rupee 88.15 84.21 82.75 87.46 Chinese Renminbi 7.36 7.22 7.08 7.63 Danish Krona 7.44 7.44 7.44 7.44 Taiwan Dollar 32.75 31.35 31.34 33.09 Australian Dollar 1.57 1.56 1.52 1.57 South Korean Won 1,342.60 1,345.90 1,357.54 1,353.18 As at 31 December 2022, the exposure to currency risk breaks down as follows: Off-Balance Currency 22Net position Net position AssetsLiabilitiesSheet Hedge In \u20ac millions before hedge after hedge Commitments US Dollar 4,670.4 1,008.8 - 3,661.6 - 3,661.6 Pound Sterling 367.0 118.8 - 248.2 - 248.2 Japanese Yen 290.7 104.6 - 186.1 - 186.1 Canadian Dollar 252.6 99.6 - 153.0 - 153.0 Indian Rupee 229.0 83.0 - 146.0 - 146.0 Chinese Renminbi 163.8 83.3 - 80.5 - 80.5 Danish Krona 152.5 55.0 - 97.5 - 97.5 Taiwan Dollar 126.4 35.5 - 90.9 - 90.9 Australian Dollar 119.8 39.2 - 80.7 - 80.7 South Korean Won 96.4 47.8 - 48.7 - 48.7 1Other700.1 323.7 19.2 357.2 - 357.2 Total 7,168.8 1,999.3 19.2 5,150.3 - 5,150.3 1 Non Euro. 2 including Intercompany positions. A 1 percentage point increase or decrease in exchange rates would have an impact of +/- \u20ac30.4m on the Group\u2019s equity and an impact on the Group\u2019s EBITAS of +/- \u20ac5.8m. Foreign exchange exposure also arises as a result of inter-company loans and deposits. When the lending company enters into such arrangements, the financing is generally provided in the functional currency of the subsidiary entity. When such loans would be considered to be part of the net investment in the subsidiary, net investment hedging would be applied. Translation exposure of foreign-currency equity invested in consolidated entities is generally not hedged. Net current-period change, before tax, of the currency translation reserve of \u20ac285.7 mainly relates to the development of the USD versus the Euro (\u20ac106.7m in 2021). As at 31 December 2022, a weakening / a strengthening of USD by 1% versus the Euro would result in a decrease / an increase in the currency translation reserve in equity of approximately \u20ac37m. Reference is made to the country risk paragraph for countries with significant foreign currency denominated equity invested. Interest rate risk Interest rate risk is the risk that the fair value or future cash flows of a financial instrument might fluctuate because of changes in market interest rates. In order to finance parts of its acquisition and expansion costs, the Company and its subsidiaries have entered into several loan and facility agreements as specified in Note 2.18. The Group had, at year-end, outstanding debt of \u20ac3,325.6 (2021: \u20ac2,754.1m), which constitutes an inherent interest rate risk with potential negative impact on financial results. The loans and facilities are either based on a fixed rate or on a variable rate. The derivative financial instruments assets include caps for an amount of \u20ac5.6m as of 31 December 2022 in order to hedge the Group\u2019s exposure to interest rate fluctuations particularly related to the 2018 Schuldschein loan (\u20ac0.5m at end of 2021). The Group has concluded hedging contracts, for an initial premium of \u20ac2.4m, in order to cap its floating interest rate against a fixed rate for a total nominal amount of \u20ac99m. In \u20ac millions Note 2022 2021 Balance as of 1 January 0.5 0.1 Amortisation of Time Value 2.7 -0.3 -0.3 Fair Value adjustments through OCI 5.4 0.8 Balance as of 31 December 2.33 5.6 0.5 The impact on the valuation of the financial instruments of a shift of +/- 1 percentage point in the yield curve would not be material on the Group\u2019s total equity. The amount booked in equity is transferred to net profit as far as the underlying instrument impacts the net profit. The Group\u2019s net exposure to interest rate risk for the borrowings (excluding lease liabilities) as per Balance Sheet date, before taking into account the above hedging transactions is presented below: 2022 2021 Borrowings at fixed interest rates 90% 88% Borrowings at floating interest rates 10% 12% Given the breakdown between fixed rate and floating rate assets and liabilities as at 31 December 2022, a 1% increase or decrease in interest rates would have a full-year impact of +/- \u20ac1.7m on results before income taxes (excluding lease liabilities). Rate Up to 2-5 Over Total In \u20ac millions 1 year years 5 years Short term deposits Fixed -54.4 - - -54.4 Floating - - - - Bonds Fixed - 750.0 1,350.0 2,100.0 Floating - - - - Schuldschein Fixed - 177.5 97.5 275.0 Variable - 231.5 30.0 261.5 Commercial paper Fixed 75.0 - - 75.0 Floating - - - - Bank borrowings Fixed 10.8 45.5 43.7 100.0 Floating 0.5 3.4 6.0 9.9 Lease liabilities Fixed 6.5 25.0 8.1 39.6 Floating 122.1 293.9 71.9 487.9 Net exposure Fixed 37.9 998.0 1,499.3 2,535.2 Before hedge Floating 122.6 528.8 107.9 759.3 Hedge Fixed - 99.0 - 99.0 Floating - -99.0 - -99.0 Net exposure Fixed 37.9 1,097.0 1,499.3 2,634.2 After hedge Floating 122.6 429.8 107.9 660.3 Credit risk Credit risk represents the loss that would be recognised at the reporting date if counterparties failed completely to perform their payment obligations as contracted. Credit risk is present within Eurofins\u2019 trade receivables and contract assets. In order to have better insight into its credit exposure, the Group performs ongoing analysis of the financial and non-financial condition of its customers and adjusts credit limits if and when appropriate. In instances where the creditworthiness of a customer is determined not to be sufficient to grant the credit limit required, there are a number of tools that can be utilised to mitigate the impact, including reducing payment terms, cash on delivery, pre-payments and pledges on assets. The rate of default experienced by the Group in proportion to its sales has been very low for the past five years. On average during this period, provision for impairment of receivables represented around 1% of the annual revenues, whilst customer terms of payment are in accordance with ordinary commercial practices in each country where the Group is active. In case of more challenging economic and/or trading conditions, the Group pays particular attention to the ability of new and existing customers to pay their debts. The Group believes its policy relating to doubtful debtors to be appropriate. The Group has a large number of customers across its business lines. The Group endeavours not to be dependent on any single customer. The biggest customer represents less than 2% of the consolidated revenues and the first 10 customers of the Group represent altogether less than 10% of the consolidated revenues. More particularly, the credit risk associated with US clinical diagnostic testing services is described in more detail in Note 1.4. The amounts relating to trade receivables, bad debt provision and the ageing balance are shown in Note 2.15. With a slight increase of overdues in percentage of total trade accounts receivable, the average observed credit losses over the last three years remain low and the expected loss rate did not materially change between 2021 and 2022. The Group invests available cash and cash equivalents with various leading financial institutions with strong credit ratings and is exposed to limited credit risk with these counterparties. The Group policy is to limit its exposure by dealing solely with leading counterparties and monitoring their credit ratings, in line with guidelines approved by the Company. The Group actively manages concentration risk of its liquidity among financial institutions and measures the potential loss under certain stress scenarios, should a financial institution default. These worst-case scenario losses are monitored and mitigated by the Company. In the context of negative short-term interest rate across many European countries, the Group may decide to ease some of the criteria listed above in order to avoid any loss on capital (i.e., no negative remuneration on cash deposit). Country risk Country risk is the risk that political, legal, or economic developments in a single country could adversely impact the Group\u2019s performance. The country risk is monitored on a regular basis (see Assets and Liabilities per currency in Note 2.30 \u2013 Currency Risk). There are a number of potential risks and uncertainties which could have a material impact on the Group\u2019s performance over the financial year 2023 and could cause actual results to differ materially from expected and historical results, including the potential risks which could arise from the conflict in Ukraine, as described in the risk section of the management report. Direct Russia & Ukraine revenues for Eurofins companies were under \u20ac3m in 2021 and less than \u20ac1.5m in 2022. 2.31. Capital risk management The Group\u2019s objectives when managing capital are to safeguard the Group\u2019s ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce its cost of capital. In order to maintain or adjust the capital structure, the Group may adjust the dividends paid to its shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt. Borrowings pledged by assets or with covenants The liabilities and borrowings listed below are already included in the Group\u2019s Consolidated Balance Sheet. The following table only repeats these amounts when these borrowings are secured by covenants or securities on assets. In \u20ac millions 2022 2021 Bank borrowings secured over buildings and other assets 80.3 51.7 1Finance leases secured over buildings and other assets41.5 42.8 Bank borrowings secured by covenants and assets 2.8 2.9 Total borrowings and leases secured 124.7 97.4 Bank borrowings secured by covenants - - Bank borrowings guaranteed by the direct parent of the borrower - - Total 124.7 97.4 1 Finance lease liabilities are effectively secured as the rights to the leased asset revert to the lessor in the event of default. Other Guarantees In \u20ac millions Total Up to 1 year 2-5 years Over 5 years Guaranteesgiven related to financing 19.2 - - 19.2 Guarantees given related to acquisitions - - - - Total 19.2 - - 19.2 Guarantees received - - - - Total guarantees, net 19.2 - - 19.2 Detail of guarantees given related to financing \u25aa The Company has counter-guaranteed the Swedish insurance company \"F\u00f6rs\u00e4kringsbolaget Pensionsgaranti\" for all amounts due that this entity should have to pay to the current and past employees of some Swedish companies that are indirect subsidiaries of Eurofins Scientific SE, as part of their pension payment obligation for a maximum amount of \u20ac19.2m (this amount is accounted for in the caption \u201cretirement benefit obligations\u201d Note 2.23). \u25aa In the context of a \u20ac1.2m public subsidy grant contract obtained in 2008 by Eurofins BioPharma Product Testing Ireland Limited, the Company gave its guarantee to the Irish governmental agency which provided the grant that it will be liable in case of Eurofins BioPharma Product Testing Ireland Limited failing to meet its commitments related to this grant. The guarantee expired in October 2022. 2.33. Exposure to market and counterparties risks In \u20ac millions Note 2022 2021 Derivative financial assets \u2013 Caps 2.30 5.6 0.5 Derivative financial assets 5.6 0.5 Derivative financial liabilities \u2013 Swaps - - Total net 5.6 0.5 2.34. Fair value of financial assets and liability The estimated fair value of financial instruments has been determined by the Group using available market information and appropriate valuation methods. The estimates presented are not necessarily indicative of the amounts that will ultimately be realised by the Group upon maturity or disposal. The use of different market assumptions and/or estimation methods may have a material effect on the estimated fair value amounts. The following tables show the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy. Fair value information for financial assets and financial liabilities not carried at fair value is not included if the carrying amount is a reasonable approximation of fair value. As of 31 December 2022 Carrying Fair value Level 1 Level 2 Level 3 In \u20ac millions amount Financial assets Financial assets carried at FVTOCI 21.8 21.8 21.8 - - Financial assets carried at FVTPL 2.6 2.6 - - 2.6 Derivative financial instruments 5.6 5.6 - 5.6 - Financial assets carried at fair value 30.0 30.0 21.8 5.6 2.6 Cash and cash equivalents 486.6 - - - - Receivables \u2013 current 1,461.7 - - - - Receivables - non-current 54.1 - - - - Financial assets carried at (amortised) costs 2,002.4 - - - - Total financial assets 2,032.4 30.0 21.8 5.6 2.6 Financial liabilities Contingent consideration 184.0 184.0 - - 184.0 Financial liabilities carried at FVTPL 184.0 184.0 - - 184.0 Derivative financial instruments - - - - - Financial liabilities carried at fair value 184.0 184.0 - - 184.0 Payables and contract liabilities 831.9 - - - - Interest accrual 38.0 - - - - Bonds 2,100.0 1,898.7 1,898.7 - - Other borrowings 1,225.6 - - - - Other liabilities 571.6 - - - - Financial liabilities carried at (amortised) costs 4,767.0 1,898.7 1,898.7 - - Total financial liabilities 4,951.0 2,082.7 1,898.7 - 184.0 As of 31 December 2021 Carrying Fair value Level 1 Level 2 Level 3 In \u20ac millions amount Financial assets Financial assets carried at FVTOCI 21.4 21.4 21.4 - - Financial assets carried at FVTPL 2.6 2.6 - - 2.6 Derivative financial instruments 0.5 0.5 - 0.5 - Financial assets carried at fair value 24.5 24.5 21.4 0.5 2.6 Cash and cash equivalents 515.3 - - - - Receivables \u2013 current 1,504.4 - - - - Receivables - non-current 51.5 - - - - Financial assets carried at (amortised) costs 2,071.2 - - - - Total financial assets 2,095.7 24.5 21.4 0.5 2.6 Financial liabilities Contingent consideration 141.1 141.1 - - 141.1 Financial liabilities carried at FVTPL 141.1 141.1 - - 141.1 Derivative financial instruments - - - - - Financial liabilities carried at fair value 141.1 141.1 - - 141.1 Payables and contract liabilities 790.7 - - - - Interest accrual 31.4 - - - - Bonds 1,500.0 1,555.6 1,555.6 - - Other borrowings 1,254.1 - - - - Other liabilities 607.9 - - - - Financial liabilities carried at (amortised) costs 4,184.0 1,555.6 1,555.6 - - Total financial liabilities 4,325.1 1,696.7 1,555.6 - 141.1 Specific valuation techniques used to value financial instruments include: Level 1 Instruments included in level 1 are comprised primarily of listed equity investments classified as financial assets carried at fair value through profit or loss or carried at fair value through Other Comprehensive Income. The fair value of financial instruments traded in active markets is based on quoted market prices at the Balance Sheet date. A market is regarded as active if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm\u2019s length basis. Level 2 The fair value of financial instruments that are not traded in an active market (for example, over-the-counter derivatives or convertible bond instruments) is determined by using valuation techniques. These valuation techniques maximise the use of observable market data where it is available and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are based on observable market data, the instrument is included in level 2. The fair value of derivatives is calculated as the present value of the estimated future cash flows based on observable interest yield curves, basis spread and foreign exchange rates. The valuation of convertible bond instruments uses observable market quoted data for the options and present value calculations using observable yield curves for the fair value of the bonds. Level 3 If one or more of the significant inputs are not based on observable market data, such as third-party pricing information without adjustments, the instrument is included in level 3. With the exception of the borrowings, the Group considers the carrying value of the financial instruments to approximate their fair value. Regarding borrowings, their fair value is based on: \u25aa A quoted price included in Level 1 of the fair value hierarchy for the Eurobond 2024 (fair value amount of \u20ac438.7m against acarrying value of \u20ac447.8m - ISIN XS1651444140).\u25aa A quoted price included in Level 1 of the fair value hierarchy for the Eurobond 2026 (fair value amount of \u20ac306.2m against acarrying value of \u20ac302.2m - ISIN XS2167595672).\u25aa A quoted price included in Level 1 of the fair value hierarchy for the Eurobond 2029 (fair value amount of \u20ac589.0m against acarrying value of \u20ac600m - ISIN XS2491664137).\u25aa A quoted price included in Level 1 of the fair value hierarchy for the Eurobond 2031 (fair value amount of \u20ac564.8m against acarrying value of \u20ac750m - ISIN XS2343114687).2.35. Earnings per share Detail of the basic and diluted weighted average number of shares outstanding (details in Note 2.26) In millions 2022 2021 Basic weighted average number of shares outstanding 192.5 191.5 Weighted average number of stock options 5.2 7.4 Weighted average number of restricted stock units 0.4 0.5 Number of potential number of shares by warrants exercise 1.1 1.3 Weighted average number of treasury shares -0.1- Diluted weighted average shares outstanding 199.0 200.6 The weighted average number of stock options decreased in 2022 due to two stock options plans not in the money (exercise price below 31 December share price value). Earnings per share Net profit for the period is allocated between hybrid capital investors (Note 2.20) and the equity holders of the Company as follows for the calculation of the earnings per share: Net Profit of the period Weighted average Earnings per share 2022 number of shares (in \u20ac millions) (in \u20ac) outstanding Basic Total 610.2 192.5 3.17 Owners of the Company 580.9 192.5 3.02 1Hybrid capital investors29.3 192.5 0.15 Diluted Total 610.2 199.0 3.07 Owners of the Company 580.9 199.0 2.92 1Hybrid capital investors29.3 199.0 0.15 1 See Note 2.20. Net Profit of the period Weighted average Earnings per share 2021 number of shares (in \u20ac millions) (in \u20ac) outstanding Basic Total 782.6 191.5 4.09 Owners of the Company 748.5 191.5 3.91 1Hybrid capital investors34.1 191.5 0.18 Diluted Total 782.6 200.6 3.90 Owners of the Company 748.5 200.6 3.73 1Hybrid capital investors34.1 200.6 0.17 1 See Note 2.20. 2.36. Contingencies The Group has contingent liabilities in respect of commercial and tax claims arising in the ordinary course of business in connection with the services they provide. The majority of commercial claims is covered by business-specific insurance. An on-going litigation or potential new litigation that could cause significant financial or reputational damage for Eurofins continues or may arise in the context of the detection of biological contaminants in dairy products in Europe. The Group\u2019s responsibility has not been proven and the damages that are claimed have been neither established nor measured. 2.37. Related-party transactions Transactions between the Company and its subsidiaries, which are related parties of the Group, are made at arm\u2019s length conditions and have been eliminated in the consolidation process and are not disclosed in the Notes. The Group is controlled by Analytical Bioventures S.C.A., a holding company of the Martin family. As of 31 December 2022, Analytical Bioventures owned 32.7% of the Company\u2019s shares and controls 65.9% of its voting rights (32.8% of the Company\u2019s shares and 65.9% of its voting rights as of 31 December 2021). Transactions with affiliates or with companies owning shares in Eurofins Group such as Analytical Bioventures S.C.A. or with companies such as International Assets Finance S.\u00e0 r.l., in which some members of the Company\u2019s Board of Directors have significant influence, are mainly related to lease agreements on laboratories/sites used by Eurofins and are disclosed as follows: In \u20ac millions 2022 2021 Consolidated Income Statement Support management services, provided to the related party 0.3 0.3 Interest expenses to related party 7.0 7.2 Depreciation of right of use 24.3 25.9 Consolidated Balance Sheet 1Receivables expected from related party 13.8 14.1 Payables owned to related party 1.1 3.7 Right of use from related party 122.9 139.9 Lease liabilities to related party 143.3 161.9 Dividends paid to related party 63.0 43.0 Beneficiary units subscribed by related party - 0.8 Off Balance Sheet commitments Bank guarantees to related party - 0.2 1 Receivables expected from related party relate to lease deposits. Other information related to the real estate transactions is provided in the Corporate Governance Statement for the period ended on 31 December 2022. For tax claims, when the Group estimates that the risk is not likely, no provision is booked. There are a limited number of pending claims, qualified as contingent liability by third-party legal advisors and the Company. The Group has entered into legal proceedings against the former shareholders of Eurofins Genoma Group Srl in Italy for breach of non-compete and other contractual clauses. The Group has an outstanding contingent consideration arrangement for this former acquisition, for which \u20ac27.5m has been accrued in \u201cAmounts due from business acquisitions\u201d within non-current liabilities on the Balance Sheet as of 31 December 2022 and current liabilities as of 31 December 2021. The final amount payable is subject to the legal proceedings. Risk factors are described in section 5 of the Management report.Based on the information available to date, the Group considers that the outcome of these disputes and legal claims currently in process is unlikely to have a significant adverse impact on the Consolidated Financial Statements other than those already provided for (Note 1.12). 2.38. Compensation of the Board of Directors and Group Operating Council (GOC) In \u20ac millions 2022 2021 Compensation of executive directors 1.6 1.9 Compensation of non-executive directors 0.3 0.3 Management compensation (GOC excluding CEO) 11.4 6.8 Post-employment benefits - - Other long-term benefits- - Termination benefits - - Long-term incentives (\u201cstock options\u201d) to GOC members 4.9 - Total 18.3 9.0 The increase is mainly due to two factors: (i) the timing of joining and leaving of GOC members between the two periods with a total number of FTE increasing from 10.3 in 2021 to 15.2 in 2022 and (ii) the absence of any equity-linked remuneration awarded in 2021. The amount of contributions paid for defined contribution pension plans of some members of the Board of Directors was \u20ac45k in 2022. Further details can be found in the section \u201cEurofins Group Remuneration Report 2022\u201d. 2.39. Auditor\u2019s remuneration In \u20ac millions 2022 2021 Audit of Eurofins Scientific SE 0.7 0.6 Audit of financial statements of subsidiaries 5.0 3.7 Audit-related services 0.1 0.1 Audit and audit-related fees payable pursuant to legislation 5.8 4.4 Taxation services - - Total fees Deloitte 5.8 4.4 In addition, with the work performed for consolidation purposes, the Group has commissioned statutory audits in a very large majority of its subsidiaries, even when not required by local regulations, performed mostly by Tier 1 and Tier 2 audit firms in order to ensure reliability and strong control of financial statements in a fast-growth phase, of which: \u25aa Tier 1 (Deloitte, PwC, EY and KPMG);\u25aa Tier 2 (RSM, Grant Thornton, BDO, Mazars, Moore Stephens, Crowe and Baker Tilly).The aggregate amount of audit fees for all auditors across the Group was \u20ac10.9m in 2022 and \u20ac8.4m in 2021. Other information related to the audit coverage is provided in section 2.1.3 (Audit Committee) of the Corporate Governance Statement for the year ended on 31 December 2022. 2.40. COVID-19 As a world leader in the provision of essential clinical diagnostic, forensic, pharmaceutical, food and environmental laboratory testing services, Eurofins has been able to draw on its scientific expertise and innovation to develop a comprehensive suite of SARS-CoV-2 tests in response to the coronavirus pandemic. During 2022, the Group continued to maintain high volumes in its COVID-related activities (human clinical testing and sale of reagents), contributing revenues just under \u20ac600m during this period. This compares to revenues of over \u20ac1,400m in 2021. These lower volumes have also driven a significant proportion of the \u20ac49m decrease in contract assets recorded as of 31 December 2022 compared to 31 December 2021. For 2023, whilst the duration and magnitude of COVID-related activities remain uncertain and testing intensity at any given time may vary period-on-period and between countries, the Group intends to continue to support health initiatives globally and leverage its scientific expertise to develop further its suite of SARS-CoV-2 tests to respond to changes in the overall testing environment. 2.41. Cyber-attack On 2 June 2019, Eurofins Scientific was hit by a criminal ransomware attack which caused disruption to many of its IT systems in several countries. Eurofins IT staff and their internal and external IT security teams and experts took prompt actions to contain the incident, mitigate its impact and worked relentlessly to return the IT operations to normal in the companies of the Group that have been affected. Eurofins teams continue to expend significant effort to further optimise and strengthen all IT operations. As business interruption insurance coverage for this criminal cyber-attack has been confirmed, the Group received for an amount of \u20ac10m in 2019, \u20ac29.8m in 2020, \u20ac12.5m in 2021 and \u20ac5m in 2022 recorded in the line \u201cOther operating expenses (income), net\u201d (Note 2.3). It is likely that discussions and efforts to determine and agree on exact damages with Group insurers will be on going for a while and additional reimbursements cannot be determined precisely at this time. 2.42. Climate change-related risks The Group regularly evaluates relevant climate-related risks as evidenced in the section \u201cRisk factors report 2022\u201d (Section 1.5.6) and in \u201cEurofins Environment, Social and Governance report 2022\u201d including its impact on the books and records of the Group. The Group reviews the disclosure obligations under Article 8 of the Taxonomy Regulation (EU) 2020/8522 and will keep monitoring going forward the disclosure requirements of the Non-Financial Reporting Directive and subsequently the Corporate Sustainability Reporting Directive. For the year-end, the potential impact of climate related matters, including legislation which may affect the fair value of assets and liabilities in the Consolidated Financial statements has been considered, especially but not limited to deferred tax assets recoverability, useful life of tangibles and intangibles and provisions. The risks in respect of climate-related matters are included as relevant and applicable key assumptions where they materially impact the determination of fair value. As of 31 December 2022, the Group does not believe that the impact of climate related matters is material to the Consolidated Financial Statements. Carbon neutrality The Group announced the goal of achieving carbon neutrality by 2025, through a focussed program of CO2 emission reduction and carbon offsetting (see paragraph \u201ccarbon neutrality objective\u201c in section \u201cClimate change\u201d in the \u201cEurofins Environment, Social and Governance report 2022\u201d). In 2022, Eurofins purchased 2.3m tons for \u20ac11.0m and retired 0.2m tons of carbon credits for \u20ac0.8m (2021: 0.15m tons). Carbon credits are recorded as intangible assets and expensed when retired. Responding to climate challenges is at the heart of the Group's strategy, and its commitment to carbon neutrality is taken into account in its financial decisions. 2.44. Post-closing events Business combinations Since the beginning of 2023, Eurofins completed 4 acquisitions of which 2 asset deals. The total annual revenues of these acquisitions amounted to approximately \u20ac11m in 2022 for an aggregate acquisition price of \u20ac16m. These acquisitions employ over 100 employees. Financing Hybrid capital with a first reset date on 24 July 2028 In January 2023, Eurofins raised \u20ac600m hybrid capital. The instrument has a perpetual maturity but is callable at par by Eurofins at the soonest in April 2028. This hybrid instrument bears a fixed annual coupon of 6.75% for the first 5.5 years (until 24 July 2028), a floating coupon of Euribor3m + 424.1 bps until 24 January 2033 and Euribor3m + 524.1 bps thereafter. The instrument is listed on the regulated market of the Luxembourg stock exchange (ISIN XS2579480307). This issuance enables the Group to return to its targeted capital structure that includes an adequate level of hybrid capital of \u20ac1bn to support its targeted range for financial leverage of 1.5-2.5x. The bonds\u2019 proceeds are available for general corporate purposes. Outside of the planned repayment of the outstanding \u20ac183m in hybrid capital callable on 29 April 2023, Eurofins has no major refinancing requirements until the outstanding \u20ac448m senior Eurobonds become due on 25 July 2024. Guarantee The Company gave a guarantee for a period of 12 months from 1 January 2023 and expiring on 1 January 2024 to the benefit of Chubb (i.e., Chubb European Group SE, ACE Ina Overseas Insurance Company Ltd. and Chubb INA Overseas Insurance Company Ltd.) in the context of the implementation of an internal reinsurance captive (Eurofins Re S.A.) in Luxembourg indirectly owned by the Company to indemnify for all losses, liabilities, costs, expenses and damages for a total amount of \u20ac25m per annual aggregate. 2.43. Inflation The Group has addressed inflationary risk and its impact on the books and records of the Group in the section \u201cRisk factors report 2022\u201d. For the year-end, the impact of rising inflation rates, and consequent interest rates, in many geographies are considered in the determination of the fair value of assets and liabilities in the Consolidated Financial Statements, including, but not limited to financial instruments, goodwill or other long-lived assets impairment testing, defined benefit retirement programs and long-term incentive plans. As of 31 December 2022, the Group believes impact of inflation is appropriately reflected and has not led to any material impacts in the Consolidated Financial Statements. 3.1. Incorporation of the year The companies below have been incorporated during the year and are fully consolidated (at 100%): % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Regional Service Centre ANZ Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 08/22 Gembloux Rue Phocas Lejeune Real Estate NV BfB Oil research SA BE 100.00% 04/22 Eurofins Digital Agency NV Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. BE 100.00% 01/22 Eurofins GSC IT Solutions & Operations SA Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 12/22 Eurofins Product Testing Service (Hangzhou) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 07/22 Eurofins Electrical Testing Service (Shanghai) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 10/22 Eurofins Discoverx Products (Shanghai) Co., Ltd. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CN 100.00% 01/22 Eurofins Cosmetic Testing Service (Shanghai) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 10/22 Eurofins Testing Technology Service (Shenzhen) Co., Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 10/22 Ltd. Eurofins Testing Inspection Certification (Xiamen) Co., Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 09/22 Ltd. Eurofins NBLSC Forensic Germany GmbH Eurofins MWG Holding GmbH DE 100.00% 01/22 Eurofins Genomics GMP Products and Services GmbH Eurofins MWG Holding GmbH DE 100.00% 07/22 Eurofins Aquatic Ecotoxicology GmbH Eurofins Agroscience Services Germany Holding DE 100.00% 08/22 GmbH Eurofins RBLSC BioPharma Product Testing Germany Eurofins BioPharma Services Holding Germany GmbH DE 100.00% 09/22 GmbH Eurofins Genomics Europe Research Products & Eurofins MWG Holding GmbH DE 100.00% 10/22 Services Synthesis GmbH Eurofins Genomics Europe IT Services GmbH Eurofins MWG Holding GmbH DE 100.00% 10/22 Eurofins Genomics Europe Pharma and Diagnostics Eurofins MWG Holding GmbH DE 100.00% 10/22 Porducts & Services Sales GmbH Eurofins Genomics Europe Research Products & Eurofins MWG Holding GmbH DE 100.00% 10/22 Services NGS GmbH Eurofins Genomics Europe Research Products & Eurofins MWG Holding GmbH DE 100.00% 10/22 Services Sanger GmbH Ishoj Baldershoj Real Estate ApS Eurofins Real Estate LUX Holding S.\u00e0 r.l. DK 100.00% 06/22 Eurofins Diagnosticos Clinicos RD, SAS Eurofins Latin American Ventures, S.L.U. DO 100.00% 11/22 Eurofins Biomed 2022 1 SAS Eurofins NSC Finance France SAS FR 100.00% 01/22 Eurofins Biomed 2022 2 SAS Eurofins NSC Finance France SAS FR 100.00% 01/22 Eurofins Biomed 2022 3 SAS Eurofins NSC Finance France SAS FR 100.00% 01/22 Eurofins Biomed 2022 4 SAS Eurofins NSC Finance France SAS FR 100.00% 01/22 Eurofins Biomed 2022 5 SAS Eurofins NSC Finance France SAS FR 100.00% 01/22 Eurofins Biomed Basse-Normandie SELAS Eurofins Labazur Provence SELAS FR 100.00% 09/22 Eurofins Biomed Ile de France Est SELAS Eurofins Labazur Provence SELAS FR 100.00% 12/22 Eurofins Newco 2023 1 SAS Eurofins NSC Finance France SAS FR 100.00% 11/22 Eurofins Newco 2023 2 SAS Eurofins NSC Finance France SAS FR 100.00% 11/22 Eurofins Newco 2023 3 SAS Eurofins NSC Finance France SAS FR 100.00% 11/22 Eurofins Newco 2023 4 SAS Eurofins NSC Finance France SAS FR 100.00% 11/22 SCI Eurofins 2023 1 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/22 SCI Eurofins 2023 2 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/22 SCI Eurofins 2023 3 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/22 SCI Eurofins 2023 4 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/22 Eurofins Biopharma Product Testing Croatia D.O.O. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. HR 100.00% 01/22 % of Date ISO interest Company Subsidiary of: of code by the entry Group Empowerdx Ireland Ltd. Eurofins Direct To Consumer Testing LUX Holding S.\u00e0 IE 100.00% 04/22 r.l Eurofins South Bengaluru Resources Private Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. IN 100.00% 02/22 Eurofins It Enabled Services India Private Limited Eurofins Support Services LUX Holding S.\u00e0 r.l. IN 100.00% 03/22 Eurofins Regulatory & Consultancy Services Italy Srl Eurofins Pharma Services Italia Holding Srl IT 100.00% 05/22 Vimodrone Via Grandi Real Estate Invest Srl Eurofins Real Estate LUX Holding S.\u00e0 r.l. IT 100.00% 06/22 Eurofins BioPharma Product Testing Europe RBLSC Eurofins Pharma Services Italia Holding Srl IT 100.00% 06/22 Srl Eurofins Clinical Testing Japan Holding Ltd. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. JP 100.00% 01/22 Imizu Hibari Real Estate KK Eurofins Real Estate LUX Holding S.\u00e0 r.l. JP 100.00% 01/22 Hamamatsu Nishijima Real Estate KK Eurofins Real Estate LUX Holding S.\u00e0 r.l. JP 100.00% 03/22 Eurofins Food & Feed Testing Japan Holding KK Eurofins Food Testing LUX Holding S.\u00e0 r.l. JP 100.00% 05/22 Eurofins Genomic Services Japan Holding KK Eurofins Genomics LUX Holding S.\u00e0 r.l. JP 100.00% 04/22 Eurofins Tribology LUX Holding S.\u00e0 r.l Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 05/22 Eurofins Direct To Consumer Testing LUX Holding S.\u00e0 Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 05/22 r.l Eurofins Re LUX Holding S.\u00e0 r.l Eurofins Scientific SE LU 100.00% 12/22 Eurofins Genomics It Solutions Latvia Sia Eurofins Genomics LUX Holding S.\u00e0 r.l. LV 100.00% 06/22 Eurofins Environment Testing Holding Malaysia Sdn. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. MY 100.00% 08/22 Bhd. Leiden Bioscience Park Real Estate B.V. Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 04/22 Amersfoort Koningsbergenweg Real Estate B.V. Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 04/22 Eurofins Project Flow B.V. Eurofins Clinical Diagnostics Netherlands Holding BV NL 100.00% 04/22 Eurofins NBLSC Food Testing Netherlands B.V. Eurofins Food Testing Netherlands Holding BV NL 100.00% 09/22 Eurofins BioPharma Product Testing Poland Sp. z.o.o. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. PL 100.00% 01/22 Katowice Real Estate Sp. z.o.o Eurofins Real Estate LUX Holding S.\u00e0 r.l. PL 100.00% 03/22 Eurofins GSC IT Romania SRL Eurofins Support Services LUX Holding S.\u00e0 r.l. RO 100.00% 02/22 Eurofins Vitamins Testing Romania SRL Eurofins Food & Feed Testing Romania Holding SRL RO 100.00% 05/22 Eurofins Clinical Diagnostics (Thailand) Co., Ltd. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. TH 100.00% 02/22 Eurofins Environment Testing Holding (Thailand) Co., Eurofins Environment Testing LUX Holding S.\u00e0 r.l. TH 100.00% 10/22 Ltd. Eurofins Eag Materials Science Taiwan Ltd. Eurofins Material Sciences LUX Holding S.\u00e0 r.l. TW 100.00% 03/22 Eurofins Genomics Europe Dtc - Population Genetics Eurofins Genomics LUX Holding S.\u00e0 r.l. UK 100.00% 03/22 Products & Services Limited Eurofins Biomnis Edinburgh Limited Eurofins Clinical Diagnostic Testing UK Holding Limited UK 100.00% 07/22 Empowerdx Uk Limited Eurofins Direct To Consumer Testing LUX Holding S.\u00e0 UK 100.00% 05/22 r.l DDC UK Services Limited Eurofins Direct To Consumer Testing LUX Holding S.\u00e0 UK 100.00% 07/22 r.l Orlando Newburyport Avenue Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 01/22 San Diego Convoy Court Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 04/22 Eurofins BioPharma Product Testing Enco, Inc. Eurofins Pharma US Holdings II, Inc. US 100.00% 04/22 St. Charles 25 Research Park Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 06/22 Cary Maynard Road Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 07/22 Fremont Bayside Parkway Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 07/22 Chicago Crossing Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 10/22 Eurofins Food Assurance US Holdings, Inc. Eurofins Assurance LUX Holding S.\u00e0 r.l. US 100.00% 11/22 Mounds View Woodale Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 12/22 3.2. Acquisition of the year The companies below have been acquired during the year and are fully consolidated (at 100%): % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Apal Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 02/22 Eurofins Euraceta NV Eurofins Food Testing LUX Holding S.\u00e0 r.l. BE 100.00% 12/22 Manara Medical Laboratories W.L.L. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. BH 100.00% 12/22 Spincontrol Am\u00e9rique du Nord, Inc. Eurofins Product Testing clinical and ex-vivo France CA 60.20% 08/22 Holding SAS Microscan Service SA Eurofins Qute Holding AG CH 100.00% 06/22 Modern Genomic Services Co., Ltd. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. CN 100.00% 03/22 TA Technology (Shanghai) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 12/22 Lunaria s.r.o. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CZ 100.00% 06/22 Cll Chemnitzer Laborleistungs GmbH Eurofins NDSC Umweltanalytik GmbH DE 100.00% 04/22 Eurofins Umweltanalytik S\u00fcd GmbH Eurofins NDSC Umweltanalytik GmbH DE 100.00% 04/22 Eurofins Food Testing S\u00fcd GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 04/22 GmbH Stella Analyse GmbH Eurofins Environment Testing Netherlands Holding BV DE 100.00% 03/22 Inpac Medizintechnik GmbH Eurofins BioPharma Services Holding Germany GmbH DE 100.00% 03/22 Reco Planegg Behringstra\u00dfe Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 03/22 BECIT GmbH Eurofins Food Testing Germany East Holding GmbH DE 100.00% 07/22 Dr. Lauk & Dr. Breitling GmbH Eurofins Forensics LUX Holding S.\u00e0 r.l. DE 100.00% 09/22 Biocontrol Y Calidad Alimentaria, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 03/22 Laboratorios Vital, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 03/22 Granada Bailen Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 04/22 Bio-9000, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 05/22 Eurofins Cavendish, S.L.U. Eurofins Environment Testing Spain Holding, S.L.U. ES 100.00% 10/22 Laboratori Cat-Gairin, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 10/22 Laboratorios Munuera, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 07/22 Cidesal Analisis Alimentos, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 08/22 Derio Idorsolo Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 07/22 Eurofins Biotalde, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 08/22 Convet, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 12/22 Clinilab Laboratorio Cl\u00ednico Huelva, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 12/22 Bestlab Oy Eurofins Environment Testing Finland Holding Oy FI 100.00% 06/22 Eurofins Bio Sant\u00e9 SELAS Eurofins Biologie M\u00e9dicale Holding France SAS FR 100.00% 10/22 Spincontrol SAS Eurofins Product Testing clinical and ex-vivo France FR 60.20% 08/22 Holding SAS Soci\u00e9t\u00e9 Financi\u00e8re Bio Callens Holding SARL Eurofins Product Testing clinical and ex-vivo France FR 60.20% 08/22 Holding SAS Centre de Recherches Biologiques et Eurofins Product Testing clinical and ex-vivo France FR 60.20% 08/22 d'Exp\u00e9rimentations Cutan\u00e9es - BIO-EC SAS Holding SAS Genex SAS Centre de Recherches Biologiques et FR 60.20% 08/22 d'Exp\u00e9rimentations Cutan\u00e9es - BIO-EC SAS GEA (Grand Est Analyses) SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 10/22 SAS Laboratories of Biological-Chemical Trials and Eurofins Food Testing LUX Holding S.\u00e0 r.l. GR 100.00% 06/22 Analyses, SA Wessling Hungary Kft. Eurofins Environment Testing Hungary Holding Kft. HU 100.00% 08/22 Wessling Vagyonkezel\u0151 Kft. Wessling Hungary Kft. HU 100.00% 08/22 % of Date ISO interest Company Subsidiary of: of code by the entry Group BIOMI Biotechnol\u00f3giai Szolg\u00e1ltat\u00f3 Korl\u00e1tolt Felel\u0151ss\u00e9g\u0171 Wessling Hungary Kft. HU 100.00% 08/22 T\u00e1rsas\u00e1g Kft. Wessling Nemzetk\u00f6zi Kutat\u00f3 \u00e9s Oktat\u00f3 K\u00f6zpont Wessling Hungary Kft. HU 100.00% 08/22 Nonprofit Korl\u00e1tolt Felel\u0151ss\u00e9g\u0171 T\u00e1rsas\u00e1g Kft. Medserv Kft. Eurofins Clinical Testing Hungary Holding Kft. HU 61.25% 09/22 Sejtdiagnosztika Kft. Medserv Kft. HU 61.25% 09/22 PT Modern Testing Services Indonesia Eurofins Product Testing LUX Holding S.\u00e0 r.l. ID 100.00% 01/22 Eurofins Limed Ltd. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. IL 50.10% 04/22 Eurofins Sisthema Srl Eurofins Assurance LUX Holding S.\u00e0 r.l. IT 100.00% 02/22 Environ-Lab Srl Eurofins Environment Testing LUX Holding S.\u00e0 r.l. IT 100.00% 06/22 Genetic Lab Co., Ltd. Eurofins Clinical Testing Japan Holding Ltd. JP 100.00% 01/22 Repertoire Genesis Inc. Eurofins Clinical Testing Japan Holding Ltd. JP 55.00% 06/22 QSAI Analysis and Research Center Co.,Ltd. Eurofins Food & Feed Testing Japan Holding KK JP 85.00% 09/22 CRA Korea Co, Ltd. Eurofins Product Testing Korea Holding Co., Ltd. KR 60.00% 06/22 Eurofins Mediscan Laboratories Sdn Bhd Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. MY 100.00% 05/22 Stella Analyse B.V. Eurofins Environment Testing Netherlands Holding BV NL 100.00% 03/22 Plm Laboratorium Services B.V. Eurofins Environment Testing Netherlands Holding BV NL 100.00% 03/22 Dia-Go B.V. Eurofins Environment Testing Netherlands Holding BV NL 100.00% 03/22 Przedsi\u0119biorstwo Bada\u0144 I Ekspertyz \u015arodowiska Eurofins Environment Testing Poland Holding Sp. z o.o. PL 100.00% 04/22 \"Sepo\" Sp. z.o.o. Lagra Laborat\u00f4rio Agr\u00edcola do Alentejo Lda. Eurofins Food Testing LUX Holding S.\u00e0 r.l. PT 100.00% 07/22 Eurofins Saudi Ajal Laboratories Eurofins Food Testing LUX Holding S.\u00e0 r.l. SA 55.00% 06/22 Svensk Arbetshygien AB Eurofins Environment Testing Sweden Holding AB SE 100.00% 10/22 Thai Environmental Technic Co., Ltd. Eurofins Environment Testing Holding (Thailand) Co., TH 75.00% 10/22 Ltd. Altair Analytical Limited Eurofins Food Testing UK Holding Limited UK 100.00% 04/22 Sensory Dimensions Limited Eurofins Sensory, Consumer research and Product UK 100.00% 09/22 design LUX Holding S.\u00e0 r.l. Bio Search (N.I.) Limited Eurofins Food Testing UK Holding Limited UK 100.00% 07/22 Eurofins Analytics LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 03/22 Human Factors Md, LLC Eurofins Pharma US Holdings II, Inc. US 100.00% 05/22 Little Rock Kanis Road Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 11/22 American Interplex, LLC Eurofins Environment Testing South Central, LLC US 100.00% 11/22 Genetic Testing Service JSC Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. VN 67.00% 02/22 3.3. Merged entities The companies below have been merged with another Eurofins entities during the year: % of ISO interest Date Company Subsidiary of: Code by the of exit Group Eurofins NSC Finance Germany GmbH Eurofins Support Services LUX Holding S.\u00e0 r.l. DE 100.00% 07/22 Eurofins NSC Finance Clinical Diagnostics Germany Eurofins Support Services LUX Holding S.\u00e0 r.l. DE 100.00% 07/22 GmbH Eurofins Alfalab Internacional, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Laboratorio Calbo, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Laboratorio Bernad-Mu\u00f1oz, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Laboratorio Cl\u00ednico Sanitario, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 % of ISO interest Date Company Subsidiary of: Code by the of exit Group Eurofins Laboratorio Dres. Cerme\u00f1o, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Laboratorio Pilar Larraz, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Laboratorio Recio, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 EUROFINS Laboratorio Medicantabria S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Laboratorio Virtudes, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Labrovet, S.L.U. Eurofins Mas Control, S.L.U. ES 100.00% 06/22 Eurofins An\u00e1lisis Cl\u00ednicos Canarias, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Laboratorio Garc\u00eda L\u00f3pez, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Prelevement Pour Le Batiment Sud Ouest Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 07/22 SAS SAS Eurofins Alpabio Prestations SAS Alpa Environnement Holding France SAS FR 100.00% 07/22 Alpa Support Services SAS Alpa Environnement Holding France SAS FR 100.00% 07/22 Alpa Hygiene Alimentaire SAS Alpa Alimentaire Holding France SAS FR 100.00% 07/22 Medical Consultants Pathology Holdings Limited Eurofins Biomnis Ireland Limited IE 100.00% 11/22 Eurofins Cyber Security Assurance & Advisory Eurofins Cyber Security Netherlands Holding BV NL 100.00% 06/22 Netherlands BV Eurofins Cyber Security Hacking & Testing BV Eurofins Cyber Security Netherlands Holding BV NL 100.00% 06/22 Eurofins Cyber Security Products & Services BV Eurofins Cyber Security Netherlands Holding BV NL 100.00% 06/22 Maser Engineering BV Eurofins Maser BV NL 90.02% 08/22 Eurofins Environment Services Polska Sp. z.o.o. Eurofins Environment Testing Poland Holding Sp. z o.o. PL 100.00% 06/22 Research For Hire, Inc. Eurofins Agroscience Services, LLC US 100.00% 10/22 Eurofins NTD, LLC Eurofins Viracor, LLC US 100.00% 12/22 Eurofins GSD Holdings, Inc. Eurofins Technologies US Holdings, Inc. US 100.00% 08/22 Eurofins Viracor Oncology, LLC Eurofins Clinical Testing US Holdings, Inc. US 100.00% 11/22 Pomona 900 Corporate Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 08/22 Eurofins Ana Laboratories, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 04/22 3.4. Discontinued operations The companies below have been liquidated or sold during the year: % of ISO interest Date Company Subsidiary of: Code by the of exit Group Eurofins GSC Finance NV Eurofins Scientific SE BE 100.00% 12/22 Eurofins Digital Testing Belgium NV Eurofins Digital Testing International LUX Holding S.\u00e0 BE 100.00% 12/22 r.l Eurofins Digital Testing Shenzhen Co., Ltd. Eurofins Digital Testing International LUX Holding S.\u00e0 CN 100.00% 12/22 r.l BELM Pet\u0151fi utca 45 Real Estate Kft. Eurofins Real Estate LUX Holding S.\u00e0 r.l. HU 100.00% 03/22 Sandyford Clinical Diagnostics Limited Eurofins Biomnis Ireland Limited IE 100.00% 11/22 Eurofins Digital Testing India Private Limited Eurofins Digital Testing International LUX Holding S.\u00e0 IN 100.00% 11/22 r.l Eurofins SAM Sensory And Marketing Italy Srl Eurofins Food & Feed Testing Italia Holding Srl IT 100.00% 03/22 Eurofins Digital Testing International LUX Holding S.\u00e0 Eurofins Product Testing LUX Holding S.\u00e0 r.l. LU 100.00% 12/22 r.l Commissum Sdn Bhd Eurofins Product Testing LUX Holding S.\u00e0 r.l. MY 100.00% 12/22 Heerenveen Leeuwarderstraatweg Real Estate BV Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 01/22 Eurofins Digital Testing and Cyber Security Netherlands Eurofins Digital Testing International LUX Holding S.\u00e0 NL 100.00% 12/22 BV r.l % of ISO interest Date Company Subsidiary of: Code by the of exit Group Eurofins Cyber Security Netherlands Holding B.V. Eurofins Product Testing LUX Holding S.\u00e0 r.l. NL 100.00% 12/22 Eurofins Digital Testing Sweden AB Eurofins Product Testing LUX Holding S.\u00e0 r.l. SE 100.00% 12/22 Eurofins Pharma Discovery Services UK Limited Eurofins Discovery Services LUX Holding S.\u00e0 r.l. UK 100.00% 03/22 Chemtest Holdings Limited Eurofins Environment Testing UK Holding Limited UK 100.00% 08/22 Southern Real Estate Investment UK Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. UK 100.00% 08/22 Eurofins Covid Testing Services Limited Eurofins Forensics LUX Holding S.\u00e0 r.l. UK 100.00% 12/22 Eurofins Digital Product Testing UK Limited Eurofins Digital Testing International LUX Holding S.\u00e0 UK 100.00% 12/22 r.l Edge Testing Solutions Limited Eurofins Digital Testing UK Holding Limited UK 100.00% 12/22 Eurofins Digital Testing UK Holding Limited Eurofins Digital Testing International LUX Holding S.\u00e0 UK 100.00% 12/22 r.l Commissum Associates Limited Eurofins Digital Testing UK Holding Limited UK 85.00% 12/22 Eurofins Digital Media Services, LLC Eurofins Product Testing US Holdings, Inc. US 100.00% 12/22 3.5. Principal subsidiary undertakings The Companies below are fully consolidated (at 100%). % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Scientific SE LU Eurofins Biomnis Middle East LLC Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. AE 100.00% 11/19 Agrohuarpes - Eurofins Agrosciences Services SA Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. AR 100.00% 08/17 Eurofins Lebensmittelanalytik \u00d6sterreich GmbH Eurofins Food Testing LUX Holding S.\u00e0 r.l. AT 100.00% 01/07 Eurofins Genomics Austria GmbH Eurofins Genomics LUX Holding S.\u00e0 r.l. AT 100.00% 09/11 Eurofins Agroscience Services Austria GmbH Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. AT 100.00% 12/12 Eurofins Environment Testing Austria Holding GmbH Eurofins Environment Testing LUX Holding S.\u00e0 r.l. AT 100.00% 03/15 Eurofins Umwelt \u00d6sterreich GmbH & Co.KG Eurofins Environment Testing Austria Holding GmbH AT 100.00% 03/15 Eurofins NUA Austria Holding GmbH Eurofins Environment Testing Austria Holding GmbH AT 100.00% 01/16 Eurofins Water & Waste GmbH Eurofins Environment Testing Austria Holding GmbH AT 100.00% 12/15 Wiener Neudorf Palmersstra\u00dfe Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. AT 100.00% 12/16 Eurofins NSC Austria GmbH Eurofins Support Services LUX Holding S.\u00e0 r.l. AT 100.00% 12/18 Eurofins Analytics & Services Austria GmbH Eurofins Environment Testing Austria Holding GmbH AT 100.00% 09/20 Eurofins Professional Scientific Services Austria GmbH Eurofins Pharma Services LUX Holding S.\u00e0 r.l. AT 100.00% 10/20 Eurofins Environment Testing Australia Pty Ltd. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. AU 100.00% 01/13 Eurofins Agroscience Services Pty Ltd. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. AU 100.00% 07/13 Eurofins Agroscience Testing Pty Ltd. Eurofins Agrosciences Services France Holding SAS AU 100.00% 07/13 Eurofins Animal Health Australia Pty Ltd. Eurofins Agrosciences Services France Holding SAS AU 100.00% 01/16 Eurofins ams Laboratories Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 03/16 Eurofins Australia New Zealand Holding Pty Ltd. Eurofins Environment Testing France Australia Holding AU 100.00% 05/16 SAS Eurofins Food Testing Australia Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 07/16 Girraween Magowar Road Real Estate Pty Ltd. Eurofins Real Estate LUX Holding S.\u00e0 r.l. AU 100.00% 05/17 Dandenong South Monterey Road Real Estate Pty Ltd. Eurofins Real Estate LUX Holding S.\u00e0 r.l. AU 100.00% 05/17 Eurofins Dermatest Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 07/17 Eurofins Technologies Australia Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 08/17 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Chemical Analysis Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 03/19 Eurofins ProMicro Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 11/20 Eurofins ARL Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 11/20 Eurofins NBLSC Environment Testing ANZ Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 11/20 AQM Bangladesh Limited AQM HK Co., Ltd. BD 100.00% 06/19 Eurofins GSC Management Services NV Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 06/01 Eurofins Belgium NV Eurofins Environment Testing Belgium Holding NV BE 100.00% 11/07 Eurofins Food Testing Belgium NV Eurofins Food Testing LUX Holding S.\u00e0 r.l. BE 100.00% 10/10 Eurofins Environment Testing Belgium Holding NV Eurofins Environment Testing LUX Holding S.\u00e0 r.l. BE 100.00% 09/11 Nazareth Venecoweg Real Estate NV Eurofins Real Estate LUX Holding S.\u00e0 r.l. BE 100.00% 09/11 Eurofins Forensics Belgium BVBA Eurofins Forensics LUX Holding S.\u00e0 r.l. BE 100.00% 10/11 Eurofins Pharmaceutical Product Testing Belgium NV Eurofins Pharma Services LUX Holding S.\u00e0 r.l. BE 100.00% 11/11 Eurofins Agro Testing Belgium NV Eurofins Food Testing LUX Holding S.\u00e0 r.l. BE 100.00% 07/13 Eurofins Professional Scientific Services Belgium NV Eurofins Pharma Services LUX Holding S.\u00e0 r.l. BE 100.00% 06/14 Eurofins GSC IT Solutions NV Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 07/14 Eurofins GSC Finance & Administration NV Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 09/16 Eurofins Biological Testing Belgium NV Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. BE 100.00% 02/17 Eurofins Asbestos Testing Belgium NV Eurofins Environment Testing Belgium Holding NV BE 100.00% 08/17 Eurofins Amatsigroup NV Eurofins Amatsigroup SAS BE 100.00% 09/17 Eurofins Labo Van Poucke BVBA Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. BE 100.00% 02/18 Eurofins NSC Belgium BVBA Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 12/18 Eurofins GSC Consulting NV Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 09/19 Eurofins Air Monitoring Belgium NV Eurofins Air Monitoring LUX Holding S.\u00e0 r.l. BE 100.00% 12/19 Transportation, Facility and Logistic Services NV Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 12/19 Eurofins GSC Transformation & Operational Excellence Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 12/20 NV Eurofins GSC Facility Management NV Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 12/20 BfB Oil research SA Eurofins IESPM SAS BE 100.00% 04/21 Eurofins GSC Finance & Controlling Systems SA Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 12/21 Eurofins Agroscience Services EOOD Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. BG 100.00% 11/08 Eurofins HOS Testing Bulgaria EOOD Eurofins Food Testing LUX Holding S.\u00e0 r.l. BG 100.00% 09/16 Eurofins do Brasil An\u00e1lises de Alimentos Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 07/03 Eurofins Agroscience Services Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 06/12 Laborat\u00f3rio ALAC Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 04/12 Integrated Petroleum Expertise Company - Servi\u00e7os Eurofins Latin American Ventures, S.L.U. BR 100.00% 09/14 em Petroleo Ltda. Eurofins Clinical Santos Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 12/17 Eurofins Clinical Imagem Santos Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 12/17 Centro de Analise e Tipagem de Genomas Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 08/19 Eurofins Clinical Testing Brazil Holding Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 06/21 Eurofins Food Testing Brazil Holding Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 06/21 Itapema Laboratorio de Analises Clinicas Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 12/22 Eurofins Experchem Laboratories, Inc. Eurofins Food Testing LUX Holding S.\u00e0 r.l. CA 100.00% 04/15 Quebec St. Bruno Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. CA 100.00% 12/16 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins CDMO Alphora, Inc. Eurofins Pharma Services Canada Holding, Inc. CA 100.00% 06/17 Eurofins NSC Canada, Inc. Eurofins Support Services LUX Holding S.\u00e0 r.l. CA 100.00% 06/17 Eurofins BioPharma Product Testing Toronto, Inc. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CA 100.00% 05/18 Oakville Portland Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. CA 100.00% 06/18 Mississauga Hadwen Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. CA 100.00% 06/18 Mississauga Speakman Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. CA 100.00% 06/18 Eurofins Environment Testing Canada, Inc. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. CA 100.00% 11/18 Eurofins Cosmetics and Personal Care Testing Eurofins Product Testing LUX Holding S.\u00e0 r.l. CA 100.00% 09/19 Canada, Inc. Eurofins Professional Scientific Services Canada, Inc. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CA 100.00% 10/20 Eurofins Pharma Services Canada Holding, Inc. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CA 100.00% 07/21 Eurofins Enviro-Works, Inc. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. CA 100.00% 12/21 Eurofins Scientific AG Eurofins Food Testing LUX Holding S.\u00e0 r.l. CH 100.00% 07/00 Eurofins Regulatory AG Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. CH 100.00% 12/11 Eurofins BioPharma Product Testing Switzerland AG Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CH 100.00% 01/13 Eurofins Professional Scientific Services Switzerland Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CH 100.00% 03/17 AG Eurofins Electric & Electronic Product Testing AG Eurofins Product Testing LUX Holding S.\u00e0 r.l. CH 100.00% 06/17 Route de Montena Real Estate AG Eurofins Real Estate LUX Holding S.\u00e0 r.l. CH 100.00% 06/17 Eurofins PHAST Pharma AG Eurofins PHAST GmbH CH 100.00% 07/18 Eurofins NSC Switzerland AG Eurofins Support Services LUX Holding S.\u00e0 r.l. CH 100.00% 01/20 SAM Sensory and Marketing International Switzerland Eurofins Sensory, Consumer research and Product CH 100.00% 12/20 AG design LUX Holding S.\u00e0 r.l. Eurofins Qualitech AG Eurofins Qute Holding AG CH 100.00% 07/21 Eurofins Qute Holding AG Eurofins Material Sciences LUX Holding S.\u00e0 r.l. CH 100.00% 07/21 Scitec Research SA Eurofins Environment Testing LUX Holding S.\u00e0 r.l. CH 100.00% 09/21 Swanfort Services SA DNA Consolidated BV CH 100.00% 08/21 AgeaCare Switzerland S.\u00e0 r.l DNA Consolidated BV CH 100.00% 08/21 Eurofins Testing Chile SA Eurofins Latin American Ventures, S.L.U. CL 100.00% 03/13 Eurofins Training Chile SA Eurofins Testing Chile SA CL 100.00% 03/13 Eurofins Agroscience Services Chile SA Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. CL 100.00% 06/17 Eurofins Product Testing Hong Kong, Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 03/06 Eurofins Technology Service (Suzhou) Co., Ltd. Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/06 Eurofins Product Testing Service (Shanghai) Co., Ltd. Eurofins Shanghai Holding, Ltd. CN 100.00% 11/09 Eurofins Testing Technology (Shenzhen) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 10/09 Eurofins Shanghai Holding, Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 08/09 Eurofins Central Laboratory China Co., Ltd. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CN 100.00% 05/12 Eurofins Food Testing Hong Kong, Ltd. Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 03/12 Eurofins NSC Shanghai Co., Ltd. Eurofins Support Services LUX Holding S.\u00e0 r.l. CN 100.00% 06/14 Eurofins NSC Hong Kong, Ltd. Eurofins Support Services LUX Holding S.\u00e0 r.l. CN 100.00% 02/14 Eurofins Sensory Consumer and Product Research Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 05/15 (Shanghai) Co., Ltd. Eurofins Food Testing Service(Dalian)Co.,Ltd. Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 06/16 Eurofins Technology Service (Qingdao) Co., Ltd. Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 06/16 Evans Materials Technology (Shanghai) Co., Ltd. Eurofins EAG Materials Science, LLC CN 100.00% 12/17 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Consumer Product Testing (Guangzhou) Co., Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 12/18 Ltd Eurofins Electrical Testing Service (Shenzhen) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/18 Eurofins EAG Materials Science China (Shanghai) Co., Eurofins Material Sciences LUX Holding S.\u00e0 r.l. CN 100.00% 09/19 Ltd. Eurofins BioPharma Product Testing (Shanghai ) Co., Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CN 100.00% 12/19 Ltd. AQM HK Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 06/19 Eurofins Technology Service (Guangzhou) Co., Ltd. Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 10/19 AQM China Co., Ltd. AQM HK Co., Ltd. CN 100.00% 06/19 Eurofins Technologies (Shanghai) Co., Ltd. Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. CN 100.00% 07/20 Eurofins Assurance China Co., Ltd. Eurofins Assurance LUX Holding S.\u00e0 r.l. CN 100.00% 05/21 Eurofins-UNPA Natural Health Product Quality Services Eurofins Food Testing Hong Kong, Ltd. CN 60.00% 08/21 (Beijing) Co., Ltd. Eurofins Wireless Testing Service (Shenzhen) Co., Ltd. A Test Lab Techno Co., Ltd. CN 100.00% 07/21 Eurofins Testing Inspection Certification (Chengdu) Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 07/21 Co., Ltd. Eurofins MTS Consumer Product Testing (Hong Kong) Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/21 Co., Ltd. Modern Testing Services (Hong Kong) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/21 Modern Testing Services (International) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/21 Eurofins Assurance (Hong Kong) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/21 Modern Testing Services(Dongguan) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/21 Eurofins MTS Consumer Product Testing (Shanghai) Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/21 Co., Ltd Eurofins Megalab Colombia, SAS Eurofins Megalab, S.A.U. CO 100.00% 09/21 Eurofins IT Infrastructure GSC S.A. Eurofins Support Services LUX Holding S.\u00e0 r.l. CR 100.00% 08/18 Eurofins Food & Feed Testing Czech Republic s.r.o. Eurofins Holding CZ s.r.o. CZ 100.00% 10/06 Eurofins Holding CZ s.r.o. Eurofins Food Testing LUX Holding S.\u00e0 r.l. CZ 100.00% 08/19 Eurofins Food Testing Hamburg Germany Holding Eurofins GeneScan Holding GmbH DE 100.00% 05/98 GmbH RECO Homburg Entenmuehlstrasse Real Estate Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 11/98 GmbH Eurofins GeneScan Holding GmbH Eurofins Food Testing LUX Holding S.\u00e0 r.l. DE 100.00% 07/03 Eurofins Analytik GmbH Eurofins GfA Lab Service GmbH DE 100.00% 12/98 Eurofins Dr. Specht International GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 04/05 GmbH Eurofins GeneScan GmbH Eurofins GeneScan Holding GmbH DE 100.00% 07/03 Eurofins SOFIA GmbH Eurofins Food Testing Pesticides Germany Holding DE 100.00% 04/06 GmbH Eurofins GfA GmbH Eurofins Air Monitoring Germany Holding GmbH DE 100.00% 01/01 Eurofins \u00d6kometric GmbH Eurofins NDSC Umweltanalytik GmbH DE 100.00% 12/02 Eurofins NDSC Umweltanalytik GmbH Eurofins Environment Testing LUX Holding S.\u00e0 r.l. DE 100.00% 03/05 Eurofins Umwelt West GmbH Eurofins Environment Testing Germany Holding West DE 100.00% 04/05 GmbH Eurofins Umwelt Ost GmbH Eurofins NDSC Umweltanalytik GmbH DE 100.00% 01/06 Eurofins Institut J\u00e4ger GmbH Eurofins NDSC Umweltanalytik GmbH DE 100.00% 04/06 Eurofins Genomics Europe Applied Genomics GmbH Eurofins MWG Holding GmbH DE 100.00% 07/01 Eurofins Agroscience Services EcoChem GmbH Eurofins Agroscience Services Germany Holding DE 100.00% 01/06 GmbH Eurofins BioPharma Product Testing Munich GmbH Eurofins BioPharma Services Holding Germany GmbH DE 100.00% 10/06 Eurofins MWG Holding GmbH Eurofins Genomics BV DE 100.00% 01/05 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Genomics Germany GmbH Eurofins MWG Holding GmbH DE 100.00% 01/07 Eurofins Food Testing Pesticides Germany Holding Eurofins Food Testing LUX Holding S.\u00e0 r.l. DE 100.00% 12/06 GmbH Eurofins Dr. Specht Laboratorien GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 03/07 GmbH Eurofins Genomics Europe Synthesis GmbH Eurofins MWG Holding GmbH DE 100.00% 01/07 Eurofins Food Testing General Chemistry Germany Eurofins Laborservices GmbH DE 100.00% 04/07 Holding GmbH Eurofins Institut Dr. Rothe GmbH Eurofins Food Testing General Chemistry Germany DE 100.00% 04/07 Holding GmbH Eurofins Product Testing Verwaltungs GmbH Eurofins Product Service GmbH DE 100.00% 03/07 Eurofins Environment Testing Germany Holding West Eurofins Environment Testing LUX Holding S.\u00e0 r.l. DE 100.00% 12/07 GmbH Eurofins Agroscience Services Germany Holding Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. DE 100.00% 04/07 GmbH FP Friedrichsdorf Professor-Wagner-Strasse Real Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 04/07 Estate GmbH Eurofins Umwelt Nord GmbH Eurofins NDSC Umweltanalytik GmbH DE 100.00% 05/07 Eurofins Laborservices GmbH Eurofins Food Testing LUX Holding S.\u00e0 r.l. DE 100.00% 04/07 Eurofins NSC IT Infrastructure Germany GmbH Eurofins Support Services LUX Holding S.\u00e0 r.l. DE 100.00% 12/07 Eurofins INLAB GmbH Eurofins Food Testing General Chemistry Germany DE 100.00% 12/07 Holding GmbH Eurofins Product Service GmbH Eurofins Scientific SE DE 100.00% 01/08 Eurofins Information Systems GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 11/07 GmbH Eurofins Consumer Product Testing GmbH Eurofins Product Testing Verwaltungs GmbH DE 100.00% 01/08 Eurofins Food Testing Germany East Holding GmbH Eurofins Food Testing LUX Holding S.\u00e0 r.l. DE 100.00% 01/08 Eurofins Agroscience Services Chem GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 02/08 GmbH Eurofins Food Control Services GmbH Eurofins Food Testing LUX Holding S.\u00e0 r.l. DE 100.00% 12/08 Eurofins WEJ Contaminants GmbH Eurofins GfA Lab Service GmbH DE 100.00% 12/08 Eurofins BioTesting Services Nord GmbH Eurofins GfA Lab Service GmbH DE 100.00% 12/08 HS Hamburg Stenzelring Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 06/08 Eurofins Global Control GmbH Eurofins Food Testing Pesticides Germany Holding DE 100.00% 04/09 GmbH Eurofins Food & Feed Testing Leipzig GmbH Dr. Appelt Beteiligungs GmbH DE 100.00% 05/09 RECO Ebersberg Anzinger Strasse Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 08/09 Eurofins BioPharma Product Testing Hamburg GmbH Eurofins BioPharma Services Holding Germany GmbH DE 100.00% 07/09 Eurofins Food Integrity Control Services GmbH Dr. Appelt Beteiligungs GmbH DE 100.00% 05/09 Eurofins Institut Dr. Appelt Hilter GmbH Dr. Appelt Beteiligungs GmbH DE 100.00% 05/09 Dr. Appelt Beteiligungs GmbH Eurofins Food Testing Germany East Holding GmbH DE 100.00% 05/09 Gold Standard Diagnostics Freiburg GmbH Eurofins Technologies Germany Holding GmbH DE 100.00% 05/09 Eurofins GfA Lab Service GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 10/10 GmbH Eurofins NDSC Food Testing Germany GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 03/11 GmbH Eurofins Agroscience Services GmbH Eurofins Agroscience Services Germany Holding DE 100.00% 07/11 GmbH Eurofins Facility Management Germany GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 11/11 GmbH Eurofins Umwelt S\u00fcdwest GmbH Eurofins Environment Testing Germany Holding West DE 100.00% 06/12 GmbH Eurofins Medigenomix Forensik GmbH Eurofins MWG Holding GmbH DE 100.00% 08/12 Eurofins Food Consulting Services GmbH Dr. Appelt Beteiligungs GmbH DE 100.00% 01/13 Eurofins GSC Germany GmbH Eurofins Support Services LUX Holding S.\u00e0 r.l. DE 100.00% 04/13 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins CLF Specialised Nutrition Testing Services Eurofins Food Testing Germany East Holding GmbH DE 100.00% 08/13 GmbH BLGG Deutschland GmbH Eurofins Agro Testing Netherlands Holding BV DE 100.00% 07/13 RECO Hamburg Neul\u00e4nder Kamp 1 Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 07/13 Eurofins HT-Analytik GmbH Eurofins NDSC Umweltanalytik GmbH DE 100.00% 03/14 Eurofins Hygiene Institut Berg GmbH Eurofins Environment Testing Germany Holding West DE 100.00% 05/14 GmbH Eurofins Agraranalytik Deutschland GmbH Eurofins Food Testing LUX Holding S.\u00e0 r.l. DE 100.00% 12/14 Eurofins BioPharma Services Holding Germany GmbH Eurofins MWG Holding GmbH DE 100.00% 03/15 Eurofins Agroscience Services Ecotox GmbH Eurofins Agroscience Services Germany Holding DE 100.00% 08/15 GmbH Eurofins Professional Scientific Services Germany Eurofins BioPharma Services Holding Germany GmbH DE 100.00% 10/15 GmbH St. Marien Krankenhaus Lampertheim GmbH Eurofins Clinical Testing Services Germany LUX DE 100.00% 08/16 Holding S.\u00e0 r.l. Eurofins Air Monitoring Germany Holding GmbH Eurofins Air Monitoring LUX Holding S.\u00e0 r.l. DE 100.00% 07/16 Eurofins Finance Transactions Germany GmbH Eurofins Support Services LUX Holding S.\u00e0 r.l. DE 100.00% 10/16 Eurofins Dr. Specht Express GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 04/16 GmbH Eurofins MVZ Medizinisches Labor Gelsenkirchen St. Marien Krankenhaus Lampertheim GmbH DE 100.00% 07/17 GmbH Eurofins Laborbetriebsgesellschaft Gelsenkirchen Eurofins MVZ Medizinisches Labor Gelsenkirchen DE 100.00% 07/17 GmbH GmbH Eurofins Genomics Europe Sequencing GmbH Eurofins MWG Holding GmbH DE 100.00% 07/17 Eurofins LifeCodexx GmbH Eurofins Genomics Europe Sequencing GmbH DE 100.00% 07/17 Eurofins Institut Nehring GmbH Eurofins Food Testing General Chemistry Germany DE 100.00% 10/17 Holding GmbH IfB Institut f\u00fcr Blutgruppenforschung GmbH Eurofins MWG Holding GmbH DE 100.00% 10/17 SAM Sensory and Marketing International GmbH KKG Holding GmbH DE 100.00% 11/17 KKG Holding GmbH Eurofins Sensory, Consumer research and Product DE 100.00% 11/17 design LUX Holding S.\u00e0 r.l. Eurofins Agroscience Services EAG Laboratories Eurofins Agroscience Services Germany Holding DE 100.00% 12/17 GmbH GmbH Evans Analytical Group Holdings GmbH Eurofins EAG Materials Science, LLC DE 100.00% 12/17 Eurofins WKS Labservice GmbH Eurofins Product Testing Verwaltungs GmbH DE 75.00% 12/17 Eurofins PHAST GmbH Eurofins BioPharma Services Holding Germany GmbH DE 100.00% 07/18 Eurofins PHAST Development GmbH & Co. KG Eurofins PHAST GmbH DE 100.00% 07/18 PHAST Development Verwaltungs GmbH Eurofins PHAST GmbH DE 100.00% 07/18 Agrartest GmbH Eurofins Agroscience Services Germany Holding DE 100.00% 07/18 GmbH NovaTec Immundiagnostica GmbH Eurofins Technologies Germany Holding GmbH DE 100.00% 08/20 Gold Standard Diagnostics Kassel GmbH Eurofins Technologies Germany Holding GmbH DE 100.00% 01/19 Eurofins Genomics Europe Shared Services GmbH Eurofins MWG Holding GmbH DE 100.00% 02/19 Eurofins Q-Bioanalytic GmbH Eurofins BioTesting Services Nord GmbH DE 100.00% 11/18 LL Leipzig Landsteiner Strasse Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 05/19 Eurofins Technologies Germany Holding GmbH Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. DE 100.00% 03/19 Gold Standard Diagnostics CD Kassel GmbH Eurofins Technologies Germany Holding GmbH DE 100.00% 01/19 Virotech Diagnostics GmbH Eurofins Technologies Germany Holding GmbH DE 100.00% 02/19 Eurofins Agroscience Services Regulatory Germany Eurofins Agroscience Services Germany Holding DE 100.00% 12/19 GmbH GmbH Eurofins BioTesting Services Ost GmbH Dr. Appelt Beteiligungs GmbH DE 100.00% 01/20 MF M\u00fcnchen Friedenheimer Br\u00fccke Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 05/20 % of Date ISO interest Company Subsidiary of: of code by the entry Group Pr\u00e4natal-Medizin M\u00fcnchen Frauen\u00e4rzte und St. Marien Krankenhaus Lampertheim GmbH DE 100.00% 05/20 Humangenetiker MVZ GmbH Eurofins BioPharma Services Consulting Munich GmbH Eurofins BioPharma Services Holding Germany GmbH DE 100.00% 11/20 RECO 2. Verwaltungsgesellschaft GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 07/21 Eurofins NBLSC Technologies Germany GmbH Eurofins Technologies Germany Holding GmbH DE 100.00% 06/21 RECO Troisdorf Gierlichstrasse Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 12/20 Eurofins Derma Tronnier GmbH Eurofins Product Testing Verwaltungs GmbH DE 100.00% 12/20 Tronnier Verwaltungs GmbH Eurofins Product Testing Verwaltungs GmbH DE 100.00% 12/20 RECO 1. Verwaltungsgesellschaft GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 01/21 Eurofins EmpowerDX Europe GmbH St. Marien Krankenhaus Lampertheim GmbH DE 100.00% 06/21 Bioskin GmbH Eurofins Product Testing Verwaltungs GmbH DE 100.00% 08/21 Modern Testing Services (Germany) GmbH Modern Technology Holdings Limited DE 100.00% 11/21 Eurofins NSC Denmark A/S Eurofins Support Services LUX Holding S.\u00e0 r.l. DK 100.00% 12/03 Eurofins Biopharma Product Testing Denmark A/S Eurofins BioPharma Product Testing Denmark Holding DK 100.00% 03/06 A/S Eurofins Product Testing Denmark A/S Eurofins Product Testing LUX Holding S.\u00e0 r.l. DK 100.00% 08/08 Eurofins Miljo A/S Eurofins Environment Denmark Holding A/S DK 100.00% 06/05 Eurofins Steins Laboratorium A/S Eurofins Food Denmark Holding A/S DK 100.00% 07/06 Eurofins Environment Denmark Holding A/S Eurofins Environment Testing LUX Holding S.\u00e0 r.l. DK 100.00% 04/07 Eurofins Food Denmark Holding A/S Eurofins Food Testing LUX Holding S.\u00e0 r.l. DK 100.00% 04/07 Eurofins Genomics Holding Denmark A/S Eurofins Genomics LUX Holding S.\u00e0 r.l. DK 100.00% 11/13 Eurofins Genomics Europe Genotyping A/S Eurofins Genomics Holding Denmark A/S DK 100.00% 01/13 Eurofins Milj\u00f8 Vand A/S Eurofins Environment Denmark Holding A/S DK 100.00% 10/13 Eurofins Agro Testing Denmark A/S Eurofins Food Denmark Holding A/S DK 100.00% 12/14 Eurofins Milj\u00f8 Luft A/S Eurofins Environment Denmark Holding A/S DK 100.00% 08/14 Eurofins BioPharma Product Testing Denmark Holding Eurofins Pharma Services LUX Holding S.\u00e0 r.l. DK 100.00% 08/15 A/S Eurofins Professional Scientific Services Denmark A/S Eurofins BioPharma Product Testing Denmark Holding DK 100.00% 08/15 A/S Eurofins Genomics Denmark A/S Eurofins Genomics Holding Denmark A/S DK 100.00% 12/15 Eurofins Safer At Work Nordics A/S Eurofins Genomics Holding Denmark A/S DK 100.00% 09/16 Eurofins Milk Testing Denmark A/S Eurofins Food Denmark Holding A/S DK 100.00% 01/17 Eurofins Vitamin Testing Denmark A/S Eurofins Food Denmark Holding A/S DK 100.00% 01/17 Aabybro Industrivej Real Estate ApS Eurofins Real Estate LUX Holding S.\u00e0 r.l. DK 100.00% 03/17 Eurofins VBM Laboratoriet A/S Eurofins Environment Denmark Holding A/S DK 100.00% 03/17 Eurofins VBM Geo ApS Eurofins Environment Denmark Holding A/S DK 100.00% 10/18 Eurofins Environment Testing Holding Estonia O\u00dc Eurofins Environment Testing LUX Holding S.\u00e0 r.l. EE 100.00% 04/17 Eurofins Environment Testing Estonia O\u00dc Eurofins Environment Testing Holding Estonia O\u00dc EE 100.00% 04/17 Rae Village Vana-Sutikase ja Tammi tee Real Estate Eurofins Real Estate LUX Holding S.\u00e0 r.l. EE 100.00% 12/19 O\u00dc Eurofins Agroscience Services, S.L.U. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. ES 100.00% 01/06 Eurofins BioPharma Product Testing Spain, S.L.U. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. ES 100.00% 01/07 Eurofins Latin American Ventures, S.L.U. Eurofins International Holdings LUX S.\u00e0 r.l. ES 100.00% 04/09 Eurofins Sicaagriq, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 07/13 Eurofins Analisis Alimentario Holding Espana S.L.U. Eurofins Food Testing LUX Holding S.\u00e0 r.l. ES 100.00% 09/13 Sensory and Marketing Spain, S.L.U. Eurofins Sensory, Consumer research and Product ES 100.00% 09/13 design LUX Holding S.\u00e0 r.l. % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins An\u00e1lisis Alimentario, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 05/14 Eurofins Food Barcelona, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 05/14 Eurofins An\u00e1lisis Agro, S.A. Eurofins Food Barcelona, S.L.U. ES 90.21% 05/14 Eurofins Product Testing, Cosmetics & Personal Care Eurofins Product Testing Holding Spain, S.L.U. ES 100.00% 07/15 Spain, S.L.U. Eurofins Trialcamp, S.L.U. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. ES 100.00% 06/15 Eurofins Laboratorio Sarr\u00f3, S.L.U. Eurofins Biologie M\u00e9dicale Holding France SAS ES 100.00% 07/15 Eurofins NSC Spain, S.L.U. Eurofins Support Services LUX Holding S.\u00e0 r.l. ES 100.00% 01/16 Eurofins Histolog, S.L.U. France Anapath Holding SAS ES 100.00% 01/16 Eurofins NDSC Food Testing Spain, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 04/16 Eurofins Product Testing Holding Spain, S.L.U. Eurofins Product Testing LUX Holding S.\u00e0 r.l. ES 100.00% 04/16 Eurofins Professional Scientific Services Spain, S.L.U. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. ES 100.00% 01/17 Eurofins Megalab, S.A.U. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. ES 100.00% 09/16 Eurofins Laboratorio \u00c1ngel M\u00e9ndez, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 09/16 Eurofins Laboratorio Surlab, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 09/16 Megalab Medio Ambiente, S.L. Eurofins Megalab, S.A.U. ES 70.00% 09/16 Eurofins Laboratorio Dr. Valenzuela, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 09/16 Eurofins Laboratorio Prefasi, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 05/17 Eurofins Villapharma Research, S.L.U. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. ES 100.00% 03/17 Eurofins Laboratorios de Castilla y Le\u00f3n, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 05/17 Eurofins Textile Testing Spain, S.L.U. Eurofins Product Testing Holding Spain, S.L.U. ES 100.00% 04/17 Fuente \u00c1lamo de Murcia - El Estrech Real Estate, Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 12/17 S.L.U. Eurofins Analclinic, S.A.U. Eurofins Megalab, S.A.U. ES 100.00% 11/17 Eurofins Technologies Holding Spain, S.L.U. Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. ES 100.00% 02/18 Madrid Garc\u00eda Noblejas Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 07/18 Eurofins Mas Control, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 03/18 Eurofins Ingenasa, S.A. Eurofins Technologies Holding Spain, S.L.U. ES 94.10% 02/18 Eurofins Agroscience Services Regulatory Spain, Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. ES 100.00% 04/18 S.L.U. Santa Cruz Diesel Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 07/18 Eurofins Audit & Inspection, S.A.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 07/18 Eurofins Agroscience Services Iberica Holding, S.L.U. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. ES 100.00% 12/18 Eurofins LGS Megalab An\u00e1lisis Cl\u00ednicos, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 07/18 Eurofins Ecosur, S.A.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 07/18 Eurofins LGS Megalab An\u00e1lisis Veterinarios, S.L.U. Eurofins LGS Megalab An\u00e1lisis Cl\u00ednicos, S.L.U. ES 100.00% 12/18 Lorqui Castillo de Aledo, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 03/19 Eurofins Environment Testing Spain Holding, S.L.U. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. ES 100.00% 04/19 Eurofins GSC Spain, S.L.U. Eurofins Support Services LUX Holding S.\u00e0 r.l. ES 100.00% 04/19 Eurofins M\u00e9todos Servicios Agr\u00edcolas, S.L.U. Eurofins Agroscience Services Iberica Holding, S.L.U. ES 100.00% 03/19 Eurofins Iproma, S.L.U. Eurofins Environment Testing Spain Holding, S.L.U. ES 100.00% 07/19 Alfredo Montoro Soriano, S.L.U. Eurofins Analclinic, S.A.U. ES 100.00% 06/19 Mazarr\u00f3n Campico Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 03/20 Abar\u00e1n Rellano Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 08/20 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Laboratorio Montoro Botella, S.L.U. Alfredo Montoro Soriano, S.L.U. ES 100.00% 06/19 Castell\u00f3n Lituania Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 03/20 Eurofins Envira Ingenieros Asesores, S.L.U. Eurofins Environment Testing Spain Holding, S.L.U. ES 100.00% 11/20 Premiumlab, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 12/20 Eurofins Quimico Onubense, S.L.U. Eurofins Environment Testing Spain Holding, S.L.U. ES 100.00% 08/21 Oricain Ezcabarte Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 03/21 Paterna Les Ones Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 07/21 Cimera Estudios Aplicados, S.L.U. Eurofins Environment Testing Spain Holding, S.L.U. ES 100.00% 05/21 Eurofins NBLSC Environment Testing Spain, S.L.U. Eurofins Environment Testing Spain Holding, S.L.U. ES 100.00% 05/21 Eurofins Centro Anal\u00ectico M\u00ecguez Mu\u00ecnos, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 08/21 Eurofins Scientific Finland Oy Eurofins Food Testing LUX Holding S.\u00e0 r.l. FI 100.00% 10/07 Eurofins Viljavuuspalvelu Oy Eurofins Food Testing LUX Holding S.\u00e0 r.l. FI 100.00% 12/12 Eurofins Environment Testing Finland Holding Oy Eurofins Environment Testing LUX Holding S.\u00e0 r.l. FI 100.00% 01/17 Eurofins Ahma Oy Eurofins Environment Testing Finland Holding Oy FI 100.00% 02/17 Eurofins Environment Testing Finland Oy Eurofins Environment Testing Finland Holding Oy FI 100.00% 04/17 Eurofins Nab Labs Group Oy Eurofins Environment Testing Finland Holding Oy FI 100.00% 06/17 Eurofins Nab Labs Oy Eurofins Nab Labs Group Oy FI 100.00% 06/17 Eurofins Expert Services Oy Eurofins Product Testing LUX Holding S.\u00e0 r.l. FI 100.00% 06/18 Eurofins Labtium Oy Eurofins Environment Testing Finland Holding Oy FI 100.00% 06/18 Oulu Nuottasaari Real Estate Oy Eurofins Real Estate LUX Holding S.\u00e0 r.l. FI 100.00% 09/19 Eurofins Product Testing Finland Holding Oy Eurofins Product Testing LUX Holding S.\u00e0 r.l. FI 100.00% 04/21 Eurofins Electric & Electronics Finland Oy Eurofins Product Testing Finland Holding Oy FI 100.00% 04/21 Eurofins Microbiologie France Holding SAS Eurofins Hygi\u00e8ne Alimentaire France LUX Holding S.\u00e0 FR 100.00% 01/99 r.l. Eurofins Analytics France SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 07/99 Eurofins Hygi\u00e8ne Alimentaire Formation SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 07/99 Eurofins Certification SAS Eurofins Assurance and Inspection Services France FR 100.00% 07/03 Holding SAS Eurofins Laboratoire De Microbiologie De L'Est SAS Eurofins Microbiologie France Holding SAS FR 100.00% 01/06 Eurofins ATS SAS Eurofins Product Testing LUX Holding S.\u00e0 r.l. FR 100.00% 01/99 Eurofins Hydrologie France Holding SAS Eurofins Hydrologie France LUX Holding S.\u00e0 r.l. FR 100.00% 07/05 Eurofins Analyses Pour L'Environnement France SAS Eurofins Analyses Environnementales Pour Les FR 100.00% 07/05 Industriels France SAS Eurofins Analyses Pour Le B\u00e2timent Est SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 01/01 SAS Eurofins BioPharma Product Testing & Professional Eurofins Pharma Services France LUX Holding S.\u00e0 r.l. FR 100.00% 06/06 Scientific Services France Holding SAS Eurofins Genomics France SAS Eurofins Genomics LUX Holding S.\u00e0 r.l. FR 100.00% 07/05 Institut Francais Des Empreintes Genetiques SAS Eurofins Forensics LUX Holding S.\u00e0 r.l. FR 75.00% 11/05 Toxlab SAS Eurofins Forensics LUX Holding S.\u00e0 r.l. FR 98.64% 02/05 Eurofins ADME Bioanalyses SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 10/04 Scientific Services France Holding SAS Eurofins Optimed SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 01/06 Scientific Services France Holding SAS Eurofins Pharma Quality Control SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 01/06 Scientific Services France Holding SAS Eurofins Agroscience Services France SAS Eurofins Agrosciences Services France Holding SAS FR 100.00% 01/06 Eurofins Agroscience Services SAS Eurofins Agrosciences Services France Holding SAS FR 100.00% 01/06 % of Date ISO interest Company Subsidiary of: of code by the entry Group Chemtox SAS Eurofins Forensics LUX Holding S.\u00e0 r.l. FR 98.90% 01/08 Eurofins Laboratoires De Microbiologie Ouest SAS Eurofins Microbiologie France Holding SAS FR 100.00% 10/06 Eurofins Cervac Sud SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 10/06 Eurofins NSC Finance France SAS Eurofins Support Services LUX Holding S.\u00e0 r.l. FR 100.00% 10/06 SAM Consumer International France SAS Eurofins Sensory Holding France SAS FR 100.00% 10/06 Eurofins Hydrologie France SAS Eurofins Hydrologie France Holding SAS FR 100.00% 01/01 Eurofins Food Chemistry Testing France Holding SAS Eurofins Food Chemistry Testing France LUX Holding FR 100.00% 09/07 S.\u00e0 r.l. Eurofins Optimed Lyon SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 09/07 Scientific Services France Holding SAS Eurofins NSC IT Infrastructure France SAS Eurofins Support Services LUX Holding S.\u00e0 r.l. FR 100.00% 12/07 Eurofins Hydrologie Centre Est SAS Eurofins Hydrologie France Holding SAS FR 100.00% 04/08 Eurofins Laboratoire Centre SAS Eurofins Microbiologie France Holding SAS FR 100.00% 07/10 Eurofins Laboratoire Nord SAS Eurofins Microbiologie France Holding SAS FR 100.00% 07/10 Eurofins Consulting Agroalimentaire SAS Eurofins Assurance and Inspection Services France FR 100.00% 07/10 Holding SAS Eurofins GSC France SAS Eurofins Support Services LUX Holding S.\u00e0 r.l. FR 100.00% 07/10 Eurofins NDSC IT Solution Food France SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 08/10 Eurofins NDSC Environnement France SAS Eurofins NDSC Environnement France Holding SAS FR 100.00% 08/10 Eurofins Analyses Pour Le Batiment France Holding Eurofins Analyses pour la Construction France LUX FR 100.00% 08/10 SAS Holding S.\u00e0 r.l. Eurofins NBLSC Analyses Pour Le B\u00e2timent France Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 09/10 SAS SAS Eurofins Analyses Environnementales Pour Les Eurofins Analyses Environnementales pour les FR 100.00% 10/10 Industriels France SAS Industriels France LUX Holding S.\u00e0 r.l. Eurofins NSC Developpement France SAS Eurofins Support Services LUX Holding S.\u00e0 r.l. FR 100.00% 10/10 Eurofins Agroscience Services Chem SAS Eurofins Agrosciences Services France Holding SAS FR 100.00% 12/10 Eurofins Analyses pour le B\u00e2timent Ile de France SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 12/10 SAS Eurofins Analyses pour le B\u00e2timent Nord SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 12/10 SAS Eurofins Analyses pour le B\u00e2timent Sud Est SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 12/10 SAS Eurofins Analyses pour le B\u00e2timent Ouest SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 12/10 SAS Eurofins Analyses des Mat\u00e9riaux et Combustibles Eurofins Expertises France Holding SAS FR 100.00% 12/10 France SAS Eurofins Hydrologie Nord SAS Eurofins Hydrologie France Holding SAS FR 100.00% 11/11 Eurofins LCAM - Eurofins Laboratoire Central Eurofins Microbiologie France Holding SAS FR 100.00% 11/11 d'Analyses de la Moselle SAS Eurofins Hydrologie Ile De France SAS Eurofins Hydrologie France Holding SAS FR 100.00% 11/11 Eurofins Hydrologie Est SAS Eurofins Hydrologie France SAS FR 100.00% 11/11 Eurofins Hydrologie Sud SAS Eurofins Hydrologie France Holding SAS FR 100.00% 11/11 Eurofins Asbestos Testing Europe SAS Eurofins Industrial Testing LUX S.\u00e0 r.l. FR 100.00% 11/11 Eurofins Laboratoire Contaminants Sud SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 12/11 Eurofins Laboratoire De Pathologie V\u00e9g\u00e9tale SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 12/11 Eurofins Hydrologie Ouest SAS Eurofins Hydrologie France Holding SAS FR 100.00% 02/12 Eurofins NBLSC Forensics SAS Eurofins Forensics LUX Holding S.\u00e0 r.l. FR 100.00% 02/12 Eurofins Ecotoxicologie France SAS Eurofins Expertises France Holding SAS FR 100.00% 04/12 Eurofins NDSC Environnement France Holding SAS Eurofins Environment Testing LUX Holding S.\u00e0 r.l. FR 100.00% 05/12 Eurofins NDSCE Support France SAS Eurofins NDSC Environnement France Holding SAS FR 100.00% 01/12 Eurofins Agrosciences Services France Holding SAS Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. FR 100.00% 12/12 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins GSC CADET SAS Eurofins Support Services LUX Holding S.\u00e0 r.l. FR 100.00% 11/12 Eurofins Environnement Logistique France SAS Eurofins Analyses Environnementales Pour Les FR 100.00% 12/12 Industriels France SAS Eurofins Pharma Products Testing France Eurofins BioPharma Product Testing & Professional FR 100.00% 12/12 Management SAS Scientific Services France Holding SAS Eurofins Pharma Products Engineering SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 12/12 Scientific Services France Holding SAS Eurofins Cerep SA Eurofins Discovery Services LUX Holding S.\u00e0 r.l. FR 95.78% 03/13 Eurofins MITOX FOPSE SARL Eurofins Agrosciences Services France Holding SAS FR 100.00% 07/13 Eurofins Analyses Pour Le Batiment Sud-Ouest SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 09/13 SAS Eurofins ID MYK SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 01/14 Scientific Services France Holding SAS Eurofins Prelevement Pour Le Batiment France Holding Eurofins Analyses pour lEnvironnement France LUX FR 100.00% 08/14 SAS Holding S.\u00e0 r.l. Eurofins Prelevement Pour Le Batiment Est SAS Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 09/14 SAS Eurofins Prelevement Pour Le Batiment France SAS Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 10/14 SAS Eurofins Prelevement Pour Le Batiment Ouest SAS Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 10/14 SAS Eurofins NSC HR France SAS Eurofins Support Services LUX Holding S.\u00e0 r.l. FR 100.00% 07/14 Eurofins Analyses Pour Le B\u00e2timent Sud SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 08/14 SAS Eurofins Prelevement Pour Le Batiment Nord SAS Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 09/14 SAS Eurofins Prelevement Pour Le Batiment Sud-Est SAS Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 09/14 SAS Eurofins Pr\u00e9l\u00e8vement pour le B\u00e2timent \u00cele-de-France Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 09/14 SAS SAS Eurofins NDSC Hydrologie France SAS Eurofins Hydrologie France Holding SAS FR 100.00% 11/14 Eurofins NDSC Microbiologie Alimentaire France SAS Eurofins Microbiologie France Holding SAS FR 100.00% 12/14 SCI Vennecy Les Esses Galerne Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 11/14 Eurofins Product Testing France Holding SAS Eurofins Product Testing LUX Holding S.\u00e0 r.l. FR 100.00% 12/14 Eurofins Analyses Pour Le B\u00e2timent Nord-Ouest Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 04/15 CEBAT SAS SAS Eurofins Evic Product Testing France SAS Eurofins Product Testing France Holding SAS FR 100.00% 07/15 Eurofins Hygi\u00e8ne Hospitali\u00e8re Sud SAS Eurofins Expertises France Holding SAS FR 100.00% 07/15 Eurofins Environment Testing France Australia Holding Eurofins Environment Testing LUX Holding S.\u00e0 r.l. FR 100.00% 06/15 SAS Eurofins Biologie M\u00e9dicale Holding France SAS Eurofins Clinical Testing Services France LUX Holding FR 100.00% 07/15 S.\u00e0 r.l. Eurofins Labazur Provence SELAS Eurofins Laboratorio Sarr\u00f3, S.L.U. FR 100.00% 07/15 Eurofins Labazur Guyane SELAS Eurofins Labazur Provence SELAS FR 100.00% 07/15 Eurofins Labazur Nice SELAS Eurofins Labazur Provence SELAS FR 100.00% 07/15 Eurofins Labazur Rhone-Alpes SELAS Eurofins Labazur Provence SELAS FR 100.00% 07/15 Eurofins Labazur Bretagne SELAS Eurofins Labazur Provence SELAS FR 100.00% 07/15 Eurofins Labazur Alpes-Sud Var SELAS Eurofins Labazur Provence SELAS FR 100.00% 07/15 France Anapath Holding SAS Eurofins Clinical Testing Services France LUX Holding FR 100.00% 07/15 S.\u00e0 r.l. Eurofins Galys SAS Eurofins Food Chemistry Testing France LUX Holding FR 100.00% 12/15 S.\u00e0 r.l. Eurofins Hydrologie Sud Ouest SAS Eurofins Hydrologie France Holding SAS FR 100.00% 11/15 Biomnis Empreintes Genetiques SAS Eurofins Forensics LUX Holding S.\u00e0 r.l. FR 100.00% 10/15 Eurofins Hydrobiologie France SAS Eurofins Expertises France Holding SAS FR 100.00% 10/15 Eurofins Biologie Sp\u00e9cialis\u00e9e France SAS Eurofins Clinical Testing Services France LUX Holding FR 100.00% 10/15 S.\u00e0 r.l. % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Biomnis Sample Library SAS Eurofins Biologie Sp\u00e9cialis\u00e9e France SAS FR 100.00% 10/15 SCI du Val d'Ouest Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 10/15 Eurofins Biomnis SELAS Eurofins Biomnis Ireland Limited FR 100.00% 10/15 Eurofins CBM69 SELAS Eurofins Labazur Provence SELAS FR 100.00% 10/15 Eurofins CEF SELAS Eurofins Labazur Provence SELAS FR 100.00% 10/15 Eurofins Bioffice SELAS Eurofins Labazur Provence SELAS FR 100.00% 10/15 Biosphere GIE Eurofins Biomnis SELAS FR 100.00% 10/15 Eurofins Biotech Germande SAS Eurofins Hydrologie France Holding SAS FR 100.00% 01/16 Eurofins Phyliae SAS Eurofins Agrosciences Services France Holding SAS FR 100.00% 11/15 Sci Garlin Bearn Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/15 Eurofins Agro-Analyses SAS Eurofins Microbiologie France Holding SAS FR 100.00% 05/16 Eurofins LCDI SAS Eurofins Hydrologie France Holding SAS FR 100.00% 07/16 SCI Lentilly Aqueduc Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 11/16 Eurofins Pathologie SELAS Eurofins Histolog, S.L.U. FR 100.00% 04/17 Eurofins NDSC Alimentaire France SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 08/17 Eurofins NDSC Chimie Alimentaire France SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 08/17 Eurofins Biologie Moleculaire France SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 08/17 Eurofins Laboratoire Nutrition Animale France SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 08/17 SAM Sensory International France SAS Eurofins Sensory Holding France SAS FR 100.00% 08/17 Eurofins Expertises France Holding SAS Eurofins Analyses Environnementales pour les FR 100.00% 09/17 Industriels France LUX Holding S.\u00e0 r.l. Eurofins Amatsigroup SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 09/17 Scientific Services France Holding SAS Immobiliere Amatsi SAS Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 09/17 Eurofins Disposable Lab SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 09/17 Scientific Services France Holding SAS Eurofins Amatsiaquitaine SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 09/17 Scientific Services France Holding SAS Eurofins Anapath France Holding SAS Eurofins Clinical Testing Services France LUX Holding FR 100.00% 09/17 S.\u00e0 r.l. Eurofins NDSC Pollution France SAS Eurofins Analyses Environnementales Pour Les FR 100.00% 09/17 Industriels France SAS Eurofins Agroscience Services Seeds France SAS Eurofins Agrosciences Services France Holding SAS FR 100.00% 09/17 SAM Retail France SAS Eurofins Sensory Holding France SAS FR 100.00% 09/17 Eurofins NSC Clinical Diagnostics France GIE Eurofins Biomnis SELAS FR 100.00% 11/17 Eurofins Agroscience Services Regulatory France SAS Eurofins Agrosciences Services France Holding SAS FR 100.00% 10/17 Eurofins Amatsi Analytics SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 10/17 Scientific Services France Holding SAS Eurofins Product Testing 2 France Holding SAS Eurofins Product Testing LUX Holding S.\u00e0 r.l. FR 100.00% 10/17 Eurofins Biologie Medicale Sud-Ouest SAS Eurofins Clinical Testing Services France LUX Holding FR 100.00% 10/18 S.\u00e0 r.l. Eurofins EAG Materials Science France SAS Eurofins EAG Materials Science, LLC FR 100.00% 12/17 Eurofins Eichrom Amiante SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 04/18 SAS Eurofins Eichrom Radioactivite SAS Eurofins Expertises France Holding SAS FR 100.00% 04/18 SCI Bruz Bastie Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 04/18 Eurofins LEA SAS Eurofins Hydrologie France Holding SAS FR 100.00% 04/18 Eurofins Lanagram SAS Eurofins Microbiologie France Holding SAS FR 100.00% 04/18 Eurofins Bactup SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 05/18 Scientific Services France Holding SAS % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins 3 Ohms SAS Eurofins Product Testing France Holding SAS FR 100.00% 07/18 Eurofins Interlab SELAS Eurofins Labazur Provence SELAS FR 100.00% 10/18 SCI Rosporden Renan Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 10/18 Eurofins Bio Lab Eurofins Labazur Provence SELAS FR 100.00% 07/18 Eurofins Biologie Medicale Ile De France SAS Eurofins Clinical Testing Services France LUX Holding FR 100.00% 07/18 S.\u00e0 r.l. Eurofins Laboratoire De Bromatologie Ouest Et Eurofins Microbiologie France Holding SAS FR 100.00% 07/18 Bretagne SAS Eurofins Hydrologie Normandie SAS Eurofins Hydrologie France Holding SAS FR 100.00% 12/18 Eurofins Pr\u00e9l\u00e8vement pour le B\u00e2timent Nord Est SAS Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 12/18 SAS Alpa Environnement Holding France SAS Eurofins Water Testing LUX S.\u00e0 r.l. FR 100.00% 12/18 SCI Lentilly Parc d'Activit\u00e9 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 Eurofins DSC Product Testing SAS Eurofins Product Testing LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 Eurofins NDSC Audit Et Consulting France SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 12/18 SCI 2 Laponie Les Ulis Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 SCI Landerneau L\u00e9on Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 SCI Loos Palissy Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 SCI Martillac Newton Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 SCI Maxeville Cuenot Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 SCI Saint Augustin Paillard Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 SCI Saint Gely Vautes Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 Eurofins Expertise Microbiologique France SAS Eurofins Expertises France Holding SAS FR 100.00% 12/18 Eurofins Dispositifs au Contact de l'Eau France SAS Eurofins Expertises France Holding SAS FR 100.00% 12/18 SCI Idron Mazerolles Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 Eurofins Laboratoire Dermscan SAS Eurofins Product Testing 2 France Holding SAS FR 100.00% 11/18 Alpa Alimentaire Holding France SAS Eurofins Water Testing LUX S.\u00e0 r.l. FR 100.00% 11/18 Eurofins Chimie Alimentaire Rouen SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 11/18 Eurofins Sensory Holding France SAS Eurofins Sensory, Consumer research and Product FR 100.00% 01/19 design LUX Holding S.\u00e0 r.l. Eurofins Alpabio SAS Alpa Environnement Holding France SAS FR 100.00% 12/18 Eurofins DiscoverX Products France SAS Eurofins Discovery Services LUX Holding S.\u00e0 r.l. FR 100.00% 03/19 Eurofins NDSC Expertises France SAS Eurofins Expertises France Holding SAS FR 100.00% 01/19 Eurofins Analyses de l'Air SAS Eurofins Analyses Environnementales Pour Les FR 100.00% 02/19 Industriels France SAS Eurofins Clinical Trial Supplies France SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 02/19 Scientific Services France Holding SAS Eurofins Analyses Nutritionnelles France SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 02/19 Eurofins Laboratoire de Microbiologie Sud SAS Eurofins Microbiologie France Holding SAS FR 100.00% 02/19 Eurofins Assurance France SAS Eurofins Assurance and Inspection Services France FR 100.00% 12/19 Holding SAS Eurofins Laboratoire Microbiologie Rh\u00f4ne-Alpes SAS Eurofins Microbiologie France Holding SAS FR 100.00% 12/19 Eurofins GeneScan Technologies France SAS Gold Standard Diagnostics France Holding SAS FR 100.00% 12/19 Eurofins Hygi\u00e8ne Hospitali\u00e8re Nord SAS Eurofins Expertises France Holding SAS FR 100.00% 12/19 Eurofins BioPharma Product Testing Biologics SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 12/19 Scientific Services France Holding SAS Eurofins Microbiologie des Eaux Ouest SAS Eurofins Microbiologie France Holding SAS FR 100.00% 12/19 Eurofins Hygi\u00e8ne Alimentaire Nord-Ouest SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 01/20 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Hygi\u00e8ne Alimentaire Sud-Est SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 01/20 Eurofins Hygi\u00e8ne Alimentaire Nord-Est SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 01/20 Eurofins Hygi\u00e8ne Alimentaire SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 01/20 Eurofins Hygi\u00e8ne Alimentaire Ile de France SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 01/20 Eurofins Hygi\u00e8ne Alimentaire Sud-Ouest SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 01/20 Eurofins Labazur Pays De La Loire SELAS Eurofins Biologie M\u00e9dicale Holding France SAS FR 100.00% 11/20 Gold Standard Diagnostics Millidrop SAS Gold Standard Diagnostics France Holding SAS FR 100.00% 11/21 Gold Standard Diagnostics France Holding SAS Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. FR 100.00% 12/20 Eurofins Electrical and Electronics France SAS Eurofins Product Testing France Holding SAS FR 100.00% 12/20 Eurofins Hygi\u00e8ne Alimentaire France Holding Eurofins Hygi\u00e8ne Alimentaire France LUX Holding S.\u00e0 FR 100.00% 12/20 r.l. Eurofins Assurance and Inspection Services France Eurofins Assurance LUX Holding S.\u00e0 r.l. FR 100.00% 12/20 Holding SAS SCI Verneuil Papin Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/20 SCI Venissieux Docteur Georges Levy Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/20 SCI Pleyben Carn Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/20 SCI Villejust Zephyr Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/20 SCI Eurofins 2021 5 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/20 Eurofins IESPM SAS Eurofins Expertises France Holding SAS FR 100.00% 07/21 Eurofins BioMed Ouest Guyane SAS Eurofins Biologie M\u00e9dicale Holding France SAS FR 100.00% 10/21 SCI Eurofins 2022 1 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/21 SCI Saint Maximin Laouve Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/21 SCI Eurofins BioMed France Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/21 SCI Management BioMed France Eurofins Real Estate France Holding SAS FR 100.00% 12/21 SCI EUROFINS 2022 5 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/21 Eurofins Toxicological and Regulatory Expertise C&PC Eurofins Product Testing France Holding SAS FR 100.00% 11/21 France SAS Eurofins Medical Device Testing France SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 11/21 Scientific Services France Holding SAS Eurofins Product Testing clinical and ex-vivo France Eurofins Product Testing France Holding SAS FR 60.20% 11/21 Holding SAS Eurofins Real Estate France Holding SAS Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 11/21 Eurofins Environnement Formation et Conseil SAS Eurofins Hygi\u00e8ne Hospitali\u00e8re France Holding SAS FR 100.00% 11/21 Eurofins Hygi\u00e8ne Hospitali\u00e8re France Holding SAS Eurofins Hydrologie France LUX Holding S.\u00e0 r.l. FR 100.00% 11/21 Eurofins NBLSC Hygi\u00e8ne Hospitali\u00e8re France SAS Eurofins Hygi\u00e8ne Hospitali\u00e8re France Holding SAS FR 100.00% 11/21 Eurofins Discovery, Central Laboratory and BioAnalysis Eurofins Discovery Services LUX Holding S.\u00e0 r.l. FR 100.00% 11/21 France Holding SAS Eurofins Laboratoire Distribution Alimentaire SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 11/21 Eurofins NewCo Fractale 2 Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 11/21 Eurofins Croatiakontrola d.o.o. Eurofins Croatia Food Testing HoldCo d.o.o. HR 99.21% 09/19 Karlovacka Real Estate d.o.o Eurofins Real Estate LUX Holding S.\u00e0 r.l. HR 100.00% 09/19 Eurofins Croatia Food Testing HoldCo d.o.o. Eurofins Food Testing LUX Holding S.\u00e0 r.l. HR 100.00% 03/20 Eurofins Agroscience Services Kft. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. HU 100.00% 09/07 Eurofins NBLSC Food&Feed Testing Hungary Kft. Eurofins Food Testing Hungary Holding Kft. HU 100.00% 08/16 Eurofins Technologies Hungary Kft. Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. HU 100.00% 05/17 Eurofins Food Testing Hungary Holding Kft. Eurofins Food Testing LUX Holding S.\u00e0 r.l. HU 100.00% 10/17 Gyula Henyei 5 utca Real Estate Kft. Eurofins Real Estate LUX Holding S.\u00e0 r.l. HU 100.00% 10/17 % of Date ISO interest Company Subsidiary of: of code by the entry Group Gyula Henyei Mikl\u00f3s utca 52 Real Estate Kft. Eurofins Real Estate LUX Holding S.\u00e0 r.l. HU 100.00% 11/17 SZE Kesely\u0171si 9 Real Estate Kft. Eurofins Real Estate LUX Holding S.\u00e0 r.l. HU 100.00% 11/17 Eurofins Minerag Kft. Eurofins Food Testing Hungary Holding Kft. HU 100.00% 12/17 Eurofins Food Analytica Kft. Eurofins Food Testing Hungary Holding Kft. HU 100.00% 01/18 Eurofins Environment Testing Hungary Holding Kft. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. HU 100.00% 07/18 BUD Foti 56 Real Estate Kft. Eurofins Real Estate LUX Holding S.\u00e0 r.l. HU 100.00% 08/18 Eurofins Clinical Testing Hungary Holding Kft. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. HU 100.00% 08/18 Eurofins NSC Hungary Kft. Eurofins Support Services LUX Holding S.\u00e0 r.l. HU 100.00% 09/18 Eurofins KVI-PLUSZ K\u00f6rnyezetv\u00e9delmi Vizsg\u00e1l\u00f3 Iroda Eurofins Environment Testing Hungary Holding Kft. HU 100.00% 07/18 Kft. Gold Standard Diagnostics International Kft. Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. HU 100.00% 06/20 Eurofins Vetcontrol Kft. Eurofins Food Testing Hungary Holding Kft. HU 100.00% 10/20 Eurofins BioPharma Product Testing Hungary Kft. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. HU 100.00% 12/21 Eurofins Scientific (Ireland) Limited Eurofins GSC LUX S.\u00e0 r.l. IE 100.00% 05/03 Eurofins Food Testing Ireland Limited Eurofins Food Testing LUX Holding S.\u00e0 r.l. IE 100.00% 04/09 Eurofins BioPharma Product Testing Ireland Holding Eurofins Pharma Services LUX Holding S.\u00e0 r.l. IE 100.00% 02/11 Limited Eurofins BioPharma Product Testing Ireland Limited Eurofins BioPharma Product Testing Ireland Holding IE 100.00% 04/11 Limited Clogherane Real Estate Investment Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. IE 100.00% 11/15 Eurofins Biomnis Ireland Limited Eurofins Biologie Sp\u00e9cialis\u00e9e France SAS IE 100.00% 10/15 Eurofins Lablink Limited Eurofins Biomnis Ireland Limited IE 100.00% 10/15 Eurofins Professional Scientific Services Ireland Limited Eurofins BioPharma Product Testing Ireland Holding IE 100.00% 07/16 Limited Medical Consultants Pathology Holdings Limited Eurofins Biomnis Ireland Limited IE 100.00% 01/17 Eurofins MC Pathology Limited Medical Consultants Pathology Holdings Limited IE 100.00% 01/17 Environmental Laboratory Services Limited Eurofins Environment Testing LUX Holding S.\u00e0 r.l. IE 100.00% 07/17 Eurofins Scientific Services Ireland Limited Eurofins GSC LUX S.\u00e0 r.l. IE 100.00% 10/17 Eurofins Environmental Testing Ireland Holding Limited Eurofins Environment Testing LUX Holding S.\u00e0 r.l. IE 100.00% 03/18 Eurofins Environment Testing Ireland Limited Eurofins Environmental Testing Ireland Holding Limited IE 100.00% 02/18 Eurofins Gynae-Screen Limited Eurofins Biomnis Ireland Limited IE 100.00% 05/18 Eurofins NSC Ireland Limited Eurofins Support Services LUX Holding S.\u00e0 r.l. IE 100.00% 01/19 Cork Real Estate Investment Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. IE 100.00% 12/19 Eurofins Genomics India Private Limited Eurofins Genomics LUX Holding S.\u00e0 r.l. IN 100.00% 01/05 Eurofins Analytical Services India Private Limited Eurofins Food Testing LUX Holding S.\u00e0 r.l. IN 100.00% 05/09 Eurofins Pharma Services India Private Limited Eurofins Pharma Services LUX Holding S.\u00e0 r.l. IN 100.00% 01/11 Eurofins IT Solutions India Private Limited Eurofins Support Services LUX Holding S.\u00e0 r.l. IN 100.00% 02/12 Eurofins Resources India Private Limited Eurofins International Holdings LUX S.\u00e0 r.l. IN 100.00% 03/12 Eurofins AgroScience Services Private Limited Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. IN 100.00% 10/13 Eurofins Clinical Diagnostics Bangalore Private Limited Eurofins Genomics LUX Holding S.\u00e0 r.l. IN 100.00% 12/15 Eurofins Product Testing India Private Limited Eurofins Product Testing LUX Holding S.\u00e0 r.l. IN 100.00% 10/16 Eurofins Advinus Private Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. IN 100.00% 10/17 Spectro Analytical Labs Private Limited Eurofins Environment Testing LUX Holding S.\u00e0 r.l. IN 100.00% 11/17 Eurofins NSC India Private Limited Eurofins Support Services LUX Holding S.\u00e0 r.l. IN 100.00% 04/18 Eurofins Advinus AgroSciences Services India Private Eurofins Real Estate LUX Holding S.\u00e0 r.l. IN 100.00% 10/17 Limited % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Amar Immunodiagnostics Private Limited Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. IN 100.00% 12/18 Eurofins Advinus BioPharma Services India Private Eurofins Pharma Services LUX Holding S.\u00e0 r.l. IN 100.00% 12/19 Limited Eurofins Advinus Discovery Services Private Limited Eurofins International Holdings LUX S.\u00e0 r.l. IN 100.00% 10/17 Alexandre Quality Management Private Private Limited AQM HK Co., Ltd. IN 100.00% 06/19 Eurofins BPO (India) Private Limited Eurofins Support Services LUX Holding S.\u00e0 r.l. IN 100.00% 01/20 Eurofins Assurance India Private Limited Eurofins Assurance LUX Holding S.\u00e0 r.l. IN 100.00% 10/20 Spectro SSA Labs Private Limited Spectro Analytical Labs Private Limited IN 100.00% 10/17 Spectro Research Lab Ventures Private Limited Spectro Analytical Labs Private Limited IN 100.00% 11/17 Spectro Testing Private Limited Spectro Analytical Labs Private Limited IN 100.00% 11/17 Eurofins AME IT Services Private Limited Eurofins Support Services LUX Holding S.\u00e0 r.l. IN 100.00% 05/21 Eurofins BioPharma Product Testing India Private Eurofins Pharma Services LUX Holding S.\u00e0 r.l. IN 100.00% 07/21 Limited Modern Testing Services (India) Private Limited Eurofins Product Testing LUX Holding S.\u00e0 r.l. IN 100.00% 11/21 Eurofins Agroscience Services Italy Srl Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. IT 100.00% 02/04 Eurofins Food & Feed Testing Italia Holding Srl Eurofins Food Testing LUX Holding S.\u00e0 r.l. IT 100.00% 07/06 Eurofins Chemical Control Srl Eurofins Food & Feed Testing Italia Holding Srl IT 100.00% 09/06 Eurofins Biolab Srl Eurofins Pharma Services Italia Holding Srl IT 100.00% 01/07 Eurofins Product Testing Italy Srl Eurofins Product Testing Italia Holding Srl IT 100.00% 10/08 Eurofins NSC Italia Srl Eurofins Support Services LUX Holding S.\u00e0 r.l. IT 100.00% 01/12 Eurofins Product Testing Italia Holding Srl Eurofins Product Testing LUX Holding S.\u00e0 r.l. IT 100.00% 10/12 Eurofins Clinical Testing Italia Holding Srl Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. IT 100.00% 10/12 Eurofins Genomics Italy Srl Eurofins Genomics LUX Holding S.\u00e0 r.l. IT 100.00% 09/12 Eurofins Pivetti Srl Eurofins Food & Feed Testing Italia Holding Srl IT 100.00% 11/12 Eurofins Pharma Services Italia Holding Srl Eurofins Pharma Services LUX Holding S.\u00e0 r.l. IT 100.00% 01/13 Eurofins Modulo Uno Srl Eurofins Product Testing Italia Holding Srl IT 100.00% 07/12 Padova Via Austria Real Estate Invest Srl Eurofins Real Estate LUX Holding S.\u00e0 r.l. IT 100.00% 04/14 Torino Via Cuorgn\u00e8 Real Estate Invest Srl Eurofins Real Estate LUX Holding S.\u00e0 r.l. IT 100.00% 03/15 Eurofins Cosmetics & Personal Care Italy Srl Eurofins Product Testing Italia Holding Srl IT 100.00% 07/15 Eurofins Food Assurance Italia Srl Eurofins Assurance LUX Holding S.\u00e0 r.l. IT 100.00% 09/15 Gold Standard Diagnostics Trieste Srl Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. IT 100.00% 06/16 Eurofins Professional Scientific Services Italy Srl Eurofins Pharma Services Italia Holding Srl IT 100.00% 12/16 Eurofins Genoma Group Srl Eurofins Clinical Testing Italia Holding Srl IT 100.00% 07/17 SAM Sensory and Marketing Italy srl Eurofins Sensory, Consumer research and Product IT 100.00% 11/18 design LUX Holding S.\u00e0 r.l. Eurofins NDSC Food Testing Italy Srl Eurofins Food & Feed Testing Italia Holding Srl IT 100.00% 02/19 Vimodrone Via Buozzi Real Estate Srl Eurofins Real Estate LUX Holding S.\u00e0 r.l. IT 100.00% 08/19 Eurofins Lab Solution Srl Eurofins Product Testing Italia Holding Srl IT 100.00% 06/19 Milano Fino Mornasco Via Tevere Real Estate Srl Eurofins Real Estate LUX Holding S.\u00e0 r.l. IT 100.00% 11/19 Cucciago Via Volta Real Estate Srl Eurofins Real Estate LUX Holding S.\u00e0 r.l. IT 100.00% 11/19 Cuneo Via Celdit Real Estate Srl Eurofins Real Estate LUX Holding S.\u00e0 r.l. IT 100.00% 03/20 Eurofins Safer@work Italy Srl Eurofins Clinical Testing Italia Holding Srl IT 100.00% 05/21 Eurofins NSC Japan KK Eurofins Support Services LUX Holding S.\u00e0 r.l. JP 100.00% 03/06 Eurofins Genomics KK Eurofins Genomic Services Japan Holding KK JP 100.00% 12/07 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Product Testing Japan KK Eurofins Food Testing LUX Holding S.\u00e0 r.l. JP 100.00% 01/09 Eurofins DNA Synthesis KK Eurofins Genomics LUX Holding S.\u00e0 r.l. JP 66.00% 07/11 Eurofins Nihon Kankyo KK Eurofins Environment Testing Japan Holding Co., Ltd. JP 100.00% 04/12 Eurofins Nihon Soken KK Eurofins Environment Testing Japan Holding Co., Ltd. JP 100.00% 07/15 Eurofins Clinical Genetics KK Eurofins Genomics KK JP 100.00% 12/15 Eurofins NBLSC Environment Testing Japan KK Eurofins Environment Testing Japan Holding Co., Ltd. JP 100.00% 04/16 Eurofins Japan Analytical Chemistry Consultants Co., Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. JP 100.00% 08/17 Ltd. Eurofins EAG Materials Science Tokyo Corporation KK Eurofins EAG Materials Science, LLC JP 100.00% 12/17 Saitama Kankyo Service KK Eurofins Environment Testing Japan Holding Co., Ltd. JP 67.00% 12/17 Eurofins BioPharma Services Japan Holding KK Eurofins Pharma Services LUX Holding S.\u00e0 r.l. JP 100.00% 09/18 Eurofins Analytical Science Laboratories KK Eurofins BioPharma Services Japan Holding KK JP 100.00% 11/18 Eurofins Taiyo Techno Research KK Eurofins Environment Testing Japan Holding Co., Ltd. JP 100.00% 12/20 Eurofins Environment Testing Japan Holding Co., Ltd. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. JP 100.00% 09/20 Eurofins Earth Consul KK Eurofins Environment Testing Japan Holding Co., Ltd. JP 100.00% 12/20 Eurofins GeneTech KK Eurofins Clinical Testing Japan Holding Ltd. JP 100.00% 09/20 Eurofins EAG Materials Science Japan Holding KK Eurofins Material Sciences LUX Holding S.\u00e0 r.l. JP 100.00% 05/21 Eurofins Food Testing Japan KK Eurofins Food Testing LUX Holding S.\u00e0 r.l. JP 100.00% 08/21 Eurofins FQL Ltd. Eurofins EAG Materials Science Japan Holding KK JP 100.00% 07/21 AQM (Cambodia) Limited AQM HK Co., Ltd. KH 100.00% 06/19 Eurofins MTS Consumer Product Testing (Cambodia) Eurofins Product Testing LUX Holding S.\u00e0 r.l. KH 100.00% 11/21 Co., Ltd. Eurofins MET Korea Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. KR 100.00% 01/18 Eurofins Korea Analytic Service Co., Ltd. Eurofins Food and Environment Testing Korea Holding KR 100.00% 04/18 Co., Ltd. Eurofins Food and Environment Testing Korea Holding Eurofins Environment Testing LUX Holding S.\u00e0 r.l. KR 100.00% 07/20 Co., Ltd. Eurofins Woosol Co., Ltd. Eurofins Food and Environment Testing Korea Holding KR 100.00% 10/20 Co., Ltd. Eurofins EAG Materials Science Korea Co., Ltd. Eurofins Material Sciences LUX Holding S.\u00e0 r.l. KR 100.00% 10/21 Eurofins Product Testing Korea Holding Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. KR 100.00% 08/21 Eurofins KCTL Co., Ltd. Eurofins Product Testing Korea Holding Co., Ltd. KR 100.00% 10/21 Modern Testing Services Lanka Private Limited Eurofins Product Testing LUX Holding S.\u00e0 r.l. LK 100.00% 11/21 Eurofins Labtarna Lietuva UAB Eurofins Food Testing LUX Holding S.\u00e0 r.l. LT 100.00% 11/17 Eurofins Food Testing LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 12/06 Eurofins Environment Testing LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 12/06 Eurofins Pharma Services LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 12/06 Eurofins GSC LUX S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 10/06 Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 07/07 Eurofins Product Testing LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 04/08 Eurofins Real Estate LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 05/10 Eurofins Genomics LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 07/10 Eurofins Forensics LUX Holding S.\u00e0 r.l. Eurofins Scientific SE (French Branch) LU 100.00% 07/10 Eurofins Industrial Testing LUX S.\u00e0 r.l. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. LU 100.00% 09/10 Eurofins International Holdings LUX S.\u00e0 r.l. Eurofins Scientific SE LU 100.00% 12/10 Eurofins Water Testing LUX S.\u00e0 r.l. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. LU 100.00% 10/11 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Pharma Services France LUX Holding S.\u00e0 r.l. Eurofins Scientific SE (French Branch) LU 100.00% 12/11 Eurofins Food Chemistry Testing France LUX Holding Eurofins Scientific SE (French Branch) LU 100.00% 12/11 S.\u00e0 r.l. Eurofins Hygi\u00e8ne Alimentaire France LUX Holding S.\u00e0 Eurofins Scientific SE (French Branch) LU 100.00% 12/11 r.l. Eurofins Analyses pour la Construction France LUX Eurofins Scientific SE (French Branch) LU 100.00% 12/11 Holding S.\u00e0 r.l. Eurofins Analyses pour lEnvironnement France LUX Eurofins Scientific SE (French Branch) LU 100.00% 12/11 Holding S.\u00e0 r.l. Eurofins Analyses Environnementales pour les Eurofins Scientific SE (French Branch) LU 100.00% 12/11 Industriels France LUX Holding S.\u00e0 r.l. Eurofins Hydrologie France LUX Holding S.\u00e0 r.l. Eurofins Scientific SE (French Branch) LU 100.00% 12/11 Eurofins Discovery Services LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 11/12 Eurofins International Support Services LUX S.\u00e0 r.l. Eurofins Scientific SE LU 100.00% 11/12 Eurofins Special Nutrition Testing LUX Holding S.\u00e0 r.l. Eurofins Food Testing LUX Holding S.\u00e0 r.l. LU 100.00% 12/12 Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 11/14 Eurofins Clinical Testing Services France LUX Holding Eurofins Scientific SE (French Branch) LU 100.00% 05/15 S.\u00e0 r.l. Eurofins Air Monitoring LUX Holding S.\u00e0 r.l. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. LU 100.00% 02/16 Eurofins Support Services LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 04/16 Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 05/16 Eurofins Re LUX SA Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 09/17 Alpha Services LUX SA Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 12/17 Eurofins Material Sciences LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 05/18 Eurofins Sensory, Consumer research and Product Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 06/18 design LUX Holding S.\u00e0 r.l. Eurofins Assurance LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 05/20 Eurofins Clinical Testing Services Germany LUX Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 12/20 Holding S.\u00e0 r.l. Eurofins Central Lab Holdings LUX S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 12/20 Eurofins Finance Luxembourg S.\u00e0 r.l. Eurofins Scientific SE LU 100.00% 06/19 Eurofins Agroscience Services Maroc S.\u00e0 r.l Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. MA 98.20% 06/18 Eurofins Sam Sensory & Marketing Morocco S.\u00e0 r.l Eurofins Sensory, Consumer research and Product MA 100.00% 10/18 design LUX Holding S.\u00e0 r.l. Eurofins Biomnis Maroc S.\u00e0 r.l. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. MA 100.00% 12/19 Eurofins Assurance Myanmar Ltd. Eurofins Assurance LUX Holding S.\u00e0 r.l. MM 100.00% 06/19 Insight Technologies Ltd. Eurofins Laboratoire Dermscan SAS MU 100.00% 11/18 Eurofins NM Laboratory Sdn Bhd Eurofins Environment Testing LUX Holding S.\u00e0 r.l. MY 100.00% 11/15 Eurofins North Malaya Laboratory Sdn Bhd Eurofins Environment Testing LUX Holding S.\u00e0 r.l. MY 100.00% 11/15 Eurofins GSC IT Malaysia Sdn. Bhd Eurofins Support Services LUX Holding S.\u00e0 r.l. MY 100.00% 01/19 Eurofins Food Testing Malaysia Sdn Bhd Eurofins Food Testing LUX Holding S.\u00e0 r.l. MY 100.00% 05/19 Eurofins Environment Testing Netherlands Holding BV Eurofins Environment Testing LUX Holding S.\u00e0 r.l. NL 100.00% 04/01 Eurofins Food Testing Netherlands BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 10/00 Eurofins Analytico BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 04/01 Eurofins Central Laboratory BV Eurofins Pharma Services LUX Holding S.\u00e0 r.l. NL 100.00% 04/01 Eurofins Genomics BV Eurofins Scientific SE NL 100.00% 06/06 Eurofins C-Mark BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 03/11 Eurofins NSC Netherlands BV Eurofins Support Services LUX Holding S.\u00e0 r.l. NL 100.00% 05/11 Eurofins Food Testing Netherlands Holding BV Eurofins Food Testing LUX Holding S.\u00e0 r.l. NL 100.00% 05/11 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Food Testing Rotterdam BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 03/12 Zandbergsestraat Graauw RE Invest BV Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 01/13 Eurofins Lab Zeeuws-Vlaanderen (LZV) BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 01/13 Eurofins Logistics Benelux BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 04/13 Eurofins MITOX BV Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. NL 100.00% 07/13 Eurofins Agro Testing Netherlands Holding BV Eurofins Food Testing LUX Holding S.\u00e0 r.l. NL 100.00% 07/13 Eurofins Agro Testing Wageningen BV Eurofins Agro Testing Netherlands Holding BV NL 100.00% 07/13 Eurofins KBBL BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 01/14 Eurofins Food Safety Solutions BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 02/14 Eurofins Omegam BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 01/14 Duivendrecht Real Estate Invest BV Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 07/14 Eurofins Professional Scientific Services Netherlands Eurofins Pharma Services LUX Holding S.\u00e0 r.l. NL 100.00% 09/14 BV Eurofins NDSC Environment Testing Benelux BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 09/14 Eurofins De Bredelaar BV Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. NL 100.00% 07/15 Nieuw Biesterveld BV Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 07/15 Eurofins BioPharma Product Testing Netherlands Eurofins Pharma Services LUX Holding S.\u00e0 r.l. NL 100.00% 01/16 Holding BV Eurofins Bactimm BV Eurofins BioPharma Product Testing Netherlands NL 100.00% 01/16 Holding BV Eurofins PROXY Laboratories BV Eurofins BioPharma Product Testing Netherlands NL 100.00% 01/16 Holding BV Eurofins Spinnovation Analytical BV Eurofins BioPharma Product Testing Netherlands NL 100.00% 01/16 Holding BV Eurofins Bureau de Wit BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 06/16 Barneveld Gildeweg Real Estate BV Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 08/16 Eurofins Survey Netherlands BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 06/17 Heerenveen Hermes Icarus Real Estate BV Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 09/17 Eurofins Sanitas Inspections BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 11/17 Sanitas Milieukundig Adviesbureau BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 11/17 Eurofins Sanitas Testing BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 11/17 Eurofins Clinical Diagnostics Netherlands Holding BV Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. NL 100.00% 03/18 Eurofins Nederlands Moleculair Diagnostisch Eurofins Clinical Diagnostics Netherlands Holding BV NL 100.00% 03/18 Laboratorium BV Eurofins LCPL BV Eurofins Clinical Diagnostics Netherlands Holding BV NL 100.00% 03/18 Eurofins EAG Materials Science Netherlands BV Eurofins Material Sciences LUX Holding S.\u00e0 r.l. NL 100.00% 12/18 ACMAA Groep BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 07/18 ACMAA Inspectie BV ACMAA Groep BV NL 100.00% 07/18 ACMAA Laboratoria BV ACMAA Groep BV NL 100.00% 07/18 Eurofins Salux BV Eurofins Clinical Diagnostics Netherlands Holding BV NL 100.00% 05/19 The Maastricht Forensic Institute BV Eurofins Forensics LUX Holding S.\u00e0 r.l. NL 100.00% 12/19 Eurofins Bacteriologisch Adviesburo BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 10/20 Eurofins Medische Microbiologie BV Eurofins Clinical Diagnostics Netherlands Holding BV NL 100.00% 01/21 Eurofins EAG Materials and Engineering Science Eurofins Material Sciences LUX Holding S.\u00e0 r.l. NL 100.00% 06/21 Netherlands Holdings BV Eurofins PAMM BV Eurofins Clinical Diagnostics Netherlands Holding BV NL 100.00% 10/21 Certification Limited company BV Eurofins E&E CML Limited NL 100.00% 02/19 DNA Consolidated BV DDC Worldwide Ltd. NL 100.00% 08/21 % of Date ISO interest Company Subsidiary of: of code by the entry Group NorthSea Marketing BV DNA Consolidated BV NL 100.00% 08/21 Eurofins Maser BV Eurofins EAG Materials and Engineering Science NL 90.02% 10/21 Netherlands Holdings BV Eurofins Environment Testing Norway AS Eurofins Environment Testing Norway Holding AS NO 100.00% 05/06 Eurofins Environment Testing Norway Holding AS Eurofins Environment Testing LUX Holding S.\u00e0 r.l. NO 100.00% 09/07 Eurofins Food & Feed Testing Norway AS Eurofins Food Testing Norway Holding AS NO 100.00% 09/07 Eurofins Food Testing Norway Holding AS Eurofins Food Testing LUX Holding S.\u00e0 r.l. NO 100.00% 08/07 Eurofins Norge NSC AS Eurofins Support Services LUX Holding S.\u00e0 r.l. NO 100.00% 12/07 Eurofins Agro Testing Norway AS Eurofins Food Testing Norway Holding AS NO 100.00% 08/14 Moss Property Invest AS Eurofins Real Estate LUX Holding S.\u00e0 r.l. NO 100.00% 08/14 Eurofins Radonlab AS Eurofins Environment Testing Norway Holding AS NO 100.00% 12/15 Eurofins Havlandet AS Eurofins Food Testing Norway Holding AS NO 56.50% 02/20 Penrose NZ Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. NZ 100.00% 04/12 Eurofins Food Analytics NZ Limited Eurofins Food Testing LUX Holding S.\u00e0 r.l. NZ 100.00% 06/12 Eurofins ELS Limited Eurofins Australia New Zealand Holding Pty Ltd. NZ 100.00% 11/12 Eurofins Agroscience Services NZ Limited Eurofins Agrosciences Services France Holding SAS NZ 100.00% 07/13 Eurofins Agroscience Testing NZ Limited Eurofins Agrosciences Services France Holding SAS NZ 100.00% 07/13 Eurofins Bay Of Plenty Limited Eurofins Australia New Zealand Holding Pty Ltd. NZ 100.00% 06/16 Eurofins Environment Testing NZ Limited Eurofins Australia New Zealand Holding Pty Ltd. NZ 100.00% 03/17 Eurofins BioPharma Product Testing NZ Limited Eurofins Australia New Zealand Holding Pty Ltd. NZ 100.00% 10/17 Wellington Port Road Real Estate Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. NZ 100.00% 06/18 Eurofins Animal Health New Zealand Limited Eurofins Agroscience Services Pty Ltd. NZ 100.00% 12/18 Eurofins Scientific Services Philippines, Inc. Eurofins Food Testing LUX Holding S.\u00e0 r.l. PH 100.00% 09/19 AQM Pakistan Pvt. Ltd. AQM HK Co., Ltd. PK 100.00% 06/19 Eurofins Agroscience Services Sp. z.o.o. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. PL 100.00% 01/06 Eurofins Polska Sp. z.o.o. Eurofins Food Testing LUX Holding S.\u00e0 r.l. PL 100.00% 07/06 Eurofins Environment Testing Polska Sp. z o.o. Eurofins Industrial Testing LUX S.\u00e0 r.l. PL 100.00% 07/15 Eurofins GSC Poland Sp. z o.o. Eurofins Support Services LUX Holding S.\u00e0 r.l. PL 100.00% 02/16 \u0141\u00f3d\u017a Dubois Real Estate Sp. z o.o. Eurofins Real Estate LUX Holding S.\u00e0 r.l. PL 100.00% 12/18 Eurofins Dermscan Poland Sp. Z.o.o. Eurofins Product Testing LUX Holding S.\u00e0 r.l. PL 100.00% 11/18 Eurofins Business Services Poland Sp. z o.o. Eurofins Support Services LUX Holding S.\u00e0 r.l. PL 100.00% 12/19 Eurofins GSC IT Poland Sp. z o.o. Eurofins Support Services LUX Holding S.\u00e0 r.l. PL 100.00% 12/19 Eurofins NSC Polska Sp. z o.o. Eurofins Support Services LUX Holding S.\u00e0 r.l. PL 100.00% 04/20 Malbork Al. Wojska Polskiego Real Estate sp. z o.o. Eurofins Real Estate LUX Holding S.\u00e0 r.l. PL 100.00% 12/19 Eurofins Environment Testing Poland Holding Sp. z o.o. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. PL 100.00% 07/19 Eurofins OBIK\u015a Polska Sp. z.o.o. Eurofins Environment Testing Poland Holding Sp. z o.o. PL 100.00% 09/19 Eurofins Lab Environment Testing Portugal, Unipessoal Eurofins Industrial Testing LUX S.\u00e0 r.l. PT 100.00% 06/15 Lda. Sobrosa, Ac\u00e1cio J.A. Pereira, Real Estate, Unipessoal, Eurofins Real Estate LUX Holding S.\u00e0 r.l. PT 100.00% 12/18 Lda. Eurofins Food Testing Lisboa, Unipessoal Lda. Eurofins Analisis Alimentario Holding Espana S.L.U. PT 100.00% 06/19 Laborat\u00f3rio de An\u00e1lises Clinicas J. Pinto de Barros, SA Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. PT 100.00% 04/21 Eurofins Agroscience Services Romania SRL Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. RO 100.00% 08/09 Eurofins Evic Product Testing Romania SRL Eurofins Product Testing LUX Holding S.\u00e0 r.l. RO 100.00% 07/15 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Food Testing SRL Eurofins Food & Feed Testing Romania Holding SRL RO 100.00% 11/16 Bucharest Preciziei Real Estate SRL Eurofins Real Estate LUX Holding S.\u00e0 r.l. RO 100.00% 03/17 Eurofins Food & Feed Testing Romania Holding SRL Eurofins Food Testing LUX Holding S.\u00e0 r.l. RO 100.00% 11/17 Eurofins Asbestos Testing Romania SRL Eurofins Industrial Testing LUX S.\u00e0 r.l. RO 100.00% 12/17 Eurofins Food Analytica SRL Eurofins Food & Feed Testing Romania Holding SRL RO 100.00% 01/18 Eurofins Agro Testing Sweden AB Eurofins Food Testing Sweden Holding AB SE 100.00% 01/04 Eurofins Milk Testing Sweden AB Eurofins Food Testing Sweden Holding AB SE 100.00% 07/06 Eurofins Food Testing Sweden Holding AB Eurofins Food Testing LUX Holding S.\u00e0 r.l. SE 100.00% 09/07 Eurofins Environment Testing Sweden AB Eurofins Environment Testing Sweden Holding AB SE 100.00% 10/07 Eurofins Environment Testing Sweden Holding AB Eurofins Environment Testing LUX Holding S.\u00e0 r.l. SE 100.00% 09/07 Eurofins Food & Feed Testing Sweden AB Eurofins Food Testing Sweden Holding AB SE 100.00% 10/07 Eurofins NSC Sweden AB Eurofins Support Services LUX Holding S.\u00e0 r.l. SE 100.00% 01/08 Eurofins Biopharma Product Testing Sweden AB Eurofins Pharma Services LUX Holding S.\u00e0 r.l. SE 100.00% 04/11 Eurofins Pegasuslab AB Eurofins Environment Testing Sweden Holding AB SE 100.00% 06/12 Uppsala Property Invest AB Eurofins Real Estate LUX Holding S.\u00e0 r.l. SE 100.00% 03/14 Eurofins Radon Testing Sweden AB Eurofins Environment Testing Sweden Holding AB SE 100.00% 09/16 Eurofins Water Testing Sweden AB Eurofins Environment Testing Sweden Holding AB SE 100.00% 08/17 Eurofins Genomics Sweden AB Eurofins Genomics Europe Sequencing GmbH SE 100.00% 07/17 Lidk\u00f6ping Sj\u00f6hagsgatan Real Estate AB Eurofins Real Estate LUX Holding S.\u00e0 r.l. SE 100.00% 12/17 Eurofins Biofuel & Energy Testing Sweden AB Eurofins Environment Testing Sweden Holding AB SE 100.00% 04/18 Eurofins Clinical Testing Sweden AB Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. SE 100.00% 03/21 Eurofins Central Laboratory Pte. Ltd. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. SG 100.00% 12/06 Gold Standard Diagnostics Singapore Pte. Ltd. Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. SG 100.00% 12/15 Eurofins Mechem Pte. Ltd. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. SG 100.00% 03/17 Eurofins EAG Materials Science Singapore, Pte. Ltd. Eurofins Material Sciences LUX Holding S.\u00e0 r.l. SG 100.00% 12/17 Eurofins Food Testing Singapore Pte. Ltd Eurofins Food Testing LUX Holding S.\u00e0 r.l. SG 100.00% 08/18 Eurofins Clinical Diagnostics Pte. Ltd. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. SG 100.00% 08/19 Eurofins Holding za okoljske raziskave d.o.o. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. SI 100.00% 06/17 Velenje nepremi\u010dnine d.o.o., poslovanje z Eurofins Real Estate LUX Holding S.\u00e0 r.l. SI 100.00% 07/17 nepremi\u010dninami Eurofins ERICo Slovenia d.o.o. Eurofins Holding za okoljske raziskave d.o.o. SI 100.00% 07/17 Eurofins Bel/Novamann s.r.o. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. SK 100.00% 10/07 Eurofins NSC Central and Eastern Europe s.r.o. Eurofins Support Services LUX Holding S.\u00e0 r.l. SK 100.00% 06/15 Nov\u00e9 Z\u00e1mky Komjatick\u00e1 Real Estate s.r.o. Eurofins Real Estate LUX Holding S.\u00e0 r.l. SK 100.00% 10/16 Eurofins Food & Feed Testing Slovakia Holding s.r.o. Eurofins Food Testing LUX Holding S.\u00e0 r.l. SK 100.00% 08/19 Eurofins Food Testing Slovakia s.r.o Eurofins Food & Feed Testing Slovakia Holding s.r.o. SK 100.00% 10/19 Eurofins Environment Testing Holding Slovakia s.r.o. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. SK 100.00% 07/20 Tur\u010dianske Teplice Robotn\u00edcka Real Estate s.r.o. Eurofins Real Estate LUX Holding S.\u00e0 r.l. SK 100.00% 11/20 Eurofins Environment Testing Slovakia s.r.o. Eurofins Environment Testing Holding Slovakia s.r.o. SK 100.00% 11/20 Eurofins RBLSC IT CEE s.r.o. Eurofins Food Testing LUX Holding S.\u00e0 r.l. SK 100.00% 04/21 Eurofins Product Service (Thailand) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. TH 100.00% 07/08 Eurofins Agroscience Services Thailand Co., Ltd. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. TH 100.00% 05/16 Eurofins Food Testing (Thailand) Co., Ltd. Eurofins International Holdings LUX S.\u00e0 r.l. TH 100.00% 02/20 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Environment Testing Data Services Bangkok TestAmerica Laboratories, Inc. TH 100.00% 11/18 Co., Ltd. EUROFINS DERMSCAN TUNISIE SARL Eurofins Laboratoire Dermscan SAS TN 100.00% 11/18 Eurofins Turkey Analiz Hizmetleri Limited \u015eirketi Eurofins Food Testing LUX Holding S.\u00e0 r.l. TR 100.00% 05/12 Eurofins \u0130stanbul G\u0131da Kontrol Laboratuvarlar\u0131 A.\u015e. Eurofins Food Testing LUX Holding S.\u00e0 r.l. TR 100.00% 03/17 Denet Endustriyel Hizmetler Anonim \u015eirket A.\u015e. Eurofins \u0130stanbul G\u0131da Kontrol Laboratuvarlar\u0131 A.\u015e. TR 100.00% 03/17 Eurofins T\u00fcketici \u00dcr\u00fcnleri Test Hizmetleri A.\u015e Eurofins Product Testing LUX Holding S.\u00e0 r.l. TR 100.00% 08/17 Eurofins \u0130zmir G\u0131da Analiz Laboratuvarlar\u0131 Limited Eurofins Food Testing Turkey Holding A.\u015e. TR 100.00% 07/18 \u015eirketi Eurofins Food Testing Turkey Holding A.\u015e. Eurofins Food Testing LUX Holding S.\u00e0 r.l. TR 100.00% 06/19 Eurofins NSC Turkey Destek Hizmetleri A.\u015e. Eurofins Support Services LUX Holding S.\u00e0 r.l. TR 100.00% 11/19 Eurofins Assurance Turkey Kalite ve Denetim AQM HK Co., Ltd. TR 100.00% 06/19 Hizmetleri Limited \u015eirketi \u0130zmir Bornova Gayrimenkul A.\u015e. Eurofins Real Estate LUX Holding S.\u00e0 r.l. TR 100.00% 06/21 Eurofins Dr. Global G\u0131da Analiz Laboratuvar\u0131 A.\u015e. Eurofins Food Testing Turkey Holding A.\u015e. TR 100.00% 11/21 Eurofins Environment Testing Holding Taiwan Co., Ltd. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. TW 100.00% 03/15 Pharmacology Discovery Services Taiwan, Ltd. Eurofins Discovery Services LUX Holding S.\u00e0 r.l. TW 100.00% 08/16 Eurofins Panlabs Discovery Services Taiwan, Ltd. Eurofins Discovery Services LUX Holding S.\u00e0 r.l. TW 100.00% 08/16 Eurofins Food Testing Taiwan, Ltd. Eurofins Environment Testing Holding Taiwan Co., Ltd. TW 100.00% 08/17 Eurofins NSC Taiwan, Ltd. Eurofins Support Services LUX Holding S.\u00e0 r.l. TW 100.00% 06/18 Eurofins Tsing Hua Environment Testing Co., Ltd. Eurofins Environment Testing Holding Taiwan Co., Ltd. TW 100.00% 01/18 Eurofins Summit Tsiande Environmental Co., Ltd. Eurofins Environment Testing Holding Taiwan Co., Ltd. TW 100.00% 01/18 Eurofins E&E Taiwan Co., Ltd. Eurofins Consumer Product Testing Taiwan Holding TW 100.00% 01/18 Ltd. Eurofins SunDream Environmental Technical Co., Ltd. Eurofins Environment Testing Holding Taiwan Co., Ltd. TW 100.00% 09/20 Eurofins Blue Formosa Environmental Technical Co., Eurofins Environment Testing Holding Taiwan Co., Ltd. TW 100.00% 09/20 Ltd. Eurofins Universe Environmental Technical Co., Ltd. Eurofins Environment Testing Holding Taiwan Co., Ltd. TW 100.00% 09/20 Eurofins Consumer Product Testing Taiwan Holding Eurofins Product Testing LUX Holding S.\u00e0 r.l. TW 100.00% 06/21 Ltd. A Test Lab Techno Co., Ltd. Eurofins Consumer Product Testing Taiwan Holding TW 100.00% 07/21 Ltd. Eurofins NSC UK Limited Eurofins Support Services LUX Holding S.\u00e0 r.l. UK 100.00% 01/06 Eurofins Food Testing UK Limited Eurofins Food Testing UK Holding Limited UK 100.00% 01/04 Eurofins Genomics UK Limited Eurofins Genomics LUX Holding S.\u00e0 r.l. UK 100.00% 07/05 Eurofins Food Testing UK Holding Limited Eurofins Food Testing LUX Holding S.\u00e0 r.l. UK 100.00% 04/07 Eurofins Agroscience Services Limited Eurofins Agroscience Services UK Holding Limited UK 100.00% 04/07 Eurofins Product Testing Services Limited Eurofins Product Testing UK Holding Limited UK 100.00% 10/10 Public Analyst Scientific Services Limited Eurofins Food Testing UK Holding Limited UK 100.00% 07/11 Wolverhampton i54 Real Estate Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. UK 100.00% 07/12 Eurofins Water Hygiene Testing UK Limited Eurofins Food Testing UK Holding Limited UK 100.00% 10/15 Eurofins Biomnis UK Limited Eurofins Biologie Sp\u00e9cialis\u00e9e France SAS UK 100.00% 10/15 Eurofins Agro Testing UK Limited Eurofins Food Testing UK Holding Limited UK 100.00% 03/16 Eurofins Biopharma Product Testing UK Limited Eurofins Pharma Services LUX Holding S.\u00e0 r.l. UK 100.00% 07/16 Eurofins NDSM Limited Eurofins Agroscience Services UK Holding Limited UK 100.00% 07/16 Eurofins Agroscience Services UK Holding Limited Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. UK 100.00% 07/16 Livingston Cochrane Square Real Estate Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. UK 100.00% 08/16 Eurofins Food Safety Solutions Limited Eurofins Assurance LUX Holding S.\u00e0 r.l. UK 100.00% 11/16 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins York Limited Eurofins Product Testing UK Holding Limited UK 100.00% 07/17 Eurofins Forensic Services Limited Eurofins Forensics LUX Holding S.\u00e0 r.l. UK 100.00% 10/17 Eurofins Professional Scientific Services UK Limited Eurofins Pharma Services LUX Holding S.\u00e0 r.l. UK 100.00% 09/17 Eurofins Product Testing UK Holding Limited Eurofins Product Testing LUX Holding S.\u00e0 r.l. UK 100.00% 12/17 Eurofins Selcia Limited Eurofins Agroscience Services UK Holding Limited UK 100.00% 12/17 Ashwood UK Limited Eurofins Food Testing UK Holding Limited UK 100.00% 12/17 Eurofins E&E Hursley Limited Eurofins Product Testing UK Holding Limited UK 100.00% 02/18 Eurofins E&E ETC Limited Eurofins Product Testing UK Holding Limited UK 100.00% 01/18 Eurofins BLC Leather Technology Centre Limited Eurofins Product Testing UK Holding Limited UK 100.00% 04/18 Eurofins County Pathology Limited Eurofins Clinical Diagnostic Testing UK Holding Limited UK 100.00% 10/18 Eurofins Integrated Discovery UK Limited Eurofins Discovery Services LUX Holding S.\u00e0 r.l. UK 100.00% 12/18 Eurofins Clinical Diagnostic Testing UK Holding Limited Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. UK 100.00% 08/19 Eurofins E&E CML Limited Eurofins Product Testing UK Holding Limited UK 100.00% 02/19 Eurofins Environment Testing UK Holding Limited Eurofins Environment Testing LUX Holding S.\u00e0 r.l. UK 100.00% 03/19 Eurofins Chemtest Limited Eurofins Environment Testing UK Holding Limited UK 100.00% 04/19 Heathrow Dukes Green Real Estate Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. UK 100.00% 09/19 Eurofins Food Testing ATL Limited Eurofins Food Testing UK Holding Limited UK 100.00% 05/21 Eurofins Electrical and Electronic UK London Limited Eurofins Product Testing UK Holding Limited UK 100.00% 10/21 Eurofins MGS Laboratories Limited Eurofins Biopharma Product Testing UK Holding UK 75.00% 08/21 Limited Eurofins Alba Science Limited Eurofins Product Testing UK Holding Limited UK 90.00% 08/21 Eurofins Biopharma Product Testing UK Holding Eurofins Pharma Services LUX Holding S.\u00e0 r.l. UK 100.00% 08/21 Limited Tamworth Tungsten Park Real Estate Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. UK 100.00% 08/21 High Street Textile Testing Services Limited Eurofins MTS Consumer Product Testing UK Limited UK 100.00% 11/21 Modern Technology Holdings Limited Eurofins Product Testing LUX Holding S.\u00e0 r.l. UK 100.00% 11/21 Eurofins MTS Consumer Product Testing UK Limited Eurofins Product Testing LUX Holding S.\u00e0 r.l. UK 100.00% 11/21 Eurofins Food Chemistry Testing Des Moines, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 01/92 Eurofins Central Laboratory, LLC Eurofins Central Lab US Holdings, Inc. US 100.00% 06/06 Eurofins Analytical Laboratories, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 04/07 Eurofins Genomics, LLC Eurofins Genomics US Holdings, Inc. US 100.00% 12/07 Eurofins Food Testing US Holdings, Inc. Eurofins Food Testing LUX Holding S.\u00e0 r.l. US 100.00% 04/07 Eurofins Agroscience Services, LLC Eurofins Agrosciences Services US Holdings, Inc. US 100.00% 01/07 Eurofins Microbiology Laboratories, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 06/09 Eurofins NSC US, Inc. Eurofins Support Services LUX Holding S.\u00e0 r.l. US 100.00% 10/10 Eurofins Pharma US Holdings II, Inc. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. US 100.00% 01/11 Eurofins Lancaster Laboratories, Inc. Eurofins Pharma US Holdings II, Inc. US 100.00% 04/11 Eurofins DQCI, LLC Eurofins Food Testing US Holdings, Inc. US 100.00% 10/11 Eurofins Environment Testing Northern California, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 01/12 Eurofins QTA, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 02/12 Eurofins Eaton Analytical, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 07/12 Eurofins Environment Testing Northwest, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 09/12 Eurofins Panlabs, Inc. Eurofins Discovery Services & Products US Holdings, US 100.00% 10/12 Inc. % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Lancaster Laboratories Environment Testing, Eurofins Environment Testing America Holdings, Inc. US 100.00% 01/13 LLC Eurofins Pharma BioAnalytics Services US, LLC Eurofins Central Lab US Holdings, Inc. US 100.00% 01/13 South Bend Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 05/14 Eurofins Environment Testing Southwest, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 05/14 Eurofins Viracor, LLC Eurofins Clinical Testing US Holdings, Inc. US 100.00% 07/14 Eurofins SF Analytical Laboratories, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 11/14 Eurofins Clinical Testing US Holdings, Inc. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. US 100.00% 11/14 Boston Heart Diagnostics Corp. Eurofins Clinical Testing US Holdings, Inc. US 100.00% 01/15 Eurofins Lancaster Laboratories Professional Scientific Eurofins Lancaster Laboratories, Inc. US 100.00% 02/15 Services, LLC Eurofins Product Testing US, Inc. Eurofins Product Testing US Holdings, Inc. US 100.00% 02/15 Eurofins BioDiagnostics, Inc. Eurofins Genomics US Holdings, Inc. US 100.00% 02/15 Eurofins Environment Testing Philadelphia, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 04/15 Eurofins Diatherix Laboratories, LLC Eurofins Viracor, LLC US 100.00% 05/15 Eurofins Environment Testing Northeast, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 07/15 Eurofins Advantar Laboratories, Inc. Eurofins Pharma US Holdings II, Inc. US 100.00% 04/16 North Kingstown (R.I.) Camp Avenue Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 05/16 Eurofins Donor & Product Testing, Inc. Eurofins Clinical Testing US Holdings, Inc. US 100.00% 09/16 DeSoto Falcon Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 09/16 Lafayette Horizon Avenue Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 09/16 Eurofins Clinical Diagnostic US NDSC, Inc. Eurofins Clinical Testing US Holdings, Inc. US 100.00% 09/16 Agawam Silver Street Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 11/16 New Berlin 170th Street Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 11/16 Eurofins DiscoverX Corporation, Inc. Eurofins Discovery Services & Products US Holdings, US 100.00% 09/17 Inc. Eurofins Abraxis, Inc. Eurofins Technologies US Holdings, Inc. US 100.00% 10/17 Eurofins Technologies US Holdings, Inc. Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. US 100.00% 09/17 Eurofins Product Testing US Holdings, Inc. Eurofins Product Testing LUX Holding S.\u00e0 r.l. US 100.00% 09/17 Eurofins EAG Materials Science, LLC Eurofins EAG Materials Science US Holding, Inc. US 100.00% 12/17 Eurofins BioPharma Product Testing Columbia, Inc. Eurofins Pharma US Holdings II, Inc. US 100.00% 12/17 Eurofins Electrical and Electronic Testing NA, Inc. Eurofins Product Testing US Holdings, Inc. US 100.00% 12/17 Eurofins CEI, Inc. Eurofins Environment Testing America Holdings, Inc. US 100.00% 01/18 Eurofins Genomics Engineering LLC Eurofins Genomics US Holdings, Inc. US 100.00% 03/18 The National Food Lab, Inc. Eurofins Sensory, Consumer Research and Product US 100.00% 08/18 Design US Holding, Inc. Eurofins Sensory, Consumer Research and Product Eurofins Sensory, Consumer research and Product US 100.00% 08/18 Design US Holding, Inc. design LUX Holding S.\u00e0 r.l. Eurofins Food Chemistry Testing Madison, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 08/18 Eurofins Botanical Testing US, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 08/18 Battle Creek 55 Hamblin Avenue Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 08/18 Eurofins EAG Agroscience, LLC Eurofins Agrosciences Services US Holdings, Inc. US 100.00% 05/18 Eurofins CRL Cosmetics, Inc. Eurofins Product Testing US Holdings, Inc. US 100.00% 08/18 Gold Standard Diagnostics Corp, Inc. Eurofins Technologies US Holdings, Inc. US 100.00% 07/20 Eurofins Nanolab Technologies, Inc. Eurofins EAG Materials Science US Holding, Inc. US 100.00% 08/18 TestAmerica Laboratories, Inc. Eurofins Environment Testing America Holdings, Inc. US 100.00% 11/18 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins EPK Built Environment Testing, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 11/18 Environmental Sampling Supply, Inc. Eurofins Technologies US Holdings, Inc. US 100.00% 11/18 Eurofins Aerotech Built Environment Testing, Inc. Eurofins EPK Built Environment Testing, LLC US 100.00% 11/18 Madison Merchant Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 08/18 Eurofins EAG Engineering Science, LLC Eurofins EAG Materials Science US Holding, Inc. US 100.00% 12/18 Eurofins EAG Materials Science US Holding, Inc. Eurofins Material Sciences LUX Holding S.\u00e0 r.l. US 100.00% 04/19 Eurofins Genomics Blue Heron LLC Eurofins Genomics US Holdings, Inc. US 100.00% 04/19 Eurofins Viracor BioPharma Services, Inc. Eurofins Viracor, LLC US 100.00% 01/20 Transplant Genomics Inc. Eurofins Clinical Testing US Holdings, Inc. US 100.00% 05/19 Eurofins J3 Resources, Inc. Eurofins Environment Testing America Holdings, Inc. US 100.00% 10/19 Eurofins DiscoverX Products, LLC Eurofins DiscoverX Corporation, Inc. US 100.00% 12/19 Tustin Dow Avenue Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 11/19 Eurofins ARCA Technology, Inc. Eurofins Diatherix Laboratories, LLC US 100.00% 01/20 Pasadena Red Bluff Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 12/19 Lenexa 99th Street Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 12/19 Eurofins Environment Testing America Holdings, Inc. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. US 100.00% 12/19 Eurofins Environment Testing South Central, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 07/20 Stafford Greenbriar Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 01/20 Eurofins Precision TEM, LLC Eurofins EAG Materials Science US Holding, Inc. US 100.00% 04/20 Eurofins NDSC Environment Testing Americas, Inc. Eurofins Environment Testing America Holdings, Inc. US 100.00% 01/20 Clinical Enterprise, Inc. Eurofins Clinical Testing US Holdings, Inc. US 100.00% 03/20 Eurofins Beacon Discovery Holdings, Inc. Eurofins Discovery Services & Products US Holdings, US 100.00% 03/21 Inc. Eurofins Beacon Discovery, Inc. Eurofins Beacon Discovery Holdings, Inc. US 100.00% 03/21 Amherst Hazelwood Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 01/21 Eurofins Genomics US Holdings, Inc. Eurofins Genomics LUX Holding S.\u00e0 r.l. US 100.00% 01/21 Eurofins Agrosciences Services US Holdings, Inc. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. US 100.00% 01/21 Eurofins Central Lab US Holdings, Inc. Eurofins Central Lab Holdings LUX S.\u00e0 r.l. US 100.00% 01/21 Eurofins Discovery Services & Products US Holdings, Eurofins Discovery Services LUX Holding S.\u00e0 r.l. US 100.00% 01/21 Inc. Eurofins Food Assurance US, LLC Eurofins Food Testing US Holdings, Inc. US 100.00% 01/21 Eurofins Food Assurance Certification US, LLC Eurofins Food Testing US Holdings, Inc. US 100.00% 01/21 Louisville Plantside Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 01/21 Columbia ABC Lane Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 02/21 Leola New Holland Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 02/21 Eurofins Pandemic Prevention Services, Inc. Eurofins Pharma US Holdings II, Inc. US 100.00% 02/21 Eurofins TestOil, Inc. Eurofins Environment Testing America Holdings, Inc. US 100.00% 07/21 Eurofins CellTx, Inc. Eurofins Clinical Testing US Holdings, Inc. US 100.00% 07/21 Dallas Harry Hines Blvd. Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 07/21 DNA Diagnostics Center, Inc. Eurofins Clinical Testing US Holdings, Inc. US 100.00% 08/21 Eurofins Reservoirs Environmental, Inc. Eurofins Environment Testing America Holdings, Inc. US 100.00% 10/21 Barberton Van Buren Avenue Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 08/21 DDC Worldwide Corp. DNA Diagnostics Center, Inc. US 100.00% 08/21 Experchem US, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 09/21 % of Date ISO interest Company Subsidiary of: of code by the entry Group Tacoma Fife 8th Street Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 09/21 West Valley City Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 09/21 Clayton Powhatan Road Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 11/21 Eurofins Environment Testing Southeast, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 09/21 Eurofins Environment Testing North Central, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 10/21 Eurofins MTS Consumer Product Testing US, LLC Eurofins Product Testing US Holdings, Inc. US 100.00% 11/21 Horsham Road Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 11/21 Eurofins Sac Ky Hai Dang Co., Ltd. Eurofins Food Testing LUX Holding S.\u00e0 r.l. VN 100.00% 05/15 Eurofins Consumer Product Testing Vietnam Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. VN 100.00% 08/17 Eurofins Assurance Vietnam Co., Ltd. Eurofins Assurance LUX Holding S.\u00e0 r.l. VN 100.00% 06/19 Modern Testing Services (Vietnam) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. VN 100.00% 11/21 Please note that for commercial confidentiality and security reasons the information provided above is not comprehensive. 3.6. Other subsidiaries undertakings The companies below are not fully consolidated: % of ISO interest Method of Company Subsidiary of: code by the consolidation Group Z.F.D. GmbH DE Eurofins \u00d6kometric GmbH 33.00% Equity method Eurofins Laboratoire C\u0153ur de France SAEML FR Eurofins Microbiologie France Holding SAS 49.00% Equity method Fasmac Co. Ltd. JP Eurofins Genomics LUX Holding S.\u00e0 r.l. 41.00% Equity method Dermscan Asia Co., Ltd. TH Eurofins Laboratoire Dermscan SAS 34.00% Equity method T-rex Ltd. ZA Eurofins Agrosciences Services LUX Holding S.\u00e0 20.00% Equity method r.l. ", "dimensions": { "concept": "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "s7_notes__6__8": { "value": "1", "decimals": 0, "dimensions": { "concept": "ifrs-full:DividendsRecognisedAsDistributionsToOwnersPerShare", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR/xbrli:shares" } }, "s7_notes__7__8": { "value": "0.68", "decimals": 2, "dimensions": { "concept": "ifrs-full:DividendsRecognisedAsDistributionsToOwnersPerShare", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:EUR/xbrli:shares" } }, "s7_notes__6__9": { "value": "1", "decimals": 0, "dimensions": { "concept": "ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR/xbrli:shares" } }, "s7_notes__6__10": { "value": "192700000", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:EUR" } }, "pp-value-165-3": { "value": "Beneficiary units Beneficiary units are allocated under certain conditions to holders of fully paid-up shares as provided in the Company\u2019s articles of association, at a price of \u20ac0.01 per unit. Upon subscription, beneficiary units from each category of Class A, Class B and Class C confer their holders with one voting right per unit but no rights to dividends. Class A beneficiary units Class A beneficiary units, which confer no right to dividends but a right to one vote each, can be allocated to holders of fully paid-up shares for which (i) proof is provided of registration in the name of the same shareholder for at least three consecutive years as provided for in article 12bis.2 of the Company\u2019s Articles of Association (ii) request to subscribe class A beneficiary units was sent in writing by the relevant shareholder to the Company at the latest by 30 June 2020 and (iii) subject to the Company receiving payment of a subscription price of \u20ac0.01 per class A beneficiary unit. Therefore, the subscription period of class A beneficiary units has now expired. Class B beneficiary units Class B beneficiary units, which confer no right to dividends but a right to one vote each, are allocated to holders of fully paid-up shares for which (i) proof is provided of registration in the name of the same shareholder for at least five consecutive years as provided for in article 12bis.3 of the Company\u2019s Articles of Association (ii) request to subscribe class B beneficiary units was sent in writing by the relevant shareholder to the Company at the latest by 30 June 2021 and (iii) subject to the Company receiving payment of a subscription price of \u20ac0.01 per class B beneficiary unit. Therefore, the subscription period of class B beneficiary units has now expired. Class C beneficiary units Class C beneficiary units, which confer no right to dividends but a right to one vote each, are allocated to holders of fully paid-up shares for which (i) proof is provided of registration in the name of the same shareholder for at least two consecutive years as provided for in article 12bis.4 of the Company\u2019s Articles of Association (ii) request to subscribe class C beneficiary units is sent in writing by the relevant shareholder to the Company at the latest by 30 June 2023 and (iii) subject to the Company receiving payment of a subscription price of \u20ac0.01 per class C beneficiary unit. The Company\u2019s main shareholder Analytical Bioventures S.C.A. paid in 2021 a cash contribution of \u20ac766k equivalent to \u20ac0.01 per Class B & C beneficiary unit (Note 2.37) (2022: 0). Movements in the number of beneficiary units issued were as follows: 2022 Beneficiary units Class A Class B Class C Total 1 January 2022 63,977,852 63,000,000 63,000,000 189,977,852 Beneficiary units subscribed - - - - Beneficiary units cancelled -177.354 - - -177,354 31 December 2022 63,800,498 63,000,000 63,000,000 189,800,498 2021 Beneficiary units Class A Class B Class C Total 1 January 2021 64,577,670 50,000,000 - 114,577,670 Beneficiary units subscribed - 13,550,000 63,000,000 76,550,000 Beneficiary units cancelled -599,818 -550,000 - -1,149,818 31 December 2021 63,977,852 63,000,000 63,000,000 189,977,852 Voting rights Voting rights attached to shares are proportional to the capital quota they represent ie. each share gives the right to one vote. In addition, class A, class B and class C beneficiary units (\u201cparts b\u00e9n\u00e9ficiaires de cat\u00e9gorie A, B et C\u201d) carrying an extra voting right each, can be allocated to fully paid-up shares fulfilling conditions as specified in previous paragraphs about class A, class B and class C beneficiary units. As at 31 December 2022, a total amount of 189,800,498 class A, class B and class C beneficiary units has been issued and the total number of voting rights amounts to 382,320,521. ", "dimensions": { "concept": "EUR:DisclosureOfBeneficiaryUnitsAndVotingRights", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-167-3": { "value": "Partial and optional acquisition price payments in Eurofins shares As at 31 December 2022 and 2021, the overall number of Eurofins shares potentially deliverable was nil. ", "dimensions": { "concept": "EUR:DisclosureOfPartialAndOptionalAcquisitionPricePaymentsInEurofinsShares", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-168-4": { "value": "Treasury shares Plan 1 \u00ab Liquidity \u00bb contract On 1 November 2021, the Company entered into an agreement with Kepler Cheuvreux in order to enhance the liquidity of its shares. This agreement was valid up until 31 December 2022 and is renewable for one-year periods thereafter. An amount of cash of \u20ac15m has been allocated to a liquidity account by the Company to fund this program. As of 31 December 2022, the Company held 135,677 of its own shares under this liquidity contract (0.07% of the total number of shares at that date) representing an amount of \u20ac9.0m (38,100 shares for an amount of \u20ac3.6m as of 31 December 2021). Plan 2 Share Repurchase Plan The Share Repurchase Plan allows the acquisition of a maximum amount representing up to 2% of the Company\u2019s share capital, over a maximum period of twelve months as per the authorisation granted by the Company\u2019s Extraordinary General Meeting of shareholders held on 25 April 2019 (the \u201cEGM\u201d). The Company may at any time interrupt this program in view of market conditions and/or evolution of its investment strategy. The shares to be purchased under this program will be primarily used to hedge the Company\u2019s Long-Term Incentive plans but may also be cancelled, used to partially finance acquisitions or for other purposes approved by the Board of Directors and within the authorization of the EGM. On 3 October 2022, the Company mandated an independent provider of financial services to buy-back some of its own shares. The first tranche was completed on 3 December 2022. Between 3 October and 3 December, 121,493 shares were repurchased at an average price of 61.31 EUR, representing 0.06% of the current share capital. It is currently intended that all purchased shares may be used as previously communicated, including to cover the Company\u2019s Long-Term Incentive plans as approved by the Board of Directors at its meeting on 19 December 2022. The second tranche will cover a maximum volume of up to one million shares or 0.52% of the Company\u2019s current share capital. The purchase period will start on 22 December 2022 and will last until 3 May 2023 at the latest. Under this plan, as of 31 December 2022, the Company held 83,883 of its own shares (0.04% of the total number of shares) representing an amount of \u20ac5.2m. ", "dimensions": { "concept": "ifrs-full:DisclosureOfTreasurySharesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-169-2": { "value": "2.28. Non-controlling interests Non-controlling interests relate to minority stakes held by third parties in consolidated group companies: \u25aa Eurofins Cerep SA for the remaining non-controlling interests of circa 4.2%. This is a level 1 fair value measurement. \u25aa QSAI Analysis and Research Center Co.,Ltd. (JP) for the remaining non-controlling interests of 15%. \u25aa The companies with remaining NCI and put and call options are: already controlled by the Group in 2021: - Havlandet Forskningslabratorium (NO): 43.5%; - Eurofins Beacon Discovery, Inc. (US): 30%; - Alba Science Limited (UK): 10%; - Maser Facilities BV (NL): 10%; - MGS Laboratories Limited (UK): 25%. newly consolidated companies in 2022: - Bio-EC Group (FR): 39.8%; - Medserv Kft. (HU): 38.75%; - Eurofins Limed (IL): 49.9%; - CRA Korea Co, Ltd. (KR): 40%; - Eurofins Saudi Ajal Laboratories (SA): 45%; - Thai Environmental Technic Co., Ltd (TH): 25%; - Genetic Testing Service JSC (VN): 33%; - Repertoire Genesis Inc. (JP): 45%. The change in the value of the Put and Call option amounts to \u20ac52m for the period 2022 (Note 2.22). This is a level 3 fair value measurement. Other companies with non-controlling interests but without put and call option are listed in Note 3. Below is the impact of the companies with non-controlling interests integrated in the Consolidated Financial Statements: In \u20ac millions 2022 2021 Revenues 151.5 140.8 Net Profit 16.8 10.5 The non-controlling interests of the companies listed above consequently bear the risks and rewards attached to their shareholding, which are recognised as non-controlling interests. Most minority shareholders are managing directors of the companies and they have a right to the dividend of the company in which they hold a non-controlling interest. The Group has elected the full goodwill method on the consolidation of these assets; the non-controlling interests have been in consequence recognised at their fair value against goodwill at acquisition time. In accordance with IAS 32.23, the Group has recognised its obligation to purchase the shares under the put option as a financial liability under the caption \u201camounts due for business acquisitions\u201d (Note 2.22). The same paragraph states that the financial liability is reclassified from equity. During 2022, the Group acquired the remaining non-controlling interests for an amount of \u20ac9.6m in 11% interest of Eurofins GSD Holdings, Inc. (US), in 15% interest of Eurofins Lab Solution Srl (Italy), in 7% interest of Toxlab SAS (FR), in 7% Cimera Estudios Aplicados, SL (ES), in 40% Insight Technologies, Ltd. (MU) and in 2% Chemtest Holdings Limited (UK) including discontinued the remaining 15% non-controlling interests in Commissum Associates (UK/SG), (part of Digital testing) for an amount of \u20ac1.6m. ", "dimensions": { "concept": "ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-171-2": { "value": "2.29. Free Cash Flow to the Firm and Equity In \u20ac millions Note 2022 2021 Free Cash Flow to the Firm (Cash Flow Statement) 491.0 1,029.8 Disposals/(acquisition) of investments, financial assets and derivative financial 1.5 -8.4 instruments, net Repayment of lease liabilities 2.18 -166.1 -153.4 Interest received (Cash Flow Statement) 2.5 1.7 Interests and premium paid (Cash Flow Statement) 2.7 -49.4 -168.8 Free Cash Flow to Equity 279.5 700.9 Free Cash Flow to the Firm decrease in 2022 compared to 2021 due to exceptional activity related to COVID-19 in 2021 and higher investments in 2022 especially in the Group\u2019s own sites. ", "dimensions": { "concept": "EUR:DisclosureOfFreeCashFlow", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-172-2": { "value": "2.30. Financial risk management The Group is exposed to several types of financial risks. This Note further analyses financial risks. The Group does not purchase or hold any derivative financial instruments for speculative purposes. Liquidity risk Liquidity risk is the risk that an entity might encounter difficulty in meeting its obligations associated with its financial liabilities. Liquidity risk for the Group is monitored through / by the Group Treasury Team, which tracks the development of the actual cash flow position for the Group and uses inputs from a number of sources in order to forecast the overall liquidity position on both a short- and longer-term basis. Eurofins invests surplus cash in short-term deposits with appropriate maturities to ensure sufficient liquidity is available to meet liabilities when due. The rating of the Company\u2019s debt may improve or deteriorate. As a result, the Group\u2019s future borrowing capacity may be influenced, and its financing costs may fluctuate. The Group has various sources to mitigate its liquidity risk. As at 31 December 2022, the Group had \u20ac486.6m in cash and cash equivalents (2021: \u20ac515.3m). Cash and cash equivalents include all cash balances and short-term highly liquid investments with an original maturity of three months or less that are readily convertible into known amounts of cash. The Group pools cash from subsidiaries to the extent legally and economically feasible. In addition to its capacity to generate cash-flows from its operations, Eurofins relies on the NEU CP market for its short-term needs as well its bank credit facilities at competitive interest rate. Those bank credit facilities can also be used to fund any type of general corporate purpose. None of those credit lines was drawn at the end of 2022 nor will be maturing in 2023. Eurofins believes it has sufficient liquidity to execute on the Group\u2019s growth plans for 2023. Ratings In July 2020, Eurofins received its first public long-term issuer credit rating by Moody\u2019s Investor Services (\u201cMoody\u2019s\u201d) which assigned an investment grade rating of Baa3 with a stable outlook. Moody\u2019s confirmed the Baa3 rating and upgraded the outlook to positive in May 2022. In May 2021, Eurofins received its second credit rating by Fitch Ratings which assigned an investment grade credit rating of BBB- with a stable outlook. Fitch Ratings confirmed the BBB- rating and the stable outlook in May 2022. Some loans/facilities are secured by contingent securities over assets determined at local level (Note 2.32). The hybrid capital, Eurobonds, Schuldschein loans and bilateral credit lines are neither secured nor include any financial covenants. The table below presents a summary of the Group\u2019s fixed contractual cash obligations and commitments as of 31 December 2022. These amounts are an estimate of future payments which could change as a result of various factors such as a change in interest rates, foreign exchange, contractual provisions, as well as changes in our business strategy and needs. Therefore, the actual payments made in future periods may vary from those presented in the following table: Financial liabilities Total Up to 1 year 2-5 years Over 5 years In \u20ac millions 2022 1Bonds2,100.0 - 750.0 1,350.0 1Schuldschein536.5 - 409.0 127.5 Commercial paper 75.0 75.0 - - 1Bank borrowings109.9 11.3 48.8 49.7 Bank overdrafts 3.4 3.4 - - Lease liabilities 527.6 128.6 319.0 80.0 Amounts due for business acq. (not 216.7 50.3 127.0 39.4 discounted) Earnings due on hybrid capital 7.7 7.7 - - 2Current and future interest due434.6 87.8 243.3 103.6 Trade accounts payable 647.7 647.7 - - Total 4,659.1 1,011.9 1,897.1 1,750.2 2021 1Bonds1,500.0 - 750.0 750.0 1Schuldschein582.0 45.5 233.5 303.0 Commercial paper 80.0 80.0 - - 1Bank borrowings71.5 10.2 32.6 28.7 Bank overdrafts 0.3 0.3 - - Lease liabilities 538.9 120.7 319.3 98.9 Amounts due for business acq. (not 141.3 56.9 78.4 6.0 discounted) Earnings due on hybrid capital 14.3 14.3 - - 2Current and future interest due292.6 61.2 173.8 57.6 Trade accounts payable 627.6 627.6 - - Total 3,848.5 1,016.7 1,587.6 1,244.2 1 Par value.2 Including interests due on borrowings until their full repayment and the impact of any derivative financial instruments. Leases The Group has lease contracts for various items of real estate, vehicles and other equipment used in its operations. The Group has multiple extension and termination options in a number of lease contracts. These are used to maximise operational flexibility in terms of managing the assets used in the Group's operations. The options considered reasonably certain are part of lease liabilities. However, the options not considered reasonably certain are not part of lease liability, which exposes the Company to potential future cash outflows amounting to \u20ac41m. In addition, the Group is not committed to leases not yet commenced. The Group's lease contracts do not contain any financial covenants. The Group has the following minimum lease payments commitments: Total Up to 1 year 2-5 years Over 5 years In \u20ac millions 1- Buildings7.1 7.1 - - - Equipments, cars and others 1.6 1.0 0.6 - Total 8.7 8.1 0.6 - 1 Undiscounted sum of future aggregate minimum lease payments, non-cancellable other than lease liabilities already reported in Note 2.18. The Group recorded in 2022 expenses of \u20ac12.4m related to short term leases and an expense of ca. \u20ac1m relating to low-value assets, which are recognised in other operating expenses. Currency risk Currency risk is the risk that reported financial performance, or the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Group operates in many countries and currencies and therefore currency fluctuations may impact Eurofins\u2019 financial results. Eurofins is exposed to currency risk in the following areas: \u25aa Transaction exposures, related to anticipated sales and purchases and on balance-sheet receivables/payables resulting from such transactions; \u25aa Translation exposure of foreign-currency intercompany and external debt and deposits; \u25aa Translation exposure of net income in foreign entities; \u25aa Translation exposure of foreign-currency-denominated equity invested in consolidated companies; \u25aa Translation exposure to equity interests in non-functional-currency investments in associates and other non-current financial assets. In 2022, the Group generated around 57% of its revenues outside of the Euro-Zone. The Group will continue to conduct its business activities in the future via subsidiaries in various countries. However, in most cases, the revenues and operating results as well as most items on the Balance Sheet of its subsidiaries (intangible, fixed and current assets, some financial and current liabilities) are settled in the domestic currency without any real exchange risk. Accounting-wise, these operating results and Balance Sheet items are recorded in the relevant foreign currency and then converted into Euro, for translation into the Consolidated Financial Statements at the applicable exchange rate. In some cases, where an exchange rate risk might be applicable with revenues and cost structures in different currencies, the Company may enter into some currency hedging instruments to avoid any exchange rate fluctuations. The most significant currencies for the Group were translated at the following exchange rates into Euro: Value Balance Sheet Income Statement of \u20ac1 End of period rates average rates 31 December 2022 31 December 2021 2022 2021 US Dollar 1.07 1.14 1.05 1.18 Pound Sterling 0.89 0.84 0.85 0.86 Japanese Yen 140.41 130.91 138.08 129.87 Canadian Dollar 1.45 1.44 1.37 1.48 Indian Rupee 88.15 84.21 82.75 87.46 Chinese Renminbi 7.36 7.22 7.08 7.63 Danish Krona 7.44 7.44 7.44 7.44 Taiwan Dollar 32.75 31.35 31.34 33.09 Australian Dollar 1.57 1.56 1.52 1.57 South Korean Won 1,342.60 1,345.90 1,357.54 1,353.18 As at 31 December 2022, the exposure to currency risk breaks down as follows: Off-Balance Currency 22Net position Net position AssetsLiabilitiesSheet Hedge In \u20ac millions before hedge after hedge Commitments US Dollar 4,670.4 1,008.8 - 3,661.6 - 3,661.6 Pound Sterling 367.0 118.8 - 248.2 - 248.2 Japanese Yen 290.7 104.6 - 186.1 - 186.1 Canadian Dollar 252.6 99.6 - 153.0 - 153.0 Indian Rupee 229.0 83.0 - 146.0 - 146.0 Chinese Renminbi 163.8 83.3 - 80.5 - 80.5 Danish Krona 152.5 55.0 - 97.5 - 97.5 Taiwan Dollar 126.4 35.5 - 90.9 - 90.9 Australian Dollar 119.8 39.2 - 80.7 - 80.7 South Korean Won 96.4 47.8 - 48.7 - 48.7 1Other700.1 323.7 19.2 357.2 - 357.2 Total 7,168.8 1,999.3 19.2 5,150.3 - 5,150.3 1 Non Euro. 2 including Intercompany positions. A 1 percentage point increase or decrease in exchange rates would have an impact of +/- \u20ac30.4m on the Group\u2019s equity and an impact on the Group\u2019s EBITAS of +/- \u20ac5.8m. Foreign exchange exposure also arises as a result of inter-company loans and deposits. When the lending company enters into such arrangements, the financing is generally provided in the functional currency of the subsidiary entity. When such loans would be considered to be part of the net investment in the subsidiary, net investment hedging would be applied. Translation exposure of foreign-currency equity invested in consolidated entities is generally not hedged. Net current-period change, before tax, of the currency translation reserve of \u20ac285.7 mainly relates to the development of the USD versus the Euro (\u20ac106.7m in 2021). As at 31 December 2022, a weakening / a strengthening of USD by 1% versus the Euro would result in a decrease / an increase in the currency translation reserve in equity of approximately \u20ac37m. Reference is made to the country risk paragraph for countries with significant foreign currency denominated equity invested. Interest rate risk Interest rate risk is the risk that the fair value or future cash flows of a financial instrument might fluctuate because of changes in market interest rates. In order to finance parts of its acquisition and expansion costs, the Company and its subsidiaries have entered into several loan and facility agreements as specified in Note 2.18. The Group had, at year-end, outstanding debt of \u20ac3,325.6 (2021: \u20ac2,754.1m), which constitutes an inherent interest rate risk with potential negative impact on financial results. The loans and facilities are either based on a fixed rate or on a variable rate. The derivative financial instruments assets include caps for an amount of \u20ac5.6m as of 31 December 2022 in order to hedge the Group\u2019s exposure to interest rate fluctuations particularly related to the 2018 Schuldschein loan (\u20ac0.5m at end of 2021). The Group has concluded hedging contracts, for an initial premium of \u20ac2.4m, in order to cap its floating interest rate against a fixed rate for a total nominal amount of \u20ac99m. In \u20ac millions Note 2022 2021 Balance as of 1 January 0.5 0.1 Amortisation of Time Value 2.7 -0.3 -0.3 Fair Value adjustments through OCI 5.4 0.8 Balance as of 31 December 2.33 5.6 0.5 The impact on the valuation of the financial instruments of a shift of +/- 1 percentage point in the yield curve would not be material on the Group\u2019s total equity. The amount booked in equity is transferred to net profit as far as the underlying instrument impacts the net profit. The Group\u2019s net exposure to interest rate risk for the borrowings (excluding lease liabilities) as per Balance Sheet date, before taking into account the above hedging transactions is presented below: 2022 2021 Borrowings at fixed interest rates 90% 88% Borrowings at floating interest rates 10% 12% Given the breakdown between fixed rate and floating rate assets and liabilities as at 31 December 2022, a 1% increase or decrease in interest rates would have a full-year impact of +/- \u20ac1.7m on results before income taxes (excluding lease liabilities). Rate Up to 2-5 Over Total In \u20ac millions 1 year years 5 years Short term deposits Fixed -54.4 - - -54.4 Floating - - - - Bonds Fixed - 750.0 1,350.0 2,100.0 Floating - - - - Schuldschein Fixed - 177.5 97.5 275.0 Variable - 231.5 30.0 261.5 Commercial paper Fixed 75.0 - - 75.0 Floating - - - - Bank borrowings Fixed 10.8 45.5 43.7 100.0 Floating 0.5 3.4 6.0 9.9 Lease liabilities Fixed 6.5 25.0 8.1 39.6 Floating 122.1 293.9 71.9 487.9 Net exposure Fixed 37.9 998.0 1,499.3 2,535.2 Before hedge Floating 122.6 528.8 107.9 759.3 Hedge Fixed - 99.0 - 99.0 Floating - -99.0 - -99.0 Net exposure Fixed 37.9 1,097.0 1,499.3 2,634.2 After hedge Floating 122.6 429.8 107.9 660.3 Credit risk Credit risk represents the loss that would be recognised at the reporting date if counterparties failed completely to perform their payment obligations as contracted. Credit risk is present within Eurofins\u2019 trade receivables and contract assets. In order to have better insight into its credit exposure, the Group performs ongoing analysis of the financial and non-financial condition of its customers and adjusts credit limits if and when appropriate. In instances where the creditworthiness of a customer is determined not to be sufficient to grant the credit limit required, there are a number of tools that can be utilised to mitigate the impact, including reducing payment terms, cash on delivery, pre-payments and pledges on assets. The rate of default experienced by the Group in proportion to its sales has been very low for the past five years. On average during this period, provision for impairment of receivables represented around 1% of the annual revenues, whilst customer terms of payment are in accordance with ordinary commercial practices in each country where the Group is active. In case of more challenging economic and/or trading conditions, the Group pays particular attention to the ability of new and existing customers to pay their debts. The Group believes its policy relating to doubtful debtors to be appropriate. The Group has a large number of customers across its business lines. The Group endeavours not to be dependent on any single customer. The biggest customer represents less than 2% of the consolidated revenues and the first 10 customers of the Group represent altogether less than 10% of the consolidated revenues. More particularly, the credit risk associated with US clinical diagnostic testing services is described in more detail in Note 1.4. The amounts relating to trade receivables, bad debt provision and the ageing balance are shown in Note 2.15. With a slight increase of overdues in percentage of total trade accounts receivable, the average observed credit losses over the last three years remain low and the expected loss rate did not materially change between 2021 and 2022. The Group invests available cash and cash equivalents with various leading financial institutions with strong credit ratings and is exposed to limited credit risk with these counterparties. The Group policy is to limit its exposure by dealing solely with leading counterparties and monitoring their credit ratings, in line with guidelines approved by the Company. The Group actively manages concentration risk of its liquidity among financial institutions and measures the potential loss under certain stress scenarios, should a financial institution default. These worst-case scenario losses are monitored and mitigated by the Company. In the context of negative short-term interest rate across many European countries, the Group may decide to ease some of the criteria listed above in order to avoid any loss on capital (i.e., no negative remuneration on cash deposit). Country risk Country risk is the risk that political, legal, or economic developments in a single country could adversely impact the Group\u2019s performance. The country risk is monitored on a regular basis (see Assets and Liabilities per currency in Note 2.30 \u2013 Currency Risk). There are a number of potential risks and uncertainties which could have a material impact on the Group\u2019s performance over the financial year 2023 and could cause actual results to differ materially from expected and historical results, including the potential risks which could arise from the conflict in Ukraine, as described in the risk section of the management report. Direct Russia & Ukraine revenues for Eurofins companies were under \u20ac3m in 2021 and less than \u20ac1.5m in 2022. ", "dimensions": { "concept": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-173-3": { "value": "Liquidity risk Liquidity risk is the risk that an entity might encounter difficulty in meeting its obligations associated with its financial liabilities. Liquidity risk for the Group is monitored through / by the Group Treasury Team, which tracks the development of the actual cash flow position for the Group and uses inputs from a number of sources in order to forecast the overall liquidity position on both a short- and longer-term basis. Eurofins invests surplus cash in short-term deposits with appropriate maturities to ensure sufficient liquidity is available to meet liabilities when due. The rating of the Company\u2019s debt may improve or deteriorate. As a result, the Group\u2019s future borrowing capacity may be influenced, and its financing costs may fluctuate. The Group has various sources to mitigate its liquidity risk. As at 31 December 2022, the Group had \u20ac486.6m in cash and cash equivalents (2021: \u20ac515.3m). Cash and cash equivalents include all cash balances and short-term highly liquid investments with an original maturity of three months or less that are readily convertible into known amounts of cash. The Group pools cash from subsidiaries to the extent legally and economically feasible. In addition to its capacity to generate cash-flows from its operations, Eurofins relies on the NEU CP market for its short-term needs as well its bank credit facilities at competitive interest rate. Those bank credit facilities can also be used to fund any type of general corporate purpose. None of those credit lines was drawn at the end of 2022 nor will be maturing in 2023. Eurofins believes it has sufficient liquidity to execute on the Group\u2019s growth plans for 2023. Ratings In July 2020, Eurofins received its first public long-term issuer credit rating by Moody\u2019s Investor Services (\u201cMoody\u2019s\u201d) which assigned an investment grade rating of Baa3 with a stable outlook. Moody\u2019s confirmed the Baa3 rating and upgraded the outlook to positive in May 2022. In May 2021, Eurofins received its second credit rating by Fitch Ratings which assigned an investment grade credit rating of BBB- with a stable outlook. Fitch Ratings confirmed the BBB- rating and the stable outlook in May 2022. Some loans/facilities are secured by contingent securities over assets determined at local level (Note 2.32). The hybrid capital, Eurobonds, Schuldschein loans and bilateral credit lines are neither secured nor include any financial covenants. The table below presents a summary of the Group\u2019s fixed contractual cash obligations and commitments as of 31 December 2022. These amounts are an estimate of future payments which could change as a result of various factors such as a change in interest rates, foreign exchange, contractual provisions, as well as changes in our business strategy and needs. Therefore, the actual payments made in future periods may vary from those presented in the following table: Financial liabilities Total Up to 1 year 2-5 years Over 5 years In \u20ac millions 2022 1Bonds2,100.0 - 750.0 1,350.0 1Schuldschein536.5 - 409.0 127.5 Commercial paper 75.0 75.0 - - 1Bank borrowings109.9 11.3 48.8 49.7 Bank overdrafts 3.4 3.4 - - Lease liabilities 527.6 128.6 319.0 80.0 Amounts due for business acq. (not 216.7 50.3 127.0 39.4 discounted) Earnings due on hybrid capital 7.7 7.7 - - 2Current and future interest due434.6 87.8 243.3 103.6 Trade accounts payable 647.7 647.7 - - Total 4,659.1 1,011.9 1,897.1 1,750.2 2021 1Bonds1,500.0 - 750.0 750.0 1Schuldschein582.0 45.5 233.5 303.0 Commercial paper 80.0 80.0 - - 1Bank borrowings71.5 10.2 32.6 28.7 Bank overdrafts 0.3 0.3 - - Lease liabilities 538.9 120.7 319.3 98.9 Amounts due for business acq. (not 141.3 56.9 78.4 6.0 discounted) Earnings due on hybrid capital 14.3 14.3 - - 2Current and future interest due292.6 61.2 173.8 57.6 Trade accounts payable 627.6 627.6 - - Total 3,848.5 1,016.7 1,587.6 1,244.2 1 Par value.2 Including interests due on borrowings until their full repayment and the impact of any derivative financial instruments. ", "dimensions": { "concept": "ifrs-full:DisclosureOfLiquidityRiskExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-177-3": { "value": "Currency risk Currency risk is the risk that reported financial performance, or the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Group operates in many countries and currencies and therefore currency fluctuations may impact Eurofins\u2019 financial results. Eurofins is exposed to currency risk in the following areas: \u25aa Transaction exposures, related to anticipated sales and purchases and on balance-sheet receivables/payables resulting from such transactions; \u25aa Translation exposure of foreign-currency intercompany and external debt and deposits; \u25aa Translation exposure of net income in foreign entities; \u25aa Translation exposure of foreign-currency-denominated equity invested in consolidated companies; \u25aa Translation exposure to equity interests in non-functional-currency investments in associates and other non-current financial assets. In 2022, the Group generated around 57% of its revenues outside of the Euro-Zone. The Group will continue to conduct its business activities in the future via subsidiaries in various countries. However, in most cases, the revenues and operating results as well as most items on the Balance Sheet of its subsidiaries (intangible, fixed and current assets, some financial and current liabilities) are settled in the domestic currency without any real exchange risk. Accounting-wise, these operating results and Balance Sheet items are recorded in the relevant foreign currency and then converted into Euro, for translation into the Consolidated Financial Statements at the applicable exchange rate. In some cases, where an exchange rate risk might be applicable with revenues and cost structures in different currencies, the Company may enter into some currency hedging instruments to avoid any exchange rate fluctuations. The most significant currencies for the Group were translated at the following exchange rates into Euro: Value Balance Sheet Income Statement of \u20ac1 End of period rates average rates 31 December 2022 31 December 2021 2022 2021 US Dollar 1.07 1.14 1.05 1.18 Pound Sterling 0.89 0.84 0.85 0.86 Japanese Yen 140.41 130.91 138.08 129.87 Canadian Dollar 1.45 1.44 1.37 1.48 Indian Rupee 88.15 84.21 82.75 87.46 Chinese Renminbi 7.36 7.22 7.08 7.63 Danish Krona 7.44 7.44 7.44 7.44 Taiwan Dollar 32.75 31.35 31.34 33.09 Australian Dollar 1.57 1.56 1.52 1.57 South Korean Won 1,342.60 1,345.90 1,357.54 1,353.18 As at 31 December 2022, the exposure to currency risk breaks down as follows: Off-Balance Currency 22Net position Net position AssetsLiabilitiesSheet Hedge In \u20ac millions before hedge after hedge Commitments US Dollar 4,670.4 1,008.8 - 3,661.6 - 3,661.6 Pound Sterling 367.0 118.8 - 248.2 - 248.2 Japanese Yen 290.7 104.6 - 186.1 - 186.1 Canadian Dollar 252.6 99.6 - 153.0 - 153.0 Indian Rupee 229.0 83.0 - 146.0 - 146.0 Chinese Renminbi 163.8 83.3 - 80.5 - 80.5 Danish Krona 152.5 55.0 - 97.5 - 97.5 Taiwan Dollar 126.4 35.5 - 90.9 - 90.9 Australian Dollar 119.8 39.2 - 80.7 - 80.7 South Korean Won 96.4 47.8 - 48.7 - 48.7 1Other700.1 323.7 19.2 357.2 - 357.2 Total 7,168.8 1,999.3 19.2 5,150.3 - 5,150.3 1 Non Euro. 2 including Intercompany positions. A 1 percentage point increase or decrease in exchange rates would have an impact of +/- \u20ac30.4m on the Group\u2019s equity and an impact on the Group\u2019s EBITAS of +/- \u20ac5.8m. Foreign exchange exposure also arises as a result of inter-company loans and deposits. When the lending company enters into such arrangements, the financing is generally provided in the functional currency of the subsidiary entity. When such loans would be considered to be part of the net investment in the subsidiary, net investment hedging would be applied. Translation exposure of foreign-currency equity invested in consolidated entities is generally not hedged. Net current-period change, before tax, of the currency translation reserve of \u20ac285.7 mainly relates to the development of the USD versus the Euro (\u20ac106.7m in 2021). As at 31 December 2022, a weakening / a strengthening of USD by 1% versus the Euro would result in a decrease / an increase in the currency translation reserve in equity of approximately \u20ac37m. Reference is made to the country risk paragraph for countries with significant foreign currency denominated equity invested. Interest rate risk Interest rate risk is the risk that the fair value or future cash flows of a financial instrument might fluctuate because of changes in market interest rates. In order to finance parts of its acquisition and expansion costs, the Company and its subsidiaries have entered into several loan and facility agreements as specified in Note 2.18. The Group had, at year-end, outstanding debt of \u20ac3,325.6 (2021: \u20ac2,754.1m), which constitutes an inherent interest rate risk with potential negative impact on financial results. The loans and facilities are either based on a fixed rate or on a variable rate. The derivative financial instruments assets include caps for an amount of \u20ac5.6m as of 31 December 2022 in order to hedge the Group\u2019s exposure to interest rate fluctuations particularly related to the 2018 Schuldschein loan (\u20ac0.5m at end of 2021). The Group has concluded hedging contracts, for an initial premium of \u20ac2.4m, in order to cap its floating interest rate against a fixed rate for a total nominal amount of \u20ac99m. In \u20ac millions Note 2022 2021 Balance as of 1 January 0.5 0.1 Amortisation of Time Value 2.7 -0.3 -0.3 Fair Value adjustments through OCI 5.4 0.8 Balance as of 31 December 2.33 5.6 0.5 The impact on the valuation of the financial instruments of a shift of +/- 1 percentage point in the yield curve would not be material on the Group\u2019s total equity. The amount booked in equity is transferred to net profit as far as the underlying instrument impacts the net profit. The Group\u2019s net exposure to interest rate risk for the borrowings (excluding lease liabilities) as per Balance Sheet date, before taking into account the above hedging transactions is presented below: 2022 2021 Borrowings at fixed interest rates 90% 88% Borrowings at floating interest rates 10% 12% Given the breakdown between fixed rate and floating rate assets and liabilities as at 31 December 2022, a 1% increase or decrease in interest rates would have a full-year impact of +/- \u20ac1.7m on results before income taxes (excluding lease liabilities). Rate Up to 2-5 Over Total In \u20ac millions 1 year years 5 years Short term deposits Fixed -54.4 - - -54.4 Floating - - - - Bonds Fixed - 750.0 1,350.0 2,100.0 Floating - - - - Schuldschein Fixed - 177.5 97.5 275.0 Variable - 231.5 30.0 261.5 Commercial paper Fixed 75.0 - - 75.0 Floating - - - - Bank borrowings Fixed 10.8 45.5 43.7 100.0 Floating 0.5 3.4 6.0 9.9 Lease liabilities Fixed 6.5 25.0 8.1 39.6 Floating 122.1 293.9 71.9 487.9 Net exposure Fixed 37.9 998.0 1,499.3 2,535.2 Before hedge Floating 122.6 528.8 107.9 759.3 Hedge Fixed - 99.0 - 99.0 Floating - -99.0 - -99.0 Net exposure Fixed 37.9 1,097.0 1,499.3 2,634.2 After hedge Floating 122.6 429.8 107.9 660.3 2.43. Inflation The Group has addressed inflationary risk and its impact on the books and records of the Group in the section \u201cRisk factors report 2022\u201d. For the year-end, the impact of rising inflation rates, and consequent interest rates, in many geographies are considered in the determination of the fair value of assets and liabilities in the Consolidated Financial Statements, including, but not limited to financial instruments, goodwill or other long-lived assets impairment testing, defined benefit retirement programs and long-term incentive plans. As of 31 December 2022, the Group believes impact of inflation is appropriately reflected and has not led to any material impacts in the Consolidated Financial Statements. ", "dimensions": { "concept": "ifrs-full:DisclosureOfMarketRiskExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-179-4": { "value": "Interest rate risk Interest rate risk is the risk that the fair value or future cash flows of a financial instrument might fluctuate because of changes in market interest rates. In order to finance parts of its acquisition and expansion costs, the Company and its subsidiaries have entered into several loan and facility agreements as specified in Note 2.18. The Group had, at year-end, outstanding debt of \u20ac3,325.6 (2021: \u20ac2,754.1m), which constitutes an inherent interest rate risk with potential negative impact on financial results. The loans and facilities are either based on a fixed rate or on a variable rate. The derivative financial instruments assets include caps for an amount of \u20ac5.6m as of 31 December 2022 in order to hedge the Group\u2019s exposure to interest rate fluctuations particularly related to the 2018 Schuldschein loan (\u20ac0.5m at end of 2021). The Group has concluded hedging contracts, for an initial premium of \u20ac2.4m, in order to cap its floating interest rate against a fixed rate for a total nominal amount of \u20ac99m. In \u20ac millions Note 2022 2021 Balance as of 1 January 0.5 0.1 Amortisation of Time Value 2.7 -0.3 -0.3 Fair Value adjustments through OCI 5.4 0.8 Balance as of 31 December 2.33 5.6 0.5 The impact on the valuation of the financial instruments of a shift of +/- 1 percentage point in the yield curve would not be material on the Group\u2019s total equity. The amount booked in equity is transferred to net profit as far as the underlying instrument impacts the net profit. 2.33. Exposure to market and counterparties risks In \u20ac millions Note 2022 2021 Derivative financial assets \u2013 Caps 2.30 5.6 0.5 Derivative financial assets 5.6 0.5 Derivative financial liabilities \u2013 Swaps - - Total net 5.6 0.5 ", "dimensions": { "concept": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-184-3": { "value": "Credit risk Credit risk represents the loss that would be recognised at the reporting date if counterparties failed completely to perform their payment obligations as contracted. Credit risk is present within Eurofins\u2019 trade receivables and contract assets. In order to have better insight into its credit exposure, the Group performs ongoing analysis of the financial and non-financial condition of its customers and adjusts credit limits if and when appropriate. In instances where the creditworthiness of a customer is determined not to be sufficient to grant the credit limit required, there are a number of tools that can be utilised to mitigate the impact, including reducing payment terms, cash on delivery, pre-payments and pledges on assets. The rate of default experienced by the Group in proportion to its sales has been very low for the past five years. On average during this period, provision for impairment of receivables represented around 1% of the annual revenues, whilst customer terms of payment are in accordance with ordinary commercial practices in each country where the Group is active. In case of more challenging economic and/or trading conditions, the Group pays particular attention to the ability of new and existing customers to pay their debts. The Group believes its policy relating to doubtful debtors to be appropriate. The Group has a large number of customers across its business lines. The Group endeavours not to be dependent on any single customer. The biggest customer represents less than 2% of the consolidated revenues and the first 10 customers of the Group represent altogether less than 10% of the consolidated revenues. More particularly, the credit risk associated with US clinical diagnostic testing services is described in more detail in Note 1.4. The amounts relating to trade receivables, bad debt provision and the ageing balance are shown in Note 2.15. With a slight increase of overdues in percentage of total trade accounts receivable, the average observed credit losses over the last three years remain low and the expected loss rate did not materially change between 2021 and 2022. The Group invests available cash and cash equivalents with various leading financial institutions with strong credit ratings and is exposed to limited credit risk with these counterparties. The Group policy is to limit its exposure by dealing solely with leading counterparties and monitoring their credit ratings, in line with guidelines approved by the Company. The Group actively manages concentration risk of its liquidity among financial institutions and measures the potential loss under certain stress scenarios, should a financial institution default. These worst-case scenario losses are monitored and mitigated by the Company. In the context of negative short-term interest rate across many European countries, the Group may decide to ease some of the criteria listed above in order to avoid any loss on capital (i.e., no negative remuneration on cash deposit). ", "dimensions": { "concept": "ifrs-full:DisclosureOfCreditRiskExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-186-2": { "value": "2.31. Capital risk management The Group\u2019s objectives when managing capital are to safeguard the Group\u2019s ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce its cost of capital. In order to maintain or adjust the capital structure, the Group may adjust the dividends paid to its shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt. ", "dimensions": { "concept": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-187-3": { "value": "Borrowings pledged by assets or with covenants The liabilities and borrowings listed below are already included in the Group\u2019s Consolidated Balance Sheet. The following table only repeats these amounts when these borrowings are secured by covenants or securities on assets. In \u20ac millions 2022 2021 Bank borrowings secured over buildings and other assets 80.3 51.7 1Finance leases secured over buildings and other assets41.5 42.8 Bank borrowings secured by covenants and assets 2.8 2.9 Total borrowings and leases secured 124.7 97.4 Bank borrowings secured by covenants - - Bank borrowings guaranteed by the direct parent of the borrower - - Total 124.7 97.4 1 Finance lease liabilities are effectively secured as the rights to the leased asset revert to the lessor in the event of default. Other Guarantees In \u20ac millions Total Up to 1 year 2-5 years Over 5 years Guaranteesgiven related to financing 19.2 - - 19.2 Guarantees given related to acquisitions - - - - Total 19.2 - - 19.2 Guarantees received - - - - Total guarantees, net 19.2 - - 19.2 Detail of guarantees given related to financing \u25aa The Company has counter-guaranteed the Swedish insurance company \"F\u00f6rs\u00e4kringsbolaget Pensionsgaranti\" for all amounts due that this entity should have to pay to the current and past employees of some Swedish companies that are indirect subsidiaries of Eurofins Scientific SE, as part of their pension payment obligation for a maximum amount of \u20ac19.2m (this amount is accounted for in the caption \u201cretirement benefit obligations\u201d Note 2.23). \u25aa In the context of a \u20ac1.2m public subsidy grant contract obtained in 2008 by Eurofins BioPharma Product Testing Ireland Limited, the Company gave its guarantee to the Irish governmental agency which provided the grant that it will be liable in case of Eurofins BioPharma Product Testing Ireland Limited failing to meet its commitments related to this grant. The guarantee expired in October 2022. 2.36. Contingencies The Group has contingent liabilities in respect of commercial and tax claims arising in the ordinary course of business in connection with the services they provide. The majority of commercial claims is covered by business-specific insurance. An on-going litigation or potential new litigation that could cause significant financial or reputational damage for Eurofins continues or may arise in the context of the detection of biological contaminants in dairy products in Europe. The Group\u2019s responsibility has not been proven and the damages that are claimed have been neither established nor measured. For tax claims, when the Group estimates that the risk is not likely, no provision is booked. There are a limited number of pending claims, qualified as contingent liability by third-party legal advisors and the Company. The Group has entered into legal proceedings against the former shareholders of Eurofins Genoma Group Srl in Italy for breach of non-compete and other contractual clauses. The Group has an outstanding contingent consideration arrangement for this former acquisition, for which \u20ac27.5m has been accrued in \u201cAmounts due from business acquisitions\u201d within non-current liabilities on the Balance Sheet as of 31 December 2022 and current liabilities as of 31 December 2021. The final amount payable is subject to the legal proceedings. Risk factors are described in section 5 of the Management report.Based on the information available to date, the Group considers that the outcome of these disputes and legal claims currently in process is unlikely to have a significant adverse impact on the Consolidated Financial Statements other than those already provided for (Note 1.12). ", "dimensions": { "concept": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-187-4": { "value": "Borrowings pledged by assets or with covenants The liabilities and borrowings listed below are already included in the Group\u2019s Consolidated Balance Sheet. The following table only repeats these amounts when these borrowings are secured by covenants or securities on assets. In \u20ac millions 2022 2021 Bank borrowings secured over buildings and other assets 80.3 51.7 1Finance leases secured over buildings and other assets41.5 42.8 Bank borrowings secured by covenants and assets 2.8 2.9 Total borrowings and leases secured 124.7 97.4 Bank borrowings secured by covenants - - Bank borrowings guaranteed by the direct parent of the borrower - - Total 124.7 97.4 1 Finance lease liabilities are effectively secured as the rights to the leased asset revert to the lessor in the event of default. Other Guarantees In \u20ac millions Total Up to 1 year 2-5 years Over 5 years Guaranteesgiven related to financing 19.2 - - 19.2 Guarantees given related to acquisitions - - - - Total 19.2 - - 19.2 Guarantees received - - - - Total guarantees, net 19.2 - - 19.2 Detail of guarantees given related to financing \u25aa The Company has counter-guaranteed the Swedish insurance company \"F\u00f6rs\u00e4kringsbolaget Pensionsgaranti\" for all amounts due that this entity should have to pay to the current and past employees of some Swedish companies that are indirect subsidiaries of Eurofins Scientific SE, as part of their pension payment obligation for a maximum amount of \u20ac19.2m (this amount is accounted for in the caption \u201cretirement benefit obligations\u201d Note 2.23). \u25aa In the context of a \u20ac1.2m public subsidy grant contract obtained in 2008 by Eurofins BioPharma Product Testing Ireland Limited, the Company gave its guarantee to the Irish governmental agency which provided the grant that it will be liable in case of Eurofins BioPharma Product Testing Ireland Limited failing to meet its commitments related to this grant. The guarantee expired in October 2022. ", "dimensions": { "concept": "ifrs-full:DisclosureOfCommitmentsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-190-3": { "value": "2.34. Fair value of financial assets and liability The estimated fair value of financial instruments has been determined by the Group using available market information and appropriate valuation methods. The estimates presented are not necessarily indicative of the amounts that will ultimately be realised by the Group upon maturity or disposal. The use of different market assumptions and/or estimation methods may have a material effect on the estimated fair value amounts. The following tables show the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy. Fair value information for financial assets and financial liabilities not carried at fair value is not included if the carrying amount is a reasonable approximation of fair value. As of 31 December 2022 Carrying Fair value Level 1 Level 2 Level 3 In \u20ac millions amount Financial assets Financial assets carried at FVTOCI 21.8 21.8 21.8 - - Financial assets carried at FVTPL 2.6 2.6 - - 2.6 Derivative financial instruments 5.6 5.6 - 5.6 - Financial assets carried at fair value 30.0 30.0 21.8 5.6 2.6 Cash and cash equivalents 486.6 - - - - Receivables \u2013 current 1,461.7 - - - - Receivables - non-current 54.1 - - - - Financial assets carried at (amortised) costs 2,002.4 - - - - Total financial assets 2,032.4 30.0 21.8 5.6 2.6 Financial liabilities Contingent consideration 184.0 184.0 - - 184.0 Financial liabilities carried at FVTPL 184.0 184.0 - - 184.0 Derivative financial instruments - - - - - Financial liabilities carried at fair value 184.0 184.0 - - 184.0 Payables and contract liabilities 831.9 - - - - Interest accrual 38.0 - - - - Bonds 2,100.0 1,898.7 1,898.7 - - Other borrowings 1,225.6 - - - - Other liabilities 571.6 - - - - Financial liabilities carried at (amortised) costs 4,767.0 1,898.7 1,898.7 - - Total financial liabilities 4,951.0 2,082.7 1,898.7 - 184.0 As of 31 December 2021 Carrying Fair value Level 1 Level 2 Level 3 In \u20ac millions amount Financial assets Financial assets carried at FVTOCI 21.4 21.4 21.4 - - Financial assets carried at FVTPL 2.6 2.6 - - 2.6 Derivative financial instruments 0.5 0.5 - 0.5 - Financial assets carried at fair value 24.5 24.5 21.4 0.5 2.6 Cash and cash equivalents 515.3 - - - - Receivables \u2013 current 1,504.4 - - - - Receivables - non-current 51.5 - - - - Financial assets carried at (amortised) costs 2,071.2 - - - - Total financial assets 2,095.7 24.5 21.4 0.5 2.6 Financial liabilities Contingent consideration 141.1 141.1 - - 141.1 Financial liabilities carried at FVTPL 141.1 141.1 - - 141.1 Derivative financial instruments - - - - - Financial liabilities carried at fair value 141.1 141.1 - - 141.1 Payables and contract liabilities 790.7 - - - - Interest accrual 31.4 - - - - Bonds 1,500.0 1,555.6 1,555.6 - - Other borrowings 1,254.1 - - - - Other liabilities 607.9 - - - - Financial liabilities carried at (amortised) costs 4,184.0 1,555.6 1,555.6 - - Total financial liabilities 4,325.1 1,696.7 1,555.6 - 141.1 Specific valuation techniques used to value financial instruments include: Level 1 Instruments included in level 1 are comprised primarily of listed equity investments classified as financial assets carried at fair value through profit or loss or carried at fair value through Other Comprehensive Income. The fair value of financial instruments traded in active markets is based on quoted market prices at the Balance Sheet date. A market is regarded as active if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm\u2019s length basis. Level 2 The fair value of financial instruments that are not traded in an active market (for example, over-the-counter derivatives or convertible bond instruments) is determined by using valuation techniques. These valuation techniques maximise the use of observable market data where it is available and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are based on observable market data, the instrument is included in level 2. The fair value of derivatives is calculated as the present value of the estimated future cash flows based on observable interest yield curves, basis spread and foreign exchange rates. The valuation of convertible bond instruments uses observable market quoted data for the options and present value calculations using observable yield curves for the fair value of the bonds. Level 3 If one or more of the significant inputs are not based on observable market data, such as third-party pricing information without adjustments, the instrument is included in level 3. With the exception of the borrowings, the Group considers the carrying value of the financial instruments to approximate their fair value. Regarding borrowings, their fair value is based on: \u25aa A quoted price included in Level 1 of the fair value hierarchy for the Eurobond 2024 (fair value amount of \u20ac438.7m against acarrying value of \u20ac447.8m - ISIN XS1651444140).\u25aa A quoted price included in Level 1 of the fair value hierarchy for the Eurobond 2026 (fair value amount of \u20ac306.2m against acarrying value of \u20ac302.2m - ISIN XS2167595672).\u25aa A quoted price included in Level 1 of the fair value hierarchy for the Eurobond 2029 (fair value amount of \u20ac589.0m against acarrying value of \u20ac600m - ISIN XS2491664137).\u25aa A quoted price included in Level 1 of the fair value hierarchy for the Eurobond 2031 (fair value amount of \u20ac564.8m against acarrying value of \u20ac750m - ISIN XS2343114687).", "dimensions": { "concept": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-190-4": { "value": "2.34. Fair value of financial assets and liability The estimated fair value of financial instruments has been determined by the Group using available market information and appropriate valuation methods. The estimates presented are not necessarily indicative of the amounts that will ultimately be realised by the Group upon maturity or disposal. The use of different market assumptions and/or estimation methods may have a material effect on the estimated fair value amounts. The following tables show the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy. Fair value information for financial assets and financial liabilities not carried at fair value is not included if the carrying amount is a reasonable approximation of fair value. As of 31 December 2022 Carrying Fair value Level 1 Level 2 Level 3 In \u20ac millions amount Financial assets Financial assets carried at FVTOCI 21.8 21.8 21.8 - - Financial assets carried at FVTPL 2.6 2.6 - - 2.6 Derivative financial instruments 5.6 5.6 - 5.6 - Financial assets carried at fair value 30.0 30.0 21.8 5.6 2.6 Cash and cash equivalents 486.6 - - - - Receivables \u2013 current 1,461.7 - - - - Receivables - non-current 54.1 - - - - Financial assets carried at (amortised) costs 2,002.4 - - - - Total financial assets 2,032.4 30.0 21.8 5.6 2.6 Financial liabilities Contingent consideration 184.0 184.0 - - 184.0 Financial liabilities carried at FVTPL 184.0 184.0 - - 184.0 Derivative financial instruments - - - - - Financial liabilities carried at fair value 184.0 184.0 - - 184.0 Payables and contract liabilities 831.9 - - - - Interest accrual 38.0 - - - - Bonds 2,100.0 1,898.7 1,898.7 - - Other borrowings 1,225.6 - - - - Other liabilities 571.6 - - - - Financial liabilities carried at (amortised) costs 4,767.0 1,898.7 1,898.7 - - Total financial liabilities 4,951.0 2,082.7 1,898.7 - 184.0 As of 31 December 2021 Carrying Fair value Level 1 Level 2 Level 3 In \u20ac millions amount Financial assets Financial assets carried at FVTOCI 21.4 21.4 21.4 - - Financial assets carried at FVTPL 2.6 2.6 - - 2.6 Derivative financial instruments 0.5 0.5 - 0.5 - Financial assets carried at fair value 24.5 24.5 21.4 0.5 2.6 Cash and cash equivalents 515.3 - - - - Receivables \u2013 current 1,504.4 - - - - Receivables - non-current 51.5 - - - - Financial assets carried at (amortised) costs 2,071.2 - - - - Total financial assets 2,095.7 24.5 21.4 0.5 2.6 Financial liabilities Contingent consideration 141.1 141.1 - - 141.1 Financial liabilities carried at FVTPL 141.1 141.1 - - 141.1 Derivative financial instruments - - - - - Financial liabilities carried at fair value 141.1 141.1 - - 141.1 Payables and contract liabilities 790.7 - - - - Interest accrual 31.4 - - - - Bonds 1,500.0 1,555.6 1,555.6 - - Other borrowings 1,254.1 - - - - Other liabilities 607.9 - - - - Financial liabilities carried at (amortised) costs 4,184.0 1,555.6 1,555.6 - - Total financial liabilities 4,325.1 1,696.7 1,555.6 - 141.1 Specific valuation techniques used to value financial instruments include: Level 1 Instruments included in level 1 are comprised primarily of listed equity investments classified as financial assets carried at fair value through profit or loss or carried at fair value through Other Comprehensive Income. The fair value of financial instruments traded in active markets is based on quoted market prices at the Balance Sheet date. A market is regarded as active if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm\u2019s length basis. Level 2 The fair value of financial instruments that are not traded in an active market (for example, over-the-counter derivatives or convertible bond instruments) is determined by using valuation techniques. These valuation techniques maximise the use of observable market data where it is available and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are based on observable market data, the instrument is included in level 2. The fair value of derivatives is calculated as the present value of the estimated future cash flows based on observable interest yield curves, basis spread and foreign exchange rates. The valuation of convertible bond instruments uses observable market quoted data for the options and present value calculations using observable yield curves for the fair value of the bonds. Level 3 If one or more of the significant inputs are not based on observable market data, such as third-party pricing information without adjustments, the instrument is included in level 3. With the exception of the borrowings, the Group considers the carrying value of the financial instruments to approximate their fair value. Regarding borrowings, their fair value is based on: \u25aa A quoted price included in Level 1 of the fair value hierarchy for the Eurobond 2024 (fair value amount of \u20ac438.7m against acarrying value of \u20ac447.8m - ISIN XS1651444140).\u25aa A quoted price included in Level 1 of the fair value hierarchy for the Eurobond 2026 (fair value amount of \u20ac306.2m against acarrying value of \u20ac302.2m - ISIN XS2167595672).\u25aa A quoted price included in Level 1 of the fair value hierarchy for the Eurobond 2029 (fair value amount of \u20ac589.0m against acarrying value of \u20ac600m - ISIN XS2491664137).\u25aa A quoted price included in Level 1 of the fair value hierarchy for the Eurobond 2031 (fair value amount of \u20ac564.8m against acarrying value of \u20ac750m - ISIN XS2343114687).", "dimensions": { "concept": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-193-2": { "value": "2.35. Earnings per share Detail of the basic and diluted weighted average number of shares outstanding (details in Note 2.26) In millions 2022 2021 Basic weighted average number of shares outstanding 192.5 191.5 Weighted average number of stock options 5.2 7.4 Weighted average number of restricted stock units 0.4 0.5 Number of potential number of shares by warrants exercise 1.1 1.3 Weighted average number of treasury shares -0.1- Diluted weighted average shares outstanding 199.0 200.6 The weighted average number of stock options decreased in 2022 due to two stock options plans not in the money (exercise price below 31 December share price value). Earnings per share Net profit for the period is allocated between hybrid capital investors (Note 2.20) and the equity holders of the Company as follows for the calculation of the earnings per share: Net Profit of the period Weighted average Earnings per share 2022 number of shares (in \u20ac millions) (in \u20ac) outstanding Basic Total 610.2 192.5 3.17 Owners of the Company 580.9 192.5 3.02 1Hybrid capital investors29.3 192.5 0.15 Diluted Total 610.2 199.0 3.07 Owners of the Company 580.9 199.0 2.92 1Hybrid capital investors29.3 199.0 0.15 1 See Note 2.20. Net Profit of the period Weighted average Earnings per share 2021 number of shares (in \u20ac millions) (in \u20ac) outstanding Basic Total 782.6 191.5 4.09 Owners of the Company 748.5 191.5 3.91 1Hybrid capital investors34.1 191.5 0.18 Diluted Total 782.6 200.6 3.90 Owners of the Company 748.5 200.6 3.73 1Hybrid capital investors34.1 200.6 0.17 1 See Note 2.20. ", "dimensions": { "concept": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-194-3": { "value": "2.36. Contingencies The Group has contingent liabilities in respect of commercial and tax claims arising in the ordinary course of business in connection with the services they provide. The majority of commercial claims is covered by business-specific insurance. An on-going litigation or potential new litigation that could cause significant financial or reputational damage for Eurofins continues or may arise in the context of the detection of biological contaminants in dairy products in Europe. The Group\u2019s responsibility has not been proven and the damages that are claimed have been neither established nor measured. For tax claims, when the Group estimates that the risk is not likely, no provision is booked. There are a limited number of pending claims, qualified as contingent liability by third-party legal advisors and the Company. The Group has entered into legal proceedings against the former shareholders of Eurofins Genoma Group Srl in Italy for breach of non-compete and other contractual clauses. The Group has an outstanding contingent consideration arrangement for this former acquisition, for which \u20ac27.5m has been accrued in \u201cAmounts due from business acquisitions\u201d within non-current liabilities on the Balance Sheet as of 31 December 2022 and current liabilities as of 31 December 2021. The final amount payable is subject to the legal proceedings. Risk factors are described in section 5 of the Management report.Based on the information available to date, the Group considers that the outcome of these disputes and legal claims currently in process is unlikely to have a significant adverse impact on the Consolidated Financial Statements other than those already provided for (Note 1.12). ", "dimensions": { "concept": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-195-2": { "value": "2.37. Related-party transactions Transactions between the Company and its subsidiaries, which are related parties of the Group, are made at arm\u2019s length conditions and have been eliminated in the consolidation process and are not disclosed in the Notes. The Group is controlled by Analytical Bioventures S.C.A., a holding company of the Martin family. As of 31 December 2022, Analytical Bioventures owned 32.7% of the Company\u2019s shares and controls 65.9% of its voting rights (32.8% of the Company\u2019s shares and 65.9% of its voting rights as of 31 December 2021). Transactions with affiliates or with companies owning shares in Eurofins Group such as Analytical Bioventures S.C.A. or with companies such as International Assets Finance S.\u00e0 r.l., in which some members of the Company\u2019s Board of Directors have significant influence, are mainly related to lease agreements on laboratories/sites used by Eurofins and are disclosed as follows: In \u20ac millions 2022 2021 Consolidated Income Statement Support management services, provided to the related party 0.3 0.3 Interest expenses to related party 7.0 7.2 Depreciation of right of use 24.3 25.9 Consolidated Balance Sheet 1Receivables expected from related party 13.8 14.1 Payables owned to related party 1.1 3.7 Right of use from related party 122.9 139.9 Lease liabilities to related party 143.3 161.9 Dividends paid to related party 63.0 43.0 Beneficiary units subscribed by related party - 0.8 Off Balance Sheet commitments Bank guarantees to related party - 0.2 1 Receivables expected from related party relate to lease deposits. Other information related to the real estate transactions is provided in the Corporate Governance Statement for the period ended on 31 December 2022. 2.38. Compensation of the Board of Directors and Group Operating Council (GOC) In \u20ac millions 2022 2021 Compensation of executive directors 1.6 1.9 Compensation of non-executive directors 0.3 0.3 Management compensation (GOC excluding CEO) 11.4 6.8 Post-employment benefits - - Other long-term benefits- - Termination benefits - - Long-term incentives (\u201cstock options\u201d) to GOC members 4.9 - Total 18.3 9.0 The increase is mainly due to two factors: (i) the timing of joining and leaving of GOC members between the two periods with a total number of FTE increasing from 10.3 in 2021 to 15.2 in 2022 and (ii) the absence of any equity-linked remuneration awarded in 2021. The amount of contributions paid for defined contribution pension plans of some members of the Board of Directors was \u20ac45k in 2022. Further details can be found in the section \u201cEurofins Group Remuneration Report 2022\u201d. ", "dimensions": { "concept": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-195-4": { "value": "2.37. Related-party transactions Transactions between the Company and its subsidiaries, which are related parties of the Group, are made at arm\u2019s length conditions and have been eliminated in the consolidation process and are not disclosed in the Notes. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-198-3": { "value": "2.38. Compensation of the Board of Directors and Group Operating Council (GOC) In \u20ac millions 2022 2021 Compensation of executive directors 1.6 1.9 Compensation of non-executive directors 0.3 0.3 Management compensation (GOC excluding CEO) 11.4 6.8 Post-employment benefits - - Other long-term benefits- - Termination benefits - - Long-term incentives (\u201cstock options\u201d) to GOC members 4.9 - Total 18.3 9.0 The increase is mainly due to two factors: (i) the timing of joining and leaving of GOC members between the two periods with a total number of FTE increasing from 10.3 in 2021 to 15.2 in 2022 and (ii) the absence of any equity-linked remuneration awarded in 2021. The amount of contributions paid for defined contribution pension plans of some members of the Board of Directors was \u20ac45k in 2022. Further details can be found in the section \u201cEurofins Group Remuneration Report 2022\u201d. ", "dimensions": { "concept": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-199-2": { "value": "2.39. Auditor\u2019s remuneration In \u20ac millions 2022 2021 Audit of Eurofins Scientific SE 0.7 0.6 Audit of financial statements of subsidiaries 5.0 3.7 Audit-related services 0.1 0.1 Audit and audit-related fees payable pursuant to legislation 5.8 4.4 Taxation services - - Total fees Deloitte 5.8 4.4 In addition, with the work performed for consolidation purposes, the Group has commissioned statutory audits in a very large majority of its subsidiaries, even when not required by local regulations, performed mostly by Tier 1 and Tier 2 audit firms in order to ensure reliability and strong control of financial statements in a fast-growth phase, of which: \u25aa Tier 1 (Deloitte, PwC, EY and KPMG);\u25aa Tier 2 (RSM, Grant Thornton, BDO, Mazars, Moore Stephens, Crowe and Baker Tilly).The aggregate amount of audit fees for all auditors across the Group was \u20ac10.9m in 2022 and \u20ac8.4m in 2021. Other information related to the audit coverage is provided in section 2.1.3 (Audit Committee) of the Corporate Governance Statement for the year ended on 31 December 2022. ", "dimensions": { "concept": "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-200-2": { "value": "2.40. COVID-19 As a world leader in the provision of essential clinical diagnostic, forensic, pharmaceutical, food and environmental laboratory testing services, Eurofins has been able to draw on its scientific expertise and innovation to develop a comprehensive suite of SARS-CoV-2 tests in response to the coronavirus pandemic. During 2022, the Group continued to maintain high volumes in its COVID-related activities (human clinical testing and sale of reagents), contributing revenues just under \u20ac600m during this period. This compares to revenues of over \u20ac1,400m in 2021. These lower volumes have also driven a significant proportion of the \u20ac49m decrease in contract assets recorded as of 31 December 2022 compared to 31 December 2021. For 2023, whilst the duration and magnitude of COVID-related activities remain uncertain and testing intensity at any given time may vary period-on-period and between countries, the Group intends to continue to support health initiatives globally and leverage its scientific expertise to develop further its suite of SARS-CoV-2 tests to respond to changes in the overall testing environment. ", "dimensions": { "concept": "EUR:DisclosureOfCovid19", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-201-2": { "value": "2.41. Cyber-attack On 2 June 2019, Eurofins Scientific was hit by a criminal ransomware attack which caused disruption to many of its IT systems in several countries. Eurofins IT staff and their internal and external IT security teams and experts took prompt actions to contain the incident, mitigate its impact and worked relentlessly to return the IT operations to normal in the companies of the Group that have been affected. Eurofins teams continue to expend significant effort to further optimise and strengthen all IT operations. As business interruption insurance coverage for this criminal cyber-attack has been confirmed, the Group received for an amount of \u20ac10m in 2019, \u20ac29.8m in 2020, \u20ac12.5m in 2021 and \u20ac5m in 2022 recorded in the line \u201cOther operating expenses (income), net\u201d (Note 2.3). It is likely that discussions and efforts to determine and agree on exact damages with Group insurers will be on going for a while and additional reimbursements cannot be determined precisely at this time. ", "dimensions": { "concept": "EUR:DisclosureOfCyberAttack", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-202-2": { "value": "2.42. Climate change-related risks The Group regularly evaluates relevant climate-related risks as evidenced in the section \u201cRisk factors report 2022\u201d (Section 1.5.6) and in \u201cEurofins Environment, Social and Governance report 2022\u201d including its impact on the books and records of the Group. The Group reviews the disclosure obligations under Article 8 of the Taxonomy Regulation (EU) 2020/8522 and will keep monitoring going forward the disclosure requirements of the Non-Financial Reporting Directive and subsequently the Corporate Sustainability Reporting Directive. For the year-end, the potential impact of climate related matters, including legislation which may affect the fair value of assets and liabilities in the Consolidated Financial statements has been considered, especially but not limited to deferred tax assets recoverability, useful life of tangibles and intangibles and provisions. The risks in respect of climate-related matters are included as relevant and applicable key assumptions where they materially impact the determination of fair value. As of 31 December 2022, the Group does not believe that the impact of climate related matters is material to the Consolidated Financial Statements. Carbon neutrality The Group announced the goal of achieving carbon neutrality by 2025, through a focussed program of CO2 emission reduction and carbon offsetting (see paragraph \u201ccarbon neutrality objective\u201c in section \u201cClimate change\u201d in the \u201cEurofins Environment, Social and Governance report 2022\u201d). In 2022, Eurofins purchased 2.3m tons for \u20ac11.0m and retired 0.2m tons of carbon credits for \u20ac0.8m (2021: 0.15m tons). Carbon credits are recorded as intangible assets and expensed when retired. Responding to climate challenges is at the heart of the Group's strategy, and its commitment to carbon neutrality is taken into account in its financial decisions. ", "dimensions": { "concept": "EUR:DisclosureOfClimateRisks", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-203-2": { "value": "2.44. Post-closing events Business combinations Since the beginning of 2023, Eurofins completed 4 acquisitions of which 2 asset deals. The total annual revenues of these acquisitions amounted to approximately \u20ac11m in 2022 for an aggregate acquisition price of \u20ac16m. These acquisitions employ over 100 employees. Financing Hybrid capital with a first reset date on 24 July 2028 In January 2023, Eurofins raised \u20ac600m hybrid capital. The instrument has a perpetual maturity but is callable at par by Eurofins at the soonest in April 2028. This hybrid instrument bears a fixed annual coupon of 6.75% for the first 5.5 years (until 24 July 2028), a floating coupon of Euribor3m + 424.1 bps until 24 January 2033 and Euribor3m + 524.1 bps thereafter. The instrument is listed on the regulated market of the Luxembourg stock exchange (ISIN XS2579480307). This issuance enables the Group to return to its targeted capital structure that includes an adequate level of hybrid capital of \u20ac1bn to support its targeted range for financial leverage of 1.5-2.5x. The bonds\u2019 proceeds are available for general corporate purposes. Outside of the planned repayment of the outstanding \u20ac183m in hybrid capital callable on 29 April 2023, Eurofins has no major refinancing requirements until the outstanding \u20ac448m senior Eurobonds become due on 25 July 2024. Guarantee The Company gave a guarantee for a period of 12 months from 1 January 2023 and expiring on 1 January 2024 to the benefit of Chubb (i.e., Chubb European Group SE, ACE Ina Overseas Insurance Company Ltd. and Chubb INA Overseas Insurance Company Ltd.) in the context of the implementation of an internal reinsurance captive (Eurofins Re S.A.) in Luxembourg indirectly owned by the Company to indemnify for all losses, liabilities, costs, expenses and damages for a total amount of \u20ac25m per annual aggregate. ", "dimensions": { "concept": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-205-3": { "value": "3.1. Incorporation of the year The companies below have been incorporated during the year and are fully consolidated (at 100%): % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Regional Service Centre ANZ Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 08/22 Gembloux Rue Phocas Lejeune Real Estate NV BfB Oil research SA BE 100.00% 04/22 Eurofins Digital Agency NV Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. BE 100.00% 01/22 Eurofins GSC IT Solutions & Operations SA Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 12/22 Eurofins Product Testing Service (Hangzhou) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 07/22 Eurofins Electrical Testing Service (Shanghai) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 10/22 Eurofins Discoverx Products (Shanghai) Co., Ltd. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CN 100.00% 01/22 Eurofins Cosmetic Testing Service (Shanghai) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 10/22 Eurofins Testing Technology Service (Shenzhen) Co., Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 10/22 Ltd. Eurofins Testing Inspection Certification (Xiamen) Co., Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 09/22 Ltd. Eurofins NBLSC Forensic Germany GmbH Eurofins MWG Holding GmbH DE 100.00% 01/22 Eurofins Genomics GMP Products and Services GmbH Eurofins MWG Holding GmbH DE 100.00% 07/22 Eurofins Aquatic Ecotoxicology GmbH Eurofins Agroscience Services Germany Holding DE 100.00% 08/22 GmbH Eurofins RBLSC BioPharma Product Testing Germany Eurofins BioPharma Services Holding Germany GmbH DE 100.00% 09/22 GmbH Eurofins Genomics Europe Research Products & Eurofins MWG Holding GmbH DE 100.00% 10/22 Services Synthesis GmbH Eurofins Genomics Europe IT Services GmbH Eurofins MWG Holding GmbH DE 100.00% 10/22 Eurofins Genomics Europe Pharma and Diagnostics Eurofins MWG Holding GmbH DE 100.00% 10/22 Porducts & Services Sales GmbH Eurofins Genomics Europe Research Products & Eurofins MWG Holding GmbH DE 100.00% 10/22 Services NGS GmbH Eurofins Genomics Europe Research Products & Eurofins MWG Holding GmbH DE 100.00% 10/22 Services Sanger GmbH Ishoj Baldershoj Real Estate ApS Eurofins Real Estate LUX Holding S.\u00e0 r.l. DK 100.00% 06/22 Eurofins Diagnosticos Clinicos RD, SAS Eurofins Latin American Ventures, S.L.U. DO 100.00% 11/22 Eurofins Biomed 2022 1 SAS Eurofins NSC Finance France SAS FR 100.00% 01/22 Eurofins Biomed 2022 2 SAS Eurofins NSC Finance France SAS FR 100.00% 01/22 Eurofins Biomed 2022 3 SAS Eurofins NSC Finance France SAS FR 100.00% 01/22 Eurofins Biomed 2022 4 SAS Eurofins NSC Finance France SAS FR 100.00% 01/22 Eurofins Biomed 2022 5 SAS Eurofins NSC Finance France SAS FR 100.00% 01/22 Eurofins Biomed Basse-Normandie SELAS Eurofins Labazur Provence SELAS FR 100.00% 09/22 Eurofins Biomed Ile de France Est SELAS Eurofins Labazur Provence SELAS FR 100.00% 12/22 Eurofins Newco 2023 1 SAS Eurofins NSC Finance France SAS FR 100.00% 11/22 Eurofins Newco 2023 2 SAS Eurofins NSC Finance France SAS FR 100.00% 11/22 Eurofins Newco 2023 3 SAS Eurofins NSC Finance France SAS FR 100.00% 11/22 Eurofins Newco 2023 4 SAS Eurofins NSC Finance France SAS FR 100.00% 11/22 SCI Eurofins 2023 1 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/22 SCI Eurofins 2023 2 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/22 SCI Eurofins 2023 3 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/22 SCI Eurofins 2023 4 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/22 Eurofins Biopharma Product Testing Croatia D.O.O. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. HR 100.00% 01/22 % of Date ISO interest Company Subsidiary of: of code by the entry Group Empowerdx Ireland Ltd. Eurofins Direct To Consumer Testing LUX Holding S.\u00e0 IE 100.00% 04/22 r.l Eurofins South Bengaluru Resources Private Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. IN 100.00% 02/22 Eurofins It Enabled Services India Private Limited Eurofins Support Services LUX Holding S.\u00e0 r.l. IN 100.00% 03/22 Eurofins Regulatory & Consultancy Services Italy Srl Eurofins Pharma Services Italia Holding Srl IT 100.00% 05/22 Vimodrone Via Grandi Real Estate Invest Srl Eurofins Real Estate LUX Holding S.\u00e0 r.l. IT 100.00% 06/22 Eurofins BioPharma Product Testing Europe RBLSC Eurofins Pharma Services Italia Holding Srl IT 100.00% 06/22 Srl Eurofins Clinical Testing Japan Holding Ltd. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. JP 100.00% 01/22 Imizu Hibari Real Estate KK Eurofins Real Estate LUX Holding S.\u00e0 r.l. JP 100.00% 01/22 Hamamatsu Nishijima Real Estate KK Eurofins Real Estate LUX Holding S.\u00e0 r.l. JP 100.00% 03/22 Eurofins Food & Feed Testing Japan Holding KK Eurofins Food Testing LUX Holding S.\u00e0 r.l. JP 100.00% 05/22 Eurofins Genomic Services Japan Holding KK Eurofins Genomics LUX Holding S.\u00e0 r.l. JP 100.00% 04/22 Eurofins Tribology LUX Holding S.\u00e0 r.l Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 05/22 Eurofins Direct To Consumer Testing LUX Holding S.\u00e0 Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 05/22 r.l Eurofins Re LUX Holding S.\u00e0 r.l Eurofins Scientific SE LU 100.00% 12/22 Eurofins Genomics It Solutions Latvia Sia Eurofins Genomics LUX Holding S.\u00e0 r.l. LV 100.00% 06/22 Eurofins Environment Testing Holding Malaysia Sdn. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. MY 100.00% 08/22 Bhd. Leiden Bioscience Park Real Estate B.V. Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 04/22 Amersfoort Koningsbergenweg Real Estate B.V. Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 04/22 Eurofins Project Flow B.V. Eurofins Clinical Diagnostics Netherlands Holding BV NL 100.00% 04/22 Eurofins NBLSC Food Testing Netherlands B.V. Eurofins Food Testing Netherlands Holding BV NL 100.00% 09/22 Eurofins BioPharma Product Testing Poland Sp. z.o.o. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. PL 100.00% 01/22 Katowice Real Estate Sp. z.o.o Eurofins Real Estate LUX Holding S.\u00e0 r.l. PL 100.00% 03/22 Eurofins GSC IT Romania SRL Eurofins Support Services LUX Holding S.\u00e0 r.l. RO 100.00% 02/22 Eurofins Vitamins Testing Romania SRL Eurofins Food & Feed Testing Romania Holding SRL RO 100.00% 05/22 Eurofins Clinical Diagnostics (Thailand) Co., Ltd. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. TH 100.00% 02/22 Eurofins Environment Testing Holding (Thailand) Co., Eurofins Environment Testing LUX Holding S.\u00e0 r.l. TH 100.00% 10/22 Ltd. Eurofins Eag Materials Science Taiwan Ltd. Eurofins Material Sciences LUX Holding S.\u00e0 r.l. TW 100.00% 03/22 Eurofins Genomics Europe Dtc - Population Genetics Eurofins Genomics LUX Holding S.\u00e0 r.l. UK 100.00% 03/22 Products & Services Limited Eurofins Biomnis Edinburgh Limited Eurofins Clinical Diagnostic Testing UK Holding Limited UK 100.00% 07/22 Empowerdx Uk Limited Eurofins Direct To Consumer Testing LUX Holding S.\u00e0 UK 100.00% 05/22 r.l DDC UK Services Limited Eurofins Direct To Consumer Testing LUX Holding S.\u00e0 UK 100.00% 07/22 r.l Orlando Newburyport Avenue Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 01/22 San Diego Convoy Court Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 04/22 Eurofins BioPharma Product Testing Enco, Inc. Eurofins Pharma US Holdings II, Inc. US 100.00% 04/22 St. Charles 25 Research Park Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 06/22 Cary Maynard Road Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 07/22 Fremont Bayside Parkway Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 07/22 Chicago Crossing Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 10/22 Eurofins Food Assurance US Holdings, Inc. Eurofins Assurance LUX Holding S.\u00e0 r.l. US 100.00% 11/22 Mounds View Woodale Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 12/22 3.2. Acquisition of the year The companies below have been acquired during the year and are fully consolidated (at 100%): % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Apal Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 02/22 Eurofins Euraceta NV Eurofins Food Testing LUX Holding S.\u00e0 r.l. BE 100.00% 12/22 Manara Medical Laboratories W.L.L. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. BH 100.00% 12/22 Spincontrol Am\u00e9rique du Nord, Inc. Eurofins Product Testing clinical and ex-vivo France CA 60.20% 08/22 Holding SAS Microscan Service SA Eurofins Qute Holding AG CH 100.00% 06/22 Modern Genomic Services Co., Ltd. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. CN 100.00% 03/22 TA Technology (Shanghai) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 12/22 Lunaria s.r.o. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CZ 100.00% 06/22 Cll Chemnitzer Laborleistungs GmbH Eurofins NDSC Umweltanalytik GmbH DE 100.00% 04/22 Eurofins Umweltanalytik S\u00fcd GmbH Eurofins NDSC Umweltanalytik GmbH DE 100.00% 04/22 Eurofins Food Testing S\u00fcd GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 04/22 GmbH Stella Analyse GmbH Eurofins Environment Testing Netherlands Holding BV DE 100.00% 03/22 Inpac Medizintechnik GmbH Eurofins BioPharma Services Holding Germany GmbH DE 100.00% 03/22 Reco Planegg Behringstra\u00dfe Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 03/22 BECIT GmbH Eurofins Food Testing Germany East Holding GmbH DE 100.00% 07/22 Dr. Lauk & Dr. Breitling GmbH Eurofins Forensics LUX Holding S.\u00e0 r.l. DE 100.00% 09/22 Biocontrol Y Calidad Alimentaria, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 03/22 Laboratorios Vital, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 03/22 Granada Bailen Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 04/22 Bio-9000, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 05/22 Eurofins Cavendish, S.L.U. Eurofins Environment Testing Spain Holding, S.L.U. ES 100.00% 10/22 Laboratori Cat-Gairin, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 10/22 Laboratorios Munuera, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 07/22 Cidesal Analisis Alimentos, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 08/22 Derio Idorsolo Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 07/22 Eurofins Biotalde, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 08/22 Convet, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 12/22 Clinilab Laboratorio Cl\u00ednico Huelva, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 12/22 Bestlab Oy Eurofins Environment Testing Finland Holding Oy FI 100.00% 06/22 Eurofins Bio Sant\u00e9 SELAS Eurofins Biologie M\u00e9dicale Holding France SAS FR 100.00% 10/22 Spincontrol SAS Eurofins Product Testing clinical and ex-vivo France FR 60.20% 08/22 Holding SAS Soci\u00e9t\u00e9 Financi\u00e8re Bio Callens Holding SARL Eurofins Product Testing clinical and ex-vivo France FR 60.20% 08/22 Holding SAS Centre de Recherches Biologiques et Eurofins Product Testing clinical and ex-vivo France FR 60.20% 08/22 d'Exp\u00e9rimentations Cutan\u00e9es - BIO-EC SAS Holding SAS Genex SAS Centre de Recherches Biologiques et FR 60.20% 08/22 d'Exp\u00e9rimentations Cutan\u00e9es - BIO-EC SAS GEA (Grand Est Analyses) SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 10/22 SAS Laboratories of Biological-Chemical Trials and Eurofins Food Testing LUX Holding S.\u00e0 r.l. GR 100.00% 06/22 Analyses, SA Wessling Hungary Kft. Eurofins Environment Testing Hungary Holding Kft. HU 100.00% 08/22 Wessling Vagyonkezel\u0151 Kft. Wessling Hungary Kft. HU 100.00% 08/22 % of Date ISO interest Company Subsidiary of: of code by the entry Group BIOMI Biotechnol\u00f3giai Szolg\u00e1ltat\u00f3 Korl\u00e1tolt Felel\u0151ss\u00e9g\u0171 Wessling Hungary Kft. HU 100.00% 08/22 T\u00e1rsas\u00e1g Kft. Wessling Nemzetk\u00f6zi Kutat\u00f3 \u00e9s Oktat\u00f3 K\u00f6zpont Wessling Hungary Kft. HU 100.00% 08/22 Nonprofit Korl\u00e1tolt Felel\u0151ss\u00e9g\u0171 T\u00e1rsas\u00e1g Kft. Medserv Kft. Eurofins Clinical Testing Hungary Holding Kft. HU 61.25% 09/22 Sejtdiagnosztika Kft. Medserv Kft. HU 61.25% 09/22 PT Modern Testing Services Indonesia Eurofins Product Testing LUX Holding S.\u00e0 r.l. ID 100.00% 01/22 Eurofins Limed Ltd. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. IL 50.10% 04/22 Eurofins Sisthema Srl Eurofins Assurance LUX Holding S.\u00e0 r.l. IT 100.00% 02/22 Environ-Lab Srl Eurofins Environment Testing LUX Holding S.\u00e0 r.l. IT 100.00% 06/22 Genetic Lab Co., Ltd. Eurofins Clinical Testing Japan Holding Ltd. JP 100.00% 01/22 Repertoire Genesis Inc. Eurofins Clinical Testing Japan Holding Ltd. JP 55.00% 06/22 QSAI Analysis and Research Center Co.,Ltd. Eurofins Food & Feed Testing Japan Holding KK JP 85.00% 09/22 CRA Korea Co, Ltd. Eurofins Product Testing Korea Holding Co., Ltd. KR 60.00% 06/22 Eurofins Mediscan Laboratories Sdn Bhd Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. MY 100.00% 05/22 Stella Analyse B.V. Eurofins Environment Testing Netherlands Holding BV NL 100.00% 03/22 Plm Laboratorium Services B.V. Eurofins Environment Testing Netherlands Holding BV NL 100.00% 03/22 Dia-Go B.V. Eurofins Environment Testing Netherlands Holding BV NL 100.00% 03/22 Przedsi\u0119biorstwo Bada\u0144 I Ekspertyz \u015arodowiska Eurofins Environment Testing Poland Holding Sp. z o.o. PL 100.00% 04/22 \"Sepo\" Sp. z.o.o. Lagra Laborat\u00f4rio Agr\u00edcola do Alentejo Lda. Eurofins Food Testing LUX Holding S.\u00e0 r.l. PT 100.00% 07/22 Eurofins Saudi Ajal Laboratories Eurofins Food Testing LUX Holding S.\u00e0 r.l. SA 55.00% 06/22 Svensk Arbetshygien AB Eurofins Environment Testing Sweden Holding AB SE 100.00% 10/22 Thai Environmental Technic Co., Ltd. Eurofins Environment Testing Holding (Thailand) Co., TH 75.00% 10/22 Ltd. Altair Analytical Limited Eurofins Food Testing UK Holding Limited UK 100.00% 04/22 Sensory Dimensions Limited Eurofins Sensory, Consumer research and Product UK 100.00% 09/22 design LUX Holding S.\u00e0 r.l. Bio Search (N.I.) Limited Eurofins Food Testing UK Holding Limited UK 100.00% 07/22 Eurofins Analytics LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 03/22 Human Factors Md, LLC Eurofins Pharma US Holdings II, Inc. US 100.00% 05/22 Little Rock Kanis Road Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 11/22 American Interplex, LLC Eurofins Environment Testing South Central, LLC US 100.00% 11/22 Genetic Testing Service JSC Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. VN 67.00% 02/22 3.3. Merged entities The companies below have been merged with another Eurofins entities during the year: % of ISO interest Date Company Subsidiary of: Code by the of exit Group Eurofins NSC Finance Germany GmbH Eurofins Support Services LUX Holding S.\u00e0 r.l. DE 100.00% 07/22 Eurofins NSC Finance Clinical Diagnostics Germany Eurofins Support Services LUX Holding S.\u00e0 r.l. DE 100.00% 07/22 GmbH Eurofins Alfalab Internacional, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Laboratorio Calbo, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Laboratorio Bernad-Mu\u00f1oz, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Laboratorio Cl\u00ednico Sanitario, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 % of ISO interest Date Company Subsidiary of: Code by the of exit Group Eurofins Laboratorio Dres. Cerme\u00f1o, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Laboratorio Pilar Larraz, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Laboratorio Recio, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 EUROFINS Laboratorio Medicantabria S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Laboratorio Virtudes, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Labrovet, S.L.U. Eurofins Mas Control, S.L.U. ES 100.00% 06/22 Eurofins An\u00e1lisis Cl\u00ednicos Canarias, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Laboratorio Garc\u00eda L\u00f3pez, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 01/22 Eurofins Prelevement Pour Le Batiment Sud Ouest Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 07/22 SAS SAS Eurofins Alpabio Prestations SAS Alpa Environnement Holding France SAS FR 100.00% 07/22 Alpa Support Services SAS Alpa Environnement Holding France SAS FR 100.00% 07/22 Alpa Hygiene Alimentaire SAS Alpa Alimentaire Holding France SAS FR 100.00% 07/22 Medical Consultants Pathology Holdings Limited Eurofins Biomnis Ireland Limited IE 100.00% 11/22 Eurofins Cyber Security Assurance & Advisory Eurofins Cyber Security Netherlands Holding BV NL 100.00% 06/22 Netherlands BV Eurofins Cyber Security Hacking & Testing BV Eurofins Cyber Security Netherlands Holding BV NL 100.00% 06/22 Eurofins Cyber Security Products & Services BV Eurofins Cyber Security Netherlands Holding BV NL 100.00% 06/22 Maser Engineering BV Eurofins Maser BV NL 90.02% 08/22 Eurofins Environment Services Polska Sp. z.o.o. Eurofins Environment Testing Poland Holding Sp. z o.o. PL 100.00% 06/22 Research For Hire, Inc. Eurofins Agroscience Services, LLC US 100.00% 10/22 Eurofins NTD, LLC Eurofins Viracor, LLC US 100.00% 12/22 Eurofins GSD Holdings, Inc. Eurofins Technologies US Holdings, Inc. US 100.00% 08/22 Eurofins Viracor Oncology, LLC Eurofins Clinical Testing US Holdings, Inc. US 100.00% 11/22 Pomona 900 Corporate Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 08/22 Eurofins Ana Laboratories, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 04/22 3.4. Discontinued operations The companies below have been liquidated or sold during the year: % of ISO interest Date Company Subsidiary of: Code by the of exit Group Eurofins GSC Finance NV Eurofins Scientific SE BE 100.00% 12/22 Eurofins Digital Testing Belgium NV Eurofins Digital Testing International LUX Holding S.\u00e0 BE 100.00% 12/22 r.l Eurofins Digital Testing Shenzhen Co., Ltd. Eurofins Digital Testing International LUX Holding S.\u00e0 CN 100.00% 12/22 r.l BELM Pet\u0151fi utca 45 Real Estate Kft. Eurofins Real Estate LUX Holding S.\u00e0 r.l. HU 100.00% 03/22 Sandyford Clinical Diagnostics Limited Eurofins Biomnis Ireland Limited IE 100.00% 11/22 Eurofins Digital Testing India Private Limited Eurofins Digital Testing International LUX Holding S.\u00e0 IN 100.00% 11/22 r.l Eurofins SAM Sensory And Marketing Italy Srl Eurofins Food & Feed Testing Italia Holding Srl IT 100.00% 03/22 Eurofins Digital Testing International LUX Holding S.\u00e0 Eurofins Product Testing LUX Holding S.\u00e0 r.l. LU 100.00% 12/22 r.l Commissum Sdn Bhd Eurofins Product Testing LUX Holding S.\u00e0 r.l. MY 100.00% 12/22 Heerenveen Leeuwarderstraatweg Real Estate BV Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 01/22 Eurofins Digital Testing and Cyber Security Netherlands Eurofins Digital Testing International LUX Holding S.\u00e0 NL 100.00% 12/22 BV r.l % of ISO interest Date Company Subsidiary of: Code by the of exit Group Eurofins Cyber Security Netherlands Holding B.V. Eurofins Product Testing LUX Holding S.\u00e0 r.l. NL 100.00% 12/22 Eurofins Digital Testing Sweden AB Eurofins Product Testing LUX Holding S.\u00e0 r.l. SE 100.00% 12/22 Eurofins Pharma Discovery Services UK Limited Eurofins Discovery Services LUX Holding S.\u00e0 r.l. UK 100.00% 03/22 Chemtest Holdings Limited Eurofins Environment Testing UK Holding Limited UK 100.00% 08/22 Southern Real Estate Investment UK Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. UK 100.00% 08/22 Eurofins Covid Testing Services Limited Eurofins Forensics LUX Holding S.\u00e0 r.l. UK 100.00% 12/22 Eurofins Digital Product Testing UK Limited Eurofins Digital Testing International LUX Holding S.\u00e0 UK 100.00% 12/22 r.l Edge Testing Solutions Limited Eurofins Digital Testing UK Holding Limited UK 100.00% 12/22 Eurofins Digital Testing UK Holding Limited Eurofins Digital Testing International LUX Holding S.\u00e0 UK 100.00% 12/22 r.l Commissum Associates Limited Eurofins Digital Testing UK Holding Limited UK 85.00% 12/22 Eurofins Digital Media Services, LLC Eurofins Product Testing US Holdings, Inc. US 100.00% 12/22 ", "dimensions": { "concept": "EUR:DisclosureOfChangeInScope", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-213-3": { "value": "3.5. Principal subsidiary undertakings The Companies below are fully consolidated (at 100%). % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Scientific SE LU Eurofins Biomnis Middle East LLC Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. AE 100.00% 11/19 Agrohuarpes - Eurofins Agrosciences Services SA Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. AR 100.00% 08/17 Eurofins Lebensmittelanalytik \u00d6sterreich GmbH Eurofins Food Testing LUX Holding S.\u00e0 r.l. AT 100.00% 01/07 Eurofins Genomics Austria GmbH Eurofins Genomics LUX Holding S.\u00e0 r.l. AT 100.00% 09/11 Eurofins Agroscience Services Austria GmbH Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. AT 100.00% 12/12 Eurofins Environment Testing Austria Holding GmbH Eurofins Environment Testing LUX Holding S.\u00e0 r.l. AT 100.00% 03/15 Eurofins Umwelt \u00d6sterreich GmbH & Co.KG Eurofins Environment Testing Austria Holding GmbH AT 100.00% 03/15 Eurofins NUA Austria Holding GmbH Eurofins Environment Testing Austria Holding GmbH AT 100.00% 01/16 Eurofins Water & Waste GmbH Eurofins Environment Testing Austria Holding GmbH AT 100.00% 12/15 Wiener Neudorf Palmersstra\u00dfe Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. AT 100.00% 12/16 Eurofins NSC Austria GmbH Eurofins Support Services LUX Holding S.\u00e0 r.l. AT 100.00% 12/18 Eurofins Analytics & Services Austria GmbH Eurofins Environment Testing Austria Holding GmbH AT 100.00% 09/20 Eurofins Professional Scientific Services Austria GmbH Eurofins Pharma Services LUX Holding S.\u00e0 r.l. AT 100.00% 10/20 Eurofins Environment Testing Australia Pty Ltd. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. AU 100.00% 01/13 Eurofins Agroscience Services Pty Ltd. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. AU 100.00% 07/13 Eurofins Agroscience Testing Pty Ltd. Eurofins Agrosciences Services France Holding SAS AU 100.00% 07/13 Eurofins Animal Health Australia Pty Ltd. Eurofins Agrosciences Services France Holding SAS AU 100.00% 01/16 Eurofins ams Laboratories Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 03/16 Eurofins Australia New Zealand Holding Pty Ltd. Eurofins Environment Testing France Australia Holding AU 100.00% 05/16 SAS Eurofins Food Testing Australia Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 07/16 Girraween Magowar Road Real Estate Pty Ltd. Eurofins Real Estate LUX Holding S.\u00e0 r.l. AU 100.00% 05/17 Dandenong South Monterey Road Real Estate Pty Ltd. Eurofins Real Estate LUX Holding S.\u00e0 r.l. AU 100.00% 05/17 Eurofins Dermatest Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 07/17 Eurofins Technologies Australia Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 08/17 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Chemical Analysis Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 03/19 Eurofins ProMicro Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 11/20 Eurofins ARL Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 11/20 Eurofins NBLSC Environment Testing ANZ Pty Ltd. Eurofins Australia New Zealand Holding Pty Ltd. AU 100.00% 11/20 AQM Bangladesh Limited AQM HK Co., Ltd. BD 100.00% 06/19 Eurofins GSC Management Services NV Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 06/01 Eurofins Belgium NV Eurofins Environment Testing Belgium Holding NV BE 100.00% 11/07 Eurofins Food Testing Belgium NV Eurofins Food Testing LUX Holding S.\u00e0 r.l. BE 100.00% 10/10 Eurofins Environment Testing Belgium Holding NV Eurofins Environment Testing LUX Holding S.\u00e0 r.l. BE 100.00% 09/11 Nazareth Venecoweg Real Estate NV Eurofins Real Estate LUX Holding S.\u00e0 r.l. BE 100.00% 09/11 Eurofins Forensics Belgium BVBA Eurofins Forensics LUX Holding S.\u00e0 r.l. BE 100.00% 10/11 Eurofins Pharmaceutical Product Testing Belgium NV Eurofins Pharma Services LUX Holding S.\u00e0 r.l. BE 100.00% 11/11 Eurofins Agro Testing Belgium NV Eurofins Food Testing LUX Holding S.\u00e0 r.l. BE 100.00% 07/13 Eurofins Professional Scientific Services Belgium NV Eurofins Pharma Services LUX Holding S.\u00e0 r.l. BE 100.00% 06/14 Eurofins GSC IT Solutions NV Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 07/14 Eurofins GSC Finance & Administration NV Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 09/16 Eurofins Biological Testing Belgium NV Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. BE 100.00% 02/17 Eurofins Asbestos Testing Belgium NV Eurofins Environment Testing Belgium Holding NV BE 100.00% 08/17 Eurofins Amatsigroup NV Eurofins Amatsigroup SAS BE 100.00% 09/17 Eurofins Labo Van Poucke BVBA Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. BE 100.00% 02/18 Eurofins NSC Belgium BVBA Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 12/18 Eurofins GSC Consulting NV Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 09/19 Eurofins Air Monitoring Belgium NV Eurofins Air Monitoring LUX Holding S.\u00e0 r.l. BE 100.00% 12/19 Transportation, Facility and Logistic Services NV Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 12/19 Eurofins GSC Transformation & Operational Excellence Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 12/20 NV Eurofins GSC Facility Management NV Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 12/20 BfB Oil research SA Eurofins IESPM SAS BE 100.00% 04/21 Eurofins GSC Finance & Controlling Systems SA Eurofins Support Services LUX Holding S.\u00e0 r.l. BE 100.00% 12/21 Eurofins Agroscience Services EOOD Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. BG 100.00% 11/08 Eurofins HOS Testing Bulgaria EOOD Eurofins Food Testing LUX Holding S.\u00e0 r.l. BG 100.00% 09/16 Eurofins do Brasil An\u00e1lises de Alimentos Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 07/03 Eurofins Agroscience Services Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 06/12 Laborat\u00f3rio ALAC Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 04/12 Integrated Petroleum Expertise Company - Servi\u00e7os Eurofins Latin American Ventures, S.L.U. BR 100.00% 09/14 em Petroleo Ltda. Eurofins Clinical Santos Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 12/17 Eurofins Clinical Imagem Santos Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 12/17 Centro de Analise e Tipagem de Genomas Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 08/19 Eurofins Clinical Testing Brazil Holding Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 06/21 Eurofins Food Testing Brazil Holding Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 06/21 Itapema Laboratorio de Analises Clinicas Ltda. Eurofins Latin American Ventures, S.L.U. BR 100.00% 12/22 Eurofins Experchem Laboratories, Inc. Eurofins Food Testing LUX Holding S.\u00e0 r.l. CA 100.00% 04/15 Quebec St. Bruno Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. CA 100.00% 12/16 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins CDMO Alphora, Inc. Eurofins Pharma Services Canada Holding, Inc. CA 100.00% 06/17 Eurofins NSC Canada, Inc. Eurofins Support Services LUX Holding S.\u00e0 r.l. CA 100.00% 06/17 Eurofins BioPharma Product Testing Toronto, Inc. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CA 100.00% 05/18 Oakville Portland Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. CA 100.00% 06/18 Mississauga Hadwen Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. CA 100.00% 06/18 Mississauga Speakman Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. CA 100.00% 06/18 Eurofins Environment Testing Canada, Inc. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. CA 100.00% 11/18 Eurofins Cosmetics and Personal Care Testing Eurofins Product Testing LUX Holding S.\u00e0 r.l. CA 100.00% 09/19 Canada, Inc. Eurofins Professional Scientific Services Canada, Inc. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CA 100.00% 10/20 Eurofins Pharma Services Canada Holding, Inc. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CA 100.00% 07/21 Eurofins Enviro-Works, Inc. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. CA 100.00% 12/21 Eurofins Scientific AG Eurofins Food Testing LUX Holding S.\u00e0 r.l. CH 100.00% 07/00 Eurofins Regulatory AG Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. CH 100.00% 12/11 Eurofins BioPharma Product Testing Switzerland AG Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CH 100.00% 01/13 Eurofins Professional Scientific Services Switzerland Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CH 100.00% 03/17 AG Eurofins Electric & Electronic Product Testing AG Eurofins Product Testing LUX Holding S.\u00e0 r.l. CH 100.00% 06/17 Route de Montena Real Estate AG Eurofins Real Estate LUX Holding S.\u00e0 r.l. CH 100.00% 06/17 Eurofins PHAST Pharma AG Eurofins PHAST GmbH CH 100.00% 07/18 Eurofins NSC Switzerland AG Eurofins Support Services LUX Holding S.\u00e0 r.l. CH 100.00% 01/20 SAM Sensory and Marketing International Switzerland Eurofins Sensory, Consumer research and Product CH 100.00% 12/20 AG design LUX Holding S.\u00e0 r.l. Eurofins Qualitech AG Eurofins Qute Holding AG CH 100.00% 07/21 Eurofins Qute Holding AG Eurofins Material Sciences LUX Holding S.\u00e0 r.l. CH 100.00% 07/21 Scitec Research SA Eurofins Environment Testing LUX Holding S.\u00e0 r.l. CH 100.00% 09/21 Swanfort Services SA DNA Consolidated BV CH 100.00% 08/21 AgeaCare Switzerland S.\u00e0 r.l DNA Consolidated BV CH 100.00% 08/21 Eurofins Testing Chile SA Eurofins Latin American Ventures, S.L.U. CL 100.00% 03/13 Eurofins Training Chile SA Eurofins Testing Chile SA CL 100.00% 03/13 Eurofins Agroscience Services Chile SA Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. CL 100.00% 06/17 Eurofins Product Testing Hong Kong, Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 03/06 Eurofins Technology Service (Suzhou) Co., Ltd. Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/06 Eurofins Product Testing Service (Shanghai) Co., Ltd. Eurofins Shanghai Holding, Ltd. CN 100.00% 11/09 Eurofins Testing Technology (Shenzhen) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 10/09 Eurofins Shanghai Holding, Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 08/09 Eurofins Central Laboratory China Co., Ltd. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CN 100.00% 05/12 Eurofins Food Testing Hong Kong, Ltd. Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 03/12 Eurofins NSC Shanghai Co., Ltd. Eurofins Support Services LUX Holding S.\u00e0 r.l. CN 100.00% 06/14 Eurofins NSC Hong Kong, Ltd. Eurofins Support Services LUX Holding S.\u00e0 r.l. CN 100.00% 02/14 Eurofins Sensory Consumer and Product Research Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 05/15 (Shanghai) Co., Ltd. Eurofins Food Testing Service(Dalian)Co.,Ltd. Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 06/16 Eurofins Technology Service (Qingdao) Co., Ltd. Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 06/16 Evans Materials Technology (Shanghai) Co., Ltd. Eurofins EAG Materials Science, LLC CN 100.00% 12/17 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Consumer Product Testing (Guangzhou) Co., Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 12/18 Ltd Eurofins Electrical Testing Service (Shenzhen) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/18 Eurofins EAG Materials Science China (Shanghai) Co., Eurofins Material Sciences LUX Holding S.\u00e0 r.l. CN 100.00% 09/19 Ltd. Eurofins BioPharma Product Testing (Shanghai ) Co., Eurofins Pharma Services LUX Holding S.\u00e0 r.l. CN 100.00% 12/19 Ltd. AQM HK Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 06/19 Eurofins Technology Service (Guangzhou) Co., Ltd. Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 10/19 AQM China Co., Ltd. AQM HK Co., Ltd. CN 100.00% 06/19 Eurofins Technologies (Shanghai) Co., Ltd. Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. CN 100.00% 07/20 Eurofins Assurance China Co., Ltd. Eurofins Assurance LUX Holding S.\u00e0 r.l. CN 100.00% 05/21 Eurofins-UNPA Natural Health Product Quality Services Eurofins Food Testing Hong Kong, Ltd. CN 60.00% 08/21 (Beijing) Co., Ltd. Eurofins Wireless Testing Service (Shenzhen) Co., Ltd. A Test Lab Techno Co., Ltd. CN 100.00% 07/21 Eurofins Testing Inspection Certification (Chengdu) Eurofins Food Testing LUX Holding S.\u00e0 r.l. CN 100.00% 07/21 Co., Ltd. Eurofins MTS Consumer Product Testing (Hong Kong) Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/21 Co., Ltd. Modern Testing Services (Hong Kong) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/21 Modern Testing Services (International) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/21 Eurofins Assurance (Hong Kong) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/21 Modern Testing Services(Dongguan) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/21 Eurofins MTS Consumer Product Testing (Shanghai) Eurofins Product Testing LUX Holding S.\u00e0 r.l. CN 100.00% 11/21 Co., Ltd Eurofins Megalab Colombia, SAS Eurofins Megalab, S.A.U. CO 100.00% 09/21 Eurofins IT Infrastructure GSC S.A. Eurofins Support Services LUX Holding S.\u00e0 r.l. CR 100.00% 08/18 Eurofins Food & Feed Testing Czech Republic s.r.o. Eurofins Holding CZ s.r.o. CZ 100.00% 10/06 Eurofins Holding CZ s.r.o. Eurofins Food Testing LUX Holding S.\u00e0 r.l. CZ 100.00% 08/19 Eurofins Food Testing Hamburg Germany Holding Eurofins GeneScan Holding GmbH DE 100.00% 05/98 GmbH RECO Homburg Entenmuehlstrasse Real Estate Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 11/98 GmbH Eurofins GeneScan Holding GmbH Eurofins Food Testing LUX Holding S.\u00e0 r.l. DE 100.00% 07/03 Eurofins Analytik GmbH Eurofins GfA Lab Service GmbH DE 100.00% 12/98 Eurofins Dr. Specht International GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 04/05 GmbH Eurofins GeneScan GmbH Eurofins GeneScan Holding GmbH DE 100.00% 07/03 Eurofins SOFIA GmbH Eurofins Food Testing Pesticides Germany Holding DE 100.00% 04/06 GmbH Eurofins GfA GmbH Eurofins Air Monitoring Germany Holding GmbH DE 100.00% 01/01 Eurofins \u00d6kometric GmbH Eurofins NDSC Umweltanalytik GmbH DE 100.00% 12/02 Eurofins NDSC Umweltanalytik GmbH Eurofins Environment Testing LUX Holding S.\u00e0 r.l. DE 100.00% 03/05 Eurofins Umwelt West GmbH Eurofins Environment Testing Germany Holding West DE 100.00% 04/05 GmbH Eurofins Umwelt Ost GmbH Eurofins NDSC Umweltanalytik GmbH DE 100.00% 01/06 Eurofins Institut J\u00e4ger GmbH Eurofins NDSC Umweltanalytik GmbH DE 100.00% 04/06 Eurofins Genomics Europe Applied Genomics GmbH Eurofins MWG Holding GmbH DE 100.00% 07/01 Eurofins Agroscience Services EcoChem GmbH Eurofins Agroscience Services Germany Holding DE 100.00% 01/06 GmbH Eurofins BioPharma Product Testing Munich GmbH Eurofins BioPharma Services Holding Germany GmbH DE 100.00% 10/06 Eurofins MWG Holding GmbH Eurofins Genomics BV DE 100.00% 01/05 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Genomics Germany GmbH Eurofins MWG Holding GmbH DE 100.00% 01/07 Eurofins Food Testing Pesticides Germany Holding Eurofins Food Testing LUX Holding S.\u00e0 r.l. DE 100.00% 12/06 GmbH Eurofins Dr. Specht Laboratorien GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 03/07 GmbH Eurofins Genomics Europe Synthesis GmbH Eurofins MWG Holding GmbH DE 100.00% 01/07 Eurofins Food Testing General Chemistry Germany Eurofins Laborservices GmbH DE 100.00% 04/07 Holding GmbH Eurofins Institut Dr. Rothe GmbH Eurofins Food Testing General Chemistry Germany DE 100.00% 04/07 Holding GmbH Eurofins Product Testing Verwaltungs GmbH Eurofins Product Service GmbH DE 100.00% 03/07 Eurofins Environment Testing Germany Holding West Eurofins Environment Testing LUX Holding S.\u00e0 r.l. DE 100.00% 12/07 GmbH Eurofins Agroscience Services Germany Holding Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. DE 100.00% 04/07 GmbH FP Friedrichsdorf Professor-Wagner-Strasse Real Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 04/07 Estate GmbH Eurofins Umwelt Nord GmbH Eurofins NDSC Umweltanalytik GmbH DE 100.00% 05/07 Eurofins Laborservices GmbH Eurofins Food Testing LUX Holding S.\u00e0 r.l. DE 100.00% 04/07 Eurofins NSC IT Infrastructure Germany GmbH Eurofins Support Services LUX Holding S.\u00e0 r.l. DE 100.00% 12/07 Eurofins INLAB GmbH Eurofins Food Testing General Chemistry Germany DE 100.00% 12/07 Holding GmbH Eurofins Product Service GmbH Eurofins Scientific SE DE 100.00% 01/08 Eurofins Information Systems GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 11/07 GmbH Eurofins Consumer Product Testing GmbH Eurofins Product Testing Verwaltungs GmbH DE 100.00% 01/08 Eurofins Food Testing Germany East Holding GmbH Eurofins Food Testing LUX Holding S.\u00e0 r.l. DE 100.00% 01/08 Eurofins Agroscience Services Chem GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 02/08 GmbH Eurofins Food Control Services GmbH Eurofins Food Testing LUX Holding S.\u00e0 r.l. DE 100.00% 12/08 Eurofins WEJ Contaminants GmbH Eurofins GfA Lab Service GmbH DE 100.00% 12/08 Eurofins BioTesting Services Nord GmbH Eurofins GfA Lab Service GmbH DE 100.00% 12/08 HS Hamburg Stenzelring Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 06/08 Eurofins Global Control GmbH Eurofins Food Testing Pesticides Germany Holding DE 100.00% 04/09 GmbH Eurofins Food & Feed Testing Leipzig GmbH Dr. Appelt Beteiligungs GmbH DE 100.00% 05/09 RECO Ebersberg Anzinger Strasse Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 08/09 Eurofins BioPharma Product Testing Hamburg GmbH Eurofins BioPharma Services Holding Germany GmbH DE 100.00% 07/09 Eurofins Food Integrity Control Services GmbH Dr. Appelt Beteiligungs GmbH DE 100.00% 05/09 Eurofins Institut Dr. Appelt Hilter GmbH Dr. Appelt Beteiligungs GmbH DE 100.00% 05/09 Dr. Appelt Beteiligungs GmbH Eurofins Food Testing Germany East Holding GmbH DE 100.00% 05/09 Gold Standard Diagnostics Freiburg GmbH Eurofins Technologies Germany Holding GmbH DE 100.00% 05/09 Eurofins GfA Lab Service GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 10/10 GmbH Eurofins NDSC Food Testing Germany GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 03/11 GmbH Eurofins Agroscience Services GmbH Eurofins Agroscience Services Germany Holding DE 100.00% 07/11 GmbH Eurofins Facility Management Germany GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 11/11 GmbH Eurofins Umwelt S\u00fcdwest GmbH Eurofins Environment Testing Germany Holding West DE 100.00% 06/12 GmbH Eurofins Medigenomix Forensik GmbH Eurofins MWG Holding GmbH DE 100.00% 08/12 Eurofins Food Consulting Services GmbH Dr. Appelt Beteiligungs GmbH DE 100.00% 01/13 Eurofins GSC Germany GmbH Eurofins Support Services LUX Holding S.\u00e0 r.l. DE 100.00% 04/13 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins CLF Specialised Nutrition Testing Services Eurofins Food Testing Germany East Holding GmbH DE 100.00% 08/13 GmbH BLGG Deutschland GmbH Eurofins Agro Testing Netherlands Holding BV DE 100.00% 07/13 RECO Hamburg Neul\u00e4nder Kamp 1 Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 07/13 Eurofins HT-Analytik GmbH Eurofins NDSC Umweltanalytik GmbH DE 100.00% 03/14 Eurofins Hygiene Institut Berg GmbH Eurofins Environment Testing Germany Holding West DE 100.00% 05/14 GmbH Eurofins Agraranalytik Deutschland GmbH Eurofins Food Testing LUX Holding S.\u00e0 r.l. DE 100.00% 12/14 Eurofins BioPharma Services Holding Germany GmbH Eurofins MWG Holding GmbH DE 100.00% 03/15 Eurofins Agroscience Services Ecotox GmbH Eurofins Agroscience Services Germany Holding DE 100.00% 08/15 GmbH Eurofins Professional Scientific Services Germany Eurofins BioPharma Services Holding Germany GmbH DE 100.00% 10/15 GmbH St. Marien Krankenhaus Lampertheim GmbH Eurofins Clinical Testing Services Germany LUX DE 100.00% 08/16 Holding S.\u00e0 r.l. Eurofins Air Monitoring Germany Holding GmbH Eurofins Air Monitoring LUX Holding S.\u00e0 r.l. DE 100.00% 07/16 Eurofins Finance Transactions Germany GmbH Eurofins Support Services LUX Holding S.\u00e0 r.l. DE 100.00% 10/16 Eurofins Dr. Specht Express GmbH Eurofins Food Testing Hamburg Germany Holding DE 100.00% 04/16 GmbH Eurofins MVZ Medizinisches Labor Gelsenkirchen St. Marien Krankenhaus Lampertheim GmbH DE 100.00% 07/17 GmbH Eurofins Laborbetriebsgesellschaft Gelsenkirchen Eurofins MVZ Medizinisches Labor Gelsenkirchen DE 100.00% 07/17 GmbH GmbH Eurofins Genomics Europe Sequencing GmbH Eurofins MWG Holding GmbH DE 100.00% 07/17 Eurofins LifeCodexx GmbH Eurofins Genomics Europe Sequencing GmbH DE 100.00% 07/17 Eurofins Institut Nehring GmbH Eurofins Food Testing General Chemistry Germany DE 100.00% 10/17 Holding GmbH IfB Institut f\u00fcr Blutgruppenforschung GmbH Eurofins MWG Holding GmbH DE 100.00% 10/17 SAM Sensory and Marketing International GmbH KKG Holding GmbH DE 100.00% 11/17 KKG Holding GmbH Eurofins Sensory, Consumer research and Product DE 100.00% 11/17 design LUX Holding S.\u00e0 r.l. Eurofins Agroscience Services EAG Laboratories Eurofins Agroscience Services Germany Holding DE 100.00% 12/17 GmbH GmbH Evans Analytical Group Holdings GmbH Eurofins EAG Materials Science, LLC DE 100.00% 12/17 Eurofins WKS Labservice GmbH Eurofins Product Testing Verwaltungs GmbH DE 75.00% 12/17 Eurofins PHAST GmbH Eurofins BioPharma Services Holding Germany GmbH DE 100.00% 07/18 Eurofins PHAST Development GmbH & Co. KG Eurofins PHAST GmbH DE 100.00% 07/18 PHAST Development Verwaltungs GmbH Eurofins PHAST GmbH DE 100.00% 07/18 Agrartest GmbH Eurofins Agroscience Services Germany Holding DE 100.00% 07/18 GmbH NovaTec Immundiagnostica GmbH Eurofins Technologies Germany Holding GmbH DE 100.00% 08/20 Gold Standard Diagnostics Kassel GmbH Eurofins Technologies Germany Holding GmbH DE 100.00% 01/19 Eurofins Genomics Europe Shared Services GmbH Eurofins MWG Holding GmbH DE 100.00% 02/19 Eurofins Q-Bioanalytic GmbH Eurofins BioTesting Services Nord GmbH DE 100.00% 11/18 LL Leipzig Landsteiner Strasse Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 05/19 Eurofins Technologies Germany Holding GmbH Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. DE 100.00% 03/19 Gold Standard Diagnostics CD Kassel GmbH Eurofins Technologies Germany Holding GmbH DE 100.00% 01/19 Virotech Diagnostics GmbH Eurofins Technologies Germany Holding GmbH DE 100.00% 02/19 Eurofins Agroscience Services Regulatory Germany Eurofins Agroscience Services Germany Holding DE 100.00% 12/19 GmbH GmbH Eurofins BioTesting Services Ost GmbH Dr. Appelt Beteiligungs GmbH DE 100.00% 01/20 MF M\u00fcnchen Friedenheimer Br\u00fccke Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 05/20 % of Date ISO interest Company Subsidiary of: of code by the entry Group Pr\u00e4natal-Medizin M\u00fcnchen Frauen\u00e4rzte und St. Marien Krankenhaus Lampertheim GmbH DE 100.00% 05/20 Humangenetiker MVZ GmbH Eurofins BioPharma Services Consulting Munich GmbH Eurofins BioPharma Services Holding Germany GmbH DE 100.00% 11/20 RECO 2. Verwaltungsgesellschaft GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 07/21 Eurofins NBLSC Technologies Germany GmbH Eurofins Technologies Germany Holding GmbH DE 100.00% 06/21 RECO Troisdorf Gierlichstrasse Real Estate GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 12/20 Eurofins Derma Tronnier GmbH Eurofins Product Testing Verwaltungs GmbH DE 100.00% 12/20 Tronnier Verwaltungs GmbH Eurofins Product Testing Verwaltungs GmbH DE 100.00% 12/20 RECO 1. Verwaltungsgesellschaft GmbH Eurofins Real Estate LUX Holding S.\u00e0 r.l. DE 100.00% 01/21 Eurofins EmpowerDX Europe GmbH St. Marien Krankenhaus Lampertheim GmbH DE 100.00% 06/21 Bioskin GmbH Eurofins Product Testing Verwaltungs GmbH DE 100.00% 08/21 Modern Testing Services (Germany) GmbH Modern Technology Holdings Limited DE 100.00% 11/21 Eurofins NSC Denmark A/S Eurofins Support Services LUX Holding S.\u00e0 r.l. DK 100.00% 12/03 Eurofins Biopharma Product Testing Denmark A/S Eurofins BioPharma Product Testing Denmark Holding DK 100.00% 03/06 A/S Eurofins Product Testing Denmark A/S Eurofins Product Testing LUX Holding S.\u00e0 r.l. DK 100.00% 08/08 Eurofins Miljo A/S Eurofins Environment Denmark Holding A/S DK 100.00% 06/05 Eurofins Steins Laboratorium A/S Eurofins Food Denmark Holding A/S DK 100.00% 07/06 Eurofins Environment Denmark Holding A/S Eurofins Environment Testing LUX Holding S.\u00e0 r.l. DK 100.00% 04/07 Eurofins Food Denmark Holding A/S Eurofins Food Testing LUX Holding S.\u00e0 r.l. DK 100.00% 04/07 Eurofins Genomics Holding Denmark A/S Eurofins Genomics LUX Holding S.\u00e0 r.l. DK 100.00% 11/13 Eurofins Genomics Europe Genotyping A/S Eurofins Genomics Holding Denmark A/S DK 100.00% 01/13 Eurofins Milj\u00f8 Vand A/S Eurofins Environment Denmark Holding A/S DK 100.00% 10/13 Eurofins Agro Testing Denmark A/S Eurofins Food Denmark Holding A/S DK 100.00% 12/14 Eurofins Milj\u00f8 Luft A/S Eurofins Environment Denmark Holding A/S DK 100.00% 08/14 Eurofins BioPharma Product Testing Denmark Holding Eurofins Pharma Services LUX Holding S.\u00e0 r.l. DK 100.00% 08/15 A/S Eurofins Professional Scientific Services Denmark A/S Eurofins BioPharma Product Testing Denmark Holding DK 100.00% 08/15 A/S Eurofins Genomics Denmark A/S Eurofins Genomics Holding Denmark A/S DK 100.00% 12/15 Eurofins Safer At Work Nordics A/S Eurofins Genomics Holding Denmark A/S DK 100.00% 09/16 Eurofins Milk Testing Denmark A/S Eurofins Food Denmark Holding A/S DK 100.00% 01/17 Eurofins Vitamin Testing Denmark A/S Eurofins Food Denmark Holding A/S DK 100.00% 01/17 Aabybro Industrivej Real Estate ApS Eurofins Real Estate LUX Holding S.\u00e0 r.l. DK 100.00% 03/17 Eurofins VBM Laboratoriet A/S Eurofins Environment Denmark Holding A/S DK 100.00% 03/17 Eurofins VBM Geo ApS Eurofins Environment Denmark Holding A/S DK 100.00% 10/18 Eurofins Environment Testing Holding Estonia O\u00dc Eurofins Environment Testing LUX Holding S.\u00e0 r.l. EE 100.00% 04/17 Eurofins Environment Testing Estonia O\u00dc Eurofins Environment Testing Holding Estonia O\u00dc EE 100.00% 04/17 Rae Village Vana-Sutikase ja Tammi tee Real Estate Eurofins Real Estate LUX Holding S.\u00e0 r.l. EE 100.00% 12/19 O\u00dc Eurofins Agroscience Services, S.L.U. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. ES 100.00% 01/06 Eurofins BioPharma Product Testing Spain, S.L.U. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. ES 100.00% 01/07 Eurofins Latin American Ventures, S.L.U. Eurofins International Holdings LUX S.\u00e0 r.l. ES 100.00% 04/09 Eurofins Sicaagriq, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 07/13 Eurofins Analisis Alimentario Holding Espana S.L.U. Eurofins Food Testing LUX Holding S.\u00e0 r.l. ES 100.00% 09/13 Sensory and Marketing Spain, S.L.U. Eurofins Sensory, Consumer research and Product ES 100.00% 09/13 design LUX Holding S.\u00e0 r.l. % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins An\u00e1lisis Alimentario, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 05/14 Eurofins Food Barcelona, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 05/14 Eurofins An\u00e1lisis Agro, S.A. Eurofins Food Barcelona, S.L.U. ES 90.21% 05/14 Eurofins Product Testing, Cosmetics & Personal Care Eurofins Product Testing Holding Spain, S.L.U. ES 100.00% 07/15 Spain, S.L.U. Eurofins Trialcamp, S.L.U. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. ES 100.00% 06/15 Eurofins Laboratorio Sarr\u00f3, S.L.U. Eurofins Biologie M\u00e9dicale Holding France SAS ES 100.00% 07/15 Eurofins NSC Spain, S.L.U. Eurofins Support Services LUX Holding S.\u00e0 r.l. ES 100.00% 01/16 Eurofins Histolog, S.L.U. France Anapath Holding SAS ES 100.00% 01/16 Eurofins NDSC Food Testing Spain, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 04/16 Eurofins Product Testing Holding Spain, S.L.U. Eurofins Product Testing LUX Holding S.\u00e0 r.l. ES 100.00% 04/16 Eurofins Professional Scientific Services Spain, S.L.U. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. ES 100.00% 01/17 Eurofins Megalab, S.A.U. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. ES 100.00% 09/16 Eurofins Laboratorio \u00c1ngel M\u00e9ndez, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 09/16 Eurofins Laboratorio Surlab, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 09/16 Megalab Medio Ambiente, S.L. Eurofins Megalab, S.A.U. ES 70.00% 09/16 Eurofins Laboratorio Dr. Valenzuela, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 09/16 Eurofins Laboratorio Prefasi, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 05/17 Eurofins Villapharma Research, S.L.U. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. ES 100.00% 03/17 Eurofins Laboratorios de Castilla y Le\u00f3n, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 05/17 Eurofins Textile Testing Spain, S.L.U. Eurofins Product Testing Holding Spain, S.L.U. ES 100.00% 04/17 Fuente \u00c1lamo de Murcia - El Estrech Real Estate, Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 12/17 S.L.U. Eurofins Analclinic, S.A.U. Eurofins Megalab, S.A.U. ES 100.00% 11/17 Eurofins Technologies Holding Spain, S.L.U. Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. ES 100.00% 02/18 Madrid Garc\u00eda Noblejas Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 07/18 Eurofins Mas Control, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 03/18 Eurofins Ingenasa, S.A. Eurofins Technologies Holding Spain, S.L.U. ES 94.10% 02/18 Eurofins Agroscience Services Regulatory Spain, Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. ES 100.00% 04/18 S.L.U. Santa Cruz Diesel Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 07/18 Eurofins Audit & Inspection, S.A.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 07/18 Eurofins Agroscience Services Iberica Holding, S.L.U. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. ES 100.00% 12/18 Eurofins LGS Megalab An\u00e1lisis Cl\u00ednicos, S.L.U. Eurofins Megalab, S.A.U. ES 100.00% 07/18 Eurofins Ecosur, S.A.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 07/18 Eurofins LGS Megalab An\u00e1lisis Veterinarios, S.L.U. Eurofins LGS Megalab An\u00e1lisis Cl\u00ednicos, S.L.U. ES 100.00% 12/18 Lorqui Castillo de Aledo, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 03/19 Eurofins Environment Testing Spain Holding, S.L.U. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. ES 100.00% 04/19 Eurofins GSC Spain, S.L.U. Eurofins Support Services LUX Holding S.\u00e0 r.l. ES 100.00% 04/19 Eurofins M\u00e9todos Servicios Agr\u00edcolas, S.L.U. Eurofins Agroscience Services Iberica Holding, S.L.U. ES 100.00% 03/19 Eurofins Iproma, S.L.U. Eurofins Environment Testing Spain Holding, S.L.U. ES 100.00% 07/19 Alfredo Montoro Soriano, S.L.U. Eurofins Analclinic, S.A.U. ES 100.00% 06/19 Mazarr\u00f3n Campico Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 03/20 Abar\u00e1n Rellano Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 08/20 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Laboratorio Montoro Botella, S.L.U. Alfredo Montoro Soriano, S.L.U. ES 100.00% 06/19 Castell\u00f3n Lituania Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 03/20 Eurofins Envira Ingenieros Asesores, S.L.U. Eurofins Environment Testing Spain Holding, S.L.U. ES 100.00% 11/20 Premiumlab, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 12/20 Eurofins Quimico Onubense, S.L.U. Eurofins Environment Testing Spain Holding, S.L.U. ES 100.00% 08/21 Oricain Ezcabarte Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 03/21 Paterna Les Ones Real Estate, S.L.U. Eurofins Real Estate LUX Holding S.\u00e0 r.l. ES 100.00% 07/21 Cimera Estudios Aplicados, S.L.U. Eurofins Environment Testing Spain Holding, S.L.U. ES 100.00% 05/21 Eurofins NBLSC Environment Testing Spain, S.L.U. Eurofins Environment Testing Spain Holding, S.L.U. ES 100.00% 05/21 Eurofins Centro Anal\u00ectico M\u00ecguez Mu\u00ecnos, S.L.U. Eurofins Analisis Alimentario Holding Espana S.L.U. ES 100.00% 08/21 Eurofins Scientific Finland Oy Eurofins Food Testing LUX Holding S.\u00e0 r.l. FI 100.00% 10/07 Eurofins Viljavuuspalvelu Oy Eurofins Food Testing LUX Holding S.\u00e0 r.l. FI 100.00% 12/12 Eurofins Environment Testing Finland Holding Oy Eurofins Environment Testing LUX Holding S.\u00e0 r.l. FI 100.00% 01/17 Eurofins Ahma Oy Eurofins Environment Testing Finland Holding Oy FI 100.00% 02/17 Eurofins Environment Testing Finland Oy Eurofins Environment Testing Finland Holding Oy FI 100.00% 04/17 Eurofins Nab Labs Group Oy Eurofins Environment Testing Finland Holding Oy FI 100.00% 06/17 Eurofins Nab Labs Oy Eurofins Nab Labs Group Oy FI 100.00% 06/17 Eurofins Expert Services Oy Eurofins Product Testing LUX Holding S.\u00e0 r.l. FI 100.00% 06/18 Eurofins Labtium Oy Eurofins Environment Testing Finland Holding Oy FI 100.00% 06/18 Oulu Nuottasaari Real Estate Oy Eurofins Real Estate LUX Holding S.\u00e0 r.l. FI 100.00% 09/19 Eurofins Product Testing Finland Holding Oy Eurofins Product Testing LUX Holding S.\u00e0 r.l. FI 100.00% 04/21 Eurofins Electric & Electronics Finland Oy Eurofins Product Testing Finland Holding Oy FI 100.00% 04/21 Eurofins Microbiologie France Holding SAS Eurofins Hygi\u00e8ne Alimentaire France LUX Holding S.\u00e0 FR 100.00% 01/99 r.l. Eurofins Analytics France SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 07/99 Eurofins Hygi\u00e8ne Alimentaire Formation SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 07/99 Eurofins Certification SAS Eurofins Assurance and Inspection Services France FR 100.00% 07/03 Holding SAS Eurofins Laboratoire De Microbiologie De L'Est SAS Eurofins Microbiologie France Holding SAS FR 100.00% 01/06 Eurofins ATS SAS Eurofins Product Testing LUX Holding S.\u00e0 r.l. FR 100.00% 01/99 Eurofins Hydrologie France Holding SAS Eurofins Hydrologie France LUX Holding S.\u00e0 r.l. FR 100.00% 07/05 Eurofins Analyses Pour L'Environnement France SAS Eurofins Analyses Environnementales Pour Les FR 100.00% 07/05 Industriels France SAS Eurofins Analyses Pour Le B\u00e2timent Est SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 01/01 SAS Eurofins BioPharma Product Testing & Professional Eurofins Pharma Services France LUX Holding S.\u00e0 r.l. FR 100.00% 06/06 Scientific Services France Holding SAS Eurofins Genomics France SAS Eurofins Genomics LUX Holding S.\u00e0 r.l. FR 100.00% 07/05 Institut Francais Des Empreintes Genetiques SAS Eurofins Forensics LUX Holding S.\u00e0 r.l. FR 75.00% 11/05 Toxlab SAS Eurofins Forensics LUX Holding S.\u00e0 r.l. FR 98.64% 02/05 Eurofins ADME Bioanalyses SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 10/04 Scientific Services France Holding SAS Eurofins Optimed SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 01/06 Scientific Services France Holding SAS Eurofins Pharma Quality Control SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 01/06 Scientific Services France Holding SAS Eurofins Agroscience Services France SAS Eurofins Agrosciences Services France Holding SAS FR 100.00% 01/06 Eurofins Agroscience Services SAS Eurofins Agrosciences Services France Holding SAS FR 100.00% 01/06 % of Date ISO interest Company Subsidiary of: of code by the entry Group Chemtox SAS Eurofins Forensics LUX Holding S.\u00e0 r.l. FR 98.90% 01/08 Eurofins Laboratoires De Microbiologie Ouest SAS Eurofins Microbiologie France Holding SAS FR 100.00% 10/06 Eurofins Cervac Sud SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 10/06 Eurofins NSC Finance France SAS Eurofins Support Services LUX Holding S.\u00e0 r.l. FR 100.00% 10/06 SAM Consumer International France SAS Eurofins Sensory Holding France SAS FR 100.00% 10/06 Eurofins Hydrologie France SAS Eurofins Hydrologie France Holding SAS FR 100.00% 01/01 Eurofins Food Chemistry Testing France Holding SAS Eurofins Food Chemistry Testing France LUX Holding FR 100.00% 09/07 S.\u00e0 r.l. Eurofins Optimed Lyon SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 09/07 Scientific Services France Holding SAS Eurofins NSC IT Infrastructure France SAS Eurofins Support Services LUX Holding S.\u00e0 r.l. FR 100.00% 12/07 Eurofins Hydrologie Centre Est SAS Eurofins Hydrologie France Holding SAS FR 100.00% 04/08 Eurofins Laboratoire Centre SAS Eurofins Microbiologie France Holding SAS FR 100.00% 07/10 Eurofins Laboratoire Nord SAS Eurofins Microbiologie France Holding SAS FR 100.00% 07/10 Eurofins Consulting Agroalimentaire SAS Eurofins Assurance and Inspection Services France FR 100.00% 07/10 Holding SAS Eurofins GSC France SAS Eurofins Support Services LUX Holding S.\u00e0 r.l. FR 100.00% 07/10 Eurofins NDSC IT Solution Food France SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 08/10 Eurofins NDSC Environnement France SAS Eurofins NDSC Environnement France Holding SAS FR 100.00% 08/10 Eurofins Analyses Pour Le Batiment France Holding Eurofins Analyses pour la Construction France LUX FR 100.00% 08/10 SAS Holding S.\u00e0 r.l. Eurofins NBLSC Analyses Pour Le B\u00e2timent France Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 09/10 SAS SAS Eurofins Analyses Environnementales Pour Les Eurofins Analyses Environnementales pour les FR 100.00% 10/10 Industriels France SAS Industriels France LUX Holding S.\u00e0 r.l. Eurofins NSC Developpement France SAS Eurofins Support Services LUX Holding S.\u00e0 r.l. FR 100.00% 10/10 Eurofins Agroscience Services Chem SAS Eurofins Agrosciences Services France Holding SAS FR 100.00% 12/10 Eurofins Analyses pour le B\u00e2timent Ile de France SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 12/10 SAS Eurofins Analyses pour le B\u00e2timent Nord SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 12/10 SAS Eurofins Analyses pour le B\u00e2timent Sud Est SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 12/10 SAS Eurofins Analyses pour le B\u00e2timent Ouest SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 12/10 SAS Eurofins Analyses des Mat\u00e9riaux et Combustibles Eurofins Expertises France Holding SAS FR 100.00% 12/10 France SAS Eurofins Hydrologie Nord SAS Eurofins Hydrologie France Holding SAS FR 100.00% 11/11 Eurofins LCAM - Eurofins Laboratoire Central Eurofins Microbiologie France Holding SAS FR 100.00% 11/11 d'Analyses de la Moselle SAS Eurofins Hydrologie Ile De France SAS Eurofins Hydrologie France Holding SAS FR 100.00% 11/11 Eurofins Hydrologie Est SAS Eurofins Hydrologie France SAS FR 100.00% 11/11 Eurofins Hydrologie Sud SAS Eurofins Hydrologie France Holding SAS FR 100.00% 11/11 Eurofins Asbestos Testing Europe SAS Eurofins Industrial Testing LUX S.\u00e0 r.l. FR 100.00% 11/11 Eurofins Laboratoire Contaminants Sud SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 12/11 Eurofins Laboratoire De Pathologie V\u00e9g\u00e9tale SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 12/11 Eurofins Hydrologie Ouest SAS Eurofins Hydrologie France Holding SAS FR 100.00% 02/12 Eurofins NBLSC Forensics SAS Eurofins Forensics LUX Holding S.\u00e0 r.l. FR 100.00% 02/12 Eurofins Ecotoxicologie France SAS Eurofins Expertises France Holding SAS FR 100.00% 04/12 Eurofins NDSC Environnement France Holding SAS Eurofins Environment Testing LUX Holding S.\u00e0 r.l. FR 100.00% 05/12 Eurofins NDSCE Support France SAS Eurofins NDSC Environnement France Holding SAS FR 100.00% 01/12 Eurofins Agrosciences Services France Holding SAS Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. FR 100.00% 12/12 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins GSC CADET SAS Eurofins Support Services LUX Holding S.\u00e0 r.l. FR 100.00% 11/12 Eurofins Environnement Logistique France SAS Eurofins Analyses Environnementales Pour Les FR 100.00% 12/12 Industriels France SAS Eurofins Pharma Products Testing France Eurofins BioPharma Product Testing & Professional FR 100.00% 12/12 Management SAS Scientific Services France Holding SAS Eurofins Pharma Products Engineering SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 12/12 Scientific Services France Holding SAS Eurofins Cerep SA Eurofins Discovery Services LUX Holding S.\u00e0 r.l. FR 95.78% 03/13 Eurofins MITOX FOPSE SARL Eurofins Agrosciences Services France Holding SAS FR 100.00% 07/13 Eurofins Analyses Pour Le Batiment Sud-Ouest SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 09/13 SAS Eurofins ID MYK SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 01/14 Scientific Services France Holding SAS Eurofins Prelevement Pour Le Batiment France Holding Eurofins Analyses pour lEnvironnement France LUX FR 100.00% 08/14 SAS Holding S.\u00e0 r.l. Eurofins Prelevement Pour Le Batiment Est SAS Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 09/14 SAS Eurofins Prelevement Pour Le Batiment France SAS Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 10/14 SAS Eurofins Prelevement Pour Le Batiment Ouest SAS Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 10/14 SAS Eurofins NSC HR France SAS Eurofins Support Services LUX Holding S.\u00e0 r.l. FR 100.00% 07/14 Eurofins Analyses Pour Le B\u00e2timent Sud SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 08/14 SAS Eurofins Prelevement Pour Le Batiment Nord SAS Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 09/14 SAS Eurofins Prelevement Pour Le Batiment Sud-Est SAS Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 09/14 SAS Eurofins Pr\u00e9l\u00e8vement pour le B\u00e2timent \u00cele-de-France Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 09/14 SAS SAS Eurofins NDSC Hydrologie France SAS Eurofins Hydrologie France Holding SAS FR 100.00% 11/14 Eurofins NDSC Microbiologie Alimentaire France SAS Eurofins Microbiologie France Holding SAS FR 100.00% 12/14 SCI Vennecy Les Esses Galerne Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 11/14 Eurofins Product Testing France Holding SAS Eurofins Product Testing LUX Holding S.\u00e0 r.l. FR 100.00% 12/14 Eurofins Analyses Pour Le B\u00e2timent Nord-Ouest Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 04/15 CEBAT SAS SAS Eurofins Evic Product Testing France SAS Eurofins Product Testing France Holding SAS FR 100.00% 07/15 Eurofins Hygi\u00e8ne Hospitali\u00e8re Sud SAS Eurofins Expertises France Holding SAS FR 100.00% 07/15 Eurofins Environment Testing France Australia Holding Eurofins Environment Testing LUX Holding S.\u00e0 r.l. FR 100.00% 06/15 SAS Eurofins Biologie M\u00e9dicale Holding France SAS Eurofins Clinical Testing Services France LUX Holding FR 100.00% 07/15 S.\u00e0 r.l. Eurofins Labazur Provence SELAS Eurofins Laboratorio Sarr\u00f3, S.L.U. FR 100.00% 07/15 Eurofins Labazur Guyane SELAS Eurofins Labazur Provence SELAS FR 100.00% 07/15 Eurofins Labazur Nice SELAS Eurofins Labazur Provence SELAS FR 100.00% 07/15 Eurofins Labazur Rhone-Alpes SELAS Eurofins Labazur Provence SELAS FR 100.00% 07/15 Eurofins Labazur Bretagne SELAS Eurofins Labazur Provence SELAS FR 100.00% 07/15 Eurofins Labazur Alpes-Sud Var SELAS Eurofins Labazur Provence SELAS FR 100.00% 07/15 France Anapath Holding SAS Eurofins Clinical Testing Services France LUX Holding FR 100.00% 07/15 S.\u00e0 r.l. Eurofins Galys SAS Eurofins Food Chemistry Testing France LUX Holding FR 100.00% 12/15 S.\u00e0 r.l. Eurofins Hydrologie Sud Ouest SAS Eurofins Hydrologie France Holding SAS FR 100.00% 11/15 Biomnis Empreintes Genetiques SAS Eurofins Forensics LUX Holding S.\u00e0 r.l. FR 100.00% 10/15 Eurofins Hydrobiologie France SAS Eurofins Expertises France Holding SAS FR 100.00% 10/15 Eurofins Biologie Sp\u00e9cialis\u00e9e France SAS Eurofins Clinical Testing Services France LUX Holding FR 100.00% 10/15 S.\u00e0 r.l. % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Biomnis Sample Library SAS Eurofins Biologie Sp\u00e9cialis\u00e9e France SAS FR 100.00% 10/15 SCI du Val d'Ouest Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 10/15 Eurofins Biomnis SELAS Eurofins Biomnis Ireland Limited FR 100.00% 10/15 Eurofins CBM69 SELAS Eurofins Labazur Provence SELAS FR 100.00% 10/15 Eurofins CEF SELAS Eurofins Labazur Provence SELAS FR 100.00% 10/15 Eurofins Bioffice SELAS Eurofins Labazur Provence SELAS FR 100.00% 10/15 Biosphere GIE Eurofins Biomnis SELAS FR 100.00% 10/15 Eurofins Biotech Germande SAS Eurofins Hydrologie France Holding SAS FR 100.00% 01/16 Eurofins Phyliae SAS Eurofins Agrosciences Services France Holding SAS FR 100.00% 11/15 Sci Garlin Bearn Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/15 Eurofins Agro-Analyses SAS Eurofins Microbiologie France Holding SAS FR 100.00% 05/16 Eurofins LCDI SAS Eurofins Hydrologie France Holding SAS FR 100.00% 07/16 SCI Lentilly Aqueduc Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 11/16 Eurofins Pathologie SELAS Eurofins Histolog, S.L.U. FR 100.00% 04/17 Eurofins NDSC Alimentaire France SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 08/17 Eurofins NDSC Chimie Alimentaire France SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 08/17 Eurofins Biologie Moleculaire France SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 08/17 Eurofins Laboratoire Nutrition Animale France SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 08/17 SAM Sensory International France SAS Eurofins Sensory Holding France SAS FR 100.00% 08/17 Eurofins Expertises France Holding SAS Eurofins Analyses Environnementales pour les FR 100.00% 09/17 Industriels France LUX Holding S.\u00e0 r.l. Eurofins Amatsigroup SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 09/17 Scientific Services France Holding SAS Immobiliere Amatsi SAS Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 09/17 Eurofins Disposable Lab SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 09/17 Scientific Services France Holding SAS Eurofins Amatsiaquitaine SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 09/17 Scientific Services France Holding SAS Eurofins Anapath France Holding SAS Eurofins Clinical Testing Services France LUX Holding FR 100.00% 09/17 S.\u00e0 r.l. Eurofins NDSC Pollution France SAS Eurofins Analyses Environnementales Pour Les FR 100.00% 09/17 Industriels France SAS Eurofins Agroscience Services Seeds France SAS Eurofins Agrosciences Services France Holding SAS FR 100.00% 09/17 SAM Retail France SAS Eurofins Sensory Holding France SAS FR 100.00% 09/17 Eurofins NSC Clinical Diagnostics France GIE Eurofins Biomnis SELAS FR 100.00% 11/17 Eurofins Agroscience Services Regulatory France SAS Eurofins Agrosciences Services France Holding SAS FR 100.00% 10/17 Eurofins Amatsi Analytics SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 10/17 Scientific Services France Holding SAS Eurofins Product Testing 2 France Holding SAS Eurofins Product Testing LUX Holding S.\u00e0 r.l. FR 100.00% 10/17 Eurofins Biologie Medicale Sud-Ouest SAS Eurofins Clinical Testing Services France LUX Holding FR 100.00% 10/18 S.\u00e0 r.l. Eurofins EAG Materials Science France SAS Eurofins EAG Materials Science, LLC FR 100.00% 12/17 Eurofins Eichrom Amiante SAS Eurofins Analyses Pour Le Batiment France Holding FR 100.00% 04/18 SAS Eurofins Eichrom Radioactivite SAS Eurofins Expertises France Holding SAS FR 100.00% 04/18 SCI Bruz Bastie Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 04/18 Eurofins LEA SAS Eurofins Hydrologie France Holding SAS FR 100.00% 04/18 Eurofins Lanagram SAS Eurofins Microbiologie France Holding SAS FR 100.00% 04/18 Eurofins Bactup SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 05/18 Scientific Services France Holding SAS % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins 3 Ohms SAS Eurofins Product Testing France Holding SAS FR 100.00% 07/18 Eurofins Interlab SELAS Eurofins Labazur Provence SELAS FR 100.00% 10/18 SCI Rosporden Renan Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 10/18 Eurofins Bio Lab Eurofins Labazur Provence SELAS FR 100.00% 07/18 Eurofins Biologie Medicale Ile De France SAS Eurofins Clinical Testing Services France LUX Holding FR 100.00% 07/18 S.\u00e0 r.l. Eurofins Laboratoire De Bromatologie Ouest Et Eurofins Microbiologie France Holding SAS FR 100.00% 07/18 Bretagne SAS Eurofins Hydrologie Normandie SAS Eurofins Hydrologie France Holding SAS FR 100.00% 12/18 Eurofins Pr\u00e9l\u00e8vement pour le B\u00e2timent Nord Est SAS Eurofins Prelevement Pour Le Batiment France Holding FR 100.00% 12/18 SAS Alpa Environnement Holding France SAS Eurofins Water Testing LUX S.\u00e0 r.l. FR 100.00% 12/18 SCI Lentilly Parc d'Activit\u00e9 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 Eurofins DSC Product Testing SAS Eurofins Product Testing LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 Eurofins NDSC Audit Et Consulting France SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 12/18 SCI 2 Laponie Les Ulis Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 SCI Landerneau L\u00e9on Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 SCI Loos Palissy Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 SCI Martillac Newton Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 SCI Maxeville Cuenot Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 SCI Saint Augustin Paillard Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 SCI Saint Gely Vautes Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 Eurofins Expertise Microbiologique France SAS Eurofins Expertises France Holding SAS FR 100.00% 12/18 Eurofins Dispositifs au Contact de l'Eau France SAS Eurofins Expertises France Holding SAS FR 100.00% 12/18 SCI Idron Mazerolles Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/18 Eurofins Laboratoire Dermscan SAS Eurofins Product Testing 2 France Holding SAS FR 100.00% 11/18 Alpa Alimentaire Holding France SAS Eurofins Water Testing LUX S.\u00e0 r.l. FR 100.00% 11/18 Eurofins Chimie Alimentaire Rouen SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 11/18 Eurofins Sensory Holding France SAS Eurofins Sensory, Consumer research and Product FR 100.00% 01/19 design LUX Holding S.\u00e0 r.l. Eurofins Alpabio SAS Alpa Environnement Holding France SAS FR 100.00% 12/18 Eurofins DiscoverX Products France SAS Eurofins Discovery Services LUX Holding S.\u00e0 r.l. FR 100.00% 03/19 Eurofins NDSC Expertises France SAS Eurofins Expertises France Holding SAS FR 100.00% 01/19 Eurofins Analyses de l'Air SAS Eurofins Analyses Environnementales Pour Les FR 100.00% 02/19 Industriels France SAS Eurofins Clinical Trial Supplies France SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 02/19 Scientific Services France Holding SAS Eurofins Analyses Nutritionnelles France SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 02/19 Eurofins Laboratoire de Microbiologie Sud SAS Eurofins Microbiologie France Holding SAS FR 100.00% 02/19 Eurofins Assurance France SAS Eurofins Assurance and Inspection Services France FR 100.00% 12/19 Holding SAS Eurofins Laboratoire Microbiologie Rh\u00f4ne-Alpes SAS Eurofins Microbiologie France Holding SAS FR 100.00% 12/19 Eurofins GeneScan Technologies France SAS Gold Standard Diagnostics France Holding SAS FR 100.00% 12/19 Eurofins Hygi\u00e8ne Hospitali\u00e8re Nord SAS Eurofins Expertises France Holding SAS FR 100.00% 12/19 Eurofins BioPharma Product Testing Biologics SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 12/19 Scientific Services France Holding SAS Eurofins Microbiologie des Eaux Ouest SAS Eurofins Microbiologie France Holding SAS FR 100.00% 12/19 Eurofins Hygi\u00e8ne Alimentaire Nord-Ouest SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 01/20 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Hygi\u00e8ne Alimentaire Sud-Est SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 01/20 Eurofins Hygi\u00e8ne Alimentaire Nord-Est SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 01/20 Eurofins Hygi\u00e8ne Alimentaire SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 01/20 Eurofins Hygi\u00e8ne Alimentaire Ile de France SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 01/20 Eurofins Hygi\u00e8ne Alimentaire Sud-Ouest SAS Eurofins Hygi\u00e8ne Alimentaire France Holding FR 100.00% 01/20 Eurofins Labazur Pays De La Loire SELAS Eurofins Biologie M\u00e9dicale Holding France SAS FR 100.00% 11/20 Gold Standard Diagnostics Millidrop SAS Gold Standard Diagnostics France Holding SAS FR 100.00% 11/21 Gold Standard Diagnostics France Holding SAS Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. FR 100.00% 12/20 Eurofins Electrical and Electronics France SAS Eurofins Product Testing France Holding SAS FR 100.00% 12/20 Eurofins Hygi\u00e8ne Alimentaire France Holding Eurofins Hygi\u00e8ne Alimentaire France LUX Holding S.\u00e0 FR 100.00% 12/20 r.l. Eurofins Assurance and Inspection Services France Eurofins Assurance LUX Holding S.\u00e0 r.l. FR 100.00% 12/20 Holding SAS SCI Verneuil Papin Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/20 SCI Venissieux Docteur Georges Levy Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/20 SCI Pleyben Carn Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/20 SCI Villejust Zephyr Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/20 SCI Eurofins 2021 5 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/20 Eurofins IESPM SAS Eurofins Expertises France Holding SAS FR 100.00% 07/21 Eurofins BioMed Ouest Guyane SAS Eurofins Biologie M\u00e9dicale Holding France SAS FR 100.00% 10/21 SCI Eurofins 2022 1 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/21 SCI Saint Maximin Laouve Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/21 SCI Eurofins BioMed France Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/21 SCI Management BioMed France Eurofins Real Estate France Holding SAS FR 100.00% 12/21 SCI EUROFINS 2022 5 Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 12/21 Eurofins Toxicological and Regulatory Expertise C&PC Eurofins Product Testing France Holding SAS FR 100.00% 11/21 France SAS Eurofins Medical Device Testing France SAS Eurofins BioPharma Product Testing & Professional FR 100.00% 11/21 Scientific Services France Holding SAS Eurofins Product Testing clinical and ex-vivo France Eurofins Product Testing France Holding SAS FR 60.20% 11/21 Holding SAS Eurofins Real Estate France Holding SAS Eurofins Real Estate LUX Holding S.\u00e0 r.l. FR 100.00% 11/21 Eurofins Environnement Formation et Conseil SAS Eurofins Hygi\u00e8ne Hospitali\u00e8re France Holding SAS FR 100.00% 11/21 Eurofins Hygi\u00e8ne Hospitali\u00e8re France Holding SAS Eurofins Hydrologie France LUX Holding S.\u00e0 r.l. FR 100.00% 11/21 Eurofins NBLSC Hygi\u00e8ne Hospitali\u00e8re France SAS Eurofins Hygi\u00e8ne Hospitali\u00e8re France Holding SAS FR 100.00% 11/21 Eurofins Discovery, Central Laboratory and BioAnalysis Eurofins Discovery Services LUX Holding S.\u00e0 r.l. FR 100.00% 11/21 France Holding SAS Eurofins Laboratoire Distribution Alimentaire SAS Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 11/21 Eurofins NewCo Fractale 2 Eurofins Food Chemistry Testing France Holding SAS FR 100.00% 11/21 Eurofins Croatiakontrola d.o.o. Eurofins Croatia Food Testing HoldCo d.o.o. HR 99.21% 09/19 Karlovacka Real Estate d.o.o Eurofins Real Estate LUX Holding S.\u00e0 r.l. HR 100.00% 09/19 Eurofins Croatia Food Testing HoldCo d.o.o. Eurofins Food Testing LUX Holding S.\u00e0 r.l. HR 100.00% 03/20 Eurofins Agroscience Services Kft. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. HU 100.00% 09/07 Eurofins NBLSC Food&Feed Testing Hungary Kft. Eurofins Food Testing Hungary Holding Kft. HU 100.00% 08/16 Eurofins Technologies Hungary Kft. Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. HU 100.00% 05/17 Eurofins Food Testing Hungary Holding Kft. Eurofins Food Testing LUX Holding S.\u00e0 r.l. HU 100.00% 10/17 Gyula Henyei 5 utca Real Estate Kft. Eurofins Real Estate LUX Holding S.\u00e0 r.l. HU 100.00% 10/17 % of Date ISO interest Company Subsidiary of: of code by the entry Group Gyula Henyei Mikl\u00f3s utca 52 Real Estate Kft. Eurofins Real Estate LUX Holding S.\u00e0 r.l. HU 100.00% 11/17 SZE Kesely\u0171si 9 Real Estate Kft. Eurofins Real Estate LUX Holding S.\u00e0 r.l. HU 100.00% 11/17 Eurofins Minerag Kft. Eurofins Food Testing Hungary Holding Kft. HU 100.00% 12/17 Eurofins Food Analytica Kft. Eurofins Food Testing Hungary Holding Kft. HU 100.00% 01/18 Eurofins Environment Testing Hungary Holding Kft. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. HU 100.00% 07/18 BUD Foti 56 Real Estate Kft. Eurofins Real Estate LUX Holding S.\u00e0 r.l. HU 100.00% 08/18 Eurofins Clinical Testing Hungary Holding Kft. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. HU 100.00% 08/18 Eurofins NSC Hungary Kft. Eurofins Support Services LUX Holding S.\u00e0 r.l. HU 100.00% 09/18 Eurofins KVI-PLUSZ K\u00f6rnyezetv\u00e9delmi Vizsg\u00e1l\u00f3 Iroda Eurofins Environment Testing Hungary Holding Kft. HU 100.00% 07/18 Kft. Gold Standard Diagnostics International Kft. Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. HU 100.00% 06/20 Eurofins Vetcontrol Kft. Eurofins Food Testing Hungary Holding Kft. HU 100.00% 10/20 Eurofins BioPharma Product Testing Hungary Kft. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. HU 100.00% 12/21 Eurofins Scientific (Ireland) Limited Eurofins GSC LUX S.\u00e0 r.l. IE 100.00% 05/03 Eurofins Food Testing Ireland Limited Eurofins Food Testing LUX Holding S.\u00e0 r.l. IE 100.00% 04/09 Eurofins BioPharma Product Testing Ireland Holding Eurofins Pharma Services LUX Holding S.\u00e0 r.l. IE 100.00% 02/11 Limited Eurofins BioPharma Product Testing Ireland Limited Eurofins BioPharma Product Testing Ireland Holding IE 100.00% 04/11 Limited Clogherane Real Estate Investment Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. IE 100.00% 11/15 Eurofins Biomnis Ireland Limited Eurofins Biologie Sp\u00e9cialis\u00e9e France SAS IE 100.00% 10/15 Eurofins Lablink Limited Eurofins Biomnis Ireland Limited IE 100.00% 10/15 Eurofins Professional Scientific Services Ireland Limited Eurofins BioPharma Product Testing Ireland Holding IE 100.00% 07/16 Limited Medical Consultants Pathology Holdings Limited Eurofins Biomnis Ireland Limited IE 100.00% 01/17 Eurofins MC Pathology Limited Medical Consultants Pathology Holdings Limited IE 100.00% 01/17 Environmental Laboratory Services Limited Eurofins Environment Testing LUX Holding S.\u00e0 r.l. IE 100.00% 07/17 Eurofins Scientific Services Ireland Limited Eurofins GSC LUX S.\u00e0 r.l. IE 100.00% 10/17 Eurofins Environmental Testing Ireland Holding Limited Eurofins Environment Testing LUX Holding S.\u00e0 r.l. IE 100.00% 03/18 Eurofins Environment Testing Ireland Limited Eurofins Environmental Testing Ireland Holding Limited IE 100.00% 02/18 Eurofins Gynae-Screen Limited Eurofins Biomnis Ireland Limited IE 100.00% 05/18 Eurofins NSC Ireland Limited Eurofins Support Services LUX Holding S.\u00e0 r.l. IE 100.00% 01/19 Cork Real Estate Investment Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. IE 100.00% 12/19 Eurofins Genomics India Private Limited Eurofins Genomics LUX Holding S.\u00e0 r.l. IN 100.00% 01/05 Eurofins Analytical Services India Private Limited Eurofins Food Testing LUX Holding S.\u00e0 r.l. IN 100.00% 05/09 Eurofins Pharma Services India Private Limited Eurofins Pharma Services LUX Holding S.\u00e0 r.l. IN 100.00% 01/11 Eurofins IT Solutions India Private Limited Eurofins Support Services LUX Holding S.\u00e0 r.l. IN 100.00% 02/12 Eurofins Resources India Private Limited Eurofins International Holdings LUX S.\u00e0 r.l. IN 100.00% 03/12 Eurofins AgroScience Services Private Limited Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. IN 100.00% 10/13 Eurofins Clinical Diagnostics Bangalore Private Limited Eurofins Genomics LUX Holding S.\u00e0 r.l. IN 100.00% 12/15 Eurofins Product Testing India Private Limited Eurofins Product Testing LUX Holding S.\u00e0 r.l. IN 100.00% 10/16 Eurofins Advinus Private Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. IN 100.00% 10/17 Spectro Analytical Labs Private Limited Eurofins Environment Testing LUX Holding S.\u00e0 r.l. IN 100.00% 11/17 Eurofins NSC India Private Limited Eurofins Support Services LUX Holding S.\u00e0 r.l. IN 100.00% 04/18 Eurofins Advinus AgroSciences Services India Private Eurofins Real Estate LUX Holding S.\u00e0 r.l. IN 100.00% 10/17 Limited % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Amar Immunodiagnostics Private Limited Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. IN 100.00% 12/18 Eurofins Advinus BioPharma Services India Private Eurofins Pharma Services LUX Holding S.\u00e0 r.l. IN 100.00% 12/19 Limited Eurofins Advinus Discovery Services Private Limited Eurofins International Holdings LUX S.\u00e0 r.l. IN 100.00% 10/17 Alexandre Quality Management Private Private Limited AQM HK Co., Ltd. IN 100.00% 06/19 Eurofins BPO (India) Private Limited Eurofins Support Services LUX Holding S.\u00e0 r.l. IN 100.00% 01/20 Eurofins Assurance India Private Limited Eurofins Assurance LUX Holding S.\u00e0 r.l. IN 100.00% 10/20 Spectro SSA Labs Private Limited Spectro Analytical Labs Private Limited IN 100.00% 10/17 Spectro Research Lab Ventures Private Limited Spectro Analytical Labs Private Limited IN 100.00% 11/17 Spectro Testing Private Limited Spectro Analytical Labs Private Limited IN 100.00% 11/17 Eurofins AME IT Services Private Limited Eurofins Support Services LUX Holding S.\u00e0 r.l. IN 100.00% 05/21 Eurofins BioPharma Product Testing India Private Eurofins Pharma Services LUX Holding S.\u00e0 r.l. IN 100.00% 07/21 Limited Modern Testing Services (India) Private Limited Eurofins Product Testing LUX Holding S.\u00e0 r.l. IN 100.00% 11/21 Eurofins Agroscience Services Italy Srl Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. IT 100.00% 02/04 Eurofins Food & Feed Testing Italia Holding Srl Eurofins Food Testing LUX Holding S.\u00e0 r.l. IT 100.00% 07/06 Eurofins Chemical Control Srl Eurofins Food & Feed Testing Italia Holding Srl IT 100.00% 09/06 Eurofins Biolab Srl Eurofins Pharma Services Italia Holding Srl IT 100.00% 01/07 Eurofins Product Testing Italy Srl Eurofins Product Testing Italia Holding Srl IT 100.00% 10/08 Eurofins NSC Italia Srl Eurofins Support Services LUX Holding S.\u00e0 r.l. IT 100.00% 01/12 Eurofins Product Testing Italia Holding Srl Eurofins Product Testing LUX Holding S.\u00e0 r.l. IT 100.00% 10/12 Eurofins Clinical Testing Italia Holding Srl Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. IT 100.00% 10/12 Eurofins Genomics Italy Srl Eurofins Genomics LUX Holding S.\u00e0 r.l. IT 100.00% 09/12 Eurofins Pivetti Srl Eurofins Food & Feed Testing Italia Holding Srl IT 100.00% 11/12 Eurofins Pharma Services Italia Holding Srl Eurofins Pharma Services LUX Holding S.\u00e0 r.l. IT 100.00% 01/13 Eurofins Modulo Uno Srl Eurofins Product Testing Italia Holding Srl IT 100.00% 07/12 Padova Via Austria Real Estate Invest Srl Eurofins Real Estate LUX Holding S.\u00e0 r.l. IT 100.00% 04/14 Torino Via Cuorgn\u00e8 Real Estate Invest Srl Eurofins Real Estate LUX Holding S.\u00e0 r.l. IT 100.00% 03/15 Eurofins Cosmetics & Personal Care Italy Srl Eurofins Product Testing Italia Holding Srl IT 100.00% 07/15 Eurofins Food Assurance Italia Srl Eurofins Assurance LUX Holding S.\u00e0 r.l. IT 100.00% 09/15 Gold Standard Diagnostics Trieste Srl Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. IT 100.00% 06/16 Eurofins Professional Scientific Services Italy Srl Eurofins Pharma Services Italia Holding Srl IT 100.00% 12/16 Eurofins Genoma Group Srl Eurofins Clinical Testing Italia Holding Srl IT 100.00% 07/17 SAM Sensory and Marketing Italy srl Eurofins Sensory, Consumer research and Product IT 100.00% 11/18 design LUX Holding S.\u00e0 r.l. Eurofins NDSC Food Testing Italy Srl Eurofins Food & Feed Testing Italia Holding Srl IT 100.00% 02/19 Vimodrone Via Buozzi Real Estate Srl Eurofins Real Estate LUX Holding S.\u00e0 r.l. IT 100.00% 08/19 Eurofins Lab Solution Srl Eurofins Product Testing Italia Holding Srl IT 100.00% 06/19 Milano Fino Mornasco Via Tevere Real Estate Srl Eurofins Real Estate LUX Holding S.\u00e0 r.l. IT 100.00% 11/19 Cucciago Via Volta Real Estate Srl Eurofins Real Estate LUX Holding S.\u00e0 r.l. IT 100.00% 11/19 Cuneo Via Celdit Real Estate Srl Eurofins Real Estate LUX Holding S.\u00e0 r.l. IT 100.00% 03/20 Eurofins Safer@work Italy Srl Eurofins Clinical Testing Italia Holding Srl IT 100.00% 05/21 Eurofins NSC Japan KK Eurofins Support Services LUX Holding S.\u00e0 r.l. JP 100.00% 03/06 Eurofins Genomics KK Eurofins Genomic Services Japan Holding KK JP 100.00% 12/07 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Product Testing Japan KK Eurofins Food Testing LUX Holding S.\u00e0 r.l. JP 100.00% 01/09 Eurofins DNA Synthesis KK Eurofins Genomics LUX Holding S.\u00e0 r.l. JP 66.00% 07/11 Eurofins Nihon Kankyo KK Eurofins Environment Testing Japan Holding Co., Ltd. JP 100.00% 04/12 Eurofins Nihon Soken KK Eurofins Environment Testing Japan Holding Co., Ltd. JP 100.00% 07/15 Eurofins Clinical Genetics KK Eurofins Genomics KK JP 100.00% 12/15 Eurofins NBLSC Environment Testing Japan KK Eurofins Environment Testing Japan Holding Co., Ltd. JP 100.00% 04/16 Eurofins Japan Analytical Chemistry Consultants Co., Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. JP 100.00% 08/17 Ltd. Eurofins EAG Materials Science Tokyo Corporation KK Eurofins EAG Materials Science, LLC JP 100.00% 12/17 Saitama Kankyo Service KK Eurofins Environment Testing Japan Holding Co., Ltd. JP 67.00% 12/17 Eurofins BioPharma Services Japan Holding KK Eurofins Pharma Services LUX Holding S.\u00e0 r.l. JP 100.00% 09/18 Eurofins Analytical Science Laboratories KK Eurofins BioPharma Services Japan Holding KK JP 100.00% 11/18 Eurofins Taiyo Techno Research KK Eurofins Environment Testing Japan Holding Co., Ltd. JP 100.00% 12/20 Eurofins Environment Testing Japan Holding Co., Ltd. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. JP 100.00% 09/20 Eurofins Earth Consul KK Eurofins Environment Testing Japan Holding Co., Ltd. JP 100.00% 12/20 Eurofins GeneTech KK Eurofins Clinical Testing Japan Holding Ltd. JP 100.00% 09/20 Eurofins EAG Materials Science Japan Holding KK Eurofins Material Sciences LUX Holding S.\u00e0 r.l. JP 100.00% 05/21 Eurofins Food Testing Japan KK Eurofins Food Testing LUX Holding S.\u00e0 r.l. JP 100.00% 08/21 Eurofins FQL Ltd. Eurofins EAG Materials Science Japan Holding KK JP 100.00% 07/21 AQM (Cambodia) Limited AQM HK Co., Ltd. KH 100.00% 06/19 Eurofins MTS Consumer Product Testing (Cambodia) Eurofins Product Testing LUX Holding S.\u00e0 r.l. KH 100.00% 11/21 Co., Ltd. Eurofins MET Korea Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. KR 100.00% 01/18 Eurofins Korea Analytic Service Co., Ltd. Eurofins Food and Environment Testing Korea Holding KR 100.00% 04/18 Co., Ltd. Eurofins Food and Environment Testing Korea Holding Eurofins Environment Testing LUX Holding S.\u00e0 r.l. KR 100.00% 07/20 Co., Ltd. Eurofins Woosol Co., Ltd. Eurofins Food and Environment Testing Korea Holding KR 100.00% 10/20 Co., Ltd. Eurofins EAG Materials Science Korea Co., Ltd. Eurofins Material Sciences LUX Holding S.\u00e0 r.l. KR 100.00% 10/21 Eurofins Product Testing Korea Holding Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. KR 100.00% 08/21 Eurofins KCTL Co., Ltd. Eurofins Product Testing Korea Holding Co., Ltd. KR 100.00% 10/21 Modern Testing Services Lanka Private Limited Eurofins Product Testing LUX Holding S.\u00e0 r.l. LK 100.00% 11/21 Eurofins Labtarna Lietuva UAB Eurofins Food Testing LUX Holding S.\u00e0 r.l. LT 100.00% 11/17 Eurofins Food Testing LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 12/06 Eurofins Environment Testing LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 12/06 Eurofins Pharma Services LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 12/06 Eurofins GSC LUX S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 10/06 Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 07/07 Eurofins Product Testing LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 04/08 Eurofins Real Estate LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 05/10 Eurofins Genomics LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 07/10 Eurofins Forensics LUX Holding S.\u00e0 r.l. Eurofins Scientific SE (French Branch) LU 100.00% 07/10 Eurofins Industrial Testing LUX S.\u00e0 r.l. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. LU 100.00% 09/10 Eurofins International Holdings LUX S.\u00e0 r.l. Eurofins Scientific SE LU 100.00% 12/10 Eurofins Water Testing LUX S.\u00e0 r.l. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. LU 100.00% 10/11 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Pharma Services France LUX Holding S.\u00e0 r.l. Eurofins Scientific SE (French Branch) LU 100.00% 12/11 Eurofins Food Chemistry Testing France LUX Holding Eurofins Scientific SE (French Branch) LU 100.00% 12/11 S.\u00e0 r.l. Eurofins Hygi\u00e8ne Alimentaire France LUX Holding S.\u00e0 Eurofins Scientific SE (French Branch) LU 100.00% 12/11 r.l. Eurofins Analyses pour la Construction France LUX Eurofins Scientific SE (French Branch) LU 100.00% 12/11 Holding S.\u00e0 r.l. Eurofins Analyses pour lEnvironnement France LUX Eurofins Scientific SE (French Branch) LU 100.00% 12/11 Holding S.\u00e0 r.l. Eurofins Analyses Environnementales pour les Eurofins Scientific SE (French Branch) LU 100.00% 12/11 Industriels France LUX Holding S.\u00e0 r.l. Eurofins Hydrologie France LUX Holding S.\u00e0 r.l. Eurofins Scientific SE (French Branch) LU 100.00% 12/11 Eurofins Discovery Services LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 11/12 Eurofins International Support Services LUX S.\u00e0 r.l. Eurofins Scientific SE LU 100.00% 11/12 Eurofins Special Nutrition Testing LUX Holding S.\u00e0 r.l. Eurofins Food Testing LUX Holding S.\u00e0 r.l. LU 100.00% 12/12 Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 11/14 Eurofins Clinical Testing Services France LUX Holding Eurofins Scientific SE (French Branch) LU 100.00% 05/15 S.\u00e0 r.l. Eurofins Air Monitoring LUX Holding S.\u00e0 r.l. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. LU 100.00% 02/16 Eurofins Support Services LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 04/16 Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 05/16 Eurofins Re LUX SA Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 09/17 Alpha Services LUX SA Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 12/17 Eurofins Material Sciences LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 05/18 Eurofins Sensory, Consumer research and Product Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 06/18 design LUX Holding S.\u00e0 r.l. Eurofins Assurance LUX Holding S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 05/20 Eurofins Clinical Testing Services Germany LUX Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 12/20 Holding S.\u00e0 r.l. Eurofins Central Lab Holdings LUX S.\u00e0 r.l. Eurofins International Holdings LUX S.\u00e0 r.l. LU 100.00% 12/20 Eurofins Finance Luxembourg S.\u00e0 r.l. Eurofins Scientific SE LU 100.00% 06/19 Eurofins Agroscience Services Maroc S.\u00e0 r.l Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. MA 98.20% 06/18 Eurofins Sam Sensory & Marketing Morocco S.\u00e0 r.l Eurofins Sensory, Consumer research and Product MA 100.00% 10/18 design LUX Holding S.\u00e0 r.l. Eurofins Biomnis Maroc S.\u00e0 r.l. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. MA 100.00% 12/19 Eurofins Assurance Myanmar Ltd. Eurofins Assurance LUX Holding S.\u00e0 r.l. MM 100.00% 06/19 Insight Technologies Ltd. Eurofins Laboratoire Dermscan SAS MU 100.00% 11/18 Eurofins NM Laboratory Sdn Bhd Eurofins Environment Testing LUX Holding S.\u00e0 r.l. MY 100.00% 11/15 Eurofins North Malaya Laboratory Sdn Bhd Eurofins Environment Testing LUX Holding S.\u00e0 r.l. MY 100.00% 11/15 Eurofins GSC IT Malaysia Sdn. Bhd Eurofins Support Services LUX Holding S.\u00e0 r.l. MY 100.00% 01/19 Eurofins Food Testing Malaysia Sdn Bhd Eurofins Food Testing LUX Holding S.\u00e0 r.l. MY 100.00% 05/19 Eurofins Environment Testing Netherlands Holding BV Eurofins Environment Testing LUX Holding S.\u00e0 r.l. NL 100.00% 04/01 Eurofins Food Testing Netherlands BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 10/00 Eurofins Analytico BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 04/01 Eurofins Central Laboratory BV Eurofins Pharma Services LUX Holding S.\u00e0 r.l. NL 100.00% 04/01 Eurofins Genomics BV Eurofins Scientific SE NL 100.00% 06/06 Eurofins C-Mark BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 03/11 Eurofins NSC Netherlands BV Eurofins Support Services LUX Holding S.\u00e0 r.l. NL 100.00% 05/11 Eurofins Food Testing Netherlands Holding BV Eurofins Food Testing LUX Holding S.\u00e0 r.l. NL 100.00% 05/11 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Food Testing Rotterdam BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 03/12 Zandbergsestraat Graauw RE Invest BV Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 01/13 Eurofins Lab Zeeuws-Vlaanderen (LZV) BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 01/13 Eurofins Logistics Benelux BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 04/13 Eurofins MITOX BV Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. NL 100.00% 07/13 Eurofins Agro Testing Netherlands Holding BV Eurofins Food Testing LUX Holding S.\u00e0 r.l. NL 100.00% 07/13 Eurofins Agro Testing Wageningen BV Eurofins Agro Testing Netherlands Holding BV NL 100.00% 07/13 Eurofins KBBL BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 01/14 Eurofins Food Safety Solutions BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 02/14 Eurofins Omegam BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 01/14 Duivendrecht Real Estate Invest BV Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 07/14 Eurofins Professional Scientific Services Netherlands Eurofins Pharma Services LUX Holding S.\u00e0 r.l. NL 100.00% 09/14 BV Eurofins NDSC Environment Testing Benelux BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 09/14 Eurofins De Bredelaar BV Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. NL 100.00% 07/15 Nieuw Biesterveld BV Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 07/15 Eurofins BioPharma Product Testing Netherlands Eurofins Pharma Services LUX Holding S.\u00e0 r.l. NL 100.00% 01/16 Holding BV Eurofins Bactimm BV Eurofins BioPharma Product Testing Netherlands NL 100.00% 01/16 Holding BV Eurofins PROXY Laboratories BV Eurofins BioPharma Product Testing Netherlands NL 100.00% 01/16 Holding BV Eurofins Spinnovation Analytical BV Eurofins BioPharma Product Testing Netherlands NL 100.00% 01/16 Holding BV Eurofins Bureau de Wit BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 06/16 Barneveld Gildeweg Real Estate BV Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 08/16 Eurofins Survey Netherlands BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 06/17 Heerenveen Hermes Icarus Real Estate BV Eurofins Real Estate LUX Holding S.\u00e0 r.l. NL 100.00% 09/17 Eurofins Sanitas Inspections BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 11/17 Sanitas Milieukundig Adviesbureau BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 11/17 Eurofins Sanitas Testing BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 11/17 Eurofins Clinical Diagnostics Netherlands Holding BV Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. NL 100.00% 03/18 Eurofins Nederlands Moleculair Diagnostisch Eurofins Clinical Diagnostics Netherlands Holding BV NL 100.00% 03/18 Laboratorium BV Eurofins LCPL BV Eurofins Clinical Diagnostics Netherlands Holding BV NL 100.00% 03/18 Eurofins EAG Materials Science Netherlands BV Eurofins Material Sciences LUX Holding S.\u00e0 r.l. NL 100.00% 12/18 ACMAA Groep BV Eurofins Environment Testing Netherlands Holding BV NL 100.00% 07/18 ACMAA Inspectie BV ACMAA Groep BV NL 100.00% 07/18 ACMAA Laboratoria BV ACMAA Groep BV NL 100.00% 07/18 Eurofins Salux BV Eurofins Clinical Diagnostics Netherlands Holding BV NL 100.00% 05/19 The Maastricht Forensic Institute BV Eurofins Forensics LUX Holding S.\u00e0 r.l. NL 100.00% 12/19 Eurofins Bacteriologisch Adviesburo BV Eurofins Food Testing Netherlands Holding BV NL 100.00% 10/20 Eurofins Medische Microbiologie BV Eurofins Clinical Diagnostics Netherlands Holding BV NL 100.00% 01/21 Eurofins EAG Materials and Engineering Science Eurofins Material Sciences LUX Holding S.\u00e0 r.l. NL 100.00% 06/21 Netherlands Holdings BV Eurofins PAMM BV Eurofins Clinical Diagnostics Netherlands Holding BV NL 100.00% 10/21 Certification Limited company BV Eurofins E&E CML Limited NL 100.00% 02/19 DNA Consolidated BV DDC Worldwide Ltd. NL 100.00% 08/21 % of Date ISO interest Company Subsidiary of: of code by the entry Group NorthSea Marketing BV DNA Consolidated BV NL 100.00% 08/21 Eurofins Maser BV Eurofins EAG Materials and Engineering Science NL 90.02% 10/21 Netherlands Holdings BV Eurofins Environment Testing Norway AS Eurofins Environment Testing Norway Holding AS NO 100.00% 05/06 Eurofins Environment Testing Norway Holding AS Eurofins Environment Testing LUX Holding S.\u00e0 r.l. NO 100.00% 09/07 Eurofins Food & Feed Testing Norway AS Eurofins Food Testing Norway Holding AS NO 100.00% 09/07 Eurofins Food Testing Norway Holding AS Eurofins Food Testing LUX Holding S.\u00e0 r.l. NO 100.00% 08/07 Eurofins Norge NSC AS Eurofins Support Services LUX Holding S.\u00e0 r.l. NO 100.00% 12/07 Eurofins Agro Testing Norway AS Eurofins Food Testing Norway Holding AS NO 100.00% 08/14 Moss Property Invest AS Eurofins Real Estate LUX Holding S.\u00e0 r.l. NO 100.00% 08/14 Eurofins Radonlab AS Eurofins Environment Testing Norway Holding AS NO 100.00% 12/15 Eurofins Havlandet AS Eurofins Food Testing Norway Holding AS NO 56.50% 02/20 Penrose NZ Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. NZ 100.00% 04/12 Eurofins Food Analytics NZ Limited Eurofins Food Testing LUX Holding S.\u00e0 r.l. NZ 100.00% 06/12 Eurofins ELS Limited Eurofins Australia New Zealand Holding Pty Ltd. NZ 100.00% 11/12 Eurofins Agroscience Services NZ Limited Eurofins Agrosciences Services France Holding SAS NZ 100.00% 07/13 Eurofins Agroscience Testing NZ Limited Eurofins Agrosciences Services France Holding SAS NZ 100.00% 07/13 Eurofins Bay Of Plenty Limited Eurofins Australia New Zealand Holding Pty Ltd. NZ 100.00% 06/16 Eurofins Environment Testing NZ Limited Eurofins Australia New Zealand Holding Pty Ltd. NZ 100.00% 03/17 Eurofins BioPharma Product Testing NZ Limited Eurofins Australia New Zealand Holding Pty Ltd. NZ 100.00% 10/17 Wellington Port Road Real Estate Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. NZ 100.00% 06/18 Eurofins Animal Health New Zealand Limited Eurofins Agroscience Services Pty Ltd. NZ 100.00% 12/18 Eurofins Scientific Services Philippines, Inc. Eurofins Food Testing LUX Holding S.\u00e0 r.l. PH 100.00% 09/19 AQM Pakistan Pvt. Ltd. AQM HK Co., Ltd. PK 100.00% 06/19 Eurofins Agroscience Services Sp. z.o.o. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. PL 100.00% 01/06 Eurofins Polska Sp. z.o.o. Eurofins Food Testing LUX Holding S.\u00e0 r.l. PL 100.00% 07/06 Eurofins Environment Testing Polska Sp. z o.o. Eurofins Industrial Testing LUX S.\u00e0 r.l. PL 100.00% 07/15 Eurofins GSC Poland Sp. z o.o. Eurofins Support Services LUX Holding S.\u00e0 r.l. PL 100.00% 02/16 \u0141\u00f3d\u017a Dubois Real Estate Sp. z o.o. Eurofins Real Estate LUX Holding S.\u00e0 r.l. PL 100.00% 12/18 Eurofins Dermscan Poland Sp. Z.o.o. Eurofins Product Testing LUX Holding S.\u00e0 r.l. PL 100.00% 11/18 Eurofins Business Services Poland Sp. z o.o. Eurofins Support Services LUX Holding S.\u00e0 r.l. PL 100.00% 12/19 Eurofins GSC IT Poland Sp. z o.o. Eurofins Support Services LUX Holding S.\u00e0 r.l. PL 100.00% 12/19 Eurofins NSC Polska Sp. z o.o. Eurofins Support Services LUX Holding S.\u00e0 r.l. PL 100.00% 04/20 Malbork Al. Wojska Polskiego Real Estate sp. z o.o. Eurofins Real Estate LUX Holding S.\u00e0 r.l. PL 100.00% 12/19 Eurofins Environment Testing Poland Holding Sp. z o.o. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. PL 100.00% 07/19 Eurofins OBIK\u015a Polska Sp. z.o.o. Eurofins Environment Testing Poland Holding Sp. z o.o. PL 100.00% 09/19 Eurofins Lab Environment Testing Portugal, Unipessoal Eurofins Industrial Testing LUX S.\u00e0 r.l. PT 100.00% 06/15 Lda. Sobrosa, Ac\u00e1cio J.A. Pereira, Real Estate, Unipessoal, Eurofins Real Estate LUX Holding S.\u00e0 r.l. PT 100.00% 12/18 Lda. Eurofins Food Testing Lisboa, Unipessoal Lda. Eurofins Analisis Alimentario Holding Espana S.L.U. PT 100.00% 06/19 Laborat\u00f3rio de An\u00e1lises Clinicas J. Pinto de Barros, SA Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. PT 100.00% 04/21 Eurofins Agroscience Services Romania SRL Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. RO 100.00% 08/09 Eurofins Evic Product Testing Romania SRL Eurofins Product Testing LUX Holding S.\u00e0 r.l. RO 100.00% 07/15 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Food Testing SRL Eurofins Food & Feed Testing Romania Holding SRL RO 100.00% 11/16 Bucharest Preciziei Real Estate SRL Eurofins Real Estate LUX Holding S.\u00e0 r.l. RO 100.00% 03/17 Eurofins Food & Feed Testing Romania Holding SRL Eurofins Food Testing LUX Holding S.\u00e0 r.l. RO 100.00% 11/17 Eurofins Asbestos Testing Romania SRL Eurofins Industrial Testing LUX S.\u00e0 r.l. RO 100.00% 12/17 Eurofins Food Analytica SRL Eurofins Food & Feed Testing Romania Holding SRL RO 100.00% 01/18 Eurofins Agro Testing Sweden AB Eurofins Food Testing Sweden Holding AB SE 100.00% 01/04 Eurofins Milk Testing Sweden AB Eurofins Food Testing Sweden Holding AB SE 100.00% 07/06 Eurofins Food Testing Sweden Holding AB Eurofins Food Testing LUX Holding S.\u00e0 r.l. SE 100.00% 09/07 Eurofins Environment Testing Sweden AB Eurofins Environment Testing Sweden Holding AB SE 100.00% 10/07 Eurofins Environment Testing Sweden Holding AB Eurofins Environment Testing LUX Holding S.\u00e0 r.l. SE 100.00% 09/07 Eurofins Food & Feed Testing Sweden AB Eurofins Food Testing Sweden Holding AB SE 100.00% 10/07 Eurofins NSC Sweden AB Eurofins Support Services LUX Holding S.\u00e0 r.l. SE 100.00% 01/08 Eurofins Biopharma Product Testing Sweden AB Eurofins Pharma Services LUX Holding S.\u00e0 r.l. SE 100.00% 04/11 Eurofins Pegasuslab AB Eurofins Environment Testing Sweden Holding AB SE 100.00% 06/12 Uppsala Property Invest AB Eurofins Real Estate LUX Holding S.\u00e0 r.l. SE 100.00% 03/14 Eurofins Radon Testing Sweden AB Eurofins Environment Testing Sweden Holding AB SE 100.00% 09/16 Eurofins Water Testing Sweden AB Eurofins Environment Testing Sweden Holding AB SE 100.00% 08/17 Eurofins Genomics Sweden AB Eurofins Genomics Europe Sequencing GmbH SE 100.00% 07/17 Lidk\u00f6ping Sj\u00f6hagsgatan Real Estate AB Eurofins Real Estate LUX Holding S.\u00e0 r.l. SE 100.00% 12/17 Eurofins Biofuel & Energy Testing Sweden AB Eurofins Environment Testing Sweden Holding AB SE 100.00% 04/18 Eurofins Clinical Testing Sweden AB Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. SE 100.00% 03/21 Eurofins Central Laboratory Pte. Ltd. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. SG 100.00% 12/06 Gold Standard Diagnostics Singapore Pte. Ltd. Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. SG 100.00% 12/15 Eurofins Mechem Pte. Ltd. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. SG 100.00% 03/17 Eurofins EAG Materials Science Singapore, Pte. Ltd. Eurofins Material Sciences LUX Holding S.\u00e0 r.l. SG 100.00% 12/17 Eurofins Food Testing Singapore Pte. Ltd Eurofins Food Testing LUX Holding S.\u00e0 r.l. SG 100.00% 08/18 Eurofins Clinical Diagnostics Pte. Ltd. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. SG 100.00% 08/19 Eurofins Holding za okoljske raziskave d.o.o. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. SI 100.00% 06/17 Velenje nepremi\u010dnine d.o.o., poslovanje z Eurofins Real Estate LUX Holding S.\u00e0 r.l. SI 100.00% 07/17 nepremi\u010dninami Eurofins ERICo Slovenia d.o.o. Eurofins Holding za okoljske raziskave d.o.o. SI 100.00% 07/17 Eurofins Bel/Novamann s.r.o. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. SK 100.00% 10/07 Eurofins NSC Central and Eastern Europe s.r.o. Eurofins Support Services LUX Holding S.\u00e0 r.l. SK 100.00% 06/15 Nov\u00e9 Z\u00e1mky Komjatick\u00e1 Real Estate s.r.o. Eurofins Real Estate LUX Holding S.\u00e0 r.l. SK 100.00% 10/16 Eurofins Food & Feed Testing Slovakia Holding s.r.o. Eurofins Food Testing LUX Holding S.\u00e0 r.l. SK 100.00% 08/19 Eurofins Food Testing Slovakia s.r.o Eurofins Food & Feed Testing Slovakia Holding s.r.o. SK 100.00% 10/19 Eurofins Environment Testing Holding Slovakia s.r.o. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. SK 100.00% 07/20 Tur\u010dianske Teplice Robotn\u00edcka Real Estate s.r.o. Eurofins Real Estate LUX Holding S.\u00e0 r.l. SK 100.00% 11/20 Eurofins Environment Testing Slovakia s.r.o. Eurofins Environment Testing Holding Slovakia s.r.o. SK 100.00% 11/20 Eurofins RBLSC IT CEE s.r.o. Eurofins Food Testing LUX Holding S.\u00e0 r.l. SK 100.00% 04/21 Eurofins Product Service (Thailand) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. TH 100.00% 07/08 Eurofins Agroscience Services Thailand Co., Ltd. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. TH 100.00% 05/16 Eurofins Food Testing (Thailand) Co., Ltd. Eurofins International Holdings LUX S.\u00e0 r.l. TH 100.00% 02/20 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Environment Testing Data Services Bangkok TestAmerica Laboratories, Inc. TH 100.00% 11/18 Co., Ltd. EUROFINS DERMSCAN TUNISIE SARL Eurofins Laboratoire Dermscan SAS TN 100.00% 11/18 Eurofins Turkey Analiz Hizmetleri Limited \u015eirketi Eurofins Food Testing LUX Holding S.\u00e0 r.l. TR 100.00% 05/12 Eurofins \u0130stanbul G\u0131da Kontrol Laboratuvarlar\u0131 A.\u015e. Eurofins Food Testing LUX Holding S.\u00e0 r.l. TR 100.00% 03/17 Denet Endustriyel Hizmetler Anonim \u015eirket A.\u015e. Eurofins \u0130stanbul G\u0131da Kontrol Laboratuvarlar\u0131 A.\u015e. TR 100.00% 03/17 Eurofins T\u00fcketici \u00dcr\u00fcnleri Test Hizmetleri A.\u015e Eurofins Product Testing LUX Holding S.\u00e0 r.l. TR 100.00% 08/17 Eurofins \u0130zmir G\u0131da Analiz Laboratuvarlar\u0131 Limited Eurofins Food Testing Turkey Holding A.\u015e. TR 100.00% 07/18 \u015eirketi Eurofins Food Testing Turkey Holding A.\u015e. Eurofins Food Testing LUX Holding S.\u00e0 r.l. TR 100.00% 06/19 Eurofins NSC Turkey Destek Hizmetleri A.\u015e. Eurofins Support Services LUX Holding S.\u00e0 r.l. TR 100.00% 11/19 Eurofins Assurance Turkey Kalite ve Denetim AQM HK Co., Ltd. TR 100.00% 06/19 Hizmetleri Limited \u015eirketi \u0130zmir Bornova Gayrimenkul A.\u015e. Eurofins Real Estate LUX Holding S.\u00e0 r.l. TR 100.00% 06/21 Eurofins Dr. Global G\u0131da Analiz Laboratuvar\u0131 A.\u015e. Eurofins Food Testing Turkey Holding A.\u015e. TR 100.00% 11/21 Eurofins Environment Testing Holding Taiwan Co., Ltd. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. TW 100.00% 03/15 Pharmacology Discovery Services Taiwan, Ltd. Eurofins Discovery Services LUX Holding S.\u00e0 r.l. TW 100.00% 08/16 Eurofins Panlabs Discovery Services Taiwan, Ltd. Eurofins Discovery Services LUX Holding S.\u00e0 r.l. TW 100.00% 08/16 Eurofins Food Testing Taiwan, Ltd. Eurofins Environment Testing Holding Taiwan Co., Ltd. TW 100.00% 08/17 Eurofins NSC Taiwan, Ltd. Eurofins Support Services LUX Holding S.\u00e0 r.l. TW 100.00% 06/18 Eurofins Tsing Hua Environment Testing Co., Ltd. Eurofins Environment Testing Holding Taiwan Co., Ltd. TW 100.00% 01/18 Eurofins Summit Tsiande Environmental Co., Ltd. Eurofins Environment Testing Holding Taiwan Co., Ltd. TW 100.00% 01/18 Eurofins E&E Taiwan Co., Ltd. Eurofins Consumer Product Testing Taiwan Holding TW 100.00% 01/18 Ltd. Eurofins SunDream Environmental Technical Co., Ltd. Eurofins Environment Testing Holding Taiwan Co., Ltd. TW 100.00% 09/20 Eurofins Blue Formosa Environmental Technical Co., Eurofins Environment Testing Holding Taiwan Co., Ltd. TW 100.00% 09/20 Ltd. Eurofins Universe Environmental Technical Co., Ltd. Eurofins Environment Testing Holding Taiwan Co., Ltd. TW 100.00% 09/20 Eurofins Consumer Product Testing Taiwan Holding Eurofins Product Testing LUX Holding S.\u00e0 r.l. TW 100.00% 06/21 Ltd. A Test Lab Techno Co., Ltd. Eurofins Consumer Product Testing Taiwan Holding TW 100.00% 07/21 Ltd. Eurofins NSC UK Limited Eurofins Support Services LUX Holding S.\u00e0 r.l. UK 100.00% 01/06 Eurofins Food Testing UK Limited Eurofins Food Testing UK Holding Limited UK 100.00% 01/04 Eurofins Genomics UK Limited Eurofins Genomics LUX Holding S.\u00e0 r.l. UK 100.00% 07/05 Eurofins Food Testing UK Holding Limited Eurofins Food Testing LUX Holding S.\u00e0 r.l. UK 100.00% 04/07 Eurofins Agroscience Services Limited Eurofins Agroscience Services UK Holding Limited UK 100.00% 04/07 Eurofins Product Testing Services Limited Eurofins Product Testing UK Holding Limited UK 100.00% 10/10 Public Analyst Scientific Services Limited Eurofins Food Testing UK Holding Limited UK 100.00% 07/11 Wolverhampton i54 Real Estate Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. UK 100.00% 07/12 Eurofins Water Hygiene Testing UK Limited Eurofins Food Testing UK Holding Limited UK 100.00% 10/15 Eurofins Biomnis UK Limited Eurofins Biologie Sp\u00e9cialis\u00e9e France SAS UK 100.00% 10/15 Eurofins Agro Testing UK Limited Eurofins Food Testing UK Holding Limited UK 100.00% 03/16 Eurofins Biopharma Product Testing UK Limited Eurofins Pharma Services LUX Holding S.\u00e0 r.l. UK 100.00% 07/16 Eurofins NDSM Limited Eurofins Agroscience Services UK Holding Limited UK 100.00% 07/16 Eurofins Agroscience Services UK Holding Limited Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. UK 100.00% 07/16 Livingston Cochrane Square Real Estate Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. UK 100.00% 08/16 Eurofins Food Safety Solutions Limited Eurofins Assurance LUX Holding S.\u00e0 r.l. UK 100.00% 11/16 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins York Limited Eurofins Product Testing UK Holding Limited UK 100.00% 07/17 Eurofins Forensic Services Limited Eurofins Forensics LUX Holding S.\u00e0 r.l. UK 100.00% 10/17 Eurofins Professional Scientific Services UK Limited Eurofins Pharma Services LUX Holding S.\u00e0 r.l. UK 100.00% 09/17 Eurofins Product Testing UK Holding Limited Eurofins Product Testing LUX Holding S.\u00e0 r.l. UK 100.00% 12/17 Eurofins Selcia Limited Eurofins Agroscience Services UK Holding Limited UK 100.00% 12/17 Ashwood UK Limited Eurofins Food Testing UK Holding Limited UK 100.00% 12/17 Eurofins E&E Hursley Limited Eurofins Product Testing UK Holding Limited UK 100.00% 02/18 Eurofins E&E ETC Limited Eurofins Product Testing UK Holding Limited UK 100.00% 01/18 Eurofins BLC Leather Technology Centre Limited Eurofins Product Testing UK Holding Limited UK 100.00% 04/18 Eurofins County Pathology Limited Eurofins Clinical Diagnostic Testing UK Holding Limited UK 100.00% 10/18 Eurofins Integrated Discovery UK Limited Eurofins Discovery Services LUX Holding S.\u00e0 r.l. UK 100.00% 12/18 Eurofins Clinical Diagnostic Testing UK Holding Limited Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. UK 100.00% 08/19 Eurofins E&E CML Limited Eurofins Product Testing UK Holding Limited UK 100.00% 02/19 Eurofins Environment Testing UK Holding Limited Eurofins Environment Testing LUX Holding S.\u00e0 r.l. UK 100.00% 03/19 Eurofins Chemtest Limited Eurofins Environment Testing UK Holding Limited UK 100.00% 04/19 Heathrow Dukes Green Real Estate Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. UK 100.00% 09/19 Eurofins Food Testing ATL Limited Eurofins Food Testing UK Holding Limited UK 100.00% 05/21 Eurofins Electrical and Electronic UK London Limited Eurofins Product Testing UK Holding Limited UK 100.00% 10/21 Eurofins MGS Laboratories Limited Eurofins Biopharma Product Testing UK Holding UK 75.00% 08/21 Limited Eurofins Alba Science Limited Eurofins Product Testing UK Holding Limited UK 90.00% 08/21 Eurofins Biopharma Product Testing UK Holding Eurofins Pharma Services LUX Holding S.\u00e0 r.l. UK 100.00% 08/21 Limited Tamworth Tungsten Park Real Estate Limited Eurofins Real Estate LUX Holding S.\u00e0 r.l. UK 100.00% 08/21 High Street Textile Testing Services Limited Eurofins MTS Consumer Product Testing UK Limited UK 100.00% 11/21 Modern Technology Holdings Limited Eurofins Product Testing LUX Holding S.\u00e0 r.l. UK 100.00% 11/21 Eurofins MTS Consumer Product Testing UK Limited Eurofins Product Testing LUX Holding S.\u00e0 r.l. UK 100.00% 11/21 Eurofins Food Chemistry Testing Des Moines, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 01/92 Eurofins Central Laboratory, LLC Eurofins Central Lab US Holdings, Inc. US 100.00% 06/06 Eurofins Analytical Laboratories, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 04/07 Eurofins Genomics, LLC Eurofins Genomics US Holdings, Inc. US 100.00% 12/07 Eurofins Food Testing US Holdings, Inc. Eurofins Food Testing LUX Holding S.\u00e0 r.l. US 100.00% 04/07 Eurofins Agroscience Services, LLC Eurofins Agrosciences Services US Holdings, Inc. US 100.00% 01/07 Eurofins Microbiology Laboratories, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 06/09 Eurofins NSC US, Inc. Eurofins Support Services LUX Holding S.\u00e0 r.l. US 100.00% 10/10 Eurofins Pharma US Holdings II, Inc. Eurofins Pharma Services LUX Holding S.\u00e0 r.l. US 100.00% 01/11 Eurofins Lancaster Laboratories, Inc. Eurofins Pharma US Holdings II, Inc. US 100.00% 04/11 Eurofins DQCI, LLC Eurofins Food Testing US Holdings, Inc. US 100.00% 10/11 Eurofins Environment Testing Northern California, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 01/12 Eurofins QTA, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 02/12 Eurofins Eaton Analytical, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 07/12 Eurofins Environment Testing Northwest, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 09/12 Eurofins Panlabs, Inc. Eurofins Discovery Services & Products US Holdings, US 100.00% 10/12 Inc. % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins Lancaster Laboratories Environment Testing, Eurofins Environment Testing America Holdings, Inc. US 100.00% 01/13 LLC Eurofins Pharma BioAnalytics Services US, LLC Eurofins Central Lab US Holdings, Inc. US 100.00% 01/13 South Bend Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 05/14 Eurofins Environment Testing Southwest, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 05/14 Eurofins Viracor, LLC Eurofins Clinical Testing US Holdings, Inc. US 100.00% 07/14 Eurofins SF Analytical Laboratories, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 11/14 Eurofins Clinical Testing US Holdings, Inc. Eurofins Clinical Testing Holding LUX S.\u00e0 r.l. US 100.00% 11/14 Boston Heart Diagnostics Corp. Eurofins Clinical Testing US Holdings, Inc. US 100.00% 01/15 Eurofins Lancaster Laboratories Professional Scientific Eurofins Lancaster Laboratories, Inc. US 100.00% 02/15 Services, LLC Eurofins Product Testing US, Inc. Eurofins Product Testing US Holdings, Inc. US 100.00% 02/15 Eurofins BioDiagnostics, Inc. Eurofins Genomics US Holdings, Inc. US 100.00% 02/15 Eurofins Environment Testing Philadelphia, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 04/15 Eurofins Diatherix Laboratories, LLC Eurofins Viracor, LLC US 100.00% 05/15 Eurofins Environment Testing Northeast, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 07/15 Eurofins Advantar Laboratories, Inc. Eurofins Pharma US Holdings II, Inc. US 100.00% 04/16 North Kingstown (R.I.) Camp Avenue Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 05/16 Eurofins Donor & Product Testing, Inc. Eurofins Clinical Testing US Holdings, Inc. US 100.00% 09/16 DeSoto Falcon Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 09/16 Lafayette Horizon Avenue Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 09/16 Eurofins Clinical Diagnostic US NDSC, Inc. Eurofins Clinical Testing US Holdings, Inc. US 100.00% 09/16 Agawam Silver Street Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 11/16 New Berlin 170th Street Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 11/16 Eurofins DiscoverX Corporation, Inc. Eurofins Discovery Services & Products US Holdings, US 100.00% 09/17 Inc. Eurofins Abraxis, Inc. Eurofins Technologies US Holdings, Inc. US 100.00% 10/17 Eurofins Technologies US Holdings, Inc. Eurofins Technology and Supplies LUX Holding S.\u00e0 r.l. US 100.00% 09/17 Eurofins Product Testing US Holdings, Inc. Eurofins Product Testing LUX Holding S.\u00e0 r.l. US 100.00% 09/17 Eurofins EAG Materials Science, LLC Eurofins EAG Materials Science US Holding, Inc. US 100.00% 12/17 Eurofins BioPharma Product Testing Columbia, Inc. Eurofins Pharma US Holdings II, Inc. US 100.00% 12/17 Eurofins Electrical and Electronic Testing NA, Inc. Eurofins Product Testing US Holdings, Inc. US 100.00% 12/17 Eurofins CEI, Inc. Eurofins Environment Testing America Holdings, Inc. US 100.00% 01/18 Eurofins Genomics Engineering LLC Eurofins Genomics US Holdings, Inc. US 100.00% 03/18 The National Food Lab, Inc. Eurofins Sensory, Consumer Research and Product US 100.00% 08/18 Design US Holding, Inc. Eurofins Sensory, Consumer Research and Product Eurofins Sensory, Consumer research and Product US 100.00% 08/18 Design US Holding, Inc. design LUX Holding S.\u00e0 r.l. Eurofins Food Chemistry Testing Madison, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 08/18 Eurofins Botanical Testing US, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 08/18 Battle Creek 55 Hamblin Avenue Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 08/18 Eurofins EAG Agroscience, LLC Eurofins Agrosciences Services US Holdings, Inc. US 100.00% 05/18 Eurofins CRL Cosmetics, Inc. Eurofins Product Testing US Holdings, Inc. US 100.00% 08/18 Gold Standard Diagnostics Corp, Inc. Eurofins Technologies US Holdings, Inc. US 100.00% 07/20 Eurofins Nanolab Technologies, Inc. Eurofins EAG Materials Science US Holding, Inc. US 100.00% 08/18 TestAmerica Laboratories, Inc. Eurofins Environment Testing America Holdings, Inc. US 100.00% 11/18 % of Date ISO interest Company Subsidiary of: of code by the entry Group Eurofins EPK Built Environment Testing, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 11/18 Environmental Sampling Supply, Inc. Eurofins Technologies US Holdings, Inc. US 100.00% 11/18 Eurofins Aerotech Built Environment Testing, Inc. Eurofins EPK Built Environment Testing, LLC US 100.00% 11/18 Madison Merchant Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 08/18 Eurofins EAG Engineering Science, LLC Eurofins EAG Materials Science US Holding, Inc. US 100.00% 12/18 Eurofins EAG Materials Science US Holding, Inc. Eurofins Material Sciences LUX Holding S.\u00e0 r.l. US 100.00% 04/19 Eurofins Genomics Blue Heron LLC Eurofins Genomics US Holdings, Inc. US 100.00% 04/19 Eurofins Viracor BioPharma Services, Inc. Eurofins Viracor, LLC US 100.00% 01/20 Transplant Genomics Inc. Eurofins Clinical Testing US Holdings, Inc. US 100.00% 05/19 Eurofins J3 Resources, Inc. Eurofins Environment Testing America Holdings, Inc. US 100.00% 10/19 Eurofins DiscoverX Products, LLC Eurofins DiscoverX Corporation, Inc. US 100.00% 12/19 Tustin Dow Avenue Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 11/19 Eurofins ARCA Technology, Inc. Eurofins Diatherix Laboratories, LLC US 100.00% 01/20 Pasadena Red Bluff Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 12/19 Lenexa 99th Street Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 12/19 Eurofins Environment Testing America Holdings, Inc. Eurofins Environment Testing LUX Holding S.\u00e0 r.l. US 100.00% 12/19 Eurofins Environment Testing South Central, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 07/20 Stafford Greenbriar Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 01/20 Eurofins Precision TEM, LLC Eurofins EAG Materials Science US Holding, Inc. US 100.00% 04/20 Eurofins NDSC Environment Testing Americas, Inc. Eurofins Environment Testing America Holdings, Inc. US 100.00% 01/20 Clinical Enterprise, Inc. Eurofins Clinical Testing US Holdings, Inc. US 100.00% 03/20 Eurofins Beacon Discovery Holdings, Inc. Eurofins Discovery Services & Products US Holdings, US 100.00% 03/21 Inc. Eurofins Beacon Discovery, Inc. Eurofins Beacon Discovery Holdings, Inc. US 100.00% 03/21 Amherst Hazelwood Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 01/21 Eurofins Genomics US Holdings, Inc. Eurofins Genomics LUX Holding S.\u00e0 r.l. US 100.00% 01/21 Eurofins Agrosciences Services US Holdings, Inc. Eurofins Agrosciences Services LUX Holding S.\u00e0 r.l. US 100.00% 01/21 Eurofins Central Lab US Holdings, Inc. Eurofins Central Lab Holdings LUX S.\u00e0 r.l. US 100.00% 01/21 Eurofins Discovery Services & Products US Holdings, Eurofins Discovery Services LUX Holding S.\u00e0 r.l. US 100.00% 01/21 Inc. Eurofins Food Assurance US, LLC Eurofins Food Testing US Holdings, Inc. US 100.00% 01/21 Eurofins Food Assurance Certification US, LLC Eurofins Food Testing US Holdings, Inc. US 100.00% 01/21 Louisville Plantside Drive Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 01/21 Columbia ABC Lane Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 02/21 Leola New Holland Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 02/21 Eurofins Pandemic Prevention Services, Inc. Eurofins Pharma US Holdings II, Inc. US 100.00% 02/21 Eurofins TestOil, Inc. Eurofins Environment Testing America Holdings, Inc. US 100.00% 07/21 Eurofins CellTx, Inc. Eurofins Clinical Testing US Holdings, Inc. US 100.00% 07/21 Dallas Harry Hines Blvd. Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 07/21 DNA Diagnostics Center, Inc. Eurofins Clinical Testing US Holdings, Inc. US 100.00% 08/21 Eurofins Reservoirs Environmental, Inc. Eurofins Environment Testing America Holdings, Inc. US 100.00% 10/21 Barberton Van Buren Avenue Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 08/21 DDC Worldwide Corp. DNA Diagnostics Center, Inc. US 100.00% 08/21 Experchem US, Inc. Eurofins Food Testing US Holdings, Inc. US 100.00% 09/21 % of Date ISO interest Company Subsidiary of: of code by the entry Group Tacoma Fife 8th Street Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 09/21 West Valley City Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 09/21 Clayton Powhatan Road Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 11/21 Eurofins Environment Testing Southeast, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 09/21 Eurofins Environment Testing North Central, LLC Eurofins Environment Testing America Holdings, Inc. US 100.00% 10/21 Eurofins MTS Consumer Product Testing US, LLC Eurofins Product Testing US Holdings, Inc. US 100.00% 11/21 Horsham Road Real Estate, Inc. Eurofins Real Estate LUX Holding S.\u00e0 r.l. US 100.00% 11/21 Eurofins Sac Ky Hai Dang Co., Ltd. Eurofins Food Testing LUX Holding S.\u00e0 r.l. VN 100.00% 05/15 Eurofins Consumer Product Testing Vietnam Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. VN 100.00% 08/17 Eurofins Assurance Vietnam Co., Ltd. Eurofins Assurance LUX Holding S.\u00e0 r.l. VN 100.00% 06/19 Modern Testing Services (Vietnam) Co., Ltd. Eurofins Product Testing LUX Holding S.\u00e0 r.l. VN 100.00% 11/21 Please note that for commercial confidentiality and security reasons the information provided above is not comprehensive. ", "dimensions": { "concept": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "language": "en", "entity": "scheme:529900JEHFM47DYY3S57", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } } } }